<SEC-DOCUMENT>0001641172-25-005110.txt : 20250709
<SEC-HEADER>0001641172-25-005110.hdr.sgml : 20250709
<ACCEPTANCE-DATETIME>20250416171946
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001641172-25-005110
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		28
FILED AS OF DATE:		20250416
<PUBLIC-REL-DATE>20250709
DATE AS OF CHANGE:		20250416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nasus Pharma Ltd
		CENTRAL INDEX KEY:			0002029039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				516022712
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07416
		FILM NUMBER:		25843609

	BUSINESS ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
		BUSINESS PHONE:		972 54-255-3956

	MAIL ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>As
submitted on April 16, 2025 to the Securities and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For
confidential review pursuant to the Jumpstart our Business Startups Act of 2012</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
No. 333-</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form
F-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nasus
Pharma Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State
    of Israel</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State or other jurisdiction
    of</I><BR>
    <I>incorporation or organization)</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary Standard Industrial</I><BR>
    <I>Classification Code Number)</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S. Employer</I><BR>
    <I>Identification Number)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Udi
                                            Gilboa</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Executive
    Chairman</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Yigal
    Alon 65</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tel
    Aviv, Israel 6744317</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tel:
    +972.3.573.6632</B></FONT></P></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Puglisi
                                            &amp; Associates</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>850
    Library Ave., Suite 204</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Newark,
    DE 19711</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tel:
    (302) 738-6680</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Address,
        including zip code, and telephone number,</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>including
    area code, of registrant&rsquo;s principal executive offices)</I></FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Name,
        address, including zip code, and telephone</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>number,
    including area code, of agent for service)</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Oded
                           Har-Even, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ron
    Ben-Bassat, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Eric
    Victorson, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Sullivan
    &amp; Worcester LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1251
    Avenue of the Americas, 19th Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>New
    York, NY 10020</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tel:
    +1.212.660.3000</B></FONT></P></TD>
    <TD STYLE="width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Reut
                           Alfiah, Adv.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Gal
    Cohen, Adv.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Sullivan
    &amp; Worcester Tel-Aviv<BR>
    (Har-Even &amp; Co.)<BR>
    28 HaArba&rsquo;a St. HaArba&rsquo;a</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Towers,<BR>
    North Tower, 35th Floor<BR>
    Tel-Aviv, Israel 6473925<BR>
    Tel: +972.74.758.0480</B></FONT></P></TD>
    <TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Leslie
                           Marlow, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Patrick
    Egan, Esq</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Hank
    Gracin, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Blank
    Rome LLP<BR>
    1271 Avenue of the Americas</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>New
    York, New York 10020<BR>
    (212) 885-5000</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Approximate
date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act, check the following box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards &dagger; provided
pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&dagger;The
term &ldquo;new or revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards Board
to its Accounting Standards Codification after April 5, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the
Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #FF0000"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #FF0000"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="width: 34%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #FF0000"><B>SUBJECT
    TO COMPLETION </B></FONT></TD>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #FF0000"><B>DATED
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>3,000,000&nbsp;Ordinary
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Nasus
Pharma Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
is a firm commitment initial public offering of 3,000,000 ordinary shares, no par value, or Ordinary Shares, of Nasus Pharma Ltd., an
Israeli company. Prior to this offering, there has been no public market for our Ordinary Shares. We anticipate that the initial public
offering price of our shares will be between $10.00 and $12.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to list our Ordinary Shares on the NYSE American LLC, or NYSE American, under the symbol &ldquo;NSRX&rdquo;. This offering is
contingent upon the Ordinary Shares being listed on the NYSE American, and no assurance can be given that our application will be approved
or that a trading market will develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are both an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and a &ldquo;foreign
private issuer&rdquo; as defined under the U.S. federal securities laws and have elected to comply with certain reduced public company
reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investing
in our Ordinary Shares involves a high degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 8. Neither the U.S. Securities
and Exchange Commission, or the SEC, nor any state securities commission has approved or disapproved these securities or determined if
this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial public offering price</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before expenses)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts
    and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering price payable to
    the underwriters. We have agreed to issue to ThinkEquity LLC, the representative of the underwriters, or the Representative, upon
    the consummation of this offering, warrants in an amount equal to 5% of the Ordinary Shares sold in this offering, or the Representative&rsquo;s
    Warrants. We refer you to &ldquo;<I>Underwriting</I>&rdquo; beginning on page 163 for additional information regarding underwriters&rsquo;
    compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have granted a 45-day option to the Representative of the underwriters to purchase up to additional 450,000 Ordinary Shares solely to
cover over-allotments, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriters expect to deliver the Ordinary Shares on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="chart_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_001">Prospectus Summary</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_002"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_003"><FONT STYLE="font-size: 10pt">Cautionary Note Regarding
    Forward-Looking Statements</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_004"><FONT STYLE="font-size: 10pt">Listing Details</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_005"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_006"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_007"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_008"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_009"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion
    and Analysis of Financial Condition and Results of Operations</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#b_010"><FONT STYLE="font-size: 10pt">Business</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fw_007">Management</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_001">Beneficial Ownership of Principal
    Shareholders and Management</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">147</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_002">Related Party Transactions</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">148</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_003">Description of Share Capital and
    Governing Documents</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_004">Shares Eligible for Future Sale</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">154</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_005">Taxation</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_006">Underwriting</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">163</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_007">Expenses</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_008">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">173</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_009">Experts</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">174</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_010">Enforceability of Civil Liabilities</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">174</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_011">Where You Can Find Additional Information</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">175</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#one_012">Index of Financial Statements</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>You
should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to
which we have referred you. We have not authorized anyone to provide you with information that is different. We are offering to sell
the Ordinary Shares, and seeking offers to buy the Ordinary Shares, only in jurisdictions where offers and sales are permitted. The information
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale
of the Ordinary Shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United
States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of
this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
this prospectus, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Nasus&rdquo; refer to Nasus
Pharma Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are incorporated in the State of Israel, and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules
of the SEC, we are currently eligible for treatment as a &ldquo;foreign private issuer.&rdquo; As a foreign private issuer, we will not
be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose
securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TRADEMARKS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this prospectus are referred to without the &reg; and &trade; symbols, but such references should not be construed
as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do
not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>MARKET,
INDUSTRY AND OTHER DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Unless
otherwise indicated, this prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available
information and independent industry publications and reports that we believe to be reliable sources, concerning our industry and the
markets in which we operate, including our general expectations and market position, market opportunity and market size estimates, is
based on information from independent industry analysts, third-party sources and management estimates. These publicly available industry
publications and reports generally state that they obtain their information from sources that they believe to be reliable, but they do
not guarantee the accuracy or completeness of the information. Although we believe that these sources are reliable, we have not independently
verified the information contained in such publications. Management estimates are derived from publicly available information released
by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made
by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we believe
the market opportunity information included in this prospectus is generally reliable and is based on reasonable assumptions, such data
involves risks and uncertainties and is subject to change based on various factors, including those discussed under the heading &ldquo;<I>Risk
Factors</I>&rdquo; and &ldquo;<I>Cautionary Note Regarding Forward-Looking Statements.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PRESENTATION
OF FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
reporting currency and functional currency is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references
in this prospectus to &ldquo;NIS&rdquo; are to New Israeli Shekels, references to &ldquo;Euro&rdquo; or &ldquo;&euro;&rdquo; mean the
currency of the European Union and references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; mean U.S. dollars. Unless otherwise noted,
all translations from NIS to U.S. dollars in this prospectus were made at a rate of NIS 3.6417 for $1.00, the exchange rate as of December
31, 2024, published by the Bank of Israel. All translations from Euro to U.S. dollars in this prospectus were made at a rate of &euro;1.00
for $1.0351, the exchange rate as of December 31, 2024, published by the H.10 statistical release of the Federal Reserve Board. The aforementioned
exchange rate is provided solely for your convenience and may differ from the actual rates used in the preparation of the consolidated
financial statements included in this prospectus and other financial data appearing in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
report our financial statements in accordance with generally accepted accounting principles in the United States, or U.S. GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_001"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully,
including the &ldquo;Risk Factors&rdquo; section and the financial statements and related notes appearing elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical
conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since
the nose is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique powder-based intranasal
technology, or PBI, with a specialized product portfolio to address acute medical conditions and public health threats. We believe that
PBI may be superior over liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity,
thus creating a larger absorption area and enabling more rapid and higher drug absorption. In addition, the uniform spherical powder
particles of our proprietary formulation may enhance the consistency and reliability of the delivered dose. The initial clinical trials
of our PBI products involving different molecules performed thus far have demonstrated quicker and higher drug absorption over similar
solution-based nasal products. However, to date we have only tested our product candidates on a relatively small patient population and
none of our products have been approved by the Food and Drug Administration, or the FDA. Prior to obtaining FDA approval of any of our
product candidates, we will need to perform additional clinical testing of our product candidates to confirm any benefits and advantages
our products may have over similar nasal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly
and immediately active PBI specialized products. To help achieve this we are focused on developing NS002, an intranasal powder epinephrine
nasal spray for the treatment of type 1 severe allergies and anaphylaxis, or Intranasal Epinephrine, and we also have been developing
NS001, an intranasal Naloxone powder nasal spray for the treatment of opioid overdose, or Intranasal Naloxone, however we currently paused
our work on NS001 and plan to pursue partnering opportunities for further development of NS001. We will need to obtain regulatory approval
for our products in order for us to grow our business. We currently have no FDA approved products. Our products have been tested on relatively
small patient populations thus far.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Obtaining
regulatory approvals and developing NS002 and NS001 will require the incurrence of significant costs and our success will depend, in
part, on gaining market acceptance. In order to gain market acceptance in the United States, we will require specific approval from the
FDA for our product candidates. We intend to seek approval of NS002 as an approved molecule and a new delivery route (with EpiPen autoinjector
as the reference device) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FFDCA, which allows the applicant to
rely in part on previous studies conducted by unrelated parties, such as another drug manufacturer, and existing sources including published
literature, for marketing approval by the FDA in the United States, and will seek approval under the comparable hybrid application pathway
in the European Union. The FDA may not agree that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory
approval. Such abbreviated approval pathways may not lead to a faster development or review process compared to traditional approval
pathways and do not increase the likelihood that NS002 or NS001 will receive regulatory approval in the United States or the European
Union. <FONT STYLE="background-color: white">See &ldquo;<I>Business &ndash; Government Regulation</I>&rdquo; and &ldquo;<I>Risk Factors
&ndash; Risks Related to Product Development, Regulatory Approval and Commercialization</I>&rdquo; for additional information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have conducted a twelve-patient pilot study of NS002, which included the testing of bioavailability of epinephrine under &ldquo;allergenic
challenge&rdquo; - the creation of severe acute allergic reaction in the nose by inserting ascending doses of allergens to the nose of
the healthy volunteers with known allergic rhinitis included in the study. The results showed that epinephrine intranasal delivery of
our NS002 followed the established characteristics of our platform technology&mdash;namely, there were higher levels of the drug in the
plasma in situations where immediate administration could be lifesaving. The Phase 2 study, which is meant to optimize the dose that
will be used in the Phase 3 study for registration, is conducted in limited patient populations to identify possible adverse effects
and safety risks, to preliminarily evaluate the dosage tolerance of the product for specific targeted diseases or conditions and to determine
dosage tolerance, optimal dosage and dosing schedule. Our Phase 2 study is aimed at defining the final clinical dose to be used in our
powder epinephrine product candidate, compared to the bioavailability of epinephrine following a various dosing of NS002 Microspheres
Epinephrine powder. The pharmacokinetic, or PK, results of our Phase 2 study are in line with the known attributes of our nasal
powder technology&mdash;namely: immediate absorption of epinephrine and reaching higher peak plasma epinephrine levels quicker compared
to intramuscular, or IM, Epinephrine injections. We intend to perform two additional Phase 2 studies of NS002. The first will be aimed
at determining whether, if necessary, during a real-life anaphylaxis a second dose of NS002 should be administered in the same nostril
as the one used for the first administration of NS002 or whether it should be in the other nostril. The second Phase 2 study will test
the &ldquo;carry-over effect,&rdquo; or whether the first dose of epinephrine changes the absorption of epinephrine of a following dose.
Each study is currently planned to include at least 12 healthy volunteers with allergic rhinitis. Prior to submission to the FDA for
marketing approval, we also intend to perform a pivotal clinical, or Phase 3, study that will include a subsection of self-administration.
We also intend to separately perform: (1) stability testing which involves testing the product candidate under various temperature and
humidity points; (2) a reliability study, which is a subset of the stability study that tests the NS002&rsquo;s administration device
in several potential conditions; (3) a usability study, which tests how user friendly the device is; (4) preclinical studies or short
animal safety studies in two animal species; and (5) a pediatric study, the details of which will be agreed upon with the FDA as we progress
with the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">With
respect to NS001 Intranasal Naloxone, we have performed a pilot study, which is a first in human study aimed at safety and bioequivalence,
and pivotal clinical study, which is the Phase 3 registration study, in 14 and 42 healthy volunteers, respectively, with the objective
of evaluating the comparative bioavailability of Naloxone between NS001 and certain competitor products. The pilot study results were
submitted to the FDA in support of the progression to the pivotal study. The results of the pilot study showed our technology having
a faster absorption rate in the immediate critical period after administration. The pivotal clinical, or Phase 3 study, is administered
to an expanded patient population to further evaluate dosage and clinical efficacy. Our pivotal clinical study consistently showed an
advantage in the first 30 minutes after administration. As of the date of this prospectus, we currently intend to focus our development
and regulatory approval efforts on our Intranasal Epinephrine and other preclinical programs and plan to pursue partnering opportunities
for further development of NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
platform technology can also be incorporated into other products as it has been tested with several additional preclinical and invitro
molecules based on our proprietary nasal powder formulation and technology. In addition to our two main products, Intranasal Epinephrine
and Intranasal Naloxone, we are exploring other potential indications for which our PBI technology may be applicable, including: NS005,
an intranasal midazolam powder nasal spray for the treatment of acute seizures, or Intranasal Midazolam; NS004, an intranasal atropine
powder nasal spray for the treatment of organophosphate poisoning, or Intranasal Atropine; and NS003, an intranasal ondansetron powder
nasal spray for the treatment of intractable vomiting, or Intranasal Ondansetron. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Competition
in the pharmaceutical industry is intense. Some of our competitors hold significant market share, have long histories and strong reputations
within the industry, greater brand recognition, and more financial and human resources than we do. They also have more experience and
capabilities in researching and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing
and marketing those products than we do. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of NS002 or NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have incurred significant operating losses, generated no revenues from existing products, and as of December 31, 2024, our accumulated
deficit was $12.7 million. We expect that we will need to raise substantial additional funding in the future. See &ldquo;<I>Risk
Factors &ndash; Risks Related to Our Financial Condition and Capital Requirements.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are an Israeli corporation and were incorporated in Israel in May 2019 under the name Nasus Pharma Ltd. Our principal executive offices
are located at Yigal Alon 65, Tel Aviv, Israel <FONT STYLE="background-color: white">6744317</FONT>. Our telephone number is +972.3.573.6632.
Our website address is <I>www.nasus-pharma.com</I>. The information contained on, or that can be accessed through, our website is not
part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
SEC also maintains an Internet website that contains reports, proxy and information statements and other information regarding issuers
that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC&rsquo;s website at <I>http://www.sec.gov</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
are an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities
Act, as modified by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting
requirements applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; such as not being required to
comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and not
being required to comply with any new or revised financial accounting standards until such date that a private company is otherwise required
to comply with such new or revised accounting standards. We could remain an &ldquo;emerging growth company&rdquo; until the end of the
fifth year following this offering, or until the earliest of (a) the last day of the first fiscal year in which our annual gross revenue
exceeds $1.235 billion, (b) the date that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the U.S. Securities
Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our Ordinary Shares that is held by non-affiliates
exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (c) the date on which we have
issued more than $1 billion in nonconvertible debt during the preceding three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Implications
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">of being a Foreign Private Issuer</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to the information reporting requirements of the Exchange Act that are applicable to &ldquo;foreign private issuers,&rdquo;
and under those requirements we file reports with the SEC. As a foreign private issuer, we are not <FONT STYLE="background-color: white">subject
</FONT>to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting
obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example,
we are not required to issue quarterly reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting
companies, or individual executive compensation information that is as detailed as that required of U.S. domestic reporting companies.
We also have four months after the end of each fiscal year to file our annual report with the SEC and are not required to file current
reports as frequently or promptly as U.S. domestic reporting companies. Our officers, directors and principal shareholders are exempt
from the requirements to report transactions in our equity securities and from the short-swing profit liability provisions contained
in Section 16 of the Exchange Act. As a foreign private issuer, we are not subject to the requirements of Regulation FD (Fair Disclosure)
promulgated under the Exchange Act. In addition, as a foreign private issuer, we are permitted to follow certain home country corporate
governance practices instead of those otherwise required under the NYSE American Listing Rules for domestic U.S. issuers (see &ldquo;<I>Risk
Factors &mdash; Risks Related to this Offering and the Ownership of Our Securities</I>&rdquo;). These exemptions and leniencies will
reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting
company. We intend to take advantage of the exemptions available to us as a foreign private issuer during and after the period we qualify
as an &ldquo;emerging growth company,&rdquo; until such time as we are no longer a foreign private issuer. We would cease to be a foreign
private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following
three circumstances applies: (i) the majority of our executive officers or directors are U.S. citizens or residents; (ii) more than 50%
of our assets are located in the United States; or (iii) our business is administered principally in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Summary
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
business is subject to numerous risks, as more fully described in the section entitled &ldquo;<I>Risk Factors</I>&rdquo; immediately
following this prospectus summary. You should read these risks before you invest in the Ordinary Shares. In particular, our risks include,
but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Financial Position and Capital Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not generated revenues
    from our continued activities, have incurred significant losses since our inception and anticipate that we will continue to incur
    significant losses for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt
    about our ability to continue as a going concern and could prevent us from obtaining new financing on reasonable terms or at all.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical stage
    pharmaceutical company and we have incurred significant operating losses since our inception and anticipate that we will incur
    continued losses for the foreseeable future.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding our legacy
    product and business activity, we have not generated revenue from any product candidate and may never be profitable, even if we receive
    regulatory approval to commercialize our products. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not believe that
    our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our
    ability to continue as a going concern. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have identified material
    weaknesses in our internal control over financial reporting. If our remediations are not effective, or if we experience additional
    material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not
    be able to accurately or timely report our financial conditions or results or operations, or prevent fraud, which may adversely affect
    investor confidence in our Company and as a result, the market price of our Ordinary Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Product Development, Regulatory Approval and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend substantially
    on the success of our proprietary intranasal powder product candidates. We cannot give any assurance that any of our product candidates
    will receive regulatory approval, which is necessary before they can be commercialized.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of our product candidates
    are in various stages of clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines
    and uncertain outcomes. If clinical trials of our product candidates are prolonged, delayed or not commercially viable, we or our
    collaborators may be unable to obtain required regulatory approvals, and therefore may be unable to commercialize our product candidates
    on a timely basis or at all, which will adversely affect our business. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The denial of regulatory
    approval for NS002 could mean that we need to delay or even cease operations, and a delay in obtaining such approval would delay
    commercialization of our products and adversely impact our ability to generate revenue, business and results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of pre-clinical
    studies, early-stage clinical trials, data obtained from real-world use, and published third-party studies may not be indicative
    of results in future clinical trials and we cannot assure you that any planned or future clinical trials will lead to results sufficient
    for the necessary regulatory approvals.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or others could discover
    that NS002, NS001, or any product candidate we may pursue in the future (including current pre-clinical programs) lacks sufficient
    efficacy, or that it causes undesirable side effects that were not previously identified, which could delay or prevent regulatory
    approval or commercialization.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials or
    the clinical trials of any of our current or potential future partners may encounter delays, suspensions or other problems.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we obtain regulatory
    approval for a product candidate, our products will remain subject to ongoing regulatory oversight. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent on manufacturers
    for Naloxone and Epinephrine. Any delay, price increase or unavailability of our manufacturers could materially adversely affect
    our ability to conduct clinical trials and, if this were to occur after we obtained commercialization and marketing approval, could
    materially impact our operations. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on a limited number
    of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find
    replacements or immediately transition to alternative suppliers on a cost-effective basis, or at all.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties
    to conduct our pre-clinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry
    out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
    approval for or commercialize our product candidates and our business could be substantially harmed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have limited manufacturing
    experience and could experience production problems that result in delays in our development or commercialization programs or otherwise
    adversely affect our business. We currently have no manufacturing facilities and anticipate reliance on third-party manufacturers
    for our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We own several issued patents
    but may require filing of additional patents in the future. There can be no assurance that all or some of our patent applications
    will result in issued patents. Consequently, our ability to protect our proprietary technology in the marketplace beyond the intellectual
    property already protected by our currently issued patents may be limited. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our proprietary position
    for our product candidates currently depends upon patents protecting the method of use, which may not prevent a competitor or other
    third party from using the same product candidate for another use.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if our patents are
    issued, because the patent status of pharmaceutical products can be complex and uncertain, we cannot predict the scope and extent
    of patent protection for our product candidates.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to enforce
    our intellectual property rights throughout the world. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Business and Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future success depends
    on our ability to retain key executives and to attract, retain and motivate qualified personnel.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates
    for which we intend to seek approval may face competition sooner than anticipated.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We manage our business
    through a small number of employees and key consultants. We will need to significantly increase the size of our organization, and
    we may experience difficulties in managing growth.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to this Offering and the Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our
    Ordinary Shares may be highly volatile, and you may not be able to resell your shares at or above the initial public offering price.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of a substantial
    number of our Ordinary Shares in the public market by our existing shareholders could cause our share price to fall.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising additional capital
    would cause dilution to our existing shareholders and may adversely affect the rights of existing shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal shareholders
    and management own a significant percentage of our Ordinary Shares and will be able to exert significant influence over matters subject
    to shareholder approval.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management will have broad
    discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Israeli Law and Our Operations in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We conduct our operations
    in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations and Israel&rsquo;s war against
    them, may affect our operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect to be exposed
    to fluctuations in currency exchange rates, which could adversely affect our results of operations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The termination or reduction
    of tax and other incentives that the Israeli government provides to Israeli companies may increase our costs and taxes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
    Pharma Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares issued and outstanding prior to this offering</B><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,362,906
    Ordinary Shares</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000&nbsp;Ordinary
    Shares<SUP>(2)</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares to be outstanding after this offering</B><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,687,800
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares or 11,137,800 Ordinary
    Shares if the underwriters exercise in full the over-allotment option to purchase additional Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment
    option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters an option for a period of up to 45 days to purchase, at the public offering price less underwriting
    discounts and commissions, up to&nbsp;450,000 additional Ordinary Shares, to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
    Warrants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will issue to ThinkEquity LLC, the Representative, or its permitted designees, Representative&rsquo;s Warrants, to purchase up to
    150,000 Ordinary Shares. The Representative&rsquo;s Warrants will have an exercise price equal to $13.75, or 125% of the per Ordinary
    Share assumed public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover
    page of this prospectus, will be exercisable beginning on a date which is 180 days from the commencement of sales under the registration
    statement of which this prospectus forms a part and will expire four and a half years from such commencement of sales.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            expect to receive approximately $29.7 million in net proceeds from the sale of Ordinary
                                            Shares offered by us in this offering (approximately $34.3 million if the underwriters
                                            exercise their over-allotment option in full), based upon an assumed public offering price
                                            of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover
                                            page of this prospectus, and after deducting the underwriting discounts and commissions and
                                            estimated offering expenses payable by us.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds from this offering for our research and development efforts as well as general and administrative
    corporate purposes, including working capital and capital expenditures. We currently expect that such use of the net proceeds from
    this offering would specifically support the development of our Intranasal Epinephrine program, including, technology scale-up, pivotal
    study, and the submission of our New Drug Application, or NDA, to the U.S. Food and Drug Administration, or the FDA, and pre-commercial
    activities; and the development of two additional early-stage indications, which we have not yet chosen and will be determined at
    a later date.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts and schedule of our actual expenditures will depend on multiple factors. As a result, our management will have broad discretion
    in the application of the net proceeds of this offering. See &ldquo;Use of Proceeds&rdquo; for more information about the intended
    use of proceeds from this offering.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock
    Up</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    directors and executive officers have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or
    otherwise dispose of any of our Ordinary Shares or securities convertible into Ordinary Shares for a period of eight months
    commencing on the date of this prospectus, and six months commencing on the date of this prospectus in the case of any other holder
    of outstanding securities. See &ldquo;<I>Underwriting</I>.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our securities involves a high degree of risk. You should read the &ldquo;Risk Factors&rdquo; section starting on page 8 of this
    prospectus for a discussion of factors to consider carefully before deciding to invest in the Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed
    NYSE American symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to apply to list the Ordinary Shares to be issued in this offering on the NYSE American under the symbol &ldquo;NSRX&rdquo;.
    This offering is contingent upon the Ordinary Shares being listed on the NYSE American. There is no assurance that such listing will
    be approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The actual number of Ordinary
    Shares that we will offer and that will be outstanding after this offering will be determined based on the actual public offering
    price.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of the Ordinary
    Shares to be outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are
    sold, and is based on 7,362,906 ordinary shares, outstanding as of December 31, 2024. This number excludes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">346,537 Ordinary
    Shares issuable upon the exercise of options, or share options, granted subsequent to December 31, 2024, at a weighted average exercise
    price of $6.05 per ordinary share; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,700 Ordinary Shares
    issuable upon the exercise of share options to directors, employees and consultants under our 2019 Incentive Option Plan, or the
    2019 Plan, outstanding as of December 31, 2024, at a weighted average exercise price of $2.77, of which 180,201 were vested as of
    December 31, 2024, and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,612 Ordinary Shares
    reserved for future grants under the 2019 Plan as of April 16, 2025. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Unless
otherwise indicated, all information in this prospectus assumes or gives effect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An assumed initial
    public offering price of $11.00&nbsp;per Ordinary Share, which is the midpoint of the price range set forth on the cover page of
    this prospectus;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the automatic conversion
    of all outstanding existing classes of ordinary shares, including Class A, Class A-1, Class A-2, Class A-3, Class A-3A, Class A-3B
    ordinary shares into 2,592,497 Ordinary Shares, which will occur upon the effectiveness of the registration statement for
    this offering;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"> 324,894 Ordinary Shares issuable upon the conversion of SAFEs entered into between March 2024
    and March 2025, or, collectively, the 2024 SAFEs, in the aggregate amount of $2,322,992, which will automatically convert
    into Ordinary Shares upon the effectiveness of the registration statement for this offering, based on an assumed public offering
    price of $11.00, which is the midpoint of the price range set forth on the cover page of this prospectus, assuming this offering
    occurs within 18 months of the execution of such SAFEs, otherwise such SAFEs will be converted into our securities on the basis of
    a previous round of equity financing consummated by the Company;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the adoption of our amended
    and restated articles of association upon the effectiveness of the registration statement for this offering (except that, where Ordinary
    Shares as of a date prior to the effectiveness of this registration statement are mentioned, the par value of our ordinary shares
    is NIS 0.01 per share), which will replace our amended and restated articles of association as currently in effect;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the underwriters&rsquo;
    over-allotment option <FONT STYLE="background-color: white">and the Representative&rsquo;s Warrants; and</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a 1-for-4.77008 forward
    share split, effected upon the effectiveness of this offering,&nbsp;and the customary adjustments to our outstanding options and
    warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SUMMARY
FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table summarizes our financial data. We have derived the following statements of operations data for the years ended December
31, 2024 and 2023 from our consolidated audited financial statements which are included elsewhere in this prospectus. We have derived
the following statements of operations data for the years ended December 31, 2024, and 2023 and balance sheet data as of December 31,
2024 from our audited consolidated financial statements, which are included elsewhere in this prospectus. Such financial statements have
been prepared in accordance with U.S. GAAP. Our historical results are not necessarily indicative of the results that may be expected
in the future. The following summary financial data should be read in conjunction with &ldquo;<I>Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations</I>&rdquo; and our financial statements and related notes, which are included elsewhere
in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
financial statements included in this prospectus were prepared in accordance with U.S. GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.dollars
    in thousands, except share and per share data</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated statements
    of operations:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">335</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">567</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">743</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">580</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,078</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,147</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss from continuing
    operations</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,078</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,147</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(29</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(49</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of convertible securities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(443</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">219</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other expenses,
    net</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,552</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,005</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net income (loss) from discontinued operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(46</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,532</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,051</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Per share data:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss per share attributable to shareholders:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.15</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diluted</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.20</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average ordinary shares outstanding
    - basic</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,027,725</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,889,708</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average ordinary shares outstanding
    - diluted</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,027,725</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,057,820</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses includes $208 thousand and $228 thousand in expenses to related parties in the years ended December 31, 2024 and 2023, respectively.
    </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative
    expenses includes $307 thousand and $288 thousand in expenses to related parties in the years ended December 31, 2024 and 2023, respectively.
    </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses includes
    $17 thousand and $27 thousand in expenses to related parties in the years ended December 31, 2024 and 2023, respectively. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of December 31, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actual</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro
    Forma</I> <SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro
    Forma </I>As Adjusted <I><SUP>(2)</SUP></I></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
    Balance Sheet Data:</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unaudited</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">284</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">969</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">31,329</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">717</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">1,402</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">31,502</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible securities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total current liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">3,929</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">2,127</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,127</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total shareholders&rsquo; deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,212</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(725</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">29,375</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <I>pro forma</I> data
    gives effect to (i) the issuance of 324,894 Ordinary Shares to be issued upon the conversion of the 2024 SAFEs into Ordinary
    Shares upon the effectiveness of the registration statement for this offering; and (ii) our receipt in January through March 2025
    of aggregate proceeds of $685,000 from the 2024 SAFEs we entered into with certain investors. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <I>pro forma</I> as
    adjusted data gives effect to the <I>pro forma</I> adjustments set forth above and the issuance of 3,000,000&nbsp;Ordinary Shares
    in this offering, at an assumed public offering price of $11.00&nbsp;per Ordinary Share, which is the midpoint of the price range
    set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering
    expenses, as if the sale of the Ordinary Shares had occurred on December 31, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_002"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>An
investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous
risks and uncertainties. You should consider carefully the risks and uncertainties described below, together with all of the other information
in this prospectus, including the financial statements and the related notes included elsewhere in this prospectus, before deciding whether
to invest in our securities. If any of the risks discussed below actually occur, our business, financial condition, operating results
or cash flows could be materially adversely affected. This could cause the trading price of our Ordinary Shares to decline, and you may
lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our
actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including
the risks faced by us described below and elsewhere in this prospectus. See &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Financial Position and Capital Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><I>We
have not generated revenues from our continued activities, have incurred significant losses since our inception and anticipate that we
will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability, which raise
a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining new financing on reasonable
terms or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have not generated revenues from our continued activities, we have incurred substantial operating losses, and funded our operations
primarily through equity financing and the raise of outside capital. As of December 31, 2024, we incurred accumulated deficit of approximately
$12.7 million. Management expects us to continue to generate substantial operating losses and to continue to fund our operations
primarily through the utilization of our current financial resources, and through additional raises of capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until
we can generate significant revenues, we expect to satisfy our future cash needs through existing cash, debt or equity financing. We
expect to require additional financing to fund our operations in the near future. Because of the numerous risks and uncertainties associated
with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if,
we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses
will also increase substantially if and as we proceed with development. We cannot be certain that additional funding will be available
to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research
or development plans for, or commercialization efforts with respect to our products and it risks our ability to continue operating as
a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
events and conditions, along with other matters, indicated that a material uncertainty existed as of December 31, 2024, that raises substantial
doubt on our ability to continue as a going concern. The report of our auditors for our financial statements for the period ended December
31, 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Our financial
statements for the year ended December 31, 2024 do not reflect any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
are a clinical stage pharmaceutical company and we have incurred significant operating losses since our inception and anticipate that
we will incur continued losses for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are an emerging pharmaceutical company with a limited operating history. We have funded our operations to date primarily through proceeds
from the private placement of securities, credit facilities, loans, convertible notes and revenues from our past legacy product and business
operations and activities. We expect to continue to incur substantial losses over the next several years during our clinical development
phase. To fully execute our business plan, which we estimate will cost between $18 and $22 million, we will need to complete Phase 2
clinical studies and certain development activities as well as manufacture the required clinical and commercial production batches in
the pilot manufacturing plant. Further, our product candidates will require regulatory approval prior to commercialization, and we will
need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures
to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact us. Management plans
to seek additional equity financing through private and public offerings or strategic partnerships and, in the longer term, by generating
revenues from product sales. We have incurred losses in each year since our inception. Our net loss for the years ended December 31,
2024 and 2023 were $1.5 million and $1.1 million, respectively. As of December 31, 2024, we had an accumulated deficit of approximately
$12.7 million. Substantially all of our operating losses resulted from costs incurred in connection with epinephrine development,
compensation and general and administrative costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until
we can generate significant revenues, if ever, we expect to satisfy our future cash needs through existing cash, debt or equity financing.
We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may
be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect
to our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect our research and development expenses to increase in connection with our planned expanded clinical trials. In addition, if we
obtain marketing approval for Intranasal Epinephrine, Intranasal Naloxone or any other current or future product candidate, we will likely
incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
in addition to such operating expenses, we expect to incur additional costs associated with operating as a public company subject to
the rules and regulations of the SEC, which we estimate will be at least $1 million dollars annually. As a result, we expect to continue
to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated
with developing a pharmaceutical candidate, we are unable to predict the extent of any future losses or when we will become profitable,
if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect to continue to incur significant losses until we are able to commercialize our product candidates, which we may not be successful
in achieving. We anticipate that our expenses will increase substantially if and as we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the research and
    development of our product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand the scope of our
    current clinical studies for our product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory and marketing
    approvals for our product candidates that successfully complete clinical studies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing,
    and distribution infrastructure to commercialize our product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify, assess,
    acquire, license, and/or develop other product candidates and subsequent generations of our current product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to maintain, protect,
    and expand our intellectual property portfolio; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to attract and retain
    skilled personnel; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create additional infrastructure
    to support our operations as a public company and our product candidate development and planned future commercialization efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Notwithstanding
our legacy product and business activity, we have not generated revenue from any product candidate and may never be profitable, even
if we receive regulatory approval to commercialize our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development
stage product candidates, other than from our legacy product and past business activities. In order to generate significant revenue,
we will need to obtain additional regulatory approvals in jurisdictions within which we already have certain regulatory approvals and
also in jurisdictions in which we currently have no regulatory approvals to market our products. Even if our current products or any
future products are approved for marketing and sale, we anticipate incurring significant incremental costs associated with commercializing
such products, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining favorable results
    from and progress the pre-clinical and clinical development of our product candidates, including Intranasal Epinephrine, Intranasal
    Naloxone and other current or future product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and obtaining
    regulatory approval for registration studies protocols for our product candidates, including Intranasal Epinephrine, Intranasal Naloxone
    and other current or future product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to successful completion
    of registration and clinical trials of Intranasal Epinephrine, Intranasal Naloxone and other current or future product candidates,
    applying for and obtaining marketing approval;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and maintaining
    supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products, and at acceptable
    costs, to support market demand for our product candidates, if marketing approval is received;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing,
    acquiring and/or developing new product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately identifying
    demand for our product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued consumer interest
    in treatments for products for intranasal drug delivery; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance
    of our product candidates, if approved for marketing, as viable treatment options;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms
    in any collaboration, licensing or other arrangements into which we may enter; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;obtaining and maintaining
    CIV labelling (no FDA imposed boxed warning, commonly referred to as a &ldquo;Black Box&rdquo; warning) of our lead product candidates,
    Intranasal Epinephrine, Intranasal Naloxone and other current or future product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and nurturing
    relationships with the leading physicians in the United States; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting, hiring and
    retaining qualified personnel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial
doubt about our ability to continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial
doubt about our ability to continue as a going concern. If we cannot continue as a going concern, our investors may lose their entire
investment in our securities. Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through
debt or equity financing. Even if we raise the proceeds from this offering, we do not believe that such proceeds will be sufficient to
complete all research and development activities necessary to commercialize our product candidates. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope
of, or eliminate research or development plans for, or commercialization efforts with respect to our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
have identified material weaknesses in our internal control over financial reporting. If our remediations are not effective, or if we
experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the
future, we may not be able to accurately or timely report our financial conditions or results or operations, or prevent fraud, which
may adversely affect investor confidence in our Company and as a result, the market price of our Ordinary Shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a public company, we will be required to maintain internal control over financial reporting and will be required to report any material
weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that we include
a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form 20-F. In
addition, once we cease to be an EGC as such term is defined in the JOBS Act, our independent registered public accounting firm must
attest to and report on the effectiveness of our internal control over financial reporting. According to the U.S. Public Company Accounting
Oversight Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such
that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on
a timely basis. If we fail to remediate the material weaknesses, or are otherwise unable to maintain effective internal control over
financial reporting, management could be required to expend significant resources and we could fail to meet our public reporting requirements
on a timely basis, and be subject to fines, penalties (including any penalties associated with late filing of tax returns), investigations
or judgements, all of which could negatively affect investor confidence and adversely impact our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we identified a material weakness with our internal control over financial reporting as we had not designed or
maintained an effective control environment and associated control activities to meet our accounting and reporting requirements. Specifically,
we did not have a sufficient complement of personnel with an appropriate degree of internal controls and accounting knowledge, we have
not performed a documented risk assessment process to identify and analyze risks of misstatement due to error and/or fraud, have not
documented our financial reporting processes, have not implemented, documented, or tested internal controls over financial reporting
and, in certain cases, we did not have appropriate reviews over journal entries and third party reported information to allow for reliable
and timely financial reporting. As of the date of this prospectus, we have not remediated this material weakness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
of our existing material weaknesses may not have been identified, and we may in the future identify additional material weaknesses. Our
management did not perform an evaluation of our internal control over financial reporting during any period in accordance with the provisions
of Sarbanes-Oxley Act. Had we performed an evaluation of our internal control over financial reporting in accordance with the provisions
of Sarbanes-Oxley Act, additional control deficiencies amounting to material weaknesses may have been identified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
will take steps to develop a plan to remediate the material weakness identified above and to strengthen our internal control over financial
reporting. This involves assessing risk factors, understanding process gaps, and pinpointing areas that needed improvement. We cannot
assure investors that our future remediation plan will be sufficient to establish and maintain effective internal control over financial
reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even
if this offering is successful, we expect that we will need to raise substantial additional funding before we can expect to complete
the development of Intranasal Epinephrine or any other product candidate. This additional financing may not be available on acceptable
terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product candidate
development efforts or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, our cash and cash equivalents were approximately $0.3 million, and we had a working capital deficit of $3.3 million
and an accumulated deficit of $12.7 million. Based upon our currently expected level of operating expenditures, we expect that
our existing cash and cash equivalents will be sufficient to fund operations through June 2025. Even if this offering is completed, we
expect that we will require substantial additional capital to commercialize our product candidates. In addition, our operating plans
may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned.
Our future funding requirements will depend on many factors, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our clinical trial results;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes
    of seeking marketing approval of Intranasal Epinephrine, Intranasal Naloxone and other current or future product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of filing and
    prosecuting patent applications and the cost of defending our patents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of prosecuting
    patent infringement actions against third parties;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development of other early-stage
    development product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with
    commercializing Intranasal Epinephrine or any other product candidate, if we receive marketing approval, including the cost and timing
    of establishing sales and marketing capabilities to market and sell such product candidates; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to receipt of marketing
    approval, revenue received from sales of approved products, if any, in the future;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or
    other lawsuits related to our products; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to
    attract and retain skilled personnel; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with
    being a public company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. Moreover, the terms of any financing may adversely affect the holdings or the rights
of holders of our securities and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance,
may cause the market price of our common shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact
our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product
candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating
results and prospects. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional
capital if market conditions are favorable or if we have specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the development or commercialization, if any, of any product candidates or be unable to expand our
operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Certain
agreements that we may enter into with lenders and future debt agreements may contain restrictions that may limit our flexibility in
operating our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may enter into credit facilities with certain lenders which contain restrictions, such as prohibiting that we merge into another company
or change our accounting standards, that could limit our flexibility in operating our business. Documents governing our future indebtedness,
or in connection with additional capital raises, if any, may contain, numerous financial and operating covenants that limit the discretion
of management with respect to certain business matters. Restrictive covenants included in the above-mentioned credit facility include
restrictions on, among others, our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create or permit to subsist any security interest over
    any of our assets;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell, transfer or otherwise dispose of any or our assets
    on recourse terms;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay dividends;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">buy back our own securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur or permit additional indebtedness;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">merge or conduct any other corporate reconstruction;
    and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">change the nature of our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to comply with these and other provisions of the existing debt agreements is dependent on our future performance, which will
be subject to many factors, some of which are beyond our control. The breach of any negative covenants in our current or future agreements
could result in an event of default, as may be defined in such agreements, thereby leading to a potential default interest rate or immediate
repayment of any borrowed amounts. These restrictive covenants which may be in place from time to time and a lack of compliance by us
could limit our flexibility in operating our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Unstable
market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, fluctuations in unemployment rates,
fluctuations in inflation rates and uncertainty about economic stability. For example, the ongoing conflicts between Ukraine and Russia
and in the Middle East have created volatility in the global capital markets and may have further global economic consequences, including
disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or
the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it
may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more
dilutive. Inflation can adversely affect us by increasing our costs. Any significant increases in inflation and related increase in interest
rates could have a material adverse effect on our business, results of operations, financial condition and our ability to raise funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Product Development, Regulatory Approval and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
depend substantially on the success of our proprietary intranasal powder product candidates. We cannot give any assurance that any of
our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have invested almost all of our efforts and financial resources in general and administrative costs and the research and development
of our intranasal powder product candidates. Our portfolio comprises a number of programs: Intranasal Epinephrine (completed Phase 2),
Intranasal Naloxone (completed pivotal study), as well as a number of preclinical proof of concept, or POC, programs. We currently intend
to focus our development and regulatory approval efforts on our Intranasal Epinephrine and POC programs. The process to develop, obtain
regulatory approval for and commercialize pharmaceutical product candidates is long, complex, costly and inherently uncertain of outcome.
We are not permitted to market any of our product candidates in the United States, European Union, or the EU, or any other jurisdiction
until we receive the requisite regulatory approvals. We cannot give any assurance that our current clinical development plan will proceed
as planned, or that our product candidates will receive regulatory approval, or that such regulatory approval, if received, will be within
a timeframe that allows us to effectively compete with our competitors, or be successfully marketed and commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
currently have no product candidates approved for marketing and are investing the majority of our efforts and financial resources in
the development of NS002 for the emergency treatment of allergic reactions and potential other indications. Successful continued development
and ultimate regulatory approval of NS002 for our initial indication or potential additional indications is critical to the future success
of our business. We will need to successfully complete our clinical development of NS002 for the emergency treatment of allergic reactions
and potential other indications. The future regulatory and commercial success of our product candidates is subject to a number of risks,
including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful completion of
    nonclinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful patient enrollment
    in clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful data from our
    nonclinical studies and clinical trials that support an acceptable risk-benefit profile of our product candidates in the intended
    populations and indications;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfaction of applicable
    regulatory requirements, including to satisfy applicable rules governing combination products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential unforeseen safety
    issues or adverse side effects;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt and maintenance
    of marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining in compliance
    with post-marketing regulatory requirements;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining
    patent and trade secret protection and regulatory exclusivity for our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making arrangements or
    maintaining existing arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and
    commercial supplies of our product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entry into collaborations
    to further the development of NS002, NS001 or any future product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing sales, marketing
    and distribution capabilities and launching commercial sales of any approved products, whether alone or in collaboration with others;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully launching
    commercial sales of our product candidates, if and when approved;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance of our product
    candidates, if and when approved, by patients, the medical community and third-party payors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining
    third-party coverage and adequate reimbursement;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">products, following approval,
    maintaining a continued acceptable safety profile;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively competing with
    other therapies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring that we promote
    and distribute our products consistent with all applicable healthcare laws; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcing and defending
    intellectual property rights and claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Many
of these risks are beyond our control, including the risks related to clinical development, the regulatory submission and review process,
potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any current or future collaboration
partner. If we are unable to develop, receive regulatory approval for, or successfully commercialize NS002 for the indications we are
developing it for, or if we experience delays as a result of any of these risks or otherwise, our business will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, of the large number of products in development in the pharmaceutical industry, only a small percentage result in the submission
of an NDA to the FDA or a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, and even fewer are approved
for marketing and commercialization. Furthermore, even if we receive regulatory approval to market NS002 for any indication, any such
approval may be subject to limitations on the indications or uses or the patient populations for which we may market the product. Accordingly,
even if we are able to obtain the requisite financing to continue to fund our development activities, we cannot assure you that we will
successfully develop or commercialize NS002 for any indication. If we or any of our current or future licensing and collaboration partners
are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize NS002 for its initial indication
or potential additional indications, we may not be able to generate sufficient revenue to continue our business. In addition, our failure
to satisfy other regulatory requirements could adversely affect our development efforts for NS002 in other indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
product candidates are in different stages of clinical development. Clinical drug development is a lengthy and expensive process with
uncertain timelines and uncertain outcomes. If clinical trials of our product candidates are prolonged, delayed or not commercially viable,
we or our collaborators may be unable to obtain required regulatory approvals, and therefore may be unable to commercialize our product
candidates on a timely basis or at all, which will adversely affect our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
obtain the requisite regulatory approvals to market and sell any of our product candidates, we or our collaborators for such candidates
must demonstrate through extensive preclinical studies and clinical trials that our products are safe, pure and potent or effective in
humans. Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical
trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target
indications and patient population. Prior to obtaining approval to commercialize a product candidate in the United States or abroad,
we or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials,
and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective
for their intended uses. Additionally, clinical testing is expensive and can take many years to complete, and its outcome is inherently
uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful.
In addition, we cannot make comparative claims regarding the use of our products against any alternative treatments without conducting&nbsp;head-to-head&nbsp;comparative
clinical studies, which would be expensive and time-consuming. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may not be able to commence or complete the clinical trials that would support our submission of an NDA to the FDA or a MAA to EMA. Drug
development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. Clinical
trials can be delayed or prevented for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties obtaining
    regulatory approval to commence a clinical trial or complying with conditions imposed by a regulatory authority regarding the scope
    or term of a clinical trial;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching or failing
    to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which
    can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient or inadequate
    supply or quality of a product candidate or other materials necessary to conduct our clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the FDA or EMA elect
    to enact policy changes, as a result of the COVID-19 pandemic or otherwise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties obtaining
    institutional review board, or IRB, approval to conduct a clinical trial at a prospective site; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges recruiting and
    enrolling patients to participate in clinical trials for a variety of reasons, including fears resulting from the COVID-19 pandemic
    or due to government actions enacted and as a result of such pandemic, size and nature of patient population, proximity of patients
    to clinical sites, eligibility criteria for the trial, nature of trial protocol, the availability of approved effective treatments
    for the relevant disease and competition from other clinical trial programs for similar indications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended
or terminated by us, the FDA, IRBs, at the sites where the IRBs are overseeing a trial, a data safety monitoring board overseeing the
clinical trial at issue or by other regulatory authorities due to a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance
    with regulatory requirements or our clinical protocols;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial
    sites by the FDA or other regulatory authorities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues or lack of effectiveness;
    and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval
of our product candidates or result in the development of our product candidates being stopped early.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
denial of regulatory approval for NS002 or NS001 could mean that we need to delay or even cease operations, and a delay in obtaining
such approval would delay commercialization of our products and adversely impact our ability to generate revenue, business and results
of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are not successful in commercializing NS002 or NS001, or are significantly delayed in doing so, our business will be materially harmed,
and we may need to curtail or cease operations. We currently have no pharmaceutical products approved for marketing, and we may never
obtain regulatory approval to market and commercialize NS002 or NS001 for any indication. The research, testing, manufacturing, labeling,
approval, sale, marketing and distribution of pharmaceutical products are subject to extensive regulation by the FDA, the EMA, and other
regulatory agencies in the United States, EU and other countries, and such regulations differ from country to country. We are not permitted
to market NS002 and NS001 until we receive approval or marketing authorization from the relevant regulatory authority. Of the large number
of pharmaceutical products in development, only a small percentage successfully complete the FDA, the EMA or other regulatory approval
processes and are commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we eventually complete clinical testing and receive approval of an NDA, MAA or other foreign marketing authorization for NS002 or
NS001, the FDA, the EMA or other applicable foreign regulatory agency may grant approval contingent on the performance of costly additional
clinical trials, which may be required after approval. The FDA, the EMA or other applicable foreign regulatory agency may also approve
NS002 and NS001 for a more limited indication and/or a narrower patient population than we originally request, and the FDA, the EMA or
any other applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of NS002 or NS001. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would delay or prevent
commercialization of NS002 and NS001 and would materially adversely impact our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
results of pre-clinical studies, early-stage clinical trials, data obtained from real-world use, and published third-party studies may
not be indicative of results in future clinical trials and we cannot assure you that any planned or future clinical trials will lead
to results sufficient for the necessary regulatory approvals.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
results of pre-clinical studies may not be predictive of the results of clinical trials, and the results of any completed clinical trials,
including studies derived from real-world use and studies in published literature, or clinical trials we commence may not be predictive
of the results of later-stage clinical trials. Additionally, interim results during a clinical trial do not necessarily predict final
results. Later clinical trial results may not replicate earlier clinical trials for a variety of reasons, including differences in trial
design, different trial endpoints (or lack of trial endpoints in exploratory studies), subject population, number of subjects, subject
selection criteria, trial duration, drug dosage and formulation and lack of statistical power in the earlier studies. The Phase 2 portion
of our NS002 study included twelve patients and the trial was not powered for statistical significance. In trials not powered
for statistical significance, there is a high chance that observed effects may not be accurate due to small sample size.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our
product candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical
development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a
negative impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
or others could discover that NS002, NS001, or any product candidate we may pursue in the future, lacks sufficient efficacy, or that
it causes undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not currently have any FDA approved products and our product candidates have been tested in relatively small patient populations and
for limited durations to date. Therefore, our product candidates require additional clinical testing and it is possible that our clinical
trials have or will indicate an apparent positive effect that is greater than the actual positive effect, if any, or that additional
and unforeseen side effects may be observed as its development progresses. The discovery that NS002, NS001 or any POC program lacks sufficient
efficacy, or that it causes undesirable side effects (including side effects not previously identified in our completed clinical trials),
could cause us or regulatory authorities to interrupt, delay or discontinue clinical trials and could result in the denial of regulatory
approval by the FDA or other non-U.S. regulatory authorities for any or all targeted indications, including, but not limited to, a determination
by the FDA that the 505(b)(2) regulatory pathway is not available for a product candidate. The most common events reported to date have
been tachycardia, hypertension, headache, anxiety, apprehension, palpitations, diaphoresis, nausea, vomiting, weakness, and tremors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
discovery that NS002, NS001, or any POC program or future product candidate, lacks sufficient efficacy or that it causes undesirable
side effects that were not previously identified could prevent us from commercializing such product candidate and generating revenues
from its sale. In addition, if we receive marketing approval for any of our current or future products and we or others later discover
that it is less effective, or identify undesirable side effects caused by them:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may withdraw their approval of the product;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to recall
    the product, change the way this product is administered, conduct additional clinical trials or change the labeling or distribution
    of the product;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional restrictions
    may be imposed on the marketing of, or the manufacturing processes for, the product;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to fines,
    injunctions or the imposition of civil or criminal penalties;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held
    liable for harm caused to patients;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product may be rendered
    less competitive and sales may decrease; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer
    generally both among clinicians and patients.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
one or a combination of these events could prevent us from achieving or maintaining market acceptance of the affected product or could
substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating
significant, or any, revenues from the sale of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
clinical trials or the clinical trials of any of our current or potential future partners may encounter delays, suspensions or other
problems.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We,
or our partners, may encounter problems in clinical trials that may cause us or the FDA or foreign regulatory agencies to delay, suspend
or terminate any such clinical trials at any phase. These problems could include the possibility that we may not be able to conduct clinical
trials at our preferred sites, enroll a sufficient number of patients for our clinical trials at one or more sites or begin or successfully
complete clinical trials in a timely fashion, if at all. Furthermore, we, our partners, the FDA or foreign regulatory agencies may suspend
clinical trials at any time if we or they believe the subjects participating in the trials are being exposed to unacceptable health risks
or if we or they find deficiencies in the clinical trial process or conduct of the investigation. If clinical trials of any of our products
fail, we will not be able to market the product which is the subject of the failed clinical trials. The FDA and foreign regulatory agencies
could also require additional clinical trials, which would result in increased costs and significant development delays. Our, or our
partners&rsquo;, failure to adequately demonstrate the safety and effectiveness of a product under development could delay or prevent
regulatory approval of the product and could have a material adverse effect on our business, prospects, financial condition and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
approval of an NDA or an MAA, even after clinical trials that are believed to be successful, is an uncertain process.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are not permitted to market our products in the United States or the EU until we receive regulatory approval of an NDA from the FDA,
or MAA from the EMA, or in any foreign countries until we receive the requisite approval from regulatory authorities in such countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we complete our planned clinical trials and believe the results to be successful, all of which are uncertain, obtaining regulatory
approval is an extensive, lengthy, expensive and uncertain process, and the FDA and EMA, and other regulatory authorities may delay,
limit or deny approval of our products for many reasons, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to demonstrate
    to their satisfaction that the product candidate is a safe or effective treatment for a given indication;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of clinical
    trials may not meet the level of statistical significance or clinical significance required by the regulatory agencies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements regarding
    the number, design, size, conduct or implementation of our clinical trials, or with our interpretation of data from pre-clinical
    studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lack of acceptance of
    the accuracy or sufficiency of the data generated at our clinical trial sites to demonstrate, among others, that clinical and other
    benefits outweigh its safety risks or to support the submission of an NDA or MAA;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties scheduling
    an advisory committee meeting in a timely manner or the advisory committee, or such other similar committee, may recommend against
    approval of our application or may recommend that such regulators require, as a condition of approval, additional pre-clinical studies
    or clinical trials, limitations on approved labeling, or distribution and use restrictions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that we
    develop a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval, which may or may not be feasible for us;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the identification of deficiencies
    in the manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial
    supplies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in approval policies
    or the adoption of new regulations by such regulators; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to be
    granted a pediatric investigation plan, or PIP, deferral which we intend to request from the EMA for delayed clinical trials and
    subsequent approval in children; this may delay our clinical trial program or approvals for adults, or we may have successful clinical
    trial results for adults but not children (if we were required to conduct pediatric studies prior to the receipt of an NDA or MMA
    for use of our product candidates in adults), or vice versa.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Generally,
before we can submit an NDA to the FDA, we must conduct Phase 3 trials (PK and bioavailability studies) that will be substantially
broader than our Phase 2 trials. An NDA must be supported by extensive clinical and pre-clinical data, as well as extensive information
regarding chemistry, manufacturing and controls to demonstrate the safety and effectiveness of the applicable product candidate. The
number and types of pre-clinical studies and clinical trials that will be required varies depending on the product candidate, the disease
or condition that the product candidate is designed to target and the regulations applicable to any particular product candidate. Obtaining
approval of an NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review
processes can take years to complete and approval is never guaranteed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
this respect, we will also need to agree on a protocol with the FDA for the Phase 3 clinical trials before commencing those trials. Phase
3 clinical trials frequently produce unsatisfactory results even though prior clinical trials were successful. Therefore, the results
of the additional trials that we conduct may or may not be successful. The FDA may suspend all clinical trials or require that we conduct
additional clinical, nonclinical, manufacturing validation or drug product quality studies and submit those data before it will consider
or reconsider the NDA. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed
by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if
performed and completed, may not be considered sufficient by the FDA to approve the NDA. If any of these outcomes occur, we would not
receive approval at such time, if any, that we seek FDA approval. We may face similar risks with respect to obtaining regulatory approval
from the EMA at such time, if any, that we seek EMA approval. The risks that we face in obtaining applicable approvals from the FDA and
EMA Intranasal Epinephrine, Intranasal Naloxone or any other product candidate that we may seek to develop, may also exist with other
regulatory authorities, such as those in Latin America or other regions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we obtain FDA, EMA or other regulatory approval for Intranasal Epinephrine or any other product candidate, the approval might contain
significant limitations related to use restrictions, warnings, precautions or contraindications, or may be subject to significant post-marketing
studies or risk mitigation requirements. If we are unable to successfully commercialize Intranasal Epinephrine or other current or future
product candidates, we may be forced to cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Preliminary
data that we or others announce or publish from time to time with respect to our product candidates may change as more data become available
and are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, we, or our partners, may publish or seek to publish preliminary data from ongoing clinical trials, which are based on a
preliminary analysis of then-available data. Positive preliminary data may not be predictive of such trial&rsquo;s subsequent or overall
results. Preliminary data are subject to the risk that one or more of the results and related findings and conclusions may materially
change following a more comprehensive review of the data or as more data become available. Therefore, positive preliminary results in
any ongoing clinical trial may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a
result, preliminary data that we report may differ from future results from the same clinical trials, or different conclusions or considerations
may qualify such results, once additional data have been received and fully evaluated. Preliminary data also remain subject to audit
and verification procedures that may result in the final data being materially different from the preliminary data we previously published.
As a result, preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final
data compared to preliminary data could significantly harm our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line
or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, in scale, our product candidates may be harmed, which could harm our
business, operating results, prospects or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
results of clinical trials conducted at clinical sites outside the United States may not be accepted by the FDA and the results of clinical
trials conducted at clinical sites in the United States may not be accepted by international regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
plan to conduct some of our clinical trials outside the United States. For example, we are planning to conduct some of our Intranasal
Epinephrine clinical studies in Canada and Israel. We have also previously performed our pivotal study for Naloxone in Canada in an FDA
approved facility. However, although the FDA may accept data from clinical trials conducted outside the United States, acceptance of
this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well-designed and conducted and
performed by qualified investigators in accordance with ethical principles such as or IRB or ethics committee approval and informed consent.
The study population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S.
medical practice in ways that the FDA deems clinically meaningful. Generally, the subject population for any clinical trials conducted
outside of the United States must be representative of the U.S. population. In addition, while these clinical trials are subject to the
applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials were conducted consistent
with all applicable U.S. laws and regulations. There can be no assurance the FDA or international regulatory authorities will accept
data from trials conducted outside of the United States or inside the United States, as the case may be, as adequate support of a marketing
application. If the FDA does not accept the data from sites in our globally conducted clinical trials, or if international regulatory
authorities do not accept the data from our U.S. clinical trials, it would likely result in the need for additional trials, which would
be costly and time-consuming and could delay or permanently halt the development of one or more of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial potential or result in significant negative consequences following regulatory approval, if obtained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the conduct of clinical trials, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal
outcome. It is possible that as we develop Intranasal Epinephrine, Intranasal Naloxone or other product candidates that we may seek to
develop, in larger, longer and more extensive clinical trials as use of our product candidates becomes more widespread if they receive
regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well
as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects
are only detectable after investigational products are tested in larger scale, Phase 2 and 3 clinical trials or, in some cases, after
they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that Intranasal
Epinephrine, Intranasal Naloxone or other product candidates that we seek or may seek to develop, have side effects or cause serious
or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received
regulatory approval, such approval may be revoked or limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally,
if any of our product candidates receives marketing approval, the FDA or EMA could require us to adopt a REMS to ensure that the benefits
outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to
patients, a communication plan to health care practitioners, and restrictions on how or where the product can be distributed, dispensed
or used. Furthermore, if we or others later identify undesirable side effects caused by Intranasal Epinephrine, Intranasal Naloxone or
other current or future product candidates, several potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may suspend or withdraw approvals of such a product candidate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may require additional warnings on the label;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may issue negative publicity regarding the affected product, including safety communications;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change
    the way the product is distributed, dispensed or administered, or conduct additional pre-clinical studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may need to voluntarily
    recall our products; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held
    liable for harm caused to patients.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could significantly
harm our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
product candidates proceed through pre-clinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way
in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing,
FDA or EMA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials
or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize
our ability to commence sales and generate revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
will need to obtain FDA approval of any proposed names for our product candidates that gain marketing approval, and any failure or delay
associated with such naming approval may adversely impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
name we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark
registration from the U.S. Patent and Trademark Office, or the U.S. PTO. The FDA typically conducts a review of proposed product names,
including an evaluation of whether proposed names may be confused with the names of other drug products. The FDA may object to any product
name we submit if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product names,
we may be required to adopt an alternative name for our product candidates, which could result in further evaluation of proposed names
with the potential for additional delays and costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Changes
in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes
to clinical trial protocols, which could result in increased costs to us, delay our development timeline or reduce the likelihood of
successful completion of our clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, as a result of which we may need
to amend clinical trial protocols. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval,
which may impact the cost, timing or successful completion of a clinical trial. If we experience delays in completion of, or if we terminate,
any of our clinical trials, the commercial prospects for our products would be harmed and our ability to generate product revenue would
be delayed, possibly materially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
development and regulatory strategy for our product candidates depends in part on published scientific literature and the FDA&rsquo;s
prior findings regarding the safety and efficacy of approved product candidates. If the FDA does not conclude that our product candidates
satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for our product candidates under
Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost significantly more and entail
significantly greater complications and risks than anticipated and in either case may not be successful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section 505(b)(2) to
the FFDCA, or Section 505(b)(2). Section 505(b)(2) permits the submission of an NDA where at least some of the information required for
approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference.
We intend to seek FDA approval through the Section 505(b)(2) regulatory pathway for Intranasal Epinephrine and may seek this regulatory
pathway for other product candidates that we seek to develop, which we believe could expedite the development program for Intranasal
Epinephrine and other current and future product candidates by potentially decreasing the amount of preclinical and clinical data that
we would need to generate in order to obtain FDA approval. However, while we believe that Intranasal Epinephrine and Intranasal Naloxone
are reformulation of already-approved drugs and, therefore, will be eligible for submission of an NDA under Section 505(b)(2), the FDA
may disagree and determine that are not eligible for review under such regulatory pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical
trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time
and financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. We may need to obtain additional funding, which could result in significant dilution to the ownership interests of our then
existing shareholders to the extent we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain
such additional financing on terms acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway
could result in new competitive product candidates reaching the market faster than our product candidates, which could materially adversely
impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure
you that our product candidates will receive the requisite approvals for commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain competitors
and others have objected to the FDA&rsquo;s interpretation of Section 505(b)(2). If the FDA&rsquo;s interpretation of Section 505(b)(2)
is successfully challenged, the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent
the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive,
and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved
drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval
of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is also not uncommon for a manufacturer
of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements
for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product.
However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds
to the petition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moreover,
even if and NS002, NS001 or any POC program or future product candidates are approved under the Section 505(b)(2) pathway, as the case
may be, the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions
of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may seek designations for our product candidates with the FDA and other comparable regulatory authorities that are intended to confer
benefits such as a faster development process or an accelerated regulatory pathway, but there can be no assurance that we will successfully
obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able
to realize the intended benefits of such designations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
FDA, and other comparable regulatory authorities, offer certain designations for product candidates that are intended to encourage the
research and development of pharmaceutical products addressing conditions with significant unmet medical need. These designations may
confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority
review. There can be no assurance that we will successfully obtain any such designation for our products. In addition, while such designations
could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations
for one or more of our product candidates, there can be no assurance that we will realize their intended benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
example, we may seek a Breakthrough Therapy designation from the FDA for one or more of our product candidates. A Breakthrough Therapy
designation is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or
life-threatening disease or condition, if preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. For therapies that have Breakthrough Therapy designation, interaction and communication between the FDA and the sponsor
of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in
ineffective control regimens. Therapies with Breakthrough Therapy designation from the FDA are also eligible for accelerated approval.
Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates
meets the criteria for Breakthrough Therapy designation, the FDA may disagree and instead determine not to make such designation. In
any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process,
review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our product candidates qualify for Breakthrough Therapy designation, the FDA may later
decide that such product candidates no longer meet the conditions for qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
may also seek Fast Track designation from the FDA for some of our product candidates. If a therapy is intended for the treatment of a
serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the
therapy sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even
if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to
grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared
to conventional FDA procedures, and receiving a Fast Track Designation does not provide assurance of ultimate FDA approval. The FDA may
withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage
clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed
or in later stage trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through
preclinical studies and initial clinical trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately
be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biologics
proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development
could harm our business and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Interim,
topline and preliminary data from our clinical trials that we announce or publish may change as more patient data become available and
are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical
trials may change as more patient data become available. Preliminary or interim data from our clinical trials are not necessarily predictive
of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change
as patient enrollment continues, more patient data become available, and we issue our final clinical trial report. Interim, topline and
preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data we previously published. As a result, preliminary and interim data should be viewed with caution until the
final data are available. Adverse changes in the final data compared to the interim data could significantly harm our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information,
and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure,
and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions,
views, activities or otherwise regarding a particular product, product candidate or our business. If the preliminary and interim data
that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our
ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results,
prospects or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to ongoing regulatory oversight.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if we obtain any regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information.
Any regulatory approvals that we receive for our product candidates also may be subject to a REMS, limitations on the approved indicated
uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. The holder of
an approved marketing application also must submit new or supplemental applications and obtain FDA approval for certain changes to the
approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are
subject to FDA review, in addition to other potentially applicable federal and state laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, requirements and adherence
to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems
with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured
or disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that
product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we fail to comply with applicable regulatory requirements, a regulatory authority may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue an untitled letter or warning letter that we
    are in violation of the law; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek an injunction or impose administrative, civil
    or criminal penalties or monetary fines;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw regulatory approval;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend any ongoing clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to approve pending applications or supplements
    to applications;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict the marketing or manufacturing of the product;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize or detain the products or require the withdrawal
    of the product from the market;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to permit the import or export of the products;
    or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to allow us to enter into supply contracts,
    including government contracts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing
business outside of the United States, Israel or the EU.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
than our headquarters and other operations which are located in Israel, we currently have limited international operations, but our business
strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product candidates.
We may plan to maintain sales representatives and conduct physician and patient association outreach activities, as well as clinical
trials, outside of the United States, Israel and Europe. If our products are approved for commercialization outside the United States,
Israel, or the EU, we will likely enter into agreements with third parties to market the drugs in these additional global territories.
We expect that we will be subject to additional risks related to entering into or maintaining international business relationships, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">different regulatory requirements
    for drug approvals in foreign countries;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing United States
    and foreign drug import and export rules, tariffs and other trade barriers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced protection for
    intellectual property rights in foreign countries;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain
    regulatory approvals for the use of our products in various countries;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">different reimbursement
    systems;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including
    inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and
    changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory
    requirements and other governmental approvals, permits and licenses;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated
    with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as
    longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and
    payment for our products and exposure to foreign currency exchange rate fluctuations, which could result in increased operating expenses
    and reduced revenues;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in
    countries where labor unrest is more common than in the United States;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting
    from any events affecting raw material supply or manufacturing capabilities abroad;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance
    risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the
    U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions or its anti-bribery provisions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential liability resulting
    from development work conducted by these distributors; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions
    resulting from a local or worldwide pandemic, such as COVID-19, geopolitical actions, including war and terrorism, or natural disasters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even
if any of our product candidates receives marketing approval, they may fail to achieve the degree of market acceptance by physicians,
patients, third-party payors, pharmacists and others in the medical community necessary for commercial success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
commercial success of our products will depend upon the acceptance of each product by the medical community, including physicians, patients
and third-party payors. The degree of market acceptance of any approved product will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the efficacy and safety
    of the product;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential advantages
    of the product compared to available therapies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the convenience and ease
    of administration compared to alternative treatments;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or warnings,
    including use restrictions contained in the product&rsquo;s approved labeling;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution and use restrictions
    imposed by the EMA, FDA or other regulatory authority or agreed to by us as part of a mandatory or voluntary risk management plan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing and cost effectiveness
    in relation to alternative treatments;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the product is included
    under physician treatment guidelines as a first-, second,- or third-line therapy;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the strength of sales,
    marketing and distribution support;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of third-party
    coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of coverage by third-party
    payors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the strength of sales,
    marketing and distribution support;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of patients
    to pay for drugs out of pocket in the absence of third-party coverage; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of the
    target patient population to try new therapies and of physicians to prescribe these therapies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
our products are approved but do not achieve an adequate level of acceptance by physicians, third party payors and patients, we may not
generate sufficient revenue from the product, and we may not become or remain profitable. In addition, our efforts to educate the medical
community and third-party payors on the benefits of the product may require significant resources and may never be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either
to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we enter into
arrangements with third parties to perform sales, marketing and distribution services for our products, the resulting revenues or the
profitability from these revenues to us are likely to be lower than if we had sold, marketed and distributed our products ourselves.
If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize any
of our product candidates that receive regulatory approval. Depending on the nature of the third-party relationship, we may have little
control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell, market
and distribute our products effectively. If we are not successful in commercializing our product candidates, either on our own or through
collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
currently have no marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements
with third parties to market and sell our product candidates, we may be unable to generate any product revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have no experience selling and marketing our product candidates, and we currently have no marketing or sales organization. To successfully
commercialize any product candidates that may result from our development programs, we will need to develop these capabilities, either
on our own or with others. If our product candidates receive regulatory approval, we intend to establish a sales and marketing organization
independently or by utilizing experienced third parties with technical expertise and supporting distribution capabilities to commercialize
our product candidates in major markets, all of which will be expensive, difficult and time consuming. Any failure or delay in the development
of our internal sales, marketing and distribution capabilities would adversely impact our ability to commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
given our lack of prior experience in marketing and selling pharmaceutical products, our initial estimate of the size of the required
sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our product
candidates. As such, we may be required to hire sales representatives and third-party distributors to adequately support the commercialization
of our product candidates, or we may incur excess costs if we hire more sales representatives than necessary. With respect to certain
geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities,
but we may be unable to enter into such agreements on favorable terms, if at all. We also may enter into collaborations with large pharmaceutical
companies to develop and commercialize product candidates. If our future collaborators do not commit sufficient resources to develop
and commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will
be unable to generate sufficient product revenue to sustain our business. We may compete with companies that currently have extensive
and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales
functions, we may be unable to compete successfully against these more established companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
efforts to educate the medical community, including physicians, hospital pharmacists and third-party payors on the benefits of our product
candidates may require significant resources and may never be successful. If any of our product candidates are approved but fail to achieve
market acceptance among physicians, patients or third-party payors, we will not be able to generate significant revenues from such product,
which could have a material adverse effect on our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even
if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations or third-party
coverage and reimbursement policies, any of which could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and reimbursement
for these products and related treatments will be available from government health administration authorities, private health insurers
and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations,
decide which medications they will pay for and impact reimbursement levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Obtaining
and maintaining adequate reimbursement for our products may be difficult. We cannot be certain if and when we will obtain an adequate
level of reimbursement for our products by third party payors. Even if we do obtain adequate levels of reimbursement, third-party payors,
such as government or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge the prices
charged for, drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and
other factors. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party
payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for drugs. We may also be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement
or the level of reimbursement relative to other therapies. If coverage and reimbursement are not available or reimbursement is available
only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval,
and the royalties resulting from the sales of those products may also be adversely impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for
which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement
does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may
not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may
be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services.
Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and
by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than
in the United States. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private
payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise
capital needed to commercialize products and our overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country.
Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause
delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be reimbursed. In many countries,
the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription drug
pricing remains subject to continuing governmental control, including possible price reductions, even after initial approval is granted.
As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that
delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate
from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more
product candidates, even if our product candidates obtain marketing approval. There can be no assurance that our product candidates,
if they are approved for sale in the United States or in other countries, will be considered medically necessary or cost-effective for
a specific indication, or that coverage or an adequate level of reimbursement will be available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
face intense competition in an environment of rapid technological change and the possibility that our competitors may develop products
and drug delivery systems that are similar, more advanced or more effective than ours. As a result, we may be unable to effectively compete
in our industry, which may adversely affect our financial condition and our ability to successfully market or commercialize our product
candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
pharmaceutical industry in which we operate is intensely competitive and subject to rapid and significant technological change. We are
currently aware of various existing therapies in the market and in development that may in the future compete with our product candidates,
including other products that address opioid overdose or anaphylactic shock, as well as other drug delivery mechanisms. Other approaches
may also emerge for the prevention or treatment of any of the indications on which we focus, and new technologies may emerge in localized
drug delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have competitors both in the United States and internationally, including major multinational pharmaceutical companies and specialty
pharmaceutical companies. The major market players within the intranasal drug market and our primary competitors in the United States
and abroad include ADAPT Pharma, Inc., Teva Pharmaceuticals Ltd., Pfizer Inc., Viatris Inc., and Kal&eacute;o, Inc., among others. Some
of these companies hold significant market share. Their dominant market position and significant control over the market could significantly
limit our ability to introduce or effectively market and generate sales and capture market share. Many of our competitors have long histories
and strong reputations within the industry. They have significantly greater brand recognition, financial and human resources than we
do. They also have more experience and capabilities in researching and developing medical devices, obtaining and maintaining regulatory
clearances, manufacturing and marketing those products and other resources, than we do. There is a significant risk that we may be unable
to overcome the advantages held by our competition, and our inability to do so could lead to the failure of our business and the loss
of your investment. In addition, we may be unable to develop additional products in the future or to keep pace with developments and
innovations in the market and lose market share to our competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
competitors may succeed in developing, acquiring or licensing on products that are more effective or less costly than any product candidate
that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than
we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete,
and we may not be successful in marketing our product candidates against competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
competition in the pharmaceutical industry is intense, and can lead to, among other things, price reductions, longer selling cycles,
lower product margins, loss of market share and additional working capital requirements. To succeed, we must, among other critical matters,
gain consumer acceptance for our products, as compared to other solutions currently available in the market. For example, since the currently
accepted treatment for opioid overdose and anaphylactic shock are Narcan (Naloxone HCI) and the EpiPen (Epinephrine Injection USP), respectively,
we will need to invest resources in educating the medical community and consumers, and establish strategic collaborations before we will
be able to gain market acceptance for our Intranasal Epinephrine and Intranasal Naloxone as a treatment in severe acute emergency situations.
If our competitors offer significant discounts on certain products and solutions, we may need to lower our prices or offer other favorable
terms in order to compete successfully. Moreover, any broad-based changes to our prices and pricing policies could make it difficult
to generate revenues or cause our revenues to decline. Moreover, if our competitors develop and commercialize products and solutions
that are more effective or desirable than products and solutions that we may develop, we may not convince our customers to use our products
and solutions. Any such changes would likely reduce our commercial opportunity and revenues potential and could materially adversely
impact our operating results. See &ldquo;<I>Business Overview - Competition.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses. The misuse
or off-label use of our products may harm our reputation in the marketplace, result in injuries that may lead to product liability suits
or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these
uses, any of which could be costly to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become
subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about
prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information
about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory
agencies as reflected in the product&rsquo;s approved labeling. If we are found to have promoted such off-label uses, we may become subject
to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion
of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter
into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed
or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant
liability, which would materially adversely affect our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
advertising and promotion of our products that obtain marketing approval in the United States may be heavily scrutinized by the FDA,
the U.S. Department of Justice, or DOJ, U.S. Department of Health and Human Services, or HHS, state attorneys general, members of Congress,
and the public. In addition, advertising and promotion of any product that obtains approval outside of the United States may be heavily
scrutinized by comparable foreign regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect that, if cleared or approved, our products, will be cleared by the requisite regulatory authorities for specific indications.
We expect to train our marketing personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications
for use, known as &ldquo;off-label uses.&rdquo; We cannot, however, prevent a physician from using our devices off-label, when in the
physician&rsquo;s independent professional medical judgment, he or she deems it appropriate. There may be increased risk of injury to
patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices for indications other than those approved
by the FDA or approved by any foreign regulatory body may not effectively treat such conditions, which could harm our reputation in the
marketplace among healthcare providers and patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the FDA or any state or foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label
use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including
the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure,
civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action
under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label
use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages,
fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. We may become
subject to such actions and, if we are not successful in defending against such actions, those actions may have a material adverse effect
on our business, financial condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, if our products are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are
not adequately trained, potentially leading to injury and an increased risk of product liability. If our products are misused or used
with improper technique, we may become subject to costly litigation by our customers or their patients. As described above, product liability
claims could divert management&rsquo;s attention from our core business, be expensive to defend and result in sizeable damage awards
against us that may not be covered by insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
product liability lawsuits are brought against us, we may incur substantial liabilities, even if we have appropriate insurance policies,
and we may be required to limit commercialization of our product candidates. Product liability or similar claims that could be expensive,
damage our reputation and harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing and use of pharmaceutical products. Currently, we have no products that have been approved for marketing or commercialization;
however, the use of our product candidates in clinical trials, and the sale of these product candidates, if approved, in the future,
may expose us to liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our
clinical trials, patients, health care providers, pharmaceutical companies, our collaborators or others using, administering or selling
any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities,
even if we have product liability or such other applicable insurance policies in effect. We may not be able to maintain adequate levels
of insurance for these liabilities at reasonable cost and/or reasonable terms. Excessive insurance costs or uninsured claims would add
to our future operating expenses and adversely affect our financial condition. As a result of such lawsuits and their potential results,
we may be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims
may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our
    product candidates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination of clinical
    trial sites or entire trial programs;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury to our reputation
    and negative media attention;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls or increased
    warnings on product labels;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical
    trial participants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of to defend the
    related litigation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management
    and our resources;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards
    to, or costly settlements with, clinical trial participants, patients or other claimants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher insurance premiums;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of initiation of investigations
    by regulators or other authorities; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to successfully
    commercialize our product candidates, if approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
our business exposes us to an inherent risk of potential product liability or similar claims. The pharmaceutical industry has historically
been litigious, and we face financial exposure to product liability or similar claims if the use of any of our products were to cause
or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our products might
necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of these policies may not
be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at
reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim,
regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer
dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against us in excess
of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may be subject to litigation for a variety of claims, including class actions, which could adversely affect our results of operations,
harm our reputation or otherwise negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may be subject to litigation for a variety of claims, including class actions and contract claims, arising from our normal business activities.
These may include claims, suits, and proceedings involving labor and employment, wage and hour, commercial, contractual and other matters.
For example, on October 5, 2022, we received a termination notice from Aptar Group Inc., or Aptar, in connection with an alleged breach
of our contractual obligations with Aptar under a master services agreement, or MSA, we entered into with Aptar on September 6, 2019.
We timely responded to such notice, exchanged correspondence with Aptar through February 2023 and have been unable to resolve the claims
and allegations made by each party. Since February 2023, we have continued to purchase products from Aptar under our MSA and related
schedules of work and,&nbsp;as of April 16, 2025, we have not received any further notices, demands or claims from Aptar.
Termination of the MSA with Aptar could result in significant delays to our commercialization efforts and adversely harm our business,
operating results, and financial condition. See &ldquo;<I>Business&mdash;Our Solution&mdash;Aptar UDS and collaboration</I>&rdquo; for
further information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
outcome of any litigation, regardless of its merits, is inherently uncertain. Further, we are unable to predict whether unknown claims
and lawsuits may be brought against us that could become material. Any claims and lawsuits, and the disposition of such claims and lawsuits,
could be time-consuming and expensive to resolve, divert management attention and resources, and lead to attempts on the part of other
parties to pursue similar claims. Any adverse determination related to litigation could adversely affect our results of operations, harm
our reputation or otherwise negatively impact our business. In addition, depending on the nature and timing of any such dispute, a resolution
of a legal matter could materially affect our operating results, cash flows and our ability to raise capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. Our failure to obtain regulatory approval in foreign jurisdictions
would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United
States would not assure approval of product candidates in foreign jurisdictions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding clinical trial design, safety and efficacy. The research, testing, manufacturing, labeling, approval, sale,
marketing and distribution of drugs are subject to extensive regulation by the FDA in the United States and other regulatory authorities
in other countries. These regulations differ from country to country. Even if we obtain and maintain regulatory approval of our product
candidates in one jurisdiction, such approval does not guarantee that we will be able to obtain or maintain regulatory approval in any
other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory
approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United
States, including additional nonclinical studies or clinical trials as investigations conducted in one jurisdiction may not be accepted
by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved
for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our
products is also subject to approval. These regulatory procedures can result in substantial delays in such countries. In other countries,
product approval depends on showing superiority to an approved alternative therapy. This can result in significant expense for conducting
complex clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we, or any third parties with whom we work, fail to comply with regulatory requirements in United States or international markets or
to obtain and maintain required approvals or if regulatory approvals in international markets are delayed, our target market may be reduced
and our ability to realize the full market potential of our products will likely be harmed. The inability to meet continuously evolving
regulatory standards for approval may result in our failing to obtain regulatory approval to market our current product candidates, which
could significantly harm our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
market is subject to intense competition, which may result in others commercializing products before or more successfully than us. If
we are unable to compete effectively, our products may be rendered non-competitive or obsolete, which may adversely affect our operating
results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
development and commercialization of new products is highly competitive. Our potential competitors include major pharmaceutical companies,
specialty pharmaceutical companies and biotechnology companies worldwide with respect to our intranasal powder products or any future
product candidate that we may seek to develop or commercialize. Our competitors may succeed in developing, acquiring or licensing technologies
and products that are more effective, have fewer or more tolerable side effects or are more convenient or less costly than our products
or any future product candidate we may develop, which could render any product candidates obsolete and non-competitive. Our competitors
also may obtain FDA or other marketing approval for their products before we are able to obtain approval for ours, which could result
in competitors establishing a strong market position before we are able to enter the applicable market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Many
of our potential competitors, alone or with their strategic partners, have significantly greater financial resources and expertise in
research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and commercializing
approved products than we do. There is a trend toward consolidation in the pharmaceutical and biotechnology industry, and additional
mergers and acquisitions in these industries may result in even more resources being concentrated among a smaller number of our competitors,
which may adversely affect us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These companies also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical trial sites and patient registration for clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, if we enter the markets of our product candidates, with such entrance remaining subject to various additional regulatory approvals,
too late in the cycle, we may not achieve commercial success, or we may have to reduce our price in order to effectively compete, which
would impact our ability to generate revenue, obtain profitability and adversely affect our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Legislative
or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or
approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory clearance or approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations
and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new
regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product
candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated,
enacted or adopted may have on our business in the future. Such changes could, among other things, require:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to manufacturing
    methods;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">change in protocol design;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional treatment arm
    (control);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall, replacement, or
    discontinuance of one or more of our products; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional recordkeeping.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, in the United States, there have been a number of legislative and regulatory proposals to change the health care system in
ways that could affect our ability to sell our products profitably. The pharmaceutical industry in the United States, as an example,
has been affected by the passage of the Patient Protection and Affordable Care Act, or Affordable Care Act, which, among other things,
imposed new fees on entities that manufacture or import certain branded prescription drugs and expanded pharmaceutical manufacturer obligations
to provide discounts and rebates to certain government programs. There have been executive, judicial and Congressional challenges to
certain aspects of the Affordable Care Act. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural
grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &ldquo;individual mandate&rdquo; was repealed
by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things,
extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year
2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program beginning in 2025 by significantly lowering
the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject
to judicial or Congressional challenges in the future. It is unclear how any such challenges and any potential future healthcare reform
measures of the Trump administration will impact the Affordable Care Act and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. These changes include,
among others, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in 2013 and,
due to subsequent legislative amendments to the statute, will remain in effect until 2032 unless additional Congressional action is taken.
Congress is considering additional health reform measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
there has been particular and increasing legislative and enforcement interest in the United States with respect to drug pricing practices
in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively short
time periods. There have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed bills designed
to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
example, in July 2021, the Biden administration released an executive order, &ldquo;Promoting Competition in the American Economy,&rdquo;
with multiple provisions aimed at prescription drugs. In response to President Biden&rsquo;s executive order, on September 9, 2021, the
Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles
for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS can take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the price of certain
high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023.
On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug
price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional drugs covered
under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare
Drug Price Negotiation Program. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on
the pharmaceutical industry. Further in response to the Biden administration&rsquo;s October 2022 executive order, on February 14, 2023,
HHS released a report outlining three new models for testing by the Centers for Medicare &amp; Medicare Services, or CMS, Innovation
Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is
unclear whether the models will be utilized in any health reform measures in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in
rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft
Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product
as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised,
it is uncertain if that will continue under the new framework. Individual states in the United States have also become increasingly active
in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and in some cases,
designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&rsquo;s
Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear
how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the
United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation
plans, when implemented, may result in lower drug prices for products covered by those programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the future, there will likely continue to be proposals relating to the reform of the U.S. healthcare system, some of which could further
limit coverage and reimbursement of drug products, including our product candidates. Any reduction in reimbursement from Medicare or
other government programs may result in a similar reduction in payments from private payors. Our results of operations could be adversely
affected by the Affordable Care Act and by other health care reforms that may be enacted or adopted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the delivery of healthcare in the European Union, including the establishment and operation of health services, is almost exclusively
a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and
approaches to the delivery of health care and the pricing and reimbursement of products in that context. Coupled with ever-increasing
EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay additional marketing
approval of product candidates or any initial marketing approval for our current or any future product candidates, restrict or regulate
post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted
in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our
business. The pendency or approval of such proposals or reforms could result in a decrease in the price of our Ordinary Shares or limit
our ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization of
our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Inadequate
funding for the FDA and other government agencies and/or potentially shifting priorities under the new administration could hinder the
FDA&rsquo;s and/or those other government agencies&rsquo; ability to hire and retain key leadership and other personnel, prevent new
products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing
normal business functions on which the operation of our business may rely, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
ability of the FDA to review and approve new products, provide feedback on clinical trials and development programs, meet with sponsors
and otherwise review regulatory submissions can be affected by a variety of factors, including government budget and funding levels;
ability to hire and retain key personnel and accept the payment of user fees; and statutory, regulatory, and policy changes, among other
factors. Average review times at the agency may fluctuate as a result. In addition, government funding of other government agencies on
which our operations may rely is subject to the political process, which is inherently fluid and unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disruptions
at the FDA and other agencies may also increase the time necessary for new drugs to be reviewed and/or approved by necessary government
agencies or to otherwise respond to regulatory submissions, such as our future-planned NDA submission for NS002, which would adversely
affect our business. For example, the&nbsp;Trump&nbsp;administration has discussed several changes to the reach and oversight of the
FDA, which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and
availability of prescription drugs. Additionally, over the last several years, the U.S. government has shut down multiple times and certain
regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities.
If funding for the FDA is reduced, FDA priorities change, or a prolonged government shutdown occurs, it could significantly impact the
ability of the FDA to timely review and process our regulatory submissions, including our future-planned NDA submission for NS002, which
could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Failure
to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might
require us to recall or withdraw a product from the market.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
after we achieve regulatory approvals to market our products in certain countries, we are still subject to ongoing and pervasive regulatory
requirements governing, among other things, the manufacture, marketing, advertising, sale, promotion, import, export, and registration.
In addition, if we receive additional regulatory approvals to market our products, we will likewise remain subject to ongoing regulation.
Failure to comply with these regulations could result in enforcement action by the FDA. Following its review of the periodic reports,
the FDA might ask for additional information or initiate further investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions
on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have
obtained the proper regulatory clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign
laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable
regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any
of the following sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled letters or warning
    letters;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, injunctions, consent
    decrees and civil penalties;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, termination of
    distribution, administrative detention, or seizure of our products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notifications
    or repair, replacement or refunds;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions
    or partial suspension or total shutdown of production;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in or refusal to
    grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended uses, or
    modifications to existing products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals or suspensions
    of product clearances or approvals, resulting in prohibitions on sales of our products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA refusal to issue certificates
    to foreign governments needed to export products for sale in other countries; and criminal prosecution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on
our reputation, business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the FDA or state or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise
existing regulations, or take other actions, which may prevent or delay clearance or approval of our future products under development
on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain
new clearances or approvals, increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Environmental,
social and corporate governance (ESG) issues, including those related to climate change and sustainability, may have an adverse effect
on our business, financial condition and results of operations and damage our reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally,
public interest and legislative pressure related to public companies&rsquo; ESG practices continue to grow. If our ESG practices fail
to meet regulatory requirements or investor, customer, consumer, employee or other stakeholders&rsquo; evolving expectations and standards
for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director
and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate
governance and transparency, our reputation, brand and employee retention may be negatively impacted, and our customers and suppliers
may be unwilling to continue to do business with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Customers,
consumers, investors and other stakeholders are increasingly focusing on environmental issues, including climate change, energy and water
use, plastic waste and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory
requirements to reduce or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements
may result in increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic
products and packaging, other components of our products and their environmental impact on sustainability, or increased customer and
consumer concerns or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products.
Complying with these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we do not adapt to or comply with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns
regarding ESG issues, investors may reconsider their capital investment in our Company, and customers and consumers may choose to stop
purchasing our products, which could have a material adverse effect on our reputation, business or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
are dependent on manufacturers for Epinephrine and other formulations. Any delay, price increase or unavailability of our manufacturers
could materially adversely affect our ability to conduct clinical trials and, if this were to occur after we obtained commercialization
and marketing approval, could materially impact our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
FDA requires identification of raw material suppliers in applications for approval of drug products. If Epinephrine and other formulations
were unavailable from a specified manufacturer, FDA approval of a new manufacturer, assuming one is found, could delay the manufacture
of the drug involved or delay any clinical trial we are then conducting or planning to conduct. Either such occurrence could have an
adverse effect on our operations and reputation and could materially impact our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
there is a risk of a sole approved manufacturer significantly raising prices. If prices for raw materials were to be significantly increased,
our profit margins and sales, if any, would be greatly reduced and, assuming our products were approved for commercialization or marketing,
delay product launches, or delay clinical trials at earlier stages of development. Such price increase occurrences could be resolved
by the successful FDA approval of an alternate supplier; however, such approval process can be lengthy and costly. There can be no guarantee
that a resolution would be reached in the event of a significant price increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may
not be able to find replacements or immediately transition to alternative suppliers on a cost-effective basis, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
source components of our technology from third parties and certain components are sole sourced. Obtaining substitute components may be
difficult or require us to re-design our products. For example, we rely on Aptar, a leading global manufacturer of inhalers, as sole
supplier for supply of its intranasal Unit Dose Spray product, or UDS, to be the delivery system for our Intranasal Epinephrine powder
and Intranasal Naloxone powder. If Aptar is unable to supply UDS to us in the quantities we require, or at all, or otherwise default
on their supply obligations to us, we may not be able to obtain alternative supplies from other suppliers on acceptable terms in a timely
manner. In addition, if we are required to change UDS manufacturers for any reason, we will be required to verify that the new manufacturer
maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also
need to verify, such as through a manufacturing comparability study, that any new manufacturer or manufacturing process for UDS will
produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. A change
in manufacturer may also require the conduct of additional clinical trials. The delays associated with the verification of a new manufacturer
could negatively affect our ability to develop product candidates in a timely manner or within budget.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
any natural or other disasters, epidemic or pandemic, acts of war or terrorism, shipping embargoes, labor unrest or political instability
or similar events at our third-party suppliers&rsquo; facilities that cause a loss of manufacturing capacity or a reduction in the quality
of the items manufactured would heighten the risks that we face. Changes to, failure to renew or termination of our existing agreements
or our inability to enter into new agreements with other suppliers could result in the loss of access to important components of our
tests and could impair, delay or suspend our commercialization efforts. Our failure to maintain a continued and cost-effective supply
of high-quality components could materially and adversely harm our business, operating results, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
rely on third parties to conduct our pre-clinical and clinical studies and perform other tasks for us. If these third parties do not
successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to
obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing pre-clinical and clinical
programs. We rely on these parties for execution of our pre-clinical and clinical studies, and control only certain aspects of their
activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol,
legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and
our CROs and other vendors are required to comply with current cGMP, Good Clinical Practices, or GCP, quality system requirements, or
QSR, and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the
Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical
development. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators,
study sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data
generated in our clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require
us to perform additional clinical studies before approving our marketing applications. We cannot assure you that upon inspection by a
given regulatory authority, such regulatory authority will determine that any of our clinical studies comply with GCP regulations. In
addition, our clinical studies must be conducted with product candidates which are produced under cGMP regulations. Our failure to comply
with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
have limited manufacturing experience and could experience production problems that result in delays in our development or commercialization
programs or otherwise adversely affect our business. We currently have no manufacturing facilities and anticipate reliance on third-party
manufacturers for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have limited experience manufacturing NS002 and NS001. We are currently only able to produce clinical trial material up to and including
Phase 2 studies of our products. We may be unable to produce commercial materials or meet demand for our product candidates if we are
unable to receive or maintain commercial regulatory approvals for our facility. Any such failure could delay or prevent our development
of our products and would have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
either of our product candidates is approved, we may need to increase the scale or capacity of our manufacturing process. We currently
do not have manufacturing facilities capable of producing our product candidates on a commercial scale and do not intend to develop facilities
for the manufacture of products for commercial purposes in the foreseeable future. We will rely on third-party manufacturers to produce
bulk drug products required for our Phase 3 clinical trials and commercial sales, if any. We plan to rely upon contract manufacturers
and, potentially, collaboration partners to manufacture commercial quantities of our drug product candidates if and when approved for
marketing by the applicable regulatory authorities. The use of new manufacturers may require obtaining new approvals. Our contract manufacturers
will need to complete process validation for the drug substance manufacturing process. Process validation involves a series of activities
taking place over the lifecycle of the product and process. If our contract manufacturers are not approved by the FDA, or other regulatory
bodies, our commercial supply of drug substance will be significantly delayed and may result in significant additional costs. If the
FDA does not consider the result of the process validation or required testing to be satisfactory, regulatory approval and/or commercial
supply after launch may be delayed. The FDA and similar foreign regulatory bodies may also implement new requirements, or change their
interpretation and enforcement of existing requirements, for manufacturers, packaging or testing of products at any time. If we, or our
contract manufacturers are unable to comply with such process validation or other requirements, we may be subject to regulatory, civil
actions or penalties which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business. In the event of a natural
disaster, business failure, strike or other difficulty, such as difficulties involving production yields, quality control and quality
assurance, we may be unable to replace a third-party manufacturer in a timely manner and the production of any product candidate or commercialized
drug would be interrupted, resulting in delays and additional costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we collaborate with contract manufacturers located outside of the United States, we may face difficulties in importing our drug substances
into the United States as a result of, among other things, FDA import inspections, incomplete or inaccurate import documentation or defective
packaging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
we may not be successful in producing sufficient quantities of our products, due to several factors, including equipment malfunctions,
facility contamination, technical process challenges, raw material shortages or contamination, natural disasters, disruption in utility
services, human error or disruptions in the operations of our suppliers. Problems with the manufacturing process, even minor deviations
from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product
liability claims or insufficient inventory. We may encounter problems achieving adequate quantities and quality of clinical- and commercial-grade
materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Slight
deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes
in the product that could result in lot failures or product recalls. There is no assurance we will not experience such failures at our
own manufacturing facility or that of a third party in the future. Lot failures or product recalls could cause delays in product supply
or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
also may encounter problems hiring and retaining the experienced specialist scientific, quality assurance, quality control and manufacturing
personnel needed to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining
compliance with applicable regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including pharmaceutical
companies, which could limit our access to additional attractive development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
and our potential collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product
candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Manufacturers
and their facilities are required to comply with extensive regulatory requirements, including ensuring that quality control and manufacturing
procedures conform to cGMPs. These cGMP regulations cover all aspects of manufacturing relating to our product candidates. These regulations
govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control
and assure the quality of investigational product candidates and products approved for sale. Poor control of production processes can
lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may
not be detectable in final product testing. We, our potential collaborators or our contract manufacturers must supply all necessary documentation
in support of an NDA or MAA on a timely basis and must adhere to GLP and cGMP QSR regulations enforced by the FDA and other regulatory
authorities through their facilities inspection program. The facilities and quality systems of some or all of our potential and future
collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition
of regulatory approval of our product candidates or any of our other potential product candidates. In addition, the regulatory authorities
may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential
product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted.
We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with
the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the product candidates
may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority,
if ever. Moreover, if our contract manufacturer&rsquo;s fail to achieve and maintain high manufacturing standards, in accordance with
applicable regulatory requirements, or there are substantial manufacturing errors, this could result in patient injury or death, product
shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could
seriously harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Any
collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop
and commercialize our current and potential future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may seek collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of our current
and potential future product candidates. We may enter into these arrangements on a selective basis depending on the merits of retaining
commercialization rights for ourselves as compared to entering into selective collaboration arrangements with other pharmaceutical or
biotechnology companies for each product candidate, both in the United States and internationally. We will face, to the extent that we
decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration
arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish
and implement collaborations or other alternative arrangements should we so choose to enter into such arrangements. The terms of any
collaborations or other arrangements that we may establish may not be favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disagreements
between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the
development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement.
These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Collaborations
with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party.
Any such termination or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Because
we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek
to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements,
collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and
consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third
parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working
with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become
known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&rsquo;s discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect
on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
own several issued patents but may require filing of additional patents in the future. There can be no assurance that all or some of
our patent applications will result in issued patents. Consequently, our ability to protect our proprietary technology in the marketplace
beyond the intellectual property already protected by our currently issued patents may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have filed patent applications in many countries worldwide. These applications cover a range of technological areas including:, compositions
of matter, such as but not limited to pharmaceutical compositions and formulations, comprising multiple active pharmaceutical ingredient/s
(API/s), which may be known or novel, specific dosage forms such a dosage unit forms of the compositions of matter, methods of treatment
of various medical/physiological conditions using the compositions of matter, including treatment regimens, and process/es of manufacturing
the pharmaceutical compositions and formulations, and the dosage unit forms. While several patent applications have been granted, others
are still pending. Unless and until our pending patent applications are granted and patents thereon are issued, their protective scope
cannot be established. It is also not possible to predict whether or how many of our patent applications will mature into issued patents.
Even if patents on pending applications are issued, they may be issued with a scope significantly narrower than that we currently seek.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
proprietary position for our product candidates currently depends upon patents protecting the method of use, which may not prevent a
competitor or other third party from using the same product candidate for another use.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
primary patent based intellectual property protection for our product candidates will be patents granted on the formulation and/or pharmaceutical
composition, optionally in dosage unit form/s, and method/s of their use in treating specific medical/physiological conditions. We have
patents and patent applications covering our products as a composition of matter, specifically formulations and pharmaceutical compositions
comprising a desired active pharmaceutical ingredient, or API, such as, but not limited to Epinephrine and Naloxone. We also have
patents and patent applications directed to methods of preparing these compositions of matter, dosage unit forms of these compositions
of matter and methods of treating medical conditions using them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Composition
of matter patent claims on the active pharmaceutical ingredient (API), <I>per se</I> or comprised in pharmaceutical drug products are
generally considered to be the favored intellectual property protection for pharmaceutical products, as such patents provide protection
irrespective of any particular method of use, manufacture or formulation of the API used. Method of use patent claims protect the use
of a product, which may be the API or a composition/formulation comprising the same, for a defined indication, by the specified method,
which may be limited, for example, to route of administration/application and/or dosing regimen. These types of patent claims do not
prevent a competitor or other third party from making and marketing an identical API or composition comprising the API, for treating
an indication that is outside the scope of the method claims or from developing a different dosing regimen. Moreover, even if competitors
or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians
may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute
to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even
if our patents are issued, because the patent status of pharmaceutical products can be complex and uncertain, we cannot predict the scope
and extent of patent protection for our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
patents that may be issued to us will not ensure the protection of our intellectual property for a number of reasons, including without
limitation the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any issued patents may
    not be broad or strong enough to prevent competition by other drug products including identical or similar drug products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we are not issued patents
    or if issued patents expire, there would be no protection against competitors making generic equivalents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be prior art
    of which we are not aware that may affect the validity or enforceability of a patent claim throughout the patent term;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be other patents
    existing, now or in the future, in the patent landscape for PBI products, or any other product candidates that we seek to commercialize
    or develop, if any, that will affect our freedom to operate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if our patents are challenged,
    a court could determine that they are not valid or enforceable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a court could determine
    that a competitor&rsquo;s technology or product does not infringe our patents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a court could determine
    we infringe a competitor&rsquo;s patents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our patents could irretrievably
    lapse due to failure to pay fees or otherwise comply with regulations, or could be subject to compulsory licensing; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we encounter delays
    in our development or clinical trials, the period of time during which we could market our products under patent protection would
    be reduced.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental or other patent authorities, and our patent protection could be reduced or eliminated for noncompliance with
these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Periodic
maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent authorities at several stages over the term
of the patent. The U.S. PTO and various foreign governmental or other patent authorities require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases
be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but
are not limited to, failure to respond to office actions within prescribed time limits, non-payment of fees and failure to properly legalize
and submit formal documents. In any such events, our competitors might be able to enter the market, which would have a material adverse
effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may not be able to enforce our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filing,
prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States and Israel can be less extensive than those in the United States
and Israel. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as laws in the United
States and Israel. Consequently, we may not be able to seek to prevent third parties from practicing our inventions in all countries
outside the United States and Israel, or from selling or importing products made using our inventions in and into the United States or
other jurisdictions. Competitors, for example, may use our technologies in jurisdictions where we have not obtained patents to develop
their own products and further, may export otherwise infringing products to territories where we have patents, but enforcement is not
as strong as that in the United States and Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Many
companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal
systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property, particularly those relating to medical devices and pharmaceutical and biotechnology products,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary
rights generally. To date, we have not sought to enforce any issued patents in any jurisdictions. Proceedings to enforce our patent rights
in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could
put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing
countries. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which
a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies
if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish
the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
we are unable to maintain effective proprietary rights for our product candidates, we may not be able to compete effectively in our markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to the protection afforded by any patents currently owned and that may be granted, historically, we have relied on trade secret
protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes
that are not easily known, knowable, understood, analyzed or easily ascertainable, and for which patent infringement is difficult to
monitor and enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how,
information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our
proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific
advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data, trade secrets and intellectual property
by maintaining physical security of our premises and physical and electronic security of our information technology systems. Agreements
or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets and intellectual
property may otherwise become known or be independently discovered by competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed in violation
of our confidentiality agreements or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual
property could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken
to maintain our trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties
for misappropriating any trade secret.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
commercial success depends upon our ability to develop, manufacture, market and sell our platform technology without infringing the proprietary
rights of third parties. There is considerable intellectual property litigation in the medical device and pharmaceutical industries.
While no such litigation has been brought against us to date and we have not been held by any court to have infringed a third party&rsquo;s
intellectual property rights, we cannot guarantee that our technology or use of our technology does not infringe third-party patents.
It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before
November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential
until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest
filing, which is referred to as the priority date. Therefore, patent applications covering our technology could have been filed by others
without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later
amended in a manner that could cover our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect
to our technology, including inter parties review, interference, or derivation proceedings before the U.S. PTO and similar bodies in
other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual
property rights that may be granted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are found to infringe a third party&rsquo;s intellectual property rights, we could be required to obtain a license from such third
party to continue developing and marketing our technology. However, we may not be able to obtain any required license on commercially
reasonable terms or at all. Any inability to secure licenses or alternative technology could result in delays in the introduction of
our products or lead to prohibition of the manufacture or sale of products by us. Even if we were able to obtain a license, it could
be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court
order, to cease commercializing the infringing technology. In addition, we could be found liable for monetary damages, including treble
damages and attorneys&rsquo; fees if we are found to have wilfully infringed a patent. A finding of infringement could prevent us from
commercializing our technology or force us to cease some of our business operations, which could materially harm our business. Claims
that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants
or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims
challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material
adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. In addition, we may receive less revenue from future products if any of our employees
successfully claim for compensation for their work in developing our intellectual property, which in turn could impact our future profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Under
applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their
inventions irrespective of their agreements with us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
generally enter into non-competition agreements with our employees and certain key consultants. These agreements prohibit our employees
and certain key consultants, if they cease working for us, from competing directly with us or working for our competitors or clients
for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees
work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants
developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a
former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests
of the employer which have been recognized by the courts, such as the secrecy of a company&rsquo;s confidential commercial information
or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable to prevent
our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be
diminished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, under Israeli law, if we wish to obtain ownership over inventions developed by our employees, which inventions were developed
while performing their employment activities, but outside the performance of their contractual duties, we are required to compensate
the employee for the rights to their respective inventions. There can be no guarantee that we will be able to obtain any such inventions
and the failure to obtain such ownership rights over employee inventions could have a material adverse effect on our operations and ability
to effectively compete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Our Business and Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
future growth and success depend to a large extent on the continued services of members of our current management including, who each
have valuable and extensive experience and knowledge of the pharmaceutical industry. In particular, Mr. Udi Gilboa, who is our co-founder
and Executive Chairman of the board of directors, Mr. Dan Teleman, who serves as our Chief Executive Officer, Dr. Dalia Megiddo, who
serves as our Chief Development Officer and Chief Medical Officer, Ms. Tair Lapidot, our Vice President of Research and Development and
Clinical Development, and Ms. Galia Temtsin Kryaz, who serves as our Director of Product, have been instrumental in formulating our business
strategies and spearheading the growth of our business and operations. We do not maintain &ldquo;key person&rdquo; insurance for any
of our executives or employees. Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development
of our product pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical
to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our development
and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing
executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals
in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize
products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel
on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience
competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on
consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization
strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory
contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality
personnel, our ability to pursue our growth strategy will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
product candidates for which we intend to seek approval may face competition sooner than anticipated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that
are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar
product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA.
In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference
product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference
product if the FDA approves a full BLA for the competing product containing the sponsor&rsquo;s own preclinical data and data from adequate
and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being
interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
manage our business through a small number of part-time employees and key consultants. We will need to significantly increase the size
of our organization, and we may experience difficulties in managing our planned growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of April 16, 2025, we had one full-time employee (Mr. Dan Teleman), one part-time employee (Ms. Tair Lapidot), three service
providors (Dr. Dalia Megiddo, Mr. Udi Gilboa, and Mr. Oren Elmaliach) and one consultant (Ms. Galia Temtsin Kryaz). Our future growth
and success depend to a large extent on the continued services of members of our current management including, in particular, Mr. Udi
Gilboa, who is our co-founder and Executive Chairman of the board of directors, Mr. Dan Teleman, who serves as our Chief Executive Officer,
Dr. Dalia Megiddo who serves as our Chief Development Officer and Chief Medical Officer, Ms. Tair Lapidot, our Vice President of Research
and Development and Clinical Development, and Ms. Galia Temtsin Kryaz, who serves as our Director of Product. Any of our employees and
consultants may leave our company at any time, subject to certain notice periods. The loss of the services of any of our executive officers
or any key employees or consultants may adversely affect our ability to execute our business plan and harm our operating results. Our
operational success will substantially depend on the continued employment of senior executives, technical staff and other key personnel,
especially given the intense competition for qualified personnel. The loss of key personnel may have an adverse effect on our operations
and financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
we currently have a very limited number of employees, in order to commercialize our products, we will need to substantially increase
our operations, including expanding our employee base of managerial, operational and financial personnel. Any future growth will impose
significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional
employees. To that end, we must be able to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our clinical trials
    and the regulatory process effectively;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop our administrative,
    accounting and management information systems and controls;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire and train additional
    qualified personnel; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">integrate current and additional
    management, administrative, financial and sales and marketing personnel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expansion
will place a significant strain on our financial, management and other resources, and will require us, among other things, to change,
expand and improve our operating, managerial and financial systems and controls and improve coordination between our various corporate
functions. Although we intend to hire a full-time Chief Financial Officer following the consummation of our initial public offering,
we presently rely entirely on one full-time employee, one part-time employee, three service providers and one consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
inability to effectively manage our growth, including the failure of any new personnel we hire to achieve anticipated performance levels,
would have a material adverse effect on our business, consolidated financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among
other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both
the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback
    Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration,
    directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal
    healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal
    false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting,
    or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Health Insurance Portability
    and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud
    any healthcare benefit program and making false statements relating to healthcare matters;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the
    Health Information Technology and Clinical Health Act, and its implementing regulations, which imposes certain requirements relating
    to the privacy, security and transmission of individually identifiable health information;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal physician sunshine
    requirements under Affordable Care Act, requires manufacturers of drugs, devices and medical supplies to report annually to the HHS
    information related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals and
    ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable
    group purchasing organizations;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state law equivalents of
    each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any
    third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical
    industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise
    restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers
    to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
    expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ
    from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">European and other foreign
    law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers,
    and the European General Data Protection Regulation, or GDPR, which became effective in May 2018 and contains new provisions specifically
    directed at the processing of health information, higher sanctions and extra-territoriality measures intended to bring non-EU companies
    under the regulation, including companies like us that conduct clinical trials in the EU; we anticipate that over time we may expand
    our business operations to include additional operations in the EU and with such expansion, we would be subject to increased governmental
    regulation in the EU countries in which we might operate, including the GDPR.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased
their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions,
convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations
that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages,
fines, imprisonment, disgorgement, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid,
reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar
settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of
the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable
laws, they may be subject to similar actions, penalties and sanctions. Efforts to ensure that our business arrangements comply with applicable
healthcare laws and regulations, as well as responding to possible investigations by government authorities, can be time- and resource-consuming
and can divert a company&rsquo;s attention from the business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Current
and future healthcare and other legislation and regulatory reform measures may have a material adverse effect on our business and results
of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and
regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement
for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In
particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare
costs and improve the quality of healthcare.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
industry is highly regulated and changes in law may adversely impact our business, operations or financial results. The Affordable Care
Act is a sweeping measure intended to, among other things, expand healthcare coverage within the United States, primarily through the
imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the
law may affect us and increase certain of our costs. Among the provisions of the Affordable Care Act of importance to our potential product
candidates, the Affordable Care Act established an annual, nondeductible fee on any entity that manufactures or imports specified branded
prescription drugs and biologic agents; expands eligibility criteria for Medicaid programs; increased the statutory minimum rebates a
manufacturer must pay under the Medicaid Drug Rebate Program; created a new Medicare Part D coverage gap discount program; required certain
Affordable Care Act marketplace and other private payor plans to include coverage for preventative services, including vaccinations recommended
by the Advisory Committee on Immunization Practices without cost share obligations (i.e., co-payments, deductibles or co-insurance) for
plan members; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative
clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation
at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, other legislative changes have been adopted since the Affordable Care Act was enacted. These changes include aggregate reductions
in Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013. These reductions went into effect in
April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2031.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare
payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to
providers from three to five years. These laws and new laws may result in additional reductions in Medicare and other healthcare funding,
which could have a material adverse effect on our customers and, accordingly, our financial operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
anticipate that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in
more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products.
Further, there have been, and there may continue to be, judicial and Congressional challenges to certain aspects of the Affordable Care
Act. For example, the U.S. Tax Cuts and Jobs Act of 2017, or TCJA, includes a provision repealing, effective January 1, 2019, the tax-based
shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage
for all or part of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; On June 17, 2021, the U.S. Supreme Court
dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &ldquo;individual
mandate&rdquo; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued
an executive order to initiate a special enrollment period from February 26, 2021 through August 15, 2021 for purposes of obtaining health
insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to
review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the Affordable Care Act. In addition, on August 16, 2022, President Biden signed
the IRA into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable
Care Act marketplaces through plan year 2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program
beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount
program. Additional legislative and regulatory changes to the Affordable Care Act, its implementing regulations and guidance and its
policies, remain possible. However, it remains unclear how any new legislation or regulation might affect the prices we may obtain for
any of our product candidates for which regulatory approval is obtained. Any reduction in reimbursement from Medicare and other government
programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other
healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing
and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and
health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of
products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions
on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory
burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict
or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted
in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our
business. The pendency or approval of such proposals or reforms could result in a decrease in the price of our securities or limit our
ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization of our
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may be subject to securities litigation, which is expensive and could divert management attention.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the past, companies that have experienced volatility in the market price of their shares have been subject to securities class action
litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs
and diversion of management&rsquo;s attention and resources, which could seriously hurt our business. Any adverse determination in litigation
could also subject us to significant liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Unsuccessful
compliance with certain European privacy regulations could have an adverse effect on our business and reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
collection and use of personal health data in the EU is governed by the provisions of the Data Protection Directive, and as of May 2018,
the GDPR. These directives impose several requirements relating to the consent of the individuals to whom the personal data relates,
the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities
and the security and confidentiality of the personal data. The GDPR also extends the geographical scope of EU data protection law to
non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and
new rights for individuals. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national
data protection laws of the EU Member States may result in fines and other administrative penalties. The GDPR introduces new data protection
requirements in the EU and substantial fines for breaches of the data protection rules. The GDPR regulations impose additional responsibility
and liability in relation to personal data that we process, and we intend to put in place additional mechanisms ensuring compliance with
these and/or new data protection rules. In addition, other jurisdictions, including Switzerland, are currently discussing or implementing
regulations similar to GDPR. Changes to these European privacy regulations (and similar regulations in other jurisdictions) and unsuccessful
compliance may be onerous and adversely affect our business, financial condition, prospects, results of operations and reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing
business outside of the United States or Israel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
than our headquarters and other operations which are located in Israel, our business strategy incorporates significant international
expansion, particularly in anticipated expansion of regulatory approvals of our products. Doing business internationally involves a number
of risks, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and
    changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory
    requirements and other governmental approvals, permits and licenses;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain
    regulatory approvals for the use of our products and services in various countries;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially
    relevant third-party patent rights;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties
    in obtaining protection and enforcing our intellectual property;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing
    and managing foreign operations;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated
    with managing multiple regulatory, governmental and reimbursement regimes;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to
    penetrate international markets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as
    longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and
    payment for our products and exposure to foreign currency exchange rate fluctuations;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political
    and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and
    other business restrictions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including,
    among others, expenses for travel, translation and insurance; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance
    risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the
    FCPA, its books and records provisions or its anti-bribery provisions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
management team has limited experience managing a U.S. reporting company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
members of our management team do not have experience or have limited experience managing a publicly traded company in the United States,
interacting with public company investors and complying with the increasingly complex laws pertaining to public companies in the United
States. Our management team may not successfully or efficiently manage our transition to being a public company in the United States
that is subject to significant regulatory oversight and reporting obligations under the U.S. federal securities laws and the continuous
scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention from our senior
management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
business and operations might be adversely affected by security breaches, including any cybersecurity incidents.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
depend on the efficient and uninterrupted operation of our computer and communications systems, and those of our consultants, contractors
and vendors, which we use for, among other things, sensitive company data, including our intellectual property, financial data and other
proprietary business information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
certain of our operations have business continuity and disaster recovery plans and other security measures intended to prevent and minimize
the impact of IT-related interruptions, our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are
vulnerable to damage from cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic
events. We could experience failures in our information systems and computer servers, which could result in an interruption of our normal
business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents
or security breaches can cause interruptions in our operations and can result in a material disruption of our targeted phage therapies,
product candidates and other business operations. The loss of data from completed or future studies or clinical trials could result in
delays in our research, development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur regulatory investigations and redresses, penalties and liabilities
and the development of our product candidates could be delayed or otherwise adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures intended to secure our data against impermissible access and to preserve the integrity and confidentiality
of our data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses,
malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet,
attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security
breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and
cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around
the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our new products development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur material legal claims and liability, including under data privacy
laws such as the GDPR, damage to our reputation, and the further development of our new products could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
though we believe we carry commercially reasonable business interruption and liability insurance, we might suffer losses as a result
of business interruptions that exceed the coverage available under our insurance policies or for which we do not have coverage. For example,
we are not insured against terrorist attacks or cyberattacks. Any natural disaster or catastrophic event could have a significant negative
impact on our operations and financial results. Moreover, any such event could delay the development of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
it is possible that a cybersecurity attack might not be noticed for some period of time. The occurrence of a cybersecurity attack or
incident could result in negative publicity resulting in reputational damage with our shareholders and other stakeholders and/or increased
costs to prevent, respond to or mitigate cybersecurity events. In addition, the unauthorized dissemination of sensitive personal information
or proprietary or confidential information could expose us or other third parties to regulatory fines or penalties, litigation and potential
liability, or otherwise harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to this Offering and the Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
market price of our Ordinary Shares may be highly volatile, and you may not be able to resell your shares at or above the initial public
offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
to this offering, there has not been a public market for our Ordinary Shares. If an active trading market for our Ordinary Shares does
not develop following this offering, you may not be able to sell your shares quickly or at the market price. The initial public offering
price for the Ordinary Shares will be determined by negotiations between us and representative of the underwriters and may not be indicative
of prices that will prevail in the trading market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
trading price of each of our Ordinary Shares is likely to be volatile. The following factors, in addition to other risk factors described
in this section, may have a significant impact on the market price of such securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain the
    approvals necessary to commence further clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory results
    of clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of regulatory
    approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the
    regulatory review process;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of therapeutic
    innovations or new products by us or our competitors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse actions taken by
    regulatory authorities with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes or developments
    in laws or regulations applicable to the treatment of opioid overdose and anaphylactic shock, or any other indication that we may
    seek to develop;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adverse changes to
    our relationship with manufacturers or suppliers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any intellectual property
    infringement actions in which we may become involved;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements concerning
    our competitors or the pharmaceutical industry in general;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commencement of, or
    involvement in, litigation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any major changes in our
    board of directors or management;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit
    and retain qualified regulatory, research and development personnel;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation in the United
    States relating to the sale or pricing of pharmaceuticals;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the depth of the trading
    market in our Ordinary Shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination of the lock-up
    agreements or other restrictions limiting our ability or that of any of our existing shareholders to sell our common shares (or any
    other securities that we may issue, if any) after this offering;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including
    inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions
    resulting from a local or worldwide pandemic, such as COVID-19, geopolitical actions, including war and terrorism, or natural disasters</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the granting or exercise
    of employee share options or other equity awards; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in investors&rsquo;
    and securities analysts&rsquo; perception of the business risks and conditions of our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the stock market in general, and the NYSE American in particular, have experienced extreme price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of small companies. Broad market and industry factors may
negatively affect the market price of our Ordinary Shares, regardless of our actual operating performance. Further, a systemic decline
in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Sales
of a substantial number of our Ordinary Shares in the public market by our existing shareholders could cause our share price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sales
of a substantial number of our Ordinary Shares in the public market or the perception that these sales might occur, could depress the
market price of our common shares and could impair our ability to raise capital through the sale of additional equity securities. We
are unable to predict the effect that sales may have on the prevailing market price of our common shares. While the Ordinary Shares sold
to non-affiliates in this offering will be freely tradable, without restriction, in the public market, substantially all of the Ordinary
Shares owned prior to this offering or purchased in this offering by our existing shareholders are expected to be subject to lock-up
agreements with the underwriters of this offering that restrict the ability of these shareholders&rsquo; to transfer our common shares
held by them for at least six months from the date of this prospectus. These outstanding shares that are subject to lock-up agreements
are expected to become eligible for unrestricted sale upon expiration of the lockup period, as described in the section of this prospectus
entitled &ldquo;<I>Shares Eligible for Future Sale</I>.&rdquo; In addition, shares issued or issuable upon exercise of share options
vested as of the expiration of the lock-up period will be eligible for sale at that time. Sales of shares by these shareholders could
have a material adverse effect on the trading price of our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Raising
additional capital would cause dilution to our existing shareholders and may adversely affect the rights of existing shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and strategic
and licensing arrangements. To the extent that we raise additional capital through the issuance of equity (such as this offering) or
otherwise including through convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation
or other preferences that adversely affect your rights as a shareholder. Future sales of our Ordinary Shares or of securities convertible
into our Ordinary Shares, or the perception that such sales may occur, could cause immediate dilution and adversely affect the market
price of our Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
principal shareholders and management own a significant percentage of our Ordinary Shares and will be able to exert significant influence
over matters subject to shareholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
executive officers, directors, five percent shareholders and their affiliates currently beneficially own approximately 78% of our Ordinary
Shares as of April 16, 2025. Following the completion of this offering, it is expected that our executive officers, directors
and principal shareholders will beneficially own 52% of our Ordinary Shares, assuming no exercise of the underwriters&rsquo; over-allotment
option to purchase additional Ordinary Shares. Therefore, these shareholders, and in particular, <FONT STYLE="background-color: white">our
largest shareholders, </FONT>Ehud Gilboa and Dr. Dalia Megiddo<FONT STYLE="background-color: white">, will have the ability to influence
us through their ownership positions. These shareholders may be able to determine all matters requiring shareholder approval. For example,
these shareholders, acting together, may be able to control elections of directors, amendments of our organizational documents or approval
of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals
or offers for our securities that you may believe are in your best interest as one of our shareholders. </FONT>See &ldquo;<I>Beneficial
Ownership of Principal Shareholders and Management</I>&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Management
will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
management will have broad discretion in the allocation of the net proceeds and could use them for purposes other than those contemplated
at the time of this offering and as described in the section entitled &ldquo;<I>Use of Proceeds</I>.&rdquo; Our management could spend
the proceeds in ways that you do not agree with or that do not improve our results of operations or enhance the value of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>As
a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise
applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors under rules applicable
to domestic U.S. issuers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
status as a foreign private issuer exempts us from compliance with certain SEC laws and regulations and certain regulations of the NYSE
American, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent
director oversight of the nomination of directors and executive compensation. In addition, we will not be required under the Exchange
Act to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities
are registered under the Exchange Act and we will generally be exempt from filing quarterly reports with the SEC. Furthermore, as a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These
exemptions and leniencies will reduce the frequency and scope of information and protections to which you are entitled as an investor.
See &ldquo;<I>Management &ndash; Differences between the Companies Law and NYSE American Requirements</I>&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>As
a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise
applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors under rules applicable
to domestic U.S. issuers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
status as a foreign private issuer exempts us from compliance with certain SEC laws and regulations and certain regulations of the NYSE
American, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent
director oversight of the nomination of directors and executive compensation. In addition, we will not be required under the Exchange
Act to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities
are registered under the Exchange Act and we will generally be exempt from filing quarterly reports with the SEC. Furthermore, as a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These
exemptions and leniencies will reduce the frequency and scope of information and protections to which you are entitled as an investor.
See &ldquo;<I>Management &ndash; Differences between the Companies Law and NYSE American Requirements</I>&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
we were to be characterized as a &ldquo;passive foreign investment company&rdquo; for U.S. tax purposes, U.S. holders of our securities
could have adverse U.S. income tax consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, we will be treated as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in any taxable year
in which either (1) at least 75% of our gross income is &ldquo;passive income&rdquo; or (2) on average at least 50% of our assets by
value produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among
other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale
or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment
of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share
of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into
account. We do not expect to be a PFIC for 2024 and we do not expect to become a PFIC in the future, although there can be no assurance
in this regard. If we are a PFIC in any taxable year during which a U.S. taxpayer holds the securities, such U.S. taxpayer would be subject
to certain adverse U.S. federal income tax rules. In particular,, if the U.S. taxpayer did not make an election to treat us as a qualified
electing fund, or QEF, or make a &ldquo;mark-to-market&rdquo; election, then &ldquo;excess distributions&rdquo; to the U.S. taxpayer,
and any gain realized on the sale or other disposition of the securities by the U.S. taxpayer: (1) would be allocated ratably over the
U.S. taxpayer&rsquo;s holding period for the securities; (2) the amount allocated to the current taxable year and any period prior to
the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each
of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that
year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each
such other taxable year. In addition, if the U.S. Internal Revenue Service, or IRS, determines that we are a PFIC for a year with respect
to which we have determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election.
U.S. taxpayers that have held the securities during a period when we were a PFIC will be subject to the foregoing rules, even if we cease
to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer
can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto.
We do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain
a valid QEF election for any year in which we are a PFIC. U.S. taxpayers that hold the securities are strongly urged to consult their
tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of
making a QEF or mark-to-market election with respect to the securities in the event that we are a PFIC. See &ldquo;<I>Taxation&mdash;U.S.
Federal Income Tax Consequences&mdash;Passive Foreign Investment Companie</I>s&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
have not paid, and do not intend to pay, dividends on our Ordinary Shares and, therefore, unless our traded securities appreciate in
value, our investors may not benefit from holding our Ordinary Shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never declared or paid any dividends on our Ordinary Shares. We do not anticipate paying any dividends in the foreseeable future.
We currently intend to retain future earnings, if any, to finance operations and expand our business. Our board of directors has sole
discretion whether to pay dividends. If our board of directors decides to pay dividends, the form, frequency and amount will depend upon
our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other
factors that our directors may deem relevant. The Israeli Companies Law, 5759-1999, or the Companies Law, imposes restrictions on our
ability to declare and pay dividends. See &ldquo;<I>Dividend Policy</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
JOBS Act allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and
to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our Company
and adversely affect the market price of our common shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
so long as we remain an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we intend to take advantage of certain exemptions
from various requirements that are applicable to public companies that are not &ldquo;emerging growth companies&rdquo; including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions of the Sarbanes-Oxley
    Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal
    control over financial reporting;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 107 of the JOBS
    Act, which provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in
    Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This means that an &ldquo;emerging
    growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private
    companies. We are electing to delay such adoption of new or revised accounting standards. As a result of this adoption, our financial
    statements may not be comparable to companies that comply with the public company effective date;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any rules that may be adopted
    by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&rsquo;s report
    on the financial statements; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to furnish
    two rather than three years of income statements and statements of cash flows in the registration statement on Form F-1 of which
    this prospectus is part.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to take advantage of these exemptions until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an emerging
growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the completion
of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large
accelerated filer, as defined in the rule under the Exchange Act, and (2) the date on which we have issued more than $1.0 billion in
non-convertible debt during the prior three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
cannot predict if investors will find our ordinary less attractive because we may rely on these exemptions. If some investors find our
Ordinary Shares less attractive as a result, there may be a less active trading market for each such traded security, and the trading
price of each may be more volatile and may decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they
adversely change their recommendations or publish negative reports regarding our business or our shares, the trading prices of our shares
and trading volume of our shares could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
trading market for our Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish
about us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance
that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our shares or provide more favorable relative recommendations about our competitors, the trading price of our shares would
likely decline. If any analyst who may cover us were to cease coverage of our Company or fail to regularly publish reports on us, we
could lose visibility in the financial markets, which in turn could cause the trading price of our shares and trading volume of our shares
to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to Israeli Law and Our Operations in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Potential
political, economic and military instability in Israel, where our headquarters, members of our management team, our production facilities,
and employees are located, may adversely affect our results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
headquarters and principal offices and most of our operations are located in the State of Israel. In addition, all of our key employees
and officers are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business.
Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and countries in
the region or groups in neighboring countries. In addition, several countries, principally in the Middle East, restrict doing business
with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result
of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability, violence in
the region or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely affect our
operations and results of operations and the market price of our Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
commercial insurance does not cover losses that may occur as a result of an event associated with war and terrorism. Although the Israeli
government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts
of war, we cannot assure you that this government coverage will be maintained or, if maintained, will be sufficient to compensate us
fully for any damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial
condition and results of operations. As of April 16, 2025, we have not incurred any direct losses or damages caused by
terrorism or war.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 7, 2023, an attack was launched against Israel by the Hamas terrorist organization. In response, the Security Cabinet of the
State of Israel declared war on Hamas and a military campaign ensued. As of March 18, 2025, the ceasefire with Hamas that had
been in place since January 2025 has ended and hostilities have resumed. To date, the State of Israel continues to be at war
with Hamas. On Israel&rsquo;s northern border, Israel has been engaged with Hezbollah in Lebanon, a terrorist organization
that has been launching missile, rocket, and shooting attacks against Israeli military sites, troops, and Israeli towns. In response
to these attacks, the Israeli army has carried out a number of targeted strikes on sites associated with Hezbollah in Lebanon. As of
the end of November 2024, Israel entered into a ceasefire agreement with Hezbollah, but there are no assurances as to whether the
agreement will hold or whether further hostilities with Hezbollah will resume. In addition, Iran and the Houthi movement in Yemen
have launched direct attacks on Israel involving drones and missiles and have threatened to continue to attack Israel.
Iran is also widely believed to be developing nuclear weapons and to have a strong influence among extremist
groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, and the Houthi movement in Yemen and various rebel militia groups
in Iraq. The continuation of the conflict with Hamas has led to heightened security concerns, potential disruptions to business
operations, and economic instability. There remains significant uncertainty regarding the duration and escalation of the conflict,
and further military actions, restrictions, or government-imposed measures could adversely affect our operations, supply chains, and
financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
the war broke out on October 7, 2023, our operations have not been adversely affected. At this time, it is not possible to predict the
intensity or duration of the war, nor can we predict how this war will ultimately affect Israel&rsquo;s economy in general, which may
involve additional credit rating agencies downgrading Israel&rsquo;s credit rating score after Moody&rsquo;s downgraded Israel&rsquo;s
credit rating from A2 to Baa1 and its outlook rating remains at &ldquo;negative.&rdquo; We continue to monitor
the situation closely and examine the potential disruptions that could adversely affect our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until
they reach the age of 40 (or older for certain reservists) and, in the event of a military conflict, may be called to active duty. In
response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. In connection with
the Israeli security cabinet&rsquo;s declaration of war against Hamas, hostilities with Hezbollah and Iran, and possible hostilities
with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate military service. Although
many such military reservists have been discharged, they may be called up again depending on how events unfold. As of April 16,
2025, none of our current employees in Israel have been called to active military duty. Moreover, we rely on service providers located
in Israel and have entered into certain agreements with Israeli counterparties. Employees of such service providers or contractual counterparties
may be called for service in the current or future wars or other armed conflicts Israel may be engaged in and such persons may be absent
from their positions for a period of time. Military service call ups that result in absences of our personnel, service providers or contractual
counterparties in Israel may disrupt our operations and absences for an extended period of time may materially and adversely affect our
business, prospects, financial condition and results of operations. As of April 16, 2025, we have not been affected by
any absences of personnel of our service providers or counterparties located in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect
our operations and results of operations. Our insurance policies do not cover losses that may occur as a result of events associated
with war and terrorism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war,
we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses
or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region
would likely negatively affect business conditions and could harm our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Several
countries, principally in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries
may impose restrictions on doing business with Israel and Israeli companies, whether as a result of hostilities in the region or otherwise.
In addition, there have been increased efforts by certain countries, activists and organizations to cause companies, research institutions
and consumers to boycott Israeli goods and cooperation with Israeli-related entities based on Israeli government policies. Such actions,
particularly if they become more widespread, may adversely impact our ability to collaborate with other third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally,
political conditions within Israel may affect our operations. Many citizens and groups have responded strongly against the Israeli government&rsquo;s
pursuit of judicial reform. To date, these initiatives have been substantially put on hold. Actual or perceived instability in Israel
or any negative changes in the political environment may individually or in the aggregate adversely affect the Israeli economy and, in
turn, our business, financial condition, results of operations and growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
expect to be exposed to fluctuations in currency exchange rates, which could adversely affect our results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
incur expenses in the new Israeli shekel, or NIS, U.S. dollars, and Euros, but our functional currency is the U.S. dollar. Accordingly,
we face exposure to adverse movements in currency exchange rates. Accordingly, we face exposure to adverse movements in the currency
exchange rate of the U.S. dollars against these foreign currencies, which may have a negative effect on our revenue and costs. If the
U.S. dollar strengthens against any of these currencies, the translation of these foreign currency denominated transactions will result
in decreased revenue in U.S. dollars. Changes in currency exchange rates may have a negative effect on our financial results. If the
U.S. dollar weakens against the NIS and Euro, the translation of the NIS and Euro currency denominated transactions to U.S. dollar will
result in increased operating expenses. Similarly, if the U.S. dollar strengthens against NIS and Euro denominated, the translation of
these NIS and Euro denominated transactions to U.S. dollars will result in decreased expenses. As exchange rates vary, sales and other
operating results, when translated, may differ materially from our or the capital market&rsquo;s expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
termination or reduction of tax and other incentives that the Israeli government provides to Israeli companies may increase our costs
and taxes.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Israeli government currently provides tax and capital investment incentives to Israeli companies, as well as grant and loan programs
relating to research and development and marketing and export activities. In recent years, the Israeli government has reduced the benefits
available under these programs and the Israeli governmental authorities may in the future further reduce or eliminate the benefits of
these programs. While we have not previously received any such benefits or grants, we may take advantage of these benefits and programs
in the future; however, there can be no assurance that such benefits and programs will be available to us. If we qualify for such benefits
and programs and fail to meet the conditions thereof, the benefits could be canceled and we could be required to refund any benefits
we might already have enjoyed and become subject to penalties. Additionally, if we qualify for such benefits and programs and they are
subsequently terminated or reduced, it could have an adverse effect on our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may be required to pay monetary remuneration to our Israeli employees for their inventions, even if the rights to such inventions have
been duly assigned to us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
enter into agreements with our Israeli employees pursuant to which such individuals agree that any inventions created in the scope of
their employment are either owned exclusively by us or are assigned to us, depending on the jurisdiction, without the employee retaining
any rights. A portion of our intellectual property has been developed by our Israeli employees during their employment for us. Under
the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the course of his or her employment
and within the scope of said employment are considered &ldquo;service inventions.&rdquo; Service inventions belong to the employer
by default, absent a specific agreement between the employee and employer otherwise. The Patent Law also provides that if there is no
agreement regarding the remuneration for the service inventions, even if the ownership rights were assigned to the employer, the Israeli
Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee
is entitled to remuneration for these inventions. The Committee has not yet determined the method for calculating this Committee-enforced
remuneration. While it has previously been held that an employee may waive his or her rights to remuneration in writing, orally or by
conduct, litigation is pending in the Israeli labor court is questioning whether such waiver under an employment agreement is enforceable.
Although our Israeli employees have agreed that we exclusively own any rights related to their inventions, we may face claims demanding
remuneration in consideration for employees&rsquo; service inventions. As a result, we could be required to pay additional remuneration
or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have non-competition agreements with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees
from competing with or working for our competitors, generally during their employment and for up to 12 months after termination of their
employment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce
those provisions for relatively brief periods of time in restricted geographical areas, and only when the employee has obtained unique
value to the employer specific to that employer&rsquo;s business and not just regarding the professional development of the employee.
If we are not able to enforce non-compete covenants, we may be faced with added competition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Provisions
of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition
of, us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Israeli
corporate law regulates mergers, requires tender offers for acquisitions of securities above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types
of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal
is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders
of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must approve
a merger. Moreover, a tender offer for all of a company&rsquo;s issued and outstanding securities can only be completed if the acquirer
receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires
approval of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the
tender offer, the acquirer would hold at least 98% of the Company&rsquo;s outstanding securities. Furthermore, the shareholders, including
those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer,
claim that the consideration for the acquisition of the securities does not reflect their fair market value, and petition an Israeli
court to alter the consideration for the acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder
that accepts the offer may not seek such appraisal rights, and the acquirer or the company published all required information with respect
to the tender offer prior to the tender offer&rsquo;s response date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not
have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free
share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances
but makes the deferral contingent on the fulfilment of a number of conditions, including, in some cases, a holding period of two years
from the date of the transaction during which sales and dispositions of securities of the participating companies are subject to certain
restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires,
the tax becomes payable even if no disposition of the securities has occurred. These provisions could delay, prevent or impede an acquisition
of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>It
may be difficult to enforce a judgment of a U.S. court against us and our executive officers and directors and the Israeli experts named
in this prospectus in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our executive
officers and directors and these experts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
were incorporated in Israel. Substantially all of our executive officers and directors reside outside of the United States, and all of
our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us,
or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be
collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process
on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally,
it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel.
Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most
appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that
Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be
governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty
associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign
court (see &ldquo;<I>Enforceability of Civil Liabilities</I>&rdquo; for additional information on your ability to enforce a civil claim
against us and our executive officers or directors named in this prospectus).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Your
rights and responsibilities as a shareholder will be governed in key respects by Israeli laws, which differs in some material respects
from the rights and responsibilities of shareholders of U.S. companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
rights and responsibilities of the holders of our securities are governed by our amended and restated articles of association and by
Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders
in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising
its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in such company,
including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&rsquo;s amended
and restated articles of association, increases in a company&rsquo;s authorized share capital, mergers and acquisitions and related party
transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In
addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders
or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company.
There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions.
These provisions may be interpreted to impose additional obligations and liabilities on holders of our securities that are not typically
imposed on shareholders of U.S. companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
articles of association to be effective upon the consummation of this offering may be deemed to have an anti-takeover effect.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain
provisions of our articles of association to be effective upon the effectiveness of the registration statement for this offering may
make a change in control of us more difficult to affect. Our articles of association will provide for a staggered board of directors
consisting of three classes of directors. Directors of each class are chosen for three-year terms upon the expiration of their current
terms and each year one class of our directors will be elected by our shareholders. This classified board provision could have the effect
of making the replacement of incumbent directors more time consuming and difficult. At least two annual meetings of shareholders, instead
of one, will generally be required to effect a change in a majority of our board of directors. Thus, the classified board provision could
increase the likelihood that incumbent directors will retain their positions. The staggered terms of directors may delay, defer or prevent
an attempt to change control of us, even though a change in control might be considered by our shareholders to be in their best interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Some
of the statements made under &ldquo;<I>Prospectus Summary</I>,&rdquo; &ldquo;<I>Risk Factors</I>,&rdquo; &ldquo;<I>Use of Proceeds</I>,&rdquo;
&ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>,&rdquo; &ldquo;<I>Business</I>&rdquo;
and elsewhere in this prospectus constitute forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo; or &ldquo;continue,&rdquo;
or the negative of these terms or other comparable terminology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements
on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory pathways
    that we may elect to utilize in seeking EMA, FDA and other regulatory approvals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining EMA and FDA approval
    of, or other regulatory action in Europe or the United States and elsewhere with respect to Intranasal Epinephrine, Intranasal Naloxone
    or other product candidates that we may seek to develop;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the commercial launch and
    future sales of Intranasal Epinephrine or any other future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding
    the timing of commencing further clinical trials, the process entailed in conducting each such trial, including dosages, and the
    order of such trials with each of our product candidates or whether such trials will be conducted at all;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payor reimbursement
    for Intranasal Epinephrine;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding
    anticipated expenses, capital requirements, and our needs for additional financing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to the patient
    market size and market adoption of Intranasal Epinephrine by physicians and patients;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, cost, regulatory
    approvals or other aspects of the commercial launch of Intranasal Epinephrine;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission of an MAA and
    NDA with the EMA and FDA for Intranasal Epinephrine;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion and receiving
    favorable results of clinical trials for Intranasal Epinephrine and Intranasal Naloxone;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our use of proceeds from
    this offering;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise capital
    through the issuance of additional securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of patents to
    us by the U.S. PTO and other governmental patent agencies and our ability to maintain, protect, and enhance our intellectual property;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development and commercialization,
    if any, of any other product candidates that we may seek to develop;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of our management
    team to lead the development of our product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding
    licensing, acquisitions, and strategic operations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market, political
    and economic conditions in the countries in which we operate, including those related to recent unrest and actual or potential armed
    conflict in Israel and other parts of the Middle East, such as the multi-front war Israel is facing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">projected capital expenditures
    and liquidity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition
    and new technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our strategy;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our
or our industry&rsquo;s actual results, levels of activity, performance or achievements to be materially different from those anticipated
by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading &ldquo;<I>Risk
Factors</I>&rdquo; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_004"></A>LISTING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to apply to list the Ordinary Shares on the NYSE American under the symbol &ldquo;NSRX&rdquo;. No public market currently exists
for our Ordinary Shares included in this offering. This offering is contingent upon the Ordinary Shares being listed on the NYSE American;
however, no assurance can be given that our application will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_005"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect to receive approximately $29.7 million in net proceeds from the sale of 3,000,000 Ordinary Shares offered by us in this
offering (approximately $34.3 million if the underwriters exercise their over-allotment option in full), based upon an assumed
public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
$1.00 increase or decrease in the assumed public offering price of $11.00&nbsp;per Ordinary Share would increase or decrease the proceeds
from this offering by approximately $2,760,000, assuming that the number of Ordinary Shares offered by us, as set forth on the
cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions. Similarly,
each increase or decrease of 500,000 Ordinary Shares offered would increase or decrease our proceeds by approximately $5,060,000,
assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to use the net proceeds from this offering for the following purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately $16 million
    to $18 million for the development of our Intranasal Epinephrine program, including, manufacturing scale-up, phase 2 and pivotal
    studies, and the submission of our NDA to the FDA and pre-commercial activities for our research and development efforts;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately $1 million
    to $1.5 million for the development of two additional early-stage indications, which we have not yet chosen and will be determined
    at a later date; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the remainder for general
    and administrative corporate purposes, including working capital, and capital expenditures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amounts and schedule of our actual expenditures will depend on multiple factors. As a result, our management will have broad discretion
in the application of the net proceeds of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Changing
circumstances may cause us to consume capital significantly faster than we currently anticipate. The amounts and timing of our actual
expenditures will depend upon numerous factors, including the progress of our global marketing and sales efforts, the development efforts,
and the overall economic environment. Therefore, our management will retain broad discretion over the use of the proceeds from this offering.
We may ultimately use the proceeds for different purposes than what we currently intend. Pending any ultimate use of any portion of the
proceeds from this offering, if the anticipated proceeds will not be sufficient to fund all the proposed purposes, our management will
determine the order of priority for using the proceeds, as well as the amount and sources of other funds needed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pending
our use of the net proceeds from this offering, we may invest the net proceeds in a variety of capital preservation investments, including
short-term, investment grade, interest bearing instruments and U.S. government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_006"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects
and other factors our board of directors may deem relevant. Under the Companies Law, repurchase of shares is considered a dividend distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
Companies Law imposes further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay
dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent
us from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution
amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available
for distribution according to our then last reviewed or audited financial statements, provided that the end of the period to which the
financial statements relate is not more than six months prior to the date of distribution, generally referred to as the Earnings Criteria.
In the event that we do not meet such earnings criteria, we may seek the approval of a court in order to distribute a dividend. The court
may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying
our existing and foreseeable obligations as they become due, generally referred to as the Solvency Criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">However,
under the exemptions applicable as of March 12, 2024, generally referred to as the Exemptions Regulations, an Israeli company whose shares
are listed outside of Israel, is permitted to perform distribution in a way of repurchasing its own shares, even if the Earnings Criteria
is not met, without the need for court&rsquo;s approval. The exemption is subject to certain conditions, including, among others: (i)
The distribution meets the Solvency Criteria; and (ii) no rejection was filed by any of the company&rsquo;s creditors to the court. If
any creditor objects to the distribution, the company will be required to obtain the court&rsquo;s approval for the distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Payment
of dividends may be subject to Israeli withholding taxes (see &ldquo;<I>Taxation&mdash;Israeli Tax Considerations and Government Programs</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_007"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth our cash and cash equivalents and our capitalization as of December 31, 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a <I>pro forma</I> basis
    to give effect to (i) the issuance of 324,894 Ordinary Shares to be issued upon the conversion of the 2024 SAFEs into Ordinary
    Shares upon the effectiveness of the registration statement for this offering; and (ii) our receipt in January 2025 through March
    2025 of aggregate proceeds of $685,000 from the 2024 SAFEs we entered into with certain investors; and.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a <I>pro forma</I> as
    adjusted basis to give effect to the issuance of 3,000,000 Ordinary Shares in this offering, at an assumed public offering price
    of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after
    deducting underwriting discounts and commissions and estimated offering expenses, as if the sale of the Ordinary Shares had occurred
    on December 31, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
<I>pro forma</I> as adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual public
offering price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should read this table in conjunction with the sections entitled &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations</I>&rdquo; and our financial statements and related notes included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of December 31, 2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actual</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro
    Forma</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro
    Forma</I><BR> As<BR> Adjusted <I><SUP>(1)</SUP></I></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unaudited</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">284</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">969</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">31,329</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible securities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo; equity (deficit):</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">13,265,593 Ordinary Shares authorized as of December 31, 2024; and 7,362,906
    Ordinary Shares issued as of December 31, 2024; 7,687,800 Ordinary Shares on a <I>pro forma</I> basis and 10,687,800
    Ordinary Shares on a <I>pro forma</I> as adjusted basis.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional Paid-In Capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,432</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">11,918</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">42,010</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total shareholders&rsquo; equity (deficit)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,212</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(725</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">29,375</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -9.85pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    capitalization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,410</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(725</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">29,375</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
number of Ordinary Shares purchased from us by existing shareholders is based on 7,362,906 Ordinary Shares issued and outstanding as
of December 31, 2024, and excludes the following as of such date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">346,537 Ordinary Shares
    issuable upon the exercise of share options granted subsequent to December 31, 2024, at a weighted average exercise price of $6.05&nbsp;per
    ordinary share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,700 Ordinary Shares
    issuable upon the exercise of share options to directors, employees and consultants under the 2019 Plan outstanding as of December
    31, 2024, at a weighted average exercise price of $2.77, of which 184,612 were vested as of December 31, 2024 and 184,612 Ordinary
    Shares reserved for future grants under the 2019 Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
adjusted information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and
other terms of our initial public offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering
price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase
(decrease) the <I>pro forma</I> as adjusted amount of each of cash, cash equivalents and shareholders&rsquo; equity (deficiency) by $2.8 million,
assuming that the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
(decrease) of 500,000 Ordinary Shares offered by us at the assumed initial public offering price would increase (decrease) each of cash,
cash equivalents and shareholders&rsquo; equity (deficiency) by $5.1 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_008"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
you invest in our Ordinary Shares, your interest will be diluted immediately to the extent of the difference between the public offering
price per Ordinary Share you will pay in this offering and the <I>pro forma</I> net tangible book value per Ordinary Share after this
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, we had a net tangible book value of $(3.2) million, corresponding to a net tangible book value of $(0.44)
per Ordinary Share. Net tangible book value per share or per Ordinary Share represents the amount of our total tangible assets less
our total liabilities, divided by 7,362,906, the total number of Ordinary Shares issued and outstanding on December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our <I>pro forma</I> net tangible
book value as of December 31, 2024 was $(0.7) million, representing approximately $(0.09) per Ordinary Share. <I>Pro forma
</I>net tangible book value per Ordinary Share represents the amount of our total tangible assets less our total liabilities, divided
by 7,687,800, the total number of Ordinary Shares outstanding at December 31, 2024, after giving effect to (i) the issuance of
324,894 Ordinary Shares to be issued upon the conversion of the 2024 SAFEs into Ordinary Shares upon the effectiveness of the
registration statement for this offering; and (ii) our receipt in January through March 2025 of aggregate proceeds of $685,000
from the 2024 SAFEs we entered into with certain investors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">After
giving effect to the <I>pro forma</I> adjustments set forth above and the sale of the 3,000,000 Ordinary Shares offered by us in this
offering, at an assumed public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the
cover page of this prospectus, assuming no exercise of the underwriter&rsquo;s option to purchase additional Ordinary Shares and after
deducting the estimated underwriting discounts and commissions and management fees and estimated offering expenses payable by us, our
<I>pro forma</I> as adjusted net tangible book value estimated at December 31, 2024 would have been approximately $29.4 million,
representing $2.75 per Ordinary Share based on 10,687,800 Ordinary Shares deemed outstanding after this offering assuming
no exercise of the underwriters&rsquo; over-allotment option. At the assumed public offering price for this offering of $11.00 per Ordinary
Share, which is the midpoint of the price range set forth on the cover page of this prospectus, this represents an immediate increase
in historical net tangible book value of $3.19 per Ordinary Share to existing shareholders and an immediate dilution in net tangible
book value of $8.25 per Ordinary Share to purchasers of Ordinary Shares in this offering. Dilution for this purpose represents
the difference between the price per Ordinary Share paid by these purchasers and <I>pro forma</I> net tangible book value per Ordinary
Share immediately after the completion of this offering.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table illustrates this dilution on a per Ordinary Share basis to purchasers of Ordinary Shares in this offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assumed public offering price
    per Ordinary Share</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.00</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Historical net tangible book value per share as of &zwnj; December 31, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0">$</P></TD><TD STYLE="text-align: right"><P STYLE="margin: 0">(0.44</P></TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Increase in <I>pro forma </I>net tangible book value per Ordinary Share attributable to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0">$</P></TD><TD STYLE="text-align: right"><P STYLE="margin: 0"> 0.35 </P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro Forma net tangible
    book value per Ordinary Share as of December 31, 2024</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(0.09</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in <I>pro forma
    </I>as adjusted net tangible book value per Ordinary Share attributable to new investors</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"> 2.84 </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro forma as adjusted
    net tangible book value per Ordinary Share after this offering</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">2.75</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dilution per Ordinary Share to new investors</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">8.25</FONT> </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage of dilution in net tangible book
    value per Ordinary Share for new investors</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">75</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
dilution information set forth in the table above is illustrative only and will be adjusted based on the actual public offering price
and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
$1.00 increase or decrease in the assumed initial public offering price of $11.00 per Ordinary Share would increase (decrease) our <I>pro
forma</I> as adjusted net tangible book value per Ordinary Share after this offering by $0.26 and the dilution per Ordinary Share
to new investors by $0.74, assuming the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains
the same, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly,
each increase or decrease of 500,000 Ordinary Shares would increase or decrease our <I>pro forma</I> as adjusted net tangible book value
per Ordinary Share after this offering by $0.33 and the dilution per Ordinary Share to new investors by $(0.33), assuming
the assumed initial offering price of $11.00 per Ordinary Share, as set forth on the cover page of this prospectus, remains the same,
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table summarizes, on a <I>pro forma</I> as adjusted basis as of December 31, 2024, the differences between the number
of Ordinary Shares acquired from us, the total amount paid and the average price per Ordinary Share paid by the existing holders of our
Ordinary Shares and by investors in this offering and based upon an assumed public offering price of $11.00 per Ordinary Share, which
is the midpoint of the price range set forth on the cover page of this prospectus before deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Consideration</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Average<BR>
    Price Per<BR> Ordinary</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Existing shareholders</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">7,687,800</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">72</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><P STYLE="margin: 0">$</P></TD><TD STYLE="width: 12%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">11,277,501</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">1.47</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">New investors</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,000,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">33,000,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">75</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.00</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">10,687,800</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">44,277,501</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">4.14</FONT> </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
<FONT STYLE="background-color: white">number</FONT> of Ordinary Shares purchased from us by existing shareholders is based on 7,362,906
Ordinary Shares issued and outstanding as of December 31, 2024, and excludes the following as of such date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">346,537&nbsp;Ordinary Shares
    issuable upon the exercise of share options granted subsequent to December 31, 2024, at a weighted average exercise price of $6.05&nbsp;per
    ordinary share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,700 Ordinary Shares
    issuable upon the exercise of share options to directors, employees and consultants under the 2019 Plan outstanding as of December
    31, 2024, at a weighted average exercise price of $2.77, of which 180,201 were vested as of December 31, 2024; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,612 Ordinary Shares
    reserved for future grants under the 2019 Plan as of April 16, 2025.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Unless
otherwise indicated, all information in this prospectus assumes or gives effect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an initial public offering
    price of $11.00&nbsp;per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the automatic conversion
    of all outstanding Class A, Class A-1, Class A-2, Class A-3, Class A-3A, Class A-3B Ordinary Shares into 2,592,497 Ordinary
    Shares, which will occur upon the effectiveness of the registration statement for this offering;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">324,894</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Ordinary Shares issuable upon the conversion of 2024 SAFEs in the aggregate amount of $2,322,992, which will automatically
    convert into Ordinary Shares upon the effectiveness of the registration statement for this offering, based on an offering price of
    $11.00, which is the midpoint of the price range set forth on the cover page of this prospectus, assuming this offering occurs within
    18 months of the execution of such SAFEs, otherwise such SAFEs will be converted into our securities on the basis of a previous round
    of equity financing consummated by the Company; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the adoption of our amended
    and restated articles of association upon the effectiveness of the registration statement for this offering, which will replace our
    amended and restated articles of association as currently in effect;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the underwriters&rsquo;
    over-allotment option and the Representative&rsquo;s Warrants; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a 1-for-4.77008 forward
    share split, effected upon the effectiveness of this offering,&nbsp;and the customary adjustments to our outstanding options and
    warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">If
all of such issued and outstanding share options had been exercised as of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">December
31, 2024, the number of Ordinary Shares held by existing shareholders would increase to 7,901,143, or 72% of the total number
of Ordinary Shares outstanding after this offering (in each case, not taking into account the conversion of SAFEs as described above),
and the average price per Ordinary Share paid by the existing shareholders would be $1.34. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the underwriters exercise their option to purchase additional Ordinary Shares in full in this offering, the number of Ordinary Shares
held by new investors will increase to 3,450,000, or 32% of the total number of Ordinary Shares issued and outstanding after this
offering and the percentage of Ordinary Shares held by existing shareholders will decrease to 68% of the total Ordinary Shares
issued and outstanding <FONT STYLE="background-color: white">(in each case, not taking into account the conversion of SAFEs as described
above)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_009"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The
following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in
this prospectus. This discussion and other parts of the prospectus contain forward-looking statements based upon current expectations
that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated
in these forward-looking statements as a result of several factors, including those set forth under &ldquo;Risk Factors&rdquo; and elsewhere
in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical
conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since
the nose is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique PBI technology with a specialized
product portfolio to address acute medical conditions and public health threats. We believe that PBI may be superior over liquid-based
solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, thus creating a larger absorption
area and enabling more rapid and higher drug absorption. In addition, the uniform spherical powder particles of our proprietary formulation
may enhance the consistency and reliability of the delivered dose. The initial clinical trials of our PBI products involving different
molecules performed thus far have demonstrated quicker and higher drug absorption over similar solution-based nasal products. However,
to date we have only tested our product candidates on a relatively small patient population and none of our products have been approved
by the FDA. Prior to obtaining FDA approval of any of our product candidates, we will need to perform additional clinical testing of
our product candidates to confirm any benefits and advantages our products may have over similar nasal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly
and immediately active PBI specialized products. To help achieve this we are focused on developing NS002, an Intranasal Epinephrine,
and we also have been developing NS001, an Intranasal Naloxone, however we currently paused our work on NS001 and plan to pursue partnering
opportunities for further development of NS001. We will need to obtain regulatory approval for our products in order for us to grow our
business. We currently have no FDA approved products. Our products have been tested on relatively small patient populations thus far.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Obtaining
regulatory approvals and developing NS002 and NS001 will require the incurrence of significant costs and our success will depend, in
part, on gaining market acceptance. In order to gain market acceptance in the United States, we will require specific approval from the
FDA for our product candidates. We intend to seek approval of NS002 as an approved molecule and a new delivery route (with EpiPen autoinjector
as the reference device) under Section 505(b)(2) of the FFDCA which allows the applicant to rely in part on previous studies conducted
by unrelated parties, such as another drug manufacturer and, existing sources, including published literature, for marketing approval
by the FDA in the United States, and will seek approval under the comparable hybrid application pathway in the European Union. The FDA
may not agree that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval. Such abbreviated approval
pathways may not lead to a faster development or review process compared to traditional approval pathways and do not increase the likelihood
that NS002 or NS001 will receive regulatory approval in the United States or the European Union. See &ldquo;<I>Business &ndash; Government
Regulation</I>&rdquo; and &ldquo;<I>Risk Factors &ndash; Risks Related to Product Development, Regulatory Approval and Commercialization</I>&rdquo;
for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have conducted a twelve-patient pilot study of NS002, which included the testing of bioavailability of epinephrine under &ldquo;allergenic
challenge&rdquo; - the creation of severe acute allergic reaction in the nose by inserting ascending doses of allergens to the nose of
the healthy volunteers with known allergic rhinitis included in the study. The results showed that epinephrine intranasal delivery of
our NS002 followed the established characteristics of our platform technology&mdash;namely, there were higher levels of the drug in the
plasma in situations where immediate administration could be lifesaving. The Phase 2 study, which is meant to optimize the dose that
will be used in the Phase 3 study for registration, is conducted in limited patient populations to identify possible adverse effects
and safety risks, to preliminarily evaluate the dosage tolerance of the product for specific targeted diseases or conditions and to determine
dosage tolerance, optimal dosage and dosing schedule. Our Phase 2 study is aimed at defining the final clinical dose to be used in our
powder epinephrine product candidate, compared the bioavailability of epinephrine following a various dosing of NS002 Microspheres Epinephrine
powder. The PK results of our Phase 2 study are in line with the known attributes of our nasal powder technology&mdash;namely:
immediate absorption of epinephrine and reaching higher peak plasma epinephrine levels quicker compared to IM Epinephrine injections.
We intend to perform two additional Phase 2 studies of NS002. The first will be aimed at determining whether, if necessary, during a
real-life anaphylaxis a second dose of NS002 should be administered in the same nostril as the one used for the first administration
of NS002 or whether it should be in the other nostril. The second Phase 2 study will test the &ldquo;carry-over effect,&rdquo; or whether
the first dose of epinephrine changes the absorption of epinephrine of a following dose. Each study is currently planned to include at
least 12 healthy volunteers with allergic rhinitis. Prior to submission to the FDA for marketing approval, we also intend to perform
a pivotal clinical, or Phase 3, study that will include a subsection of self-administration. We also intend to separately perform: (1)
stability testing which involves testing the product candidate under various temperature and humidity points; (2) a reliability study,
which is a subset of the stability study that tests the NS002&rsquo;s administration device in several potential conditions; (3) a usability
study, which tests how user friendly the device is; (4) preclinical studies or short animal safety studies in two animal species; and
(5) a pediatric study, the details of which will be agreed upon with the FDA as we progress with the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">With
respect to NS001 Intranasal Naloxone, we have performed a pilot study, which is a first in human study aimed at safety and bioequivalence,
and pivotal clinical study, which is the Phase 3 registration study, in 14 and 42 healthy volunteers, respectively, with the objective
of evaluating the comparative bioavailability of Naloxone between NS001 and certain competitor products. The pilot study results were
submitted to the FDA in support of the progression to the pivotal study. The results of the pilot study showed our technology having
a faster absorption rate in the immediate critical period after administration. The Phase 3 study is administered to an expanded patient
population to further evaluate dosage and clinical efficacy. Our pivotal clinical study consistently showed an advantage in the first
30 minutes after administration. We currently intend to focus our development and regulatory approval efforts on our Intranasal Epinephrine
and other preclinical programs, and plan to pursue partnering opportunities for further development of NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
platform technology can also be incorporated into other products as it has been tested with several additional preclinical and invitro
molecules based on our proprietary nasal powder formulation and technology. In addition to our two main products, Intranasal Epinephrine
and Intranasal Naloxone, we are exploring other potential indications for which our PBI technology may be applicable, including Intranasal
Midazolam, Intranasal Atropine and Intranasal Ondansetron. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Competition
in the pharmaceutical industry is intense. Some of our competitors hold significant market share, have long histories and strong reputations
within the industry, greater brand recognition, and more financial and human resources than we do. They also have more experience and
capabilities in researching and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing
and marketing those products than we do. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of NS002 or NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have incurred significant operating losses, generated no revenues from existing products, and as of December 31, 2024, our accumulated
deficit was $12.7 million. We expect that we will need to raise substantial additional funding in the future. See &ldquo;<I>Risk
Factors&ndash;Risks Related to Our Financial Condition and Capital Requirements.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Components
of Operating Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Operating
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
current operating expenses consist of two components &ndash; research and development expenses and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Research
and Development Expenses.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
and development expenses consist primarily of costs incurred in connection with our research and development activities. This includes
conducting clinical trials and preclinical studies, manufacturing development efforts and activities related to regulatory filings for
product candidates, as well as overhead costs. Our research and development expenses primarily consist of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries and personnel-related
    costs, including benefits and share-based compensation expense, for our scientific personnel for executing clinical trials, preclinical
    studies, regulatory activities and for performing research and development activities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to executing
    clinical trials and preclinical studies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of third-party clinical
    consultants and expenses related to conducting clinical and pre-clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to acquiring,
    developing and manufacturing materials for such clinical trials and preclinical studies; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other related overhead
    costs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
and development expenses are expensed as incurred. We record accrued expenses for research and development activities conducted, on our
behalf, by third-party service providers, which include the performance of clinical trials and the conduct of preclinical studies. We
record these accrued expenses based upon research and development activities performed by such third-party service providers and reported
to us, and we include these costs in accrued liabilities in the consolidated balance sheets and within research and development expense
in the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
inception though December 31, 2024, we have incurred approximately $11.5 million in research and development expenses to advance the
development of our product candidates, as well as other preclinical research and development programs. Substantially all of our research
and development expenses for the years ended December 31, 2024 and 2023 were related to the development of NS001 and NS002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect that our research and development expenses will materially increase as we enter into the Phase 2 and Phase 3 clinical development
stage of our product candidates, start Chemical Control and Manufacturing activity, or CMC, and recruit additional research and development
employees. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary
to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence
from sales of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General and
Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of salaries and related expenses, professional service fees for accounting, legal and bookkeeping,
facilities, travel expenses and other general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect our general and administrative expenses will increase in the future to support continued research and development activities.
We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs,
as well as investor, public relations and compliance expenses, associated with operating as a public company. We expect increased expenses
if any of our product candidates receives regulatory approval and we determine to build a commercial infrastructure to support commercial
sales and marketing of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Comparison
of the Year Ended December 31, 2024 to the Year Ended December 31, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Results
of Operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table presents our results of operations for the year ended December 31, 2024 and 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated statements of operations:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating Expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">335</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">567</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">743</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">580</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,078</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,147</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss from continuing operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,078</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,147</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(29</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(49</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of convertible securities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(443</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">219</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other expense,
    net</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,552</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,005</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net income (loss) from
    discontinued operations</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(46</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,532</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,051</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses includes $208 thousand and $228 thousand in expenses to related parties in the years ended December 31, 2024 and 2023, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative
    expenses includes $307 thousand and $288 thousand in expenses to related parties in the years ended December 31, 2024 and 2023, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses includes
    $17 thousand and $27 thousand in expenses to related parties in the years ended December 31, 2024 and 2023, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Research and
Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
research and development expenses for the year ended December 31, 2024 amounted to $335 thousand representing a decrease of $232 thousand,
or 41%, compared to $567 thousand for the year ended December 31, 2023. The decrease was primarily attributable to a reduction in clinical
trial costs as we have not conducted clinical trials during 2024, while clinical trial costs incurred in 2023. For further information
regarding our research and development activities, <I>see</I> &ldquo;<I>Business &ndash; Research and Development</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General and
Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
general and administrative expenses totaled $743 thousand for the year ended December 31, 2024, representing an increase of
$163 thousand, or 28%, compared to $580 thousand for the year ended December 31, 2023. The increase was primarily attributable to
costs associated with this offering that do not meet the criteria for capitalization as deferred issuance costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Operating
Loss from Continuing Operations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss totaled $1,078 thousand for the year ended December 31, 2024, representing a decrease of
$69 thousand, or 6%, compared to $1,147 thousand for the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Change
in Fair Value of Convertible Securities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
in fair value of convertible securities consists of changes in fair value as done from time to time. We recognized financial income of
$443 thousand for the year ended December 31, 2024, representing an increase of $662 thousand, or 302%, compared
to financial expense of $219 thousand for the year ended December 31, 2023. The increase was due to an increase in the fair value
of the Company&rsquo;s SAFE instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Net
Loss (Income) from Discontinued Operations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
income from discontinued operations totaled $20 thousand for the year ended December 31, 2024, representing an increase of
$66 thousand, or 143%, compared to $46 thousand in net loss from discontinued operations for the year ended December 31, 2023. The
decrease was primarily attributable to effect of changes in foreign currency in connection with current liabilities related to
discontinued operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Net Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result of the foregoing, our net loss totaled $1,532 thousand for the year ended December 31, 2024, representing an increase
of $481 thousand, or 31%, compared to $1,051 thousand for the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
our inception through December 31, 2024, we have funded our operations principally with approximately $10.7 million (net of issuance
expenses) through proceeds from equity financing and the issuance of convertible securities in the form of SAFEs. As of December 31,
2024, we had approximately $284 thousand in cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
table below presents our cash flows for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(665</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,029</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash used in investing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">770</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,055</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase decrease in cash and cash equivalents</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">101</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Net
cash used in operating activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities of $0.7 million during the year ended December 31, 2024 compared to $1.0 million during the year ended
December 31, 2023. The decrease is mainly due to a change in other current assets as of December 31, 2024 and higher operational costs
in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities during the year ended December 31, 2024 was primarily attributable to our net loss from continuing
operations of $1,552 thousand, adjusted for non-cash expenses of $891 thousand, which includes a $443 thousand loss
from change in convertible securities, share-based compensation of $10 thousand, and a net decrease in working capital of $438
thousand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities during the year ended December 31, 2023 was primarily attributable to our net loss from continuing
operations of $1,005 thousand, adjusted for non-cash expenses of $23 thousand, which includes a $219 thousand income from change in convertible
securities, share-based compensation of $39 thousand, and a net decrease in working capital of $203 thousand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Cash
used in investing activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
had no net cash used in investing activities during the year ended December 31, 2024 and 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Net
cash provided by financing activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash provided by financing activities was $0.8 million for the year ended December 31, 2024, as compared to $1.1 million for the year
ended December 31, 2023. The decrease was mainly attributable to deferred issuance costs incurred during 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Between
February 2022 and April 2022, we entered into the 2022 <FONT STYLE="background-color: white">SAFEs</FONT> for aggregate proceeds of $966,000.
Per the terms of the 2022 SAFEs, since an initial public offering, merger, acquisition, equity financing other liquidity event or dissolution
event did not take place within 15 months from the execution of such the 2022 SAFEs, on August 28, 2024, the subscription amounts under
such SAFEs were converted into Class A-3A Ordinary Shares. Upon the effectiveness of the registration statement for this offering, such
Class A-3A Ordinary Shares will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
July 2022, we received a loan, or the July 2022 Loan, from Dr. Ronnie Hershman, a director and shareholder, and Michael Gibber, a shareholder,
pursuant to which we received a principal amount of $500,000, for a term of twelve (12) months, at an interest rate of 8% per annum.
On August 28, 2024, we and each of Dr. Ronnie Hershman and Michael Gibber entered into an exchange letter, or the July 2022 Loan Exchange
Letter, according to which our obligations in connection with the loan were discharged in consideration for the issuance of a SAFE under
the same terms as the 2024 SAFEs, under which it is deemed that Dr. Hershman invested an amount of $284,154 and Michael Gibber invested
an amount of $286,210.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In
February 2023, we received a loan in an aggregate amount of $60,000 from Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa,
or the February 2023 Loan, under substantially the same terms as the July 2022 Loan</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
for a term of twelve (12) months, at an interest rate of 8% per annum. <FONT STYLE="background-color: white">A definitive agreement for
the February 2023 Loan was not executed. In August 2024, we and each of Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa entered
into an exchange letter, or the February 2023 Loan Exchange Letter, according to which our obligations in connection with the February
2023 Loan were discharged in consideration for the issuance of a SAFE under the same terms as the 2024 SAFEs, under which Dr. Ronnie
Hershman was deemed to have invested an amount of $43,954, Dr. Dalia Megiddo was deemed to have invested an amount of $11,286, and Mr.
Udi Gilboa was deemed to have invested an amount of $10,963 in said SAFEs. See &ldquo;<I>Related Party Transactions&mdash;SAFEs</I>&rdquo;
for information regarding the terms of the 2024 SAFEs.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2023 through April 2023, we entered into the 2023 SAFEs for aggregate proceeds of $995,000. Per the terms of the 2023 SAFEs, since
an initial public offering, merger, acquisition, equity financing or other liquidity event or dissolution event did not take place within
15 months from the execution of the 2023 SAFEs, on August 28, 2024, the subscription amounts under such SAFEs were converted into Class
A-3B Ordinary Shares. Upon the effectiveness of the registration statement for this offering, such Class A-3B Ordinary Shares will automatically
convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2024 through March 2025, we entered into the 2024 SAFEs <FONT STYLE="background-color: white">in the aggregate amount </FONT>of
$1,986,500, of which $300,000 were canceled and terminated in November 2024. In addition, pursuant to the terms of the July 2022
Loan Exchange Letter and the February 2023 Loan Exchange Letter, the July 2022 Loan and February 2023 Loan were converted into 2024 SAFEs
in the amount of $570,364 and $66,203, respectively; however, no additional proceeds were received pursuant to said exchanges. Our co-founders
and members of our board of directors participated in the 2024 SAFEs (see <FONT STYLE="background-color: white">&ldquo;<I>Related Party
Transactions&mdash;SAFEs</I>&rdquo;)</FONT>. Per the terms of the 2024 SAFEs, upon an initial public offering, merger, acquisition, qualified
equity financing or other liquidity event, the subscription amounts under such SAFEs will be converted into our Ordinary Shares upon
the effectiveness of the registration statement for this offering, at a conversion price reflecting a discount of 35%. However, if such
events do not occur within 18 months of the execution of such SAFEs, such SAFEs will be converted into our securities of such class of
shares having certain rights identical to the respective rights of the most senior class of shares on the basis of a previous round of
equity financing consummated by the Company at a conversion price reflecting a discount of 35%, as prescribed in such SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Current
Outlook</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, our cash and cash equivalents were approximately $0.3 million, and we had a working capital deficit of $3.3 million
and an accumulated deficit of $12.7 million. Based upon our currently expected level of operating expenditures, we expect that
our existing cash and cash equivalents will be sufficient to fund operations through June 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have financed our operations to date primarily through proceeds from equity financing and the issuance of convertible securities in the
form of SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect to generate revenues from the sale of our products and other revenues in the future. However, we do not expect these revenues
to support all of our operations in the near future. We expect our expenses to increase in connection with our activities, particularly
as we continue the development of our products, and continue our commercialization efforts. Accordingly, we expect that we will require
substantial additional funding in connection with the growth of our operations, continuing our research and development activity, and
commercializing our products. Until we can generate recurring revenues and profit, we expect to satisfy our future cash needs through
debt and equity financings. However, there is no assurance that we will be successful accomplishing these plans. If we are unable to
obtain sufficient capital, we may need to reduce, delay, or adjust our operating expenses, including commercialization of our products
or be unable to expand our operations, as desired. We expect to continue incurring losses and negative cash flows from operations until
our products reach profitability. As a result of these expected losses and negative cash flows from operations, along with our current
cash position, our management has concluded that a material uncertainty exists that raises substantial doubt about our ability to continue
as a going concern. The proceeds from this offering may or may not alleviate the going concern. Even if we raise the proceeds from this offering, we do not believe that such proceeds will be sufficient
to complete all research and development activities necessary to commercialize our product candidates. See also &ldquo;<I>Risk Factors
&ndash; Risks Related to Our Financial Position and Capital Requirements &mdash; We have not generated revenues from our continued activities,
have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable
future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going
concern and could prevent us from obtaining new financing on reasonable terms or at all.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Seasonality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Seasonality
does not materially affect our business or the results of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not engaged in any off-balance
sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Quantitative
and Qualitative Disclosure About Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. Our current investment policy is to invest available cash in bank
deposits with banks that have a credit rating of at least A-. Accordingly, a substantial majority of our cash and cash equivalents is
held in deposits that bear interest. Our market risk exposure is primarily a result of foreign currency exchange rates, which is discussed
in detail in the following paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Foreign
Currency Exchange Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
operate primarily in Israel, and part of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents
the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to
fluctuations in foreign currency rates in connection with these arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, we have not entered into any hedging transactions, but we may do so in the future. Even if we do enter into such
hedging transactions in the future, we cannot guarantee that such measures will effectively protect us from adverse effects due to the
impact of fluctuations in currency exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Critical
Accounting Policies and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
describe our significant accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2024. We
believe that the accounting policy below is critical in order to fully understand and evaluate our financial condition and results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
prepare our financial statements in accordance with U.S. GAAP. At the time of the preparation of the financial statements, our management
is required to use estimates, evaluations and assumptions which affect the application of the accounting policy and the amounts reported
for assets, obligations, income and expenses. Our management believes that the estimates, judgment and assumptions used are reasonable
based upon information available at the time they are made. These estimates, judgment and assumptions can affect reported amounts and
disclosures made. Actual results could differ from those estimates. Any estimates and assumptions are continually reviewed. The changes
to the accounting estimates are credited during the period in which the change to the estimate is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Fair
Value Measurements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Critical
accounting estimates include the valuation of our convertible securities, including SAFEs, which are measured at fair value on a recurring
basis with changes in fair value reported in the consolidated statements of operations. We elected the fair value option in accordance
with ASC 825, Financial Instruments. The SAFEs are measured at fair value each period by using the probability-weighted expected return
model. In estimating the fair value of our SAFEs, we used the assistance of a third-party valuation specialist and considered factors
we believed are material to the valuation process, including, but not limited to, the likelihood of a SAFE mandatory conversion, qualified
equity finance or liquidity event or dissolution and fair value of Ordinary Shares, risk free rate, time to maturity and weighted average
cost of capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Share-based
compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
account for share-based compensation in accordance with ASC Topic 718, &ldquo;Compensation-Stock Compensation.&rdquo; We calculate the
fair value of share options on the date of grant using the Black-Scholes option-pricing model, and the expense is recognized over the
requisite service period for awards expected to vest using the graded vesting method. This model requires various significant judgmental
assumptions in order to derive a final fair value determination for each type of award, including the expected term, expected volatility,
expected dividend yield, risk-free interest rate, and fair value of our share on the date of grant. The requisite service period for
share options is generally four years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
there is no public market for our Ordinary Shares, the fair value of our equity is being approved by our board of directors as of the
date share-based awards were granted. In estimating the fair value of our Ordinary Shares, we used the assistance of a third-party valuation
specialist and considered factors we believed are material to the valuation process, including, but not limited to, the price at which
recent equity was issued by us to independent third parties or transacted between third parties, risks, prospects, and economic and market
conditions, among other factors. We believe the combination of these factors provided an appropriate estimate of our expected fair value
and reflects the best estimate of the fair value of our Ordinary Shares at each grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
fair value of the Ordinary Shares underlying our option awards was determined by our board of directors, with input from management.
We believe that our board of directors has the relevant experience and expertise to determine the fair value of our Ordinary Shares as
of each respective grant date. The valuations of our Ordinary Shares were determined in accordance with the guidelines outlined in the
American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>,
or the AICPA Practice Aid. The assumptions used in the valuation model are based on future expectations combined with management judgment.
Our board of directors, with input from management, exercised significant judgment and considered numerous objective and subjective factors
to determine the fair value of our Ordinary Shares as of the date of each option grant, including the following factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">independent valuations
    performed at periodic intervals by independent third-party valuation specialist;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our current business projections;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stage of development;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prices, rights, preferences
    and privileges of our convertible classes of Ordinary Shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">current business conditions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of a liquidity
    event for the Ordinary Shares underlying these share options, such as an initial public offering or sale of our company, given prevailing
    market conditions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adjustments necessary
    due to the lack of marketability of our Ordinary Shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase of our Ordinary
    Shares by third party investors in arms-length transactions; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market performance
    of comparable publicly traded companies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Impact
of Inflation and Currency Fluctuations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
functional and reporting currency is the U.S. dollar. We incur some of our expenses in other currencies. As a result, we are exposed
to the risk that the rate of inflation in countries in which we are active other than the United States will exceed the rate of devaluation
of such countries&rsquo; currencies in relation to the dollar or that the timing of any such devaluation will lag behind inflation in
such countries. To date, we have not been materially affected by changes in the rate of inflation or the exchange rates of other countries&rsquo;
currencies compared to the dollar, and we cannot assure you that we will not be adversely affected in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
annual rate of inflation in Israel was 3% in 2024 and 3% in 2023. The NIS weakened against the U.S. dollar by approximately 1% in 2024
and 3.07 % in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>JOBS Act
Accounting Election</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are an &ldquo;emerging growth company.&rdquo; Under the JOBS Act, an emerging growth company can delay adopting new or revised accounting
standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably
elected to avail ourselves of this exemption from new or revised accounting standards, and, therefore, will not be subject to the same
new or revised accounting standards as public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="b_010"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Company Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical
conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since
the nose is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique PBI technology with a specialized
product portfolio to address acute medical conditions and public health threats. We believe that PBI may be superior over liquid-based
solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, thus creating a larger absorption
area and enabling more rapid and higher drug absorption. In addition, the uniform spherical powder particles of our proprietary formulation
may enhance the consistency and reliability of the delivered dose. The initial clinical trials of our PBI products involving different
molecules performed thus far have demonstrated quicker and higher drug absorption over similar solution-based nasal products. However,
to date we have only tested our product candidates on a relatively small patient population and none of our products have been approved
by the FDA. Prior to obtaining FDA approval of any of our product candidates, we will need to perform additional clinical testing of
our product candidates to confirm any benefits and advantages our products may have over similar nasal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly
and immediately active PBI specialized products. To help achieve this we are focused on developing NS002, an Intranasal Epinephrine,
and we also have been developing NS001, an Intranasal Naloxone, however we currently paused our work on NS001 and plan to pursue partnering
opportunities for further development of NS001. We will need to obtain regulatory approval for our products in order for us to grow our
business. We currently have no FDA approved products. Our products have been tested on relatively small patient populations thus far.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Obtaining
regulatory approvals and developing NS002 and NS001 will require the incurrence of significant costs and our success will depend, in
part, on gaining market acceptance. In order to gain market acceptance in the United States, we will require specific approval from the
FDA for our product candidates. We intend to seek approval of NS002 as an approved molecule and a new delivery route (with EpiPen autoinjector
as the reference device) under Section 505(b)(2) of the FFDCA which allows the applicant to rely in part on previous studies conducted
by unrelated parties, such as another drug manufacturer, and existing sources including published literature, for marketing approval
by the FDA in the United States, and will seek approval under the comparable hybrid application pathway in the European Union. The FDA
may not agree that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval. Such abbreviated approval
pathways may not lead to a faster development or review process compared to traditional approval pathways and do not increase the likelihood
that NS002 or NS001 will receive regulatory approval in the United States or the European Union. See &ldquo;<I>Business &ndash; Government
Regulation</I>&rdquo; and &ldquo;<I>Risk Factors &ndash; Risks Related to Product Development, Regulatory Approval and Commercialization</I>&rdquo;
for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have conducted a twelve-patient pilot study of NS002, which included the testing of bioavailability of epinephrine under &ldquo;allergenic
challenge&rdquo; - the creation of severe acute allergic reaction in the nose by inserting ascending doses of allergens to the nose of
the healthy volunteers with known allergic rhinitis included in the study. The results showed that epinephrine intranasal delivery of
our NS002 followed the established characteristics of our platform technology&mdash;namely, there were higher levels of the drug in the
plasma in situations where immediate administration could be lifesaving. The Phase 2 study, which is meant to optimize the dose that
will be used in the Phase 3 study for registration, is conducted in limited patient populations to identify possible adverse effects
and safety risks, to preliminarily evaluate the dosage tolerance of the product for specific targeted diseases or conditions and to determine
dosage tolerance, optimal dosage and dosing schedule. Our Phase 2 study is aimed at defining the final clinical dose to be used in our
powder epinephrine product candidate, compared the bioavailability of epinephrine following a various dosing of NS002 Microspheres Epinephrine
powder. The PK results of our Phase 2 study are in line with the known attributes of our nasal powder technology&mdash;namely:
immediate absorption of epinephrine and reaching higher peak plasma epinephrine levels quicker compared to IM Epinephrine injections.
We intend to perform two additional Phase 2 studies of NS002. The first will be aimed at determining whether, if necessary, during a
real-life anaphylaxis a second dose of NS002 should be administered in the same nostril as the one used for the first administration
of NS002 or whether it should be in the other nostril. The second Phase 2 study will test the &ldquo;carry-over effect,&rdquo; or whether
the first dose of epinephrine changes the absorption of epinephrine of a following dose. Each study is currently planned to include at
least 12 healthy volunteers with allergic rhinitis. Prior to submission to the FDA for marketing approval, we also intend to perform
a pivotal clinical, or Phase 3, study that will include a subsection of self-administration. We also intend to separately perform: (1)
stability testing which involves testing the product candidate under various temperature and humidity points; (2) a reliability study,
which is a subset of the stability study that tests the NS002&rsquo;s administration device in several potential conditions; (3) a usability
study, which tests how user friendly the device is; (4) preclinical studies or short animal safety studies in two animal species; and
(5) a pediatric study, the details of which will be agreed upon with the FDA as we progress with the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">With
respect to NS001 Intranasal Naloxone, we have performed a pilot study, which is a first in human study aimed at safety and bioequivalence,
and pivotal clinical study, which is the Phase 3 registration study, in 14 and 42 healthy volunteers, respectively, with the objective
of evaluating the comparative bioavailability of Naloxone between NS001 and certain competitor products. The pilot study results were
submitted to the FDA in support of the progression to the pivotal study. The results of the pilot study showed our technology having
a faster absorption rate in the immediate critical period after administration. The Phase 3 study is administered to an expanded patient
population to further evaluate dosage and clinical efficacy. Our pivotal clinical study consistently showed an advantage in the first
30 minutes after administration. We currently intend to focus our development and regulatory approval efforts on our Intranasal Epinephrine
and other preclinical programs, and plan to pursue partnering opportunities for further development of NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
platform technology can also be incorporated into other products as it has been tested with several additional preclinical and invitro
molecules based on our proprietary nasal powder formulation and technology. In addition to our two main products, Intranasal Epinephrine
and Intranasal Naloxone, we are exploring other potential indications for which our PBI technology may be applicable, including Intranasal
Midazolam, Intranasal Atropine and Intranasal Ondansetron.. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Competition
in the pharmaceutical industry is intense. Some of our competitors hold significant market share, have long histories and strong reputations
within the industry, greater brand recognition, and more financial and human resources than we do. They also have more experience and
capabilities in researching and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing
and marketing those products than we do. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of NS002 or NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
date, we have incurred significant operating losses, generated no revenues from existing products, and as of December 31, 2024, our accumulated
deficit was $12.7 Million. We expect that we will need to raise substantial additional funding in the future. See &ldquo;<I>Risk
Factors&ndash;Risks Related to Our Financial Condition and Capital Requirements.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
Intranasal Drug Delivery Product Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intranasal
administration is a non-invasive route for drug delivery, which was widely used for the local treatment of rhinitis or nasal polyposis.
Since drugs can be quickly absorbed into the systemic circulation through the nasal mucosa, this route can also be used in a range of
acute or chronic conditions requiring considerable or rapid systemic exposure. Indeed, such drug administration offers advantages such
as ease of administration, rapid onset of action, and avoidance of first-pass metabolism (in the liver).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
nasal mucosa is highly vascularized and enables quick and efficient drug delivery to the systemic circulation. The olfactory tissues
also provide a direct conduit to the central nervous system, bypass first-pass metabolism, and lead to an onset of action similar to
IV drug administration. The intranasal route of administration has also been shown to decrease delays in drug administration, especially
in the pre-hospital and community setting of emergency medical situations, which can have a profound impact in a variety of scenarios,
such as anaphylactic shock, opioid overdose, seizures, acutely agitated or combative patients, and trauma management. Intranasal administration
of Midazolam (Nazylam UCB pharma) Lorazepam, Flumazenil, Ketamine, (Spravato, Jennssen) Fentanyl, (Lazanda, Archimedes Pharma) Glucagon
(Baqsimi, Eli Lili) or Sumatriptan (Sumatryptan nasal spray, Snadoz, Immitrex, SGK) has been shown to be an effective alternative to
the same molecules given as intramascular (IM) or intravenous (IV) administration (the names referred to here in this paragraph are the
generic molecule and in parenthesis are the name of the commercial product).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intranasal
drug delivery is especially suitable for potential medical emergency situations such as, anaphylaxis opioid overdose, seizures and the
like, most of which occur either at home or in the streets. While injectable drugs are available in the hands of professional health
personnel, immediate administration of the necessary drugs is essential for preservation of life. The availability of user-friendly,
non-invasive intranasal drug can significantly enhance the prospects of patients&rsquo; survival.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to a Research and Markets report entitled &ldquo;Intranasal Drug Delivery - Global Market Trajectory &amp; Analytics,&rdquo; the intranasal
drug delivery market in the United States was estimated at $21.9 billion in 2021, currently accounting for a 42.05% share in the global
market. China, the world&rsquo;s second largest economy, is forecast to reach an estimated market size of $5.7 billion by the year 2026,
trailing a compound annual growth rate, or CAGR, of 8.4% from 2021-2026. Other noteworthy geographic markets include Japan and Canada,
each forecast to grow at 4.8% and 5% respectively over the same period. Within Europe, Germany is forecast to grow at approximately 5.9%
CAGR while the rest of the European market will reach $6.1 billion by the close of the analysis period. The following graphic depicts
the forecasted growth of the global market for intranasal drug delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to a market monitoring report published in July 2023 entitled &ldquo;Nasal Drug Delivery Market: Global Industry Analysis and Forecast
(2023-2029),&rdquo; the total market, as depicted below, was estimated at $59 billion in 2022 and is expected to grow at CAGR of 6.9%
reaching $93.7 billion in 2029. The following graphic demonstrates the high estimated CAGR and that the major part of the market is in
the US and Europe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Anaphylaxis
and Severe Allergy Type 1</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Anaphylaxis
is a severe, potentially life-threatening allergic reaction that exists on a spectrum and is influenced by both intrinsic (i.e., genetic
predisposition) and extrinsic factors (i.e., allergenic source and route of exposure). It can occur within seconds or minutes of exposure
to an allergen, such as drugs peanuts or bee stings. Anaphylaxis causes the immune system to release a flood of cellular mediators that
can cause shock, with sudden blood pressure drops and airways narrowing, blocking breathing. Signs and symptoms include a rapid, weak
pulse; a skin rash, nausea, vomiting, respiratory distress and death. The following graphic demonstrates the different stages of an allergic
reaction:</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_004.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emergency
                                            treatment of anaphylactic reactions: guidelines for healthcare providers. Resuscitation Council
                                            (UK); 2016.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yu
                                            RJ et al. J Allergy Clin Immunol Pract. (2021).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
World Allergy Organization anaphylaxis guidance in 2020 shows a global anaphylaxis incidence of 50-112 episodes per 100,000 persons per
year; recurrence <FONT STYLE="background-color: white">of reactions occurs in 26.5&ndash;54.0% of anaphylaxis patients.</FONT> According
to an article titled Fatal Anaphylaxis: Mortality Rate and Risk Factors, by Turner at al., dated 2017,</FONT> or the Cantor Fitzgerald
Research, anaphylaxis can be even fatal in 1% of cases. According to the Cantor Fitzgerald research and Raymond James research
from 2024, there are approximately 40 million patients with type 1 allergies in the United States alone, of which approximately
20 million patients who experience severe type 1 allergic reactions that may lead to anaphylaxis. Further, according to such researches,
among such patients with type 1 allergies in the United States, only approximately 7 million have been prescribed with
Epinephrine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Epinephrine,
also called adrenaline, is the first-line therapy for anaphylaxis. It is an endogenous ligand of adrenergic receptors that is produced
in the adrenal glands. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">According to a summary review entitled &ldquo;Update
on the usage and safety of Epinephrine auto-injectors, 2017&rdquo; by Posner published in the Drug Health and Patient Safety Journal
in 2017 , <FONT STYLE="background-color: white">administration of exogenous Epinephrine can counteract some of the most severe symptoms
of anaphylaxis </FONT>through adrenergic (<FONT STYLE="background-color: white">alpha and beta) </FONT>receptor, signaling <FONT STYLE="background-color: white">decreased
vasoconstriction and peripheral vascular resistance, decreased upper airway mucosal edema, increased bronchodilation, and decreased mediator
release from mast cells and basophils. </FONT>Epinephrine has been in use for more than 100 years, and it can be administered via different
routes. A review entitled &ldquo;Adrenaline in the Acute Treatment of Anaphylaxis,&rdquo; published in the Deuttsch Arztebl Int. 2018
stated that in accordance with FDA approval of autoinjectors (for example EpiPen) and the many studies supporting this therapeutic mode
the method of choice in the initial phase of anaphylaxis, especially for self-medication, is intramuscular injection. The first Epinephrine
auto-injector, EpiPen and EpiPen Jr., was approved by FDA in 1987. Several generic versions of EpiPen have been in the market as well.
Additional recent Epinephrine auto-injectors are now also FDA approved (AUVI-Q, Adrenaclick), and the prescribed dosage is 0.3 mg per
delivery for adults and 0.15 mg per delivery for children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the last several decades, there has been a dramatic increase in anaphylactic episodes, especially among children with peanut allergies.
Anaphylaxis requires an immediate injection of Epinephrine and an evacuation to an emergency room. Allergic people are required to carry
with them two Epinephrine autoinjectors at all times and make sure that injections are never more than a few feet away. According to
a study published in the World Allergy Organization Journal, the annual cost of Anaphylaxis in direct cost in the United States is over
$600 million and indirect annual costs are estimated at $1.2 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The unmet
need for Anaphylaxis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">In
many cases, adrenalin injections are not used readily or adequately, which contributes to fatality and severe morbidity cases, creating
a need for a convenient and rapid delivery of Epinephrin in patients with anaphylaxis. Lack of availability of autoinjectors due to high
prices, low availability and lack of education regarding treatment options of anaphylaxis are among the leading causes. Other issues
preventing prompt use of adrenaline injections concern patients and caregivers, hesitance and &ldquo;needle fear&rdquo; since injection
is perceived as &ldquo;aggressive,&rdquo; especially in young children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Epinephrine
in solution form is widely known for its stability issues shortening its effective expiration date and necessitating frequent and expensive
change of the Epinephrine injection. In addition, careful observation of the required storage condition is required in order to preserve
the effective dose within the autoinjectors. Further, the size and weight of a typical two autoinjector package is quite large and cumbersome,
requiring a special carrying bag. According to the Cantor Fitzgerald Research and </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Raymond
James Research <FONT STYLE="background-color: white">published in 2024, out of approximately 7 million patients prescribed with
Epinephrine in 2023, approximately 50% do not carry Epinephrine.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Additionally,
the price for a package containing two autoinjectors are high: the price for EpiPen ranges between $650 to $700 and the price for generics
are about half: $347-$481, according to a 2024 study by Leigh Ann Anderson</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">published
in April 2024 on drugs.<FONT STYLE="background-color: white">com. This extremely high price and the need to acquire a new set every 12-18
months is a major obstacle in the treatment of the ever-expanding life-threatening condition of anaphylaxis. According to a Cantor Fitzgerald
Research and Raymond James Research published in 2024, out of approximately 7 million patients prescribed with Epinephrine, approximately 50% do not refill regularly.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Rise
in prevalence</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
lifetime prevalence of anaphylaxis is about 2% in the U.S. and up to 3% in Europe. Anaphylaxis accounts for up to 0.26% of overall hospital
admissions. A comprehensive study by Turner entitled &ldquo;Global Trends in Anaphylaxis Epidemiology and Clinical Implications,&rdquo;
published recently in the Journal of Allergy and Immunology practice (April 2020) reports that in recent decades, there have been multiple
reports from around the globe describing a dramatic increase in cases of Anaphylaxis, especially related to food allergy (mainly nuts)
and among younger children. The following graphics depict the rate of hospital admissions for anaphylaxis in various countries from 1995-2015,
including two United States data sources for each figure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_005.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
1: Hospital admissions for anaphylaxis from all allergens</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mullins R.J.,
    Wainstein B.K., Barnes E.H., Liew W.K., Campbell D.E. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp
    Allergy. 2016;46:1099&ndash;1110. - PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeppesen A.N., Christiansen
    C.F., Froslev T., Sorensen H.T. Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through
    2012. J Allergy Clin Immunol. 2016;137:1143&ndash;1147. &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tejedor-Alonso M.A., Moro-Moro
    M., Mosquera Gonzalez M., Rodriguez-Alvarez M., Perez Fernandez E., Latasa Zamalloa P. Increased incidence of admissions for anaphylaxis
    in Spain 1998-2011. Allergy. 2015;70:880&ndash;883. &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yao T.C., Wu A.C., Huang
    Y.W., Wang J.Y., Tsai H.J. Increasing trends of anaphylaxis-related events: an analysis of anaphylaxis using nationwide data in Taiwan,
    2001-2013. World Allergy Organ J. 2018;11:23. - PMC &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner P.J., Gowland M.H.,
    Sharma V., Ierodiakonou D., Harper N., Garcez T. Increase in anaphylaxis-related hospitalizations but no increase in fatalities:
    an analysis of United Kingdom national anaphylaxis data, 1992-2012. J&nbsp;Allergy Clin Immunol. 2015;135:956&ndash;963.e1. doi:
    10.1016/j.jaci.2014.10.021.&nbsp;[DOI] [PMC free article] [PubMed] [Google Scholar].</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motosue M.S., Bellolio
    M.F., Van Houten H.K., Shah N.D., Campbell R.L. Increasing emergency department visits for anaphylaxis, 2005-2014. J Allergy Clin
    Immunol Pract. 2017;5:171&ndash;175.e3. &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motosue M.S., Bellolio
    M.F., Van Houten H.K., Shah N.D., Li J.T., Campbell R.L. Outcomes of emergency department anaphylaxis visits from 2005 to 2014. J
    Allergy Clin Immunol Pract. 2018;6:1002&ndash;1009.e2. &ndash; PubMed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Source:
Turner PJ, Campbell DE, Motosue MS, Campbell RL. Global Trends in Anaphylaxis Epidemiology and Clinical Implications. J Allergy Clin
Immunol Pract. 2020 Apr;8(4):1169-1176. doi: 10.1016/j.jaip.2019.11.027. Epub 2019 Nov 28. PMID: 31786255; PMCID: PMC7152797.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_006.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
2: Prevalence of hospitalization for food allergy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 98%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mullins R.J.,
    Wainstein B.K., Barnes E.H., Liew W.K., Campbell D.E. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp
    Allergy. 2016;46:1099&ndash;1110. doi: 10.1111/cea.12748.&nbsp;[DOI] [PubMed] [Google Scholar].</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kivisto J.E., Protudjer
    J.L., Karjalainen J., Wickman M., Bergstrom A., Mattila V.M. Hospitalizations due to allergic reactions in Finnish and Swedish children
    during 1999-2011. Allergy. 2016;71:677&ndash;683. &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wang Y., Koplin J.J., Ho
    M.H.K., Wong W.H.S., Allen K.J. Increasing hospital presentations for anaphylaxis in the pediatric population in Hong Kong. J Allergy
    Clin Immunol Pract. 2018;6:1050&ndash;1052.e2. &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nocerino R., Leone L.,
    Cosenza L., Berni Canani R. Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: an analysis of
    the Italian Ministry of Health database. J Allergy Clin Immunol. 2015;135:833&ndash;895.e3. &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner P.J., Gowland M.H.,
    Sharma V., Ierodiakonou D., Harper N., Garcez T. Increase in anaphylaxis-related hospitalizations but no increase in fatalities:
    an analysis of United Kingdom national anaphylaxis data, 1992-2012. J&nbsp;Allergy Clin Immunol. 2015;135:956&ndash;963.e1. doi:
    10.1016/j.jaci.2014.10.021.&nbsp;[DOI] [PMC free article] [PubMed] [Google Scholar].</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ma L., Danoff T.M., Borish
    L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075&ndash;1083.
    - PMC &ndash; PubMed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motosue M.S., Bellolio
    M.F., Van Houten H.K., Shah N.D., Campbell R.L. National trends in emergency department visits and hospitalizations for food-induced
    anaphylaxis in US children. Pediatr Allergy Immunol. 2018;29:538&ndash;544. &ndash; PubMed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Source:
Turner PJ, Campbell DE, Motosue MS, Campbell RL. Global Trends in Anaphylaxis Epidemiology and Clinical Implications. J Allergy Clin
Immunol Pract. 2020 Apr;8(4):1169-1176. doi: 10.1016/j.jaip.2019.11.027. Epub 2019 Nov 28. PMID: 31786255; PMCID: PMC7152797.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Current treatment
limitations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Needle
fear:</I> Perception of the current injections as invasive and risky leads to a delay in prompt administration. Parents have reservations
about administering Epinephrine to their children due to concerns over injury, incorrect use, and poor outcomes. A more user-friendly
treatment is required. Despite the potentially life-saving benefits of using Epinephrine auto-injectors, Epinephrine is not used to treat
the majority of anaphylactic reactions. A major obstacle to prompt the Epinephrine administration in the community setting is the availability
of an auto-injector, partially caused by price issues and misleading information regarding side effects and risks of injections. Analysis
of fatal and near fatal anaphylaxis both in children, teenagers and adults consistently showed that delay or hesitancy in timely administering
IM injection was the root cause in all cases. In the case of teenagers, a UK-based study showed that the current injection dose of 0.3
was inadequate and larger doses were required to create effective plasma levels. The NHS has encouraged Epinephrine manufacturer to produce
larger dosage auto-injectors (0.5 mg instead of the 0.3) with little success. It is widely agreed by professional organizations that
failure to administer the adequate dose or doses of epinephrine immediately and up to 30 minutes following an event is the single most
important risk factor associated with fatal or near fatal incidences of anaphylaxis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Needle
size: </I>A review by Dreborg published in Allergy Asthma Clin Immunol in 2016 entitled &ldquo;Do epinephrine auto-injectors have an
unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?&rdquo; points out that one of
the major limitation in the use of autoinjectors is needle size. The current indication for autoinjectors calls for injecting in the
lateral side of the thigh muscle. Absorption of drugs from muscle is significantly quicker than its absorption from the fat tissue. Since
the amount of fat covering the thigh differs widely between men and women, and differs in relation to the body mass of the user, it cannot
be expected that a single size needle will ensure the injected epinephrine will indeed reach the muscle in all people&mdash;yet all autoinjectors
have one single needle size (one of adults and one for children- irrespective of age). In a recent formal publication of the Royal College
of Physicians of Ireland in June 2022, the College stated that while the required length of a needle to reach the thigh muscles is between
25 mm up to 38-40mm for those weighing more than 100 kg, <I>none of the currently approved autoinjectors carries an adequate length needle.
</I>As a result, the opinion of the Royal College of Physicians of Ireland was that the epinephrine injected into the fat tissue below
the skin creates a delay of 10-15 minutes in epinephrine absorption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, absorption of Epinephrine from the muscle is not immediate and may not always promptly create therapeutic levels of epinephrine
in the blood. Most studies averaged a period of approximately 15 minutes for &ldquo;time to 100pg/ml&rdquo; &ndash; the time for reaching
the start of the clinical effect. This major limitation is reviewed and discussed by Sclar in &ldquo;Bioequivalence evaluation of epinephrine
autoinjectors with attention to rapid delivery&rdquo; &ndash; published in Ther Clin Risk Management journal in 2013. This major limitation
further shortens the therapeutic window for intervention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Stability
and price</I>: The auto-injectors consisting of Epinephrine in an aqueous solution suffer from severe issues of instability and loss
of the active ingredient of the Epinephrine due to creation of enantiomers. Despite the addition of many stabilizers and lowering the
acidity of the Epinephrine solution, multiple independent studies have shown that the stability of Epinephrine as a solution is highly
volatile and unpredictable. After the use-by date, and oftentimes even before the expiration date, the solution gradually loses effectiveness,
even though it stays clear and colorless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Epinephrine
was found to lose about 30% of its active compound after 12 weeks of a heat cool cycle. The molecule is highly sensitive to light and
should not be exposed to light. It can also be easily oxidized and therefor all epinephrine solutions contain low acidity and bisulphites.
Due to the known stability issues of Epinephrine in solution autoinjectors, injectors need to be replaced every 12-18 months.
The cost of EpiPen 2 -injectors package (the leading brand and largest market share) can reach up to $650-700, and the cost of generic
autoinjectors is about 50-60% of that amount. Despite many government investigations and political pressure, the cost did not change
significantly even after the introduction of generics into the market and still poses an economic burden. The volatility of epinephrine
thus necessitates frequent restocking, and given the high prices of new Epinephrine package, further contributes to the lower availability
of proper treatment options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Opioid
overdose</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Opioid
overdose can occur in both drug abusers and patients treated with prescribed medications for pain. Opioid intoxication is manifested
by reduced consciousness and respiratory depression, which may deteriorate to cardiac arrest and death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the U.S. Center for Disease Control, or CDC, press release dated November 17, 2021, misuse and abuse of opioids has evolved into a
worldwide epidemic, particularly in the U.S. where it is declared a national public health emergency. According to a CDC Morbidity and
Mortality Weekly report from 2021 entitled &ldquo;Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Death,&rdquo;
overdose deaths involving synthetic opioids were nearly 12 times higher in 2019 than in 2013. More than 36,000 people died from overdoses
involving synthetic opioids in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nearly
108,000 Americans died of drug overdoses in 2022, according to final federal figures released on March 2024. Over the last two decades,
the number of U.S. overdose deaths has risen almost every year and continued to break annual records &mdash; making it the worst overdose
epidemic in U.S. history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following graphic depicts age-adjusted rate of drug overdose deaths by gender in the United States from 2002&ndash;2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_007.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Source:
Spencer, M.R, M.P.H., Garnett, M.F, M.P.H. and Mini&ntilde;o, A.M., M.P.H. Drug Overdose Deaths in the United States, 2002&ndash;2022.
- CDC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally,
the U.S. Substance Abuse and Mental Health Service Administration, has reported that the immediate treatment for opioid overdose is rapid
administration of Naloxone. Naloxone is a medication approved by the FDA, designed to rapidly reverse opioid overdose. It is an opioid
antagonist, or in other words, it binds to opioid receptors and can reverse and block the effects of other opioids, such as heroin, morphine,
and oxycodone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to a CDC publication from April 2021 entitled &ldquo;State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose &mdash;
United States, 2017&rdquo; Naloxone is currently available in injections (auto injectors or solution for injection), intranasal or intravenous
solutions. In 2017, the FDA approved the first liquid based intranasal Naloxone (Narcan 4 mg, by Adapt Pharma) and has since approved
generic versions, and an 8 mg Naloxone nasal solution (Kloxxado, Hikkma). The U.S. economic cost of opioid use disorder ($471 billion)
and fatal opioid overdose ($550 billion) during 2017 totalled $1.021 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The
Unmet Need for Opioid Overdose Treatment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
unparalleled increase in the use of synthetic opioids such as Fentanyl, Isotonitazene, or ISO, and other extremely dangerous New Synthetic
Opioids, or NSOs, have changed the scope of immediate treatment of opioid overdose. While Narcan (solution based intranasal Naloxone)
was approved in 2017 in a 4 mg dosage, the FDA approved label for Narcan indicated that if respiratory depression is not improved within
2-3 minutes, then there is a need for an additional dose, followed by a third one until emergency health professionals have reached the
victim. According to reports by the FDA Advisory Committee on the Most Appropriate Dose or Doses of Naloxone to Reverse the Effects of
Life-threatening Opioid Overdose in the Community Settings (2016) a third of opioid overdose victims required two doses of Narcan and
about 16% required a third dose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Two
conclusions can be reached from the changing landscape of opioid overdose in recent years:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of Naloxone
    needed to overcome the new highly potent synthetic opioids is higher according to a review article entitled &ldquo;Naloxone dosage
    for opioid reversal: current evidence and clinical implications,&rdquo; published by Dr. Lyn and colleagues from the University of
    Denver in &ldquo;Therapeutic Advances in Drug Safety&rdquo; Journal in 2018; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the first few minutes are
    the critical period for effective intervention since, in these first few minutes, the maintenance of high plasma levels of Naloxone
    is imperative, attested by the need for repeat dosages in the prehospital and community setting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Current
treatment limitation:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
intranasal Naloxone administration is most suitable for out of hospital opioid overdose and offers non-invasive, easy to use, immediately
available first aid, the currently approved liquid based products such as Narcan and Kloxxado (Naloxone HCI Nasal Spray) do not create
sufficient plasma levels of Naloxone, especially in the first few minutes (10-15 -30) where maintaining adequate levels of Naloxone in
the plasma is vital for restoration of respiration and life as reflected in the high percentage of victims, requiring a second and third
dose. Notably, Narcan and Kloxxado are distributed in a 2-inhaler package.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our Solution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently developing a number of intranasal powder products aimed at assisting patients in severe acute emergency situations such
as anaphylactic shock, opioid overdose and other medical emergencies. Intranasal administration is most suitable for those situations
in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use and non-invasiveness.
Our portfolio comprises a number of programs: NS002 Intranasal Epinephrine (completed Phase 2); NS001 Intranasal Naloxone (completed
pivotal study) and a number of preclinical POC programs, such as NS005 Intranasal Midazolam (acute seizures); NS004 Intranasal
Atropine (organophosphate poisoning); NS003 Intranasal Ondansetron (intractable vomiting) and others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
technology provides an inexpensive, non-invasive, needle-free, and user-friendly solution to the limitations described above through
the administration of a <I>powder-based</I> nasal spray to treat opioid overdose and anaphylaxis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that our cost structure enables us to compete in the market and maintain extremely high margins. Our powder epinephrine nasal
spray is stable and devoid of the stability issues of liquid-based epinephrine products in the market. Due to the inherent advantage
of drug delivery through the highly vascularized nasal tissue, our results show a dramatic advantage in bringing clinical levels of epinephrine
into the plasma much higher and quicker compared to IM Injections especially in the first critical 30 minutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moreover,
in our limited clinical studies with small patient sample sizes, our product candidates have been shown to maintain, and even increase,
the absorption rate as compared to the currently known results of our potential competitors developing liquid based epinephrine nasal
sprays, even with the presence of nasal congestion common in anaphylaxis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Nasus&rsquo;s
Well Differentiated and Diversified Technology Platform &ndash; Intranasal Powder</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
intranasal emergency drugs approved by the FDA in recent years are liquid based. Powder nasal spray products are extremely rare since
the proper technology for the creation of nasal powder is not obvious or simple and requires deep understanding and proprietary knowledge.
Nasus&rsquo; proprietary powder composition for intranasal delivery is comprised of uniform spherical APIs and carriers approved
for inhalations. The active compound&rsquo;s particles&rsquo; shape, size, and morphology, in combination with a carrier and a device
provide rapid and precise delivery of the drug to the blood stream and brain. Our patented technology (manufacturing device and process)
creates a unique combination of two homogenous particle populations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Small, unified API particles
    ensure stable and repeatable absorption of the drug</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large lactose particles
    serve as disaggregants and carriers for the powder into the nose.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following graphic depicts the size distribution of the powder particles showing two distinct populations: the active ingredient and the
carrier molecule. The ability to control the size of the API particles is critical for effective absorption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_008.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
3a: Nasus powder technology: Particle size</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following graphic depicts the shape of powder particles as seen under scanning electron microscopy showing a mixture of two distinct
populations: the active ingredient and the carrier molecule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_009.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
3b: Nasus powder technology: Particle shape</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
has been long established that powder spray into the nose covers a significantly larger surface area of the nasal cavity compared to
liquid nasal spray. The liquid particles are heavier and tend to accumulate at the lower area of the nasal cavity (an area that is covered
by an epithelium that is less absorbent compared to the respiratory epithelium at the upper parts of the nasal cavity). According to
a review by Djupesland from 2013 in Drug Delivery and Translational Research entitled &ldquo;Nasal drug delivery devices: characteristics
and performance in a clinical perspective&mdash;a review,&rdquo; due to the significantly larger absorbent area after powder nasal administration,
drug absorption is more rapid and larger compared to liquid nasal spray. This phenomenon was also found in our clinical studies when
compared head-to-head with similar liquid nasal products. The following graphic depicts the drug liquid nasal spray distribution versus
powder drug distribution in the nasal cavity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_010.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
4a: Powder nasal spray achieves significantly larger absorption area compared to liquid spray.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table depicts
the comparative distribution of powder and liquid solution nasal sprays in a laboratory model called Nasal Cast. This table
was published by Aptar to demonstrate the difference between generic powder formulation (Lactose) and generic liquid formulation (Lactose),
using Aptar&rsquo;s UDS. The Nasal Cast in-vitro model includes representation of most of the potentially impacted areas of interest
within the nasal cavity. This includes the nose, nasal valve, floor of nasal cavity, turbinates, ethmoids, rhinopharynx and lung fractions.
This enables an understanding of the distribution of nasal drugs in the different compartments of the nose, that differ in their absorption
efficacy and potential brain penetrance. The data shown in this graphic uses Aptar&rsquo;s UDS product which is also used by us as
the delivery system for our intranasal powders. However, it does not specifically reflect the distribution of our powder formulation.
Nonetheless, the Nasal Cast model is an acceptable modeling method to determine the optimal device and formulation delivery approach
for specific products, as well as the inherent difference between powder and liquid nasal formulations. Although the model is not specific
to our powder formulation, it highlights key differences between powder-based and solution-based nasal spray, using the same formulations,
in terms of their distribution within the nasal cavity. In this specific table, it is shown that 50% of the liquid based nasal spray
can be found at the tip of the nasal cavity, an area that has less absorbent capacity, while the areas in which the absorption is efficient
such as the middle zone and the olfactory zone receive only about 36% of the solution. In comparison, almost 70% of nasal powder spray
land on the high-absorbent areas of the middle and olfactory zone. Thus, while the model does not represent our specific powder formulation,
we believe it provides useful comparative data that may support the understanding of nasal drug distribution, and may be relevant to
evaluating the potential of superior performance of powder-based nasal sprays over solution-based nasal sprays more generally. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_011.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
4b: Powder nasal spray achieves significantly larger absorption area compared to liquid spray.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Source:
Williams et al, In Vitro and In Vivo Assessment of Regional Nasal Deposition using Scintigraphy from a Nasal Spray and a Nasal Powder,
Respiratory Drug Delivery (2021).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
creation of uniform and spherical powder particles ensures that drug absorption will be stable without the known volatility of absorption
when particles with different sizes and shapes are used&mdash;therefore reducing the reproducibility of results. The following graphic
depicts powder particles as seen under scanning electron microscopy. On the left, irregular sizes of different third-party particles
that are used in the pharmaceutical industry. The top three images on left side of the graphic show examples of various nasal powder
formulations produced by adding different polymers using common milling technology. The bottom three images on the left side of the graphic
show particles of the same three compounds depicted above them, after processing them again for two hours, using the same common milling
technology. The powders on the left have various shapes and un-controlled particles. The right side of the graphic depicts the uniform
particles created by our PBI technology, as seen under scanning electron microscopy. Spheric drug-loaded particles are seen, among large
&ldquo;rocky shape&rdquo; lactose carrier particles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_012.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
5: Powder morphology -commercial and Nasus Pharma.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source for left side of
    Figure 5: Gieszinger P, Cs&oacute;ka I, Pallagi E, Katona G, J&oacute;j&aacute;rt-Laczkovich O, Szab&oacute;-R&eacute;v&eacute;sz
    P, Ambrus R. Preliminary study of nanonized lamotrigine containing products for nasal powder formulation. Drug Des Devel Ther. 2017
    Aug 23;11:2453-2466. doi: 10.2147/DDDT.S138559. PMID: 28860716; PMCID: PMC5574602.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Tech
Transfer, Scalability and Nasal Inhaler</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have previously been successful in completing</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> our scalability and
technology transfer to a European GMP FDA approved manufacturing facility and succeeded in manufacturing three commercial batches as
was required for NDA submission and filling the nasal inhaler device with powder. We recently initiated the tech transfer to
the European GMP FDA approved manufacturing facility <FONT STYLE="font-size: 10pt">for commercial size production of NS002 and expect
to utilize our prior experience for a successful completion of our scalability and technology transfer, including the manufacturing of
commercial batches for NDA submission and filling of NS002</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Aptar UDS
and collaboration</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have a collaboration agreement with Aptar, a leading global manufacturer of inhalers. On September 6, 2019, we entered into the MSA with
Aptar for services, including the performance of certain work, studies and analytical services in connection with our drug device product
development program. The MSA provides that the work and services to be performed are to be enumerated in schedules of work signed by
the parties for fees set forth in such schedules. Pursuant to the MSA, Aptar is required to use reasonable commercial efforts to meet
agreed upon timelines for providing the services to us. The MSA remains in effect for the later of a period of three years and the completion
of the services or other obligations set forth in executed schedules, unless earlier terminated in accordance with the terms and conditions
set forth therein. The rights and obligations of the parties under the MSA are ongoing and the MSA is in effect as of the date of this
prospectus. In addition, there are rights and obligations under the existing schedules that remain in effect for seven years following
the future launch of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Concurrently
with signing of the MSA, on September 6, 2019, we entered into a schedule of work related to Naloxone with Aptar, or the Naloxone SOW,
which provides that, for a fee of $1,350 thousand, comprising of $200 thousand in development stage, $350 thousand upon submission of
an NDA with the FDA (or equivalent) and $800 thousand at market launch, Aptar will provide support to us for the use and submission of
its intranasal UDS to be the delivery system for our Intranasal Naloxone powder. Any additional services requested by us, not included
in the Naloxone SOW, will be negotiated by us and Aptar in good faith on a fee for services basis. The Naloxone SOW also provides for
tier-based royalty payments upon commercialization of Intranasal Naloxone using Aptar&rsquo;s UDS for a period of up to seven years following
the first commercial sale which are as follows: 1% for up to $30 million; 1.2% for $30 million to $60 million; 1.4% for $60 million to
$100 million; and 1.6% for over $100 million. The Naloxone SOW has a termination fee of $450 thousand to be paid to Aptar if our Intranasal
Naloxone program is terminated for whatever reason, other than Aptar&rsquo;s breach of the agreement, or if we do not make applicable
filings to regulatory authorities within three years of the effective date of the agreement (which may be extended upon mutual agreement
for a period of six months). Through December 2020, we made a pre-IND filing with the FDA, and an additional filling related to Type
C meetings to review questions related to drug development. In addition, we made an equivalent IND filing with Health Canada before conducting
a registration study in Canada. As of the date of this prospectus, we have paid $200 thousand to Aptar in connection with the Naloxone
SOW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
April 20, 2020, we entered into a schedule of work related to Epinephrine, or the Epinephrine SOW, with Aptar governed under the same
terms and conditions set forth in the Naloxone SOW, the purpose of which was to extend Aptar&rsquo;s services to Intranasal Epinephrine.
For a fee of $675 thousand, comprising of $150 thousand in the development stage, $225 thousand upon a submission of an NDA with the
FDA (or equivalent) and $300 thousand at market launch. Aptar will provide support to us for the use and submission of its intranasal
UDS product to be the delivery system for our Intranasal Epinephrine powder. Any additional services requested by us, not included in
the Naloxone SOW, will be negotiated by us and Aptar in good faith on a fee for services basis. The Epinephrine SOW provides for certain
tiered-based royalty payments upon commercialization of Intranasal Epinephrine using Aptar&rsquo;s UDS for a period of up to seven years
following the first commercial sale. The Epinephrine SOW has a termination fee of $450 thousand to be paid to Aptar if our Intranasal
Epinephrine program is terminated for whatever reason, other than Aptar&rsquo;s breach of the agreement, we do not make applicable filings
to regulatory authorities within three years of the effective date of the agreement (which may be extended upon mutual agreement for
a period of six months). We made a pre-IND filing with the FDA, as well as equivalent filings with Health Canada and the Israeli
Health Ministry before performing our Phase 2 and Phase 3 studies of Intranasal Epinephrine. As of the date of this prospectus, we have
paid $150 thousand to Aptar in connection with the Epinephrine SOW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 16, 2021, we entered into a change order with respect to the Naloxone SOW, for the provision of additional services and deliverables
by Aptar related to Intranasal Naloxone, including but not limited to, the authoring of a reliability protocol (excludes execution of
the protocol), drafting of a fault tree analysis, data analysis post-execution of the reliability protocol, and authoring of the reliability
report, for a fee of &euro;100 thousand ($103), of which &euro;40 ($41) thousand was paid to Aptar prior to January 1, 2022, and the
remaining amounts will be paid upon NDA submission and FDA approval of Intranasal Naloxone, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the services received under the agreement by April 2022, there is an amount of $529 thousand outstanding to be paid to Aptar, which has
not been paid to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 5, 2022, we received a written notice from Aptar, or the Notice, based on our alleged breach of our contractual obligations under
the MSA concerning failure to cooperate with and outstanding payments in connection with services rendered by Aptar&rsquo;s subdivision,
NextBreath, in an aggregate amount of $1 million (which also includes termination fees of $450,000 in connection with the Naloxone SOW),
which set forth a period to cure the alleged breach within 15 days. We responded to the Notice on October 13, 2022 and on October 19,
2022, contesting Aptar&rsquo;s allegations set forth in the Notice and rejecting any grounds for termination by Aptar. Since our response
letters were sent in October 2022, we and Aptar discussed and exchanged further correspondence regarding the Notice through February
2023 and were unable to resolve the claims and allegations made by each party. Since February 2023, we have continued to purchase UDS
products from Aptar and, as of April 16, 2025, we have not received any further notices, demands or claims from Aptar concerning
the Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that we have operated and continue to operate in accordance with our contractual obligations under the MSA, Naloxone SOW and
Epinephrine SOW, or the Aptar Agreements. We further believe that Aptar and we are still operating based on the terms of the Aptar Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aptar
has collaborated, supported and performed the development of our drug device program with appropriate information and studies to support
the device information part submission to the FDA. The MSA calls for certain services to be performed to support our future NDA submission.
Aptar&rsquo;s UDS is a single-use, ready-to-use one-step nasal delivery device that can deliver a powder formulation in an emergency
situation quickly and easily. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release
the drug in a single powder puff into the nose, where the drug can be quickly absorbed via the nasal mucosa. Aptar&rsquo;s nasal UDS
is an alternative to injectable kits that may require assembly, including multistep, time-consuming steps. The UDS powder system we use,
depicted below, was recently approved by the FDA in conjunction with Eli Lilly and Company&rsquo;s emergency use glucagon for hypoglycaemia
(Baqsimi).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_013.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
6: Aptar&rsquo;s powder unidose system</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Intranasal
Epinephrine (NS002)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NS002
Intranasal Epinephrine, our primary product, is aimed at assisting in severe allergic reaction emergency situations. Clinical data has
shown that our product offered faster and quicker epinephrine absorption by needle-free treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Development
status</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
powder based intranasal epinephrine, NS002 or Intranasal Epinephrine, is being developed for acute intervention in cases of severe allergy
and anaphylactic shock. We are developing NS002 as a Section 505(b)(2) program. Our reference device is the EpiPen Autoinjector 0.3 mg
(EpiPen, Mylan Specialty L.P., USA). Our pilot study was prepared by a proprietary spray drying and blending process using the final
nasal inhaler that will be used in our commercial product. We have developed stable clinical trial material and performed a POC/pilot
study for NS002 followed by a dose finding/safety Phase 2 study. We have completed a 2-year stability study for our clinical trial material
proving complete stability of our powder that remained 100% pure without the characteristic enantiomeric conversion that usually develops
in liquid-based epinephrine formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Our pilot
study (NP002)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
conducted a pilot study of NS002 which we called NP002. Developing a successful intranasal product for anaphylaxis requires testing under
conditions of nasal congestions to reflect the status of the nasal mucosa during an anaphylaxis. To that end, our NP002 pilot study included
the testing of bioavailability of epinephrine under &ldquo;allergenic challenge&rdquo;- the creation of severe acute allergic reaction
in the nose by inserting ascending doses of allergens to the nose of the healthy volunteers with known allergic rhinitis included in
the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NP002
was an open-label, single-dose, two-period, three-treatment and fixed-sequence clinical study that compared epinephrine bioavailability
in 12 adults with seasonal allergic rhinitis. All participants received all treatments. NS002 (1.6 mg and 3.2 mg Epinephrine) was administered
intranasally to adults with and without a nasal allergenic challenge and compared to intramuscular, or IM, epinephrine (0.3 mg) injection
(EpiPen, Mylan Specialty L.P., USA). Epinephrine PKs were evaluated based on 21 plasma samples from each subject on each dosing
day. Clinical and safety assessments were done at screening, on dosing days and at the end of the study visit. The study was performed
at Hadassah Medical Center, Jerusalem, and approved by the hospital ethics committee, in accordance with GCP (NCT04696822 on clinicaltrials.gov.).
The results showed that epinephrine intranasal delivery of our NS002 followed the established characteristics of our platform technology&mdash;namely,
there were significantly higher levels of the drug in the plasma in situation where immediate administration could be lifesaving. Specifically,
time to plasma concertation of 100pg/ml is considered crucial since it is accepted that at this plasma level a clinical effect is starting.
Our 3.2 mg dosage under allergenic challenge was three times shorter compared to IM EpiPen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: 31pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: 31pt">NS002 (3.2 mg) Epinephrine
administered following an allergen challenge had the shortest median time to, the highest concentration of drug in the blood, or Cmax,
and the shortest median time to reach the clinical plasma threshold of 100 pg/mL. Both results reached statistical significance compared
to all other administrations. Mean epinephrine total amount of drug absorbed 0-8 hours following administration of NS002 3.2 mg
with and without an allergen challenge were similar but not significantly to higher than mean epinephrine total amount of drug absorbed
0-8 hours for EpiPen in all other administrations. Analysis showed that NS002 was well tolerated at both concentrations and most treatment-emergent
adverse events, or AEs, were mild and resolved spontaneously. Intranasal absorption of epinephrine was faster compared to that with EpiPen,
offering a clinical advantage in the short therapeutic window for the treatment of anaphylaxis while total epinephrine exposure was comparable.
The below graphic depicts the PK results of our Phase 1 study, which was aimed to test the safety of NS002 and evaluate the PK versus
the reference product:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: 31pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_014.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
7: NS002 PK results vs EpiPen, first 30 minutes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_015.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have published the detailed results of our pilot study in a prestigious scientific journal, the Journal of Allergy and Clinical Immunology,
in June 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Our Phase
2 dose-finding/safety study - NP006</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Phase 2 portion of our NS002 study, or NP006, aimed at defining the final clinical dose to be used in our powder epinephrine product.
The NP006 study compared the bioavailability of epinephrine following a single nasal dose of NS002 Microspheres Epinephrine powder either
3.6 mg, or 4 mg with EpiPen 0.3 mg intramuscular injection in healthy adult volunteers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NP006
was an open-label, single-dose, three-treatment, randomized, three-sequence, comparative bioavailability study. Twelve healthy volunteers
were randomized to receive intranasal 3.6 mg, 4.0 mg and Epinephrine IM 0.3 mg at weekly intervals. Epinephrine PKs were evaluated
based on 13 plasma samples of the first two hours after administration from each subject on each dosing day. Clinical and safety assessments
were done at screening, on dosing days and at the end of the study visit. The study was performed at Hadassah Medical Center, Jerusalem,
and approved by the hospital ethics committee, in accordance with GCP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PK results of our Phase 2 study are in line with the known attributes of our nasal powder technology&mdash;namely: immediate absorption
of epinephrine and reaching higher peak plasma epinephrine levels quicker compared to IM Epinephrine injections. No less significant
are the pharmacodynamic results that are fully comparable to those of our reference product&mdash;IM Epinephrine&mdash;reflecting the
actual effect of Epinephrine in the body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
is well established that the therapeutic window in anaphylactic shock is very short and ranges between a few minutes up to 25 minutes.
The immediate creation of clinically significant levels of epinephrine in the plasma could well mean saving lives. In this context the
results of our Phase 2 study, these results potentially indicate the advantages of our nasal powder Epinephrine over IM injection as
well as other competing technologies below. Further clinical testing will need to be performed to confirm these results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
that context it is worth noting the following: the levels of Epinephrine in the plasma after 3.6 mg and 4 mg in the first 4, 10, 20 and
30 minutes was consistently higher compared to those after IM Epinephrine administration. Although the Phase 2 study was not powered
for statistical significance, the result of the study indicated a very strong and robust effect of NS002 compared to EpiPen, resulting
in reaching statistical significance after four minutes. However, in trials not powered for statistical significance, there is a high
chance that observed effects may not be real due to small sample size. The following graphic depicts the area under the curve, or
AUC, of Epinephrine concentration in the plasma in the first 30 minutes after administration showing higher amounts of Epinephrine
in the plasma after intranasal administration of either 3.6 mg and 4 mg Epinephrine compared to intramuscular injection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_016.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
8: AUC after dosing Phase 2 study</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
significant results observed in the NP006 study were:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The time to reach a clinical
    threshold level in the plasma (T100pg) was about a third compared to IM injections (3.6 minutes compared to 9 minutes or 0.15h compared
    to 0.067h)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The time until maximums
    amounts of Epinephrine were absorbed (T max) was shorter after nasal administration (10 minutes or 0.17h compared to 14.6 minutes
    or 0.245 h)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total amount of Epinpehrine
    absorbed was higher compared to IM administration (477pg/ml vs 360pg/ml)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following graphic depicts that in additional PK parameters NS002 was better compared to intramuscular injection: the time to maximum
concentration of epinephrine in the blood, or T max, and the time to the clinical threshold (T100pg) was shorter and the Cmax (maximum
concentration) was higher.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_017.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
9: PK results Phase 2 study</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
less important are the pharmacodynamic results which point to the potential biological activity of the absorbed epinephrine compared
to the injected reference product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
two main pharmacodynamics, or PD, and safety parameters reflect the biological effect of epinephrine: systolic blood pressure and heart
rate. These two hemodynamic parameters are the mainstay of the epinephrine activity in the body and potentially safety indicators. As
can be seen there is no significant difference in the effect of epinephrine on blood pressure and heart rate and more importantly (as
will be discussed in the competitor analysis) the PD characteristics of our intranasal epinephrine follow the same trend of the IM reference
EpiPen. The following graphics depicts the changes in heart rate and blood pressure following administration of either intranasal
doses (3.6 mg and 4 mg) compared in intramuscular injection (EpiPen). As can be seen the pharmacodynamic changes follow closely the pattern
of EpiPen and all changes from base line still remain within normal limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_018.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Sans-Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_019.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Figure
10: PD parameters systolic BP and HR</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
our studies of NS002, the primary objective was to evaluate the comparative bioavailability of NS002 against the reference product, EpiPen,
and the secondary objective was to evaluate the safety and tolerability of NS002. None of the studies of NS002 were powered for statistical
significance, but a statistically significant difference was found nonetheless. The result of the study indicated a very strong and robust
effect of NS002 compared to EpiPen, resulting in reaching statistical significance. However, in trials not powered for statistical significance,
there is a high chance that observed effects may not be real due to small sample size. Specifically, the NP002 study showed comparable
or superior PK profile especially during the first 30 minutes in a simulation of the real-life nasal congestion that occurs in severe
allergic reactions, while the NP006 study indicated that 4mg of NS002 is absorbed faster and achieves the clinical threshold faster than
the reference product. There were no significant adverse events and NS002 was tolerated at both concentrations tested whether it was
with or without an allergen test. No unexpected safety signals were observed in the NP002 studies we performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intranasal
Naloxone (NS001)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our Naloxone has the answer to the issues of slower and lower absorption of Naloxone in currently approved products during
medical emergencies that necessitate immediate drug administration. It is able to create significantly higher plasma levels of Naloxone
in the blood starting from first minutes and up to one hour against the 4 mg Narcan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
explained above, our powder technology enjoys an inherent advantage over liquid nasal products based on larger absorption area achieved
by powder and a rapid and repeatable absorption based on the uniform spherical powder particles of our proprietary formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to focus our development and regulatory approval efforts on our Intranasal Epinephrine and other preclinical programs,
and plan to pursue partnering opportunities for further development of NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Development
status of NS001 &ndash; Powder Naloxone program.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paused our development of NS001. We currently plan to pursue partnering opportunities for further development of NS001. Future development
under partnership, if any, would include (1) a stability study with reliability study, (2) a usability study and (3) a short two-week
preclinical safety study in rats to study the effects of the products in histology of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NS001
was being developed under a Section 505(b)(2) application under the FFDCA as an approved molecule and a similar delivery route. The reference
device is Narcan. The following are the steps that need to be completed in order to submit an NDA dossier for marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
    scale up of manufacturing and manufacturing of three commercial batches;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filling
    up the devices; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
    a stability study.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
pilot study and a pivotal clinical study of NS001, NP001 and NPNAL004, were performed in 14 and 42 healthy volunteers, respectively,
according to a similar protocol. The primary objective in both studies was to evaluate the comparative bioavailability of naloxone between
NS001 (FMXIN001) Naloxone Microspheres Powder 4 mg for Nasal Application (Nasus Pharma, Israel) and Narcan&reg; (naloxone HCl) nasal
spray 4 mg (Adapt Pharma, Inc., USA) after a single dose in healthy subjects under fasting conditions. The secondary objective was to
evaluate the safety and tolerability of the study treatments (NCT04713709). The pilot study results were submitted to the FDA in support
of the progression to the pivotal study. The results of the pilot study showed our technology having a significantly faster absorption
rate in the immediate critical period after administration and that it was well tolerated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    partial AUC0-4 minutes was approximately 7-fold higher;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    partial AUC0-10 minutes was approximately 4-fold higher;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    partial AUC10-30 minutes was approximately 1.6-fold higher;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    total systemic exposure was approximately 1.26-fold higher;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    peak systemic exposure was approximately 1.6-fold higher; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    median Tmax occurred approximately 5 minutes earlier.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graphic depicts the levels of Naloxone in the blood after administration of either our NS001 Intranasal Naloxone or Narcan.
Our NS001 creates higher levels of Naloxone in the blood as well as creates higher levels in the first few minutes &ndash; the important
therapeutic window.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;<IMG SRC="formdrsa_020.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
11: NSOO1 (FMXIN001) pilot study PK profile compared to Narcan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pivotal study comprised of 42 healthy volunteers and consistently showed the same characteristics: significant advantage in the first
30 minutes after administration. We have completed a majority of the development plan and will need to establish a full stability study
before submitting to FDA. If our management so decides, based on market conditions, demand for the product candidate and our ability
to obtain appropriate financing, we believe we will be able to complete the program within the next 24 months. The following graphic
depicts the results of the pivotal study of NS001 versus Narcan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Table
1: Results of pivotal study NS001 (FMXIN001) vs Narcan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrsa_021.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrsa_022.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
12: NS001 Pivotal study results</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrsa_023.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
13: NS001 vs Narcan Pivotal study- significant higher absorption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
NS001 and Narcan were well tolerated by the volunteers in the study. The incidence of mild side effects that resolved spontaneously before
the study ended (within a few hours) was similar between the study treatments. The most common side effect was nasal congestion. No serious
side effects were found, and all volunteers completed the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our studies of NS001, NP001 and NPNAL004, the primary objective was to evaluate the comparative bioavailability of NS001 against the
reference product, Narcan, and the secondary objective was to evaluate the safety and tolerability of NS001. Only the NPNAL004 study
of NS001 was powered for statistical significance, but a statistically significant difference was found in both studies. Specifically,
14 subjects were enrolled into this study (NP001). The sample size chosen for this study was not based on any formal calculation or published
literature but was considered to be adequate for this explorative PK bioequivalence study. The study was not expected to demonstrate
statistical power, or the means to learn the statistical significance, but to provide preliminary assessment of the PK and safety profiles
for Naloxone. Nonetheless, the result of the study indicated a very strong and robust effect of NS001 compared to Narcan, resulting in
reaching statistical significance. Overall, the results were specifically significant in that 4mg of NS001 displayed greater peak and
total systemic exposure, with earlier onset of action when compared to the reference product after a single dose in healthy subjects
with allergic rhinitis. In NPNAL004, the results were statistically significant in the working assumption that the NS001 drug delivery
system is either comparable or superior to the reference product while maintaining the effectiveness of the treatment. However, in trials
not powered for statistical significance, there is a high chance that observed effects may not be accurate due to small sample size.
There were no significant adverse events in these studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our powder intranasal technology showed consistent advantage, including quicker and higher absorption, over the current
market leader in intranasal Naloxone. This advantage is highly meaningful clinically since it creates higher plasma levels of the antidote
in the most critical first few minutes of overdose rescue. We have published our results in a highly respected journal in an article
titled &ldquo;A Novel Faster-Acting, Dry Powered-Based, Naloxone, Intranasal Formulation for Opioid Overdose,&rdquo; published in Pharmacy
Res in 2022, providing a scientific overview of our NS001 product. NS001 was named as having a high (4.2) impact factor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a unique intranasal powder technology that has been tested in multiple clinical studies as well as in preclinical work
in multiple molecules. This technology enables quick and efficient absorption of the drug through the nasal cavity, making it especially
suitable for the treatment of medical emergencies. Using a nasal inhaler for immediate rescue of a patient is simple and does not require
waiting for medical professionals to reach the patient. Our PBI technology has been scaled up for commercial uses and passed successfully
both the tech transfer and the commercial scaleup.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
leadership and executives are highly experienced biotech executives that have accumulated precious experience with regards to our technology
as well as relevant industry experience. Further, we maintain a strong IP position with multiple patents already approved and many others
in different stages of examination worldwide. We have developed a strong strategy covering further development and product commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Commercialization Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategic objective is to develop and commercialize our PBI products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to further advance our breakthrough technologies and commercialization efforts. To achieve these objectives, we plan to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Seek
    partnerships to accelerate and maximize the potential for our advanced programs.</I> As we continue to generate data, we will seek
    partnering opportunities with pharmaceutical companies that have established development and sales and marketing capabilities to
    potentially enhance and accelerate the development and commercialization of our products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Seek
    partnerships to potentially commercialize our products. </I>We plan to pursue partnering opportunities for NS001. We plan to focus
    our development efforts on our other programs, NS002 and additional pipeline programs for different indications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Explore
    regulatory approval of our products outside the United States</I>. We are working on getting scientific advice from several European
    countries to advance our products approval in the European Union. </FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    our platform technology and accumulated knowledge and experience to further develop additional pipeline programs for different indications
    than anaphylaxis and opioid overdose. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competitors
and Market for NS001</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
Emergent BioSolutions Inc.&rsquo;s acquisition of Narcan in 2017, its sales of Narcan consistently beat the market expectation as well
as the company&rsquo;s own estimation. The intranasal Naloxone Narcan sales since first launched showed a CAGR above 23%:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Table
2: Narcan sales 2018 &ndash; 2021 (U.S. dollars in millions)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 83%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sales</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">280</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">373</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">434</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">374</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">488</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reached
    119 in first quarter</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the end of 2021, several new players entered the market. Teva and Sandoz Inc. recently won an intellectual property legal battle against
Emergent, the sole manufacturer of Narcan in the last 4 years. Given this, they are allowed to distribute authorized generics of Narcan
at a price around $40-80 compared to the $130-140 market price for Narcan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notably,
however, according to a market study by Vantage Market Research in 2022 entitled &ldquo;Naloxone Spray Market,&rdquo; intranasal Naloxone
is gradually replacing the $2 billion injectable Naloxone market, and therefore, the whole market is estimated to reach $785 million
in 2025 at a CAGR of 22.3%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, the FDA approved Summit Biosciences Inc.&rsquo;s Rozeopy, which is a 10 mg nasal solution for emergency treatment of known
or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients.
Another recent entrant to the market is Hikma Pharmaceuticals, with its product, Kloxxado. This product recently received emergency use
authorization from the FDA for an 8 mg liquid nasal spray, compared to 4 mg of Narcan. Our NS001 creates high plasma levels in the first
minutes after administration, the critical therapeutic window in our clinical studies performed thus far, which have had small patient
sample sizes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competitors
and Market for NS002</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no approved PBI epinephrine products in the market. Based on an article titled Anaphylaxis &ndash; StatPearls published in
the National Library of Medicine, the estimated prevalence of anaphylaxis among the global population is approximately between 1% and
3%. According to market research by Fortune Business Insights, the global epinephrine market size was valued at $2.3 billion in 2024
and is projected to grow to $4.4 billion by 2032. Most of the growth is attributed to growth of the autoinjector sections and anaphylaxis.
Based on <FONT STYLE="background-color: white">the Cantor Fitzgerald Research and </FONT>Raymond James Research, in 2024, the
revenues in the global epinephrine market increased by more than 12.7% year-over-year in 2023 at a CAGR of 6.5% from 2010 to 2023, mainly
as a result of sales growth of Epinephrine. There are a number of companies working on alternative administration routes and formulas
of Epinephrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epinephrine
IM injections are currently considered the standard of care for severe allergic reaction and anaphylactic shock. We believe our PBI technology
is superior to the reference product used in our studies, EpiPen, because it had a higher nasal absorption rate in head-to-head studies
(albeit in small patient populations) due to the physical properties of powder particles versus solution particles. Absorption area of
powder in the nose is larger and, therefore, the initial absorption rate is quicker and higher. At this time there are a number of programs
in development aiming to find an alternative to injections. Two programs are developing intranasal liquid-based epinephrine&mdash;ARS
Pharmaceuticals, Inc. (whose product, Neffy, was recently approved by the FDA) and Bryn Pharma. There is another program that is developing
PBI epinephrine (Orexo). Another program that is competing in this field is Aquestive Therapeutics Inc., which is developing a sublingual
film of epinephrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PK
Data of Competing Products </I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
PK parameters provide insight into the absorption characteristics of each product. We believe it is important to interpret the results
of clinical studies in the context of the intranasal epinephrine market.&nbsp;Although there has not been a head-to-head study comparing
the four product candidates, the four studies presented below were conducted to&nbsp;explore the PK of epinephrine to support FDA approval
of the product candidates and included similar study designs, patient populations, study endpoints and follow-up periods in compliances
with FDA standard requirement &nbsp;for 505(b)(2) approval.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ARS</I></B></FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the FDA Briefing Document NDA/BLA# 214697 prepared for the Drug Advisory Committee meeting in May 2023, which preceded Neffy&rsquo;s
approval, ARS&rsquo;s intranasal epinephrine product demonstrated a Cmax of 341 pg/ml, with a median time to reach Cmax (Tmax) of 30
minutes. The early exposure profile showed an AUC of 712 h/pg/ml over the first 10 minutes, increasing to 4,901
h/pg/ml over 30 minutes. The median and mean times to reach a plasma concentration of 100 pg/ml (T100 pg/ml) were 10 and 21 minutes,
respectively. At 5 minutes, 15% of subjects had reached this concentration, increasing to 60% at 10 minutes and 83% at 30 minutes.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bryn
Pharma</I></B></FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on a study published by David A. Dworaczyk et al in the Journal of Allergy and Clinical Immunology (JACI) in December 2023 entitled &ldquo;A
13.2 mg Intranasal Epinephrine Spray Demonstrates Comparable Pharmacokinetics, Pharmacodynamics, and Safety to 0.3 mg Epinephrine Autoinjector,&rdquo;
Bryn Pharma&rsquo;s intranasal epinephrine product achieved a Cmax of 429 pg/ml, with a Tmax of 20 minutes. The AUC over the first 10
minutes was 1,130 h/pg/ml, and over 30 minutes, it reached 6,789 h/pg/ml. While the median and mean T100 pg/ml values were not reported,
the percentage of subjects reaching a plasma concentration of 100 pg/ml was 17% at 5 minutes and 60% at 10 minutes.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orexo</I></B></FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to publicly available patent filings (U.S. Patent No. 11,957,647 and related patents), Orexo&rsquo;s intranasal epinephrine formulation
exhibited a Cmax of 377 pg/ml, with a Tmax of 25 minutes. The early exposure profile showed an AUC of 912 h/pg/ml over the first 10 minutes
and 5,796 h/pg/ml over the first 30 minutes. The mean time to reach a plasma concentration of 100 pg/ml was reported as 5 minutes.</FONT> </P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Aquestive</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-indent: 0.5in; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
reported in a Cantor research report from December 2024, Aquestive&rsquo;s intranasal epinephrine product demonstrated a Cmax of 497
pg/ml, with a Tmax of 15 minutes. The early exposure AUC was 1,074 h/pg/ml over the first 10 minutes and 6,900 h/pg/ml over the first
30 minutes. The mean time to reach a plasma concentration of 100 pg/ml was 10 minutes. At 10 minutes, 82% of subjects had reached this
concentration, increasing to 91% at 15 minutes.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graphic depicts our PBI products in terms of long-term stability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrsa_025.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Figure:
Enantiomeric stability Nasus vs EpiPen and EpiPen Junior</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legacy
Product</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
legacy product, Taffix, an innovative personal powder nasal spray which is used to block viruses within the nasal cavity, has been discontinued
in order for us to focus on our current products and activities. We started the wind-down of operations with respect to Taffix in December
2021, and ceased all operations by end of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek patent protection as well as other effective intellectual property rights for our products and technologies in the United States
and internationally. Our policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the
technology, inventions and improvements that are commercially important to the development of our business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intranasal powder-based Naloxone technology is covered by a granted U.S. patent, US 11,202,757 B2, with a priority date of December 1,
2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current intellectual property portfolio consists of two patent families.
Patents of the first family relate to dry powder formulations for intranasal delivery, and cover our basic powder formulation for intranasal
administration of APIs. In this family we have four granted patents in the U.S. (one of which is specifically covering Naloxone), one
granted patent in India, one granted patent in Japan and one granted patent in Israel. We have pending applications under examination
in Europe by the European Patent Office, or EPO, Australia, Canada and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second family of patents relates to dry powder formulations for intranasal delivery of epinephrine. In this family we have one granted
patent in the U.S., and pending applications in the U.S., Argentina, Taiwan, Australia, Brazil, Canada, China, Europe, India, Israel,
Japan, Mexico, New Zealand and South Korea.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables below provide certain information regarding our intellectual property portfolio, all of which we owned as of April 16,
2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dry
powder compositions for intranasal delivery</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
                                            No./</B></FONT></P>
    <P STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
    No.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                            Date/</B></FONT></P>
    <P STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pub.
    Date</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 9%"><P STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
                                            Date<SUP>(2)</SUP></B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/20/2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    Ended</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WO</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/038756
    A1</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Phase entered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Fee Paid</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    Action due: 10/22/2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    110996912 A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/10/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    in progress</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3668490</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/24/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416927</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/05/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proof
    of Use due: 9/30/ 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">272220</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/02/2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7334145</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/18/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,331,270</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/17/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/19/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,844,859</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
    Specific to opioid receptor antagonists (Naloxone etc.)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,202,757</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,116,723</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    Cooperation Treaty, or PCT.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    dates for pending patents or PCT applications are estimated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Treatment
with powdered intranasal Epinephrine</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    No./ </B>Publication No.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Date/ Publication Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Status</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date<SUP>(1)</SUP></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    Ended</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,400,045</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/02/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR121593
    A1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/22/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WO
    2021/186437</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/23/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Phase entered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request
    for Exam: 11/16/2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request
    for Exam: Mar 16, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    115279340 A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/01/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    in progress</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4121005</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/25/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    in progress</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awaiting
    Examination</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2022/011
    464</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/13/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Phase entered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    dates for pending patents or PCT applications are estimated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sustained-release
intranasal pharmaceutical composition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
                                            No./</B></FONT></P>
    <P STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
    No.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                            Date/</B></FONT></P>
    <P STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pub.
    Date</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 29%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    Provisional</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convention
    due 4/15/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/15/2045</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    dates for pending patents or PCT applications are estimated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain
that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed
by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially
useful in protecting our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in part, on an intellectual property portfolio that supports future revenue streams and erects barriers to our competitors.
We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing
and acquiring new patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
these measures, any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or
misappropriated. Intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market
trends or otherwise to provide competitive one (see &ldquo;<I>Risk Factors&mdash;Risks Related to our Intellectual Property</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;<I>Related Party Transactions&mdash;Formulex License Agreement</I>&rdquo; for information regarding our license agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Production
and Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on prior work already completed for our Naloxone product, we identified and were successful in building a manufacturing process through
FDA and EMA approved vendors in Europe and the U.S. We have succeeded in scaling up the manufacturing process for commercial quantities
as well as collaborating with a filling and packaging FDA approved vendor for adaptation of a specific filling line to our specific needs.
We expect to utilize our prior experience in successfully building a manufacturing process for our other product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described herein, we are developing NS002 Intranasal Epinephrine to treat anaphylactic shock and severe allergic reaction. NS002 is being
developed under a Section 505(b)(2) application under the FFDCA Act as an approved molecule and a new delivery route. The reference device
is EpiPen autoinjector. The following are the steps, based on discussions with the FDA, that need to be completed in order to submit
our NDA dossier for marketing approval, all of which is subject to consummation of this offering and us obtaining sufficient funding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scaling
    up of powder production to commercial size batches. We initiated the tech transfer to a third-party manufacturer for commercial
    size production in the first quarter of 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
    studies, or short two-week animal safety studies in two animal species. These studies will entail giving several doses of Intranasal
    Epinephrine to the animals and later estimating via histology if there is potential damage to the relevant tissues such as the nose,
    pharynx or lungs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    effect of two concurrent doses and the effect of prior dose on the absorption of the next dose, or the Carry-Over Effect study (Phase
    2). We intend to perform two additional Phase 2 studies of NS002. The first will be aimed at determining whether, if necessary, during
    a real-life anaphylaxis a second dose of NS002 should be administered in the same nostril as the one used for the first administration
    or whether it should be in the other nostril as it is important to learn which method of administration is more effective and safer
    for use in case a second dose is deemed necessary. The second Phase 2 study will test the &ldquo;carry-over effect,&rdquo; or whether
    the first dose of epinephrine changes the absorption of epinephrine of a following dose. In other words, this study will test how
    efficiently the absorption was after a first dose was already administered. The primary objective will be to make sure that Intranasal
    Epinephrine did not lower the absorption of a second dose. These studies have been agreed upon with the FDA as required studies for
    submission. We intend to initiate the first additional Phase 2 study of NS002 in the second quarter of 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    submission is planned for the first quarter of 2026 following the successful completion of the additional Phase 2 studies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of our Phase 3 study, or pivotal clinical study, prior to submission to the FDA for marketing approval, subject to the successful
    completion of the additional Phase 2 studies. The study will be conducted in healthy volunteers where NS002 or EpiPen will be administered
    by health care professionals. The study will also include a subsection of self-administration by the subjects to collect information
    on self-use. This requirement of the study for submission has also been agreed upon with the FDA as a required study for submission.
    We intend to initiate the study by the first quarter of 2026. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
    study, the details of which will be agreed upon with the FDA as we progress with the program. We intend to initiate the study
    by the second quarter of 2026 </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stability
testing that will test the product under various temperature and humidity points.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliability
    testing, which is a subset of the stability study that tests the products administration device in several potential conditions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Usability
    study, which tests how user friendly the device is.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on prior work already completed for our Intranasal Naloxone product, we identified and were successful in building a manufacturing process
through FDA and EMA approved vendors in Europe and the U.S. We have succeeded in scaling up the manufacturing process for commercial
quantities as well as collaborating with a filling and packaging FDA approved vendor for adaptation of a specific filling line to our
specific needs. We intend to submit our NDA dossier for marketing approval of NS002 by the fourth quarter of 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paused our development of NS001 Intranasal Naloxone to treat opioid overdose. We currently plan to pursue partnering opportunities
for further development of NS001. Future development under partnership, if any, would include (1) a stability study with reliability
study, (2) a usability study and (3) a short two-week preclinical safety study in rats to study the effects of the products in histology
of the product. NS001 was being developed under a Section 505(b)(2) application under the FFDCA, which allows the applicant to rely in
part on previous studies conducted by unrelated parties, such as another drug manufacturer and virtually any source including published
literature, for marketing approval by the FDA in the United States, as an approved molecule and a similar delivery route. The reference
device is Narcan. The following are the steps that need to be completed in order to submit an NDA dossier for marketing approval:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
    scale up of manufacturing and manufacturing of three commercial batches;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
    study, or short two-week animal safety studies in one animal species (we have already completed one such study in a second animal
    species). This study will entail giving several doses of Intranasal Naloxone to the animals and later estimating via histology if
    there is a potential damage to the relevant tissues such as the nose, pharynx or lungs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filling
    up the devices; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
    a stability study.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
perform the above steps, three batches of NS001 will need to be manufactured in quantities that are equivalent to the quantities that
will be needed for commercial use in the future (i.e. commercial batches) and fill the nasal inhalers with the powder. NS001 will then
need to be tested at various temperature (room temperature or accelerated conditions) and humidity points (40% and 75%) to determine
whether they continue to function in terms of the characteristics of the powder emitted and quality and activity of the molecules. The
room temperature program is a two-year program, during which devices are tested every three months in the first year and later twice
a year until the 24<SUP>th</SUP> month. The accelerated program is for six months only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
development under a partnership would require completion of the following studies after we receive FDA input on our suggested protocols:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliability
    study, which is a subset of the stability study that tests the products administration device in several potential conditions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Usability
    study, which tests how use-friendly the device is; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    short preclinical study in rats that will involve a one-time administration of NS001 to animals and follow up at different time points
    up to two weeks to study the histology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently intend to submit an NDA for NS001 to the FDA for marketing approval. If we submit an NDA for NS001 in the future under
a partnership or otherwise, our submission may not lead to a faster development or review process compared to traditional approval pathways
and does not increase the likelihood that NS001 will receive regulatory approval in the United States or the European Union. For further
information, see &ldquo;<I>Risk Factors&mdash;Our product candidates are in different stages of clinical development. Clinical drug development
is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates are
prolonged, delayed or not commercially viable, we or our collaborators may be unable to obtain required regulatory approvals, and therefore
may be unable to commercialize our product candidates on a timely basis or at all, which will adversely affect our business</I>&rdquo;
and &ldquo;<I>Risk Factors&mdash;Our development and regulatory strategy for our product candidates depends in part on published scientific
literature and the FDA&rsquo;s prior findings regarding the safety and efficacy of approved product candidates. If the FDA does not conclude
that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for
our product candidates under Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost
significantly more and entail significantly greater complications and risks than anticipated and in either case may not be successful</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, we entered into a non-recurring research and development arrangement with a governmental body. As part of the arrangement,
we performed certain research and development activities in connection with NS001. We no longer provide services under this arrangement
and do not have any future obligations or other contractual commitment to repay the amounts received or otherwise under this arrangement
in the future, and intellectual property and know-how, if any, resulted from the performance of such research and development activities
will remain with the Company. Additionally, we do not provide research and development services as part of our central operations. For
further information, see &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Research
and Development Expenses</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our two main products, Intranasal Epinephrine and Intranasal Naloxone, we are exploring other potential indications for which
our PBI technology may be applicable, including: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NS005:
                                            An Intranasal Midazolam powder nasal spray for the treatment of acute seizures; </FONT> </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NS004:
                                            An Intranasal Atropine; and </FONT> </TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &#9679; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NS003:
                                            An Intranasal Ondansetron powder nasal spray for the treatment of intractable vomiting.</FONT> </TD></TR>
                                                                                                                                                                                                                                               </TABLE>

<P STYLE="margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="vi_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have conducted feasibility studies to evaluate the potential of developing nasal powder formulations for ondansetron, atropine, and midazolam.
These studies included small-scale manufacturing, analytical method development, and, in the case of atropine, preclinical PK evaluations
in animals. The results of these studies are summarized below.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NS003:
Intranasal Ondansetron</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lab-scale proof-of-concept study demonstrated the feasibility of producing ondansetron hydrochloride as a nasal powder formulation. Small-scale
manufacturing yielded a white, flowable powder with no aggregation issues, and an appropriate analytical method was developed to characterize
the formulation. The total yield was 77.8%, with an assay result of 352 mg/g of ondansetron hydrochloride. Based on these findings, the
maximum dose of the active ingredient that can be incorporated into the device as a solo API is 20 mg.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NS004:
Intranasal Atropine</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lab-scale proof-of-concept study was conducted to evaluate the feasibility of developing a nasal powder formulation of atropine. Small-scale
manufacturing produced a white, flowable powder without aggregation, and laser particle size distribution analysis confirmed two distinct
populations: API with a mean particle size of 12 microns and lactose with a mean particle size of 100 microns. The total yield was above
80%, and an analytical method was developed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further assess the feasibility of intranasal atropine administration, an animal study was conducted in male Sprague Dawley (SD) rats.
&nbsp;&nbsp;The study compared the PK profile of atropine following intranasal administration at doses of 3 mg and 9 mg (human-equivalent
doses) to that of an IM dose equivalent to 1 mg of atropine in humans. The bioanalytical method used in the study was developed. The
results demonstrated that intranasal administration of atropine is feasible and can serve as an alternative to IM injection. Furthermore,
dose adjustments of the intranasal formulation can be performed to achieve the required blood concentration levels. Based on prior experience
with similar drug formulations, it is estimated that a 20 mg dose of nasal atropine using our powder technology would be bioequivalent
to a 2 mg IM injection. The formulation was observed to be well tolerated in the animal study, with no safety concerns observed.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NS005:
Intranasal Midazolam</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
specialized formulation is being developed for midazolam to enhance its water solubility while maintaining a pH suitable for nasal delivery.
The formulation produced was a white, flowable powder with two distinct particle populations, as confirmed by laser diffraction analysis:
API with a mean particle size of 10 microns and lactose with a mean particle size of 100 microns. An appropriate analytical method was
developed, and the formulation demonstrated a yield of 62% with an assay result of 193 mg/g. Based on this feasibility study, the maximum
dose of midazolam hydrochloride that can be incorporated into the device as a solo API is 10 mg.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
feasibility studies support the potential for developing intranasal powder formulations of Intranasal Ondansetron, Intranasal Atropine,
and Intranasal Midazolam. Further development, including clinical evaluations, will be necessary to assess their safety and efficacy
in humans.</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon
the clinical development, manufacturing and marketing of pharmaceutical products. These agencies and other federal, state and local entities
regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage,
packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Government Regulation of Drug Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the FFDCA and its implementing regulations. The process of obtaining regulatory approvals
and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of
substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the
FDA&rsquo;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before drug product candidates may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nonclinical
    laboratory and animal tests that must be conducted in accordance with good laboratory practices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    of an IND, which must become effective before clinical trials may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ethical
    approval of the clinical research by an independent institutional review board, or IRB, for each clinical site or centrally before
    each trial may be initiated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended
    use, performed in accordance with good clinical practices, or GCPs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA and payment of user fees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and GCPs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    of the drug product in accordance with good manufacturing practices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    approval of an NDA to permit commercial marketing for particular indications for use; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy,
    or REMS, and the potential requirement to conduct post-approval studies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing and approval process requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation
of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess potential safety
and efficacy. Prior to commencing the first clinical trial in the U.S. with a product candidate, we must submit the results of the preclinical
tests and preclinical literature, together with manufacturing information, analytical data and any available clinical data or literature,
among other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions
about the conduct of the clinical trial or information in the IND, which may result in a clinical hold. In such a case, the IND sponsor
and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND does not result in FDA authorization
to commence a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements. A separate submission of the clinical protocol to the existing IND must be made for each successive
clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent
IRB for each study site proposing to conduct the clinical trial must review and approve the plan for any clinical trial, its informed
consent form and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee
the clinical trial while it is being conducted, including any changes to the study plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that
the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&rsquo;s
or the IRB&rsquo;s requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business
objectives or competitive climate. Some studies also include a data safety monitoring board, which receives special access to unblinded
data during the clinical trial and may advise the study sponsor to halt the clinical trial if it determines that there is an unacceptable
safety risk to subjects or other grounds, such as no demonstration of efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1&mdash;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships,
    mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease
    or condition. If possible, Phase 1 clinical trials may also be used to gain an initial indication of product effectiveness.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2&mdash;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to
    evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical
    trials may be conducted to obtain information prior to beginning larger and more expansive Phase 3 clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3&mdash;These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical
    efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials
    are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These
    clinical trials may be done globally to support global registrations so long as the global sites are also representative of the U.S.
    population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may
be made a condition to be satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate
and can provide important safety information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted under the supervision of qualified investigators in accordance with GCP requirements, which includes the requirements
that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and
approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to
make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives
of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical
analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within
specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs
and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling
and distribution. Further, the export of investigational drug products outside of the United States is subject to regulatory requirements
of the receiving country as well as U.S. export requirements under the FFDCA. Progress reports detailing the results of the clinical
trials must be submitted at least annually to the FDA and the IRB and more frequently if serious adverse effects occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product.
Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orange
Book Listing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims
cover the applicant&rsquo;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published
in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
applicant who files a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA (1) that no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) that such patent has expired; (3) the date
on which such patent expires; or (4) that such patent is invalid or will not be infringed upon by the manufacture, use or sale of the
drug product for which the application is submitted. This last certification is known as a Paragraph IV certification. Generally, the
505(b)(2) NDA cannot be approved until all listed patents have expired, except where the 505(b)(2) NDA applicant challenges a listed
patent through a Paragraph IV certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification
to the holder of the NDA for the reference listed drug and the patent owner once the application has been accepted for filing by the
FDA. The applicant may also elect to submit a &ldquo;section viii&rdquo; statement certifying that its proposed label does not contain
(or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. The NDA holder
or patent owner may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing
of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification prevents the FDA from approving the application
until the earlier of 30 months from the date of the lawsuit, expiration of the patent, settlement of the lawsuit, a decision in the infringement
case that is favorable to the applicant or such shorter or longer period as may be ordered by a court. This prohibition is generally
referred to as the 30-month stay. In instances where a 505(b)(2) NDA applicant files a Paragraph IV certification, the NDA holder or
patent owner regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months
or years to resolve. Thus, approval of a 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification
the applicant makes and the reference drug sponsor&rsquo;s decision to initiate patent litigation. To our knowledge, we will not need
to challenge intellectual property rights via a Paragraph IV certification in connection with our 505(b)(2) NDA filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA provides periods of non-patent regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition
in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&rsquo;s
approval of the NDA. Five years of exclusivity are available to new chemical entities, or NCEs. An NCE is a drug that contains no active
moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions
of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent,
or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (<I>i.e.</I>, formed by the chemical interaction
of two compounds), chelate (<I>i.e.</I>, a chemical compound), or clathrate (<I>i.e.</I>, a polymer framework that traps molecules),
of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept
for review or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the
previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires
if a Paragraph IV certification is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available
to the holder of an NDA, including a 505(b)(2) NDA, if one or more new clinical trials, other than bioavailability or bioequivalence
trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity
period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the particular condition of the new drug&rsquo;s approval or the
change to a marketed product, such as a new formulation for a previously approved drug. Five-year and three-year exclusivity will not
delay the submission or approval of a 505(b)(1) NDA; however, an applicant submitting a 505(b)(1) NDA would be required to conduct or
obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Generating Antibiotic Incentives Now Act, or GAIN Act, which was enacted as part of the Food and Drug Administration
Safety and Innovation Act, or FDASIA, which was signed into law in July 2012, the FDA may designate a product as a Qualified Infectious
Disease Product, or QIDP. In order to receive this designation, a drug must qualify as an antibiotic or antifungal drug for human use
intended to treat serious or life-threatening infections, including those caused by either (1) an antibiotic or antifungal resistant
pathogen, including novel or emerging infectious pathogens, or (2) a so-called &ldquo;qualifying pathogen&rdquo; found on a list of potentially
dangerous, drug-resistant organisms to established and maintained by the FDA. A sponsor must request such designation before submitting
a marketing application. Upon approving a marketing application for a QIDP-designated product, the FDA will extend by an additional five
years any non-patent marketing exclusivity period awarded, such as a three-year exclusivity period awarded for new clinical investigations
of previously approved products. This extension is in addition to any pediatric exclusivity extension awarded, and the extension will
be awarded only to a drug first approved on or after the date of enactment of the GAIN Act. The GAIN Act prohibits the grant of an exclusivity
extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent
application for a specified change to an approved product, or is an application for a product that does not meet the definition of QIDP
based on the uses for which it is ultimately approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hatch
Waxman Amendments and the 505(b)(2) Regulatory Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
505 of the FFDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization
for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section
505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information
required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained
a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&rsquo;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application. Specifically, the applicant may rely upon the FDA&rsquo;s prior findings of safety and efficacy for an approved product
that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform additional
studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new product candidate for
all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by
the 505(b)(2) applicant. Lastly, the FDA permits marketing applications through Section 505(j), which establishes an abbreviated approval
process for a generic version of approved drug products through the submission of an ANDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration,
labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &ldquo;abbreviated&rdquo;
because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead,
generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator
drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject&rsquo;s
bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written
for the reference listed drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
FDA Expedited Review and Approval Programs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including Fast Track Designation, breakthrough therapy designation, accelerated approval, and priority review,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment
of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the fast track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication
as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a Fast Track Designation,
the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease
or condition and demonstrates the potential to address an unmet medical need, or that the drug qualifies as a QIDP under the GAIN Act.
The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy
that may be potentially superior to existing therapy based on efficacy or safety factors. Fast Track Designation provides additional
opportunities for interaction with the FDA&rsquo;s review team and may allow for rolling review of NDA components before the completed
application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept
sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the
first section of the NDA. However, the FDA&rsquo;s time period goal for reviewing an application does not begin until the last section
of the NDA is submitted. The FDA may decide to rescind the Fast Track Designation if it determines that the qualifying criteria no longer
apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a sponsor can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more
other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. Drugs designated as breakthrough therapies are eligible for intensive guidance from the
FDA on an efficient drug development program, organizational commitment to the development and review of the product including involvement
of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough
therapy products are also eligible for accelerated approval and/or priority review, if relevant criteria are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDA&rsquo;s accelerated approval regulations, the FDA may approve a drug for a serious or life threatening illness that provides
meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict
clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,
or prevalence of the condition and the availability or lack of alternative treatments. A drug candidate approved on this basis is subject
to rigorous post marketing compliance requirements, including the completion of Phase 4 or post approval clinical trials to confirm the
effect on the clinical endpoint. Failure to conduct required post approval studies, or confirm a clinical benefit during post marketing
studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates
approved under accelerated approval regulations are subject to prior review by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an NDA is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if FDA determines
that the product, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal
for the FDA to review an application is six months, rather than the standard review of ten months under current The Prescription Drug
User Fee Act, or PDUFA, guidelines. Under the current PDUFA agreement, for new molecular entities, these six and ten months review periods
are measured from the 60-day filing date rather than the receipt date for NDAs for non-new molecular entities, which typically adds approximately
two months to the timeline for review from the date of submission. Most products that are eligible for fast track breakthrough therapy
designation are also likely to be considered appropriate to receive a priority review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational
drug for a serious or life threatening disease is required to make available, such as by posting on its website, its policy on responding
to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority
review do not change the standards for approval and may not ultimately expedite the development or approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NDA
Submission and Review by the FDA</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical and preclinical testing, among other items, the results of product development, including
chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling,
as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the
time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions
are available in some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees,
including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced
or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing
application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form,
dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which
the product is safe and effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have
not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring
it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory
committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation
as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the
manufacturing controls are adequate to assure and preserve the product&rsquo;s identity, strength, quality and purity. Before approving
an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless
it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with
cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive
review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of
the NDA. The FDA&rsquo;s NDA review times may differ based on whether the application is a standard review or priority review application.
The FDA may give a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements
in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the goals and policies agreed
to by the FDA under PDUFA, the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of
a standard NDA for a new molecular entity, or NME, and make a decision on the application. For non-NME standard applications, the FDA
has set the review goal of 10 months from the date that the FDA receives the application to complete its initial review and to make a
decision on the application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months
of the 60-day filing date and non-NME applications within six months of the date that the FDA receives the application. Such deadlines
are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The PDUFA date may
be extended by the FDA in certain circumstances. These include circumstances such as a &lsquo;major amendment,&rsquo; for example, where
data submitted to a final study report is updated or data inadvertently omitted is supplied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the FDA&rsquo;s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter.
A CRL indicates that the review cycle of the application is complete and the application is not ready for approval. A CRL generally contains
a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical
or preclinical testing, or other information or analyses in order for the FDA to reconsider the application. Upon completion of the deficient
information, the updated NDA is resubmitted. The FDA has the goal of reviewing 90% of application resubmissions in either two or six
months of the date that the FDA receives the application, depending on the FDA classification of resubmission. Even with the submission
of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
If and when those conditions have been met to the FDA&rsquo;s satisfaction, the FDA may issue an approval letter. An approval letter
authorizes commercial marketing of the drug with specific prescribing information for specific indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information
and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including
distribution restrictions or other risk management mechanisms. For example, the FDA may require a REMS as a condition of approval or
following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit
further marketing of a product, or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance
programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional
labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety
information arise, additional testing, product labeling or FDA notification may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be
marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning.
A Black Box warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable
evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of labeling claims necessary
for successful marketing. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory
standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4
post-marketing studies to monitor the effect of approved products, and may limit further marketing of the product based on the results
of these post-marketing studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-approval
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing,
periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval
requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting
requirements, including adverse experiences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review
and approval. There also are continuing, annual user fee requirements for any approved products and the establishments at which such
products are manufactured, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their
subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products,
and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other
requirements, which impose procedural and documentation requirements upon us and our third-party manufacturers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to the manufacturing process are strictly regulated and often require prior FDA approval, or FDA notification, before being implemented.
FDA regulations also require investigation and correction of any deviations from cGMPs and specifications, and impose reporting and documentation
requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue
to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Later
discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing
processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to
the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess
new safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy, purity
and potency that are approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available
products for uses that are not described in the product&rsquo;s labeling and that differ from those tested by us and approved by the
FDA. We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing
Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration
and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical
product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations
on manufacturers of pharmaceutical products related to product tracking and tracing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with any of the FDA&rsquo;s requirements could result in significant adverse enforcement actions. These include a variety of
administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of
an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification
of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or
partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals
of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs,
restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply
with the FDA&rsquo;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal
and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result in
adverse publicity, among other adverse consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Healthcare Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business activities, including but not limited to, research, sales, promotion, distribution, medical education and other activities are
subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including the
Department of Justice, the HHS and its various divisions, including CMS and the Health Resources and Services Administration, the Department
of Veterans Affairs, the Department of Defense and state and local governments. Our business activities must comply with numerous healthcare
laws and regulations, including those described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting
or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for,
the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility,
item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The Anti-Kickback Statute has been interpreted
to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on
the other hand. The term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions
and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and
require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to
meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se
illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based
on a cumulative review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as
amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, amended the intent requirement
of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have
actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The Affordable
Care Act also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert
that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the
federal civil False Claims Act, or FCA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil and criminal false claims laws, including the FCA, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or approval by, the U.S. federal government, including the Medicare and Medicaid
programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
or to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud
Enforcement and Recovery Act of 2009, a claim includes &ldquo;any request or demand&rdquo; for money or property presented to the U.S.
government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors
if they are deemed to &ldquo;cause&rdquo; the submission of false or fraudulent claims. The FCA also permits a private individual acting
as a &ldquo;whistleblower&rdquo; to bring actions on behalf of the federal government alleging violations of the FCA and to share in
any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages
and mandatory penalties. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or
asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free products to customers
with the expectation that the customers would bill federal programs for the products; providing consulting fees and other benefits to
physicians to induce them to prescribe products; engaging in promotion for &ldquo;off-label&rdquo; uses; and submitting inflated best
price information to the Medicaid Rebate Program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate
and report to CMS their Average Manufacturer Price, or AMP, which is used to determine rebate payments shared between the states and
the federal government and, for some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part
B, to also calculate and report their average sales price, which is used to determine the Medicare Part B payment rate for the drug.
In January 2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program, or MDRP, effective April 1, 2016, that, among other
things, revised the manner in which the AMP is calculated by manufacturers participating in the program and implemented certain amendments
to the Medicaid rebate statute created under the Affordable Care Act. In addition, the MDRP requires pharmaceutical manufacturers to
enter into and have in effect a National Drug Rebate Agreement, or NDRA, with the Secretary of HHS as a condition for states to receive
federal matching funds for the manufacturer&rsquo;s outpatient drugs furnished to Medicaid patients. On March 23, 2018, CMS finalized
updates to the NDRA, or the Updated NDRA, to incorporate a number legislative and regulatory changes, including changes to align with
certain provisions of the Affordable Care Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
that are approved under a biologics license application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement
to calculate and report the manufacturer&rsquo;s best price for the drug and inflation penalties which can substantially increase rebate
payments. For BLA and NDA drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans
Affairs a different price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government
no more than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires
manufacturers to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly
submitting false pricing information to the government creates potential federal False Claims Act liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
created additional federal criminal statutes that prohibits, among other things, knowingly and willfully executing, or attempting to
execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or
promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether
the third-party payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully
obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any
trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery
of, or payment for, healthcare benefits, items or services relating to healthcare matters. Additionally, the Affordable Care Act amended
the intent requirement of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge
of the statute, or the specific intent to violate it, to have committed a violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the Affordable Care
Act and its implementing regulations, requires some manufacturers of drugs, devices, biologicals and medical supplies for which payment
is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with specified exceptions) to report annually
information related to specified payments or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners) and teaching
hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to
report annually specified ownership and investment interests held by physicians and their immediate family members. Failure to submit
timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests
may result in civil monetary penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct
our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing
regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information held
by covered entities, their business associates and covered subcontractors. Among other things, HITECH makes HIPAA&rsquo;s security standards
directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive, maintain
or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created
new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal
HIPAA laws and seek attorneys&rsquo; fees and costs associated with pursuing federal civil actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services
reimbursed by any third-party payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical
companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures and pricing information, state and local laws that require
the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance
efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will
likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or
future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government
funded healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations
and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with
these laws, and curtailment of our operations, any of which could substantially disrupt our operations. If the physicians or other providers
or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement
for the procedures utilizing our product candidates, performed by health care providers, once approved, will be available from government
health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors,
such as private health insurers and health maintenance organizations, determine which procedures, and the products utilized in such procedures,
they will cover and establish reimbursement levels. Assuming coverage is obtained for procedures utilizing a given product, by a third-party
payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high.
Patients who undergo procedures for the treatment of their conditions, and their treating physicians, generally rely on third-party payors
to reimburse all or part of the costs associated with the procedures which utilize our products. When used in connection with surgical
and certain other procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of
the payment received by the provider for the procedure only. Treating physicians are unlikely to use and order our products unless coverage
is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize our products.
A decision by a third-party payor not to cover or adequately reimburse for our product candidates or procedures using our product candidates,
could reduce physician utilization of our products once approved. Therefore, coverage and adequate reimbursement for procedures which
utilize new products is critical to the acceptance of such new products. Coverage decisions may depend upon clinical and economic standards
that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become
available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities and other third-party payors are developing increasingly sophisticated methods of cost containment, such as including price
controls, restrictions on coverage and reimbursement and requirements for substitution of less expensive products and procedures. Government
and other third-party payors are increasingly challenging the prices charged for health care products and procedures, examining the cost
effectiveness of procedures, and the products used in such procedures, in addition to their safety and efficacy, and limiting or attempting
to limit both coverage and the level of reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists among
third-party payors in the United States, which causes significant uncertainty related to the insurance coverage and reimbursement of
newly approved products, and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement can
differ significantly from payor to payor and health care provider to health care provider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that coverage and reimbursement will be available for any product that we commercialize, or the procedures which utilize
such product, and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the
demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available
or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain
marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Reform Measures</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some non-U.S. jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed
to change the healthcare system. Among policy makers and payors in the United States and elsewhere, there is significant interest in
promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.
In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by
major legislative initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the pharmaceutical industry in the United States has been affected by the passage of Affordable Care Act, which, among other
things: imposed new fees on entities that manufacture or import certain branded prescription drugs; expanded pharmaceutical manufacturer
obligations to provide discounts and rebates to certain government programs; implemented a licensure framework for follow-on biologic
products; expanded health care fraud and abuse laws; revised the methodology by which rebates owed by manufacturers to the state and
federal government under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including products that are
inhaled, infused, instilled, implanted or injected; imposed an additional rebate similar to an inflation penalty on new formulations
of drugs; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care
organizations; expanded the 340B program which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified
hospitals, clinics and community health centers; and provided incentives to programs that increase the federal government&rsquo;s comparative
effectiveness research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, on June 17, 2021,
the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety
because the &ldquo;individual mandate&rdquo; was repealed by Congress. Further, on August 16, 2022, President Biden signed the IRA into
law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act
marketplaces through plan year 2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program beginning
in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is
possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such
challenges and any potential future healthcare reform measures of the Trump administration will impact the Affordable Care Act and our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the
Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2.0% per fiscal year,
which went into effect in April 2013, and due to subsequent legislative amendments, including the BBA, will remain in effect until 2032,
unless additional U.S. Congressional action is taken. In addition, in January 2013, President Obama signed into law the American Taxpayer
Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the
Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, ended the use of the statutory formula for clinician payment and established
a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways
to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or
MIPS. Under both APMs and MIPS, performance data collected each performance year will affect Medicare payments in later years, including
potentially reducing payments. At this time, the full impact to overall physician reimbursement as a result of the introduction of the
Quality Payment Program remains unclear. Any reduction in reimbursement from Medicare or other government programs may result in a similar
reduction in payments from private payors. Congress is considering additional health reform measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been particular and increasing legislative and enforcement interest in the United States with respect to drug pricing
practices in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively
short time periods. Specifically, there have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, reduce the cost of prescription drugs under Medicare and reform government program
reimbursement methodologies for pharmaceutical products. For example, in July 2021, the Biden administration released an executive order,
&ldquo;Promoting Competition in the American Economy,&rdquo; with multiple provisions aimed at prescription drugs. In response to President
Biden&rsquo;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines
principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential
administrative actions HHS can take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the
price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part
B and Medicare Part D to penalize price increases that outpace inflation. These provisions took effect progressively starting in fiscal
year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the
Medicare drug price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional
drugs covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to
the Medicare Drug Price Negotiation Program. It is currently unclear how the IRA will be implemented but is likely to have a significant
impact on the pharmaceutical industry. Further in response to the Biden administration&rsquo;s October 2022 executive order, on February
14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their
ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized
in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control
the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute
of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While
march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. In addition, individual
states in the United States have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
For example, on January 5, 2024, the FDA approved Florida&rsquo;s Section 804 Importation Program (SIP) proposal to import certain drugs
from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be
chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals
that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products
covered by those programs. In the future, there will likely continue to be proposals relating to the reform of the U.S. healthcare system,
some of which could further limit coverage and reimbursement of products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Foreign Corrupt Practices Act</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment or offering
of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any
act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also
obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to
maintain books and records that accurately and fairly reflect all transactions of the companies, including international subsidiaries,
and to devise and maintain an adequate system of internal accounting controls for international operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-U.S.
Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any of our product candidates, once approved, are sold in a country outside of the United States, we will be subject
to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance,
anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to
healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market our future products in the EEA (which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein)
and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can
only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee
    for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure
    is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products
    indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized
    Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute
    a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are
    available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized
    for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition
    Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously
    in various Member States through the Decentralized Procedure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data
and Marketing Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from
relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or
biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized
in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the
EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period
can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains
an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are
held to bring a significant clinical benefit in comparison with existing therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pediatric
Investigation Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted
in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&rsquo;s Pediatric Committee,
or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing
authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until
there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric
clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective
or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product
does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization
is obtained in all Member States of the EU and study results are included in the product information, even when negative, the product
is eligible for six months&rsquo; supplementary protection certificate extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Environmental,
Health and Safety Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel, governing,
among other things: the use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; chemicals,
air, water and ground contamination; air emissions and the cleanup of contaminated sites, including any contamination that results from
spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our operations use chemicals and produce waste
materials and sewage and require permits from various governmental authorities including, local municipal authorities, the Ministry of
Environmental Protection and the Ministry of Health. The Ministry of Environmental Protection and the MOH, local authorities and the
municipal water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations.
These laws, regulations and permits could potentially require the expenditure by us of significant amounts for compliance or remediation.
If we fail to comply with such laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions,
including the revocation of permits and licenses necessary to continue our business activities. In addition, we may be required to pay
damages or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to hazardous
substances we use, store, handle, transport, manufacture or dispose of), property damage or contribution claims. Some environmental,
health and safety laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be
identified as a responsible party under such laws. Such developments could have a material adverse effect on our business, financial
condition and results of operations. In addition, laws and regulations relating to environmental, health and safety matters are often
subject to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to penalties
for activities that were previously permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organizational
Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any subsidiaries. Until February 2023, we had a United Kingdom incorporated subsidiary, Nasus Pharma UK Ltd., which
was never active.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
and Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
offices are located in Israel. We currently lease one facility located at Yigal Alon 65, Tel Aviv, Israel from TopNotch Ltd.
for a monthly fee of NIS 12,000 ($3,295).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider that our current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the
conduct of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 16, 2025, we have five members of senior management (including our Chief Executive Officer), of which one is a
full-time employee, one is a part-time employee, and three are service providers. As of April 16, 2025, we also have one
consultant. In 2023, we reduced our workforce by two employees due to discontinued operations and a slowdown of our NS001 program. We
had no changes in workforce in 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our employees are represented by labor unions or covered by collective bargaining agreements. However, in Israel, we are subject to
certain Israeli labor laws, regulations and national labor court precedent rulings, as well as certain provisions of collective bargaining
agreements applicable to us by virtue of extension orders issued in accordance with relevant labor laws by the Israeli and Industry of
Economy and which apply such agreement provisions to our employees even though they are not part of a union that has signed a collective
bargaining agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our employment and consulting agreements include employees&rsquo; and consultants&rsquo; undertakings with respect to non-competition
and assignment to us of intellectual property rights developed in the course of employment and confidentiality. The enforceability of
such provisions is limited by Israeli law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not
currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our
business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fw_007"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Directors
and Senior Management</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding our executive officers and directors as of April 16, 2025:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 58%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Teleman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi
    Gilboa <SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder
    and Executive Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Dalia Megiddo<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder,
    Director, Chief Development Officer and Chief Medical Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tair
    Lapidot, Pd.D.<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Research and Development and Clinical Development</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galia
    Temtsin Kryaz, Ph.D.<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of CMC and Product Development</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren
    Elmaliach<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Finance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronnie Hershman<SUP>(7)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Silberman<SUP>(4)(5)(6)(7)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Sharon Shacham<SUP>(4)(5)(6)(7)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isaac
    Israel<SUP>(4)(5)(6)(7)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Nominee</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
    Provider</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part-Time
    Employee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the compensation committee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the audit committee and financial statement examination committee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (as defined under Israeli law)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (as defined under NYSE American LLC Company Guide Manual Section 803(A)(2), or NYSE American Section 803(A)(2))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dan
Teleman<FONT STYLE="background-color: white">, Chief Executive Officer</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mr.
Dan Teleman</I> has served as our Chief Executive Officer since January 2025. Prior to this appointment Mr. Teleman served as Pharma
Two B Ltd.&rsquo;s Chief Executive Officer from May 2023 to January 2025, and as its President from October 2022 to May 2023. Mr. Teleman
brings over 20 years of experience in the biotechnology industry. From May 2022 to May 2023, Mr. Teleman was an Executive Partner at
Israel Biotech Fund, a life science venture capital firm. From January 2023 to November 2023, Mr. Teleman also served as a board member
of 4C Biomed, an early stage immune-oncology company developing a novel antibody. From July 2021 to May 2023, Mr. Teleman served as the
chairman of Tamarix Pharma Ltd, an early-stage ophthalmology company developing novel anti apoptotic molecules. From January 2010 to
May 2022, Mr. Teleman was the chief executive officer of Atox Bio Ltd., where he led the company through an NDA submission for Reltecimod,
the first immunomodulator developed for NSTI. Previously, Mr. Teleman was the co-founder and chief executive officer of PainReform Ltd.
(NASDAQ: PRFX), head of business development for Pharmos Corporation and held marketing and sales roles at Amgen (NASDAQ: AMGN). Mr.
Teleman holds an MBA from the Fuqua School of Business at Duke University and an MSc in Biochemical engineering from Ben-Gurion
University in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Udi
Gilboa<FONT STYLE="background-color: white">, Co-Founder and Executive Chairman</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Mr. </I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi
Gilboa </FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">has
served as our Co-Founder and Executive Chairman since 2019. Since January 2012, Mr. Gilboa has been serving as a director, Senior
Vice President of Operations and the Chief Financial Officer of Bioblast Pharma Ltd. (NASDAQ: ORPN). Mr. Gilboa is the founder and
managing partner of TopNotch Capital Ltd., a prominent Israeli life sciences investment bank. He is also the founder of a number of
medical device and pharmaceutical companies. Mr. Gilboa is Chairman of the Board of Samson NeuroSciences Ltd. Mr. Gilboa has served
as a director of InsuLine Medical Ltd. (TASE: INSL) until 2014 and served, until 2010 as a director and chairman of the board of
directors of Topspin Medical Ltd. Mr. Gilboa holds a Bachelor&rsquo;s degree and M.B.A. from Tel Aviv University. We believe Mr.
Gilboa&rsquo;s skills and experiences in the pharmaceutical and medical device industry as a founder, board member and in management
positions, specifically in publicly traded companies, make him a beneficial addition to our board of directors.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Dr.
Dalia Megiddo, Co-Founder, Director, Chief Development Officer and Chief Medical Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Dalia Megiddo</I> is one of our Co-Founders and has served as our Chief <FONT STYLE="background-color: white">Development Officer
and Chief Medical Officer</FONT> since June 2019. Dr. Megiddo also served as our Chief Executive Officer from March 2020 to January
2025. She has founded and served as management or a director for multiple biopharma and medtech companies, including Chiasma Inc.
(<FONT STYLE="background-color: white">NASDAQ</FONT>: CHMA) from 2002 to 2008 as co-founder and director; Medingo Ltd. (sold to
Roche Holding AG) from 2005 to 2007 as co-founder and director; Alcobra Pharmaceuticals Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>:
ADHD) from 2008 to 2013 as co-founder and director; and Bioblast Pharma Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>:
ORPN) from February 2012 through its public offering in February 2015 as CEO and director from February 2012 to March 2019. Dr.
Megiddo managed two venture capital funds: 7 Health Ventures from 2006 through 2010 and <I>InnoMed Ventures</I>, since 2000. Dr
Megiddo has been involved in the Life Science Venture Capital Industry since 1999 and is well recognized as one of the leaders in
the healthcare investment and entrepreneurial community both in Israel and internationally. She is a frequent speaker at local and
international meetings and served as a board member at Given Imaging Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>:
GIVN), Elron Ventures Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>: ELRN), Alcobra, and Bioblast. Dr. Megiddo is member
of the scientific-investment advisory boards to several academic institutes in Israel including the Technion and Tel Aviv
University. Dr. Megiddo holds an MBA from Kellogg-Recanati School of Business, and teaches at various entrepreneurial programs in
Israeli universities. She completed her medical studies at the Hebrew University&rsquo;s Hadassah Medical School and a specialty
program in Family Medicine. After spending a few years as a faculty member in the Family Medicine department at the Hebrew
University in Jerusalem, Dr. Megiddo founded and sold two successful businesses in the medical field: <I>The Journal Club </I>-
Israel&rsquo;s leading provider of Continuing Medical Education for physicians, and <I>Academia Medica</I> &ndash; a medical
multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians. We believe Dr.
Megiddo&rsquo;s skills and experiences as an investor, board member, <FONT STYLE="background-color: white">Chief Development
Officer</FONT> and <FONT STYLE="background-color: white">Chief Medical Officer</FONT>, as well as her professional experience as a
practicing physician with drug development capabilities make her a beneficial addition to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Tair
Lapidot, Pd.D., Vice President of Research and Development and Clinical Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Tair Lapidot</I> has served as our Vice President of R&amp;D and Clinical Development since 2019. Since 2002 Dr. Lapidot has been managing
scientific projects and product development activities in the Israel Life-Science industry, from early preclinical research, clinical
trials, and regulatory approval. Dr. Lapidot served as Chief Scientific Officer of Algatech Ltd. (sold to Solabia) from 2016 to 2019.
She served as Director of Product Development &amp; RA at Epitomee Medical (TLV: EPIT) 2010- 2016. She managed analytical and research
activities in Chiasma Inc. (<FONT STYLE="background-color: white">NASDAQ</FONT>: CHMA), BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), and
Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN). Dr. Lapidot received her Ph.D. in Biochemistry from the Hebrew University of Jerusalem and
had graduated Cum Laude Food Technology, B.Sc.Agri, also from the Hebrew University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Galia
Temtsin Kryaz, Ph.D., Director of CMC and Product Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Dr.
Galia Temtsin Kryaz, Ph.D. </I>has served as our Director of CMC and Product Development since 2019. Dr. Kryaz serves as CEO of Formulex
Pharma Innovations Ltd., or Formulex, where she has worked for the past 15 years. Dr. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kryaz
<FONT STYLE="background-color: white">received her Ph.D. in chemistry with specialization in organic chemistry and nanomaterials from
Ben-Gurion University of the Negev.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Oren
Elmaliach, Director of Finance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Mr. </I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren
Elmaliach</FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <FONT STYLE="background-color: white">has
served as our Director of Finance since 2019. In September 2015, Oren Elmaliach founded Accounting Team Ltd., a financial
consultancy and service provider to public companies traded in Israel and abroad, and has acted as Account Manager since then. Since
February 2017, Mr. Elmaliach has served as controller of Ayala Pharmaceuticals Inc. (NASDAQ: AYLA), and since Februray 2022 he has
served as Chief Financial Officer of Igentify. In addition, since September 2015, Mr. Elmaliach has served as an Israel Authorities
Reporting Officer of LG Electronics Israel and since September 2015 he has served as Local Financial Report Consultant of Chiasma
Inc. (NASDAQ: CHMA). From May 2017, Oren has served as chairman of the audit committee of Mysize, Inc (NASDAQ: MYSZ). From July 2011
until August 2015, Mr. Elmaliach served as CPA, Financial Director of CFO Director Ltd. and from June 2010 until July 2011 he served
as Risk Management Consultant of RSM International Limited. Mr. Elmaliach holds a Bachelor of Arts in Accounting/Economics and a
Msc. in Finance/Accounting from Tel Aviv University, Israel. He is a licensed Certified Public Accountant in
Israel.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Ronnie Hershman<FONT STYLE="background-color: white">, Director</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Dr.
</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronnie Hershman</FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
has served on our board of directors since January 2019. He has been a cardiologist in New York for the last 30 years. In addition to
being a medical practitioner, for the last 15 years, Dr. Hershman has also been an active Angel Investor. As an Angel Investor, he is
the Founder and Principal Owner of Hershman Holdings LLC, a company he founded in 2004. He has also been co-founder of several other
companies, including HealthEffect in August 2015 and InvestEffect in 2017. Dr. Hershman holds an M.D. from Icahn School of Medicine at
Mount Sinai and a B.S. from Sophie Davis CCNY Center for Biomedical Education. We believe Dr. Hershman&rsquo;s skills and experiences
as an active physician and as an experienced healthcare investor combined with his intimate familiarity with the US healthcare industry
make him a beneficial addition to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
Silberman<FONT STYLE="background-color: white">, Director Nominee</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>David
Silberman</I> is a director nominee </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and will serve on
our compensation committee and on our audit and financial statement examination committee. Mr. Silberman has served as the Chief Financial
Officer of Compugen Ltd. (NASDAQ: CGEN) Since August 2024. Mr. Silberman previously served as the Chief Financial Officer of Oramed Pharmaceuticals,
Inc. (NASDAQ: ORMP) from May 2021 to May 2024. From April 2018 to May 2021, Mr. Silberman served as a Corporate Financial Planning and
Analysis associate director and director at Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), a global pharmaceutical company, committed
to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. From 2014 to
2018, Mr. Silberman served as Global Internal Audit senior manager at Teva Pharmaceutical Industries Ltd. From 2009 to 2014, Mr. Silberman
provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. From
January 2009 until June 2009, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm. Mr. Silberman
holds DCG and DSCG degrees from the French Ministry of Higher Study and Research and is a certified public accountant in Israel. We
believe Mr. Silberman&rsquo;s in-depth knowledge in finance and experience in management positions, in particular in pharmaceutical publicly
traded companies make him a beneficial addition to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Sharon Shacham<FONT STYLE="background-color: white">, Director Nominee</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Dr.
Sharon Shacham</I> is a director nominee</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and will serve
on our compensation committee and on our audit and financial statement examination committee. Dr. Shacham has served as a director at
Acrivon Theraputics, Inc. (NASDAQ: ACRV) since May 2021, non-executive director at exteRNA since August 2024 and director of Protai Therapeutics
since January 2023. Dr. Shacham co-founded Karyopharm (NASDAQ: KPTI) in 2008 and served as its Chief Scientific Officer and head of Research
and Development from 2010 until May 2022, and as President from 2013 until May 2021. Dr. Shacham has previously led scientific and clinical
work that led to the discovery, development and regulatory approval of first-in-class drug candidates. Prior to joining Karyopharm, Dr.
Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development
at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, where she led the company&rsquo;s efforts in GPCR modeling,
computational chemistry, lead optimization and development of clinical trials. Dr. Shacham holds a B.S. in chemistry, a Ph.D. in biophysical
chemistry, and an M.B.A. from Tel Aviv University. We believe Dr. Shacham&rsquo;s experience as board member, Chief Scientific Officer,
co founder and research and development positions, as well as her professional drug development capabilities make her a beneficial addition
to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Isaac
Israel<FONT STYLE="background-color: white">, Director Nominee</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Isaac
Israel </I>is a director nominee</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and will serve on our
compensation committee and on our audit and financial statement examination committee. <FONT STYLE="background-color: white">Mr. Israel
was the founding chief executive officer of BeeContact Ltd. (formerly TASE: BCNT), from 2001 until 2007. Since 2008, Mr. Israel has served
as founding chief executive officer of Uneri Capital Ltd., a consulting firm, owned by Mr. Israel, which specializes in the healthcare
sector. Mr. Israel served as a member of the board of directors and chief executive officer of Purple Biotech (NASDAQ: PPBT) from
2012 until 2022 and served as Acting Chief Executive Officer from March 2023 to August 2023. Mr. Israel served as a member of the
board of directors of various private and public healthcare corporations, including as chairman of the board of a public healthcare corporation,
NextGen Biomed Ltd. (TASE: NXGN). We believe Mr. Israel&rsquo;s skills and experiences as a founder, Chief Executive Officer and board
member, including in healthcare companies and in publicly traded companies, make him a beneficial addition to our board of directors.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Family
Relationships</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships between any members of our executive management and our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Arrangements
for Election of Directors and Members of Management</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
are currently no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our
executive management or our directors were selected (see &ldquo;<I>Related Party Transactions</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents in the aggregate all compensation we paid to all of our directors and senior management as a group for the year
ended December 31, 2024. The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing
us with services during this period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Salary,
    Bonuses and Related Benefits</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pension,
    Retirement and Other Similar Benefits</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share
    Based Compensation</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All directors and senior management
    as a group, consisting of 5 persons</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">513,578</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,619</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,135</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
so long as we qualify as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic
companies regarding disclosure of the compensation of certain executive officers on an individual basis. Pursuant to Israeli Law, we
will be required, after we become a public company, to disclose the annual compensation of our five most highly compensated officers
on an individual basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing
such disclosure, at the latest, in the annual proxy statement for our first annual meeting of shareholders following the closing of this
offering, which will be filed under cover of a report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Services
Agreements with Executive Officers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into written services agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered
by directors and officers insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
a description of the terms of our share options and share option plan (see &ldquo;<I>Management&mdash;Equity Incentive Plan</I><FONT STYLE="font-variant: small-caps">&rdquo;
</FONT>below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Dan Teleman, our Chief Executive Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2025, we entered into an agreement with Mr. Dan Teleman, pursuant to which, Mr. Teleman provides us with services as our Chief
Executive Officer. Pursuant to the terms of the services agreement, Mr. Teleman is entitled to a gross monthly salary in the amount of
NIS 30,000 ($8,238) as of the commencement date of January 7, 2025 and until March 2025. As of April 1, 2025, Mr. Teleman is entitled
to a gross monthly salary of NIS 40,000 ($10,984), to be increased to NIS 70,000 ($19,222) as of and subject to consummation of this
offering until the first anniversary of this offering, and thereafter to NIS 75,000 ($20,595) until the second anniversary of this offering
and to NIS 80,000 ($21,968) thereafter. The services agreement also provides for other benefits such as reimbursement of expenses and
certain bonus payments, including a one-time bonus payment of NIS 240,000 ($65,903) upon and subject to consummation of this offering,
or the IPO Bonus. Mr. Teleman will be entitled to an annual bonus in between 10%-20% of Mr. Teleman&rsquo;s annual gross salary, or the
Annual Bonus. Both parties may terminate the services agreement for any reason with 30 days&rsquo; written notice during the first 12
months of employment or with 60 days&rsquo; written notice thereafter. In addition, pursuant to an option agreement entered into in January
2025, Mr. Teleman was granted share options, with a grant date of January 16, 2025, to purchase up to 318,856 Ordinary Shares
under our 2019 Plan at an exercise price of $6.05, vesting over a period of 36 months commencing on January 7, 2025. Mr. Teleman&rsquo;s
option grant letter agreement contains an acceleration clause, whereby the options will become fully vested immediately prior to the
closing of any transaction, as defined under the 2019 Plan to mean any merger in which we no longer continue to exist as a legal entity,
or sale of all, or substantially all, of our issued and outstanding shares to a third party or the sale of all or substantially all of
our assets. A transaction, for the avoidance of doubt, does not include an initial public offering. Any unexercised options will expire
ten years from the date they were granted, in accordance with the 2019 Plan. In March 2025, our board of directors and shareholders ratified
and amended the agreement with Mr. Teleman. The amendment to the agreement introduces several changes, to be effective upon completion
of the offering as follows: (i) our compensation committee and our board of directors may increase, from time-to-time, without requiring
shareholder approval, Mr. Teleman&rsquo;s monthly gross salary up to the maximum monthly gross salary determined in the Company&rsquo;s
compensation policy, as may be in effect from time to time; (ii) our compensation committee and our board of directors may grant Mr.
Teleman, without requiring shareholder approval, equity-based awards up to the maximum annual equity compensation in accordance with
the Company&rsquo;s compensation policy, as may be in effect from time to time; (iii) an acceleration mechanism allowing for the acceleration
of up to all of the equity-based awards granted to Mr. Teleman in the event of a change of control, as shall be determined by our compensation
committee and our board of directors; (iv) the Annual Bonus range shall be adjusted from 10%-20% to 20%-30%; (v) Mr. Teleman shall be
entitled to a one-time bonus of $75,000 if the Phase 3 clinical trial of NS002 successfully meets its primary end-point. Further, Mr.
Teleman&rsquo;s car maintenance allowance shall be increased from NIS 3,500 ($961) to NIS 4,500 ($1,236), effective March 17,
2025. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Services
Agreement with Udi Gilboa, our Co-Founder and Executive Chairman</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2019, we entered into an agreement with TopNotch Ltd., a company beneficially owned by Mr. Udi Gilboa, pursuant to which Mr.
Gilboa provides us with services as our Executive Chairman. Pursuant to the terms of the services agreement, Mr. Gilboa is entitled to
a monthly salary in the amount of NIS 20,000 ($5,492), which was increased to NIS 45,000 ($12,357) on May 1, 2020 per an amendment to
the services agreement. In February 2022, Mr. Gilboa agreed to a voluntarily reduction in his monthly salary to NIS 36,000 ($9,885).
In November 2022, Mr. Gilboa again agreed to a voluntarily reduction in his monthly salary to NIS 18,000 ($4,943). The services agreement
also provides for other benefits such as reimbursement of expenses and certain bonus payments. Both parties may terminate the services
agreement for any reason with 90 days&rsquo; written notice. In March 2025, our board of directors and shareholders ratified and amended
the agreement with TopNotch Ltd, or the Second Amendment to the TopNotch Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Second Amendment to the TopNotch Agreement provides compensation adjustments upon completion of the offering, as follows: (i) NIS 86,000
($23,615) monthly consultation fee in the first year following the offering, (ii) NIS 90,300 ($24,796) monthly consultation fee in the
second year following the offering, and (iii) NIS 94,814 ($26,036) monthly consultation fee from the third year following the offering;
(iv) monthly car allowance and maintenance expenses of NIS 3,621 ($994); (v) annual bonus of up to 25% of the annual consulting fees,
subject to approval of our board of directors; and (vi) one-time bonus of NIS 1,068,195 ($293,323) upon completion of the offering. Further,
under the Second Amendment to the TopNotch Agreement, our compensation committee and our board of directors, may grant Mr. Gilboa: (i)
a special bonus of up to 1.5% of the proceeds of a qualified merger, sale, or assignment as provided therein; (ii) an equity financing
bonus equal to up to 2% of the cash proceeds in a private placement or other equity financing transaction, and (iii) a one-time bonus
for special efforts performed by Mr. Gilboa and/or in respect of the significant contribution of Mr. Gilboa to the Company&rsquo;s operations,
special projects or extra ordinary achievements which are not in the Company&rsquo;s ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Services
Agreement with Dr. Dalia Megiddo, our Co-Founder, Chief Development Officer and Chief Medical Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
&nbsp;&nbsp;&nbsp;June 1, 2019, we entered into a services agreement with D.M. Medica Ltd., a company beneficially owned by Dr. Dalia
Megiddo, pursuant to which Dr. Megiddo provides us with services as our Chief Executive Officer. Pursuant to the terms of the services
agreement, Dr. Megiddo is entitled to a monthly salary in the amount of NIS 20,000 ($5,492), which was increased to NIS 45,000 ($12,357)
on May 1, 2020, per an amendment to the services agreement. In February 2022, Dr. Megiddo agreed to a voluntarily reduction in her monthly
salary to NIS 36,000 ($9,885). In November 2022, she again agreed to a voluntarily reduction in her monthly salary to NIS 18,000 ($4,943)
per month. The services agreement also provides for other benefits such as reimbursement of expenses. The amendment to the services agreement
additionally provides for an annual bonus which is paid out for any top line revenues. Both parties may terminate the services agreement
for any reason with 90 days&rsquo; written notice. On January 7, 2025, Dr. Dalia Megiddo&rsquo;s service as our Chief Executive Officer
has terminated with the appointment of Mr. Dan Teleman as our new Chief Executive Officer. Dr. Dalia Megiddo continues to serve as our
Chief Development Officer and Chief Medical Officer, in addition to her service as our director. In March 2025, our board of directors
and shareholders ratified and amended the agreement with D.M. Medical Ltd., or the Second Amendment to the D.M. Agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Second Amendment to the D.M. Agreement redefines the services provided by Dr. Megiddo from Chief Executive Officer to Chief Development
Officer, and provides compensation adjustments upon completion of the offering, as follows: (i) NIS 86,000 ($23,615) monthly consultation
fee in the first year following the offering, (ii) NIS 96,560 ($26,515) monthly consultation fee in the second year following the offering,
and (iii) NIS 105,613 ($29,001) monthly consultation fee from the third year following the offering; (iv) monthly car allowance and maintenance
expenses of NIS 4,344 ($1,193); (v) annual bonus of up to 25% of annual consulting fees, subject to approval of our board of directors;
one-time bonus of NIS 854,556($234,658) upon completion of the offering. Further, under the Second Amendment to the D.M. Agreement, our
compensation committee and our board of directors, may grant Dr. Megiddo (i) a special bonus of up to 1.5% of the proceeds of a qualified
merger, sale, or assignment as provided therein; (ii) a one-time bonus for special efforts performed by Dr. Megiddo and/or in respect
of the significant contribution of Dr. Megiddo to the Company&rsquo;s operations, special projects or extra ordinary achievements which
are not in the Company&rsquo;s general course of business; (iii) a bonus of NIS 1,068,195 ($293,323) upon NDA submission of NS002 to
the FDA; and (iv) a bonus of NIS 2,136,390 ($586,646) upon FDA approval of an NDA for NS002. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Tair Lapidot, Pd.D., our Vice President of Research and Development and Clinical Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2019, we entered into an employment agreement with Dr. Tair Lapidot<I>,</I> pursuant to which Dr. Lapidot provides us with services
as our Vice President of Research and Development and Clinical Development. Pursuant to the terms of the services agreement, Dr. Lapidot
is entitled to a monthly salary in the amount of NIS 35,000 ($9,611), which was decreased to NIS 28,000 ($7,689) on March 13, 2022 pursuant
to an amendment to the employment agreement. The agreement also provides for other benefits such as reimbursement of expenses. In addition,
pursuant to an option agreement entered into on January 30, 2020, Dr. Lapidot was granted share options (with a grant date of November
28, 2019) to purchase up to 69,209 Ordinary Shares under our 2019 Plan, with 55,366 options having an exercise price of $1.23 and 13,843
options having an exercise price of $4.30, vesting over a period of four years commencing on July 17, 2019 and January 30, 2020. Both
parties may terminate the services agreement for any reason with 30 days&rsquo; written notice. Pursuant to an option agreement entered
into on January 23, 2023, Dr. Lapidot was granted additional options to purchase 9,135 Ordinary Shares under our 2019 Plan, with
a grant date of January 23, 2023, at an exercise price of $0.002, vesting over a period of 18 months commencing on January 31,
2023. Dr. Lapidot&rsquo;s option grant letter agreement contains an acceleration clause, whereby the options will become fully vested
after the consummation of an initial public offering or after any transaction, as defined under the 2019 Plan to mean any merger in which
we no longer continue to exist as a legal entity, or sale of all, or substantially all, of our issued and outstanding shares to a third
party or the sale of all or substantially all of our assets. Any unexercised options will expire ten years from the date they were granted,
in accordance with the 2019 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Services
Agreement with Oren Elmaliach, our Director of Finance</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 13, 2019, we entered into a consulting services agreement with Accounting Team Ltd., or Accounting Team, a company beneficially
owned by Mr. Oren Elmaliach, pursuant to which Accounting Team provides us with part-time accounting services in consideration for a
monthly fee of NIS 2,000 ($549). Pursuant to an amendment dated December 5, 2024, we have ratified the agreement to reflect that as of
February 1, 2021, Accounting Team has been entitled to a monthly fee of NIS 8,000 ($2,197). Accounting Team is also entitled to receive
an aggregate amount of NIS 325,000 ($89,244) in connection with accounting services related to this offering and will be entitled to
a one-time payment of NIS 250,000 ($68,649) upon and subject to consummation of this offering. On December 5, 2024, we have also entered
into a separate consulting agreement directly with Mr. Elmaliach, reflecting that since August 1, 2020, we have engaged Mr. Elmaliach
directly as our part time external Director of Finance. Under such agreement, Mr. Elmaliach is entitled to an additional monthly fee
of NIS 2,000 ($549) with effect from such date. In addition, pursuant to an option agreement entered into in January 2020, Mr. Elmaliach
was granted share options, with a grant date of November 28, 2019, to purchase up to 27,681 Ordinary Shares under our 2019 Plan at an
exercise price of $1.23, vesting over a period of four years commencing on June 13, 2019. Mr. Elmaliach&rsquo;s option grant letter agreement
contains an acceleration clause, whereby the options will become fully vested six months after the consummation of an initial public
offering or six months after any transaction, as defined under the 2019 Plan to mean any merger in which we no longer continue to exist
as a legal entity, or sale of all, or substantially all, of our issued and outstanding shares to a third party or the sale of all or
substantially all of our assets. Pursuant to an option agreement entered into in January 2025, Mr. Elmaliach was granted additional share
options, with a grant date of January 16, 2025, to purchase up to 27,681 Ordinary Shares under our 2019 Plan at an exercise price of
$6.05, vesting over a period of 36 months commencing on January 7, 2025. Mr. Elmaliach&rsquo;s option grant letter agreement contains
an acceleration clause, whereby the options will become fully vested immediately prior to the closing of any transaction, as defined
under the 2019 Plan to mean any merger in which we no longer continue to exist as a legal entity, or sale of all, or substantially all,
of our issued and outstanding shares to a third party or the sale of all or substantially all of our assets. A transaction, for the avoidance
of doubt, does not include an initial public offering. Any unexercised options will expire ten years from the date they were granted,
in accordance with the 2019 Plan. Both parties may terminate the services agreement for any reason with 60 days&rsquo; written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Directors&rsquo;
Service Contracts</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than with respect to our directors that are also executive officers, we do not have written agreements with any director providing for
benefits upon the termination of his employment with our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Differences
between the Companies Law and NYSE American Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act, as well as related rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply
with various corporate governance practices. In addition, following the listing of the Ordinary Shares on the NYSE American, we will
be required to comply with NYSE American rules. Under those rules, we may elect to follow certain corporate governance practices permitted
under the Companies Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the NYSE American
rules for U.S. domestic issuers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Israeli law and practice and in reliance on the relief available to foreign private issuers pursuant to Section 110
of the NYSE American LLC Company Guide, or NYSE Rules, we have elected to follow the provisions of the Companies Law as well
as Israeli practice, in lieu of such NYSE Rules, with respect to the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quorum</I>.
    In lieu of Section 123 of the NYSE Rules, which provides for a quorum of at least 33&#8531;%, to follow Israeli practice,
    pursuant to which a company is allowed to determine in its articles of association the required quorum for a shareholder meeting.
    . Our amended and restated articles of association provide that the quorum for a general meeting of shareholders will consist of
    two or more shareholders holding at least 25% of the total voting rights in person or by proxy, or, for any adjourned shareholder
    general meeting, the quorum set forth in our amended and restated articles of association shall consist of at least one shareholder
    present in person or by proxy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nomination
    of our directors</I>. In lieu of Section 804 of the NYSE Rules, which provides that nominations by our board of directors may be
    made by a majority of independent directors or by a nominating committee of the Board consisting solely of independent directors,
    the nominations for directors, which are presented to the Company&rsquo;s shareholders by the Board, are generally made by the Board
    itself, in accordance with the provisions of our amended and restated articles of association and the Companies Law. With the exception
    of directors elected by the board of directors and external directors (if applicable), the Company&rsquo;s directors are then elected
    by an annual meeting of the Company&rsquo;s shareholders (i) to hold office until the next annual meeting following his or her election
    or (ii) for three-year term, as described below under &ldquo;<I>Management&mdash;Board Practices&mdash;External Directors</I>.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
    of officers</I>. Israeli law and our amended and restated articles of association do not require that the independent members of
    our board of directors (or a compensation committee composed solely of independent members of our board of directors) determine an
    executive officer&rsquo;s compensation, as is generally required under NYSE Section 805 with respect to the chief executive officer
    and all other executive officers. Instead, compensation of executive officers is determined and approved by our compensation committee
    and our board of directors, and in certain circumstances by the Company&rsquo;s shareholders, either in consistency with the compensation
    policy or, in special circumstances in deviation therefrom, taking into account certain considerations stated in the Companies Law
    (see &ldquo;<I>Management&mdash;Board Practices&mdash;Approval of Related Party Transactions under Israeli Law</I>&rdquo;).</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
    approval</I>. The Company will not seek shareholder approval for corporate actions which are not subject to shareholder approval
    under Israeli law. In particular, Section 711 of the NYSE Rules requires shareholder approval for the establishment or material amendment
    of a stock option or purchase plan or other equity compensation arrangement pursuant to which options or stock may be acquired. Israeli
    law does not require shareholder approval for such plans. In addition, Section 713 of the NYSE Rules requires shareholder approval
    when the Company issues additional shares in a transaction that is not considered a public offering. Israeli law does not require
    shareholder approval for such transactions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Annual
    Shareholders Meeting</I>. As opposed to Section 704 of the NYSE Rules, which mandates that a listed company hold its annual shareholders
    meeting within one year of the company&rsquo;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders
    meeting each calendar year and within 15 months of the last annual shareholders meeting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Written
    Notice</I>. As opposed to Section 703 of the NYSE Rules, that mandates each issuer to provide shareholders with written notice at
    least 10 days in advance of all shareholder meetings and to provide for such notice in its by-laws, the Company is required, under
    Companies Law and our amended and restated articles of association, to provide either 14 or 21 days written notice.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Practices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Introduction</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors presently consists of three members, as the Companies Law does not mandate the appointment of external directors to
the board. Immediately following the completion of this offering, our board is expected to consist of seven directors. Based upon information
requested from and provided by each director concerning such director&rsquo;s background, employment and affiliations, including family
relationships, our board of directors determined that, four members of our directors following the completion of this offering, are &ldquo;independent
directors&rdquo; as defined under the listing standards of the NYSE American rules. Our amended and restated articles of association
provide that the number of board of directors&rsquo; members (including external directors) shall be set by the general meeting of the
shareholders provided that it will consist of not less than two and not more than nine. Pursuant to the Companies Law, the management
of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are
not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and
have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the
discretion of, our board of directors, subject to the employment agreement that we have entered into with him. All other executive officers
are appointed by our Chief Executive Officer. Their terms of employment are subject to the approval of the board of directors&rsquo;
compensation committee and of the board of directors, and are subject to the terms of any applicable employment agreements that we may
enter into with them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
director, except external directors, will hold office until the next annual general meeting of our shareholders following his or her
appointment, or until he or she resigns or unless he or she is removed by a majority vote of our shareholders at a general meeting of
our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our amended and restated articles
of association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under certain circumstances, our amended and restated articles of association allow our board of directors to appoint directors
to fill vacancies on our board of directors or in addition to the acting directors (subject to the limitation on the number of directors),
until the next annual general meeting or special general meeting in which directors may be appointed or terminated. External directors
may be elected for up to two additional three-year terms after their initial three-year term under the circumstances described below,
with certain exceptions as described in &ldquo;External Directors&rdquo; below. External directors may be removed from office only under
the limited circumstances set forth in the Companies Law (see &ldquo;<I>Management&mdash;Board Practices&mdash;External Directors</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, nominations for directors may be made by any shareholder holding at least one percent or a higher percent, as may
be required by the Companies Law from time to time, of our outstanding voting power. Under the Exemptions Regulations, one or more shareholders
of an Israeli company whose shares are listed outside of Israel (e.g., listed on NYSE American), may request its company&rsquo;s board
of directors to include an appointment of a candidate for a position on the board of directors or the termination of a board member as
an item on the agenda of a future general meeting, provided that the shareholder hold at least five percent of the voting rights of the
company, instead of the one percent required in the past.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such shareholder may make such a nomination only if a written notice of such shareholder&rsquo;s intent to make such nomination has been
given to our board of directors. Any such notice must include certain information, the consent of the proposed director nominee(s) to
serve as our director(s) if elected, and a declaration signed by the nominee(s) declaring that (i) there is no limitation under the Companies
Law preventing their election and (ii) that all information that is required to be provided to us in connection with such election under
the Companies Law and our amended and restated articles of association has been provided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decision whether to include the suggested item on the agenda is subject to the Company&rsquo;s discretion, under the provisions of the
Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting and financial
expertise. In determining the number of directors required to have such expertise, our board of directors must consider, among other
things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that the
minimum number of directors of our company who are required to have accounting and financial expertise is two. Upon the effectiveness
of the registration statement for this offering, our directors who have financial expertise will be Mr. David Silberman, Mr. Isaac Israel,
and Dr. Sharon Shacham.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors must elect one director to serve as the chairman of the board of directors to preside at the meetings of the board
of directors, and may also remove that director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any
of his or her relatives is permitted to serve as the chairman of the board of directors, and a company may not vest the chairman or any
of his or her relatives with the chief executive officer&rsquo;s authorities. In addition, a person who reports, directly or indirectly,
to the chief executive officer may not serve as the chairman of the board of directors; the chairman may not be vested with authorities
of a person who reports, directly or indirectly, to the chief executive officer; and the chairman may not serve in any other position
in the company or a controlled company, but he or she may serve as a director or chairman of a controlled company. However, the Companies
Law permits a company&rsquo;s shareholders to determine, for a period not exceeding three years from each such determination, that the
chairman or his or her relative may serve as chief executive officer or be vested with the chief executive officer&rsquo;s authorities,
and that the chief executive officer or his or her relative may serve as chairman or be vested with the chairman&rsquo;s authorities.
Such determination of a company&rsquo;s shareholders requires either: (1) the approval of at least a majority of the shares of those
shareholders present and voting on the matter (other than controlling shareholders and those having a personal interest in the determination)
(shares held by abstaining shareholders shall not be considered); or (2) that the total number of shares opposing such determination
does not exceed 2% of the total voting power in the company. Currently, we have a separate chairman and chief executive officer. In accordance
with the Companies Law regulations, such determination of a company&rsquo;s shareholders that was made after a company first offered
its securities to the public, or that the company described in the prospectus, will be for a period not exceeding five years from the
date the company became public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees of the board,
and it may, from time to time, revoke such delegation or alter the composition of any such committees, subject to certain limitations.
Unless otherwise expressly provided by the board of directors, the committees shall not be empowered to further delegate such powers.
The composition and duties of our audit committee, financial statement examination committee and compensation committee are described
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors oversees how management monitors compliance with our risk management policies and procedures, and reviews the adequacy
of the risk management framework in relation to the risks faced by us. The board of directors will be assisted in its oversight role
by an internal auditor. The internal auditor will undertake both regular and ad hoc reviews of risk management controls and procedures,
the results of which are reported to our audit committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>External
Directors</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an Israeli company whose shares have been offered to the public or whose shares are listed for trading on a stock
exchange in or outside of Israel is required to appoint at least two external directors, or External Directors, to serve on its board
of directors. External Directors must meet stringent standards of independence. However, the Company adopted an exemption for appointment
of external directors, as further specified below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
regulations promulgated pursuant to the Companies Law, a company with no controlling shareholder whose shares are listed for trading
on specified exchanges outside of Israel, including the NYSE American, may adopt exemptions from various corporate governance requirements
of the Companies Law, so long as such company satisfies the requirements of applicable foreign country laws and regulations, including
applicable stock exchange rules, that apply to companies organized in that country and relating to the appointment of independent directors
and the composition of audit and compensation committees. Such exemptions include an exemption from the requirement to appoint external
directors and the requirement that an external director be a member of certain committees, as well as exemption from limitations on directors&rsquo;
compensation. We do not currently have a controlling shareholder and we use this exemption from the requirement described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Independent
Directors Under the Companies Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;independent director&rdquo; is either an external director or a director who meets the same non-affiliation criteria as an external
director (except for (i) the requirement that the director be an Israeli resident (which does not apply to companies such as ours whose
securities have been offered outside of Israel or are listed outside of Israel) and (ii) the requirement for accounting and financial
expertise or professional qualifications), as determined by the audit committee, and who has not served as a director of the company
for more than nine consecutive years. For these purposes, ceasing to serve as a director for a period of two years or less would not
be deemed to sever the consecutive nature of such director&rsquo;s service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations
promulgated pursuant to the Companies Law provide that a director in a public company whose shares are listed for trading on specified
exchanges outside of Israel, including NYSE American, who qualifies as an independent director under the relevant non-Israeli rules and
who meets certain non-affiliation criteria, which are less stringent than those applicable to independent directors as set forth above,
would be deemed an &ldquo;independent&rdquo; director pursuant to the Companies Law provided: (i) he or she has not served as a director
for more than nine consecutive years; (ii) he or she has been approved as such by the audit committee; and (iii) his or her remuneration
shall be in accordance with the Companies Law and the regulations promulgated thereunder. For these purposes, ceasing to serve as a director
for a period of two years or less would not be deemed to sever the consecutive nature of such director&rsquo;s service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
pursuant to these regulations, such company may reappoint a person as an independent director for additional terms, beyond nine years,
which do not exceed three years each, if each of the audit committee and the board of directors determine, in that order, that in light
of the independent director&rsquo;s expertise and special contribution to the board of directors and its committees, the reappointment
for an additional term is in the company&rsquo;s best interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent directors, upon the effectiveness of the registration statement for this offering, will be Mr. David Silberman, Mr. Isaac
Israel, Dr. Sharon Shacham and Ronnie Hershman. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Alternate
Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
amended and restated articles of association provide, as allowed by the Companies Law, that any director may, subject to the conditions
set thereto including approval of the nominee by our board of directors, appoint a person as an alternate to act in his place, to remove
the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason
whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as
a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director.
Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of
the board of directors so long as he or she is not already serving as a member of such committee, and if the alternate director is to
replace an external director, he or she is required to be an external director and to have either &ldquo;financial and accounting expertise&rdquo;
or &ldquo;professional expertise,&rdquo; depending on the qualifications of the external director he or she is replacing. A person who
does not have the requisite &ldquo;financial and accounting experience&rdquo; or the &ldquo;professional expertise,&rdquo; depending
on the qualifications of the external director he or she is replacing, may not be appointed as an alternate director for an external
director. A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed
as an alternate director of an independent director qualified as such under the Companies Law. Unless the appointing director limits
the time or scope of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director
or terminates the appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish three standing committees, the audit committee, the compensation committee and the Financial Statement
Examination Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, we are required to appoint an audit committee. The audit committee must be comprised of at least three directors,
including all of the external directors (one of whom must serve as chairman of the committee). The audit committee may not include the
chairman of the board; a controlling shareholder of the company or a relative of a controlling shareholder; a director employed by or
providing services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder;
or a director who derives most of his or her income from a controlling shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a majority of the members of the audit committee of a publicly traded company must be independent directors under the Companies
Law. However, under the Exemptions Regulations, a company with no controlling shareholder may be exempted from certain obligations mentioned
above. Our audit committee will be comprised, upon the effectiveness of the registration statement for this offering, of Mr. David Silberman,
Mr. Isaac Israel, and Dr. Sharon Shacham.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, our audit committee is responsible for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
    whether there are deficiencies in the business management practices of our company, and making recommendations to the board of directors
    to improve such practices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
    whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and
    whether such transaction is extraordinary or material under Companies Law) and establishing the approval process for certain transactions
    with a controlling shareholder or in which a controlling shareholder has a personal interest (see &ldquo;<I>Management&mdash;Board
    Practices&mdash;Approval of Related Party Transactions under Israeli law</I>&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
    the approval process for transactions that are &ldquo;non-negligible&rdquo; (i.e., transactions with a controlling shareholder that
    are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as
    determining which types of transactions would require the approval of the audit committee, optionally based on criteria which may
    be determined annually in advance by the audit committee;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining
    our internal controls and internal auditor&rsquo;s performance, including whether the internal auditor has sufficient resources and
    tools to dispose of its responsibilities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining
    the scope of our auditor&rsquo;s work and compensation and submitting a recommendation with respect thereto to our board of directors
    or shareholders, depending on which of them is considering the appointment of our auditor;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for the handling of employees&rsquo; complaints as to deficiencies in the management of our business and the protection
    to be provided to such employees; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
    the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the
    board of directors and proposing amendments thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee may not conduct any discussions or approve any actions requiring its approval (see &ldquo;<I>Management&mdash;Board Practices&mdash;Approval
of Related Party Transactions under Israeli law</I>&rdquo;), unless at the time of the approval a majority of the committee&rsquo;s members
are present, which majority consists of independent directors under the Companies Law, including at least one external director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors adopted an audit committee charter to be effective upon the listing of our Ordinary Shares on NYSE American setting
forth, among others, the responsibilities of the audit committee consistent with the rules of the SEC and NYSE American Rules (in addition
to the requirements for such committee under the Companies Law), including, among others, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight
    of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of
    our independent registered public accounting firm to the board of directors in accordance with Israeli law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal
    auditor and reviewing effectiveness of our system of internal control over financial reporting;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board
    of directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and monitoring, if applicable, legal matters with significant impact, finding of regulatory authorities&rsquo; findings, receive
    reports regarding irregularities and legal compliance, acting according to &ldquo;whistleblower policy&rdquo; and recommend to our
    board of directors if so required.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NYSE
American Requirements for Audit Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NYSE American rules, we are required to maintain an audit committee consisting of at least three members, each of whom is independent
and financially literate, and at least one of whom has accounting or related financial management expertise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, upon the effectiveness of the registration statement for this offering, the members of our audit committee will include
Mr. David Silberman, Mr. Isaac Israel, and Dr. Sharon Shacham, each of whom is an independent director under the Companies Law and &ldquo;independent,&rdquo;
as such term is defined in under NYSE American rules. The chairman of our audit committee will be elected by the members of the audit
committee following the offering. All members of our audit committee meet the requirements for financial literacy under the NYSE American
rules. Our board of directors has determined that each member of our audit committee is an audit committee financial expert as defined
by the SEC rules and has the requisite financial experience as defined by the NYSE American rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Statement Examination Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of a public company incorporated in Israel must appoint a financial statement examination committee,
which consists of members with accounting and financial expertise or the ability to read and understand financial statements. &nbsp;The
function of a financial statements examination committee is to discuss and provide recommendations to its board of directors (including
the report of any deficiency found) with respect to the following issues: (1) estimations and assessments made in connection with the
preparation of financial statements; (2) internal controls related to the financial statements; (3) completeness and propriety of the
disclosure in the financial statements; (4) the accounting policies adopted and the accounting treatments implemented in material matters
of the company; and (5) value evaluations, including the assumptions and assessments on which evaluations are based and the supporting
data in the financial statements. Our independent registered public accounting firm and our internal auditor are invited to attend all
meetings of our financial statements examination committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the provisions of the Companies Law and the regulations promulgated pursuant to it and under certain conditions, an Israeli
company may merge its audit committee and the financial statement examination committee into one committee, or the Joint Committee. As
of the date hereof, the Company meets such conditions and therefore formed a Joint Committee. The members of our Joint Committee will
consist of Mr. David Silberman, Dr. Sharon Shacham and Mr. Isaac Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of any public company must establish a compensation committee. The compensation committee must
be comprised of at least three directors, including all of the external directors, who must constitute a majority of the members of the
compensation committee. Each compensation committee member that is not an external director must be a director whose compensation does
not exceed an amount that may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions
as the audit committee as to: (a) who may not be a member of the committee; and (b) who may not be present during committee deliberations
as described above. However, under the Exemptions Regulations, a company with no controlling shareholder might be exempted from certain
obligations mentioned above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will act pursuant to a written charter and will be comprised, upon the effectiveness of the registration statement
for this offering, of Mr. David Silberman, Mr. Isaac Israel, Dr. Sharon Shacham. Our compensation committee will comply with the provisions
of the Companies Law, the regulations promulgated thereunder, and our amended and restated articles of association, on all aspects referring
to its independence, authorities and practice. Our compensation committee will follow home country practice as opposed to complying with
the compensation committee membership and charter requirements prescribed under the NYSE American rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will review and recommend to our board of directors: with respect to our executive officers&rsquo; and directors&rsquo;:
(1) annual base compensation (2) annual incentive bonus, including the specific goals and amounts; (3) equity compensation; (4) employment
agreements, severance arrangements, and change in control agreements and provisions; (5) retirement grants and/or retirement bonuses;
and (6) any other benefits, compensation, compensation policies or arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duties of the compensation committee include the recommendation to the company&rsquo;s board of directors of a policy regarding the terms
of engagement of office holders, to which we refer as a compensation policy, in the form adopted by our board of directors and shareholders
for a period of five (5) years from the offering. Such policy must be adopted by the company&rsquo;s board of directors, after considering
the recommendations of the compensation committee. The compensation policy is then brought for approval by our shareholders, which requires
a special majority (see &ldquo;<I>Management&mdash;Board Practices&mdash;Approval of Related Party Transactions under Israeli law</I>&rdquo;).
Under the Companies Law, the board of directors may adopt the compensation policy if it is not approved by the shareholders, provided
that after the shareholders oppose the approval of such policy, the compensation committee and the board of directors revisit the matter
and determine that adopting the compensation policy would be in the best interests of the company. Our compensation policy was approved
by our shareholders on January 23, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of executive officers
and directors, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment
or engagement. The compensation policy must relate to certain factors, including advancement of the company&rsquo;s objectives, the company&rsquo;s
business and its long-term strategy, and creation of appropriate incentives for executives. It must also consider, among other things,
the company&rsquo;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following
additional factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    education, skills, expertise and accomplishments of the relevant director or executive;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    director&rsquo;s or executive&rsquo;s roles and responsibilities and prior compensation agreements with him or her;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relationship between the cost of the terms of service of an office holder and the average median compensation of the other employees
    of the company (including those employed through manpower companies), including the impact of disparities in salary upon work relationships
    in the company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit
    on the exercise value of non-cash variable compensation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service
    period, the company&rsquo;s performance during that period of service, the person&rsquo;s contribution towards the company&rsquo;s
    achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must also include the following principles:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    the exception of office holders who report directly to the chief executive officer, the link between variable compensation and long-term
    performance and measurable criteria;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relationship between variable and fixed compensation, and the ceiling for the value of variable compensation at the time of its grant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    conditions under which a director or executive would be required to repay compensation paid to him or her if it was later shown that
    the data upon which such compensation was based was inaccurate and was required to be restated in the company&rsquo;s financial statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    minimum holding or vesting period for variable, equity-based compensation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum
    limits for severance compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must also consider appropriate incentives from a long-term perspective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee is responsible for: (1) recommending the compensation policy to a company&rsquo;s board of directors for its approval
(and subsequent approval by the shareholders); and (2) duties related to the compensation policy and to the compensation of a company&rsquo;s
office holders, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval
    of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the board of directors periodic updates to the compensation policy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing
    implementation of the compensation policy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
    whether the terms of compensation of certain office holders of the company need not be brought to approval of the shareholders; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
    whether to approve the terms of compensation of office holders that require the committee&rsquo;s approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy is designed to promote our long-term goals, work plan and policy, retain, motivate and incentivize our directors
and executive officers, while considering the risks that our activities involve, our size, the nature and scope of our activities and
the contribution of an officer to the achievement of our goals and maximization of profits, and align the interests of our directors
and executive officers with our long-term performance. To that end, a portion of an executive officer compensation package is targeted
to reflect our short and long-term goals, as well as the executive officer&rsquo;s individual performance. On the other hand, our compensation
policy includes measures designed to reduce the executive officer&rsquo;s incentives to take excessive risks that may harm us in the
long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between the variable and
the total compensation of an executive officer and minimum vesting periods for equity-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy also addresses our executive officer&rsquo;s individual characteristics (such as his or her respective position,
education, scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among our
executive officers, and considers the internal ratios between compensation of our executive officers and directors and other employees.
Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses,
equity-based compensation, benefits and retirement and termination of service arrangements. All cash bonuses are limited to a maximum
amount linked to the executive officer&rsquo;s base salary. In addition, our compensation policy provides for maximum permitted ratios
between the total variable (cash bonuses and equity based compensation) and non-variable (base salary) compensation components, in accordance
with an officer&rsquo;s respective position with the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The
annual cash bonus that may be granted to executive officers other than our chairman or Chief Executive Officer may be based entirely
on a discretionary evaluation. Our Chief Executive Officer will be entitled to recommend performance objectives to such executive officers,
and such performance objectives will be approved by our compensation committee (and, if required by law, by our board of directors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance measurable objectives of our chairman and Chief Executive Officer will be determined annually by our compensation committee
and board of directors. A less significant portion of the chairman&rsquo;s and/or the Chief Executive Officer&rsquo;s annual cash bonus
may be based on a discretionary evaluation of the chairman&rsquo;s or the Chief Executive Officer&rsquo;s respective overall performance
by the compensation committee and the board of directors based on quantitative and qualitative criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
equity-based compensation under our compensation policy for our executive officers (including members of our board of directors) is designed
in a manner consistent with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives
being to enhance the alignment between the executive officers&rsquo; interests with our long-term interests and those of our shareholders
and to strengthen the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive
officer compensation in the form of share options or other equity-based awards, such as restricted shares and phantom, options, in accordance
with our equity incentive plan then in place. Share options granted to executive officers shall be subject to vesting periods in order
to promote long-term retention of the awarded executive officers. The equity-based compensation shall be granted from time to time and
be individually determined and awarded according to the performance, educational background, prior business experience, qualifications,
role and the personal responsibilities of the executive officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our compensation policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses
paid in excess, enables our Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer
(provided that the changes of the terms of employment are in accordance our compensation policy) and allows us to exculpate, indemnify
and insure our executive officers and directors subject to certain limitations set forth thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy also provides for compensation to the members of our board of directors either: (i) in accordance with the amounts
provided in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by
the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be
amended from time to time; or (ii) in accordance with the amounts determined in our compensation policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Internal
Auditor </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor nominated by the audit committee.
We intend to appoint our internal auditor within 90 days following the consummation of this offering. The role of the internal auditor
is to examine, among other things, whether a company&rsquo;s actions comply with the law and proper business procedure. The audit committee
is required to oversee the activities, and to assess the performance of the internal auditor as well as to review the internal auditor&rsquo;s
work plan. An internal auditor may not be an interested party or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&rsquo;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the outstanding shares or voting rights of a company, any person or entity that has the right to appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not our employee, but partner of a firm which specializes in internal auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Remuneration
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, remuneration of directors is subject to the approval of the compensation committee, thereafter by the board of directors
and thereafter, unless exempted under the regulations promulgated under the Companies Law, by the general meeting of the shareholders.
In case the remuneration of the directors is in accordance with regulations applicable to remuneration of the external directors then
such remuneration shall be exempt from the approval of the general meeting. Where the director is also a controlling shareholder, the
requirements for approval of transactions with controlling shareholders apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fiduciary
Duties of Office Holders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law imposes a duty of care and a duty of loyalty on all office holders of a company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would
have acted under the same circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    on the advisability of a given action brought for his approval or performed by him by virtue of his position; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    other important information pertaining to these actions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of loyalty of an office holder requires an office holder to act in good faith and for the benefit of the company, and includes a
duty to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal
    affairs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any action that is competitive with the company&rsquo;s business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    to the company any information or documents relating to the company&rsquo;s affairs which the office holder has received due to his
    position as an office holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Insurance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may obtain insurance for any of its office holders against the following liabilities incurred due to acts
he or she performed as an office holder, if and to the extent provided for in the company&rsquo;s articles of association:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of his or her duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of
    the office holder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause
    to assume that his or her act would not prejudice the company&rsquo;s interests; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    financial liability imposed upon him or her in favor of another person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have directors&rsquo; and officers&rsquo; liability insurance, providing total coverage of $3.0 million for the benefit of
all of our directors and officers, in respect of which we paid an 18-month premium of approximately $5,250, which expires on October
1, 2026. We are currently in the process of obtaining directors&rsquo; and officers&rsquo; liability insurance that will be
in place upon completion of this offering, up to a maximum coverage of $25,000,000 as approved by our board of directors in March 2025.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnification</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder
against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking
made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity
    as an office holder, including a settlement or arbitrator&rsquo;s award approved by a court;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys&rsquo; fees, expended by the office holder (a) as a result of an investigation or proceeding
    instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment
    (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no
    financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as
    a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense
    that does not require proof of criminal intent; or (b) in connection with a monetary sanction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys&rsquo; fees, expended by the office holder or imposed on him or her by a court,: (1) in
    proceedings that the company institutes, or that another person institutes on the company&rsquo;s behalf, against him or her; (2)
    in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require
    proof of criminal intent; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation
    expenses and reasonable attorneys&rsquo; fees. An &ldquo;Administrative Procedure&rdquo; is defined as a procedure pursuant to chapters
    H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement
    Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates
to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following
foreseen events and amount or criterion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    events that in the opinion of the board of directors can be foreseen based on the company&rsquo;s activities at the time that the
    undertaking to indemnify is made; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable
    under the circumstances.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with all of our directors and with all members of our senior management. Each such indemnification
agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent
that these liabilities are not covered by directors and officers insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exemption</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an Israeli company may not exempt an office holder from liability for a breach of his or her duty of loyalty, but
may exempt in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such
exemption is included in its articles of association. Our amended and restated articles of association provide that we may exempt, in
whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty
of care, but prohibit an exemption from liability arising from a company&rsquo;s transaction in which our controlling shareholder or
officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exempt and release our
office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors and shareholders entered into an indemnification and exemption agreements with certain directors and officers, as
may be from time to time, effective upon the completion of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides that we may not exempt or indemnify an office holder nor enter into an insurance contract that would provide coverage
for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless
(in the case of indemnity or insurance only, but not exemption) the office holder acted in good faith and had a reasonable basis to believe
that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally
or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal personal benefit;
or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exemption, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association permit us to exempt (subject to the aforesaid limitation), indemnify and insure our office
holders to the fullest extent permitted or to be permitted by the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions summarize the material aspects and practices of our board of directors. For additional details, we also refer
you to the full text of the Companies Law, as well as of our amended and restated articles of association, which are exhibits to this
registration statement of which this prospectus forms a part, and are incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no service contracts between us or our Subsidiary, on the one hand, and our directors in their capacity as directors, on the other
hand, providing for benefits upon termination of service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Approval
of Related Party Transactions under Israeli Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, we may approve an action by an office holder from which the office holder would otherwise have to refrain, as described
above, if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    office holder acts in good faith and the act or its approval does not cause harm to the company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the
    company at a reasonable time before the company&rsquo;s approval of such matter.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disclosure
of Personal Interests of an Office Holder</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law requires that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at
which the transaction is first discussed, any direct or indirect personal interest that he or she may have and all related material information
known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction,
the office holder must also disclose any personal interest held by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    office holder&rsquo;s relatives; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director
    or general manager or has the right to appoint at least one director or the general manager.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">An
office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her
relative in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction
is a transaction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    in the ordinary course of business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    on market terms; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    is likely to have a material effect on the company&rsquo;s profitability, assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law does not specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders
to make such disclosures to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, once an office holder complies with the above disclosure requirement, the board of directors may approve a transaction
between the company and an office holder, or a third party in which an office holder has a personal interest, unless the articles of
association provide otherwise and provided that the transaction is in the company&rsquo;s interest. If the transaction is an extraordinary
transaction in which an office holder has a personal interest, first the audit committee and then the board of directors, in that order,
must approve the transaction. Under specific circumstances, shareholder approval may also be required. Generally, a person who has a
personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at
such a meeting unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present
in order to present the transaction that is subject to approval. A director who has a personal interest in a transaction, which is considered
at a meeting of the board of directors or the audit committee, may not be present at this meeting or vote on this matter, unless a majority
of members of the board of directors or the audit committee, as the case may be, has a personal interest. If a majority of the board
of directors has a personal interest, then shareholder approval is generally also required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disclosure
of Personal Interests of a Controlling Shareholder</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a
private placement in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether
directly or indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions
concerning the terms of engagement and compensation of a controlling shareholder or a controlling shareholder&rsquo;s relative, whether
as an office holder or an employee, require the approval of the audit committee or the compensation committee, as the case may be, the
board of directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a
shareholders&rsquo; meeting. In addition, the shareholder approval must fulfill one of the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting
    must be voted in favor of approving the transaction, excluding abstentions; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more
    than 2% of the voting rights in the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest
with a term of more than three years requires the abovementioned approval every three years; however, such transactions not involving
the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer
term is reasonable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction
with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in
the vote in question. Failure to so indicate will result in the invalidation of that shareholder&rsquo;s vote. However, according to
the Companies Law Regulations (exemptions for companies whose securities are listed for trading on a stock exchange outside of Israel)
5760-2000, by signing and submitting a proxy card, a shareholder declares and approves that he has no personal interest in the approval
of any of the items on a general meeting agenda that requires such declaration under the Companies Law, with the exception of a personal
interest that the shareholder positively informed the Company about.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
term &ldquo;controlling shareholder&rdquo; is defined in the Companies Law as a shareholder with the ability to direct the activities
of the company, other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in a company or has the right to appoint 50% or more of the directors of the company or its general
manager. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company.
For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approval
of the Compensation of Directors and Executive Officers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation of, or an undertaking to indemnify, insure or exculpate, an office holder who is not a director requires the approval of
the company&rsquo;s compensation committee, followed by the approval of the company&rsquo;s board of directors, and, if such compensation
arrangement or an undertaking to indemnify, insure or exculpate is inconsistent with the company&rsquo;s stated compensation policy,
or if the said office holder is the chief executive officer of the company (subject to a number of specific exceptions), then such arrangement
is subject to the approval of our shareholders, subject to a special majority requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors</I>.
Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval
of the board of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general
meeting of our shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided
that those provisions that must be included in the compensation policy according to the Companies Law have been considered by the compensation
committee and board of directors, shareholder approval by a special majority will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Executive
officers other than the chief executive officer.</I> The Companies Law requires the approval of the compensation of a public company&rsquo;s
executive officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&rsquo;s
board of directors, and (iii) only if such compensation arrangement is inconsistent with the company&rsquo;s stated compensation policy,
the company&rsquo;s shareholders by a special majority. However, if the shareholders of the company do not approve a compensation arrangement
with an executive officer that is inconsistent with the company&rsquo;s stated compensation policy, the compensation committee and board
of directors may override the shareholders&rsquo; decision if each of the compensation committee and the board of directors provide detailed
reasons for their decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
executive officer.</I> Under the Companies Law, the compensation of a public company&rsquo;s chief executive officer is required to be
approved by: (i) the company&rsquo;s compensation committee; (ii) the company&rsquo;s board of directors, and (iii) the company&rsquo;s
shareholders by a special majority. However, if the shareholders of the company do not approve the compensation arrangement with the
chief executive officer, the compensation committee and board of directors may override the shareholders&rsquo; decision if each of the
compensation committee and the board of directors provides detailed reasons for their decision. In addition, the compensation committee
may exempt the engagement terms of a candidate to serve as the chief executive officer from shareholders&rsquo; approval, if the compensation
committee determines that the compensation arrangement is consistent with the company&rsquo;s stated compensation policy, that the chief
executive officer did not have a prior business relationship with the company or a controlling shareholder of the company, and that subjecting
the approval to a shareholder vote would impede the company&rsquo;s ability to attain the candidate to serve as the company&rsquo;s chief
executive officer (and provide detailed reasons for the latter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval of each of the compensation committee and the board of directors, with regard to the office holders and directors above, must
be in accordance with the company&rsquo;s stated compensation policy; however, under special circumstances, the compensation committee
and the board of directors may approve compensation terms of a chief executive officer that are inconsistent with the company&rsquo;s
compensation policy provided that they have considered those provisions that must be included in the compensation policy according to
the Companies Law and that shareholder approval was obtained by a special majority requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Duties
of Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable
manner in exercising his rights and performing his obligations toward the company and other shareholders, including, among other things,
in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment
    of the articles of association;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    in the company&rsquo;s authorized share capital;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of related party transactions and acts of office holders that require shareholder approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
shareholder also has a general duty to refrain from oppressing other shareholders. The remedies generally available upon a breach of
contract will also apply to a breach of the above mentioned duties, and in the event of oppression of other shareholders, additional
remedies are available to the injured shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any
shareholder that, under a company&rsquo;s articles of association, has the power to appoint or prevent the appointment of an office holder,
or has another power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not
describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in
the event of a breach of the duty to act with fairness, taking the shareholder&rsquo;s position in the company into account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Equity
Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2019 Plan was adopted by our board of directors, or the &ldquo;board,&rdquo; in July 2019. The 2019 Plan provides for the grant of share
options to our directors, officers, employees, office holders, service providers and their employees, or charitable entities (collectively,
&ldquo;optionees&rdquo; or &ldquo;participants&rdquo;). On January 6, 2025, the Company increased the maximum number of Ordinary Shares
reserved for issuance under the 2019 Plan from 246,170 Ordinary Shares to 723,178 Ordinary Shares. As of April 16, 2025,
the total number of Ordinary Shares reserved for future grants of share options under our 2019 Plan was 184,612. As of April 16,
2025, the total number of Ordinary Shares issuable upon the exercise of share options to directors, employees and consultants under our
2019 Plan was 538,237.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2019 Plan is administered by our board or our Compensation Committee; however, the board is empowered to alter, amend, or rescind any
act taken by the Compensation Committee. The power to administer the 2019 Plan includes, but is not limited to: (i) approval of option
grants, or &ldquo;Option Grants,&rdquo; and the determination of the terms and provisions of the respective Option Grants, including,
the vesting schedules of the share options the Exercise Price thereof; provisions concerning the time or times when and the extent to
which Options may be exercised; the nature and duration of restrictions as to transferability; or any other special conditions relating
to an Option Grant; (ii) the acceleration of any participant&rsquo;s right to exercise Options, in whole or in part; (iii) the interpretation
of the provisions of the 2019 Plan; (iv) altering, amending or rescinding any resolution or act previously taken by the Compensation
Committee; and (v) the determination of any other matter which is necessary or desirable for, or incidental to, the administration of
the 2019 Plan. The board has the exclusive discretion and power to grant Options. The board also has the power to grant optionees a cashless
exercise mechanism for all or part of the Option Grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise determined by the board with the consent of at least one investor director, Option Grants vest over four years&mdash;25% of
which vests on the first anniversary of the Option Grant, and each additional one twelfth (1/12) balance vests on the last day of each
three-month period following the first anniversary of the Option Grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligible
employees, officers and directors would qualify for provisions of Section 102 of the Israeli Income Tax Ordinance of 1961 (New Version),
or the Tax Ordinance. Section 102 of the Tax Ordinance allows employees, directors and officers who are not controlling shareholders
and are considered Israeli residents to receive favorable tax treatment for compensation in the form of shares or share options. Section
102 includes two alternatives for tax treatment involving the issuance of share options or shares to a trustee for the benefit of the
grantees and also includes an additional alternative for the issuance of share options or shares directly to the grantee. Section 102(b)(2)
of the Tax Ordinance, the most favorable tax treatment for the grantee, permits the issuance to a trustee under the &ldquo;capital gain
track.&rdquo; However, under this track we are not allowed to deduct an expense with respect to the issuance of the share options or
shares. Non-employees may only be granted share options under section 3(i) of the Tax Ordinance, which does not provide for similar tax
benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a default, our 2019 Plan provides that upon termination of a an optionee&rsquo;s employment or service with us or any of our affiliates,
other than in the event of death, disability or cause, all unvested share options will terminate and the underlying Options will immediately
expire, and all vested share options will generally be exercisable for 90 days following such termination, subject to the terms of the
2019 Plan and the governing option agreement. Notwithstanding the foregoing, in the event the engagement is terminated for cause (including,
inter alia, due to breach of his/her employment agreement (whether written or oral) including without limitation, a breach of non-compete
obligations, or breach of his/her fiduciary duties towards us or a related entity as determined by the Compensation Committee, in its
sole discretion, or any other termination for &ldquo;cause&rdquo; or in the case that competent court or other authority resolves that
such employee is not entitled to discharge compensation), all share options granted to such optionee, whether vested or unvested, will
not be exercisable and will terminate on the date of the termination. Upon termination of a service agreement due to death or disability,
all the share options vested at the time of termination will generally be exercisable for six months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a merger or consolidation with or into another corporation resulting in such other corporation being the surviving entity,
an acquisition of all or substantially all of our outstanding capital stock, or the sale of substantially all of our assets, each outstanding
option shall be assumed for an equivalent option or right substituted by the successor corporation or a parent or subsidiary of the successor
corporation, and appropriate adjustments shall be made in the number of share options in order to reflect such an action. In the event
that the successor corporation refuses to assume or substitute for the option, the vesting periods defined in the Option Grants may be
fully or partially accelerated by the Compensation Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any variation in our share capital, including a share dividend, share split, combination or exchange of shares, recapitalization,
or any other like event, the number, class and kind of shares subject to the 2019 Plan and outstanding options, and the exercise prices
of the share options, will be appropriately and equitably adjusted so as to maintain the proportionate number of shares without changing
the aggregate exercise price of the share options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_001"></A>BENEFICIAL
OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding beneficial ownership of our Ordinary Shares as of April 16, 2025 by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding Ordinary Shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors and executive officers; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our directors and executive officers as a group.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to Ordinary Shares.
Ordinary Shares issuable under share options that are exercisable within 60 days after April 16, 2025, are deemed outstanding
for the purpose of computing the percentage ownership of the person holding the share options but are not deemed outstanding for the
purpose of computing the percentage ownership of any other person. Percentage of shares beneficially owned before this offering is based
on 7,362,906 shares outstanding on April 16, 2025. The number of Ordinary Shares deemed outstanding after this offering
is based on 10,687,800 Ordinary Shares which assumes no exercise of the underwriters&rsquo; over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and
there are no arrangements known to us which would result in a change in control of our company at a subsequent date. Except as indicated
in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to
all securities shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted
below, each beneficial owner&rsquo;s address is: Nasus Pharma Ltd., Yigal Alon 65, Tel Aviv, 6744317, Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares<BR>
    Beneficially<BR>
    Owned<BR>
    Prior to this<BR>
    Offering***</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Percentage</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Owned<BR>
    Prior to this<BR>
    Offering***</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares<BR>
    Beneficially<BR>
    Owned<BR>
    After this<BR>
    Offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Percentage</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Owned<BR>
    After this</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Offering</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders of more than 5% of our voting securities:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi Gilboa*(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,865,807</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,865,807</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dalia Megiddo*(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,865,853</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,865,853</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronnie Hershman*(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,295,936</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,295,936</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Point Ltd.(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">425,129</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">425,129</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phoenix Solutions Ltd (5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">429,307</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">429,307</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hershman Holdings LLC (6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">477,008</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">477,008</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors, Director Nominees and senior
    management who are not 5% holders:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan Teleman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galia Temtsin Krayz(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,723</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,723&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tair Lapidot, Pd.D.(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,344</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,344 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Elmaliach(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,294</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,294
    </FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Silberman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Sharon Shacham</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isaac Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
    directors, director nominees and senior management as a group (10 persons)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5,309,957</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>70</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>%</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5,309,957</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>49</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    director of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1%.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
    conversion of the 2024 SAFE at $11.00 into 324,894 Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 1,846,019 Ordinary Shares; (ii) 6,068 Class A-3A Ordinary Shares; (iii) 8,525 Ordinary Shares issuable upon conversion 2024
    SAFEs; and (iv) 5,195 Class A-3A Ordinary Shares held by Formulex. Mr. Gilboa is a beneficial owner. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 1,846,019 Ordinary Shares; (i) 6,068 Class A-3A Ordinary Shares; (ii) 8,571 Ordinary Shares issuable upon conversion
    2024 SAFEs; and (iii) 5,195 Class A-3A Ordinary Shares held by Formulex of which Dr. Megiddo is a beneficial owner. Dr. Megiddo does
    not have sole nor share voting and investment power over the shares held by Formulex. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 477,006 Ordinary Shares held by Hershman Holdings LLC, which Dr. Hershman beneficially owns; (ii) 133,639 Class A-1 Ordinary
    Shares held by Hershman Holdings LLC; (iii) 69,820 Class A-3A Ordinary Shares held by Hershman Holdings LLC; (iv) 26,002 Class A-3A
    Ordinary Shares held by Hershman Holdings LLC; (v) 30,276 Class A-3B Ordinary Shares held by Hershman Holdings LLC; (vi) 66,868 Ordinary
    Shares issuable upon conversion of 2024 SAFEs held by Hershman Holdings LLC; (vii) 429,307 Ordinary Shares held by Phoenix Solutions
    Ltd. Dr. Hershman is the controlling shareholder of Phoenix Solutions Ltd. Phoenix Solutions Ltd. is also a non-beneficial owner
    of Formulex; and (viii) 63,018 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60
    days. Dr. Hershman has sole voting and investment power over the shares held by Hershman Holdings LLC but not over those held by
    Phoenix Solutions Ltd. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 407,699 Ordinary Shares; (ii) 17,430 Class A-3A Ordinary Shares. Capital Point Ltd. is a public company traded on the
    Tel Aviv Stock Exchange with an address of Azreli Tower 1, Floor 22, Tel Aviv Israel.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 429,307 Ordinary Shares. Dr. Hershman is the beneficial owner of Phoenix Solutions Ltd. and has shared voting and investment power
    over the shares held by Phoenix Solutions Ltd. The address of Phoenix Solutions Ltd is Remez David 19, Tel Aviv, Israel. These
    shares are also included in Dr. Hershman&rsquo;s shares listed in footnote (3) above. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 477,008 Ordinary Shares. These Ordinary Shares are also included in Dr. Hershman&rsquo;s shares under footnote (3). Dr. Hershman
    is the beneficial owner of Hershman Holdings LLC and has sole voting and investment power over the shares held by Hershman Holdings
    LLC. The address of Hershman Holdings LLC is 1999 Marcus Ave, # 220, New Hyde Park, New York 11042.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 171,723 Ordinary Shares. Dr. Galia Temtsin Krayz is the chief executive officer of Formulex.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 78,334 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 32,294 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Record
Holders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 16, 2025, there were 77 shareholders of record of our Ordinary Shares, all of which are located in Israel. These
numbers are not representative of the number of beneficial holders of our shares nor is it representative of where such beneficial holders
reside, since many of these shares were held of record by brokers or other nominees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_002"></A>RELATED
PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Services
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into written services agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered
by directors and officers insurance. Members of our senior management are eligible for bonuses each year. The bonuses are payable upon
meeting objectives and targets that are set by our Chief Executive Officer and approved annually by our board of directors that also
set the bonus targets for our Chief Executive Officer. For more information on the written services agreements with each of our executive
officers, please see &ldquo;Management&mdash;Compensation&mdash;Services Agreements with Executive Officers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have granted share options to purchase our Ordinary Shares to our officers and certain of our directors. Such option
agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option
plans under &ldquo;Management&mdash;Equity Incentive Plan.&rdquo; If the relationship between us and an executive officer or a director
is terminated, except for cause (as defined in the various option plan agreements), share options that are vested will generally remain
exercisable for three months after such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loan
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we received the July 2022 Loan from Dr. Ronnie Hershman, a director and shareholder, and Michael Gibber, a shareholder, pursuant
to which we received a principal amount of $500 thousand, for a term of twelve (12) months, at an interest rate of 8% per annum. On August
28, 2024, we and each of Dr. Ronnie Hershman and Michael Gibber entered into an exchange letter, or the July 2022 Loan Exchange Letter,
according to which our obligations in connection with the loan were discharged in consideration for the issuance of a SAFE under the
same terms as the 2024 SAFEs, under which it is deemed that Dr. Hershman invested an amount of $284,154 and Michael Gibber invested an
amount of $286,210.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, we received a loan in an aggregate amount of $60 thousand from Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa,
or the February 2023 Loan, under substantially the same terms as the July 2022 Loan, for a term of twelve (12) months, at an interest
rate of 8% per annum. A definitive agreement for the February 2023 Loan was not executed. On August 28, 2024, we and each of Dr. Ronnie
Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa entered into the February 2023 Loan Exchange Letter, according to which our obligations
in connection with the February 2023 Loan were discharged in consideration for the issuance of a SAFE with the same terms as the 2024
SAFEs, under which Dr. Ronnie Hershman was deemed to have invested an amount of $43,954, Dr. Dalia Megiddo was deemed to have invested
an amount of $11,286, and Mr. Udi Gilboa was deemed to have invested an amount of $10,963 in said SAFEs. See &ldquo;<I>&mdash;SAFEs</I>&rdquo;
below for information regarding the terms of the 2024 SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Formulex
License Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, we entered into a license agreement with Formulex. Formulex is an Israeli corporation, owned by our co-founders, Mr. Ehud Gilboa,
Dr. Dalia Megiddo, and director Dr. Ronnie Hershman. Ms. Galia Temtsin Kryaz, our director of product development, is the chief executive
officer of Formulex. Pursuant to the license agreement, Formulex granted the company an exclusive license for the development, manufacture
and commercialization of Formulex&rsquo;s patent for dry powder compositions for intranasal delivery and rights in the know-how of its
intranasal and inhaled formulations, combination products, and particle engineering, together, the Licensed Products. Pursuant to the
License Agreement, we pay Formulex royalties of the Licensed Products in the amount of 0.5% of net sales of the licensed products, which
are capped at $100,000 in the aggregate. The royalty payment period commenced on the effective date of the agreement and will continue
on a country-by-country, product-by-product basis for the longer of: (i) 15 years from the date of the first commercial sale of such
Licensed Product in such country, or (ii) until the licensed patent expires in such country. We may terminate the license agreement for
any reason upon 60 days prior written notice. The agreement does not provide for termination by Formulex. In the event of termination
by us, we have the right to acquire the Licensed Technology in an amount equal to the balance between the amount actually paid to Formulex
prior to the date of termination and the amount of $100,000. Termination of the agreement does not relieve the parties of obligation
accrued prior to such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Formulex
Service Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2019, we entered into a services agreement with Formulex, as amended in March 2020, for the provision of certain services by
Formulex. Formulex provides us with services relating to chemical manufacturing and controls for our PBI products, including preclinical
formulation development of dry intranasal powder, development and validation of analytical methods, packaging in an intranasal device,
preparation of clinical batches for bioavailability studies, stability studies, and quality assurance, for a fixed monthly cost of $5,000.
The services agreement was for a term of three years from the amendment date, and automatically renews every year for a period of one
year, unless terminated by either party upon 30 days&rsquo; written notice, in accordance with the terms and conditions set forth therein.
We may also terminate the agreement for any reason upon 30 days&rsquo; written notice to Formulex. In connection with the same, Formulex
has provided the Company with one-time development services in 2023 and 2022 for additional fees of $22,000 and $11,000, respectively,
and no such services were provided to the Company in 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Formulex
Subcontractor Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2024, we entered into a subcontractor agreement with Formulex. Under the terms of the agreement, we may retain the services
of Formulex as a subcontractor, on a non-exclusive basis, in connection with our potential participation in tenders to render certain
services to end-clients. The services provided by Formulex shall be decided by the parties on a case-by-case basis, and may include,
among other services, assisting us with applying to, and participating in, certain tenders, and performing certain tasks for the projects
underlying tenders for which we are selected. Payment for services would be dependent upon the project and, pursuant to the contract,
would need to be pre-itemized in the form of a budget before a project commences. However, the maximum consideration paid to Formulex
in the aggregate under the agreement shall not exceed $800,000. The term of the subcontractor agreement is thirty-six months from its
effective date, unless terminated by either party upon 30 days&rsquo; written notice at any time and for any reason. Each subcontract
under the agreement terminates upon the earlier of completion of the services provided thereunder or the expiration or termination of
the subcontractor agreement, unless otherwise provided by the parties in any specific subcontract with respect thereto. The agreement
is subject to ratification and approval by our shareholders, which we expect to obtain prior to the closing of this offering. In 2024,
Formulex has provided the Company with subcontractor services for a total amount of $116,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secretarial
Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2019, we entered into an agreement with Topnotch Consultancy (2009) Ltd., or Topnotch, a company owned by our co-founder and
Executive Chairman of the Board of Directors, Mr. Udi Gibloa, pursuant to which Topnotch will provide us with secretarial and administrative
services incurred in connection with Mr. Gilboa&rsquo;s services to the Company, in the amount of NIS 5,000 per month ($1,373), which
was raised to NIS 15,000 ($4,119) in December 2024. Per the agreement, Mr. Gilboa is not entitled to any further compensation, reimbursement
of expenses, fees, or commissions that are not in connection with the performance of office or secretarial services. The agreement shall
continue until terminated by either party upon 30 days&rsquo; written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
Lease and Office Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2019, we entered into a services agreement with Topnotch, pursuant to which we receive certain office services and the lease
of our office space in return for a monthly fee of NIS 12,000 ($3,295). Per the agreement, Mr. Gilboa is not entitled to any further
compensation, reimbursement of expenses, fees, or commissions that are not in connection with the performance of office or secretarial
services. The agreement shall continue until terminated by either party upon 30 days&rsquo; written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SAFEs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022 through April 2022, we entered into the 2022 SAFEs for aggregate proceeds of $966,000. Our co-founders, a member of our
board of directors, several shareholders at that time, and Formulex participated in these 2022 SAFEs. Specifically, Mr. Udi Gilboa participated
in the amount of $35,000, Dr. Dalia Megiddo participated in the amount of $35,000, Dr. Ronnie Hershman (through Hershman Holdings LLC)
participated in the amount of $150,000 and Formulex participated in the amount of $30,000. Per the terms of the 2022 SAFEs, since an
initial public offering, merger, acquisition, equity financing other liquidity event or dissolution event did not take place within 15
months from the execution of the 2022 SAFEs, on August 28, 2024, the subscription amounts under such SAFEs were converted into Class
A-3A Ordinary Shares. Upon the effectiveness of the registration statement for this offering, such Class A-3A Ordinary Shares will automatically
convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023 through April 2023, we entered into the 2023 SAFEs for aggregate proceeds of $995,000. A member of our board of directors,
Dr. Hershman (through Hershman Holdings LLC) participated in the amount of $100,000. Gabriel Hershman, a relative of Dr. Hershman, also
participated in the amount of $25,000. Per the terms of the 2023 SAFEs, since an initial public offering, merger, acquisition, equity
financing other liquidity event or dissolution event did not take place within 15 months from the execution of the 2023 SAFEs, in August
28, 2024, the subscription amounts under such SAFEs were converted into Class A-3B Ordinary Shares. Upon the effectiveness of the registration
statement for this offering, such Class A-3B Ordinary Shares will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024 through March 2025, we entered into the 2024 SAFEs in the aggregate amount of $1,986,500, of which $300,000 were canceled
and terminated in November 2024. In addition, pursuant to the terms of the July 2022 Loan Exchange Letter and the February 2023 Loan
Exchange Letter, the July 2022 Loan and February 2023 Loan were converted into 2024 SAFEs in the amount of $570,364 and $66,203, respectively;
however, no additional proceeds were received pursuant to said exchanges. Our co-founders and members of our board of directors participated
in the 2024 SAFEs. Specifically, Mr. Gilboa participated in the amount of $60,963, Dr. Megiddo participated in the amount of $61,286
and Dr. Hershman participated in the amount of $478,108. Per the terms of the 2024 SAFEs, upon an initial public offering, merger, acquisition,
qualified equity financing other liquidity event, the subscription amounts under such SAFEs will be converted into our Ordinary Shares
upon the effectiveness of the registration statement for this offering at a conversion price reflecting a discount of 35%. However, if
such events do not occur within 18 months of the execution of such SAFEs, such SAFEs will be converted into our securities of such class
of shares having certain rights identical to the respective rights of the most senior class of shares on the basis of a previous round
of equity financing consummated by the Company at a conversion price reflecting a discount of 35%, as prescribed in such SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_003"></A>DESCRIPTION
OF SHARE CAPITAL AND GOVERNING DOCUMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SHARE CAPITAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following descriptions of our share capital and provisions of our amended and restated articles of association as in effect upon the
effectiveness of the registration statement for this offering are summaries and do not purport to be complete. A form of our amended
and restated articles of association was filed with the SEC as an exhibit to our registration statement, of which this prospectus forms
a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
effectiveness of this offering, a 1-for-4.77008 forward share split of our Ordinary Shares will take effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context expressly dictates otherwise, all references to share and per share amounts referred to herein reflect the issuance of the
foregoing forward share split, and the customary adjustments to our outstanding options and warrants. The description of the Ordinary
Shares reflects changes to our capital structure that will occur upon the effectiveness of the registration statement for this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 16, 2025, our authorized share capital consisted of 13,265,593 Ordinary Shares, par value NIS 0.01 per share,
comprised of: 9,540,160 Ordinary Shares, 815,684 Class A Ordinary Shares; 1,431,034 Class A-1 Ordinary Shares; 477,008 Class A-2 Ordinary
Shares; 524,709 Class A-3 Ordinary Shares, 171,723 Class A-3A Ordinary Shares and 305,285 Class A-3B Ordinary Shares, of which 7,362,906
shares were issued and outstanding as of such date. All our outstanding Ordinary Shares have been validly issued, fully paid and non-assessable.
Our Ordinary Shares are not redeemable and are not subject to any preemptive right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registration number with the Israeli Registrar of Companies is 516022712.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion
of Classes of Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the effectiveness of the registration statement for this offering, all of our Class A, Class A-1, Class A-2, Class A-3, Class A-3A, and
Class A-3B Ordinary Shares outstanding will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last three years, we have issued an aggregate of 329 Ordinary Shares for share options exercised as part of our option plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Articles of Association</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Purposes
and Objects of the Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
purpose is set forth in Article 1 of our articles of association and includes every lawful purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Powers of the Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors shall direct our policy and shall supervise the performance of our Chief Executive Officer and his actions. Our board
of directors may exercise all powers that are not required under the Companies Law or under our amended and restated articles of association
to be exercised or taken by our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rights
Attached to Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Ordinary Shares shall confer upon the holders thereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal
    right to attend and to vote at all of our general meetings, whether regular or special, with each Ordinary Share entitling the holder
    thereof, which attend the meeting and participate at the voting, either in person or by a proxy or by a written ballot, to one vote;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal
    right to participate in distribution of dividends, if any, whether payable in cash or in bonus shares, in distribution of assets
    or in any other distribution, on a per share pro rata basis; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal
    right to participate, upon our dissolution, in the distribution of our assets legally available for distribution, on a per share
    pro rata basis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Election
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our amended articles of association to be in effect upon the effectiveness of the registration statement for this offering, our directors
are elected at an annual general meeting of our shareholders and serve on the board of directors until the next annual general meeting
(except for external directors) or until he or she resigns or unless he or she is removed by a majority vote of our shareholders at a
general meeting of our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our articles of
association. The directors are classified, excluding the external directors (when applicable), with respect to the term for which they
each severally hold office, into three classes, as nearly equal in number as practicable, and designated as Class I, Class II and Class
III. The Board may assign members of the Board already in office to such classes at the time such classification becomes effective. If
the number of directors is changed, any newly created directors or decrease in directors must be apportioned by the board among the classes
to make them equal in number. Pursuant to our articles of association, other than the external directors, for whom special election requirements
apply under the Companies Law, the vote required to appoint a director is a simple majority vote of holders of our voting shares, participating
and voting at the relevant meeting. In addition, our articles of association allow our Board of Directors to appoint directors to fill
vacancies and/or as an addition to the Board of Directors (subject to the maximum number of directors) to serve until the next annual
general meeting. External directors are elected for an initial term of three years, may be elected for additional terms of three years
each under certain circumstances, and may be removed from office pursuant to the terms of the Companies Law. See &ldquo;<I>Management&mdash;Board
Practices&mdash;External Directors</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Class I members which will hold office initially for a term expiring at the annual general meeting of shareholders to be held in 2025,
shall be Dr. Sharon Shacham and David Silberman;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Class II members which will hold office initially for a term expiring at the annual general meeting of shareholders to be held in 2026,
shall be Isaac Israel and Dr. Ronnie Hershman;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Class III members which will hold office initially for a term expiring at the annual general meeting of shareholders to be held in 2027,
shall be Dr. Dalia Megiddo and Udi Gilboa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Annual
and Special Meetings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year, at such time and place
which shall be determined by our board of directors, that must be no later than 15 months after the date of the previous annual general
meeting. All meetings other than the annual general meeting of shareholders are referred to as special general meetings. Our Board of
Directors may call special meetings whenever it sees fit and upon the request of: (a) any two of our directors or such number of directors
equal to one quarter of the directors then at office; and/or (b) one or more shareholders holding, in the aggregate, (i) 5% or more of
our outstanding issued shares and 1% of our outstanding voting power or (ii) 5% or more of our outstanding voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general
meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and forty days prior
to the date of the meeting. Resolutions regarding the following matters must be passed at a general meeting of our shareholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments
    to our amended and restated articles of association;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise of our board of director&rsquo;s powers by a general meeting if our board of directors is unable to exercise its powers
    and the exercise of any of its powers is required for our proper management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment
    or termination of our auditors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment
    of directors, including external directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    of acts and transactions requiring general meeting approval pursuant to the provisions of the Companies Law (mainly certain related
    party transactions) and any other applicable law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases
    or reductions of our authorized share capital; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    merger (as such term is defined in the Companies Law).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notices</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law and our amended and restated articles of association require that a notice of any annual or special shareholders meeting
be provided at least 21 days prior to the meeting, and if the agenda of the meeting includes the appointment or removal of directors,
the approval of transactions with office holders or interested or related parties, approval of the company&rsquo;s general manager to
serve as the chairman of the board of directors or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Quorum</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted under the Companies Law, the quorum required for our general meetings consists of at least two shareholders present in person,
by proxy, written ballot or voting by means of electronic voting system, who hold or represent between them at least 25% of the total
outstanding voting rights. If within half an hour of the time set forth for the general meeting a quorum is not present, the general
meeting shall stand adjourned the same day of the following week, at the same hour and in the same place, or to such other date, time
and place as prescribed in the notice to the shareholders and in such adjourned meeting, if no quorum is present within half an hour
of the time arranged, any number of shareholders participating in the meeting, shall constitute a quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a special general meeting was summoned following the request of a shareholder, and within half an hour a legal quorum shall not have
been formed, the meeting shall be canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adoption
of Resolutions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless
otherwise required under the Companies Law or our amended and restated articles of association. A shareholder may vote in a general meeting
in person, by proxy, by a written ballot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changing
Rights Attached to Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided by the terms of the shares and subject to any applicable law, any modification of rights attached to any class of
shares must be adopted by the holders of a majority of the shares of that class present a general meeting of the affected class or by
a written consent of all the shareholders of the affected class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights attached
to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitations
on the Right to Own Securities in Our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no limitations on the right to own our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
Restricting Change in Control of Our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no specific provisions of our amended and restated articles of association that would have an effect of delaying, deferring or preventing
a change in control of the Company or that would operate only with respect to a merger, acquisition or corporate restructuring involving
us (or our Subsidiary). However, as described below, certain provisions of the Companies Law may have such effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law includes provisions that allow a merger transaction and requires that each company that is a party to the merger have the
transaction approved by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of
the majority of shareholders, and, in the case of the target company, also a majority vote of each class of its shares. For purposes
of the shareholder vote of each party, unless a court rules otherwise, the merger will not be deemed approved if shares representing
a majority of the voting power present at the shareholders meeting and which are not held by the other party to the merger (or by any
person or group of persons acting in concert who holds 25% or more of the voting power or the right to appoint 25% or more of the directors
of the other party) vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority
approval that governs all extraordinary transactions with controlling shareholders. Upon the request of a creditor of either party to
the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that as a result
of the merger the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give
instructions to secure the rights of creditors. If the transaction would have been approved by the shareholders of a merging company
but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still
approve the merger upon the petition of holders of at least 25% of the voting rights of a company. For such petition to be granted, the
court must find that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration
offered to the shareholders. In addition, a merger may not be completed unless at least (1) 50 days have passed from the time that the
requisite proposals for approval of the merger were filed with the Israeli Registrar of Companies by each merging company and (2) 30
days have passed since the merger was approved by the shareholders of each merging company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law also provides that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by
means of a &ldquo;special&rdquo; tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more
of the voting rights in the company, unless there is already another holder of at least 25% or more of the voting rights in the company
or (2) the purchaser would become a holder of 45% or more of the voting rights in the company, unless there is already a holder of more
than 45% of the voting rights in the company. These requirements do not apply if, in general, the acquisition (1) was made in a private
placement that received shareholders&rsquo; approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting
rights in the company which resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was
from a holder of more than 45% of the voting rights in the company which resulted in the acquirer becoming a holder of more than 45%
of the voting rights in the company. A &ldquo;special&rdquo; tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo;
tender offer may be consummated only if (1) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be
acquired by the offeror and (2) the offer is accepted by a majority of the offerees who notified the company of their position in connection
with such offer (excluding the offeror, controlling shareholders, holders of 25% or more of the voting rights in the company or anyone
on their behalf, or any person having a personal interest in the acceptance of the tender offer). If a special tender offer is accepted,
then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity
may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target
company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an
offer or merger in the initial special tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
as a result of an acquisition of shares, the acquirer will hold more than 90% of an Israeli company&rsquo;s outstanding shares or of
certain class of shares, the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the
outstanding shares of such class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not
tendered in the tender offer and more than half of the offerees who have no personal interest in the offer tendered their shares, all
the shares that the acquirer offered to purchase will be transferred to it by operation of law. However, a tender offer will also be
accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of shares. Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the
tender offer or not, may request, by petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii)
that the fair value should be paid as determined by the court, for a period of six months following the acceptance thereof. However,
the acquirer is entitled to stipulate, under certain conditions, that tendering shareholders will forfeit such appraisal rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
Israeli tax law treats some acquisitions, such as stock-for-stock exchanges between an Israeli company and a foreign company, less favorably
than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his Ordinary Shares
for shares in another corporation to taxation prior to the sale of the shares received in such stock-for-stock swap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in Our Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general meeting may, by a simple majority vote of the shareholders attending the general meeting:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our registered share capital by the creation of new shares from the existing class or a new class, as determined by the general meeting;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel
    any registered share capital which have not been taken or agreed to be taken by any person;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate
    and divide all or any of our share capital into shares of larger nominal value than our existing shares;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subdivide
    our existing shares or any of them, our share capital or any of it, into shares of smaller nominal value than is fixed; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
    our share capital and any fund reserved for capital redemption in any manner, and with and subject to any incident authorized, and
    consent required, by the Companies Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_004"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, no public market existed for our Ordinary Shares. Sales of substantial amounts of our Ordinary Shares following this
offering, or the perception that these sales could occur, could adversely affect prevailing market prices of our Ordinary Shares and
could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the underwriters
do not exercise their over-allotment option with respect to this offering and assuming no exercise of options outstanding following the
offering, we will have an aggregate of Ordinary Shares outstanding upon completion of this offering. Of these shares, the Ordinary Shares
sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased
by &ldquo;affiliates&rdquo; (as that term is defined under Rule 144 of the Securities Act), who may sell only the volume of shares described
below and whose sales would be subject to additional restrictions described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining Ordinary Shares will be held by our existing shareholders. Because substantially all of these shares were sold outside the
United States to persons residing outside the United States at the time, they also will be freely tradable without restriction or further
registration, except that shares held by affiliates must be sold pursuant to Rule 144 or another available exemption, and except for
the lock-up restrictions described below. Further, substantially all of our Ordinary Shares outstanding prior to this offering are subject
to lock-up agreements described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our executive officers, directors, and certain shareholders have agreed not to offer, sell, agree to sell, directly or indirectly,
or otherwise dispose of any Ordinary Shares or any other securities convertible into or exchangeable for Ordinary Shares except for the
Ordinary Shares offered in this offering without the prior written consent of the representative for a period of six months after the
date of this prospectus without the prior written consent of ThinkEquity LLC. After the expiration of such day period, the Ordinary Shares
held by our directors, executive officers or certain of our other existing shareholders may be sold outside of the United States subject
to the restrictions under applicable Israeli securities laws or by means of registered public offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, any person who is not our affiliate (and has not been an affiliate of ours for the last three months) and has
held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell
shares without restriction as long as we continue to file required public information with the SEC. In addition, under Rule 144, any
person who is not an affiliate of ours (and has not been an affiliate of ours for the last three months) and has held their shares for
at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited
number of shares immediately upon the completion of this offering without regard to whether current public information about us is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person who is our affiliate or who was our affiliate at any time during the preceding three months and who has beneficially owned restricted
securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to
sell a number of shares within any three-month period that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
    percent of the number of ordinary shares then outstanding; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    average weekly trading volume of our Ordinary Shares on the NYSE American during the four calendar weeks preceding the filing of
    a notice on Form 144 with respect to the sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an affiliate acquires &ldquo;restricted securities,&rdquo; those securities will also be subject to holding period requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our outstanding Ordinary Shares are expected to be either unrestricted or to be eligible for sale under Rule 144. We cannot estimate
the number of our Ordinary Shares that our existing shareholders will elect to sell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
S under the Securities Act provides that securities owned by any person may be sold without registration in the United States, provided
that the sale is affected in an offshore transaction and no directed selling efforts are made in the United States (as these terms are
defined in Regulation S), subject to certain other conditions. In general, this means that our Ordinary Shares may be sold in some manner
outside the United States without requiring registration in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Rule 701 under the Securities Act, provides that each of our employees, consultants or advisors who received our Ordinary Shares
from us in connection with a compensatory share plan or other written agreement executed prior to the completion of this offering is
eligible to resell such Ordinary Shares in reliance on Rule 144, but without compliance with some of the restrictions, including the
holding period, contained in Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
S-8 Registration Statement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of this offering, we intend to file one or more registration statements on Form S-8 under the Securities Act to register
Ordinary Shares issued or reserved for issuance under our 2019 Plan. The registration statement on Form S-8 will become effective automatically
upon filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares issued upon exercise of a share option and registered under the Form S-8 registration statement will, subject to vesting and lock-up
provisions and Rule 144 volume limitations applicable to our affiliates, be available for sale in the open market immediately unless
they are subject to a lock-up, in which case, immediately after the term of the lock-up expires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL SHARE TRANSFER RESTRICTION MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE
INVESTOR. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN LEGAL ADVISOR REGARDING THE PARTICULAR SECURITIES LAWS AND TRANSFER RESTRICTION
CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF THE ORDINARY SHARES INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE
LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_005"></A>TAXATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our Ordinary Shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well
as any tax consequences that may arise under the laws of any state, local, foreign, including Israeli, or other taxing jurisdiction.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ISRAELI
TAX CONSIDERATIONS AND GOVERNMENT PROGRAMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of the material Israeli income tax consequences of the ownership of our Ordinary Shares. The following also
contains a description of material relevant provisions of the current Israeli income tax structure applicable to companies in Israel,
with reference to its effect on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial
or administrative interpretation, there can be no assurance that the tax authorities will accept the views expressed in the discussion
in question. The discussion is not intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all
possible tax considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our Ordinary Shares. Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation,
as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
Corporate Tax Structure in Israel</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
companies are generally subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the corporate
tax rate was reduced to 24% and as of January 1, 2018, the corporate tax rate is 23%. However, the effective tax rate payable by a company
that derives income from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company
are generally subject to the prevailing corporate tax rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation,
a corporation will be considered as an &ldquo;Israeli resident company&rdquo; if it meets one of the following: (i) it was incorporated
in Israel; or (ii) the control and management of its business are exercised in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Law
for the Encouragement of Industry (Taxes), 5729-1969</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax
benefits for &ldquo;Industrial Companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Industry Encouragement Law defines an &ldquo;Industrial Company&rdquo; as an Israeli resident-company, of which 90% or more of its income
in any tax year, other than income from defense loans, is derived from an &ldquo;Industrial Enterprise&rdquo; owned by it. An &ldquo;Industrial
Enterprise&rdquo; is defined as an enterprise whose principal activity in a given tax year is industrial production.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following corporate tax benefits, among others, are available to Industrial Companies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization
    of the cost of purchased a patent, rights to use a patent, and know-how, which are used for the development or advancement of the
    company, over an eight-year period, commencing on the year in which such rights were first exercised;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
    limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    related to a public offering are deductible in equal amounts over three years.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility
for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Tax
Benefits for Research and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they
are incurred. Expenditures are deemed related to scientific research and development projects, if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    research and development must be for the promotion of the company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    research and development is carried out by or on behalf of the company seeking such tax deduction.&#9;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific
research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is
related to an expense invested in an asset depreciable under the general depreciation rules of the income Tax Ordinance, 1961. Expenditures
not so approved are deductible in equal amounts over three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we may apply the Israel Innovation Authority for approval to allow a tax deduction for all research and development expenses
during the year incurred. There can be no assurance that such application will be accepted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taxation
of our Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares
in an Israeli resident company might be exempt from Israeli tax upon meeting the following terms: (1) the shares sold were purchased
after January 1, 2009; (2) the capital gain is not derived from the permanent establishment of the foreign resident in Israel; (3) the
purchase of shares was not from a relative; (4) and the shares are not traded on the Israeli stock exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax
treaty. For example, under Convention Between the Government of the United States of America and the Government of the State of Israel
with respect to Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares
by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to
claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli
capital gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in
Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising
from the such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv) such Treaty
U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12-month period
preceding the disposition, subject to certain conditions; or (v) such Treaty U.S. Resident is an individual and was present in Israel
for 183 days or more during the relevant taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
all instances where our shareholders may be liable for Israeli tax on the sale of their Ordinary Shares, the payment of the consideration
may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax
on their capital gains in order to avoid withholding at source at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt
of dividends paid on our Ordinary Shares at the rate of 25%, which tax will be withheld at source, unless relief is provided in a treaty
between Israel and the shareholder&rsquo;s country of residence. With respect to a foreign resident who is a &ldquo;substantial shareholder&rdquo;
at the time of receiving the dividend or on any time during the preceding twelve months, the applicable tax rate is 30%. A &ldquo;substantial
shareholder&rdquo; is generally a person who alone or together with such person&rsquo;s relative or another person who collaborates with
such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &ldquo;means of control&rdquo; of the corporation.
&ldquo;Means of control&rdquo; generally include the right to vote, receive profits, nominate a director or an executive officer, receive
assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. However,
a distribution of dividends to non-Israeli residents is subject to withholding tax at source at a rate of 20% if the dividend is distributed
from income attributed to a Preferred Enterprise, unless a reduced tax rate is provided under an applicable tax treaty. For example,
under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our
Ordinary Shares who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated
by a Preferred Enterprise, that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout
the tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25%
of the gross income for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends
distributed from income attributed to a Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject
to a withholding tax rate of 15% for a shareholder that is a U.S. corporation, provided that the condition related to our gross income
for the previous year (as set forth in the previous sentence) is met. If the dividend is attributable partly to income derived from a
Preferred Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative portions
of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will reduce
shareholders&rsquo; tax liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U.S.
FEDERAL INCOME TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR
TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES
OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND
POSSIBLE CHANGES IN THE TAX LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the limitations described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences
to a &ldquo;U.S. Holder&rdquo; arising from the purchase, ownership and sale of the Ordinary Shares. For this purpose, a &ldquo;U.S.
Holder&rdquo; is a holder of Ordinary Shares that is: (1) an individual citizen or resident of the United States, including an alien
individual who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal
income tax laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other
than a partnership that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the
laws of the United States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable
in gross income for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to
exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial
decisions of the trust; or (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S.
Treasury regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income
tax considerations that may be relevant to a decision to purchase our Ordinary Shares. This summary generally considers only U.S. Holders
that will own our Ordinary Shares as capital assets. Except to the limited extent discussed below, this summary does not consider the
U.S. federal tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&rsquo;s
status as a U.S. Holder. This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final,
temporary and proposed U.S. Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, (including
with respect to the Tax Cuts and Jobs Act of 2017), and the U.S./Israeli Income Tax Treaty, all as in effect as of the date hereof and
all of which are subject to change, possibly on a retroactive basis, and all of which are open to differing interpretations. We will
not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment in our Ordinary Shares by U.S. Holders
and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based
on such holder&rsquo;s particular circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state,
local, excise or foreign tax considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a
U.S. Holder who is: (1) a bank, life insurance company, regulated investment company, or other financial institution or &ldquo;financial
services entity;&rdquo; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares in connection
with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder
that holds our Ordinary Shares as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction
transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a
U.S. Holder that expatriates out of the United States or a former long-term resident of the United States; or (9) a person having a functional
currency other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns,
directly or constructively, at any time, Ordinary Shares representing 10% or more of our voting power. Additionally, the U.S. federal
income tax treatment of partnerships (or other pass-through entities) or persons who hold Ordinary Shares through a partnership or other
pass-through entity are not addressed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
prospective investor is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing,
holding or disposing of our Ordinary Shares, including the effects of applicable state, local, foreign or other tax laws and possible
changes in the tax laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taxation
of Dividends Paid on Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under
the heading &ldquo;<I>Passive Foreign Investment Companies</I>&rdquo; below and the discussion of &ldquo;qualified dividend income&rdquo;
below, a U.S. Holder, other than certain U.S. Holder&rsquo;s that are U.S. corporations, will be required to include in gross income
as ordinary income the amount of any distribution paid on Ordinary Shares (including the amount of any Israeli tax withheld on the date
of the distribution), to the extent that such distribution does not exceed our current and accumulated earnings and profits, as determined
for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and profits will be treated first as a
non-taxable return of capital, reducing the U.S. Holder&rsquo;s tax basis for the Ordinary Shares to the extent thereof, and then capital
gain. We do not expect to maintain calculations of our earnings and profits under U.S. federal income tax principles and, therefore,
U.S. Holders should expect that the entire amount of any distribution generally will be reported as dividend income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, preferential tax rates for &ldquo;qualified dividend income&rdquo; and long-term capital gains are applicable for U.S. Holders
that are individuals, estates or trusts. For this purpose, &ldquo;qualified dividend income&rdquo; means, inter alia, dividends received
from a &ldquo;qualified foreign corporation.&rdquo; A &ldquo;qualified foreign corporation&rdquo; is, among others, a corporation that
is entitled to the benefits of a comprehensive tax treaty with the United States which includes an exchange of information program. The
IRS has stated that the Israeli/U.S. Tax Treaty satisfies this requirement and we believe we are eligible for the benefits of that treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dividends will be qualified dividend income if our Ordinary Shares are readily tradable on the NYSE American or another
established securities market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year
the dividend is paid or in the prior year, as a PFIC, as described below under &ldquo;<I>Passive Foreign Investment Companies</I>.&rdquo;
A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder has not held our Ordinary Shares for at least 61
days of the 121 day period beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is
under an obligation to make related payments on substantially similar property. Any days during which the U.S. Holder has diminished
its risk of loss on our Ordinary Shares are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to
treat the dividend income as &ldquo;investment income&rdquo; pursuant to Code section 163(d)(4) will not be eligible for the preferential
rate of taxation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of a distribution with respect to our Ordinary Shares will be measured by the amount of the fair market value of any property
distributed, and for U.S. federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by
us in NIS will be included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the
date the dividend is includible in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal
income tax purposes equal to such U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise
disposes of it, any subsequent gain or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary
exchange gain or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taxation
of the Disposition of Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided under the PFIC rules described below under &ldquo;<I>Passive Foreign Investment Companies</I>,&rdquo; upon the sale, exchange
or other disposition of our Ordinary Shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between
such U.S. Holder&rsquo;s tax basis for the Ordinary Shares in U.S. dollars and the amount realized on the disposition in U.S. dollar
(or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the date of disposition, if the amount realized
is denominated in a foreign currency). The gain or loss realized on the sale, exchange or other disposition of Ordinary Shares will be
long-term capital gain or loss if the U.S. Holder has a holding period of more than one year at the time of the disposition. Individuals
who recognize long-term capital gains may be taxed on such gains at reduced rates of tax. The deduction of capital losses is subject
to various limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Passive
Foreign Investment Companies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
U.S. federal income tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for
U.S. federal income tax purposes for any taxable year that either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75%
    or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25%
    or more of the shares by value), in a taxable year is passive; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share
    of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of,
    or produce, passive income.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
this purpose, passive income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities
transactions and from notional principal contracts. Cash is treated as generating passive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tests for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets
which are relevant to this determination. In addition, our PFIC status may depend in part on the market value of our Ordinary Shares.
We do not expect to be a PFIC for 2024 and we do not expect to become a PFIC in the future, although there can be no assurance in this
regard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we currently are or become a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon
receipt of certain distributions by us and upon disposition of our Ordinary Shares at a gain: (1) have such distribution or gain allocated
ratably over the U.S. Holder&rsquo;s holding period for the Ordinary Shares, as the case may be; (2) the amount allocated to the current
taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income;
and (3) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the
applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the
resulting tax attributable to each such other taxable year. In addition, when shares of a PFIC are acquired by reason of death from a
decedent that was a U.S. Holder, the tax basis of such shares would not receive a step-up to fair market value as of the date of the
decedent&rsquo;s death, but instead would be equal to the decedent&rsquo;s basis if lower, unless all gain were recognized by the decedent.
Indirect investments in a PFIC may also be subject to these special U.S. federal income tax rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PFIC rules described above would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has
held the Ordinary Shares while we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder
who has made such a QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder&rsquo;s pro
rata share of our ordinary earnings as ordinary income and such U.S. Holder&rsquo;s pro rata share of our net capital gains as long-term
capital gain, regardless of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only
if we make available certain required information. The QEF election is made on a shareholder-by-shareholder basis and generally may be
revoked only with the consent of the IRS. We do not intend to notify U.S. Holders if we believe we will be treated as a PFIC for any
tax year. In addition, we do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and
to make and maintain a valid QEF election for any year in which we are a PFIC. Therefore, the QEF election will not be available with
respect to our Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the PFIC rules described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder
of our Ordinary Shares which are regularly traded on a qualifying exchange, including the NYSE American, can elect to mark the Ordinary
Shares to market annually, recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the
taxable year between the fair market value of the Ordinary Shares and the U.S. Holder&rsquo;s adjusted tax basis in the Ordinary Shares.
Losses are allowed only to the extent of net mark-to-market gain previously included income by the U.S. Holder under the election for
prior taxable years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders who hold our Ordinary Shares during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be
a PFIC. U.S. Holders are strongly urged to consult their tax advisors about the PFIC rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
on Net Investment Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including
dividends on and gains from the sale or other disposition of our Ordinary Shares), or in the case of estates and trusts on their net
investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&rsquo;s total
adjusted income exceeds applicable thresholds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
Consequences for Non-U.S. Holders of Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided below, an individual, corporation, estate or trust that is not a U.S. Holder referred to below as a non-U.S. Holder, generally
will not be subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of,
our Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. Holder may be subject to U.S. federal income tax on a dividend paid on our Ordinary Shares or gain from the disposition of our
Ordinary Shares if: (1) such item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United
States and, if required by an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in
the United States; or (2) in the case of a disposition of our Ordinary Shares, the individual non-U.S. Holder is present in the United
States for 183 days or more in the taxable year of the disposition and other specified conditions are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, non-U.S. Holders will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares if
payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United
States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable
IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder&rsquo;s U.S. federal
income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Information
Reporting and Withholding</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder may be subject to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of Ordinary
Shares. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup
withholding will not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations.
Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder,
provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder with interests in &ldquo;specified foreign financial assets&rdquo; (including, among other assets, our Ordinary Shares, unless
such Ordinary Shares are held on such U.S. Holder&rsquo;s behalf through a financial institution) may be required to file an information
report with the IRS if the aggregate value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time
during the taxable year (or such higher dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a
Report of Foreign Bank and Financial Accounts, or FBAR, if the aggregate value of the foreign financial accounts exceeds $10,000 at any
time during the calendar year. You should consult your own tax advisor as to the possible obligation to file such information report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_006"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
is acting as Representative. On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, we entered into an underwriting agreement with the Representative, or the Underwriting Agreement. Subject
to the terms and conditions of the Underwriting Agreement, we have agreed to sell, and each underwriter named below has severally agreed
to purchase, the number of Ordinary Shares listed next to each underwriter&rsquo;s name in the following table, at the public offering
price less the underwriting discounts set forth on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriters</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    <BR>
    of Shares</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
    LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters have committed to purchase all of the Ordinary Shares offered by us in this offering other than those covered by the over-allotment
option described below. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the
Underwriting Agreement. Furthermore, pursuant to the Underwriting Agreement, the underwriters&rsquo; obligations are subject to customary
conditions, representations, and warranties, such as receipt by the underwriters of officers&rsquo; certificates and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering Ordinary Shares subject to prior sale when, as, and if issued to and accepted by them, subject to approval
of legal matters by their counsel and other conditions. The underwriters reserve the right to withdraw, cancel, or modify offers to the
public and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters propose to offer the Ordinary Shares to the public at the public offering price set forth on the cover of the prospectus.
After Ordinary Shares are released for sale to the public, the underwriters may from time to time change the offering price and other
selling terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to the underwriters an option, exercisable for 45 days from the date of this prospectus, to purchase up to additional 450,000
Ordinary Shares (15% of the Ordinary Shares sold in this offering) at the initial public offering price, less the underwriting discounts
and commissions. The underwriters may exercise the option solely for the purpose of covering over-allotments, if any, in connection with
this offering. To the extent that the option is exercised, each underwriter must purchase additional Ordinary Shares in an amount that
is approximately proportionate to that underwriter&rsquo;s initial purchase commitment (set forth in the table above). Any Ordinary Shares
issued or sold under the option will be issued and sold on the same terms and conditions as the other Ordinary Shares that are the subject
of this offering. If this option is exercised in full, the total offering price to the public will be $38.0 million and the total
net proceeds to us, before expenses, will be $35.3 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative has advised that the underwriters propose to offer the Ordinary Shares to the public at the public offering price per
share set forth on the cover page of this prospectus. The underwriters may offer the Ordinary Shares to securities dealers at that
price less a concession of not more than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, of which up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may be re-allowed to other dealers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the public offering price, underwriting discounts and commissions, and proceeds to us before expenses, assuming
both no exercise and full exercise by the underwriters of the over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Without
    <BR>
    Over-<BR>
    Allotment</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>With
    <BR>
    Over-<BR>
    Allotment</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discount (7%) <SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds,
    before expenses, to us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to pay a non-accountable expense allowance to the Representative equal to 1% of the gross proceeds received in this offering
    (excluding proceeds received from exercise of the underwriters&rsquo; over-allotment option) which is not included in the underwriting
    discounts and commission.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid an expense deposit of $20,000 to the Representative, which will be applied against the Representative&rsquo;s accountable out-of-pocket
expenses (in compliance with FINRA Rule 5110(f)(2)(C)) that are payable by us in connection with this offering. We have agreed to reimburse
the Representative for the fees and expenses of its legal counsel in connection with the offering in an amount not to exceed $125,000,
the fees and expenses related to the use of Ipero&rsquo;s book building, prospectus tracking and compliance software for the offering
in the amount of $29,500, up to $15,000 for background checks of our officers and directors, the costs associated with bound volumes
of the offering materials as well as commemorative mementos and lucite tombstones in an amount not to exceed $3,000, data services and
communications expenses up to $10,000, the actual accountable &ldquo;road show&rdquo; expenses up to $10,000 and the costs of market
making and trading and clearing firm settlement expenses up to $30,000; provided however that the aggregate accountable expenses reimbursement
will not exceed $175,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the expenses of this offering payable by us, not including underwriting discounts and commissions, will be approximately
$980,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representatives&rsquo;
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue to the Representative, upon the consummation of this offering, warrants to purchase up to an aggregate of 150,000
Ordinary Shares (5% of the Ordinary Shares sold in this offering), or the Representative&rsquo;s Warrants. The Representative&rsquo;s
Warrants are exercisable at a per share price equal to 125% of the public offering price per share in this offering. The Representative&rsquo;s
Warrants are exercisable at any time and from time to time, in whole or in part, commencing on the six-month anniversary of the effective
date of the registration statement of which this prospectus is a part and expiring on the date that is five years following the commencement
of sales of Ordinary Shares in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative&rsquo;s Warrants are deemed underwriter compensation by FINRA and are therefore subject to a 180-day lock-up pursuant
to FINRA Rule 5110(g)(1). The Representative (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge,
or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period
of 180 days from commencement of sales in this offering. In addition, the Representative&rsquo;s Warrants provide for registration rights
upon request, in certain cases. The one-time demand registration right provided will not be greater than five years from the commencement
of sales of this offering in compliance with FINRA Rule 5110(f)(2)(G)(iv). The piggyback registration right provided will not be greater
than seven years from the commencement of sales of this offering in compliance with FINRA Rule 5110(g)(8). We will bear all fees
and expenses attendant to registering the securities issuable on exercise of the Representative&rsquo;s Warrants other than underwriting
commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the Representative&rsquo;s
Warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization,
merger, or consolidation. However, neither the Representative Warrant exercise price, nor the number of Ordinary Shares underlying such
warrants, will be adjusted for issuances of Ordinary Shares by us at a price below the exercise price of the Representative&rsquo;s Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to certain &ldquo;lock-up&rdquo; agreements, we for a period of 6 months and our executive officers and directors as of the date of this
prospectus have agreed, for a period of 8 months from the date of this prospectus, and as for any other holder of our outstanding securities
for period of 6 months, not to engage in any of the following, whether directly or indirectly, without the Representative&rsquo;s consent:
offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, our Ordinary Shares or any securities convertible
into or exercisable or exchangeable for our Ordinary Shares, or the Lock-Up Securities; enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities; make any demand for
or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration
of any Lock-Up Securities; enter into any transaction, swap, hedge, or other arrangement relating to any Lock-Up Securities, subject
to customary exceptions; or publicly disclose the intention to do any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
18 months from the closing date of this offering, the Representative will have an irrevocable right of first refusal to act as sole investment
banker, sole book-runner, and/or sole placement agent, at the Representative&rsquo;s sole discretion, for each and every future public
and private equity and debt offering, including all equity linked financings, during such 18 month period, for us, or any successor to
or any subsidiary of us, on terms customary for the Representative. The Representative will have the sole right to determine whether
any other broker-dealer shall have the right to participate in any such offering and the economic terms of any such participation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there was no established public market for our Ordinary Shares. The public offering price was negotiated between us
and the underwriters. In determining the price, we considered our history and prospects, our business potential and earnings prospects,
an assessment of our management, general securities market conditions at the time of the offering, and such other factors that we deemed
relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
active trading market for our Ordinary Shares may not develop. It is also possible that the Ordinary Shares will not trade in the public
market or above the initial public offering price following the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against liabilities relating to this offering that may arise under the Securities Act and from
any breach of the representations and warranties contained in the Underwriting Agreement. We have further agreed to contribute to payments
that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus in electronic format may be made available on websites or through other online services maintained by one or more of the underwriters,
or by their affiliates. Other than this prospectus in electronic format, the information on any underwriter&rsquo;s website and any information
contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this
prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be
relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside of the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken that would permit a public offering of our Ordinary Shares in any jurisdiction where
action for the purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor
may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be
distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and
regulations of that country or jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about
and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute
an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an
offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Australia</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian
Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter
6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to
whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions
set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons
as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the
offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations
Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer
to the offeree under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Canada</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ordinary Shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>China</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&rsquo;s
Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region
and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly
to &ldquo;qualified domestic institutional investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European
Economic Area&mdash;Belgium, Germany, Luxembourg and Netherlands</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under
the Directive 2003/71/EC, or the Prospectus Directive, as implemented in Member States of the European Economic Area, each, a Relevant
Member State, from the requirement to produce a prospectus for offers of securities. An offer to the public of securities has not been
made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive
as implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose
    corporate purpose is solely to invest in securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance
    sheet of more than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an
    annual net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive)
    subject to obtaining the prior consent of the company or any underwriter for any such offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall
    result in a requirement for the publication by the company of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>France</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers)
in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code Mon&eacute;taire et Financier) and Articles
211-1 et seq. of the General Regulation of the French Autorit&eacute; des march&eacute;s financiers, or AMF. The securities have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval
in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&eacute;s)
acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D.744-1, D.754-1;
and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified
investors (cercle restreint d&rsquo;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg;
and D.411-4, D.744-1, D.754-1; and D.764-1 of the French Monetary and Financial Code and any implementing regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly
or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3
of the French Monetary and Financial Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ireland</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed
with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities
in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005, or the Prospectus Regulations. The securities
have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering,
except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal
persons who are not qualified investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Israel</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority, or the ISA, nor have
such securities been registered for sale in Israel. The Ordinary Shares may not be offered or sold, directly or indirectly, to the public
in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering
or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered
an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities
offered by this prospectus is subject to restrictions on transferability and must be made effective only in compliance with the Israeli
securities laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Italy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione
Nazionale per le Societ&agrave; e la Borsa, or &ldquo;CONSOB&rdquo;) pursuant to the Italian securities legislation and, accordingly,
no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in
a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998, or Decree No. 58, other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    Italian qualified investors, as defined in Article 100 of Decree no.58 by reference to Article 34-ter of CONSOB Regulation no. 11971
    of 14 May 1999, or Regulation no. 1197l as amended, or Qualified Investors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of
    Regulation No. 11971 as amended.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements
    where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
    by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative
    Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable
    laws; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules
provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply
with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring
the securities for any damages suffered by the investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Japan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan
(Law No. 25 of 1948), as amended, or the FIEL, pursuant to an exemption from the registration requirements applicable to a private placement
of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations
promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities
may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities
is conditional upon the execution of an agreement to that effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Portugal</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios)
in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The
securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document
and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market
Commission (Comiss&atilde;o do Mercado de Valores Mobili&aacute;rios) for approval in Portugal and, accordingly, may not be distributed
or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify
as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to
persons who are &ldquo;qualified investors&rdquo; (as defined in the Portuguese Securities Code). Only such investors may receive this
document and they may not distribute it or the information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sweden</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority).
Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances
that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel
med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &ldquo;qualified investors&rdquo; (as
defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the
information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Switzerland</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for
issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses
under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland.
Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial
Market Supervisory Authority (FINMA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is personal to the recipient only and not for general circulation in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
Kingdom</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services
Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as
amended, or the FSMA) has been published or is intended to be published in respect of the securities. This document is issued
on a confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and
the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document,
except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not
be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in
the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the
issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be
communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters
relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005, or FPO, (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth
companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &ldquo;relevant
persons&rdquo;). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase
will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any
of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts, or NI 33-105, the underwriters are not required to comply with
the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales. Stabilizing transactions permit bids to purchase
shares so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding
a decline in the market price of the Ordinary Shares while the offering is in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
transactions involve sales by the underwriters of shares in excess of the number of shares that the underwriters are obligated to purchase.
This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position,
the number of shares over-allotted by the underwriters is not greater than the number of shares that the underwriters purchase in the
over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares that the underwriters
purchase in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or
purchasing shares in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
covering transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate
short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things,
the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise
of the over-allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option and,
therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position
is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the
Ordinary Shares in the open market that could adversely affect investors who purchase in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
bids permit the representative to reclaim a selling concession from a syndicate member when the Ordinary Shares originally sold by that
syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price
of our Ordinary Shares or preventing or retarding a decline in the market price of our Ordinary Shares. As a result, the price of our
Ordinary Shares in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the
underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our
Ordinary Shares. These transactions may be affected in the over-the-counter market or otherwise and, if commenced, may be discontinued
at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters and their affiliates may in the future provide various advisory, investment and commercial banking and other services for
us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have
no present arrangements with any of the underwriters for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_007"></A>EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is an itemization of the total expenses, excluding underwriting discounts, expected to be incurred in connection with the
offer and sale of our Ordinary Shares by us. With the exception of the SEC registration fee and the FINRA filing fee, all amounts are
estimates:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    registration fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE
    American listing fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA
    filing fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
    agent fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printer
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_008"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters concerning this offering will be passed upon for us by Sullivan &amp; Worcester LLP, New York, New York. Certain legal
matters with respect to the legality of the issuance of the securities offered by this prospectus and other legal matters concerning
this offering relating to Israeli law will be passed upon for us by Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Tel Aviv,
Israel. Certain legal matters related to the offering will be passed upon for the underwriters by Blank Rome LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_009"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Nasus Pharma Ltd. as of December 31, 2024 and 2023 and for each of the two years in the period ended December
31, 2024, included in this prospectus, have been audited by Brightman Almagor Zohar &amp; Co., a firm in the Deloitte Global Network,
an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are included
in reliance upon the report of such firm given their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_010"></A>ENFORCEABILITY
OF CIVIL LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and senior management and the
Israeli experts named in the registration statement of which this prospectus forms a part, a substantial majority of whom reside outside
of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and a
substantial of our directors and senior management are located outside of the United States, any judgment obtained in the United States
against us or any of our directors and senior management may not be collectible within the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been informed by our legal counsel in Israel, Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), that it may be difficult to
assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation
of U.S. securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court
agrees to hear a claim, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can
be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have irrevocably appointed Puglisi &amp; Associates as our agent to receive service of process in any action against us in any U.S. federal
or state court arising out of this offering or any purchase or sale of securities in connection with this offering. Subject to specified
time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions,
is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including
a monetary or compensatory judgment in a non-civil matter, provided that among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment is obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the
    judgment is given and the rules of private international law currently prevailing in Israel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment is final and is not subject to any right of appeal;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts;
    however, the court may enforce a foreign judgment, even without reciprocity, based on the request of the Attorney General, under
    certain circumstances;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    service of process has been affected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liabilities under the judgment are enforceable according to the laws of the State of Israel and the judgment and the enforcement
    of the civil liabilities set forth in the judgment is not contrary to the law or public policy in Israel nor likely to impair the
    security or sovereignty of Israel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment was not obtained by fraud, there was reasonable opportunity for the defendant to present their case, the judgment was given
    by an authorized court to issue it under the applicable international private law rules in Israel, and the judgement does not conflict
    with any other valid judgments in the same matter between the same parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the
    foreign court;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
    may be denied if it could harm the sovereignty or security of Israel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a foreign judgment is declared enforceable by an Israeli court, it generally will be payable in Israeli currency. The conversion to Israeli
currency will be based on the latest official exchange rate published by the Bank of Israel before the payment date. However, the obligated
party will fulfill its duty by the judgment even if they choose to make the payment in the same foreign currency, subject to the laws
governing the foreign currency applicable at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli CPI plus
interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable
exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_011"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our Ordinary Shares.
This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC
allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus
concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized,
but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration
statement, you may read the document itself for a complete description of its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC.
Our filings with the SEC are also available to the public through the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those
requirements are filing reports with the SEC. Those other reports or other information may be inspected without charge at the locations
described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content
of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered
under the Exchange Act. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time
as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting
firm, and intend to submit to the SEC, on Form 6-K, unaudited interim financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a corporate website at www.nasuspharma.com. Information contained on, or that can be accessed through, our website does not
constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and
regulations, including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings
of our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
<A NAME="one_012"></A>PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audited
consolidated financial statements of Nasus Pharma Ltd. and its subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fw_001">Report
    of Independent Registered Public Accounting Firm</A> (PCAOB ID 1197)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fw_002">Consolidated
    Balance Sheets</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fw_003">Consolidated
    Statements of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fw_004">Consolidated
    Statements of Changes in Shareholders&rsquo; Deficit</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fw_005">Consolidated
    Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#fw_006">Notes
    to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 181; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements give effect to a 1-for-4.77008 forward share split of Nasus Pharma Ltd. which will take place on
the effective date of the registration statement. The following report is in the form which will be furnished by Brightman
Almagor Zohar &amp; Co., an independent registered public accounting firm, upon completion of the 1-for-4.77008 share split of the ordinary
shares of Nasus Ltd. described in Note 7(d) to the financial statements, assuming that from March 21, 2025 to the date of such completion,
no other material events have occurred that would affect the accompanying financial statements or disclosures therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/
    Brightman Almagor Zohar &amp; Co.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certified
    Public Accountants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
    Firm in the Deloitte Global Network</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv,
    Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fw_001"></A>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
the Shareholders and the Board of Directors of Nasus Pharma Ltd</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Nasus Pharma Ltd. and its subsidiary (the &ldquo;Company&rdquo;) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in shareholders&rsquo; deficit, and cash flows, for each
of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1.B to the financial statements, the Company&rsquo;s lack of revenues and accumulated operating losses raise substantial doubt about
its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note 1.B. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brightman
    Almagor Zohar &amp; Co.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certified
    Public Accountants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
    Firm in the Deloitte Global Network</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel&nbsp;-Aviv,
    Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&rsquo;s auditor since 2024.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fw_002"></A>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Amounts in
    thousands, except share and per share amounts)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">284</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">193</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets (of which $116 and $0 are to related parties as of December 31, 2024 and December 31, 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">146</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">234</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">457</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">444</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred offering cost</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">260</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">717</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">444</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities and Shareholders&rsquo;
    Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">651</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">655</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued expense and other
    current liabilities (of which $711 and $451 are to related parties as of December 31, 2024 and December 31, 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">987</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">616</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible securities
    (of which $605 and $365 are to related parties as of December 31, 2024 and December 31, 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,830</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Short-term debt from shareholders
    (of which $- and $344 are to related parties as of December 31, 2024, and December 31, 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">627</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    liabilities related to discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">489</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,929</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,241</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,929</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,241</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments and contingencies (see Note
    &nbsp;6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo; deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ordinary Shares(*)(**), par value NIS 0.01
    per share; 13,265,593 and 12,788,585 shares authorized as of &nbsp;December 31, 2024 and 2023, respectively; 7,362,906 and
    &nbsp;6,889,709 shares issued as of &nbsp;December 31, 2024 and 2023, respectively.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid-in capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,432</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,316</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,132</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Shareholders&rsquo; Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,212</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,797</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Liabilities and Shareholders&rsquo; Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">717</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">444</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise stated, the term Ordinary Shares in these consolidated &nbsp;financial statements refers to all classes of shares, including
    Class Ordinary Shares, Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    giving effect to the forward share split, see also Note 7(d).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fw_003"></A>CONSOLIDATED
STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Amounts in
    thousands, except share and per share amounts)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and
    development (of which $208 and $228 are with related parties in 2024 and 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">335</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">567</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative (of which $307 and $288 are with related parties in 2024 and 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">743</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">580</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,078</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,147</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,078</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,147</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense (of which
    $17 and $27 are with related parties in 2024 and 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(29</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(49</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of
    convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(443</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">219</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    expense, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,552</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,005</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    income (loss) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per share data:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss per share attributable to shareholders:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average Ordinary Shares outstanding
    &ndash; basic(*)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,027,725</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,889,708</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average Ordinary Shares outstanding
    &ndash; diluted(*)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,027,725</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,057,820</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    giving effect to the forward share split, see also Note 7(d). </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fw_004"></A>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; DEFICIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ordinary
    Shares* (**)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional<BR>
    Paid- in</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholders&rsquo;</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,889,709</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,277</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10,081</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,785</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share-based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,889,709</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,316</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11,132</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,797</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share -based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of SAFE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">473,197</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,106</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,107</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,362,906</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,432</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12,664</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,212</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise stated, the term Ordinary Shares in these consolidated&nbsp; financial statements refers to all classes of shares, including
    Class Ordinary Shares, Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    giving effect to the forward share split, see also Note 7(d).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fw_005"></A>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Amounts in
    thousands)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from operating
    activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,051</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less: Net loss (income)
    from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,552</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,005</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments to reconcile loss from continuing
    operations to net cash used in operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share-based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">443</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(219</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect of exchange rates</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued interest on short-term debt from shareholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">49</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in operating assets and liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses and other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">88</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(116</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued expense and other
    current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">322</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">271</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash used in operating activities from continuing
    operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(661</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(982</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in &nbsp;operating
    activities from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(47</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(665</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,029</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from investing
    activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash used in investing
    activities from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash used in investing activities from discontinued
    operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash used in investing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash flows from financing
    activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from issuance of convertible securities
    (of which $200 and $100 are with related parties in 2024 and 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">995</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from short-term debt from shareholders
    (of which $0 and $60 are with related parties in 2024 and 2023, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payments in connection with deferred</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
    offering costs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(230</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">770</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,055</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash used in financing activities from discontinued
    operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash provided by financing
    activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">770</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,055</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect of exchange rate changes on cash, cash
    equivalents and restricted cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash and cash equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">101</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash, cash equivalents
    and restricted cash at beginning of year</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">210</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">171</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash,
    cash equivalents and restricted cash at end of year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">311</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">210</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><B>Supplemental disclosure of non-cash financing activities:</B></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Offering cost included in accrued expense and other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of short-term
    debt from shareholders to 2024 SAFEs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">636</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
to the total of the same such amounts shown on the consolidated statements of cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">284</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">193</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash,
    cash equivalents and restricted cash at end of year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">311</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">210</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="fw_006"></A>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    1:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGANIZATION
    AND NATURE OF THE BUSINESS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of the Business</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
Pharma Ltd. (the &ldquo;Company&rdquo;) was incorporated in May 2019 under the laws of the State of Israel. The Company is a clinical
stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions.
The Company is developing a powder-based intranasal technology with a specialized product portfolio to address acute medical conditions
and public health threats. The Company&rsquo;s lead product candidate is NS002, an intranasal powder Epinephrine nasal spray for the
treatment of type 1 severe allergies and anaphylaxis. The Company has also been developing NS001, an intranasal Naloxone powder nasal
spray for the treatment of opioid overdose, however, the Company currently paused its work on NS001 and plans to pursue opportunities
for further development of NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had a wholly-owned subsidiary in the United Kingdom which had no operations since its incorporation in September 2020 through
its dissolution in February 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
    and Going Concern</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&ldquo;U.S.
GAAP&rdquo;) on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course
of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has devoted most of its efforts to business planning, research and development, clinical trials and raising capital.
The Company is still in its development and clinical stage and has not yet generated revenues from its existing products under development
and, accordingly, the extent of the Company&rsquo;s future operating losses and the timing that the Company will become profitable are
uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company incurred a net loss of $1,532 (and a loss of $1,552 from continuing operations)
and used net cash flows from operations of $665 (and cash used in continuing operations was $661). Additionally, as of December 31, 2024,
the Company had cash and cash equivalents of $284 to fund its operations and an accumulated deficit of $12,664.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has funded its operations to date primarily through equity financing and the issuance of convertible securities in the form of
simple agreement of future equity (&ldquo;SAFE&rdquo;) (see Note 4 and Note 14). Additional funding will be required to complete
the Company&rsquo;s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts
of the Company&rsquo;s products and to achieve a level of sales adequate to support the Company&rsquo;s cost structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
conditions raise substantial doubts about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans include,
but are not limited to, an initial public offering (&ldquo;IPO&rdquo;) in the United States. While the Company has been able to raise
outside capital in the past, there can be no assurance that it will be able to successfully consummate an IPO or obtain additional financing
on a timely basis in terms acceptable to the Company, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
expects that the Company will continue to generate losses from the clinical development and regulatory activities of its product candidates,
which would result in negative cash flow from operating activity. This has led management to conclude that there is substantial doubt
about the Company&rsquo;s ability to continue as a going concern. The Company&rsquo;s consolidated financial statements do not reflect
any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>c.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
    split</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share amounts for Ordinary Shares, share options and loss per share amounts have been adjusted to give retroactive effect
to the forward share split for all periods presented in these financial statements. See also Note 7(d).</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    2:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT
    ACCOUNTING POLICIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
    of presentation and principles of consolidation:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements are prepared in accordance with U.S. GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include accounts of the Company&rsquo;s wholly-owned subsidiary in the United Kingdom that was dissolved
in February 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>b.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of estimates:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from
those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
items subject to such estimates and assumptions include identifying the existence of embedded derivatives, share-based compensation and
the determination of the fair value of the Company&rsquo;s Ordinary Shares and share options and the fair value of convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the estimates, and judgments they made, are reasonable based upon information available to them at the time that these
estimates and judgments are made. To the extent that there are material differences between these estimates and actual results, the Company&rsquo;s
consolidated financial statements will be affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>c.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    statements in U.S. dollars:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional and reporting currency of the Company is the United States dollar (&ldquo;USD&rdquo; or &ldquo;U.S. dollar&rdquo;) as the
U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company balances and transactions denominated in U.S. dollars are presented at their original amounts. Non-U.S. dollar transactions and
balances have been remeasured to U.S. dollars in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) 830 of the Financial
Accounting Standards Board (&ldquo;FASB&rdquo;). All transaction gains and losses from remeasurement of monetary balance sheet items
denominated in non-U.S. dollar currencies are included within other expense&nbsp;, net in the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>d.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
    equivalents:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, and restricted
cash. The Company&rsquo;s cash and cash equivalents consist of demand deposits with financial institutions. The associated risk of concentration
is mitigated by banking with creditworthy institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less as
of the date acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>e.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
    cash:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash primarily consists of amounts used to secure the &nbsp;Company&rsquo;s corporate credit cards, and are invested in highly liquid
deposits, with maturities of three months or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>f.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
    offering costs:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs, which consist of direct incremental legal, accounting, and consulting fees relating to the planned IPO, are capitalized.
The deferred offering costs will be reclassified to shareholders&rsquo; equity and offset against the proceeds of the offering
upon the consummation of the IPO. In the event the planned IPO is terminated, the deferred offering costs will be expensed. As of December
31, 2024, there were $260 deferred offering costs recorded on the consolidated balance sheet. There were no offering costs
recorded as of December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>g.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Severance
    pay:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Israeli Severance Pay Law, 1963 (&ldquo;Severance Pay Law&rdquo;), all of the Company&rsquo;s employees are entitled to severance
payment, following the termination of their employment. Under the Severance Pay Law, the severance payment is calculated as one-month
salary for each year of employment, or a portion thereof. The Company&rsquo;s liability for severance pay is covered by the provisions
of Section 14 of the Severance Pay Law (&ldquo;Section 14&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 14 employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, contributed on their behalf to their
insurance funds. Payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore,
the Company does not recognize a liability for severance pay due to its employees beyond the monthly deposits they are required to make
and, accordingly, the amount deposited under Section 14 are not recorded as an asset in the Company&rsquo;s balance sheets. Severance
expenses for the years ended December 31, 2024 and 2023 amounted to $10, and $10, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>h.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
    value measurement:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures and discloses the fair value of financial assets and liabilities in accordance with ASC Topic 820, &ldquo;Fair Value
Measurement.&rdquo; Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value
into three broad levels, which are described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices (unadjusted) in active markets for identical assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    other than quoted prices included within Level 1 that are observable directly or indirectly.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances
included in the consolidated financial statements measured at fair value on a recurring basis include convertible securities. When developing
fair value measurements, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. However, for
estimating the fair value of convertible securities the Company utilizes unobservable inputs in determining fair value due to the lack
of observable inputs in the market, which requires greater judgment in measuring fair value. In instances where there is limited or no
observable market data, fair value measurements for assets and liabilities are based primarily upon the Company&rsquo;s own estimates,
and the measurements reflect information and assumptions that management believes a market participant would use in pricing the asset
or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>i.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
    and Administrative</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation-related expenses for management and other employees. Also, it consists
of expenses for facilities, professional services fees, management fees, insurance costs, and other general overhead costs. General and
administrative expenses are expensed as incurred with the exception of share-based compensation, which is recognized over the requisite
service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>j.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
    and development costs:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include compensation-related expenses, consulting costs, external contract research and development expenses,
clinical trial costs, raw materials, third party manufacturing costs. Research and development costs are expensed as incurred, except
for share-based compensation, which is recognized over the requisite service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>k.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    Costs</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and related patent costs are expensed as incurred as their realization is uncertain. Costs related to patent registration are classified
as general and administrative expenses, and costs related to acquired patents are recorded in research and development expenses within
the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>l.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contingent
    liabilities</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its contingent liabilities in accordance with ASC No. 450, &ldquo;Contingencies&rdquo;. A provision is recorded
when it is both probable that a liability has been incurred, and the amount of the loss can be reasonably estimated. With respect to
legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. See Note 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>m.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
    tax</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future
tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income or expense in the period that includes the enactment date. A valuation allowance
is established when necessary to reduce deferred income tax assets to the amount expected to be realized based on management&rsquo;s
consideration of all positive and contradictory evidence available. As of December 31, 2024, and 2023, a full valuation allowance was
established by the Company to reduce the deferred tax assets to the amount supported by future reversals of existing taxable temporary
differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates uncertainty in income tax positions based on a more-likely-than-not recognition standard. If that threshold is met,
the tax position is then measured at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If
applicable, the Company records interest and penalties as a component of income tax expense. The Company applies a more-likely-than-not
recognition threshold to uncertain tax positions based on the technical merits of the income tax positions taken. The Company does not
recognize a tax benefit unless it is more likely than not that the tax position will be sustained upon examination, including resolution
of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these
positions is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The
Company believes that its tax positions are all highly certain of being upheld upon examination. As such, as of December 31, 2024 and
2023, the Company has not recorded any liability for unrecognized tax benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>n.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-based
    compensation:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures and records the expense related to share-based compensation awards made to employees, directors, and non-employee service
providers based on estimated fair values of those awards as determined on the date of grant. The Company recognizes share-based compensation
expenses based on the accelerated attribution method over the requisite service period. The Company recognizes forfeitures of awards
as they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes-Merton (&ldquo;Black-Scholes&rdquo;) option-pricing model to determine the fair value of share options.
The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, which determine the fair value
of share-based compensation awards, including the Class Ordinary Share price, expected volatility of the underlying Class Ordinary
Share, expected option term (the time from the grant date until the share options are exercised or expire), and expected divided yield.
The Company calculates the fair value of share options granted using the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    Ordinary Share Price &ndash; Since the Company&rsquo;s Class Ordinary Shares are not publicly traded, the expected volatility is
    based on the historical and implied volatility of similar companies whose stock or option prices are publicly available, after considering
    the industry, stage of life cycle, size, market capitalization, and financial leverage of the other companies. The Company estimated
    its Class Ordinary Share price based on third party valuation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Volatility &ndash; The Company estimated volatility for share option grants by evaluating the average historical volatility of a
    peer group of companies for the period immediately preceding the share option grant for a term that is approximately equal to the
    share options&rsquo; expected term.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Term&mdash;The expected term of the Company&rsquo;s share options represents the period that the share options are expected to be
    outstanding. The Company has elected to use the &ldquo;simplified&rdquo; method for share options granted to employees and directors,
    as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns
    and post-vesting employment termination behavior. Under this approach, the midpoint of the share options vesting term and contractual
    expiration period to compute the expected term. The simplified method makes the assumption that the employee will exercise share
    options evenly over the period when the share options are vested and ending on the date when the share options expire. The expected
    term for share options granted to non-employees is based on the contractual term.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free
    Interest Rate&mdash;The risk-free interest rate is based on the implied yield currently available on US Treasury zero-coupon issues
    with a term that is equal to the share options&rsquo; expected term at the grant date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Yield&mdash;The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend
    yield has been estimated to be zero.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>o.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basic
    and diluted net loss per share</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share attributable to holders of Ordinary Shares is computed by dividing the net loss by the weighted average number of Ordinary
Shares outstanding during the period. Diluted loss per share attributable to holders of Ordinary Shares is computed by dividing the net
loss attributable to holders of Ordinary Shares and assumed conversions by the weighted average number of Ordinary Shares outstanding
together with the number of additional Ordinary Shares that would have been outstanding if all potentially dilutive Ordinary Shares had
been issued. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive Ordinary
Shares are anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>p.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
    and Uncertainties</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical
studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need
to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary
technology, compliance with government regulations, development by competitors of technological innovations and reliance on third parties
to assist in discovery and development activities, and conducting the Company&rsquo;s clinical trials and performing data collection
and analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>q.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentrations
    of Risk</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank
deposits are held by financial institutions and these deposits may at times not be insured. The Company limits its credit risk associated
with cash and cash equivalents by placing them with financial institutions that it believes are of high-quality credit rating. The Company
has not experienced any losses on its deposits of cash or cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>r.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
    Growth Company Status</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company (&ldquo;EGC&rdquo;), as defined in Section 2(a) of the United States Securities Act of 1933 (&ldquo;Securities
Act&rdquo;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). Section 102(b)(1) of the JOBS
Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies (that is, those
that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the
Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an EGC can elect
to opt out of the extended transition period and comply with the requirements that apply to non-EGCs but any such election to opt out
is irrevocable. The Company has not elected to opt out of such extended transition period which means that when a financial accounting
standard is issued or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt
the new or revised standard at the time private companies adopt the new or revised standard. The Company will be eligible to use this
extended transition period under the JOBS Act until the earlier of the date it (i) is no longer an EGC or (ii) affirmatively and irrevocably
opts out of the extended transition period provided in the JOBS Act. As a result, the Company&rsquo;s financial statements may not be
comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards
that are applicable to public companies, which may make comparison of the Company&rsquo;s financials to those of other public companies
more difficult.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will cease to be an EGC on the date that is the earliest of (i) the end of the Company&rsquo;s fiscal year in which its total
annual gross revenue exceeds $1.235 billion, (ii) the last day of the Company&rsquo;s fiscal year following the fifth anniversary of
the date on which initial public offering has been consummated, (iii) the date on which the Company has issued more than $1.0 billion
in non-convertible debt during the preceding three-year period or (iv) the last day of the Company&rsquo;s fiscal year in which the market
value of the Company&rsquo;s Ordinary Shares held by non-affiliates exceeds $700 million as of the last business day of its most recently
completed second quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>s.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
    Adopted Accounting Standards</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an EGC, the JOBS Act allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies
until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under
the JOBS Act. The adoption dates discussed below reflects this election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 193; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &ndash; Credit Losses (Topic 326): Measurement of Credit Losses on
Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial
asset measured at amortized cost to be presented at the net amount expected to be collected. The new guidance was adopted for the Company
on January 1, 2023 and the adoption did not have a material impact on the Company&rsquo;s consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <I>Segment Reporting (Topic 280) &ndash; Improvements to Reportable Segment Disclosures</I>.
This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.
This ASU is effective for our annual fiscal year 2024, and interim periods starting in fiscal year 2025. A public entity should apply
the amendments in this ASU retrospectively to all prior periods presented in the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new guidance was adopted by the Company for fiscal year 2024 annual consolidated financial statements and this standard was applied retrospectively
for the prior period presented in the financial statements. See Note 10 &ndash; Segment Reporting for further information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>t.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
    Issued Accounting Standards Not Yet Adopted</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, Income Statement&mdash;Reporting
Comprehensive Income&mdash;Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. This update
aims to enhance the transparency of financial reporting by requiring public business entities (PBEs) to provide disaggregated disclosure
of certain income statement expense captions into specified categories in disclosures within the footnotes to the financial statements.
The ASU is effective for annual fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after
December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective
application is permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements
and disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    3:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHORT-TERM
    DEBT FROM SHAREHOLDERS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July 2022, the Company received a loan in the amount of $500 from two existing shareholders (Messrs. Ronnie Hershman and Michael Gibber),
including a director of the Company, for a term of twelve (12) months, at an interest rate of 8% per annum (the &ldquo;July 2022 Loan&rdquo;).
On August 28, 2024, the Company and each of said shareholders entered into an exchange letter (the &ldquo;July 2022 Loan Exchange Letter&rdquo;),
according to which the Company&rsquo;s obligations in connection with the loan were discharged in consideration for the issuance of a
Simple Agreement for Future Equity (&ldquo;SAFE&rdquo;) under the same terms as the 2024 SAFEs (see Note 4). The balance of the July
2022 Loan was $560 as of December 31 2023 (included in short-term debt from shareholders), and after considering interest accrued during
2024 through the date the July 2022 Loan Exchange Letter was executed and withholding taxes to be paid on behalf of the said shareholders,
it was deemed that Dr. Ronnie Hershman invested an amount in the SAFE of $284 and Michael Gibber invested an amount in the SAFE of $286.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the Company received a loan in an aggregate amount of $60 from its co-founders, Mr. Udi Gilboa and Dr. Dalia Megiddo,
and director, Dr. Ronnie Hershman, or the February 2023 Loan, under substantially the same terms as the July 2022 Loan, for a term of
twelve (12) months, at an interest rate of 8% per annum. The balance of the February 2023 Loan, including interest accrued, was $67 as
of December 31, 2023 and included in Short-term debt from shareholders. On August 28, 2024, the Company and each of these investors entered
into an exchange letter (the &ldquo;February 2023 Loan Exchange Letter&rdquo;), according to which the Company&rsquo;s obligations in
connection with the February 2023 Loan were discharged in consideration for the issuance of a SAFE under the same terms as the 2024 SAFEs
(see Note 4), under which Dr. Ronnie Hershman was deemed to have invested an amount in the SAFE of $44, Dr. Dalia Megiddo was deemed
to have invested an amount in the SAFE of $11, and Mr. Udi Gilboa was deemed to have invested an amount in the SAFE of $11 in said SAFE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    4:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE
    SECURITIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has raised funds through the issuance of SAFE.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
SAFE requires conversion into shares of the Company upon the occurrence of certain events, or at the maturity date of the SAFE. The number
of shares to be issued upon conversion of the SAFE are not fixed and will be dependent upon the nature of the event that occurred that
resulted in its conversion, the fair value of shares as of the event&rsquo;s date, and other factors as defined in the related agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAFEs
are classified as a liability and the Company elected the fair value option in accordance with ASC 825, Financial Instruments (&ldquo;ASC
825&rdquo;). Accordingly, the liability is adjusted to fair value at each balance sheet date, with the change in fair value being recorded
as change in fair value of convertible securities within the consolidated statements of operations. The Company reclassifies the SAFE
amount from liability to equity once it converts into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 194; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 17, 2022, the shareholders approved the issuance of SAFEs&nbsp; (the &ldquo;2022 SAFEs&rdquo;) to certain shareholders and
    third parties up to a maximum aggregate amount of $1,000. In March 2022 and April 2022, the Company raised $966 under the 2022 SAFE.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 SAFE investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most senior
shares outstanding upon conversion of the 2022 SAFEs in the event of an equity financing or liquidity event occurs prior to the termination
of the 2022 SAFEs as defined in the related agreement. The investors will &nbsp;receive a 40% discount on the share price in any of such
event. If a dissolution event occurs prior to the termination of the 2022 SAFE, each SAFE investor will be entitled to receive, prior
to consummation of the dissolution event, a portion of the related proceeds equal to its investment amount, or in case the applicable
proceeds upon dissolution are insufficient to permit a full payment of the amounts invested under the 2022 SAFEs, a prorated amount in
par with the other SAFE investors. In the event that the 2022 SAFEs mature after 15 months from its issuance, all amounts invested under
the 2022 SAFEs are converted into the Company&rsquo;s outstanding most senior shares based on a $41,000 valuation divided by number of
outstanding shares including any outstanding share options. The 2022 SAFEs will expire and terminate immediately upon the earliest to
occur of (1) the issuance of shares upon its conversion due to equity financing or liquidity event, or upon maturity; or (2) the payment,
or setting aside for payment, of amounts due to the occurrence of dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June and July 2023, the 2022 SAFEs matured and, accordingly, it should have been converted into 168,112 most senior outstanding
shares. As of December 31, 2023, the shares had not been issued, and therefore, the 2022 SAFEs remained outstanding. On August
28, 2024, the 2022 SAFEs were converted into 168,112 Class A-3A Ordinary. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 15, 2023, the shareholders approved the issuance of additional SAFEs to certain shareholders and third parties up to the maximum
    aggregate amount of $1,000 (the &ldquo;2023 SAFEs&rdquo;). In March and April 2023, the Company raised $995 under the 2023 SAFEs.
    In addition, the Company paid $15 as finder fees for issuance of the 2023 SAFEs which was recorded as other expense, net within
    the consolidated statements of operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 SAFEs investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most senior
shares outstanding upon conversion of the 2023 SAFEs in the event of an equity financing or liquidity event occurs prior to the termination
of the 2023 SAFEs as defined in the related agreement. The investors will &nbsp;receive a 40% discount on the share price in any of such
event. If a dissolution event occurs prior to the termination of the 2023 SAFEs, each SAFE investor will be entitled to receive, prior
to consummation of the dissolution event, a portion of the related proceeds equal to its investment amount, or in case the applicable
proceeds upon dissolution are insufficient to permit a full payment of the amounts invested under the 2023 SAFEs, a prorated amount in
par with the other SAFE investors. In the event the 2023 SAFEs mature after 15 months without a conversion prior to 15 months from its
issuance, all amounts invested under the 2023 SAFEs are converted into the Company&rsquo;s outstanding most senior shares based on a
$24,600 valuation divided by number of outstanding shares including any outstanding share options. The 2023 SAFEs will expire and terminate
immediately upon the earliest to occur of (1) the issuance of shares upon its conversion due to equity financing or liquidity event,
or upon maturity; or (2) the payment, or setting aside for payment, of amounts due to the occurrence of dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June, July and August 2024, the 2023 SAFEs have matured. On August 28, 2024, the 2023 SAFE were converted into 305,085 Class A-3B
Ordinary. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 9, 2024, the Board of Directors approved the issuance of additional SAFEs to certain shareholders and third parties up to the
    maximum aggregate amount of $1,500, which increased on August 28, 2024 to $2,000 (the &ldquo;2024 SAFEs&rdquo;). The Company raised
    $1,000 under the 2024 SAFEs during the year ended December 31, 2024. In addition, 2024 SAFEs in the amount of $636 were issued in
    connection with the discharge of the Company&rsquo;s obligations under &nbsp;the July 2022 Loan and February 2023 Loan (see Note
    3). </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 SAFEs investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most senior
shares outstanding upon conversion of the 2024 SAFEs in the event that an initial public offering, merger, acquisition, qualified equity
financing or other liquidity event occurs prior to the termination of the 2024 SAFEs as defined in the related agreement. The investors
will &nbsp;receive a 35% discount on the share price in any of such event. If a dissolution event occurs prior to the termination of
the 2024 SAFEs, each SAFE investor will be entitled to receive, prior to consummation of the dissolution event, a portion of the related
proceeds equal to its investment amount, or in case the applicable proceeds upon dissolution are insufficient to permit a full payment
of the amounts invested under the 2024 SAFEs, a prorated amount in par with the other SAFE investors. If such events had not occurred
within 18 months of the execution of the 2024 SAFEs, all amounts invested under the 2024 SAFEs are converted into the Company&rsquo;s
outstanding most senior shares based on the previous round of equity financing consummated discounted in 35% and divided by number of
outstanding shares including any outstanding share options. The 2024 SAFEs will expire and terminate immediately upon the earliest to
occur of (1) the issuance of shares upon its conversion due to a qualified equity financing or liquidity event as aforesaid, or upon
maturity; or (2) the payment, or setting aside for payment, of amounts due to the occurrence of a dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company measured the 2022 SAFEs, the 2023 SAFEs and 2024 SAFEs upon receiving the cash and on each period end at its fair value in
    accordance with ASC 825-10 with the changes &nbsp;in fair value reported in the condensed consolidated statements of operations.
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SAFEs were valued at the end of the year using a probability-weighted expected return model, which incorporated significant unobservable
inputs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the following significant inputs in measuring the SAFEs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 1in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of Ordinary Share*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.40</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average cost of capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk free rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16%
                                            - 4.24&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.06</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Time to maturity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.49-0.93</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.48</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including
    inputs and assumptions on the likelihood of a SAFE mandatory conversion, qualified equity financing or liquidity event or dissolution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    5:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FAIR
    VALUE MEASUREMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provide the liabilities carried at fair value measured on a recurring basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measured as of December 31, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
    liabilities at fair value:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    financial liabilities at fair value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measured as of December 31, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
    liabilities at fair value:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,830</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,830</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    financial liabilities at fair value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,830</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,830</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changes in the fair value of the Company&rsquo;s Level 3 financial liabilities, which are measured on a recurring basis are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif">January 1, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,054</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from issuance of 2023 SAFE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">995</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of
    convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(219</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,830</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds from issuance of 2024 SAFEs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of SAFEs to Ordinary Shares*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,107</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion of short-term debt from shareholders
    &nbsp;to 2024 SAFEs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">636</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of
    convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">443</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,802</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)
This amount is measured based on the fair value of the Class A-3A Ordinary Shares and Class A-3B Ordinary Shares issued upon the
conversion of the 2022 SAFEs and 2023 SAFEs, respectively (see Note 4b and 4c). The fair value of such shares is based on a probability-weighted
expected return model. The calculation incorporated significant unobservable inputs, including inputs and assumptions on the likelihood
of consummation of an IPO. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between fair value measurement levels during the years ended December 31, 2024 and 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of the Company&rsquo;s cash and cash equivalents, restricted cash, other current assets, accounts payable, accrued
expense and other current liabilities and short-term debt from shareholders approximates their carrying values as these financial instruments
are highly liquid or short-term in nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    6:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTINGENT
    LIABILITIES AND COMMITMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
    time to time, the Company may be involved in various claims and legal proceedings. The Company reviews the status of each matter
    and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and
    the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. The Company discloses pending claims
    and legal proceedings litigation if the Company believes a possibility exists that the claims and legal proceedings litigation will
    have a material effect on its financial results. Legal costs are accounted for as they are incurred.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    May 2022, the Company received a letter from a supplier associated with the Taffix business, which demanded that the Company pay
    professional fees billed to the Company in connection with services provided by the supplier. In August 2022, the supplier commenced
    legal proceedings in the magistrate court of Tel Aviv, in an amount of $92. The Company recorded the entire contractual expenses
    prior to January 1, 2023 and a liability of $92 is recorded as current liabilities related to discontinued operations within the
    Company&rsquo;s consolidated balance sheets as of December 31, 2024 and 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    May 2019, the Company entered into a license agreement (&ldquo;License Agreement&rdquo;) with Formulex Pharma Innovations Ltd. (&ldquo;Formulex&rdquo;).
    Formulex is an Israeli corporation, owned by the Company&rsquo;s shareholders, Mr. Ehud Gilboa, Dr. Dalia Megiddo and Dr. Ronnie
    Herschman. Pursuant to the License Agreement, Formulex granted the Company a license for the development, manufacture and commercialization
    of Formulex&rsquo;s patent for dry powder compositions for intranasal delivery and rights in the know-how of its intranasal and inhaled
    formulations, combination products, and particle engineering, together, the Licensed Products. Also pursuant to the License Agreement,
    the Company pay Formulex royalties of the Licensed Products in the amount of 0.5% of net sales of the licensed products, which are
    capped at $100 in the aggregate. The royalty payment period commenced on the effective date of the agreement and will continue on
    a country-by-country, product-by-product basis for the longer of: (i) 15 years from the date of the first commercial sale of such
    Licensed Product in such country, or (ii) until the licensed patent expires in such country. The Company may terminate the License
    Agreement for any reason upon 60 days prior written notice. In the event of such termination, the Company has the right to acquire
    the Licensed Technology in an amount equal to the difference between the amount of royalty &nbsp;actually paid to Formulex prior
    to the date of termination and the amount of $100. Termination of the agreement does not relieve the parties of obligation accrued
    prior to such termination.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2019, the Company entered into a service agreement with Formulex, as subsequently amended in March 2020, to facilitate the flow
of information and know how, as well as help develop the Company products. The Company pays $5 a month under the service agreement. The
services agreement automatically renews every year for a period of one year, unless terminated by either party upon 30 days&rsquo; written
notice, in accordance with the terms and conditions set forth therein. In connection with the same, Formulex provided the Company with
one-time development services in 2024 and 2023 for additional fees of $0 and $22, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024,&nbsp; the Company signed an additional agreement with Formulex to provide services which support the Company in providing
services to the governmental body (see Note 6b). As of December 31, 2024, an amount of $116 paid by the Company for future services to
be provided by Formulex to the Company is recorded in the consolidated balance sheet as part of prepaid expenses and other current assets&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2024 the Company entered in a non-recurring research arrangement with a government
                                            body to perform research and development activities in connection with a new formulation,
                                            that is intended to be used through intranasal delivery. As of December 31, 2024, the research
                                            and development activity related to that arrangement have not commenced, and an amount of
                                            $108 received as advance from the governmental body is recorded in the consolidated
                                            balance sheet as part of accrued expenses and other current liabilities.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2019, the Company entered into a master service agreement and schedules of work
                                            (the &nbsp;&ldquo;Aptar Agreement&rdquo;) with Aptar Group Inc. (&ldquo;Aptar&rdquo;)
                                            under which Aptar granted the Company technology access to co-development and support
                                            for the development and submissions to regulatory bodies of intranasal to deliver NS001 and
                                            NS002 using Aptar&rsquo;s technology.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with NS001, the Company is required to pay Aptar up to $1,350 in the aggregate comprising of $200 in development stage, $350
upon submission of New Drug Application (&ldquo;NDA&rdquo;) with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) (or equivalent
body outside the U.S.) and &nbsp;$800 at market launch. The Company paid $200 to Aptar prior to January 1, 2022. In August 2021, the
Company entered into a change order with respect to NS001, for the provision of additional services and deliverables to be provided by
Aptar for an additional fee of 100 Euro ($103), out of which 40 ($41)  Euro paid to Aptar prior to January
1, 2022, and the remaining amounts will be paid upon NDA submission and FDA approval of NS001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with NS002, the Company is required to pay Aptar up to $675 in the aggregate comprising of $150 in development stage, $225
upon submission of NDA with the FDA (or equivalent) and $300 at market launch. The Company paid $150 to Aptar prior to January 1, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also obligated to pay Aptar for each final product that achieves certain sales-based milestone events and tiered royalties
on net sales of each final product by the Company or its affiliates or sublicensees at rates ranging from a low single-digit percentage,
depending on the total annual worldwide net sales of each such final product up to seven years after first commercial sale. The Aptar
Agreement has an early termination fee in case the Company terminate NS001 or NS002 programs for whatever reason, other than a breach
of the agreement by Aptar, of $450 for each product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, the Company entered into an agreement with Aptar&rsquo;s subdivision, NextBreath, which is subject to terms and conditions
of the Aptar Agreement, to perform laboratory and development services in connection with NS001. For the services received under the
agreement by April 2022, there is an amount of $529 outstanding payable to Aptar, which has not been paid to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2022, Aptar sent Nasus a Notice of Default Letter, which followed by Notice of Termination Letter sent on October 5, 2022, in
which Aptar claimed for alleged breach of the contractual obligations of the Aptar Agreement made by Nasus and stated the outstanding
amounts of $529 and in addition a termination fee of $450 related to NS001. The Company did not agree with the alleged breach
made by Aptar and the existence of any grounds for termination of the Aptar&rsquo;s Agreement. Since then, the Company and Aptar discussed
and exchanged further correspondence, but were unable to resolve the claims and allegations made by each party. There is no legal proceeding
between Nasus and Aptar. As of December 31, 2024 and 2023, a liability of $529 &nbsp;&nbsp;is recorded as accounts payable within
the consolidated balance sheets. The Company has not recorded a liability for the termination fees of $900 ($450 for NS001 and $450 for
NS002), as the Company believes it is not probable that it will be required to pay such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    7:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHAREHOLDERS&rsquo;
    </B>&nbsp;<B>DEFICIT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&rsquo;s authorized capital shares consist of 13,266 thousand shares of Ordinary Shares, comprised of: 9,540 thousand Class
    Ordinary Shares, 816 thousand Class A Ordinary Shares; 1,431 thousand Class A-1 Ordinary Shares; 477 thousand Class A-2 Ordinary
    Shares; 525 thousand Class A-3 Ordinary Shares ,172 thousand Class A-3A; and 305 thousand Class A-3B Ordinary Shares, of which 7,363
    shares were issued and outstanding. Holders of each share class have the right to one vote per share. All share classes have the
    similar rights attached to them (noting that there are certain shareholders rights which are triggered based on a holding rate ),
    except that, (i) Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares, Class A-3; Class A-3A Ordinary Shares;
    and Class A-3B Ordinary Shares differ in Original Issue Price (as prescribed in the Company&rsquo;s Articles of Association and noted
    below), (ii) while the Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares ,Class A-3 Ordinary Shares Class
    A-3A Ordinary Shares and Class A-3B Ordinary Shares are entitled to certain conversion ratio adjustments, such adjustment is affected
    by split or reverse split of such shares (with no special rights provided as down-round protection) and (iii) the appointment of
    board members is not determined at a general meeting, but rather through a specific mechanism of nomination, as detailed in the Company&rsquo;s
    Articles of Association. Subject to the forgoing, each Class of the Company&rsquo;s Ordinary Shares are treated equally, identically
    and rateably, on a per share basis, with respect to any dividends or distributions as may be declared and paid from time to time.
    Upon the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, holders of Ordinary Shares will
    be entitled to receive rateably all assets of the Company available for distribution to its shareholders. None of the shares have
    preferred rights in liquidation preferences or redemption rights. Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary
    Shares, Class A-3 Ordinary Shares, Class A-3A Ordinary Shares and Class A-3B Ordinary Shares will automatically be converted into
    Ordinary Shares upon completion of an IPO. See also Note 14(f) for changes made to the share capital of the Company after
    December 31, 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of Class A Ordinary Shares; Class A-1 Ordinary Shares; Class A-2 Ordinary Shares; Class A-3 Ordinary Shares; Class A-3A Ordinary
    Shares; and Class A-3B Ordinary Shares is convertible, at the option of the holder at any time, into the number of Class Ordinary
    Shares as is determined by dividing the original issue price for such series of shares by the conversion price for such series of
    shares that is in effect at the time of conversion. The conversion price, adjusted to give effect to the forward stock split described
    in Note 7(c), for Class A Ordinary Shares; Class A-1 Ordinary Shares; Class A-2 Ordinary Shares; Class A-3 Ordinary Shares; Class
    A-3A Ordinary Shares; and Class A-3B Ordinary Shares is. $1.2264, $2.9931, $4.2965 and $6.0462, a price of applicable per share regarding
    each respective 2022 SAFE, as adjusted, and applicable price per share regarding each respective 2023 SAFE, as adjusted, respectively.
    The applicable conversion price of each is subject to adjustment upon share splits or combinations, recapitalizations, of the Company&rsquo;s
    Class Ordinary Shares, and distribution of bonus shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Class A Ordinary Shares; Class A-1 Ordinary Shares; Class A-2 Ordinary Shares; Class A-3 Ordinary Shares; Class A-3A Ordinary Shares
and Class A-3B Ordinary Shares will automatically be converted into Class Ordinary Shares, at the then effective conversion price,
upon the consummation of an initial public offering or the affirmative consent of the holders of majority of the Class A Ordinary Shares
with respect to the Class A Ordinary Shares; (iii) the affirmative consent of the holders of majority of the Class A-1 Ordinary Shares
with respect to the Class A-1 Ordinary Shares; (iv) the affirmative consent of the holders of majority of the Class A-2 Ordinary Shares
with respect to the Class A-2 Ordinary Shares and (v) the affirmative consent of the holders of majority of the Class A-3 Ordinary Shares,
with respect to the Ordinary A-3 Shares (vi) the affirmative consent of the holders of majority of the Class A-3A Ordinary Shares with
respect to the Ordinary A-3A Shares; and, (vii) the affirmative consent of the holders of majority of the Class A-3B Ordinary Shares
with respect to the Ordinary A-3B Shares.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            August 28, 2024 the shareholders of the Company approved the issuance of Class A-3A Ordinary
                                            Shares and Class A-3B Ordinary Shares (see Note 7a and 7b).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            March 17, 2025, the shareholders of the Company approved, subject to the effectiveness of
                                            the registration statement, to effect a forward share split at a ratio of 1-for-4.77008, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will take place on the effective
date of the registration statement</FONT>.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    share and per share amounts for Ordinary Shares, Share Options and loss per share amounts have been adjusted to give retroactive
    effect to the forward share split for all periods presented in these financial statements. Any fractional shares that resulted from
    the reverse share split have been rounded up to the nearest whole share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024*</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023*</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
    Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,540,160</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,770,409</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,540,160</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,770,409</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class A Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">815,684</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">766,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">815,684</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">766,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class A-1 Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,431,024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">367,506</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,431,024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">367,506</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class A-2 Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">477,008</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">465,479</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">477,008</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">465,479</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class A-3 Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">524,709</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">519,839</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">524,709</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">519,839</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class A-3A Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">171,723</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">168,112</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class A-3B Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">305,285</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">305,085</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,265,593</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,362,906</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,788,585</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,889,709</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    giving effect to the forward share split, see also Note 7(d).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    8:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARE-BASED
    PAYMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Incentive Plan</B> &ndash; The Company has established the 2019 Incentive Option Plan (the &ldquo;2019 Plan&rdquo;) whereby the Company
may grant share options to purchase its Class Ordinary Shares, for the purpose of providing incentives to our directors, officers,
employees, office holders, service providers and their employees, or charitable entities. Share options granted under
the 2019 Plan generally have 10-year terms and vest over a four-year period starting from the date specified in each agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of share options of Class Ordinary Shares that may be issued under the 2019 Plan is 246,170 shares. As of December
31, 2024, there were 54,140 share options available for issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of share options activity for the years ended December 31, 2024 and 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share
    Options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Exercise Price Per Share Option</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    Average Remaining Contractual Life</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Value</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding as of January 1, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">206,010</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.64</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">79</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,905</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(36,143</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.89</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,997</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">179,775</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.71</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.36</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">278</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,925</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.71</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding as of December 31, 2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">191,700</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.77</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.64</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">227</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested and Exercisable as of December 31,
    2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">180,201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.72</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.06</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">227</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value was calculated as the difference between the exercise price of the share options and the fair value of the
underlying Class Ordinary Shares as December 31, 2024 and 2023. The weighted-average grant-date fair value of share options granted
during the years ended December 31, 2024 and 2023 was $1.72 and $2.33, respectively. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the total share-based compensation expense resulting from share options granted to employees, directors and
non-employee service &nbsp;providers included in the Company&rsquo;s consolidated statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total share-based compensation
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, unamortized share-based compensation expense was $16 and $6, respectively, related to non-vested share
options, which is expected to be recognized over weighted average period of 0.9 and 0.46 years, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Share Options</B>&ndash; The Company estimates the fair value of share option awards on the date of grant using the Black-Scholes
option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair
value of each share option. The assumptions used to estimate the fair value of share options granted are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Amounts in dollars, except percentages)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63.63</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66%-68</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected dividends</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected term (in years)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.75</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-5.47</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk free rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.64</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.59%-3.66</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value of Class Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.47</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.02-$2.64</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
    Value of Class Ordinary Shares</B> &ndash; Since the Company&rsquo;s Class Ordinary Shares are not publicly traded,
    the fair value of the Company&rsquo;s Class Ordinary Shares was approved by the Company&rsquo;s Board of Directors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
estimating the fair value of the Company&rsquo;s Class Ordinary Shares, management uses the assistance of third-party valuation
specialist and consider factors management believes are material to the valuation process, including, but not limited to, the price at
which recent equity was issued by the Company to independent third parties or transacted between third parties, actual and projected
financial results, risks, prospects, and economic and market conditions, among other factors. Management believes the combination of
these factors provides an appropriate estimate of the expected fair value and reflects the best estimate of the fair value of the Company&rsquo;s
Class Ordinary Shares at each grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected
    Volatility</B> &ndash; The expected volatility is based on the historical and implied volatility of similar companies whose stock
    or share option prices are publicly available, after considering the industry, stage of life cycle, size, market capitalization,
    and financial leverage of the other companies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk-Free
    Interest Rate</B> &ndash; The risk-free interest rate assumption is based on observed U.S. Treasury yield curve interest rates in
    effect at the time of grant appropriate for the expected term of the share options granted.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected
    term (years) </B>&ndash; Expected term represents the period that the Company&rsquo;s share option grants are expected to be outstanding.
    There is not sufficient historical share exercise data to calculate the expected term of the share options. Therefore, the Company
    elected to utilize the simplified method to value share option grants. Under this approach, the weighted-average expected life is
    presumed to be the average of the shortest vesting term and the contractual term of the share option.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected
    dividend yield</B> &ndash; The Company does not anticipate paying any dividends in the foreseeable future.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    9:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAXES
    ON INCOME</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
    rates applicable to the income of the Company:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli corporate income tax rate was 23% in 2024 and 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table displays net deferred income tax:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 86%; margin-left: 1in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred tax assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net operating loss carryforward</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,262</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">172</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vacation accrual</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gross deferred tax assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,357</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,649</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,357</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,649</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net deferred tax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>b.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
    reconciliation of the Company&rsquo;s Israeli corporate </B>&nbsp;<B>income tax rate to effective tax rate is as follows:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 86%; margin-left: 1in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Israel corporate income tax rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-deductible share-based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.85</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect of change in fair value of convertible
    securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28.92</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.97</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in valuation allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(43.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective tax rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 202; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>c.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carry
    forward losses for tax purposes and other temporary differences:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company&rsquo;s Israeli tax loss carryforward was approximately $10 million. Such losses can be carried forward
indefinitely to offset against future taxable income of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available evidence, management believes that it is more likely than not that its deferred tax assets will not be realized and
accordingly, a full valuation allowance has been provided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>d.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Final
    tax assessments:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, all of Company&rsquo;s tax assessments in Israel are not final.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>e.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Uncertain
    tax positions:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a
taxation authority. As of December 31, 2024, and 2023, the Company has not recorded any uncertain tax position liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    10:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEGMENT
    REPORTING</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
information is prepared on the same basis that the Company&rsquo;s chief operating decision maker (&ldquo;CODM&rdquo;), the Chief Executive
Officer, manages the business, makes business decisions and assesses performance. The Company has one operating and reportable segment
specializing in the development of intranasal drugs to treat emergency medical conditions, as described in Note 1(a). All of the Company&rsquo;s
assets are located in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CODM assesses performance for this segment and decides how to allocate
resources based on net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents. The Chief Executive
Officer performs the assessment of segment performance by using the reported measure of segment profit or loss to monitor actual results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Significant segment
    expenses </U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left">Payroll and payroll related (*)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">77</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">62</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Subcontractors and consultants (*)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">444</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">737</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Professional services (*)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">583</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">142</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">224</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">167</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other segment items:
    </U></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Loss (income) from change in fair value of convertible securities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">443</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(219</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other expense, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(260</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; text-align: left">Net loss (income) from discontinued operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,532</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: normal 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: normal 10pt Times New Roman, Times, Serif; text-align: right">(1,051</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)
Excluding&nbsp;share-based compensation&nbsp;expenses and including costs capitalized as deferred issuance costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    11:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET
    LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed using the weighted average number of shares of Ordinary Shares outstanding for the period. Diluted net
loss per share reflects the effect of the assumed exercise of any share options, and the conversion of any convertible securities, in
each case only in the periods in which such effect would have been dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, net loss per share amounts were the same for Class Ordinary Shares, Class A Ordinary Shares,
Class A-1 Ordinary Shares, Class A-2 Ordinary Shares, Class A-3 Ordinary Shares, Class A-3A Ordinary Shares and Class A-3B Ordinary Shares
because the holders of each class are entitled to equal per share dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 203; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the computation of basic and diluted net loss per share:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Numerator:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,552</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,005</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss (income) from
    discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss attributable
    to holders of Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect of dilutive securities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of convertible securities
    related to dilutive effect*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">361</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,552</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,366</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss (income) from
    discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss attributable
    to holders of Ordinary Shares and assumed conversions</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,532</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,412</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Denominator***:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted-average number of Ordinary Shares
    used to compute net loss per share, basic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,027,725</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,889,708</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect of dilutive securities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022 SAFE**</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">168,112</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted-average number of Ordinary Shares
    used to compute net loss per share, diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,027,725</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,057,820</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net income (loss)
    per share, basic:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss per share,
    basic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net income (loss)
    per share, diluted:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss per share,
    diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dilutive effect on the numerator (net loss) in calculating the diluted net loss per share for the year ended December 31, 2023 represents
    the change in fair value in connection with the 2022 SAFEs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dilutive effect on the denominator (the weighted average number of Ordinary Shares) in calculating the diluted net loss per share
    for the year ended December 31, 2023 is based on the assumption the conversion of the 2022 SAFE into shares will occur upon its maturity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    giving effect to the forward share split, see also Note 7(d).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the number of securities that were excluded from the calculation of diluted net loss per share as the effect would
have been anti-dilutive:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">191,700</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">179,777</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022 SAFE*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">168,112</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023 SAFE**</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">305,085</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">305,085</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024 SAFE***</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">473,197</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    weighted average number of Ordinary Shares in connection with the 2022 SAFE for the year ended December 31, 2024 is based on the
    conversion of the 2023 SAFE into shares on its maturity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    weighted average number of Ordinary Shares in connection with the 2023 SAFE for the years ended December 31, 2024 and 2023 is based
    on the conversion of the 2023 SAFE into shares on its maturity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    weighted average number of Ordinary Shares in connection with the 2024 SAFE for the year ended December 31, 2024 is based on the
    assumption the conversion of the 2024 SAFE into shares will occur upon its maturity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    12:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED
    </B>&nbsp;<B>PARTIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Ehud Gilboa and Dr. Dalia Meggido are shareholders and each hold approximately 25% of the Company&rsquo;s issued and outstanding
    Ordinary Shares. Mr. Gilboa is the Chairman of the Board of Directors and Dr. Meggido is a member of the Board of Directors, Chief
    Development Officer <FONT STYLE="background-color: white">and Chief Medical Officer</FONT> of the Company, and former Chief Executive
    Officer of the Company (until January 6, 2025).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronnie Hershman is a member of the Board of Directors and beneficially holds approximately 18% of the Company&rsquo;s outstanding
    Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa and Dr. Meggido are each entitled to management fee of NIS 45 (approximately $13) plus customary social benefits of additional
    25% of the management fee. In February 2022, both Mr. Gilboa and Dr. Meggido agreed to a voluntary deferral of such fee of NIS 9
    (approximately $3), and an additional deferral of NIS 18 (approximately $5) in November 2022. As of December 31, 2024 and 2023, the
    aggregate deferred liability amounted to $530 and $318, respectively. For the years ended December 31, 2024 and 2023, management
    fees in the amount of $369 and 366, respectively, recorded as operating expense within the Company&rsquo;s consolidated statements
    of operations. See Notes 14(d) and 14(e) for changes in 2025 to the these arrangements with Mr. Gilboa and Dalia Meggido.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 204; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa subleases office space for a monthly fee of NIS 12 (approximately $3) and Topnotch Consultancy (2009) Ltd., a company owned
    by Mr. Gilboa, provides the Company with secretarial services for a monthly fee of NIS 15 (approximately $4), which increased from
    a monthly fee of NIS 5 (approximately $2) starting April 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa, Dr. Megiddo and Dr. Ronnie Hershman have all participated in SAFEs issued by the Company (see Note 4). Mr. Gilboa, Dr. Megiddo,
    Formulex and Dr. Hershman invested $35, $35 $30 and $100 respectively in the 2022 SAFEs, Dr. Hershman invested $100 in the 2023 SAFEs,
    Mr. Gilboa, Dr. Megiddo and Dr. Hershman invested $50, $50 and $100 respectively in the 2024 SAFEs. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa, Dr. Megiddo and Dr. Ronnie Hershman invested $10, $10 and $290 in the short-term debt from shareholders as part of the July
    2022 Loan and the February 2023 Loan, which was later exchanged to 2024 SAFEs (see Note 3).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa, Dr. Megiddo and Dr. Hirshman are major shareholders of Formulex which granted services and additional services and license
    to the Company (see Notes 6).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following related party balances are included in the consolidated balance sheets:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">CURRENT ASSETS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses and other current
    assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">116</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">CURRENT LIABILITIES:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Short-term debt from shareholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">344</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">605</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued expense and other current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">711</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">451</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following related party transactions are included in the consolidated statements of operations:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">208</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">228</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">307</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">288</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    13:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCONTINUED
    OPERATIONS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company&rsquo;s research and development team in Israel developed a nasal powder that creates a hostile microenvironment in
the nose where many airborne viruses can&rsquo;t survive, which was marketed as Taffix (&ldquo;Taffix&rdquo;). At the end of 2021, the
Company started the wind-down of Taffix by selling of all the manufacturing equipment, ceasing marketing efforts, seeking alternatives,
fulling final orders but not accepting new orders, disposal of inventory and terminating of engagements with employee contractors and
manufacturers. As of December 2022, the Company was no longer engaged in the development, production, marketing or sales of Taffix.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 205; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with applicable accounting guidance, the results of Taffix are presented as net income (loss) &nbsp;from discontinued operations
in the consolidated statements of operations. Further, the Company reclassified the liabilities of Taffix current liabilities related
to discontinued operations on the consolidated balance sheets as of December 31, 2024 and 2023. The consolidated statements of cash flows
are presented on a consolidated basis for both continuing operations and discontinued operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents key components of &ldquo;Net income (loss) &nbsp;from discontinued operations&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(44</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expense),
    net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net income (loss) from
    discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents liabilities that are classified as discontinued operations on the consolidated balance sheets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">142</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">158</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued expense and other current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">85</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advances from customers</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">255</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current liabilities related
    to discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">489</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    14:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
    EVENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated subsequent events from the date of the consolidated balance sheet of December 31, 2024 through March 21, 2025,
the date the consolidated financial statements were available to be issued, and has determined that, there have been no subsequent events
that require recognition or disclosure in the consolidated financial statements as follows&nbsp;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January through March 2025, the Company entered into agreements to raise additional $280 under the terms of the 2024 SAFEs
    (see Note 4). The proceeds from the issuance of the additional 2024 SAFEs were received during February and March 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            January 2025, the Board of Directors approved the engagement with Dan Teleman as Chief Executive
                                            Officer (&ldquo;CEO&rdquo;). The CEO is entitled to a gross monthly salary in the amount
                                            of NIS 30 ($8) beginning January 7, 2025 and until March 2025.
                                            As of April 1, 2025, the CEO is entitled to a gross monthly salary of NIS 40 ($11), to be
                                            increased to NIS 70 ($19) as of and subject to consummation of the IPO until the first anniversary
                                            of the IPO, and thereafter to NIS 75 ($21) until the second anniversary of the IPO and to
                                            NIS 80 ($22) thereafter. Additionally, the CEO will be entitled to an annual bonus in between
                                            10%-20% of his annual gross salary (the &ldquo;CEO Annual Bonus&rdquo;).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
    CEO also entitled for other benefits such as reimbursement of expenses and certain bonus payments, including a one-time bonus payment
    of NIS 120 ($33) upon and subject to consummation of the IPO (the &ldquo;CEO IPO Bonus&rdquo;).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
    March 2025, the shareholders and the Board of Directors approved, subject to the consummation of the IPO, the following amendments
    to the agreement with the CEO (1) an increase in the CEO Annual Bonus from 10%-20% of his annual gross salary to 20%-30%; (2)
    one-time bonus of $75 if the Phase 3 clinical trial of NS002 successfully meets its primary end-point; and (3) an increase
    in the CEO IPO Bonus to NIS 240 ($66).</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 206; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January 2025, the Company granted the CEO and its Director of Finance 318,856 share options and 27,681 share options, respectively,
    to purchase 346,537 Class Ordinary Shares at an exercise price of $6.05. The share options are to vest over a period of 36 months,
    commencing January 7, 2025, with the share options granted to the CEO vesting fully upon change of control, other than IPO, as defined
    in the agreement. In addition, the Company increased the maximum number of Ordinary Shares reserved for issuance under the 2019 Plan
    by 477,008, from 246,170 Ordinary Shares to 723,178 Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    March 2025, the shareholders and the Board of Directors approved compensation adjustments upon completion of the IPO to Mr.
    Udi Gilboa, as follows: (i) NIS 86 ($24) monthly consultation fee in the first year following the IPO, (ii) NIS 90 ($25) monthly
    consultation fee in the second year following the IPO, and (iii) NIS 95 ($26) monthly consultation fee from the third year following
    the IPO; (iv) monthly car allowance and maintenance expenses of NIS 4 ($1); (v) annual bonus of up to 25% of the annual consulting
    fees, the specific amount of which is subject to further approval of our Board of Directors; and (vi) one-time bonus of NIS
    905 plus VAT ($250) upon completion of the IPO. Further, the compensation committee and Board of Directors, may grant Mr. Gilboa:
    (i) a special bonus of up to 1.5% of the proceeds of a qualified merger, sale, or assignment as provided therein; (ii) an equity
    financing bonus equal to up to 2% of the cash proceeds in a private placement or other equity financing transaction, and (iii) a
    one-time bonus for special efforts performed by Mr. Gilboa and/or in respect of the significant contribution of Mr. Gilboa to the
    Company&rsquo;s operations, special projects or extra ordinary achievements which are not in the Company&rsquo;s ordinary course
    of business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    March 2025, the Board of Directors and the Company&rsquo;s shareholders approved compensation adjustments upon completion of the
    IPO to Dr. Dalia Megiddo, as follows: (i) NIS 86 ($24) monthly consultation fee in the first year following the IPO, (ii) NIS 97
    ($27) monthly consultation fee in the second year following the IPO, and (iii) NIS 106 ($29) monthly consultation fee from the third
    year following the IPO; (iv) monthly car allowance and maintenance expenses of NIS 4 ($1); (v) annual bonus of up to 25% of annual
    consulting fees, subject to approval of our Board of Directors; one-time bonus of NIS 724 plus VAT ($200) upon completion of the
    IPO. Further, the compensation committee and the Board of Directors, may grant Dr. Megiddo (i) a special bonus of up to 1.5% of the
    proceeds of a qualified merger, sale, or assignment as provided therein; (ii) a one-time bonus for special efforts performed by Dr.
    Megiddo and/or in respect of the significant contribution of Dr. Megiddo to the Company&rsquo;s operations, special projects or extra
    ordinary achievements which are not in the Company&rsquo;s general course of business; (iii) a bonus of NIS 905plus VAT ($249) upon
    NDA submission for NS002 to the FDA; and (iv) a bonus of NIS 1,811 plus VAT ($497) upon FDA approval of an NDA for NS002.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            March 17, 2025, the shareholders approved, subject to the effectiveness of
                                            the registration statement, the following changes to the Company&rsquo;s share capital, which
                                            will take place on the effective date of the registration statement:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convert
    all shares of Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares, Class A-3 Ordinary Shares, Class A-3A
    Ordinary Shares and Class A-3B Ordinary Shares into Class Ordinary Shares on a ratio of 1-for-1;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect
    a forward share split at a ratio of 1-for-4.77008. See also Note 7(d);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Execute
    a change in the par value of its Class Ordinary Shares such that following the change the Class Ordinary Shares have no
    par value; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase
    the Company&rsquo;s authorized Class Ordinary Shares by 9,540 thousand shares. Following such increase, the Company&rsquo;s
    authorized capital shares will consist of 22,806 thousand shares of Class Ordinary Shares, no par value.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 207; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>3,000,000</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>
Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_020.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Nasus
Pharma Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
and including , 2025 (the 25<SUP>th</SUP> day after the date of this offering), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation
to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 208 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
6. Indemnification of Directors, Officers and Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnification</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli Companies Law 5759-2999, or the Companies Law, and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that
a company may indemnify an office holder against the following liabilities and expenses incurred for acts performed by him or her as
an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association
include a provision authorizing such indemnification:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity
    as an office holder, including a settlement or arbitrator&rsquo;s award approved by a court;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys&rsquo; fees, expended by the office holder (a) as a result of an investigation or proceeding
    instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment
    (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no
    financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as
    a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense
    that does not require proof of criminal intent; or (b) in connection with a monetary sanction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys&rsquo; fees, expended by the office holder or imposed on him or her by a court,: (1) in
    proceedings that the company institutes, or that another person institutes on the company&rsquo;s behalf, against him or her; (2)
    in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require
    proof of criminal intent; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation
    expenses and reasonable attorneys&rsquo; fees. An &ldquo;Administrative Procedure&rdquo; is defined as a procedure pursuant to chapters
    H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement
    Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates
to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following
foreseen events and amount or criterion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    events that in the opinion of the board of directors can be foreseen based on the company&rsquo;s activities at the time that the
    undertaking to indemnify is made; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable
    under the circumstances.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with all of our directors and with all members of our senior management. Each such indemnification
agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent
that these liabilities are not covered by directors and officers insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 209; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exculpation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but
may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such
exculpation is included in its articles of association. Our amended and restated articles of association provide that we may exculpate,
in whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty
of care, but prohibit an exculpation from liability arising from a company&rsquo;s transaction in which our controlling shareholder or
officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release
our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that would
provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty
of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable
basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was
carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive
an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office
holders to the fullest extent permitted or to be permitted by the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7. Recent Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the sales of all securities by the Company since April 2022, which were not registered under the Securities Act.
The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2)
of the Securities Act, Rule 701 and/or Regulation S under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022 through May 2022, we entered into certain investment agreements, which we refer to as Simple Agreements for Future Equity,
or SAFEs, for aggregate proceeds of $966,000, collectively, the 2022 SAFEs. Per the terms of the 2022 SAFEs, since an initial public
offering, merger, acquisition, equity financing other liquidity event or dissolution event did not take place within 15 months from the
execution of the 2022 SAFEs, on August 28, 2024, the subscription amounts under such SAFEs were converted into 168,112 Class A-3A Ordinary
Shares. Upon the effectiveness of the registration statement for this offering, such Class A-3A Ordinary Shares will automatically convert
into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we received a loan, or the July 2022 Loan, from Dr. Ronnie Hershman, a director and shareholder, and Michael Gibber, a shareholder,
pursuant to which we received a principal amount of $500 thousand, for a term of twelve (12) months, at an interest rate of 8% per annum.
On August 28, 2024, we and each of Dr. Ronnie Hershman and Michael Gibber entered into an exchange letter, or the July 2022 Loan Exchange
Letter, according to which our obligations in connection with the loan were discharged in consideration for the issuance of a SAFE under
the same terms as the 2024 SAFEs, under which it is deemed that Dr. Hershman invested an amount of $284,154 and Michael Gibber invested
an amount of $286,210.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, we received a loan in an aggregate amount of $60 thousand from Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa,
or the February 2023 Loan, under substantially the same terms as the July 2022 Loan, for a term of twelve (12) months, at an interest
rate of 8% per annum. A definitive agreement for the February 2023 Loan was not executed. On August 28, 2024, we and each of Dr. Ronnie
Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa entered into an exchange letter, or the February 2023 Loan Exchange Letter, according
to which our obligations in connection with the February 2023 Loan were discharged in consideration for the issuance of a SAFE under
the same terms as the 2024 SAFEs, under which Dr. Ronnie Hershman was deemed to have invested an amount of $43,954, Dr. Dalia Megiddo
was deemed to have invested an amount of $11,286, and Mr. Udi Gilboa was deemed to have invested an amount of $10,963 in said SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023 through April 2023, we entered into SAFEs for aggregate proceeds of $995,000, collectively, the 2023 SAFEs, Per the terms
of the 2023 SAFEs, since an initial public offering, merger, acquisition, equity financing other liquidity event or dissolution event
did not take place within 15 months from the execution of the 2023 SAFEs, on August 28, 2024, the subscription amounts under such SAFEs
were converted into 305,085 Class A-3B Ordinary Shares. Upon the effectiveness of the registration statement for this offering, such
Class A-3B Ordinary Shares will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024 through March 2025, we entered into SAFEs in the aggregate amount of $1,986,500, or the 2024 SAFEs, of which $300 thousand
were canceled and terminated during November 2024. In addition, pursuant to the terms of the July 2022 Loan Exchange Letter and the February
2023 Loan Exchange Letter, the July 2022 Loan and February 2023 Loan were converted into 2024 SAFEs in the amount of $570,364 and $66,203,
respectively; however, no additional proceeds were received pursuant to said exchanges. Per the terms of the 2024 SAFEs, upon an initial
public offering, merger, acquisition, qualified equity financing or other liquidity event, the subscription amounts under such SAFEs
will be converted into our Ordinary Shares upon the effectiveness of the registration statement for this offering at a conversion price
reflecting a discount of 35%. However, if such events do not occur within 18 months of the execution of such SAFEs, such SAFEs will be
converted into our securities of such class of shares having certain rights identical to the respective rights of the most senior class
of shares on the basis of a previous round of equity financing consummated by the Company at a conversion price reflecting a discount
of 35%, as prescribed in such SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
April 2022, we granted our directors, officers, consultants and employees options to purchase 372,367 Ordinary Shares under
our 2019 Incentive Option Plan, at an exercise price ranging between $0.002 and $6.05 per Ordinary Share. Further, since March
2022, 329 Ordinary Shares were issued upon exercise of options at an exercise price of $8.80, and options to purchase 79,164 Ordinary
Shares were forfeited and expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 210; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8. Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Association of Nasus Pharma Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Association of Nasus Pharma Ltd. to be in effect upon the effectiveness of the registration statement for this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&amp;+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Representative&rsquo;s Warrants.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&amp;+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
    Pharma Compensation Policy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Israeli counsel to Nasus Pharma Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sullivan &amp; Worcester LLP, U.S. counsel to Nasus Pharma Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
    Pharma 2019 Incentive Option Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement, dated May 1, 2019, by and between Nasus Pharma Ltd. and Formulex Pharma Innovations Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of 2022 SAFE.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of 2023 SAFE.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of 2024 SAFE.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Brightman Almagor Zohar &amp; Co., a firm in the Deloitte Global Network. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.) (included in Exhibit 5.1).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Sullivan &amp; Worcester LLP (included in Exhibit 5.2).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
    of Attorney (included on the signature page of this Registration Statement).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of David Silberman as director nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Dr. Sharon Shacham as director nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Isaac Israel as director nominee</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    Fee Table.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or any compensatory plan, contract or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Statement Schedules:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules have been omitted because either they are not required, are not applicable or the information required
therein is otherwise set forth in the Company&rsquo;s financial statements and related notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9. Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned Registrant hereby undertakes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
    if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set
    forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 211; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F
    at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required
    by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective
    amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other
    information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with
    respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and
    information required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are
    contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d)
    of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the registrant is relying on Rule 430B:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
    date the filed prospectus was deemed part of and included in the registration statement; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
    Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information
    required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement
    as of the earlier of the date such form of prospectus is first used after effectiveness of the date of the first contract or sale
    of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
    person that is at that date and underwriter, such date shall be deemed to be a new effective date of the registration statement relating
    to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time
    shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement
    or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into
    the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
    sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that
    was part of the registration statement or made in any such document immediately prior to such effective date; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 212; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
    to an offering, other than registration statements relying on Rule 430B or other prospectuses filed in reliance on Rule 430A, shall
    be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
    however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
    document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
    statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
    was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
    prior to such date of first use.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
    of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
    to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
    are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller
    to the purchaser and will be considered to offer or sell securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements,
    certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each
    purchaser.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
    as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the registrant has been advised that
    in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
    In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
    or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
    is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
    unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
    the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
    adjudication of such issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
    as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
    to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
    time it was declared effective.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form
    of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
    such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 213; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by
the undersigned, thereunto duly authorized, in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;on  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasus
    Pharma Ltd.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Teleman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="one_013"></A>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned officers and directors of Nasus Pharma Ltd. hereby constitute and appoint each of Mr. Udi Gilboa and Mr. Dan Teleman with
full power of substitution, each of them singly our true and lawful attorneys-in-fact and agents to take any actions to enable the Company
to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection with this registration statement
on Form F-1, including the power and authority to sign for us in our names in the capacities indicated below any and all further amendments
to this registration statement and any other registration statement filed pursuant to the provisions of Rule 462 under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following
persons in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Teleman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder
                                            and Executive Chairman of the</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi
    Gilboa </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    of Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder,
    Director </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Dalia Megiddo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Finance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren
    Elmaliach</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;,
    2025</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronnie Hershman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 214; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Act of 1933, as amended, the undersigned, Puglisi &amp; Associates, the duly authorized representative in the United
States of Nasus Pharma Ltd., has signed this registration statement on , 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    J. Puglisi</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 215; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>














































































































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>vi_001.jpg
<TEXT>
begin 644 vi_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $] W@# 2(  A$! Q$!_\0
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M'_P NO\ Y-KX(^#G[6GP)^./A;Q#XK\)^,'\.P^#?$L/@WQSX>^*6FW'PO\
M&7@3Q9=1F:Q\/>+_  WXL>SN-*U'4H@TFF!)[FVU)4E^Q7,[12*GKD/Q(^'=
MQ8ZMJEO\0/ MSIF@6^G7FOZE;^+M FT_0;35PK:3=:U>QZ@UMI5MJRNK:9/?
M2P1WRLIMFE!KI>&HK>A%>JEOV^+S5N]U;='.L35=K5IN^JM*.VO]WR>Z6VMF
M?3?_  OWQY_S[Z#_ . %U_\ )M'_  OWQY_S[Z#_ . %U_\ )M?)/B_XU_"'
MP!>V6F>-/BAX"\-:OJ6HZ'I.G:%J7B;2T\07VI>)KF.T\/V=IH,=S)K%Q)JU
MQ+&EFT5DT4BMYQ=8 T@\H^.G[8OP=_9_\9>'?AKXGM/B9XY^)WBCP_>^,--^
M&7P6^&NO_%3QW!X,T^[DL+OQCJ^C:&8(=%\-I?0SV<-]J5];R7EQ;W"65O<"
M"5D:PM)VM0B[W:TEJENTW)*R[[>>UQXFJKMUIJV_O1T?;2#U\M_(_0W_ (7[
MX\_Y]]!_\ +K_P"3:/\ A?OCS_GWT'_P NO_ )-KX=^'7[4'P&^*7PST/XO>
M&?B;X9L/ FOZAJ&BVFH^-KZ#P%?6GB'2)VM=8\,ZOI7BR;2[W3/$>D72/;ZC
MI$Z&X@=-XWQ.CGTC6?B1\._#LT=MXA^(7@/P_<S65AJ4-MKGC#P_I4\VFZK-
M]GTO48HK_4;=Y+#4K@B#3[Q%:WO)B(K>21SMI?5J*=G0CUZ3Z;[-^6U]T"Q%
M9JZK3:[\T>NWV>O3Y]G;Z:_X7[X\_P">&@_^ %U_\FT?\+]\>?\ /#0/_ "Y
M[Y_Z??8U\4?'+]HKX1?L[_#[QA\2/B=XKLK/2O!7@^Y\=ZAX>T2ZTK5O'NK^
M&K.YL[:XOO"G@^75=/U'Q$8WO86_T-EB,(FE$X1#FYX=^.'A'7=;^*&F7]KJ
MW@K2_A0?!+:SXR\=RZ!X>\(:Q:>._"MGXMTW4-!U1];N'6ST^RO(M.U=M<MM
M(:WU5)8+9;R)!<,_JU*U_81MWM+_ .2UW6R>Z6^@OK-6]O;SOVO'_P"0T^9]
ME_\ "_?'G_/OH/\ X 77_P FT?\ "_?'G_/OH/\ X 77_P FU\-^ _VFO@S\
M1C\7I="\6V]CI'P/\=1?#KQWXI\3S:5X?\''Q#<Z/I6NVL_A[Q/<:M+I6MZ'
M=V.L6 M-86:TCN+IY+>*%@HD9?%'[4?P"\'>-_A5\/=>^*'A>'Q-\;#J?_"M
M8[+4+;4M)U]-*0M/*^O6,\VCZ;!<2 VNFSWUY%%J=^#8V#3W8\DGU:E=KV$;
MKI:?1)O[3V33?;\$?6:N_MY6_P 4>]OY>KT7GH?<?_"_?'G_ #[Z#_X 77_R
M;1_POWQY_P ^^@_^ %U_\FU\YZ?XT\':MKNH^%M*\7^%-3\4:.C2:QX:T[Q'
MH][XATE$94=]3T6VO)=2L$1G17:ZMH@A90QRP!Z0G@$=_7TP3_(5/U>A_P ^
M8?=+_P"2']8K?\_I_?'_ .1/:/\ A?OCS_GAH/\ X 7/_P FT?\ "_?'G_/#
M0?\ P NO_DVOBO\ :(_:#^'7[+GPD\3?&WXKOXCC\">$9-+CUF3PIH+>)-<5
MM8U*VTNT-IHZWMBUT@N;J,S,+E&2'?(J.5VGS37_ -N+]G'P_KO[,7AH^+M1
MUS5OVO;O2K;X)V_A?1?[;6]MM85%L=9\6.E_;GPIH?VHR:;-?7"WCQZM:W=@
MMM*]K,PI86D]J$7OLI=%S/[72.OI\[)XFJMZ\EMNX_:=E]CJ]%YGZ/\ _"_?
M'G_/OH/_ ( 77_R;1_POWQY_SPT'_P  +K_Y-KYDNOB+X%MKKQ+I:^+_  S?
MZ]X/TG4=:\2>%M*UW2-1\6:5I^EV<M[=R77ANWOCJMNZP1$HES! '=HT,B;P
MP\]^''[27P=^)WPC\$?''2_%UEX4^'WQ$AFF\*W_ ,3+G2_ 6H7ABO)[-[::
MQU;56ACO6FMI&6TAO;B0Q['P V OJU%JZH1MHKVEU3:^U?9-[;#^L5=O;2Z_
M:AT=G]FVCTWW/MW_ (7[X\_Y]]!_\ +K_P"3:/\ A?OCS_GWT'_P NO_ )-K
MYQUKQMX-\--I">)/&/A+PZ_B"1(= 37O$FCZ0VNRR",Q1Z,-0O;<ZH\HEC,2
MV(G+[TVAMPR7?C;P;8#Q$;_QCX2L%\(OI\?BUKWQ'H]JOA-]7Q_9*^)FN+Q%
MT%M3#!].&JFT^W)\UJ)01D^KT?\ GS#KTGTT[_UMOH'UBM_S^GIO[T=.NONZ
M::^FNQ]'?\+]\>?\^^@_^ %U_P#)M'_"_?'G_/OH/_@!=?\ R;7Q)X"_:.^%
M/Q$OOC-9:/K-WHT7P#\<GX>?$C5_&=K:>%= L?$(TVVU82:7K-]J4EGJ.CM:
M7<.S4Y'LE>8F,0G 8^OZ-KNB^(],M=:\.:QI'B'1KY&>PUC0=2LM8TJ]6-MD
MC6FHZ?/<6=PJ/E6\F9]K*RL0010\-16]""MWYO7^;MJ"Q%9ZJM-KUCZ?R'OG
M_"_?'G_/OH/_ ( 77_R;1_POWQY_S[Z#_P" %U_\FUXR/IC_ #_2BE["A_SY
MA_Y-_P#)![>M_P _9_?'_P"0/9O^%^^//^??0?\ P NO_DVC_A?OCS_GWT'_
M , +K_Y-KQFBCV%#_GS#_P F_P#D@]O6_P"?L_OC_P#('LW_  OWQY_SPT'_
M , +K_Y-H_X7[X\_Y]]!_P# "Z_^3:^-?B)\=? 7PL\>_ SX;>+&U]?%'[17
MC36O 'PV72-%_M/2W\1>'_#=UXJU!?$NH?;+;^P=/_LBSF:"^\B^^T7I2W$"
M;]Z]CHWQ%^'WB348='\.>/\ P-X@U>XM[B[@TC0_%_A_5M5FM+6XEM+NZBL-
M/U">Z>WM+J":UN9UA,5O<PRPRLDD;(K^K4;7]A&W>TK;V[]_3]0^L5KV]M.]
M[6YH]5=?9[?U?0^F?^%^^//^>&@_^ %U_P#)M'_"_?'G_/#0?_ "Y]_^GWV-
M? OB[]K'X,^$_'GA_P"&5MK5UXY\;^*? OQJ\?:/I7PX&A^*K1;'X!Z3H>L>
M/-!UG5;?7H+/P_XNGM_$>EP^&]$U3R_[6N6N8Y[K3XK1YF]"\._&'P+K?A3X
M>>*=6UO3/ 4GQ.T+2=<\,>%O'^N^'/#_ (ME.KP1SPZ0VF-J]Q#>:Q;M(L%W
M;:1=:C&LX,<4TAY#^K4M'[".NVDO/IS7Z/II;47UFJ]J\M/[T/+KRVZKK?78
M^N/^%^^//^??0?\ P NO_DVC_A?OCS_GAH/_ ( 77_R;7S?>>.?!6G>(;?PC
MJ/C3P?IWBR[@6YM?"VH>)]%LO$=Q;,CR+<PZ)<WT6I36[1QR2++':LAC1G#%
M5)KYRT+]M;X&>-M+L]6^&&JZQ\5K:3XX:5\!-8B\%V>G?;?"WBO5=1ETM==U
MVSU_5=$F'@>VNHF/_"1:<-0BU*(E](BOPK4+#4GM0B_E+S_O>3^X'B:J_P"7
MTM=O>CY=HONOO/T=_P"%^^//^??0?_ "Z_\ DVC_ (7[X\_Y]]!_\ +K_P"3
M:^<X?&7@^?Q)>^#+;Q?X4N?&.G1-<:AX2@\1:1-XGL+9(UD-S>Z!'>MJUK (
MV65I9[.- C!BWS<4M&^(OP^\2:FNB^'/'W@;Q#K+6DU^NCZ%XMT'5]5:QMI3
M!<WBZ=I^H7%X;6"=6AFG\CRH959)&5E(I?5Z/_/F'3I/9[/?9]'M;6X_K%;_
M )_3_P# H?\ R/X;^70^F?\ A?OCS_GWT'_P NO_ )-H_P"%^^//^??0?_ "
MZ_\ DVO&,\X_7MVZ'H>O'K@^E+2]A0_Y\P_\F_\ D@]O6_Y^S^^/_P @>S?\
M+]\>?\^^@_\ @!=?_)M'_"_?'G_/OH/_ ( 77_R;7C-%'L*'_/F'_DW_ ,D'
MMZW_ #]G]\?_ ) ]F_X7[X\_Y]]!_P# "Z_^3:/^%^^//^??0?\ P NO_DVO
M&:*/84/^?,/_ ";_ .2#V];_ )^S^^/_ ,@>S?\ "_?'G_/OH/\ X 77_P F
MT?\ "_?'G_/OH/\ X 77_P FUXS11["A_P ^8?\ DW_R0>WK?\_9_?'_ .0/
M9O\ A?OCS_GWT'_P NO_ )-H_P"%^^//^??0?_ "Z_\ DVO&:*/84/\ GS#_
M ,F_^2#V];_G[/[X_P#R![-_POWQY_S[Z#_X 77_ ,FT?\+]\>?\^^@_^ %U
M_P#)M>,T4>PH?\^8?^3?_)![>M_S]G]\?_D#V;_A?OCS_GWT'_P NO\ Y-H_
MX7[X\_Y]]!_\ +K_ .3:\9I"<=B?8#)X&3^@-'L*'_/F'_DW_P D'MZW_/V?
MWQ_^0/9_^%^^//\ GWT'_P  +K_Y-H_X7[X\_P"??0?_   NO_DVO@S]H_\
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M>U>3_P"WHW^YQ7KMJM5IJ?9/_"_?'G_/OH/_ ( 77_R;1_POWQY_S[Z#_P"
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M %U_\FT?\+]\>?\ /OH/_@!=?_)M>,T4>PH?\^8?^3?_ "0>WK?\_9_?'_Y
M]F_X7[X\_P">&@#ZV%U^7_'[U/:C_A?OCS_GWT'_ , +K_Y-KQ=B 1GO_P#6
M/X\@'\/P/QS\<?VY/A%\ OB3%\)_%'@WX]^,_&9\ R_$^\M?@]\']2^)=EHW
M@>WO9K&[UW7+K2]6M9].M;*6WD>\=K*1(;?,A=LE*<<-1D[1H0;WLN;_ .20
M/$5HJ[K32;LFVM7V^#7_ (?Y?I=_PO[QYW@T ?\ ;A<].?\ I^]J/^%^^//^
M>&@_^ %U_P#)M?GY\-_VM_@W\5=3T]/">J7P\':Y\,? WQ1\-?%+Q ='\-^
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M)][=^^GKV#ZS5U_?RTW]Z':_\O;_ (%SZJ_X7[X\_P">&@?A87)Q]?\ 3?\
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M>^'?A#^V1\1/!_[$W@GQ=^SG;_"O0_V'['1/'T^JZM\2O#'B'Q)\5?'WP_\
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M@4L3#^>CKN_:6LKMI:3Z7LK6>N^Z%]6F]XU;?X+]KO6+6K2WT71)'\ZFG_\
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M\_\ AMC7V53^2?\ X!/R7\OD<?178?\ "N?'_P#T*FM?^ G_ ->C_A7/C_\
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MR5[S3LME[LX[>GWGX??\.+OA%_T>'^W_ /\ B4'C?_X_1_PXN^$7_1X?[?\
M_P")0>-__C]?N",\\D8SZ<],'I]:!DD\]/<']-H_7\*?UO$7M[76]MJ>_P#X
M*_0CZK1_Y]1_\G_^6GX??\.+OA%_T>'^W_\ ^)0>-_\ X_1_PXN^$7_1X?[?
M_P#XE!XW_P#C]?N%@^I_3_"D.1CYN^.<>_?''K],T/%XE*[J_P#DL.O_ '"#
MZK1_Y]1_\G_^6GX??\.+OA%_T>'^W_\ ^)0>-_\ X_1_PXN^$7_1X?[?_P#X
ME!XW_P#C]?N#SQSU^G7_ +YY_3]>$.1@9Y/?@<_E_6CZWB/^?VUK^[#2_?\
M=?UTN'U6C_SZC_Y/_P#+?O/P_P#^'%WPB_Z/#_;_ /\ Q*#QO_\ 'Z/^'%WP
MB_Z/#_;_ /\ Q*#QO_\ 'Z_<+!]3^G^%&#ZG]/\ "G]:Q/\ S]_\EA_\J#ZK
M1_Y]1^^?_P M/P]_X<7?"+_H\/\ ;_\ _$H/&_\ \?H_X<7?"+_H\/\ ;_\
M_$H/&_\ \?K]PL'U/Z?X48/J?T_PH^M8G_G[_P"2P_\ E0?5:/\ SZC]\_\
MY:?A[_PXN^$7_1X?[?\ _P")0>-__C]'_#B[X1?]'A_M_P#_ (E!XW_^/U^X
M6#ZG]/\ "C!]3^G^%'UK$_\ /W_R6'_RH/JM'_GU'[Y__+3\/?\ AQ=\(O\
MH\/]O_\ \2@\;_\ Q^C_ (<7?"+_ */#_;__ /$H/&__ ,?K]PL'U/Z?X48/
MJ?T_PH^M8G_G[_Y+#_Y4'U6C_P ^H_?/_P"6GX>_\.+OA%_T>'^W_P#^)0>-
M_P#X_1_PXN^$7_1X?[?_ /XE!XW_ /C]?N%@^I_3_"C!]3^G^%'UK$_\_?\
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M?4_I_A1@^I_3_"CZUB?^?O\ Y+#_ .5!]5H_\^H_?/\ ^6GX>_\ #B[X1?\
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M8_\ R97[2X'O^9_QHP/?\S_C1]=Q7_/_ /&C_P#* ^K4/^?,?NJ__+3\6O\
MAR/\(_\ H\/_ (*"?^)-^,?_ ),H_P"'(_PC_P"CP_\ @H)_XDWXQ_\ DROV
MEP/?\S_C1@>_YG_&CZ[BO^?_ .-'_P"4!]6H?\^8_=5_^6GXM?\ #D?X1_\
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MQ\(/^CP_^"@?_B3WC/\ ^2Z_;7Y?[W_CQ_QH^7^]_P"/'_&CZ]B?^?GXT_\
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MX2?]'A_\% __ !)OQE_\F4?\.2OA)_T>'_P4#_\ $F_&7_R97[18'O\ F?\
M&C ]_P S_C1]=Q7_ #]?W4O_ )0'U6A_SYC]]3_Y<?B[_P .2OA)_P!'A_\
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M[BS,3@*JA222< <G&*_"WX!?\%%]9\2_&+X[^);[XF6_Q&\ _$+P#\=?B1\
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M_P")#G7_ ,M#_B*O&_\ T,L+_P"&G*O_ )0?U&?\1#OPX_Z->\>?^'*\-_\
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M'UQ^3MC)K7Q_^'WQK^/OQ'_::^)7P'_9UF_:"OM9MY/!WC?6/ 4E[^SQ\$-
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MDBW*R;G&S]UR;35[I):M;-JX>WIVYDINRNTH2NM>5)IVLV]EUZ=#]9SGMUI
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MMPZ6M];07(T9_P!N=]2O'\2^(O@CX8U?Q_I^@_'KP=X2\7KXZ\<6T?AOP?\
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MZTIE/C[QT ;BYG\K[?I0C"W%DMF+?;_8Y(@MW7[=;KNWI?%I'=XB(0>RI?\
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M001P(#HQ(@TAH&GTA22\$UQ.UR]VC)&B]E2_Z"%_X)K?U_5MP^OYC_T)I_\
MAUROUW^[[STK(]1Z=>_I1D>H_,5YNG@6_1XG/Q \=N([BSG,;W^D^7*+2V-N
M\$@7158P7C'[3>*K*SW(#1-$G[NH5^']^L<<9^(OQ 8QV=O:&1M1TCS)'@U
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MR_R"S[O[Y?\ R9%M/]T_]]#_  K UL8^S]>KC@]2 ,]",8XXY/KVKI*^!_\
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MF3T?+.:OM)JS?]\.>O!SSSN)['W]OT^F0')/'T^8Y_#GGZ#'\J_@<_XB/?\
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M]2Q_#OP>AYZ<^F: >.^>_P V.><]^#TS[Y&!4E%'W=.D>G_;O]65K6#7N_\
MP*I_\L(\^G_H?/3MR><]/7THSSW_ !<?X_U-244?)?\ @,?\@U_FE_X%4_\
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M::1]OM<#)\P\;L]4;/K^HY/3/6NXVGCY3W[J<<8SG;U^OJ<5Q6F_\?\ :?\
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MZ9XA\-7D&DSQI<Q6]Y<_LCXD_P""?O[+GBO]HSQI^U'K7@%KCXH_$CX1:O\
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MO./+SVN]5&UH1O9IQ2,I0Q%DO:7=FF[QBT]HN+<+I+3F^U*UTU)G#:K_ ,%
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MVD7&G>)M*U[4/#OAC5M6UVTNO 6L:'H5LEWXF@^J8/V$?@K]B\6RZOJWQ/\
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M3YDZB4OY1OA1X9TOQG\5?A?X-UM;HZ+XO^(?@KPOK"V%Q]EOVTK7_$6GZ5J
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M"3_A+-,\87=O>:7:R^'GT9[J_6ZZ?5OVL/VG[;X,_&[P[:_'?XL^&O&WA?\
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M10 4444 %%%% &+JWWK?_MI_):R:UM6^];_]M/Y+630 4444 %%%% !1110
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M !7.Z[]ZV_[:?R%=%7.Z[]ZV_P"VG\A0!@T444 %%%% !1110 4444 %%%%
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MT+X-_LB_ S]J#XI>+?''[0GAW3/%Y\$?$?P_XWUK6=-M#'\+8X/''Q)T'2O
M&JZG$GV'P=X;\6,9HY=7\)WIT^PU(="JF[).SU]^"2Z6YG+E33T<=[M+M=>W
MI_S/6UO<G=IZI\O+S6:NT]G9]FC]EZ*_+#7?^"H7@^R^.ES\+= ^'J^)O">C
M?$CX>_"KQ+XAM/&ES'\2;?Q+\1-'T+6+/6?#OPFM?!&I6.N>!O#,?B?0HO%^
MO:C\2?#6KZ89K^XT_P +ZQ;:9<2M^IW3 )R?Y^_MG!J9TYT^7GBX\R;5[='9
MWLW9KJG9ZIVLTRX5(3OR24K-)VOVTZ).]GMH+1114%A1110 G/TY^N1_]?\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #, ]\'N
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M#F;X4^)FLU&28QK&I^!H+Z[10<*TZ[B "Q9LDX?_ !"X_LOCG_AJ_P#::/\
MW ?@T>0>O'@P @$_GT-?>U.*>&Z]Y5:E=RDJ=W+!8E32IS=6FN:-3W7"<F[Q
M>[U<EM^WU_$GP\QJY\37Q<JE2GAXS]IE&8*I%8>K*O2CS4ZWNRI59SE>G+5N
M49<\-%_.99?\%(?&MG\,K3X=_P#"I/!+NG@"P^'^K:C!XG\8:?HVL6UE\3)O
MB=/XGN/"NGW%LK>-==U.1=,\1^)[K6K_ %34;.WM[NWGL;Y6D;I=9_X*D?$'
M4=1T[4++X2^#;>;3?$'P:\1KJ.K>)?$/B/Q3?77P5_:)T7]HSP_8:QXMO+>V
MU;6M)DUO0[7PE9Q:N;V_T;PQ(P@U&]O@)3_0;_Q"X?LOG_FZ_P#::[CG0O@U
MCUZ_\(8._..Y/Y*?^#7']E\=/VK_ -ID#C.-"^#1X)SU'@S S_\ 7]*P_M_A
M-ZWJ6U>N#QK5W&VWMMK)Q6MK?S;KC_UW\+GUQ.\I6>5YJU[T7"UGBK?![B5W
M:+M>H]8_SB3_ /!0W4M)T3QOX8^&7P"^''PQ\-_$34OC=XM\6Z5IOB/Q=XA^
MV_$?XXP6=EKGC&WN]<E,]I;^'[&T:UT/PW&&T[_2[B:\N)G*;=77?^"E/B3Q
M%XG.MZC\#O 4NB:U??M)77Q!\*+XI\61VOCBU_:I^ W@[X"_%6P&K _VAX9$
MVC^$(/$6AW.EB:33-8U"XMMLMC!$I_HF_P"(7#]F#J/VK_VF1CGC0?@R./7G
MP9S]<?7/%'_$+C^R_P#]'7_M-<YZZ#\&SGV_Y$P>P_"G_;_"F[=9M[MX7&RD
M[M7<I.O>3TBTWK%I-;*[?'/A>]7/%2=VW*>69O.;DTK2G.6*<IRCRQY93<I1
M<8N%G%,_F9_:B_:9\.?$OX'_ ++WP*\$ZE>:_9?"/P:UQ\1O&=_X9?PKJ/BO
MQ5')?:?X \+7D4NI:G<>(-+^"G@6]F\#>'/$M]-#+JEE*)([&RC@2,_">W!'
M&<GD=NO'3/')'/;/ K^U(_\ !KC^S /^;K_VFO4_\2+X-'KGKCP8,'/T]Z/^
M(7']E_/_ "==^TSSC'_$A^#6?S_X0SOGJ,=><UO1XJX=P]-4Z6(Q/+S5)MRP
M6)NY5*DIS;]Y*[<VE96244OA.[!>)O . H1P^'S#'J"J5JTG/*<?*4JF(K5*
M]6<FI15W.H[6BE"$81@DHI/^*S:?[I_,#^GZ]^O>C:?[I_[Z'^%?VI_\0N/[
M,/\ T=?^TU_X(?@Y_P#,;1_Q"X_LP_\ 1U_[37_@@^#G_P QM;?ZX9#_ -!&
M)_\ "+%?I5L=/_$6."/^ACC?_#/C_P#Y8?Q6;3_=/_?0_P *-I_NG_OH?X5_
M:G_Q"X_LP_\ 1U_[37_@@^#G_P QM36__!K=^S!)/#&W[5W[33*\L:%?[#^#
MD>X.P7'F?\(5(4Z_>",1UVL,J7_KAD/_ $$8G_PCQ7_RT/\ B+'!'_0QQO\
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MLTC%13MU;DVVY-R=KMMZMNR7DDDDD@HHHJ2@HHHH **** "BBB@#%U;[UO\
M]M/Y+636MJWWK?\ [:?R6LF@ HHHH **** "BBB@ HHHH **** "BBB@"[IO
M_'_:?]=?_9'KNZX33?\ C_M/^NO_ +(]=W0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 48'I110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7.ZZ/FMO^VG\AWKHJYW7?O6W_
M &T_D* ,' _*C&?YT44 &/\ #V_+I1C_  _S_G^=%% "8'^<_P"<>W2EHHH
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M29''OP/QI?ZT %%%']:+KN 4444 %%%% !129'/MG/X=:-P]?\X)_D#0 M%
M(/(I,@_K^G7^= "T44?Y_P _G1< HHHH **** "BBB@ HHHH **** "BBB@
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M:?\ P^)_X)@#_F]+X0\\_P"O\1__ "EH_P"'Q/\ P3 _Z/2^$/\ W_\ $?\
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MT*P>*O\ @G5XL^(LOQ*UOXE_M-Z[XL\8_$'P9^S_ .#1J<7PP\.Z+X9LM/\
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M)S2;TLDG#31MK3XHVTB[LD\2]8J*U22:BW:VKNI+JDM7=1=]9*QVWPL_;7\
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MN 74]"!D@[N0",>O)K8T+2I/$5QJ5M::IX:T\Z3X>\2>*+VY\2^*=!\*:?\
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M_P#UJ+?UI_G^(G**T;2^_P#R9)14?F?[/Z_IT_S_ "/,_P!GT[^I^G;K1?\
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MRQ>5XS#YAE^)GA<9A:BJT*U)VE"2T::E"4)PG%RA4ISC*%2G.<)IQEI_G/\
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M]2>!WXK_ $AMGOZ]OR[]Q^72G)E'1P,E'#8.!DHP..IZ\$^@([T?Z]9G_P!
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MK?\ [:?R6LFM75B<P''3S,<]?NC\!SQZ_B*R0<]1@]>N>#G!_0_E1KV?W?\
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MFCW7W_\ VI)14?F?[/Z__6H\SV_7_P"M1_7]:BYH_P R_'_Y$DHJ/S/;]?\
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M^R*/_07F_7_F<YA_\E_PQYDND?% .A;QEX(>,30-(@^'VJH[6ZVOEW422?\
M">L%FGO/])@F:-TMK;_1'@N9/]+J%-&^+(BC5_&_@1IA:VT<DH^&VKK&]\FH
M227ES'"?B&[1VMQIQCM+>S,TDEI>A[][V[AD%A'ZG28'H/RH^L2_Y]T/_">D
M+^R*/3&9O_X><P\O[WE^+MNSS"31_BH1,(_&O@5&:/41"S_#G5I/*EEE5M)>
M51\08Q,EA"'COXU\@ZG(RR0R::J&)WC2/BCO+'QCX($1N(66+_A7NJF1;9;
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M%I9VF]WL;P"^FN+V,BT7T#Y?[W;U]>I^OO1E<_>''N/?GZ\T*O+1>SP^EO\
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M=:6Y7XV^'==GBN+WPA<>197?AXOXHT?7-3\/13:E'T>G?MU?"?4?'VE>$?\
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M^'>V8_\ A=+_ .5$_P#$Z_C=WX*_\12G_P#/<_I&_P"'KO[+'I\2O_"$N?\
MY+H_X>N_LL>GQ*_\(2Y_^2Z_FYV+Z?J?\:-B^GZG_&C_ (A_P[VS'_PNE_\
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MS^&[DXQ2MJVY:*U[-V/UDHK\K_@[_P %#-=_X9\\ _$#XO\ P8^,/B[Q/?\
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M*GB<?&E/"X'%X+,*5#"TOKKIY=3J9AEV#Q^,CEL,']?QM!8O'/$UYU)SJI"
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MT@ '2DZM1Q<>9<KO=<JZRYG;M>[3MNK+96;5.*:E;WE97N];*RNKZVZ7OKJ
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M2^#&I_#+X?76KZA%\-O$WP;\5>*O%*^(M#\6:IK=YJWB?4#XQT_6([^'3/[
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M$8*I@,PRROBG&:PD\7AG2>%Q<X3I4L50IQQ$50K3J4OY=OA9\8_$_P (=/\
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M-]_!:0ZW((;R#XR>%?\ A$H[599=,DDM7\,V,<4C70$AUJ1&#1:<) 4^N?\
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M?_EU1_PZ*^(O_1=? ?\ X1'BG_Y=4?ZX\,_]#?#_ /@K%?\ S,'_ !*YX_\
M_1LLX_\ "[A__P"?I^2=%?K9_P .BOB+_P!%U\!_^$1XI_\ EU1_PZ*^(O\
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MMMKW=&VWM;9>@.A3:4>5V2LES2VLE;?79;^?5W/S5U']AKXLZ+>:G/\ "/\
M:B3X>0>*OV:?@_\ LS^,;?4O@SH_C$W>A_">#Q]:VWCKPW<R^,]$E\/^-;NU
M^(.K6^FI<?VSX;TL'S;[1-<G6S>SQ?%G_!,7P3KNE:WX.TCQ_+I7P\U3X%?
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M_$U>^PC_ )Z'_OD?_%4?81_ST/\ WR/_ (JC7^9_^3?_ "8>SA_)#_P&E_\
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M_7"G*[V]?T'^%&]O7]!_A75?\(Y%_P _4G_?M?\ XJC_ (1R+_GZD_[]K_\
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'U]S:_0#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "H 2@# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH **** $(R,4=*0<4N* %I#ZTM,D) ^7&?4T
M-+8DPV./NFG]1Z^]9EUJ"+?P64N4><-M &<X]^U/C6YMKT*6C&GA, L?GW>]
M -,TJ*C23<6&#\OZU)0 4444 %%%% !1110 4444 (>1S^E(@PH')^M'.?:G
M4 %(:.XILN[8=I ;MNZ4 ,W-YIWJ HZ$U)D#UK.O-22VNK6UFSYMP2J@#.?Q
M[4)%<6EW"D;QBQ"$/YA^<MGC% 6-(44Q9 7*#.1SFB@"2BBB@ HHHH ****
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M;* 2R' 5AZ<'FN9Q=5V2T/1K59Y;3C5>\NC/N#P%(DWA>QDB:5H7C#QBX^^
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M,><T[X6?#+Q9J'BN76M?L+?PYHJPFS71T*R/*@ "R;P.,^E?0%CIT6G6D=O
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MWT$FHK]Z+< XSTR*5.;EH=;IV5T=C7SC_P %#CC]C_XB_P#7C_45]'5\X?\
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MZO\ &3PC9G?PNNVMNN?I.,?K7:?\$JOVRQX[\/I\*/%MZ#KVFQ;M)N)FYN(
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M_P $M1%]<:Y]GU&+5+%)MJSQC&UL_=&.,8HK5&7*XZ/4_G9^)?\ R/\ K_\
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M_.OZ4OB)Q^S=KO\ V+,G_I-7\UET,W4W_70_SH _1W_@BA_R5GQS_P!@M/\
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MH#)461&5E#HPPR,,@CWKQ[XA_LA_"'XI2>;XA\"Z7<3\_O8(O);ZY3%>R44
M?$?BC_@D;\$-=NVFM(]4T=6.?*M;@%1^8K#A_P""-OP<CD#-JVOR ?PF9?\
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M _\ CM '-?\ !4;]H6/XO?"#PS8)X*\3>&S!JQE,^M68ACD&S&U3DY-?IO\
M!G+?"3P7G!/]CVG;_IDM?$?_  6H8#X%^#03C.MG_P!%&OM[X,<_"/P9_P!@
M>U_]%+0!V=-)P13J3/- '/:M'#?Z_:VES;+/ J&12ZY4-_C7Y>?MF:Q9Z/\
M\%,_AW>7MQ'96MJ+1I)Y6"J@'<GL*_5M;1%NVF4D,>N1P:_)W]M#1K#7/^"F
M/@+3]4M(KZPNOLD<UM*,K(IZ@BI2L[E.3M8^T/VJ_C)\-/%G[//Q TM/%FB:
ME/+I4WE6HN4<LX'&!ZYKSO\ X)#ZE<:A^RC''-([I;ZI<1Q@G[J[N@]J[K]I
MW]F[X7>'/V?O'^IZ?X#T6TOK;29I(9XK959& X(/M7GO_!'DY_94?_L+W/\
MZ%5$GW112"EH 1NAKX+_ ."R _XQCTLD<KK<!_1J^]#TKX,_X+)G_C&'3O\
ML-P_R- 'U!^S"PE_9Q^'3/C8=!M<[NF/+'7\*_/+]@4A?^"B7Q272!LTC%WY
MJP?ZO[WRYQQ][->@_M):;\3[/]A#X;^*?ASK]YI=OIN@6Z:O9V;E6EMVC&7!
M'IW]J]B_X)M:=\)[KX)6NO?#VT2/6[M0FO2W,GF7GV@<L'8\[2>1VYH ^O$!
M Y&#WIU-0]<]13J "N8^)5S]C^''BJ?<%\O2KI@?0B)JZ>N"^/-X-/\ @KXX
MG/1-'NNOO&PH _*#_@G_ ."=?T_P9XS^,W@PS7/BCPSJY%SIBL2FI6+*&FB(
M[L!DK[U]=^./B5;?MU:9<^'?"%Y<P?#?3M+DO_$ET%,<DMQY;&.R^JL,M]*Y
M'_@C%9$? OQC<,H,=UKA//(($8!K[;L_A[X>\$>$_$-EX>T>TTB"_6XN9X[6
M,*))74[F/N: /S\_X(]31MX1\=^'YK=)K>+6MY,J;AD)@?2OTQCA$:A57"@8
MP.!7YK?\$AI2GB3XRZ<9,"'5V?8!_ME?Z5^EPI62*E)["T444R3Y2_X*>#/[
M'OC#C/\ J^,_[5<%_P $V/C'X(\(_LH^&M-UOQ;I>F7R2RYMKFY5'7+<<'I7
M>?\ !3PX_8]\7\X/[OG_ (%7F?\ P3<^ 7PY\<_LK^'M5U_P9I.K:G+--YEU
M=6X=VPW&2: /)_#?B#2+W_@KHFI>';ZUOM/U"U8-/9.&C8E &R1WXK]4J_*G
M2O"&B^"?^"MNGZ3X?TNWTG38[7<+:V0+'DIR<"OU6H **** *FHV$&JZ?<V5
MU&LUK<1M%*C<AT888?D:Y+X8?!KP9\'-/NK/P9H-MH-K=2>;-':YQ(_J<T44
M =LO>G444 %%%% #3R3S7!^'?@;X%\)^/-1\::3X<M;+Q/J 876I1@^9*#U!
MY]J** +'Q-^$'@[XS:1;:=XST*VU^QMI?/ABN 2J/C&X8-=5IFG6VCZ;;V-G
M$+>TMXUBBC3@(@& !^ HHH N4UC@CC\:** &;/WA;<3D?=K@=?\ @%X \5>/
M;'QKJWAJTO?%%EM\C490?,3'3'..*** .P\0:#I_BK1;W2=5M4O=-O8C#/;R
M#Y9$/4&L7X<_"_PO\)- .B>$=&@T/2O,:4VUL"%WGJ>:** .L'2EHHH 1AD8
MKD/B5\*?"GQ=T*/1O&&BV^NZ8DHF6VN0=H<=#Q110!JVOA'1K/PO'X;BT^%=
M"CMOL:V)7,?DXV[,'MBN8^&OP%\!_!V>]E\%^'+7P^]]_KQ:;@KX]03BBB@#
MT!1C/%.HHH *S=>T2R\2Z/=Z7J=NEWI]W&T4\#]'0]0:** .?^&OPH\)_"#1
M9-(\':);:%ILDAF:VMLA6<]^:ZN6)9HGC<;T8%67U'0BBB@#B_AY\$O!/PJU
M35;[PIH-MHUSJC;[QK<$>:V<Y/OFN[HHH **** .?\=>!= ^(_ARYT+Q-IL.
MK:/<@"6UG^XWUIG@3X?>'_AEX;M]!\+Z9#H^D6Y)BM( 0JY.3110!CR_!/P1
?+\1H_'C^'K7_ (2U$V#5,'S<>G6N[HHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'A M # 2(  A$! Q$!_\0
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MS0PV@LQ  Y))X'O4=M<PWL7F6TT5Q%TWQ.'7/U% R3;[FC;[FE(..E&#]<4
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MYV__ %S7^0J;%,LP/L5O_P!<U_D*FP* &8HQ3\"C H 9BC%/P*,"@!F*,4_
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M$]"<'ICZUY5\6=6C^#?[7>G^/_$]K</X4O=,-G'J4<)D6TD (.<=.>?QKD]
MNF^)7C_XU?$;1;.YM?",WAZ>SBN9H3&+N38.0#U^[D_A36%HU::FT]5>]]+M
M_"2\76I3<$UII:VMDMSW#X2_M6>&_C)XFLM$T72=8@N)[62YDN+F)1#;E>?+
M9P2"Q&#Q7)?MTZC=Z?X,\%O9W=Q9L_B")6:WE:,LNT\'!Y'M72?L2Q0C]G'P
MS)'&BM(92[*N"QWGJ>]<G^WPP3P3X(). ?$40Z?[-94H4XX]0IK1-K5]KG16
ME4GE[G4=VTME;L=OXZ_:?\/_  U\:P>$-0TC6;_4FTZ*[C;3X1*)2PXC"YW;
MN#SC%9,?[5^D^+?ASXNU30-$UR+7=&C,<NEO OVJW+ A9L9P44\MZ8Z5R5\Z
MG]OOPXI.3_PCL9''_3,U0^'D$E[^T#^TA:VL9DN)+"5$BC'+,8^ !ZDFM%A\
M.HJ36J2EOYVL8RQ&(<G%2T;<=MM#1^"7[4NI1? _5?$OC6PUC69](?=+JB01
MQQW8=]JI$<@$KWZ5VWA[]K_P=XBTC6]5BTW7(]-TN*%S-]C+_:7DZ11!<EF!
MR">GOBOFKP[XVTNZ_8A\6>$1)+'KNC7 GO+:2)E\M7F&WD]^*]O^(_BWQ+\/
M/V/_  GJ?@R,VUV;"R2XN[6 ,]M"T8WR*N.#G^+M6M;"T>=KDLW.RULK6O<R
MH8JOR)\]THW>FM[VL=GX)_:AT'Q9XQT_PQJ.@Z]X3U/4EWZ>NMVHC6Z&,_*0
M3VZ9K(UO]L;PUHVO^(M$7PWXBU'4]%G,4L5C;K)YBKG<X(/RJ/\ :Q7S@/$6
M@ZS\<?@_<Z1XP\0^+U%[%]JU'7G8HDQ/*19 "\GD#/:O8/V<F5_V@/C^!@E9
M".?]YZFI@L/2O.4;Z)VN][V]1TL;B*MH1EUM>U]+7/5=/_:4\(:G\*AX]@6_
MDTSS_LALHK9I+H3_ ///8N>??I53P+^TWH7C3QC:^%KS0M<\)ZS>Q^=90:W;
M",7*XZH03^M?+W@/QUXH\"?LL^(+[PE)-:S2^+98+V_MH?,DM+<CYG48..@&
M>V:72=?T'5OVD?A3<Z'XKU_Q;;[PLNIZ^S',Y)+1QDJ.!GD#C)J_[.I?O$MM
M;._97U)>95?W>JZ75N[_ *V/HSQ-^U[X8\/ZQK%I9Z!K_B&PT63RM3U?2K4/
M;6K X;))R<=\"NC\3_M&>%M!\)Z!KUC#J7B6/7EW:;;:3:M++-['LF#P=W>O
ME;QKX@\/>#/$'CJ\\,^)O$OPM\5?:Y'E\*7MM]IM-3EY^:, $%6/KD<UUWQ(
M^+7CO3/A]\)O[9FN_A_HFLQ[M?U'1K01RP_-@;0%_=[E^; '?\*R>!I2Y.2.
M^]WY7[?D:+'UE[12>J\O.W]7/;/"GQ^T+XJ:9XMT6+3]3T#Q!IVGS//I.KPB
M.<(4(W#!((Z5R/[!''P(?))_XFUQU.?2O'_@[J>DWW[2'C.72M6U;6M/E\,7
M0M[_ %LL;FY 1?FRP!*\'''2O8?V!F5_@/(5/_,6N.OX4\3AZ=##U(QV;B]?
MF/"UZE?$4YRW2DOR.)^.GAE_B%^V#X?\)7.M:KI>EWVE(SG3;MHF! <@@#CG
M SQ6UX+U'Q#^SU^T)I/PWO?$5]XG\(>([;S;!]3;?/:R9(^]]1@]CD'M6#\<
M/'>C?#?]M?PUX@UV=[?3+324\V2-"Y&0X' Z\UI^&]0E_:9_:@T#QEHFGWEK
MX+\+6WEIJ%W"8Q<2DDX7/7)(_ &MFI.A#G_A\GEOT^9SZ+$3]F_WG/Y[?Y'<
MZ9^V1X5U7QB/#%OH>N2:J=3_ +,VI"C*/F*F9F!PJ9'?!KJO 7[0>B_$'PYX
MPUJSTS4+>#PP\L=S'/LW3&,$DI@D?PGK7F'[$\<$GBKXN2E(VE&N[#(5^8#<
M_&?2O*?AA\2M*^$?A_XR^"_$4%_;^)-1N;H6ME%:N[2Y5QD8'3G.>F*YY8.E
M*4Z=.+NN7KO>USIAC*T80J5):/FZ=MCZ6A_:C\(CX-VWQ'O8;RPTNYF:WM[&
M15:YFD!QL !QV]:Q/#O[8?ASQ!XJ\/>'G\,>(M+U/6IEABCOX%B$8;[LA.[Y
ME/MGI7S:^B7\W[*7PN\106<NI:7H&N27-_# A?\ =^8/F(].,9]Z[CQ]\8?#
M?QD_:4^#NH^&GN9K.VNEC>6>W:)=Y;.Q<]2.^*V6!H:\J;^+6^UMC!X^O:+D
M[?#I;>^[^1]%_M*W$UI\"/&\T$KP31V#E98G*LIR.01R*^9?"/P<UNV_9]L/
MBGX:\>>(K+Q5!9M?/;37?F6LBHQW+M;GH/4U],?M08'P \='M_9[YQ]17S+X
M4_:-T*V_9BL/A[H=K?ZWXUN;%]/6RMK9B$9V/);TP:QP*J?5U[-?;U]+:W-L
M>Z?UENH_LZ;[]+'O7AC]IS0E^ N@^/\ Q.S6\]X#:M9VB;GGNE)5EC7OG&?;
M-:/PS_:5\/?$CQ+)X;?3-7\,:ZT+3PV6M0>4UQ&!R4.2.G.*^;OBW\%/$/P[
M^!7PK\Z._DCT&YDN=7&F#,UHTK!MZ>ZXQGID5TOP>MO 7CKXT>'=2T?QGXY\
M9:SIT$DZ7FK1*UO;#:<Q2/M!&<GCIFKEA,,Z<JL;O5VMTL]#..+Q2J1IRTT5
M_.ZU./\ A/=:39?LO?%637;C6+73O[;VR2Z'*%NE);C:7.,9Z@U]'^!_C?H&
MEZQX \!+8ZRKZSI$5QIVIZ@Z,)%V$[9"#G?P<X&,U\J>&)$_X8^^+C9P/[>3
M/!Z[Z]0^,.F3Z#\ O@]\2]-3.H^%$M)'(ZF%U Y]MV/S-=%>E3K3<7I>32]>
M56_$QH5JE**E%?#%-Z=.;7_@'N6C_M"^'-4\5>-=):"[LK/PC%YFHZO/L%L#
MG&U<')/7MVKE=!_;+\'ZOK-A;7&D:_H^E:A-Y%GKE_9[+6=LX'.<@'WKRWPS
M\+-:\5?L?>-=4L;=YO$?BZ[?6&@7EYHEDRL8[D;0V![UYWX=D\!^,_"_AOP[
MK/C+XB7FLK<0PMX6AA61+256 W*I3Y47D^N*QA@L-:;=WRNVCO;3?[_D;3QV
M)O#9<ROMOKM]WS/ISQY^U_X5^'WC?6/"U[H^LW>I:<8U46<2R+<%L'Y.<C .
M23CI74>#/C]HOB[QKXD\*OIU_HVI:%;BZG-]LVR1X#;DVD]B#SBO)OA7:P+^
MV[\086"RM;Z3&B-*@9A@1C=TX/KBN7_;5L-5^''CVP\<>'T\M_$.FRZ'>E1]
MYRNU>G<J>/I64<)AZE2.'BK.44[WZ[FTL7B:=.5>3NE*UK=#Z/\ @S\8]/\
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M;3ZT -VCTHVCTIVT^M&T^M #=H]*-H]*=M/K1M/K0 W:/2C:/2G;3ZT;3ZT
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MK%$Z+I["<&PM2+@YG'V=,2GU?CYOQJU#!'!&L<4:Q1H,*B *JCT '2G[??\
M2EV'U_2B_<:26Q5@TZUMIIIH;6"&:;_6RQQ*K2?[Q R?QI!I=FMJULMI;K;.
M26@$*B-B?5<8-6]A]:-OO2NQ<J[%5M-M'LQ:-:6[6@ 'V=H5,>!T^7&/TI$T
MFQCF65;*U65$\I7$"!E3IM!QD#VZ5;VGUHV^].X<J[%6UTZUL8/)M[:"W@YS
M%%$J(<]?E Q34TFQCM&M$LK9+1OO6ZP*(S]5Q@_E5S'O1M]Z+L=EU*HTNR%G
M]D^QVWV3&/L_DKY?_?.,?I4EO:PV<2PV\4<$2?=CB0(J_0# %3;3ZT;/>B[V
M%RJ][%:WT^TLWD>WM8+=Y3F1XHE0N?4D#G\:+C3K6[DADN+6">2$[HWEB5V0
M^JDCC\*L[3ZT;3ZT7=[CLMK$-Q:07D+0W$$5Q"WWHYD#J?P--CL;>*U^S);P
MI;8*^2L8$>#U&W&,?A5C:?6@J?6B[V"RW(+:S@L85AMH(K>%1Q'"@11] .*;
M=Z?:WZHMU;072HVY1/$KA3ZC(.#[U9V_[5!'O1?4+*UBL=.M3=BZ-K ;I5V+
M<&)?,"^@;&<>U$-A;6]Q+<16T,5Q+_K)HXE5W_WF R?QJSM]Z-I]:5V%EV*1
MT73F6<'3K-EG.9@;=,2'U;CG\:L+;Q+#Y(BC$.W9Y00;-O3&.F/:I=I]:-I]
M:=V]V%D4!H>FJL*KIUDJPMOB MD_=MZKQP?<5+#IUK;S32PVL$4LW,LB1*K2
M?[Q Y_&K6SWHVGU_2AMO<7*ET*L&FVEK \,%I;PPR9WQ1PJJ-GKE0,'/O42Z
M)IR" +I]HH@.8L6R 1GU7CY?PJ_M/K1M/K3YF'+'JBI<:597<Z3SV=M/.@PD
MLL*NZ_1B,BI+JS@OX6ANH([F%_O1S('4^G!!%3%??]*7:?7]*5WIJ'*NQ472
MK%)A*MC:B4)Y8D$"!@G]W..GM3[2PM;"'RK6VAM8L[O+@C5%SZX %6-OO^E&
M/?CZ4-M[L%%+9%&[T/3M0E$MWI]G=2 8WSVZ.V/3)!-6;>WCM(4A@C2")/NI
M$@51] .*DQ[TNW%%V'*D5K;3[6R,AMK6"W,AW.88E0N?4X'/XTU]+LY;DW#V
M=N]P5V><T*ERO3!;&<>U6MOO^E&/>B[6MQN*?0XKXD>"=6\1>#'TKPEK@\'W
MZRK+'<6ULC1M@Y,;)C&UN^!7EW@?]F[Q))\2-'\9?$+Q38ZY<Z(I_LS3M(LA
M;6T3'^,@=\\_6OH;;[\T;>F3713Q-2G%PCHGUL<M3"4ZLU4FKM>>A%/;1743
MQ3Q1SQN,.DJ!E/U!X-5[31-.T^4RVNG6EK+C;YD%ND;8],@ U>"XI,9[_I7.
MFTK'4TF[C60,"" 01@@C@CN,5!9Z;::<KK:6MO:*YRZV\2QAC[X S5G'O^E+
MCW_2ETL%E>Y171-.2UEMETZS6WE;=)"MN@1SZE<8)^M3/8VTMI]E>VA>UV[?
M(:-3'CTVXQBK&WWI I]?TIW8**6@R*".WC6.&-8HT&%2-0JK] .E0QZ9:0W;
M7<=I;1W;9W3I"HD;ZL!FK6T^M&T^M%VM@LGN58["TBNWN4M8$N9!AYUB42./
M=L9->,^/?@5XA^)WQ;TO5M>\2P2^ ])N([RRT"*$AS,H'WVZ$$BO;ROO05!R
M3^=:TJLZ3<H/78QJT854HSVO?_AQ,!CG%&T>E.VGUHVGUK$V0W:/2C:/2G;3
MZT;3ZT#&[1Z4;1Z4[:?6C:?6@!NT>E&T>E.VGUHVGUH ;M'I1M'I3MI]:-I]
M: &[1Z4;1Z4[:?6C:?6@!NT>E&T>E.VGUHVGUH ;M'I1M'I3MI]:-I]: &[1
MZ4;1Z4[:?6C:?6@!NT>E0WH L;C_ *YM_(U8VGUJ&^7_ $&XY_Y9M_*@!;$?
MZ#;8&?W2?^@BIN?2H[#FQMN/^62?^@BK&* (^?2CGTJ3%&* (^?2CGTJ3%&*
M (^?2CGTJ3%&* (^?2CGTJ3%&* (^?2CGTJ3%&* (^?2CGTJ3%&* (^?2CGT
MJ3%&* (^?2CGTJ3%&* (^?2CGTJ3%&* (^?2CGTJ3%&* (^?2CGTJ3%'?O0!
MQ/QB\=7'PP^&>O\ BFUT]=4N=,@$L=F\A03,6 "[AR.34WPX^(=C\0?AOI7B
M\ 6-K<VAN+F)VR;1U!\Z-CZHP8<^E<K^U9)Y/[/GC!\[=L,1R3C_ );)7D7B
MLW_A?Q%K/P@TY9K>V^(US!?Z;-"IVVUO(!_:0SVP%)'_ %TH ];_ &?/CFWQ
MRT#Q#K,NCC0[33M0>V@\R7)F@VADE;.-N5(./>O2=+\0:5K4$T^FZI8ZA# 2
M)9+2Y258\?WBI./QKY2?5M*\)^!_CC%)I$>H:7%XNM]-6S:9X;>)-D$:/.T?
MS"%."V.H&.]5_!$L.E_'6_L+/6/"=XEQX*O7NH?!UM]FM,JPV;P&978 G!Z@
M=: />/B]\6T\&>$X-2\/7>F:I>G4K&UDB\Y90D,\P0N0IR.#P:]&^W6IU)]/
M6Z@>]2,2M:B0&54)P&*YR 3WKXSO/"6G>'/V*_!VH^'-.L+/7=3O=*D>\D7_
M %\WVD;/-;JRANWITK>@FU70OA5\7=)FCD3XUQQ-/JMZI+RW]LQ^2>UZ'R!'
MN4(O*E2.M 'U%;>)]&OFO$M]8T^X>R!-T(KN-O( ZE\'Y<>]8?PY^*?ASXJV
M5_=>'KP7"V-Y+9S1NRB0-&Q7> &/R-C*MW%?.?PL\&6NI^-/ EY;^+?AVUKY
M+JVG^'-/DBN]2MVB(>*X!=LCH3Y@SD5Z%^R/9Z!IN@>,;.PM["UU>W\2:C%<
MP0(BSQ1"<^4KJ/F"X^[GCTH V_'OQ:U2#XKZ+X"\+W_AVUOI8?MNH76M3;BB
M;PJV\<:L"96R2,]/0UZ=<>(-)L]4BTV?5+*#49N8[*6Y19G^B$Y/X"O([SPM
MH=S^UO:7$ND6$MY_PC1NQ+);H7\Y;@!9<XSN XW=:\ILH_A_/\'?'\_C9K+_
M (6,M[?&Y>[(&J)<B1OLPM_X\8\O;LX_6@#ZSOO$&EZ5-Y5]J5E92@*=ES<)
M&V&.U3@D=3P/4T7/B#2[+4X-.N-3LK?4)AF*TFN$6:0?[*$Y/X"OG'P7X4@\
M9?M"^'SXVTRWU36K+X?V-S+'>H'V7)FPSE3QNSW/0YKR_P#L'4/%-MXZC\0>
M*/ V@ZX=9N5N9?$-C*=8M2)/W#0R;P=H4*4\L8_&@#[>U;7M,T!(WU34K/3$
MD;;&U[<)$';T&XC)J34-7L-)LC>W]];65F #]IN)ECCP>GS$@5\[6=IX4E^-
M'B:#XISZ9?&+0M.&C3:[M%M+;>4WVB2(2<;S)RW\72L3Q%?^%%T;X8Z!H@L+
MC2)X[ZXTO6_'YD:RMXED(\ORB5$C$'$>\\(HQF@#ZF@U*SNM/6_AN[>:P9#(
M+J.56B*CJV\'&/?-95WX[\/VOAN^UX:S83Z39(SS74%U&Z# SMW!L;CT SR:
M^1_"K:3JGP9^*6E7_B>VL-#C\6Q1P:AH]F[:="Q,; -""2MLSC#<XP2>E=9X
M)M-$U'7?'OAZZ\.^%[V_D\,M<2WO@Z4RZ1<A=VP26Q^6.<-R",DCO0!]$> /
M'>C_ !*\*6'B#0KC[187<8D56*^;'D9VR*"=K#N":S_"OQ;\,^,_%VO^&]*U
M&.XU7171)X_,3;*67=F(AB7"]&..#Q7*?LH#11\ _"2Z.+'=]B07HLMH/VC'
MS"3;T?L<\UY-J&E6>@>+OVB8/#EE9:?XL%G!-ID5I$D=WY36^9G@ YP>22O>
M@#ZFL?$&E:G>W%G9:I97EY;_ .NMX+E))(_]Y021^-7I)%AC=Y&6*- 69G.
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MLXZ)&"WY57U[]HKP7_PCFEWNCW=OXMO-7GMX++0M.E1[J5I& ^:,_<" EF+
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MVQ0!9T'XV36L.K+XQTJ#2+JSM[6[C32KDWBSI<';#&HP"92>-O0]0<5ZL,D
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M 4444 %%%% !1110 4444 %5-4_Y!UU_UR?_ -!-6ZJ:I_R#KK_KD_\ Z":
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MWD%[$?XX) X_0U<'!QBOS;TC6]1\/72W.E7]SITZGB2UE*'\<=:^F/@!\?\
M5O%.NP>&O$6VYN)48VU\B[68J,E7 X/'<5Y.)RRI1BYQ=TCUL-F<*\E":LSZ
M.%+3%R>:5>]>,CVQU%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *J:I_R#KK_KD__H)JW535/^0==?\ 7)__ $$T &E_\@ZU
M_P"N2?\ H(JW532_^0=:_P#7)/\ T$5;H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "D/2EI#TH \P_:1)7X/ZZ02I 3!'^
M^*^)DMHY^A\I_3JM?;7[2?\ R1S7O]V/_P!#%?%$'4&OJLI?[A^O^1\GFNM>
M/H1'3KC!98Q(N,DH<X'OZ5"\3QD!T="1G#*16] ..Q],UJVY8GEB>QSS7L.;
M1XZ@F<2&!Z$4N:[\:?:7  EM8G _V0*6ZT#36  LT4D=5X-3[5%>P?<\_P T
M5ULN@V$8(%OD^I<U1FTVT4'$&,?[1JU43,W3:W,#-&:T)8((^D"GZDU3FGCC
M7BWC_,_XU=R&K$=)D>M4YM0DCD)54'^R5R*S;O6;MCPZQD<_(H%:*+9#:1OC
MD9 )'<^E-FE2V4M,ZP@#=F1@./6N+OM4O99&+7,GS#! ; (_"L"Z^?!;YC_M
M'/\ .MHT;[LQ=5+H=OJ/C72=/#!9FNI!_# ,C_OH\5U'[+_C"\U_]HWPK"0+
M>S G(@3N1&<%CWKPNY/).*]7_8]'_&1WA;Z7'_HLTL51C'#5&NS'A:LI8FFO
M-'ZB@YH%(.OX4ZOR]'ZB%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *J:I_R#KK_KD__H)JW535/^0==?\ 7)__ $$T &E_
M\@ZU_P"N2?\ H(JW532_^0=:_P#7)/\ T$5;H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.US7].\-V#WVJW]MIMDA"M
M<7<HCC4G@ L>!FM&OFG_ (*'(LG[+VOJRAQ]KM.",C_6B@#Z!U;Q/I.A06T^
MI:G:6$-S(L,$ES,J+*[?=523R3V J#7_ !KH'A0Q#6];T[2#*<1B^NDA+_3<
M1FOF/]M6-'^&?PBRBLH\4:21D9[K7,_&;X<7?ASX[>*/&OBGX='XR^"]2@BB
MC6TE66YT,*/G"P$\YZY&#[B@#[$U;QCH>@:=#J&IZQ8:?83$"*ZN+A$C<D9&
MUB<'-/T#Q7H_BNU:YT35K+5H%;:TEC<+,H/H2I-? GQ6TWP+>?LQ_#ZV\&:C
MJ&N^%+GQM OV;7#OEM-S$/:LIY4+TV^_6O4/&O@S1?V??VG/A)<> K&+0+3Q
M4\^F:KI-CE+>=%4,LGEYP&!/6@#Z_P!Q K-T_P 3Z3J]_?6-CJ5K>7MBP2ZM
MX)E>2!CT#@'*GZUYK^TO\:(_@UX"$MI/;)XDUB8:=H\=U($C$[\>:Y/ 1 =Q
M/L*^8?V7M(7P]XJ^/7ACPUXHMM9\375DAL=46X1GO[HPLTDL9!^8"1NHZ<4
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MNJFJ?\@ZZ_ZY/_Z": #2_P#D'6O_ %R3_P!!%6ZJ:7_R#K7_ *Y)_P"@BK=
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M )!UU_UR?_T$T &E_P#(.M?^N2?^@BK=5-+_ .0=:_\ 7)/_ $$5;H ****
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M\=*8.E/'2OZ86[/RT6BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
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M6K4O6JLG6O)J[G=#8IOUKWSX4?\ (CZ?_P "_P#0C7@;]:]\^%'_ "(^G_\
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M "BBB@ HHHH **** "BBB@ IK=*=36Z4GL!Y)XS_ .1IO/HO\JH1=JO^,_\
MD:;SZ+_*J$745^,XO_?*O^)GVU'^!#T1=BZ"KT74_2J,705?A^\?I7;0,JFQ
M=3H?I4<O>I$Z&HYAAJ])_"<BW*<IY)JH]6Y?O'TJH_%>95.N!5E^^?I51^<F
MK<OWC]*IOWKR*NQVP*<OW?PJJ_6K4OW?PJJ_6O)J]3LIE27K563K5J7K563K
M7DU=SMAL4WZU[Y\*/^1'T_\ X%_Z$:\#?K7OGPH_Y$?3_P#@7_H1KZ[@G_D8
MS_PO\T>)GW^[1_Q?YG7T445^X'P84444 %%%%)@<[XZ_Y%F[_P" _P Z\NM^
MOXUZCXZ_Y%F[_P" _P Z\NM^OXU^9\2?[['_  K]3ZC*OX+]?\B[!]U:O0_=
M_"J,'W5J]#]W\*\JB=DR_#]P5-)T/TJ&'[@J:3H?I7L4_A9PO=%1R>?I562K
M<GW3522N.J=$"F_0U6EZ59?H:K2]*\BH=M,I2U5EZFK4M59>IKR:AV0*<O4_
MC527[IJW+U/XU4E^Z:\BJ=L"K+]T_6M[X9_\CWIW_ __ $&L&7I^-;WPS'_%
M=:=_P/\ ]!IY;_O]#_$OS)QG^ZU/1GT&.E/'2F#I3QTK^F%NS\M%HHHI@%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !535/^0==?
M]<G_ /035NJFJ?\ (.NO^N3_ /H)H -+_P"0=:_]<D_]!%6ZJ:7_ ,@ZU_ZY
M)_Z"*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4UNE.IK=*3V \D\9_\C3>?1?Y50CZK6AXS_Y&F\_X#_*L^+G%?C.+
M_P!\J_XF?;4?X$/1%V+H*OP_>/TJA%T%7HCAC^%=M RJ;%Y/NGZ4RX^\*?$<
MJ:CGY->D]CD6Y3EZM523J:MR]3520UYE4ZX%63[Q_&J;]ZN/R2?453DXKR*F
MQVP*<OW?PJJ_6K4O0>XJJ_6O)J]3L@5)>M59.M6I>M59.M>35W.V&Q3?K7OG
MPH_Y$?3_ /@7_H1KP-^M>^?"C_D1]/\ ^!?^A&OKN"?^1C/_  O\T>)GW^[1
M_P 7^9U]%%%?N!\&%%%% !11128'.^.O^19N_P#@/\Z\NM^OXUZCXZ_Y%F[_
M . _SKRZWZ_C7YGQ)_OL?\*_4^HRK^"_7_(NP?=6KT/W?PJC!T7Z9J]#]S\*
M\JB=DR_#]P5-)T/TJ"'[@J>3H?I7L4_A9PO=%63[IJI)5N3H:J25QU=SH@4W
MZ&JTO2K4G JI*W%>15.V!3EJK+U-6Y>M5)>IKR:AV0*<O4_C527[IJW+U/XU
M4E^Z:\BJ=L"K)_6M_P"&G_(\Z;_P/_T&L"3^M;_PT_Y'G3?^!_\ H-/+?^1A
M0_Q+\R<7_NU3T9]!#I3QTI@Z4\=*_IA;L_+1:***8!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 54U3_ )!UU_UR?_T$U;JIJG_(
M.NO^N3_^@F@ TO\ Y!UK_P!<D_\ 015NJFE_\@ZU_P"N2?\ H(JW0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36Z4ZF/
MT-)[ >2^,_\ D:;SZ+_*J$(J_P"-/^1IO/HO\JH1]17XSB_]\J_XF?;T?X$/
M1%V+H*O1#+'Z"J,705?A^\?I7;0,:FQ=C4;:CFJ1.E1S?UKT7\)RK<IS=352
M2K<V-QJI)]>:\VJ=4"K+PQ^E4Y.]7)#EC]*IOSFO(JG;$IR]!["JK]:M2_=_
M"JK]:\FKU.RF5)>M59.M6I:J/U->15W.V&Q4?K7OGPH_Y$?3_P#@7_H1KP)^
M]>^?"AA_P@VGY('WO_0C7V'!6F8S_P +_-'B9[_NT?\ %^C.PHI,TM?MY\&%
M%%% !11128'.^.O^19N_^ _SKRZWZ_C7J/CK_D6+O\/YUY=;_P!:_-.)/]]C
M_A7YGU&5_P %^O\ D78/NK5Z'[OX51@^ZM7H?N_A7E43LF7X?N"II.A^E0P_
M=J>3H:]>G\+.&6Z*DG>JDE6Y.A]:J25QU3H@4WY%591Q5M^AJK+TKR:IVP*4
MO6JLO4U:EJM-WKR*AV0*4O4_C527[IJW+W_&JDOW37D53M@5)<X_&N@^&G_(
M\Z;_ ,#_ /0:P).GXUO?#/\ Y'C3CG^__P"@U66?\C"A_B7YDXO_ ':IZ,^@
MQTIXZ4Q>:>*_I?N?EHM%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *J:I_R#KK_KD_\ Z":MU4U3_D'77_7)_P#T$T &E_\
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MF44 /HIE% #Z*910 ^BF44 /JIJG_(.NO^N3_P#H)JQ5;4_^0==<_P#+)_\
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M #]U&ZF;C[4;C[4 /W4;J9N/M1N/M0 _=1NIFX^U&X^U #]U&ZF;C[4;C[4
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M7/?$#PYX,\1_L@3:)\)]3G\86WA[5K;4-=GMX)5NKMBVZ>4AE4EB,GCH![4
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MFY/M1D^U #LGUHR?6FY/M1D^U #LGUJM?D_8KK_KDW_H)J?)]J@OCFRN>/\
MED__ *": &V3C[%;=?\ 5(/_ !T5-O\ 8U6LCFRMO^N:?RJ?- #M_L:-_L:;
MFC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC-
M#M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L
M:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L
M:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC
M- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M
M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-
M_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;
MFC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC-
M#M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L
M:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:-_L:;FC- #M_L:AOF
M'V&XZ_ZMOY5)FHKT_P"A3C_IFW\C0 RR_P"/*V_ZY+_(5-QZ"J]G_P >EO\
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MV."O2L/6O$L]_P##Y[6>22'4[&=(IL,58KV;UYKQL5Q%2PM:I1E"_+!23O\
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M;/EP@Y(SC/KCO5^QT?[+/87M_HEY+X.6^NY(M+,#2-"'4")VBZ[<[\#L6Z4
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MTF\EOKJ>PNKEF9[3 (D[@M]36NOQM\(/KUQHR:A++J$!:.1([5V3S53S&A#
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MH:,'T- %:^TRTU*YL;BYC$TUC+YUNY)!C?:5R/P)JWNYSNY]>]-P?0T8/H:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"FR_ZB7_ '&_E110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (L M # 2(  A$! Q$!_\0
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M?QKXD%U_8VEJK7'V2+S)<%@HVKD9Y-%P.MV7?_/:+_O@T;;O_GM%_P!\&HM
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M^)_BKX;^*OB#J.C^$M2$$EW:16T6@Z<X*@P2*WSR#D?,.NX5[MX-U>X\1?\
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M FT'KS1C I:* $Q1BEHH 3%(5S3J* &[!2[:6B@!NT"EQ2T4 )BD"@=*=10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8YXDE_,5\;]?7\S/NEA%_*ON1P^]_P#GK)_WV:-SD'YY,>I<UW'_  @]B?\
MEI+^8KB_B+IJ: UG#;2/LG5F;=UX/%;4<4JM1039G5HQI1<G%?<8^H:X8B8X
M)7=^A8.<"OO3]A=GE^!L3N[NYOIB2YR>HK\[!@X[>U?HG^PH,? J'_K^F_F*
M_1>&%RXMIN^A^8\5M3P<6EU/H@#I4E-'WC3J_5#\E"BBB@ HHHH **** "BB
MB@ I,XI:Y'XC?$2W^'6BQW\NE:MKD\TRV]OIVBVAN;F>0@G"J,   $DD@8%
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MQ6^%.N:Q\2_$<URNLZ9X8URTTY?#]S8^"CJ]QIT$<:J460_/9R(Z[L8'KS2
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MR0AC<30-AHT; 0'&21T[T >VT4U3D9IU !1110 4444 %%%% !1110 4444
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MP<\#>$VU%M'\'Z)IAU&(V]Z+6R1!<1DDE'P/F7D\&@#YX^-/QZU[2[KXM_\
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M<TT(+211SJS1@=20#D"G:/KNG^(],AU'2[V'4+"8'R[BW?<CX.#@CW!KX+^
M7@2\\5V7AO5M!\%3>'[G1]=UB^U?QM(\<:ZC;>;.A@7:Q>;=D#$@ 7;D<UT/
MP4\3>)_A=H7P=U!_&3WOASQ3)J&G3Z%/:(+2Q6-)YTFB*CS"R^7ALD[@3@"F
M!]P;L=^O2EWX)['WZ5\':)^T/XWM/$6JFV\2ZYJ>F:UX-U7Q#8W>N65I#"DL
M 4PS64<3%UA.\Y2;G 7OFNX%S\3'T[X1Z-)\5+X7WCQI+W5-3CL8 ]NOV-'\
MFS7;B-0^2"VX\G- 'UT&.<'TSF@.2>HZ5\7^ OB/\1]+M/ WB;6_'\VN6S^+
MY/!=SIKV4,<-W;K))&+J4J-WVGY 25(7MMK.\-?M'>++3XF66H6FLZSXGT#7
M],UF]@AU2UMK?3I39Q,\9LDC8SH-R%6\WDC)ZFD!]P+)TYR:42$CGBOC#7?B
M1XY^'WP'M?&EM\2)O&VK>++?3Y/L:V]MNTDW<B*\UH!M&V,2,H$I(RJ[CUJ[
MI7Q%^*7A"RL(=:O-:M-#;Q9I5G!K'B<67VVX@G<)-!(("4"[BH5N#\V* /KZ
M2ZCA ,DBQ D %V &3T'/>FQWT4L\D*31M-& 7B# LF>F1U&:^'_CKXJUSXDC
MQ_8IXYO=+TGPWX^T.RM9M)$'[A)/*W*S,IY61MW/? .1Q6]XT^(GB'P#XJ\?
M:58^(((+E]0\.Z"?%%S:Q?:+6.Y1_,NI&50'8;0%W?*"P^E 'V09,#.>U9Y\
M1:>-=71/ML']KM;&\%EO'FF ,$,FW^[N8#/J:^6/BKXH\0^!M%L/!VG_ !0\
M2^)M>*W=^EWH5G8MJ'DQ+D_:))2L(C4G!"C><CBL/P=XV\8_$CQ!X<\2Z)=6
M*^.=1^$EU+;75UA(#<?VA N]L<#.,^F3Z4P/M(3=.]2UXA^RWXMG\1^$-9L=
M3UKQ#K'B'2=2-KJD7B6.W6YLYC'&_E*UN/+>/#;E8$GYN:]N%(!:3UI:3UH
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M]*\R^,'-UI/'_+*3_P!"%>DECZC'<UYM\7_^/K2^>?+<8].17HX#2O$X,;_
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M$@4!").&R.!D\UZK\/?$?B;7M+N&\5^%QX7U2&79]GBO5NX9$(R'210,^A!
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MACQ#;1C,DS>BCO7P?\7OC;XD^+E^RWHFLM&1LPZ9$&"#T+_WC7T5^UDI;5M
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MN-.NY%=L3#/\(3/'7<,5V]A\=O &H>/Y/!%MXMTRX\5H74Z6DW[PLH!91V+
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M,;>Y2%PQAD&,HV.A&1Q[T :5%,#DGH:!)['\J 'TGK2T@[T 5+/[]S_UV/\
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M]$N&NM-TB\=?L]LY/; R:Z76/AA)X@\#:KX8U+Q/JMU#J-P99;V389EB+9,
MXQL[5XV8X[ 5L92Q&&J**@DG[OGKI;HO^ ?1X'!XREAJM&O!OF;:U^[\3S/X
M5Z+XC\0_".ZU75?'VJZ/I=W?/=1ZA<.IN4L4RJX8\(6/)_*NA^!UUX@O_A7K
M5QKMY=ZE;/<7 TJ]OE(GFM0#M=OK72?$3X/:?\1?!6E^&3J5YH6GZ>Z-'_9X
M4EPB[55P>"._UJSX>\%77@CPOK-O<>)]3\3"2W/EOJ00>0 I&$"CH?Z5GB\Q
MPV+PM2TDI2G=1Y=4D^]NJWU+H8+$8>O"\7RQC9OFT;?EY'E Z <U[)^R)_R7
M_P -_P#;3_T$UXV,\>F*]C_9#_Y+_P"&_P#MI_Z#7HY:T\32TZH\;-=,'5]&
M?IP.M/'2FXIPZ5^W'X2A:0]J6D/:@8C=14-U_P >\O\ N'^53'K4-U_Q[R_[
MAJ)NT'Z,I?$C\_\ 6/\ D-ZC_P!?,O\ Z&:JKT'TJWK'_(:U'_KYE_\ 0S51
M.@^E?R97_C3]7^9_6V%_@0]%^0H[TM(.]+6!UB'I7FGQ?_X^])_ZY/\ ^A"O
M2STKS/XP?\?>D_\ 7)__ $(5Z.7_ .\1/.QW\%GGH^\M?HI^PI_R0J'_ *_9
MOZ5^=>/F%?HG^PI_R0N'_K^F_I7ZUPW_ +Y;R/R3BG_<X^J/HH=:=35SFG5^
MI'Y0%%%% !1110 4444 %%%% "&J.H:=9ZK;M;WMI#>V['F*XC612?H1BKQK
MQC]H[Q5K>EP>"?#.AZ@=$F\7Z]'H\^K1@&6T@,;R.8L\"1@FT'MG(YQ0!ZG%
MX?TNVTUM,ATVSAT]\A[1+=%A;/7* 8.?I4,?A70[?39-.CTC3X["4[I+5;2,
M1.?5DQ@_E7C/B:/6?V>M*TW2O"NK:EXNUGQ3JD.F:7;^+KYIX+.4JS/-)* )
M"@1"=@.2<8Q7-ZO^TGX_\.WMYX2N]"\.WGCNV\2:?HAE@EFCTZ6"\C:2*<!B
M74J$8,A)SC@\TP/I*70]-G%HLEA:2+9D-:J\"D0$< IQ\I'M1;:'IUIJ$]_#
M86L.H3KMFNHX%660>C,!D]NIKYBB_:7^)6F-J-QK/AWPR-*\-^*(?#6MS6D\
MV^[:5D'GVJL?W:H)%RDFXL<X(JYJ?[2?C_3I==\0GPYH#>"-#\4#P]=H)Y3J
M%Q&TRQ"YC.=B;2ZDHP).#@CBD!]&ZCH%AJ6F2V,D"QV[HZ#R5"-'N!!9"/NM
M@GD<\U!X7\)Z1X.\-6/A_1[..STFRA\B&V R G<'/7))SGKFOG^]_:IU'3/C
MQHG@V5O#=_IVL:Q)HJ6>FO/+?6C+&SI/+-CR64[#NC7#+N R2#5#P3^TA\1_
M$%OX-UK5?#_AFRT'Q;>W>CV%O!-,UW#=IO$$DC$[6BD,9RH 901R: /I72_#
MFCZ%)++IVE66GR3*%=[2V2)F'7!*@9J6Z\.Z9J%H+:YTZTN;4-YBPS6Z.BOU
MW!2,9Y/->)_#;]HR_P#B;XD\"Z+8:1:PWM[I]Y?^)HY&?.F>2Y@")ZLTXQAO
MX>:]\C^X.OXTP*TNE6<Z2K):02+* LBM$I#@= W'('O3DTVUC8,MM"C!S("L
M8!#'JWU]ZM44@,F^\+:/J1C^UZ38W1C<RH9[5'VN>K#(X)]>M37>@Z=J-S;7
M5W86MU=6QS!-/ KO$<Y^5B,K^%:%% %5M.MG\[=;PMYX ES&#Y@'0-Z_C3;[
M2;/4K%K.[M8+JT8!3;SQ*\9 Z J1BKE% %&WT:QM8X8X+*V@2$[HUCA50AQC
M*@#CCCBF7F@:=J-K);75A:75M*V^2&:!71V_O$$8)]ZT:* (+:TAM%*0Q1Q*
M3DB-0HSZX%3T44 %%%% !2&EHH ^>/VHKS0]/\>_!FY\1R:?!I*:]-YTNI[/
M(7_1VQDO\H]LUXG\0=8^Q>(OB-J7POU:X\.^%M0U3PY8-JVA +;O>O<[;@VX
MQL8^4RJ[+\N2.XK[AUS0-,\0VRV^JZ;9ZG;JV[RKVW69 ?7# BF6^A:;9:;%
MI\&G6D&GPD&.UCMT6%"#D%4 P.>>* .6\(:GX:\':O;_  VM-=NM0UZTL3J(
MMM3N)+BZ:W,A'F-*P^8;CCKFOD?]H7P]K.J^._CQ<6=CHM]H$&FZ:=:BGT\R
MZHMJ4(FELYNB.D>YP"IY48P<5]TBSM1=FZ\F+[5L\KSP@\S;UV[NN/:E&GVS
MO.YMH=TXVRML&9!C&&XY'UH ^#/'WC/Q9JOQ'U'3="\00Z7IVFZ7I9\(WFJ>
M+SH\4L+0JQG>'RG^U[F&ULL,<C'>LSX_^*%\2>$OBM)XP\<:AIWC'3=0L-/L
MO#%G<.MK+;%H&#+!@^9'(Q=C+V '(K[TU'P/X?U<VOV_0=+OOLJ[+?[391R>
M2.N$RORCV%2W/A/1KN_%]/I&GS7@B\C[1):HTGE_W-Q&=O XZ<4 ?!WQ^\2V
MFO:;\59/$OC;5=*\6:5KMKIND^%H9V$$E@&A:-OLV")!)ND+2]MO48KT;6/%
M7BV?XLW?P/CUK4DN=2UBW\01:E'*PEA\/O'F:))/]F:)H_4"5<5]77'A;2+O
M4AJ,^E6$^H"+R1=R6J-+Y?\ =WD9Q[9Q7.6GPLL8?BY??$"6ZEN=2FTF+1[:
MV=%$=I$LC.Y0@9)=BN<GC8,4 >"_M+:);_"7PEX.M]$UQ=(\(Z''<27?A6UU
MPZ7J&J#@B6&<!FED5MQ,9'[PORP-=)^TWKNGS_!CP+K5P7T_37US2+HMJAV/
M"A8$&4GHP'7/>O=]5\*:/KTUO-J>DV&HS6S;H9+RV29HCZH6!V_A5C4M%LM:
MM&M-0L[:_M6/S0742R(?3*L"* /E']JSXSZ3J\%E8^&O$,ETK:;>7J7^G^)U
MTBQ1XP5&+A(Y#/,&QB 8R.37G4?B/3/%GB/0=:\;>.]2\)7MY\,;6]:]M+QK
M)Y[H-G)? W-D9\ON>U?<(^'OAD64-G_PC>C_ &*&0S16_P!@B\N-SU=5VX!]
MQS5C4/".C:K'&E[I&GWL<>-B7-I&X3!R,9!QB@#XNC\;WWC*WL8?BKX\UCP*
M+?P39ZEI3VMX=,;4+IU;SIV/_+20$1?NNV[IS6_\'-:\8?$#XA6>H^.=<\16
M,^C^!=)URYT2R<P))>MYI>1X1U9@HS'G&>"*^MM6\+:1X@,!U32K'4C;MN@^
MV6R2^4>.5W XZ#IZ5;%A"MTURL42W#*$:8( [*.@+=2,GI0!^>_@?XAZI\1_
M&VHZ#;ZIJ]QHOB_P3J]_/:R^)3?7;31E/*+0K$HLI?G(,:EA@X[5N> ;[1--
M^'/P3\-R^/M4T7X?:I!=OJVK1:LT;C4(47RK)KG.8%!+GR^-Q7%?;VG>$]&T
M>YDN=/TC3[&YD+%Y;:U2-V)ZY8#)S@9J*3P/H$^FR:=)H6E/I\DOG26C649B
M=\YWE-N"WOC-,#Y \'ZCXE\=:[\,/"MSXP\0CPO<Z[XBMK;4[>Z,5SJVFV\*
MM;-)+C+#<3AQR0N<UB>/_'GB[2;;7-*L;^<Z'+\3KK2=1NY=6_LOR+*.R1XH
MVO1&QA#2@ L5)8G&>:^Z8]&LX?LOEV=M&;12EN5B4>0",$)Q\HQQ@5%=>'=-
MU"TN;2ZTZSN;6Z;?<0S6Z.DS<<NI&&/ Y/I2 ^(/$6L>,--^$VA:AKGCK2I]
M(TW5;V==%TWQIMO=2LE1#&JZB(P998F+@Q[/G#)D@U]J>"]3@UOPIHNH6T=W
M!!=6<4J1WP(G52H($@/.[UJ)_ASX6>"U@/AK1C!:N7@B.GP[8F)!)0;<*20.
M1Z"N@$>.F,4 /STH%'I0* *EG]^Y_P"NQ_D*MK]T54L_OW/_ %V/\A5M?NBF
M]R8E.]_X^+3_ *Z_TJUZU5O?^/BT_P"NO]*M>M#V'U'T444AA1110 4444 %
M(>E+3&Z>E,#YJ_:QYU70?]QZ\$!VKQQS7O?[6)_XFN@_]<WKP,CY>N!UQ7\W
M\5_\C>K\OR/Z0X2_Y%%'Y_F*!GFC!8\FC&1U-&/<U\B?8: 5')QS[51ULDZ)
MJ'_7!_Y&KV#_ 'C5'6V T341Z6[\?A6M/XXLSJ6<'8\ 7E?;%>R?LB_\E^\-
M\_\ /3_T&O+_  QX7U7QGK-MI&AV$NHZC.=J00C)'J2?X1[FOOK]FW]D^S^$
M\D7B'7IAJ/BMDPJQG$%D#U5/[S>K&OUO)<#6Q%>%2,?=1^3Y[C\/AL/.C-^]
M)62/HX'.:>.E,B7C&<X]*DK]=/QI!2'M2T4#&GK4-U_Q[R_[A_E4I(S4%TQ$
M$F/[I_E6=3X'Z,<=9(^ M8/_ !/-1ST^TR_^AFJBC&/I5G6!G6K_  ?^7F7_
M -#-5=OO7\G8A-5IW[O\S^ML*_W$/1?D.'>EIFW_ &J-O^U6!UW''I7F?Q?.
M;O2?^N3_ /H0KTIN!U)->:?%_ N-+;@ 1/U]<BO1P'^\1//QS_<L\_ RW6OT
M2_83.?@3"<?\O\_\Q7R5\#/V:?$GQJNH[I5?2?#2OB74Y4Y?'58E/WC[]*_1
M3X<?#O1OA?X6M- T* V]A!D_,Q9G8]68]R:_:.',%5IU7B)JT6C\2XFQ]&I3
M6%@[R3NSK .]+2*,"EK]#/SH**** "BBB@ HHHH **** $-<G\1/AUH?Q2\.
MR:)K]N\UKYB3PRP2&.>VF0Y26)QRCJ>0?YUUAZUY;\=?B5JO@'2M"T[PU:6]
MWXK\3:DFCZ5]N)%M#*RL[2RXY*HB,VT?>( XH H77[,_AS4O"]SHVJ:YXGUJ
M>2YBO(-9OM59]0LIH_N/!*%'ED9/;G)SFK.E_LV>$=/@L!+)JNHZA:ZS#K[Z
MI?WIEN[J[B4I&TSX&]55B N  *\C\1_%KQ3H'@[XEV(^*_A_Q9KVBZ2;C9IF
MF_8+[3[A9%5CY>]U>/G[QY!XKNO$G[2\?PX;PQ:ZWH&H7.GW45C%?>(!/ B0
M23JH#^46$DB[B,E%(&?:@#K=2_9Z\(:II_B*RN(KW[/K^MQZ_>A;D@M=(4*E
M3_"O[M?E^M>:^!/V4;6X\2^(=:\7RZF4G\42ZW;:)!J9.G7.&#0330@8+@@'
M&<94<5UEE^U#HEWXYG\'2:-J=IXEL[N=+^QG50;*QC4L-0<]/(<8VD<DG&,U
MF^%_VK[#6];T6/4O".M^'O#GB*.>3P_X@O#&T.I^6AE"K&I+QEXE9U#@9 QU
MI@:MC^RAX,L/%^GZ_#>:Z!IVL2:]9:2=1/V"WO) XDD2''\7F,2"3R:V[#]G
M[PCI6B^$-+ACO!:>%=2.JZ:&N266<EB2Y_B'SMQ7#V?[7EI+\*[KQ_<^#-7M
M]#-U;6NGI%<03SWQG?8F$1B8R"5RKX(S5:X_;!%C-K$-_P##CQ+:2^'KJ&#Q
M""T++I<<V##*6#8E#*P;:F2HZT =!\!?@U<?#_QW\6/%-]8QV%SXJU]KJV@2
M82!;9%"JP(^Z9&RY7UKVH/C@C%?+'Q+_ &EO%WA"YG'A?1[CQ<R>.[3P]);>
M1!;"."15/E(YD^=GSA9#C!ZC%-G_ &D_$'@7XJ?$[^VO#VMZQX;TB'2;F:"V
M:';HD4L!,I))!D.[DA23QQ2 ^JS)@4!\\5\T^%OVA)[3XX>.?"DTUWXGOI]3
MLUT70[/9YEO9M C37+9QMA4MDLQY) ')JE\)/C9KL_\ 94&N:W<WDU]XN\26
M"J;2.3?;VDKF.(OD>6$4  @-GO0!]2*V[.*=7SYX _:^TKQBNBWU_P"%=:\,
M>&M;TVXU33=<U+RS%/' ADF!56+)A 6!(PPZ5H?"O]J?2?B;XLL-#?1;K0GU
M>TDOM$FNKNWF_M*%,%B$C=FC.TJV' X/K0![B7PV*-_YU\K_ !K^,WCGPY\1
MO'=KHWC/PYX:TKPIH-KJ\.G:OIXE?4I'+EHC+Y@90=@4;5)!85WGPC^,FM^/
M_B%XFT[5;&/2M-L=!TG58;-HR+BWDN8G>5)#GG!4 <#O0![4)0?8^E.4Y%?/
M7PV\8?%3XNP+XXTG5-$T;PM+J,D%EX9N[ R2W%G'*8VEDN@^4D8!F550@?*"
M>37T)&<K^- #Z*** "BBB@ I"<"EI#0!Y#\9?$^KZ%\2/A+9:??RVMIJFLRV
M]["A 6>,0L0K>O/-<=K_ (]^(FB_M2ZC8I=:*W@*Q\.#4[FSD:<W(B5SO=%'
MR^:<8&?EQ[UZ?\5_@_IOQ6_L.6\U?6]"O=%NFN[*_P!"NE@GC<J5.2R,",$\
M8K(M_P!GS24\1:+KMQXC\2:AJFGV,NF7$UW>HW]J6SMN,=V!&!( 2<;=I%,#
MQ/0?B9X_^(WQ7^ WB+6M*TW1_"?B*>_OM.73+R4S"%K&5HH[M&^5W*E6^7A2
M#[5]@1\'&.?45X?X2_9(\'^#=<T#4[;5O$UT/#HN(]%LKS4_,MM,BFC>-XH4
M"C"!7XW$E=JX/%>G?#WP;:?#SP?I7ARQN[^_M-.B\F.XU2X-Q<R#).9)#RQY
MZT@.FHIJG-+0 M%)FF[^_P"% #Z*9OYZ=Z=0 M%)FF!]Q [4 244G04T/ZT
M/HI,TM !1110 4444 %)2TGK0!4L_OW/_78_R%6U^Z*J6?W[G_KL?Y"K:_=%
M-[DQ*=[_ ,?%I_UU_I5KUJK>_P#'Q:?]=?Z5:]:'L/J/HHHI#"BBB@ HHHH
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M%NLMFJ^3:!9XV,D[$C:F >1GI7M9K/U74['0[&:^U*]M]/L8@#+<W<RQ1IR
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MRR;?E"YP ,"H?"O['/@CPA)>FQO-?=7TZYTK34N-1+C1+6<DRQV7&8LYZ\D
M  U[S10!\^:+^QIX<T3X:ZA\/X?%OC!O!]W8'3AI9U)52&(MD["J ACSDDG.
M3FN^^$_P>B^$EB=/LO$>OZSIR0QV]M9ZO<I)%:1H,*L2JJ[> !7H;.!^%)O
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MSZ'UZ4 /HI@?V/Y4I8#B@!U%-W#\?2E% "T444 %%%% !1110 4444 %%%%
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MM<1\/]5^(OBG4?@[9W?Q5UG;\0]"N]0U1XH80UNT,:.GV0[?W1._#$[L@>]
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MHZ?XB<Q)/8.B% (HPNP*R,RL"/FW<T ;WP8^*^H_$-/$NE>(-&CT/Q5X9O\
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M!U%,,BCO2[Q0 ZBF[AZT;@.] #J*0L!1N% "T4FX8ZT%@* %HIGF+CK2AP:
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M4WN3$IWO_'Q:?]=?Z5:]:JWO_'Q:?]=?Z5:]:'L/J/HHHI#"BBDH 6D(IID
MICR4 .8C!-<UXT^'?A;XB645MXI\.:5XCMHFWQQ:I:).J'U4,#BMYI<<]J8;
M@<4 5="\/:7X6TJVTO1=.M=*TRV79!9V<*Q11CT55  K0$@V]NF*I/= =ZA:
M\&>#GUI: :1<9ZTHD7'O63]L ZL!0+]=W)_*CT V PHW#ZUE)>@ Y)J9;D$
MYH T<_2E&":J1W Z9J59,BFM0)'0DC'\JQ])\':+H6K:KJNG:/96.IZK(LNH
M7EO J2W;JH56E8#+D 8&:V Y-/6@!%3CFEVTZB@!NT4NVEHH ;@=Z#MH;M3=
MP'M0 [:.U&!GM3 P!YH#8/3% #F7CUK'O/"ND:CKMAK=UI5I<ZQ8(\=IJ$L*
MM/ K_?5'/*@]P.M;"R;NF*<30@(BG!X_2LQ_"FCR>(XM??2K1]<CMS:QZD8%
M-PD).3&'QD+GG%:Y<#%&[&1TH 4# I:8T@&/RI0X(ZT .HI P/>EH **;OHW
MB@!U%(&![TM !1110 4444 %%%% !1110 4@I"U4M1U>ST:U>ZOKN"RMP0#+
M<2!%!^IH6NPFTMR]D4M<T?B3X4_Z&32<_P#7Y'_C0/B5X3'_ #,NE?\ @9'_
M (UI[.?9D>TAW1TM)C\JYO\ X67X3_Z&72O_  ,C_P :/^%E^$_^AETK_P #
M$_QH]G/L'M(?S(Z3%&T5S7_"S/"7_0RZ5_X&)_C1_P +,\)?]#+I7_@8G^-'
MLY]F'M(=T=)M%!4&N;_X69X2_P"AETK_ ,#$_P :/^%F>$O^AETK_P #$_QH
M]G/LP]I#NCI-N*4*!7-?\++\)_\ 0RZ3_P"!B?XTO_"R_"?_ $,NE?\ @8G^
M-+V<_P"5A[2'\R.CVTH %<U_PLOPG_T,ND_^!D?^-'_"R_"?_0RZ3_X&)_C3
M]G/L'M(?S(Z7;2%>XZUSG_"R_"?_ $,NE?\ @8G^-)_PLOPG_P!#+I/_ (&)
M_C3]G/L'M(?S(W5M(A.9A#&LIZR!!N/XU,J_A7.?\++\)_\ 0RZ5_P"!<?\
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M$\)!>_)O\#Q)YU6;]U)'VY9?M?\ A'4KL6]O::FQ*EB6B X'XULP_M+^$Y&
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M8KN_VJ?B+X[\'> /!EQ\/9[:#Q-K7B"SL5BNH5DCG1HI9&A^8<%]@4,.1FJ
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MMZO<Y?\ X5_:?\]Y/^^12'X?6G_/Q(/^ BNIY]_RHY]_RH^KTNP>WJ=SEO\
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M6 11QTI<4M% "8HQ2T4 )@>E&!Z4M% "8%&!2T4 )BC ]*6B@ HHHH ****
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M_P#S]7W_ '\_^M1_PROX7!_X^;[_ +^?_6KVH=*6C_5_*_\ GP@_M[-/^?\
M+[SQ/_AECPQSFZO?^_E2:?\ LO>#+75[*_O+>?5&LG,D,%TVZ(,>Y7N1[U[1
M28K2GD>749*<**31E5SK,*T7"I6DT_,@B18@J*-J@8"@<"I@N>M+BEKW=M#Q
M0HHHH *3UI:3UH J6?W[G_KL?Y"K:_=%5+/[]S_UV/\ (5;7[HIO<F)2O/\
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M9PT9/RRKW5O:OLWP#XWLO&F@VNJ6+?+(,21=XG[J1VQ7PR#_ #KN_@]\0Y?
M'BB/SI&&DW;"*Y0]$'9Q]*^5SS*HXRDZU->_$^ER7,WA*BI5'[DOP/N2UN-R
MCC)K0C?*G^M<UIUV)55U</&V&5EY# C((]L5N02YK\G::T9^J)IJZ+ZMFAF"
MU&K#:/6H-1G-M9SRKC,<;.,]R!FHE)13;*2NTBV'YQ0'!KY1/[4GBEI@OV#3
M%!?;C#^N.N:ZS]J[XEZOX#\ ^";W3O$5UX5CU;Q)9:?J&IV%DMW/%;R1R,WE
MQ%7R257HI/6O(R_-L+F<IQP[OR[GK8_*L5EJ@\3&W-JM3Z"W4N17A/P[^+2Z
M?K7@#PJ=;U3QTOBN/4KF+Q%J5JME+$+8*2C0"-#CYL [1T[UDS?M6ZCJ%EX-
MC\/^!)]6UCQ1J>HZ9;63ZA'"D+6BLQDDD(/R,%/0$BO:/(/HS(]:3=^=?.6M
M?M3ZWI4FJZU%X!DN_ &@WR:9K6O+J*++#<919C!;E<RQ(TBC?D;L-@<4GB3]
MJS6=%UGQH]G\/KC4?"G@O58[#7=:&HQHRQ/%%)YT$6,R%%E!9,C Q@G-(#Z/
M)H!%?,'AG]MO2/$GQ T[3(],LD\+ZIJC:-I^I+K$3W[SKN'F26(^>.$E<!B<
M\J<<U].)D'UH DHHHH **** "BBB@ HHHH ***BDF6)@'=4+' #'&: ):2HF
MF5'",ZJS?=4D GZ4?:$\WR]Z[\9V9^;'KB@"7-+5=;V%WVK-&Y] X)_*IL\#
MM0 ,U<GXV^)7AKX=6*WOB35[?2H9&VH922S_ $4<G\JZ>1B%)SV-?G%\58F\
M8^/-7O-9N+B^GCN)(XO,E.V- W"J.@Z5[65Y;+,:K@G:QXN:9C_9U-2M>Y]A
M']K+X4CC_A+K?_OS+_\ $TH_:S^%0'_(W6__ 'XD_P#B:^$#X/TH\_9VSZ!S
MBC_A#M*_YX-_WV:^L_U7A_,SY?\ UEJ_RH^[_P#AK3X5?]#=;_\ ?B3_ .)H
M_P"&M/A5_P!#=;_]^)/_ (FOA#_A#M*_YX-_WU1_PAVE?\\&_P"^J?\ JO#^
M9B_UEK?RH^[_ /AK3X5?]#=;_P#?B3_XFC_AK3X5?]#=;_\ ?B3_ .)KX/\
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M^9/_ (FC_AJ3X9#_ )F>'_OS)_\ $U\5CPCI7_/!O^^S2_\ "(Z5_P \&/\
MVT-?'?Z]8C_GVC['_4/"_P#/R7X'VG_PU)\,O^AGA_[\R?\ Q-'_  U)\,?^
MAGA_[\R?_$U\6'PEI7:!O^_AH_X1'2O^?=O^_AH_UZQ'_/M!_J'A?^?LOP/M
M/_AJ3X9?]#/#_P!^9/\ XFE_X:E^&7_0T0_]^9/_ (FOBO\ X1'2O^>!_P"^
MS1_PB.D_\^Y_[^&G_KSB/^?:#_4/"_\ /R7X'VG_ ,-2?#'_ *&>#_OS)_\
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M#=01FG>!_P!F+2O Y\!/'KVI:A-X1O+^^BEN@A:[DNT99/,(' &XD8KV[%!
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M\$?] 2'\S1_J+C?YT+_7W!_\^I?@?%^RAA@<5]H?\*)\$?\ 0$A_6D/P(\$
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M* # HVCCVI:* $(S112T -(I *1F/TKR_P"+'[1'A#X//%;ZQ>M<:C+RMA:
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M S5_^_2_XT?V?BO^?;^X/[1PG_/Q'TQL'K1M/K7S/_PWUX$_Z!FK_P#?I?\
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M$MQI;N$AO%W+DX_>+_\ 6K['A3%QPN91YWI+0^+XMPDL7ED^5:QU/J.Q;*J
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MU*,5<QQX0T15_P"05:$?]<5_PIW_  B.BG_F$VG_ 'Y7_"M;&.U%<7U7#_\
M/M?<CL5>K_._O9D?\(AHG_0*M/\ OR/\*7_A$-$_Z!5K_P!^1_A6M_GK1^7Y
MT?5:'_/M?<A^WJ_SO[V9/_"(:)_T"K7_ +\C_"C_ (1#1/\ H%6O_?D?X5K?
ME^='Y?G1]5P__/M?<@]O5_G?WLR/^$0T3_H%6G_?D?X4?\(AHG_0*M/^_*_X
M5K_YZT<8Y-+ZKA_^?:^Y![>K_._O9D?\(AHG_0*M?^_*_P"%+_PB6C!@1I=G
MD=,P+_A6KGID\TX#FFL+0W5-?<A>WJO>;^]C5A"J% P!P !TIRC' %/I,<UT
MVM8Q%HHHI@%%%% !1110 4444 %%%% !1110 4GK2TGK0!4L_OW/_78_R%6U
M^Z*J6?W[G_KL?Y"K:_=%-[DQ*&H_>MO>0_\ H)K$OH_;&.36WJ S+:#OYO\
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M?^A.B_\  AO_ (FO+@/;]*7)_P BOP__ %OS/^?\C]O_ -3LJ_D_%_YGJ/\
MPW7J/_0G1_\ @0W_ ,31_P -UZC_ -"?'_X$-_\ $UY=S[?E1S[?E1_KAF?\
M_P"1?^I^5?R?B_\ ,]1_X;KU'_H3X_\ P(;_ .)H_P"&Z]1_Z$^/_P "&_\
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MM_S[1X'^K$/^?GX'YP_\(EKI_P"8'J'_ (#M_A0?"6O#_F":C_X#M_A7Z/\
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M^ QX9UC_ *!5[_WX;_"C_A&=8_Z!5[_WX;_"OOS[/'_<7\J/(C_N#\J_//\
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M DC;>:\/_:E\.>-/B!H?AKP?X/TZVN$U/58KG5+W4BXLH+6W(EV2F,A\R.J
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MKJ5)U'>;;,Z=*%)6A&QS=C\-_#6FW7B.>#1[82>(Y1-JXD4NMX^P)EP<C[H
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MCSX)Z'X^ETRYFN]7T/4=/A-M!J6A7[V=SY)',3.OWDR <'N :I:I^S]H&O\
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M@!U%-R?2C)]* '44W)]*,GTH =13<GTHR?2@!U%-R?2C)]* '44W)]*,GTH
M=13<GTHR?2@!U%-R?2C)]* '44W)]*,GTH =13<GTHR?2@!U%-R?2C)]* '4
M4W)]*,GTH =13<GTHR?2@!U%-R?2C)]* '4GK29/I2;C0!6LS\]U_P!=C_(5
M;7A:I69_>70_Z;'^0JXIIO<2V*]S;O/Y923RV1MP)7.:00W?>Z3_ +]?_7JU
MVI#P11<96\F[_P"?I/\ OU_]>CR;O_GZ3_OU_P#7JU2T7 J>3=_\_2?]^O\
MZ]'DW?\ S])_WZ_^O5NBBX%3R;O_ )^D_P"_7_UZ/)N_^?I/^_7_ ->K=%%P
M*GDW?_/TG_?K_P"O1Y-W_P _2?\ ?K_Z]6Z*+@5/)N_^?I/^_7_UZ/)N_P#G
MZ3_OU_\ 7JW11<"IY-W_ ,_2?]^O_KT>3=_\_2?]^O\ Z]6Z*+@5/)N_^?I/
M^_7_ ->CR;O_ )^D_P"_7_UZMT47 J>3=_\ /TG_ 'Z_^O1Y-W_S])_WZ_\
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M_P!>K=%%P*GDW?\ S])_WZ_^O1Y-W_S])_WZ_P#KU;HHN!4\F[_Y^D_[]?\
MUZ/)N_\ GZ3_ +]?_7JW11<"IY-W_P _2?\ ?K_Z]'DW?_/TG_?K_P"O5NBB
MX%3R;O\ Y^D_[]?_ %Z/)N_^?I/^_7_UZMT47 J>3=_\_2?]^O\ Z]'DW?\
MS])_WZ_^O5NBBX%3R;O_ )^D_P"_7_UZ/)N_^?I/^_7_ ->K=%%P*GDW?_/T
MG_?K_P"O1Y-W_P _2?\ ?K_Z]6Z*+@5/)N_^?I/^_7_UZ/)N_P#GZ3_OU_\
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-Y.,58&*=35I/<#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $! MH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\(3^$-#?QMK2SW5O;PZU(;""TA5?,DFF,&\/O<(%1&!/.<5RV@?MAVVJ>.O
M^@W7AIM+M=;>XM-4O)[L-_9-Y%.]OY9PNV1&E10'R.''&>*Q]OC6KQE^7]="
MXSJOJ?:*_&;56_Y<;/\ \?\ \:D'QAU0_P#+E9_^/?XU\)Z3^VS=:W9Q36_A
MO1](BN?$CZ';W?B'66M+40?9?M,5S+)Y1V;TVX7!^\.:[35OVG;_ $RR\3>(
M8/"]IJ'@GPEJ$.E:]JL.IGS_ #V$?G/:1>7B6*(S)RS*6&2!42JYA%V<G^!K
M>KU9]>+\7=3/_+E:?^/?XT]?BSJ1_P"7.U_\>_QKXT\'_M3Z_P".OB+<>$=%
M\*Z)>7;7^JZ?;E=:D,EM]B< 3WT:PDP0S9PC#<2Q QWKT?\ 9^^*'B#XP>##
MXEUC0M,T*SFGF@M(K"_DNI&:*:2*4R;XD"C=&"N"<@\XKGJXG'THN4IV^[K_
M ,,RN::W9]$+\5=2)_X\[7_Q[_&I!\4=0/\ RZ6W_CW^-<,G45.M<+S/&?\
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M.)-::36)UA9 ER;,Q )"X?[V\X/'-'UK,E#G<W;Y>7^:+4*#=K'T'_PDT_\
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ML<$;L -BM%6Q[^W^*Z_U_5RN7"_R_F?8A\8W6?\ 40_K_C2'QC=#_EA#^O\
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M)Z<5],?\(5%_S]/_ -\BC_A"8O\ GZD_[Y%6L'CM?/S74I8C":>7DSY)\/\
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M9^I:K]DD2W@B-Q>2#*Q#H!ZL>PJ^[B-&<]%!)_"LGP]&9()+^3F>Z8MGT7/
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M4=5;6LO/NS*F_:U'56UK+S[O_(****ZSL"BBB@ HHHH **** "BBB@ HHHH
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MK_QZP_[@_E4M16O_ !ZP_P"X/Y5+4'KK9!1110,**** "BBB@ HHHH ****
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M4DU=!TII.:"<T4 %-)H)S2$XH *:QR*"<TUC@4 =C:?\>D/^XO\ *IJAM/\
MCTA_W%_E4U0>NMD%%%% PHHHH **** "BBB@ HHHH **** "BBB@#B5^#/@_
MSM6DFTDWKZI;O:7/VVYFN,P.V]HDWN?+0MSA,#('H*T=%^''A[P_X8OO#]E8
M&/2[\2_:TDFDDDG,B[79Y&8NQ(XR3G 'I7E,W[1$Y^*7BO0(9K!M.L[*\CL
M$;SOMMK$LDN\YVE#N< #G]RWK61X6_:8U@Z?=R^)+6TL[K3/"9UF[ABC8+/.
MSI]G>)BQ_=RK(O')#9&>*NTF>*L7@HRT26ZO9=-_\_0]9/P1\%>;)*-#C663
M[#OD660,WV/_ (]LG=_!@?7 SG%2:#\&_"/AN^M;RQTMDN+6:ZGA>:ZFEVO<
M "<X=R#OP,@_UKQU?V@/%>K>!O#K:8]G=^)9M7N])OCIVGO=)+)';R31F&(R
M(0K 1Y);@%CVK4U3XY^,]'U._P!/O-"ACGM;[0[6XGAV/;V;72PF>-R9 ['=
M(P0JI XS3M(E8G!:24/GRKMS?\'U/0H_@+X&M]"M='M]$-G8VEQ-=6PM;N:&
M2"27B79(KAU5@<%0<8XQQ6Z/AUX<1/#<<>EQ0Q>'6WZ7'$S(ML?+,? !P?E)
M'.>N>M>1:W\8/&^BQ>/1/%IL2^$G2%KEHCMNVGG1H& W_*%MW&X=W;C &*U?
MBA\?X_!?Q$\,Z19WFG2:7)Y4NJN^7?RII1#%Y3*=H*MN=L_PK2M)FBQ&#IQ<
MN5*UELEUM^#7X:':CX-^%EO=7NHK>^MY-6EDGNUM]4NHXWE<@M($60*KY5?F
M4 C'!K;\)>"]'\#V$]IHUH;:.XG:YG>25Y99Y6QN>21R6=C@#))X KP_Q%\<
MO%.GZW\0M,M[_1T3PS8WM_;7CV[,MZ45"D(&X#=#N*RD$\NF .:ZKPK\2]>N
M_BO;>']8OK".PNK-9=/6TMA)]N*P(\S-()2875V)\MDP5P0QHLQT\1A5.T(6
M=[7LNK?ZKY]+W1[%1114'KA1110 4444 %%%% !1110 4444 %%%% !5?4=0
MM]*T^YO;N00VMM$TTLC=$102Q/T -6*YOXB>#V\?^#M1\/\ ]H2Z7%?JL4UQ
M H:3RMP+JN>A905SVST-!$W)1;BKOH4M ^+/AOQ-8^&;O3[N66'Q$\L=AN@=
M2S1JS.'!&4("-]['2JVN?$SPFOAF\UF_1[S3]-U4:>RFR:9UO$F$:A$P22)"
M,,/J#7,VOP!N]$GLYM&\77,,]EJUQJMM+J-FETRM/!Y4J-\R!@26<' P6INI
M_ *\U70/$6B3>)HY-+U35/[7C@ETM'\F<W"SL&R^)$)7;M('!ZU?NGF>TQG(
MTX*]O*U[>O>_RL;-S\5/!4GB:'2+VRN(]1U:&VMIFNM*D"E9P_D03N5PI;$@
M",?7UJKK?Q&^'^MZ)J-SJ&CR:SH&AQ23_;9-$>>R B81OY#E"KE3D?)V5L<
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MAU22#5GN(9%5H \8A6 PO$06Q\P.X/PRD<9!()H;26(<4^17YM=OA\M=]O\
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M7K^9[C6($%_=+,$LDN839F,$C]Z8?/".3O8GYCG&$7RKN?1;NJ#<[*@SC+'
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MDU"*ZECCN+F-BX**&:15ZA#$0Q)85U?Q'\<7_ACQ]XDN4N)+6YBATK3-/EE
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M;R:QX?TG6;VT!<1V][+]HCD"(_*!T@B;:<$8R1EC7MM !1110 4444 %%%%
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M:'[1,\SQD[B'P\CX.%XP,$C)Z6@ HHHH **** "BBB@ HHHH **** "BBB@
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M(PCN$@:4,QVA=TBG!YY4=6%4[GXS?#_P2-.T;3=4L/L:WPTZ6*QDQ%I^]9Y
MS#^X6@D4!<\]. <,UCX"Z+K18S:EJ$>Z^OK_ #'Y?#W5Q!/(.5Z!K9 /8G.3
MC',_"OX!:EX2O+.;6=1B9-/NHKZ%;68SM-<JMRA;<\:F*#9=';""VU@3NY.0
M?NGIUQ\3_"MLY27Q/IL?^B&^):Z7;]G\OS#)N^[CR_GZYV_-C'-37'Q \/6>
ME:?J<VN6L-AJ+[;.X>0A;@X/W.YX!.<8QR>*\RL?V5/"VG:;J%A'>7$EM>V)
MLY'GM;>2X1_L@M/.CE*;D/E #:.,Y[$@^A>(_!IUS5M U6VU6ZTC4]%$T<%S
M!''+OBE1$E1E<$<B-,,.05]"103[HDWQ7\(Q"]:3Q5IJBRE6&X)N1\CM(8U7
M_:)D4H-N?F&WKQ65;?$OX<SW5WX@M_$FB2W)B@M)]0CN S-&S.T,6>I!;S<*
M/X@PZC%8^E_ '2-+N]&E_M;4;F+0Y(/[*@D6,"UABNQ="$D+F0&14!9OFVJ,
M<DDY>I?L]K:MX8E\/Z[<6-YI%S:_Z3<1QR%88KJXN2RKL(,A>X(P>-H['F@=
MH]ST)OB7X7"PL?$FGA)K1KZ*0W V-;JA=I W3 168\Y"J3C J.U^*'A2[:&.
MW\3:>QF@-S&//VAH@I<MDX&-J,WNJENG-><3?LL:!+Y*-KNKO!';30".01.=
M\UM/!*ZL5R@87$C^6N%WG/3BM;6OV>O#>O:MK-Y>222QZM:K!<Q/;PO(CK:_
M91+%,5+QGR@O XR.P+ @K1[E]_CGX/O/#/C'5[F]$GAC0IX[*]O AGBN!-%$
MW" $D?OE0@CU[5?\'7/@31=1GT+PQ/IEO?R(LLMG;2EI75(UVYW$D[$9,)GY
M%8< &J/_  J.*Y\-^,=+U#7]0U"Y\4/'+>:BT4,<D3QPQ11F-%4( !"AP0<G
M.>#4NC_"JVTKQ1#K4FKWE[Y%[=ZG#9R1QI&EY=1^7<394;B&&\A"<*7.,X&&
M'NG<TUCD4$YIK'@TC(]'T[_D'VW_ %R7^0JQ5?3O^0?;?]<E_D*L5![D=D%%
M%% PHHHH **** "BBN1\6?%?POX'\7^$O#&M:D;/6_%4\UMI%MY$C_:)(D\R
M0;E4JF%[L1G/% '1ZMI5KKNE7NFWT(N+*\A>WGA)(#QNI5ER.1D$CBN1F^"O
MA">UU"T.G3I8WZJ+BSCO[A(&=0@641APJRCRHR)% ?*@YSDUT'C/6IO#?@_7
M=7MXTFN+"PGNHXY,[69(V8 XYP2*\@^'G[1=WK*"+4+'_A)9[FV@NK"7PO9.
MJW&8!)=1[992#Y!:(%@_)GC4#=D4 =?=_LZ^ +[3[FRGT65X+L7*W@_M"Y#7
MBW$GF3+,PDS*&?YL,2 22,9.=67X-^#9QJX?1(V&K03V][^^D'G1S2F653\W
M&YV+<8QGC KG#^TMX.DT_4M0MC>W6FV$-K+)>)&B(3<>3Y*[7=77=]HC^=U6
M,8?+@HV,;5_COJ5M\1=$TFRT^>_M;F[,$^EVUF#>(#IINE4R&7RB<C)8$+CY
M<DD$@&WX7^"$>A_$J/Q1+/:Q06(OUT^PL5G6-#=RH\K,LDKHA.P9$2HI9F8C
MH!O:A\&/"6HW=U=/87$-S<74EXTUK?W$#I+(@24H4D!02*!O"X#$ D$C->?Z
M?^U#HT.I:[=WTQGT:22U.BPPQK%<21M8K<3;_-=1E22""0<D* 20#T_Q%^-^
MG^'O!<FHZ#%=:[J%YH-QKM@EC;^;BV2(,MQ(K,OR9>,;1\S9P%.#@ Z/5?A1
MX3UJSL[2ZT6!K>SL3IMM'$S1""W+Q.%3:1M(:"%E8892@((JJ/@QX3\NWC>R
MNIHXKK[<R3:A<.L]R&5UFF!D/FR*RJ59\E=JXQ@8Y?P]^TCX:NC::;?7#/K*
MV1>=HC$L3W,=JMQ-"H,@96"$G+ )\K#?D$5S?B?]J>.]T'4KGPGI%W<B+0-;
MU#[?.L;):75AY8\N1%D^=295.4+9#)C.3M /6+/X7>&K30-9T9M/:\LM98OJ
M/VZXEN9;MC&L>Z261B[$(B*#G("+C&*31OA9X:T+4K;4K>QEEU.WEEG6_N[N
M:XG9Y(UC=GDD<L_R(BC<3@* ,4O@+X@VGCE-0@2TO=.U'37BCN[/4(1%(IDB
M65' #,-K*XQSD$$$ @BNKH XR_\ A!X5U*XU2:;3Y1_:<HN;F**\FCB-P&1A
M<*BN%28&*,B50'RN<\G+(_@QX.2UO(&T<3"]L[BPNY)KB622XAG</,)'+EF+
ML 2Q.[@#..*[:B@#AKGX+>$[R[FO)K*ZDU&1XG34&U&X-U!Y9D,:PS>9OB5?
M.E 5"!B1AC!(IEY\#?!=\LHDTJ5#,TYN'BOKB-KA9@GG)*RN#(C^6FY&RIVY
MQR:[RB@#@V^!_@[^W)-7BTVXM;]GFECDM=0N(5@DE14E>)$D"Q,X1<L@!.,]
M2<SV'P9\&Z;I]S96^B1K;W7V?[0&FD8S&&X>YC9V+9+":220L>6+'<37:T4
M<0?@UX7.BW.CK!J$>D7&5>PCU6Z6 1D,&B5!)A8B'8&-<+C QP,:7A[X<Z!X
M6UBXU73K)X[^:!;3SI;B2;RH%8LL,8=B(XPS$A$PH].!72T4 %%%% !1110
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M73HUNM'<QIH;3W2Q,LN_3[UIV51MY61& !)!#(.".F1=_L[W'P]T3PC=6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5#6O\ CQ/^\***#.I\#.>/6BBBK/+&M2444 -/6DHHH ;11103T&'K
M2-THHH$-I&Z444 )3#UHHH :W6FM110@&GI3:**H!&Z4VBBI)&GK33UHHH :
MU-/2BBF VF-T-%%(#U'3/^0;:?\ 7%/_ $$5:HHJ#VX[(****"@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_005.jpg
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %/ HL# 2(  A$! Q$!_\0
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M/PHU/P1>Z#!X)T>"::P-G'?+:J)E;9A7W8SG.#FO<-G/KSGFEV\#/- 'P_\
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M^%-=LM=@MW$<TEE*'$9]#75K]T4 +1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(:6DQF@"-SA20<>]>-_$;XK^//"WB>;3M!^'DVOZ>J K?K/L5B>HQ7M!4$4
MT1@=ZRJ1<E:(,^7O$W[3?Q*\+:+/J5]\*;F*",<LLQ8Y^@IOA3]I[XD^*]$M
M]2L/A3<36\HX=I]A!'7(/-?44D"3(5D574_PL,BDBMHX%"Q(L:C^%!@?D*\_
MZKB+W]L_N,N1WW/'OAO\5?'GBOQ,NGZ]\/I?#VG&,L;U[C< >PQ7L2\@>O\
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MV=/B!XVTOXO_ -G:&9)/$-KHR6*-(,RF IYH/IC!H ]:U3XZ^.G\2'P]X/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHVB:#J!C\,^'FM)$-Q.N0;F7Y<#G[H]Z^S8\\Y&">:H0V%E*WFBSA!!#!O*
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M3(M(9F>]8#"R.",#CK7U\WPP\'7$[S2>%](>60[V=K*,EB>Y..M=3L4'.*4
M T ?'W[$5C;:7\8/V@+6RMHK.UB\0H(X84V(HV'H*^P1R*^1?V,/^2V?M"_]
MC"G_ * :^NZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "F2'"^GXXI20.<_A00'&T\\=*3 \
MY^+'QLT7X/-H']LDXUB]6RCVL!L)_B.>V:[^"83*)$97C<;D93D8^M97B'P1
MH/BLP'6=*M=3,!S%]IC#[#ZC/2MB"W2WB2.- B(H55'0 =!6,>>^H$HZ4M(*
M6MP"BBB@ HHHH **** "DQFEI#2>@"'M2'BE:FDX%3HNH"X%& *CWX!). !G
M-.#@C(.<\T_4-1XQ2TP'CB@Y'0\T)IA81HE9@<D'VIS*K]>U>;_&CXZ^'_@=
MH4&H:T+F\O+N3R+#2+"/S;J\?TC0<D^]<M\%?VM/#?QB\2R^&WT?6O"/B9(?
MM"Z5X@MC!)+'W9#T;'<"F![B(E'3C\:/* HRV1_*D\P^F/7/&*8"F,$8H*[1
M@5R?Q)^(MO\ #;1[34+K3[[48[BZCM1'80F212YP&('0#N:ZD,612W<<=J $
M?;'&S,VQ "22< #USVJCI&LZ=K]N;G3-0M=2MPQ0RV<ZRH&'4;E)Y]JR_B%H
MFB^)_"%_I'B.Z-IH]X!!<.+CR-P) "[\C&>G'K7S?^SGX3M/A+^T%XD\.IX7
M/P]L]0L3)I.BVEXUU::A%$X#W1)/R2?, 5_4THZB>B/K8QJ3[T!,'.<T^BF,
M:%QT&*=110 4444 %%%% !1110 F,9-?,/[3'@W2;@>'-"NO%WBC3]2US5W-
MM%H+YEPP&XOZ1(!DFOI^OG_]IOP=J5]J?AK7_#'BS2?"OC&-I-,L7UE?,AN$
MF&'55Z[\<@B@#YF_9ZFT6Q_:(M;1?$?C^?1K:^FL++6-4F']F:G<Q\-&,=3Q
MQ7Z),JS*5= 58%65AP0>Q]J^-/A[X=\):GX_\!_#;3_'.G7UAX'DDOKFUBC(
MGO\ 5=Q:3$A^7"L2< YK[,23>"?NGTH \1^*GPI\3W6IV3?#[1?!-G9[6-V-
M6TQ7=GSP1M%>;>$M;\;?#;]HOPEX3\9Z3X.@M->MIY+/4=$T\12F1!S'G&1Z
MU9_;.UO3]'U30U7Q9XTMO$4D$@L_"_@OYI;P9Y=QV ]37#_LH:=X-\0_%^TU
MCQ5<>.+;XEV5F\>F:?XZDP1 ?OF =&/KCF@#[LHI@D4G&>>X]*<#D4 +1110
M 4444 ?(G[%__);?VA?^QA3_ - -?7=?(G[%_P#R6W]H7_L84_\ 0#7UW0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%(:3G/% #J86[#]:4MV[UYGXQ^-FC>$/BEX9\$W2EKW6T9ED4'$
M9'0'ZUG*7+N!WVIZG'INGW-ZZLT<$;2%5&6; Z >M><_!#XOS_%'0-2O]0T6
MZ\/3VMT\9BO4*;H\_*XSZBKOQ-^-7AKX9VDIO;I;W56&(-*M3ON)CZ!1S7DV
MGZ%\2OVC(F;Q$&\">#9^1I]M\MY.O;<W:O/K8BTDJ;N^W0S<NB/3[SX_^&H_
M'.G^%=.>76]2NI-DIL1OCMAZR-T%>FQNQ)]CBN0^'GPI\._##3$LM"TZ.W 7
M#W+#=-*?5G/)KL=N.G KJI>TDKST+5[:CZ6D Q2UU#"BBB@ HHHH **** "D
MSBEI,XH 9)G!XKGM5TS6+F[WV>I);Q8^ZR9KHV&>O(II7/3BN>I2C55GH4I<
MIY1\3/!GC37/"DMGI&N+#.6#21J"K3(.J!NQ-3?#GPAXST;PM;6FIZRIG4DI
M&Z[VA3LC-_$1ZUZCY?/]:"IQTS7%]1AUD_O-/:OL8&D:=J]M<[KN_2>''W0N
M*W^,8(HVF@KD<@>]=M*E[/1;&;E<^<OVC/AJOCWXH^!M7\+^+]-T+XH^&A-<
M:78:CAXKN!QB0%.O3N.E8>E?$_Q58?&CPKH7QA^'FF6.K7:3PZ!XJTF?S8WF
MVY:+!^920,UZ?\:OV==(^,>J:'KHU*]\-^+M!9GTS7M-;$T(;[R,.C(>X-9'
MA?\ 9PO;#QQ8>,_&7C?4O'&K:3%(--ANHEBM[5F7!D5%)R^,C/O702?/F@_#
M?Q]X^^$_B;XE7GQ5UFUUG2KV\FTBUM9<6\$4,K?NY5_B+ 8K4^*/Q+M?B59^
M!)]=\6^(].AO-&6ZD\*^#X7>^EG;CS967[J9Y'K4WP(_9FUOQ=\.O$MI?^+]
M>\.:+K6MW<NHZ(L8S*GG' 1SRBL ,XKV75?V7Q:?$-/&/@OQ-=>$-2DTR#1[
MJ-8%N$EMHL;  WW6&.HH ^2_"'QH\=_\* U"*37M7%YH_C^VTJWGU+B]^RM(
MO[N7\#BO1D^'WBWXX^+OC+-=_$C7=$L/#=^Z:59Z=+L6&40A\L>XSVKT[1_V
M&?#>D^%=6T+_ (2'5[N+4?$$7B.:YN6#S&Y1@V,_W21T[5ZCX.^"VG>#+OQS
M<6MY<3/XLN&N;H/C$3-'LPOX4 ><_LU7#_M(?LGZ/!\00-9EO(Y;.[E/R-*T
M4A59 1R&^4'([UV/P:_9JT'X-ZA=ZG#J^M>)=9G4PIJ.OWC74T$&<B&,M]U>
M!]<5M_ [X/V/P+^'=CX1TR[GOK.UEEE6>Y^^3(Y8_J:]!!R*%H#UT%HHHH *
M*** "BBB@ HHHH **** $W"OFW]J?3O$ECXA\*^-?"FBV7B^[T;S[;^R+B[C
MA\N21<+.I<XW(?QKZ1/3_&ODG]KOP%X.U5=!\*'P1J7CGQ)J][-?V>FVFJ/9
MA#@>9*\@(^7@<4 <[X"^#6IZ?>_"7PU!8:=%)8WTWB3Q!XAM[R$R&Z<EC;IM
M.YB2<'M@5]J+R2W4^GK7PC\ OV9&\%?%C0M:_P"%'WGA<VS,3JLGBE[I8??R
MRQS]*^[QR.>I[T ?)?[44OQ&^&OQ?T+XG>!=(T.\TVVTU[#5YM>OEMD\LL"H
M0GD'W%>17/CGX_\ QQ^)7AKXA^&_ W@_7-/\,+*EI!9:VLC>;(,,7<#(&.U>
ME_M7KX(E^/O@I?C(\Z?#9;"0V0FW?8#?[AD7)7_9Z;N*P/AL/AK!^U3X7_X9
M]EBDTR2UE'BF/1B3I@AQ^[)_A$N<].V* /K[X;W_ (EUCP;I=[XNTFWT7Q%+
M'F\L;:7S(XF] W>NKI,'=GM3J (Y9DA1F=@JJ"Q8] !U-8GAKQWH'C'29M4T
M/6+35--A=XY+JVD#1JR_>!/M7 _M*> _%WQ$\!3:5X7\6MX/@996U.\AAWSR
M0!#\D9_A)YYKY9_84L-;C_8)\8:?X9M6U'6VGU*TLXBVTRR$E,Y]3DF@#[/T
MGXS^!-=U2'3=.\6Z1>ZA,Q6.V@NT:1B.H !S79@Y-?DG^S[\.M#_ &8OC+\.
MK/XO?"8^'_$NKLS:1XCLM6>=GNN21-&&V@G.,8K[!U3]NB\TO6;RP'P5\>7/
MV>=XO/AL\I)@D;E/H>M %#]B_P#Y+;^T+[>(4'_CAKZ[KXF_X)Y^+&\<^._C
MEKS:==:,U[KR2?V??)MGA^0\/[U]L#I0 M%%% !1110 4444 %%%% !1110
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M[0IQ_P S"G_H!KZZKY$_8O\ ^2V?M"_]C"G_ * :^NZ "BBB@ HHHH ****
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M,MM+,NV.X9/13W[9H \]\(_$2V^-WQ8\'IXO^)GA"^.DW+7>F^'/#8=I+JX
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M#+?*/4]/SH20.@9?G!Z%3G-'F!+C\J,^E1[NY!%*7.3TX[&A/4!Q^88/2FE
M!W]:\V\;?&[2? _Q:\$> KNWGEU+Q7YYM)E^Y'Y2Y;-2_%[XSZ7\'/\ A&!J
MMM/<_P!OZM'I-OY/\$CYP6]N*L#T38,<]/>D"@]L9[BO,?A[\=]%^(GCCQ]X
M9M(9;.[\&W*VU_/.0$)*[L@^F/6J7P=_:)T;XV^)_$MCX:TZ\FT71)3;MKLB
M;;>YE!PRQ'^+'J* /7, 9P #W-&T'J,@]>*X3XK_ !5TOX4:9IUW?))=7FHW
M<5A96$'^LGD=@.![=2:\@\8_MH/X<^(6O>%-(^''B+Q5<Z&RQWEQIB!DC8C(
M&?QH ^FEC5> ,#M3M@!)QG->4_ SXU7_ ,8;34Y[SP5K'@_[(X54U9-IFSW6
MO5@XR1W'6@!U-+4,PR!W/:N-'Q)L3\5V\">3)_:(TK^U?/\ X?+\S9CZYH [
M->E+30PR1G+=2,\T;P!DG ]30 IZ4W=@^O\ 2AF'(Z$<\UXYKO[0]EI7Q$\6
M^"[31KK4M9\/Z2NLND)&)XB"=J^K8'2CJ![&6..!50ZWIXN?LQO[47.=ODF9
M=^?3;G.:Y[P#X]L/B1X'TSQ5I#DV-_;&9$DX*-W5O0@@@_2OC+PW\.KWX9^/
M+7XE^.?AOH5_:7_B%R/$4.KRSZE')-/M@<(#Y>P9 P#FE'WG84O=5S[[!S2U
M'&WRCG.><T[<* 6HI/%>4>)/VG_A=X4UV^T75O%EK::E9R>5<V[QR$H^,X.%
MQ7JQ^OO7SY\?M4UBW\;^&_"O@W2/#\&M:RD]Y<:KK%D)E6.)<E0 ,LQ.!3&=
M;X3_ &COAAXX\0V^F:%XEM+_ %BZRJ)' XDD ZC)4?SKT36-.CU?2KW3I<K'
M=P/;NR]55E()'YU\<?"[QI\0[7Q)\//$'B?5O"B^&==OIM.D32-,$5Q#=*2J
M1;L=&(K[#\0P74N@ZG%8,4U!K:5;=L])"IVD'ZXH ^+[OXN?$#]F.TMO NFZ
M[\/O$VG:<&2VEOM4^R7,498L$E4!AD9ZUV?PCL]<_:&^)?AWXA^*?$7AEO\
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M'@R*JCE\=ZS$?&'B?P9\3/B/\9/VFM'\#3K9Z/;:K;ZAJ8B<I<:D$0$VB$=
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M0WRV_O'/TI$C*L23G-2TF*10#VI:** "HFA#'H"/>I:* &A><TZBB@ HHHH
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MU91110 44E!.#0 M%)NZ]Z,YH ^1?V+_ /DMO[0O_8PI_P"@&OKNOD7]B_\
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MV'.Z1O; [U\;?$SPS\=OBGXSN[F.*728+ "]AL1(2D+C@;3W;':O=]-_9_\
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MMO$FD1",WLLPV1)*!TD#$5]&>.?V8? 'Q \22>(+W2YM/UZ8!;C4M+G:VEG
M[.5^]QZU4@_9.^%MGH$&BQ^&(S9I?)J4F^1B]Q<)]UI6/+XZX/I0!\9>(_A-
M\3? /P.^'WB"#P-;:1JW@N^7Q!>Z]#J"O//%(^ZX!7J=RMR/:OT9\)>);#QE
MX6TK7=-=9;'4;9+N%E.>' /]:EU/1;+6]%N]+OH%N-/N8&MIH7'#QLNTJ?PJ
MCX \ Z+\,_"=CX<\/6IL='LU*V]N7+>6"<X!/:DP.A502#S3\4@;)QT([4N>
ME A:***8PHHHH **** "BBB@ HHHH 3(]:^>_P!I_4_$'B36?#'PU\+ZE9^'
MM3\0M)/)K=];+.MO%%U6-&X,ASQ7T$3]!]>U?!W[8W[1O@75Y=3\)>-/ 7Q
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M3,>'(/\ #7OO[.VG>-?!NF^)+3Q9XOL?&G@VR;S=#UY)E>Z>W"Y83[>,CUH
M]W) ZD?2O.?C:?B<-#LG^&%QX<MM021C=OXCCD:$1 ?P[&!!ZYS7R#\*/VBO
M'%O\=-+\<>*+B:/X:>/]2N-&TVWF&(K)HCMA<'_IH0:^Q?CU;>(K[X3>(++P
MK9F^UV\@^S01JX3 <@,V?9<TF!QG[*WCWXE?$30=>U+Q^/#[VT5\UMI5YX?5
MUBNXT^5Y/G8G;NZ'N*]RSQ]*PO!'ABU\&>$M&T*QB$-KI]K';HBC@84?UK?'
M6B6XD+1113&%%%% !1110 4444 %%%% #3U]>_TKXJ_;V^/'@W4_A=KO@JSO
M[BX\2V>IVHGM(;.1F3;(K-R%P1CTK[6Q69/X:TJYN'FETJQEE<Y:22V1F;ZD
MCF@#R?X;_M/_  Y\8W6A^&])UN2YUF>W2-+7['*G(09RQ4 ?G7LR_*IXZ>AZ
MU2@\-Z7:3":WTRRMYEZ216Z*P^A S6@5PF,=>M 'RM^U)X^\87/C6?P5X7\0
M6GA&.V\-76O3ZBUNDMU<&/[L4(;@>^*Q?AG\7/%VF^-_@G;7^I6.L:?XVT0O
M>6;VR+=P3HN?M 91G:V<'/%6OVU]"\*?$/6-#\+IX.U?Q?\ $3[++<:<-$N/
MLK6]N<!_-FZ!#Z$<URG[)OA7P[\*/B;IFD>,_!NM>&/B)>V30:)<:S??;H6M
MEY>*&0 !"/[N.: /N>BF;B<>M.'2@ -9?B+0+#Q1H][I.JVL=[IM["T%Q;RK
ME9$(P1BM6D(!ZT ?/?P8_89^%'P-\5R>)/#^D7,^KC<+6;4[EK@62D\K"&^X
M/I7T&@P!G&?:EVCTHQ0!\B_L7_\ );?VA/\ L84_] -?7=?(G[%__);?VA?^
MQA3_ - -?71H *0XH)&<4UFVBH<DMP./^+6E>)=:\#ZG8^$I[>UUNYC,45Q<
MDA8L_P 5+\,K+Q'I/@C3;+Q7+;W.N6\2Q33VQ.V7' ;GUKH=7U>VT/2KK4;Q
MQ%:6L;2RN>=J@9-?/6H_%WQW\:;L6OPMT\:?X?/[N?Q#J<93KWB4]<5P5:T:
M;YUJ^R$Y<NA+\7_%6D>!?BOI^K:FVG2)Y/F".. 2WS.OW47N,]JQ+C4?&?QX
M\V3Q#<K\.O >[<D$KA+VZQ_>R1A:W;+]DY-,U:VU>#Q!-?:^P_TS4KY?-D=O
M5,\+5_QMX \ ?#C0+KQ/X^UJ:ZMK1-\LE_<_*WH F>?H*\&E@\?BJ\J5.F[2
M>U]']QW0A!J,ISM;MN2>&_$WP^^%-A]D\/A];U #$D]M'YL\G_ O2N>\4-XM
M^+6KZ7<V?A:72A:2;UN+MRNY.P85RN@_MU_ K3=+3_A%K&]O[_)6/3M/T\O<
M'TZ>OUKC_'WQR_:C\?:QIES\/_AW/X9T*9]J/?HK/(IZ/(#]T 5]=2X,S+%/
MV.+FJ,5_-:/_  7]QVQQ<*,N>G"[[L^A]1^'/B"XT>YO?%7BV2&*&%Y?LUB?
M+0A025R?IBOD;]G;]JOX:3:OXO;QS9K8S6-R1IJRN9Y)XPQ&T+_>XKVNT_8W
M\8?%&W6Y^+GQ/UC4W?##3-&?[-#'GJI(ZUZ?\-?V//A3\*W671_"EI+=)@_:
M[Q?.D)]<MWKVL-E7#N HU(8INM5TY6ME;S>_W'.\?7LXIZ/Y'R/\?_&;_M>6
MVF>'O"?P;URXL+*4RVVKW<9M$1_H1RIKUOPI^SI\;/'/A/3]'\9>/8O!6@6\
M"P+HOAF/:PB P 7/(-?8:1K%&J1J(T P%48 %+T..]=<LZE"C##8:FHQCM?W
MFGY7V.+VS:LSYN\ _L!_";P5?+?7FFW/BG5!RUWK4QF+GU(KT;XK_L[^"/C!
MX"'A#6-+6VT=762-=/ @>)AT((%>F%%W9'&/>C:,YKS*N:9A6K*O.M)RCL[[
M>G8SYKZ,YSX?> ])^&7@_2_#&AQF#2].B$4",<L!ZD]R:PK[X">!-0^)=OX]
MGT"V?Q7 FU+\CD>_UKT%0 #C@GO1P3CICTKB6)KJ<JJFU*6[OO?<5QR#"@&G
M#WXJ,$Y)).!2;\KN49.>:P2^0;DI )S01FHRQ)(Y'O3&DP0,DXH270FY(V,#
MFJUW>Q6:J9)$B4D#<YP"3V^M>8>._P!I7X?_  ^D>#5->BEO%8H+.T!EEW#J
M"!7A_P"TYXE^(OC*;P]_P@,5W>://"NK-!Y6V2 K]W=['GBL*U>-.+DM?0]S
M!Y55Q-6$:O[M2ZRT1]6>*?$]GX0T&^UB_P I:V<9D;D#('IFOG[X>_MJZ+X[
M\<7>A6^G74WG3".P,2;B1CDOZ >M;OP\^&.I?$KX4W]MX_\ $T_B2UUQ5D$2
M)Y/V7 Y0=^#6[X&_9=\#?#W5=)U3PY9RV%_8(8O/#Y,RGJ'S6,GB)SC*&D?,
MZJ,<NPM*K2Q*<ZB=DUL?._[0/Q2^.4.EW<K:>GAS3Y;IK>UMK/\ >WLZJ>'7
M'08&:]-^"OPTTOXW^'M$\>>.]/AU378X!;H"Y(PO&9%/&[CFOH2Y\.:=?:M;
M:G<6JS75NC1Q.XSM!ZX]ZDTS0K#08Y8K&W6UBED,A1!@%CU..W-.&%FJKJ3E
M=/IT%5SF+P<:-&FH27VEN[]":PTNSTZV2UM+>&WA486*) JJ!Z"KT8(&#TZ=
M*@C4><N2N>W-3*Q//3WSUKO227*MCYOFE)WE?YDG R1VIZ<J#4&<-CIQTI1-
MMXZ =<]A2370+$_TH&::C@IGU]*</K3&+1113 **** "BBB@ HHHH **** "
MF2-MQ[T^D(!ZT 0-MV_[59EYX:TK49O-N]-M+J;^_+$&/YXK8V]@*1H\].M)
MI25F.+<'>.C/._B!\%O#GQ#T:WTF]M5MM,2=;B6WM%"+.PZ!L=LU!\-_@=X9
M^%UK=VVEV"R0O/Y\8G0.8B>R$] *]+,>1[4HC  %9JE3O?E.KZYB/9.@IOE?
M0RUTFS%Z;S[+ MUC!F$8\PCZ]:T4/R@GGZBG-'SFG;1C%:V1R-M[GRS^UKH>
MI>'?BE\)?BQ:Z9>:SIOA2\FAU&VT^(RRI#,NWS HY.,US/Q8\:6?[57Q(^%_
MAGP=IVKR:9I&LIK6J:K=6$EO#!'&I^0%P,L2<8%?9(BP#@XS0L(C4A0 #R0H
MQ0!\A^*/BO GQ+\9>#_CKX#6^\+QR^9X>UZWTI[F*:W(YC<H"P<'O7A/A2WU
M;X=^&OB[_P *T\*>(]-\%^*[FWT;0M-U&*1F667Y9KB)#RD84D\]*_3)[=9!
MA@''HPR*7RN0<\CI[4 ?$WQ&_8AU"T^!4.G6OQ"\2ZLWAJV34M-T>8J8?M,/
M[P* .>6R/QKZB^"7CFZ^(_PJ\->(;[3[C2M0O+-#=65TA22*8##@@^X-=OY6
M>IS^%.5 . !^ I,! "/:E''-+M%&*+ +1113 **** "BBB@ HHHH **** "B
MBB@ IK\BG4A&: /F?X_?#+XP77Q@\/>./A)=:':SVU@]CJ<.L@D7*%@57VQC
MJ*\M\6?"G]K3Q=\3- \8W,_@99M!CD&G61+F))'&&D;N3CBONAHPW4"@)CTH
M YCX;_\ "5CP9I@\:_86\3^7_IW]F@B#?_L9YQ74CI30@&/;I3Z "BDI&;;0
M ZBD# T4 ?(O[%Y_XO;^T+_V,*?^@&OKG)[_ *5\B_L8G'QJ_:&/_4PI_P"@
M&OH?XG?%3P_\'_!]YXG\47ILM(MB%=PNXDGH !UJZ<)5:D:5-7E+1+N!V3'G
M\*C<D<]J^3)_VTO$OQ(C\GX1_#75]?8\_P!H:I']GM=O]X$]:\(T'6/VC?VB
M?C5>^!_$NMZEX"T^R5GN6TN'RX@,\ /W-?3T.&L34YY8F<:2@KM2?O6]$4D?
M>7Q$^+/@7P#IDW_"6:_IUC R'?!<2J6=>_R=37@\_P"WAX+NB-&^&7A75_&E
MXN(X8M/LS';HW;<V, >]8GQ _P"";OA;Q-X O+&PU?4+SQ<WS1:UJ]PTI#=^
M/0^E>T_LO_ -/V>OA9I_AIYX-0U&,E[B]2, NQZ@'&<52HY!AL'[:,I5:U[<
MK]U6[]7;YCLMT?+7BKXM_M8>-?B-IWAB#PS'X(L-4QB>.(3K;1]V9_[P]*]8
ML?V"]*\6^7=_%'QAK7CS46^^DLQCMA]$'%?5_D[AR Q]3UIP3"_RK"OGU5QC
M'!TXT;?RK5^=W=BNCS7X4?L[?#_X+V'V7PKX>M[,LY<W$JB28D_[9YKT@1@'
M(Z^G84]%(ZX_"EVD'-?.5ZU;$SYZTW*3ZMW%=C F >WTI"VU<G %,OKD6MM-
M,V[9$A=MHYP!GBO)O!'Q_L_%.I7UM>6;V1CS);&(EP\6<8?^ZV0>*XZE6%'X
MW8$G+8G^-W[17AWX%6^FR:]#<RI?,1%]G3<<CL:?I7[2GP_U/1+34CXCL[9)
MXPXAFD D7/8CUK@/VD=:T#7=-T@W7A7_ (2 B4E+BZB;RX1_< '.YN@JWX>^
M%'PQO='LKI_AS]EFEC#-;30Y*$CH:\OZ]^\?+)6/>I0R]T(JK&7/UM:Q!HO[
M=/PXU?Q5>Z/-/-I\5MN!OYP/)?'H?>M^\_;+^$]C$6'BB.<AMFR*-B<UYIX)
M\.^#M8^)6J:/)\--.:")2R0"'][:@<?O<\?-U&#7F7_!1RWT_P"&?P+L=0\.
M>!;2PO)=02 7$$ W1KC/;UI4L;5J/D35_0[)+)W5BN2:CUU7^1](K^VC\*)X
MED7Q"2#GCR6X]JQY?V\/A?%J'V9;J^D7/^L6V;!_"OE7]G;XJ?$N3X4:!>V/
M[-=MXDTV1"!J@D19)B/XBK<BN/U?X6?&O4OBI-\2E\ 7^G7L>H)/#X,2&,V[
MP 8.7SCFNF<L4DK6^X*?]AJI+GA-KIJO\C[ED_;>^&X1G5]4D@4'S)!9/M3Z
MG%,MOVV/ E_'G3;36=0R<#[-9LXS]0*^8_CK\>_B[:?"3Q%)JW[/O]AZ8L($
MU\K)B).YPO)KAOV//V@/B?-\/M1F\%_!R7Q'8?;VS=1NH$38Y0;L&LY2QD7>
M*T]#./\ 8_L6W"7/?1<VGY'U%XI_X* :;HGB.WT^#PMJ4D3E0WVB,QS')_A0
M\FM+Q_\ M57&I^#[\:=X1\4:7<-&?)O?LG .."1CI7Q!\>/VL_%VD_&6UL?%
MGPS_ +)\8I]G;2[21E)3<V,D#AMW05]$^)/VC_C/;>$=3-W\&M<LUAM'9[K<
MA2(;<E\9Z=ZYG/'RO%QW\C=XC*J;ISI4M5J[O_@'G'[-VO2)\0=7UO4_"EYX
MOU"5C)A(AE&)Y+ U[A\6/B#\:/%<^F7'@_PE<^%X8V\N5II(QYZ_PI@_CQ[U
M\V_LO_M>^)_&.NZZOA#X6ZAK(@MT^UP:9, 1+DYD8G&"?2M']J'5/VC_ (S3
M>&V\(?#OQ3X2CTUB]P/M(_?MD8/!ZBL*&&Q>M-IJ_6YZ.-XAHU\2L3&BG96L
MVVE\M$?7.F?%WXOZ?I26T?PNCC,,7[V22[10S8Y8 5YC\/\ ]I3X[:[XHN[$
M^%[>=1NVPW$?DHF#Q\W>C0OC]\5]%\+6=IJ'P'\27=];V?ERW\ETK;Y%7F3&
M>N>:^?\ X#?MS7.L_$<64/@S7?%.J"&<:C86["1I9 _RL!GY=HXK6=/,$TH;
M>;_X!YE+,L&HS=3#Q;?K_F?2/Q@^.GQV\.^'!?MH^F:%!#(!+/;RK*Q)X VF
MK?A+XG_M#ZGX;LKKR_#\BS#*R71Q(1ZD"O+/V@_VTK?PYX/M+G6_A%XA\).9
ML6E]J,2M$7QRK+GG(S]*ZCX2?MD_:O &CW/ASX&^*];THI^[U!45A.<_,P.?
M7M0\+F,Y7=1(3S?"*DJ:PL;]]?\ ,B^&GC/XGGX[QS>)=>,F@+>/#</ W^BB
M7&?*7Z5]8?$3XAWD/A>Z/A=EFU@8X=/NIW(]3CI7YH:%\6?CK8?M-7/BV;X9
M>()O!#:A),GAU;+ "MT/IN]Z^H_%O_!0.?X?:'-K?B#X&^*-(TFW(\ZZGB0*
MF??-=%/"XR,7%U%]QP8_,8XV<9NFHV5K(]Z^$GCW7Y/#LI\51S-.+@_8Y##^
M]>+'5P. <^E9GB3X@^,KKXGZ38:):7,>E2%=L3V^8[A?^6AD<_<V]O6O%/!O
M_!37P]X_TV34/#/PC\:ZW9Q/Y4EQ8VB21J^,[<@]:\B^*G[<WQON_C1HUWX/
M^'?BK2O L9A%]I=YI9:>;G]YM8<#(K>GA\0K<\[V\CR93B]4C]/%("8 QQT]
M*=G';BOAWXB?MY>(=<\"ZYI_ACX0?$#2=?N+5DT^]DL!MAF/W6//05Y%^RI^
MUS\</AU;ZZ?B_P""_'?C5KC9]@,%F#Y _BSG'6O5MW,3]0,F@DBOS#_:6_;H
M^..MZEHW_"JOA[XK\-6R(1=KJ>E%S*Q/&,5^C/PZU'4-7\">'KW5U:/5+BPA
MEND9=I$I0%@1VYI@=+1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  3_ &AOC=\*-"\:1_M$ZAI@U:(R_9?LF[9R1C/X5Z /V/?VB<?\G+ZA_P"
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M^/\ PXMDT5O( ]A=,FTAO89K]%]AQC)Z>M(L90<'_P"O0!^<%S^S;\1?@_\
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_006.jpg
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $P J<# 2(  A$! Q$!_\0
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M+Y9(9<>N1C%>6>-?C9+X7\7?"_XBV9O4\&>-732;O3KM2AA>3F&4J>AX/YT
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M'FOVPHSCZT >M19\M0W+8&3[T^FKGO3J "BBB@ HHHH **** "BBB@ HHHH
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M+*S86]HSCL5'45]-(OR@GK_.O&K4X4GRTY<Q)(N*=30?:G5BE8 HHHI@%(V
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M  5I6D>(_'GB2.9"FGS6U].DS#=;]PJC^(] :^,K;X0ZCJ]I%XCTC]G^ZN/
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MTW>8_M-JVY-PZC- '0@8&*6D!R*6@ HHHH *0J#2T4 -P #BOC3]KS_D[O\
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M'K7)[&M-2BWH_P #U*N+P5'V?LX7E#KT?J?*'P>\"?'W0;>[\+QZQ:Z7;V1
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M]T>E.I!TI: "BBB@ HHHH 0]*^,_VO/^3N_V:_\ L(W7_H%?9AZ5\9_M>?\
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M@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,GPX<Z>?\
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M9^'/[-WQ<U:Z^&WPG\2^%HM'\'> -;FU1_$B3AH[^+<6C6->H;IG-?I,I
MX X I1'@8)S]:?CC% "UYG^T+KWC7P[\*M:N?AYHXUOQ?)$8K*!F"A&;C>3[
M=<5Z932O.<T ?G1^SE\#_B'<>$/''@CQE\-Y])UWQEIMP-8\>WEX)9)YV&50
M#J$YQ@4?"/\ 9\^*WB?Q[\'O#OC#PM'X?\-?"F.>&75O/#+JNX$(8@.G!YS7
MZ+E<@\TC1[EQF@#\S1^S%\6Y;75/@7<>%(O^$'U+Q>?$C^+1<#RTM!)O$6WK
MOKU+]H/P]\7+D>,?A]IWPLT/Q=HWB2S2RTCQ'!&D;62[0K&Y)&6(ZC'I7W!L
M.W&ZD"-W?\J .#^ 7P]N_A1\'/"7A+4+S[??:381VTTX.0S@<X]J] I%&!ZT
MM &=XAN[FPT._N;.U^VWD,#R0VV<>:X!*K^)P*_.CX-Z!\<E_:,F^(WQ)^$,
MGB'5KZ\6VLK^6\ AT.S)PQCCSC.._6OTG-(02>O% 'YJ^/OV;?B]HNL_&'X;
M>'_#,.K>&?BEK$6H1>)S, FFQ[@9!(O7/&.*^C/VI_@KK_B+]DFS^'_A2T_M
M75+$:?"L8;:'6%EW-].#7TZJ;5VT*FU< X]Z /C3]H3X3>/-"\>?";XM^#?#
MP\57_A/3?[.O] CD"32*\87=&3Q\IKM_V&O@GXD^$/@'Q'>^+HHK/7O%6L2Z
MU/8QMN-J'/RQL>A8 \U](^6X/6I%7'7F@!1TIA&3_GBI*3'!% 'YW_M3^&_C
M1\5/CW;_ &SX:7'B[X6>')EGT[1X+L01W\X (DF)Z@'M72?%?P;\5-/^(W@#
MXW^&?A\+[5$T&;1-4\(PSA9+1I%*H0W0JN>U?= C*]&./2E"8)([]: /F']F
MSX">(/A-^RGKGAC4HHV\5:U'?WL]O$V526<,5BS[9Q7-_#OX6?%#X>?L5:!X
M=TCP]H]]XUTR<W$NC:V@DBFC$K,RKV#E>AK[#,8_'UI-C9^]0!\8_L]?"SQO
MXM_:DU/XU^(O!T?PWTQM$718]"#*9;B08S(P7C'I7VBHP*0+ZTZ@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,CP[_ ,@YL?\ /5J^,_VY/^"?VM_M:_$+1O$N
MF^*K/08M/L?LGDW,3,6;=G((K[-\.#&G'_KJU:7E9.?TH _+)/\ @DE\46B2
M*3XRE8E7;L#S_*.PZ]*]7_9>_P""6FB?!3X@VWC3QAXA/C#5K1O,LX=A$4<O
M]]B>2?K7WOLR<D\T>6._0=J %_K3J3%+0 4444 %%%% !1110 4444 %%%%
M!1110 4E+10 4444 %%%% "8I:** "BBB@ HHHH **** "BBB@!*6BB@ HHH
MH **** "DI:* $Q2T44 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_007.jpg
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $F C0# 2(  A$! Q$!_\0
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M6DPW)(G1A0!HT4W)QWI1F@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ*** /G+PY_R>YXH_P"Q?@_G7T8.]?.?AS_D]SQ1_P!B_!_.OHP=Z %HHHH
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M3-!\#^);;6XM5O[NZ@Z>?(2#7NZ\#K7J8:5><;UH\K];F\)2E\2L.HHHKM-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "#K3&..:7.>*\6_:-^/-M\+-%6PL"+KQ)?#R[:W3DJ3W_^M7)B
M<1#"TG5FS.<U3BY,Y+]ISX[7>F36_@CPB_VCQ%?GRY&BY,2GKT[UV'[.OP%L
MOA5H(O;Q?M?B*]_>7-U)RRD\[<UR?[,7P$N-%,OC?Q:#<^)=1)F FY,0//?H
M?:OI,)BO)P6'GB*GUS$+7HNQA3@Y/VD^HF!VH P?:G;:*^@.O83&?2E Q2;:
M6A*P"T444P"BBB@ J&YG%M"\K E4&2!UJ:F/@Y!Z'MUH ^0_%GA?Q3JWQCMM
M4T+6(DTV2Z5I;:8*&4 \X%?6.H7CZ9I<UP(GN9(8]WEQ\LYQT%?(_P 3+7P_
MKOQV_LRQM]3T?4H;J)Y-;24BT'/W,=,GI7V!"IBA56.2J@%CWXH ^!M$^)GB
MOQ7X^^+5OXPDUWPM9!8A&X4B*T@S]Y/<CK7U+^S]?33Z#=P07SZMX?A91IVH
M2_>G7').?>O2;W1-.U*.X2[LK>X6X79*)(P?,4=CZU)IFDV>BV,5G8VL5I:Q
M#"0PKM5?H* /D'QM)\28_P!LGQ!_PKR+27F.@P_:#JF<#GC&*^I?ATWB=O"E
MH?& M%UXY\\67^J'IBO%_#7'[;?BD _\P"'/YU]&T +1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A
M. : .#^,OQ0L_A/X+N]9N,/.%*P0D\N_M7@?[/'PHU+XE>*YOB=XW5IGE8OI
M]I(/E1<\'%4?BYJ%U\=_C]I?@VSQ/H6D2":>5#P''4&OKG2]-@T?3K>SMD$<
M,"!%51@<5\Q"/]I8N4I_PZ>B7=G$DZU3F^RBU&H7@  >U24U1S[4ZOIE9:([
M;6"BBBF 4444 %%%% !1110 5',=L;D@MP>!U(]*DICG!]#VH ^)?B;H%_K/
MQ)U*!/$_]F^%+NZC$NE0@?;HIL_+(HZXS7V/X8TR;1M"L;*YOI=2GAB"M=3#
M#R^Y]Z^/?B7I7BC2_C9J7C32_ACJ>L>(M.GCBMKQ)/\ 1;F$GD[?4"OL7P[J
M4^KZ-9WEU:/8W,T8:2WDZQL1R* -.BBB@#YR\.?\GN>*/^Q?@_G7T8.]?.?A
MS_D]SQ1_V+\'\Z^C!WH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBD8T -;FN!^-?Q"A^&GP^U+5GE"7.P
MI;YZ&0]*[_L:^.?CQJK_ !R^-.D> -*F>33K&0-J&W[JL#7D9EB70P_N?%+1
M>K.>M/DC9;L[']C3X>S6'A[4/&>IQ2)JNNS-,T<PY1<]OK7TH.E4M&TF+1M)
MM+"$!8K>-8P!Z 8J^..M=&"P_P!5H1I]473@H040 Q2TA/IUK@/C+J/BO2?"
M[WOA2ZL[6ZAY?[8FY6%=R-3T"BO O#7Q^U#2-"MW\1)#J<\P(%W9X2(28_U9
M![TLG[5^FZ!X6LM9\3Z5/HL5U<M;?,P;RCG"%O3-,#WH\'KS_*A3FO"=%\?:
MAXM^)&GPQWCVKHF\IM/E21GGCMG%>[*2>HH =1110 4444 %5KY9)+69(9/*
ME9"$D_NMC@U9IC]#GD8Z>M 'R5/X[^)FB^++O3I-8O=2O+2]1/L\-IFWDB9O
M^>GL*^LX'+1H6&&*C/L:^,O'GB^[\+_'M8(M<U/3+&XNHT73]F4.3S@^AK[-
MA.8T/7*CK0!+129Q1N&: /G/PY_R>YXH_P"Q?@_G7T8.]?.?APX_;<\3^_A^
M'^=?1@[T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1129H 6BD!!HS0 M%%% !36."*=36ZB@#BOC#X^MOAM\/]6UJX?R_*B98S
MG^(CBO%_V-? $YT[4_'FL('U;6)6:.7'WHB<@US?[2&OWGQ:^+>B_#;2V,EE
M$ZRW\:G(=<\Y^@KZM\-Z#:>&-"L=+L8A#:VL0CC0=@*^:I_[?CG/[-/1>IQQ
M?M:CET7YFIM)'6EQ11D"OI#K$(Y^M9'BC3+/6='FL[Z58K>7@LQQ4GB'Q%9^
M&[!KJ[E5%'0$\DUY,HUGXNZH[!GM-&B;  XW5I&%]7L1*5M$6[_X,^#;N^TP
MOJ*II]D?,%F) %>3^^3ZUS?B3]G#P1XH@E@O];$]K/<+/<0R295]IRH'/&*[
M?_A0^DR8,MY=LV/[_%65^!^B*.9KDGUWU5H=R5*3Z&KX6M_#6CI%:6,UO/,
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M_!_.OHP=Z^<_#G_)[GBC_L7X/YU]&#O0 M%%% !1110 4444 %%%% !1110
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MFM:G:?M0G2+?P6MYJD\B.FK;2+?R^_MD5]FQ@[4#8W <X]: '@>M)M'TIU%
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MK&A^(<];^4^A/^$UT'_H,67_ '^6H[CQ]X=M(R\NM62+ZF85\_\ _##>D?\
M0QZE_P!_34MM^P[X?$G^EZ[J5Q">J&0\T?6<R>BH+[PYZW\IW_BW]J/X?>$&
M"W.L+.Q[6PW_ ,JX#6_VVM&>!QX=T6^U:?\ @4Q$!J[/PO\ LH?#_P ,L&_L
M[^T".<79WUZ%IOP]\-:1L^Q:)9P;.FR(<4N3,ZWQ3C#TU':M+K8^8X_V@/C%
M\08VM]$\%R:&[<+-.OZ\T^R_9\^+?Q$+OXT\7/8JW06CX('IQ7UTD:( %55
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M>'[? ]16Y-\5] A_Y>=W^Z*H3_&S0(6P#*_T0UZG]FT/^?2*M2[%>+]GCP#
MX=- MP1_LBK?_"C/!)_Y@-K_ -\"LYOCGI]R=MG9SRL.N4-,'QI&3_Q+)N.^
MTU:RZCTIH+4^QJ?\*+\$_P#0!M?^^!2'X%>"&!7^P+7G_8%9O_"ZA_T#)O\
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M I)W80<CZ5\>^,]8TV3XU_8+FS@@TVVN4,,&W-W-(3]['7;7V'" 84 X7:,
M^F* /(]2^/4]II7B"2'P_/-JFG2^5!I^</<\X!%=9\,OB#+XZT9Y+[3VT?6;
M<A;O3I&W-"3T!-8?CKX*/XN?7;FUURXTG4+]$6"Y@49MBO<>M;_PU^'K> ](
M:*ZU*76-5GPUWJ$R@-.PX!(H ^?]1^(V@?#[]M'Q)/KEVUJLF@0A-J%LX//2
MOIKPUXGT_P 8:+#JNE3^?93<I(5(S^%?/VDZ-8:G^VUXI6\M(;H'P_#_ *Y
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M3GG/:OH"UL[>RB$5O#'!$.0D2A5'X"GJ+8E7BG4BTM,84444 %%%% !1110
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MX?L=:D@TU-.OW\J%V1LR$\8V]:Z"V^%/PGM[^WTR#1-+BN+B(W,<"+C>G=J
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M%K">#<'\J6/<NX=#CUH T(_BUX-,:,?$NG N@;_7#O3_ /A;G@S_ *&;3O\
MO^*SV^!/@0GGPW9_]\URFK^$_@]H7B&#1-0L-/M=1GQMCD4@<].>E ')_M(_
M';3-$/@=M!\9V5I]IUN*"Y6.7/F1$\@XKV=OBQX-B8HWB73@PZ@SBO-[CPK\
M#KW4-0M+C2])N+K1?WTZ21EC#CG</7\*@?\ X4<^B6FLF"P:PO)?*BF$;'<W
MICJ* /8="\<:!XGG>'2=7M-0E3[RP2!B*W*Y/P7X#\*^&E^V^'=.MK5;A0WF
MP?Q UUE !1110 4444 %%%% !1110!S/Q%N]0L?!^ISZ7I,>MWZ1$PV$IPLK
M>]?.^C^ /$,6GOXLD\,PWWB&XB>&^T5U"V[%ONX7IQZU]74F #TH ^:-,^'_
M (IL+#2-%N_"UK="\!DEO]_SZ=W\M#Z?2MGX-:!KVL>,KW6?%7A^#P[/92&V
ML;&T4*I1>!,S#[Q8<U[_ $F!G.!GUH 6BBB@#SOXZZIXCTKP++)X7\/6_B75
M'F2,6MUC8BGK)@]2O6O#;GX/:KILFHW]AI?]HR:Y8"VEBG7"PW1^\Z#^''J*
M^MJ3 ]* /EGPO\*?&NF7WAW0/L<-O-IT#^=XI.&F 9?]7GN!75?LK?"_Q%\+
MH_&MKXACW-=ZJ9[>[,FXW*<_.:]]I* !3D9]:1J=10!Y)\>KSQ&MKIECX>\/
MVVJF]F$=U?7"!_L4>>74'O7E?B'X.^))-9\36&FZ<L]KK440M-5D;$D#+C>1
MW4&OJ[&:,4 ?'^L_!/Q9XBUK01_9D6G:;H,'DW\L1PVIG^ZP_B%>X_ #P_K7
MASPA<6VL64.F[KIVMK6'HD1/RUZA10 U>!CTI6Z'O2T4 >$?&S3M>\5^+]&\
M.P:!"?#URX>\UYD#RP8Z*OI7&>(?A3XKUK3];\/6'A^WTN&SE$UKJ2/^\U",
M?P2'KS7U20#VI: /D?7?A=XEUT6^J'PW!;V!LQ;2Z2APB2@8#X'J>]?0?P<T
M74_#OP[TC3]8B6"_ACP\:MN"C/ S]*[3 I: "BBB@#YP\<>']:\>_$M-/OO#
M<>G:/:2>99ZK /WLDH[,1R :TM"\'ZYXGG\3KJGAFW\/P):O##]D(!OGQ@,V
M*]\P#VI: /E+4OA=XL32M#LY=%AN&?2I+#SGY-K(6RKCWQ7TAX(T>X\/^$='
MTV\E,]U:VR122D_>8#FMVB@ J*4LL4A50QP2%]3Z5+10!\J3^ _$/Q&\2W^J
M:[X>31]0TZYW:7;VORB2-3\V\_Q;O?UK:T;X8ZQXJ\%^)AJV@0Z1-/?K<6%E
M:MA,C'SD"OI# SG'/K2T ?.FL:#XG\2_$G1M$U30H+#PKIEM%(^JQ*#/>2X'
M[O=U !KZ&@010HB A5 4 ]<5(0#U&:6@ K-\17%S;:'J,MG:+?W<=N[16K'
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C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_008.jpg
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $  M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z0]*6D;
MI0 TFE)Z5QWQ%^)%M\/UT6%K&YU74]:O5T^PL+3:&ED*EB2S$*JJJL22>U?-
M.C_M5^,KOP8E_*MH;V#1KN^NB;8#$S:A]EMEP#P% +''7%82JQB['?0P-:O#
MVD%I_P /_D?8P-&<UY3\(?'7B+Q#X>\7V>H^5K7B#PYJ<^G).J"V2]*HKQEL
M?*A.\*<<#&<5YMX(^/7CJ3PWH>K^*%TQ96\<W/AC4[73XB8TB)9(?+8_,2KA
M<D_>S5>TCIY_YV_42P55N25KQ\_*_P"A]0BEK+\,ZO/KNB6U]<Z9=:/-,"6L
MKT*)HL$C#;21SC/![UJ5J<35G8:20:3(-*W(KQK]H+XC>,OA]=^"I/#MKIPT
M?4-;M+#5+V[8M*J2RJ@2*/N2"26)XQZU,GRFE&E*O/DCN>R9XHS7CGP>^(GC
M'Q7\4_B9H'BJUT^QM]#ELSIUI8,9&2&59#F20_><A5)P,#.!7/:SXW^(4/Q&
M\?Z;X9U-_$EMX>T4SKIKV$"L=0F!-M CK@D*HW-NSG(K-U$DG;<Z/J=3G<&U
M=)/?36UM?FCZ$X!SFC/O7R'JW[0'CS1/"V)KJ\@U/11=?\)!<W.DQ3^1>Q0)
M+%: 09412@L1+U&,9!KZA\%>(3XL\(:)K9B\AM1LH;HQ?W"Z!B/UJH34[V%7
MPE3#Q4I[/L;J]*6D%+6AQA29I&;%>(S_ +6'AJ"S2Y;2M4,;'6  %3/_ !+L
M^=_%_%CY?UQ42G&.[-Z5&I6_AJ_]?\ ]PHKP.R_:VTN;4%M[KPIK5A +C3H)
M[F5H66$7R@VK$*Y)W9P0!E<<U[V.E-24M@JT*E&WM%:XM%%%48!1110 4444
M %%%% !1110 4444 %%%% !1110 AZ4WO3ZYCXB^/-.^&?@_4/$>JK*]I9J/
MW-NNZ25V8*B*/5F('XU+:BKLJ,7.2C%:LZ7/X4F?6OERW_:/\72>-M4T2YLD
MT^:+Q-]D6SFB1Y(+&+3Q=3*64D.S'@,#QFNK_9Y^+GB3QQK4NG>(IX+TWNAV
M?B*UD@MQ%]G2=G4VYQ]X+M&&/)R<UG&K&3LCOJY?6HP<Y6LK=>Y[SN [T#FO
ME'5?CI\0O"UMXSE\01W&CZY:I/J^D:/=6ENUM/ID-RJ,=Z$R"0Q\D.?X@17T
MCX2\2OXH@N;@:9=Z?;I(JP2W07%U&45A+'@GY3NQS@Y!XIPFI[&-;"U*"4I6
MMY/T_P S?IIQ3J:>M:G()FBOFGQ)\=_&GA;XOOHUY9.;6[U.73-.T==/;_2(
M1;&6*Z2XZ,S2*4*9P!V'6NP_9]^(/B3Q':ZQI/C9KN+QMIL4%Q?Z5+;P)';K
M*K,@B:+.]2!CYCN!%81JQEL=]3!5:=/VDK6T>_?^K'L_&*,BOE[1?C!XQM=
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M$'AC1+;3+:>ZN8+<$++>SM/*V23\SMR>O>M2O-/[2^+H_P"8!X/_ /!O<_\
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M '@__P &]S_\CUFH16R.KZU7T]]Z>9Z3&H1 HZ 8IU>:_P!I?%W_ * '@_\
M\&]S_P#(]']I_%W_ * '@_\ \&]S_P#(]:'*>E45YK_:?Q=_Z '@_P#\&]S_
M /(]']I_%W_H >#_ /P;W/\ \CT >E45YK_:?Q=_Z '@_P#\&]S_ /(]']I_
M%W_H >#_ /P;W/\ \CT >E45YK_:?Q=_Z '@_P#\&]S_ /(]']I_%W_H >#_
M /P;W/\ \CT >E45YK_:?Q=_Z '@_P#\&]S_ /(]']I_%W_H >#_ /P;W/\
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MI)YJ"<?\M,29?GN36KX?^"G@SPEXYN?%NC:#::7K%Q9BQD>SB6*/R@Y?A%
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M+? G_DB7@#_L 6'_ *3I0!F_\)[\1/\ HEC_ /A06O\ A1_PGOQ$_P"B6/\
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M(_\  @4A_:+^&0!)\;:. .I-P* (O^$]^(G_ $2Q_P#PH+7_  H_X3WXB?\
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M;1P!W-P* (O^$]^(G_1+'_\ "@M?\*/^$]^(G_1+'_\ "@M?\*F_X:*^&?\
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M=0P74_$4$GB6T5Y/]U3R?PKY(3XI>,9T^'L%M\3]6LK.TLT6_ENI()+IKXW
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MQ$_Z)8__ (4%K_A74^$/B'X:\?174GAS6[+65M&5)_LDH<Q,1E0P[9'(KHJ
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M^^?:@V5O_P )*@\B+_CT/\ _OCVJ;PU_R!8/J_\ Z&U!_P"1F3_KS/\ Z&*
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MU &-:V=N=>OQ]GBQY47\ _VJT38VV#_H\7_? JI:?\A_4/\ KE%_[-6D>AH
MQ_#ME;MHEH3;Q9V?W!ZFA;*W_P"$D<>1%C[(/X!_?-3>&_\ D!VG^Y_4T#_D
M97_Z]!_Z&: (+JSMQX@L!Y$6/(F_Y9CU2EN+*W'B"S'V>+'V>7_EF/5/:I;O
M_D8;#_KA-_-*6X_Y&&R_Z]Y?_0DH K6MG;_VEK'^CQ<>7_RS']RJ:6EO_8F@
MG[/%S+ /]6/3Z5HVW_(2UK_MG_Z+JFG_ "!- _ZZP?R- &Y]AMO^?>+_ +X%
M'V&V_P"?>+_O@5/10!!]AMO^?>+_ +X%9OB.RMQH=X1;Q?<_N"MFLSQ)_P @
M*\_W/ZT 6UL;;:/]'BZ?W!2FQMO^>$0_X *F7[H^E+0!YAX$B2+XW_$T(BH/
M)TK[HQ_RQDKT[I7F?@?_ )+A\3?^N.E?^B9*]-H **** "BBB@ HHHH \S\*
M?\E[^('_ &"])_G<UZ97F?A3_DO?Q _[!>D_SN:],H **** "BBB@ HHHH *
M*** ,_Q!_P @+4O^O:7_ -!-<M\"?^2)> /^P!8?^DZ5U/B#_D!:E_U[2_\
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M1S1_&OXF+/*)G\G2OF";?^6,G:O4J\R\#_\ )</B;_UQTK_T3)7IM !1110
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M]M81KFF@0Q@%9>-H]!2_98/^$D(\F/'V3.-H_OT >?\ CW4;74HX="2[@/\
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MO&F!]@V^K60U#6#]LM\-Y>#YJ\_)]:J+JED-&T-?M<&Y9821YJY''?FOG_\
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MXO[*-_-:ZD,:RQAF)!B!9L<9P!DTDMG_ %M<'I==O\T?0/\ ;6G_ //];?\
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M(DJ>3I7S(P(_U,GI7J->8^!46/XW?$U54*/)TK@#'_+&2O3J "BBB@ HHHH
M**** /,_"G_)>_B!_P!@O2?YW->F5YGX4_Y+W\0/^P7I/\[FO3* "BBB@ HH
MHH **** "BBB@#/\0?\ ("U+_KVE_P#037%_!V5X/@'X(DCM6O73PY9,+92
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MW6X&9N/E_P!VM#SM7S_QZVO_ '_;_P")H 7P[_R"U_ZZ2?\ H;4L7_(Q7/\
MUZQ_^A/6;H,NJ#35\NVMF7S).3,P_C/^S2QRZI_;UP?LUKO^S1Y'G-C&Y_\
M9H T'_Y&.'_KU?\ ]#6AO^1DC_Z]&_\ 0Q6>\NJ?V_"?L]KO^S/QYQQC<O\
MLT-+JG]OQ_Z-:^9]E;CSFQC>/]F@">+_ )C_ /OG_P!%+3'_ ./+P]_OQ_\
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M?S,=/VT_@\J*/^$OCX _Y=9O_B:=_P -J?![_H;H_P#P%F_^)KT5?"T!5?\
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M9)<CS&[ >]<GJ7AJTO?C5HJ(FV*PT>XGD0NWS^;(J+@Y[;#^==Y??\A[3/\
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M)!&WYOD;IS6[I',NK?\ 7RW_ *"M4+'_ (\O#G^^?_0&K4X32_MB?_H%7?\
MXY_\52'6)_\ H%WG_CG_ ,56K10!YI\4=3FM+#2-<73KJ*32=3MYMV%W-&[>
M4Z YXW"09]A74:[JLS:/?(=-NE!A<%CMP./K3?B1HTVO^ /$.G6I1;FXL9HX
M6<X"N4.TY[8.#FHK+6(O$'P[@U.WW^1=Z:L\?F<-AHP1GWYK):39UR][#P?9
MM?)V:_4U(]8GV+_Q*KOH/[G_ ,53O[8G_P"@5=_^.?\ Q5:,7^K7Z"GUJ<AS
M=MJLPUN^;^S+HDQ1?*-N1][WJ^=8GP?^)5=_^.?_ !5.M/\ D/ZA_P!<HO\
MV:M)NAH YS0-5GCT>U4:9=. OWAMP>3_ +5 U:;_ (2!W_LVZS]E V_+G[YY
M^]6CX;_Y =I_N?U- _Y&1_\ KT'_ *&: ,VYU68Z[9-_9MT"(91M^7)Y3WI9
MM6F.NVC?V9= B"4;3MR>4]ZT+K_D8;#_ *X3?S2EN!_Q4-E_U[R_S2@#+M]4
MF&H:L?[-NB6V9 VY'R=^:JIJ4O\ 8^B+_9]SA9(2&^7#<=N:VK;_ )"6M?\
M;/\ ]%U33C0] _ZZP?R- %_^V)_^@5=_^.?_ !5']L3_ /0*N_\ QS_XJM2B
M@#+_ +8G_P"@5=_^.?\ Q59^OZM-)HUXITRZ0;/O-MQ_Z%725F>)/^0%>?[G
M]: &KK$^!_Q*KO\ \<_^*I?[8G_Z!5W_ ..?_%5IK]T?2EH \M^'T[7'QK^)
MCM#) ?)TKY),9_U,GH:]2KS+P/\ \EP^)O\ UQTK_P!$R5Z;0 4444 %%%%
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M&I6=XA_Y =]_UR;^5,_X1ZV_YZ77_@0_^-4==T&VBT>]<27!(B8X-PY'3ZT
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M?R\OEU/6P]>.(IJK#9[>?GZ/H=)2'I69_P (];?\]+K_ ,"'_P :/^$>MO\
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M;?=/TKF]+UI4NM2/V*];=<9P(#Q\B]:T&UY=I_T"_P#_  '- #O#?_("L_\
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M/N>I/J:F\1?\@>;TW)_Z&M<3%K?BWPJP\VROO&%BQQNCM4MKN$=R1D)( .P
M;/KFM7_A-K'Q/X8-[8V]\\#L%.ZW*E&60!E8=B"",5R>T<Y-R>OF=#PSHP3A
M9PVNOZNOFCM:0]*S/[>7_GPO_P#P'-(=>7_GPO\ _P !S5&(NF_\AC5_^ND?
M_HM:U*YK3]:":IJC?8KT[GCX$!R/W8ZUH_V\O_/A?_\ @.: #PW_ ,@6#ZO_
M .AFFN<>)4_Z]#_Z&*H:#K(BTF%?L=ZV"_*P$C[QK(\7^-$\.Q7NJ&QO'>"P
M8)$T)!=RX"C&>Y('%)M)79<(2J34([MV,[P(?[9\6:EXC<%6O[F:TB7MY-N-
MBD>N27.?<#M7<X_XJ4_]>G_L]<AX0M_^$6TKPWIDEM>R2VMO*)#Y!^9V^9MO
ML"3^&*WO[:'_  D!?[%>_P#'KC;Y!S]_K4P5HJYOBIJ=:3CLM%Z+1?@7M(_U
MNK_]?+?^@K5"Q_X\O#G^^?\ T!J32]9"2ZG_ *%>G=<D_+ >/E7K5*TU95M-
M!'V2[.QR>(#\WR-TJSE.THK+&O#_ )\+_P#\!S1_;R_\^%__ . YH TSTKS?
MXQ*-,3P_KI_U=C>-;RLWW$CGC:)G/?@LN/<UVO\ ;R_\^%__ . YKGO'TB^(
M?!.NZ;]COHS=6<L2L8, $J<<GISWJ)IN+MN=.&G&%:+GML_1Z/\ !G8PC$:_
M0=:DKC/ GC;^W?">G74MA=K=^4(KJ*. D13K\LB?@P/X8-;_ /;R_P#/A?\
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M*\S\*?\ )>_B!_V"])_G<UZ90 4444 %%%% !1110 4444 9_B#_ ) 6I?\
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M& &R')_\?+>M=:D20Z_#&BJB+:-A5& /G7M2]Z7D5>A1V]^7W1_S?X(Y#2/
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MN47_ +-6DS<&M#C,[PW_ ,@.T_W/ZF@?\C(__7H/_0S1X<.-$M/]S^II ?\
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M,TNULYS$<H9(XE1MI[C(.*Z7%+0 4444 %%%% !1110 4444 %%%% !1110
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4OW#' _>+C\:[(48I: "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_009.jpg
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $@ 18# 2(  A$! Q$!_\0
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MA)IFKB:Z-HN\-8PE@@/0GTK%\#?LV>-M8NKB\L]'D>*UDW9NL1M* <G:#UH
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M$>Y[>W".;.,9#*.#GH*^6]!U^S\,6"RO;37-PIQE4.$/^T>U:%SXA&O1F5U
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M6WO+2"$@/@CE0*]5U?\ 9D^''BKX<WUJRKI&HPQ%8E)VR*0..#0!X=-\4O\
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M]X8\8Z:9]&MC#'8Q%Y"X R6'0>IKS?X0Z?)XL\">+?%UQJ[>'?#&EEA'9F4
M3)W7:>WM7&^'/@II/QTU/2/^$*M9+NWN;K;.DC%5"C[S-Z#VH [_ /8%^&VI
M7?Q U/XN^(]-8Z T;BU#KG#-_&!Z8[UF?M7?M8:78?$"&VT?2'62UN1(YE^3
M>N*]?^,?B?Q%^S1\,M/\$:?('T^13;A%PQC &?O>E?#/Q-N-+\=Z"EX\3MXC
M:81;D'0>] 'U:ES\*?'>C6'B;Q?K3OJ-]&H%M;SD1PJ!T"@]?>BO%_A9^R>G
MBGP?'J<U].BF3R\*W ..<44 ?8UI8);VNR1"(QR#C!%36=VQ1[5S#.Q R7YD
MV Y(3T)K5TF..Y^U+(PFMV'RL#P!1),1906PM%<12;A=; 'V],;O2@!;:R;6
MYA/!8QZ38@>6D<IR[G^]FL3X@1RZQ?Q6L1\Z6SA#PPN^?.4?> KK-5L4=3%;
MWZLZ $QYQM'KBL&Q\-K>ZHEX\KK,A!W=0<=0/0&@#FKRQO?%&IVESI(N=/G2
MVV[HK@J4 [9SQSVJ2UL;^+PM?:1J6@Q3?;YM\&KS-B6&0=3GJ<U>\3:'9Z[X
MA.H^'KPZ9>LI22U8XC<]RN/6L&VN[M[B2TN9Y4E# &WD/\7M]: .JTV_72="
MCTN+49)+IN'2#D*?J*IW^M1Z>?(69I[@CYW?M4Z/'X9L&8H!<29&YNV1VKB;
MF5KEV:5MS@]CUYH H>/M,@\=>'[JSN8\N1\DC 91NQKXGDUCQ)/\0T\/Y6.:
MTN!;F7'"8/6ON9XQ<2!&544<G)_G7BGQI\$7*6]UJ6AZ0EOJ#-YINE&?.7V/
MK0!N^(/%$7A[P+9Z7XH2SD$<D<MM?D@ ,IS\P^E:'QYOK35/!,.KV$]M)'-
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M&AZ.NA>) J&_OI6.V-1UP>AKY-^('QRU3PEXE?P-%J U&,RC%Y;R]5SR1[T
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MIVL_M'ZS!I=Y(EO;V@,TTG)8_G7H'Q0^%MMH7AW2-'M\"! 50,,;W)QD^O-
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MX4UC0?$%OIB69:2="8_+'6OH'X4>'[OX4:';SW8:_P!2U.,(B/SL)'&3U&*
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M?%OCCP3IAE_X2;4FL]0N2VGN\X.^WV YZ<X)QGVKS.T^*OBS4[F&VN]>N[B
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MW_H/^'_^_C?X4?\ #F+XN_\ 0?\ #_\ W\;_  H ^'/[8T;_ * (_P# MO\
M"E_MG1Q_S A_X%M_A7W%_P .8OB[_P!!_P /_P#?QO\ "C_AS%\7?^@_X?\
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F ^'/[8T;_H C_P "V_PHK[C_ .',7Q=_Z#_A_P#[^-_A10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_010.jpg
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $^ M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]-:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **,XHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBC(H **,BC(H **,BC(H **,BB@ HHH_&@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .#^/'Q1/P4^#OBWQV--&KG0;(W?V$R^4)L,J[2^#
MM^]G.#TK\^_^'V0!Y^$*?^#P_P#QJOLC]N[_ ),\^+7_ &!6_P#1L=?SZ#=@
M#L*:5QGZA_\ #[(=?^%0K_X/#_\ &:/^'V@/_-(E_P#!X?\ XS7Y>%<]>*:0
ML?/-(1^HO_#[(8_Y)"O_ (/#_P#&J0_\%M5''_"HD_\ !X?_ (U7Y=D[P,9
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M_P %%=;TN-FC^%0N2HW;4U<YQ_W[JCX;_P""GJZ[J!L)?AT;2\'(C.J;L_\
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M/M7R2?\ @MG+_P!$AA_\'K?_ !FNJ_X+4\?"_P"&WK_:US_Z*6OR2;)Y!R*
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M%?>)H9;"%S9:=C877G(KL#X*U*YM%1K>X\I%[)@4W^S(]/M2CK)"!P2R':*
M.&T#X2Z3X?>6>UOYQ.QR7)QFDU'X5Z/?ZG97$\;74@;<68D;A78P?8IK=K6.
M\B,I((RV3]*T6M7:^M@J@^3&,XZ&@"E:>'=-LX0MK:K"HZ@US^I:99:!.NMQ
M*X>)]KQH/E;-=;?P2>7)%N:*60<$=JJV^B7=O8"*0+<IU(EYYH YWQ;X$M/%
M6GVRW495W(=7 YY[5R>H>!;>VN6TVPTLF:)>;@L1CWKTC4=,GO)K?;<NCQ'=
ML!XK*UFZUC7(KBRTV$VEVG6[[MB@#C=3LO%,.@)9K:QO'G#.6R=M;V@>+-%T
MZPMK.2%8KR,!#O3G=[5T/@&^U2^TTIJ:2>= Q0N5R'QWK4\1>#K#47BU![*$
MW$;;AM&&SZT 8_B7PY%XOT,R*H-W%S$Y&,&O(/$WA]/$.G7VD7*BVUBW4A9.
MI88_K7M.H^.-)T6P#/-B=VV"%!D@^]>"^,'URS\2?VY)#-';W$@^?;\K)0 ?
ML^>-[_P_-<?#N\MR%U*1GM)1SLD [>F<5^T?P566/X0^#4G!$PTN(/NZYYK\
M5?%^CR)I-GXX\,S;-3TJ3S)UB./+ /WL5^S'[.7B&X\5_ /X>ZQ=8-S>Z+;S
M2$=-Q!S0!Z+1110 4444 %%%% !1110 4444 %%%% !1110 4'I10>E 'YS_
M /!:90?AA\->,_\ $WN?_12U^2V,<&OUH_X+3G'PS^&8'?5[G_T4M?DP>#@]
M:  8 IK(&J1%RV3TH?:K=>3VH 8P 1, CL:] ^"7@)_'7C"TB:V::SMV\VX;
M^':#TK@B=P5<'.":^IO@S9Q_#OX-7.L2#_B8:H66,+]X+ZT 4/CS\0(KB:/2
M-#D:VT]!Y9CA..!QBJW@O2CX7\/1,X"S3_.S+]X@] :X"XL6UWQS9V:'=D^:
M[8KTW4-26UNTRN;9!MZ< B@!)+*:1#J$L1$*GD?WJM+;6.L6P-H!'/U((ZUJ
MV6I6NO:;<+&^=BY*C@5YO_:\UM?30P97#D;@: .NTF9XKYXIW^SA.-I/6J&L
M7%UK&N0VRVH6V<[5D#=#ZUT_A3X?R7GE7U]=&0N,[3W!KJ->ATK1+"-71+>9
M,E7V\F@#*L/A-:O'#<7MY-)M'"@\5JW=C-X*L/.TRZWPC_EE)SNJ"'QK%<:7
MLM%GN9R, [?E_.J3Z=KUY;"\E"(J'*V\C=: +%F-7\7-%+=+Y=B_WH^]=*+.
MQ\,6.;95'< CYLUE:)XG6_!AD:2UN P4A4_=@UT%IHEW+J9GF*3QA1M!&1F@
M"GIJ7%K=OJ&J,%5U#QHAZ>U0>)/#^J?$:U,37,=A8@Y3*_,PKJF\.RS2+)++
M^Z')1E.,5:NK19(UBMW5?0'CB@#B]#^&$_AS2A:V^J,8G."0*BTKX4V%OX@G
MN)[J=]PR0KG&?I7HHL'F6U5)%PA^?#9S3XK-_M5U-MRAX ]Z ,&^\(:9<6OD
M-:QF/HLA7Y@?7-4M+L;73VDT!S]K+_O$WC@#TK?U*SOYYX$@PL8/S&IO[.EC
MNXKC[,IN FWS&H \RUSX165SK,NI-F"VBCS)#$.]9MGHL]K,EUI*70A#8V,_
M!%>GQ/>Z5<75W??OK5_O(G/%<_K^OZM;7,5]I6GK_8BD;@5P?RH YW6-5ENM
M8LWU2S>WL8A^\.<@UW6BWWAR:5#IMK"'/(/E@&N@TR&TUNV0W%K%.91G9)'T
MK'@\%6'A'69+MK<Q^=]W+?*M ',^/_!C:7?KK-A&H209D6,<L.^:\0^*G@\R
MVD&MZ,$1=XWQIPP<]Z^C_&?C"QL=-FMK6:*ZOS&5\A3G'TKP70M6<ZK+I>IH
MPMY22=W&,GM]*!'OG[,GQ"'CSQ#X"DMU9;_3-6L[/4#(/F<^8N#]*_6>;_72
M?[QK\5/V>=1U'X-_M.>%]/$276C:_K%I!')(,##2@!A[C-?M7*,32#.<,1^M
M QE%%% !1110 4444 %%%% !1110 4444 %%%% '@_[=_P#R9Y\6O^P*W_HV
M.OY]R%9>3C XK^@C]N__ ),[^+/_ &!6_P#1L=?S[A5D4@D@@"JB4MF" 8)!
M! %.54?&.>/RIKA-RJO"=Z0(JR_(3LJ2148!1NR5!KZ+^&2+IOP5::-L37,S
M$@=2/>OG$G*D!<Y/2O?S<OX4^#ECE"CF/*D]RQH YS2"GB;XBVJ<-!; $KC\
MZ[_5=5-IX@+IYC6T9"B%1FO-/A-+YOBVX*OM9XBPD)YS7J6BG3KWQ=:QS/++
M(ZMOP<#([T :2>)/##E7NK8QR'EE=""*S?$&G^&)K9[J*22:213L2/)VUMZW
MX$CN899+.Y5P1N>*0 M70>#+&RL= 5%LX7=6PS;06% #O 6C/'X.MO[-?<2,
MLK?*3[5BZ_<:GXAUNWTA8GBAC/\ I !X(^M;^J^*]+T6,K;F19@?]2BD >]4
M/#UMJ>JZM'%;2HIOV"M(_P!Y%)Y(H 9;?#^_EU^&R\)6[22,NV;'//N:]U\&
M_ )[*%;GQ7(ZN%!,,4G'XXKU#X>^ M/^'VC_ &73E%Q-.H,MT_+9]C6+\:O#
M7B#7?"-S!H4C03LIW.'(8J!T% '-:U\4OA1\+G>*U:U%U]UUB0NY]<FN,\3_
M +7_ (9TJ<+H6E0W@(!!92*^5KOPMJ-C>.+J(M(&.Z5\LV<^IKK_ (2_"G5/
M&_B00&VVV8R3+(N!U]: /=],_:WU760D-CX>%Q(XXBB!.:]-\)Z_XG\56"F_
M\)PVL=P,LD[ ''XUB:3=:#\/C'X?\+Z3;W?B%4Q+<[<B/CDDFN>UOPUXXUJ[
M,\OB%@&Z)&Q55]AB@#TJ7X0>&]<*RW6DQZ9=J<F2UGVD'UZU;TSX.Z38WC,-
M=NW7^%&=3^M?-WBK1/&/A<27<\EY<V(',B3$8KE(_'TD01DU^^TRZ7D;Y"RY
M_&@#[.OOA18R*[0WKM<!04$BUYUXELI=!NXK'4U:-I<X<#Y2,^M'[-OQJ?Q-
MI5YI/B75[:;6XI\6^\[3+&1P0:])^*TVGP^%Y7NS&S0M^[:5@6SGM0!Y6FFP
M6@+*6<MT)-5[5$DAE3826;DK3Y;V6YC1K=UEB*YR.U/6\MH--9@65&/"CJ6[
MXH LVDT>DVXDRBKCA,5R%[X@UJXUMWM[$FV)P)&'%:5E;:[/KV^>R271'3=;
M@CY@WH:Z2+7&M[<V]SIQ0*V"$3I0!D^&/#/AO3);J\O4,E_=D,=R[D4]\9KI
M2-$\6V,NGI9H;>!2&9D[>U9LNI:==AHYM+>*./GSQD 5<\)>)M*U/4[C2=-6
M,I;J!(R]6)[9H ^>==\-66D^+I]+C>1-.O5,,L(Z8(.#C\J_6#]F_3/[&^ /
MP]L<@^1HT,>1[9K\W_C/X6^R1R:K'$T3Q_,9%[ &OTF_9ZN&N_@5X F;[SZ/
M Q_(T >A4444 %%%% !1110 4444 %%%% !1110 4444 %!Z44'I0!^<O_!:
M@?\ %L/AJ>XU>Y_]%+7Y+D,S9!!^M?K1_P %JC_Q;#X:^G]K77_HI:_)B.$N
MT9/3O0!((\@9:B2)=N<<CO3"&E9PI"A>E-+NI&_D>U $D0)F0=V(0?G7U#XF
M/]C^$M T\OLA6V#[!],FOFG2;<WVJVD*+\SS*OTYKW3XL:U]BT^PM1(-Y4(&
MSR %Z4 9'PNB&HZUJNJ.NWRLK$WI7:Z%J>F:BTL.JM''+NX!-<A\)"1X8O<;
M1NE*ENW2NT\/>#8M;TF5DN8+BX$A7('Z9H UQX9TI%D73KT0SR<!5;(:N7'@
MA+7Q#:6[:@)I)),NA%3+X.O++6;47"2VR!\!HWX(KTF+P3H-O=0W#*8[E?F\
M^20DDT 7Y)I-#1/.B*01+PR#( KAY([CXE:I-'YQ2TA)VL5ZBNQUWQ.MO:RV
M$=S#-(R[50?-QZ4GPU\-WWBNYAT+2+1K1R=]S<XQQZ T <[X4T[4S?G2M-L7
MNO*;8DH7K[U[WX/^ M[J2))XBU0P6[C<;=1@X]*]:\)>#])\%Z?#;V-H!<J/
MWT\@#,6^M>"?M1^/O&.CN+32XY[*Q?A[B-#D^P/:@#U/^ROAQX+@;2I&MD8G
MS-Q;+$^N:YB\_:"^&>A7(MTCN+B8-CY(@1Q7Q!=3W]RS7$]Q<SR?QM+(<UZ+
M\%OA!+\0+HS/'<6]HK?/,W'R]^: /IF__:;\!7""(VD\N[@!(*W$N?"GCBQC
M_P! O8HL ^8D90BN9E\/^"O $/V7PEI,7B'54YDEG&\!O3TK*E^)/Q-0.L.F
M06=N.B1VX^6@#IY/@3>IJ!N_#FLR0QNN1!>KG/XUNZ+\)O$<4/EWEY9\G)(;
MG->,W'[0OC73KAK:[U1+*1#@"6#O2Q_M*>.-"Q>>98ZW:*=TB< X]A0![#JO
M@34_#J&9HTN$DR=\;9P:Y2XM9-0E&RZ"JHPZ>]>X^#?$4/C3PCINJB-!'>Q"
M4QXRH)ZK7FGC'0+/0/$TC6:O%]H4R&-C\N?:@#EIK01VDD&=XXS1<6D=PD<8
M 2,  ICAJ4WOVV39(ODY;!;'!J74KF.RB#;T!1=P '+$4 7;G4+70M,9YXA&
MP7@ <UQJ>(/^$PM;JPBAD660$":3HGN*O:'K-GX@LS=ZE#.A639Y,J]JZ9+;
MPR^V2)H[8+U$>0: ,_PC\-/#WA^W@NM0DAO+Q1^\G<_-65\3OAEH>N:3+J-E
M:1Q2Q\QS XS76/I>C:@RO;:FTD./WB$XP*TS;6.J^'9K>S,C6Z?*IZY/M0)G
MSS\+-)O=?^*'PYCFE6YET?Q1I[HOI'YZY/X5^S<W^OD_WS_.OR1^&>G_ /",
M_M ^#+< M'+K5JI+<?\ +45^MTPQ-)G^\?YT#&4444 %%%% !1110 4444 %
M%%% !1110 4444 >#_MW?\F>?%K_ + K?^C8Z_GT4A6YZ8K^@O\ ;N_Y,\^+
M7_8%;_T;'7\^9&0*J)2V'OL,?')'O3%^Z#[U(%V@\=>]-4@=?NYY%22=7\-/
M!EQ\0/%=IIENK-EMSL!P%ZUW?QQ\61FXM_#=N41+$"-V'0[1C'UKI/V2(%T^
M;7=85&>1(Q#'QP*\D^+$0/Q$UIHL,IF)()[]Z (/ MZ\'B.&>WD$3*I !/6O
M=_!_A"VO;Z/4=1=UDDR048@5\^:;#'8S6=RI =6&\-Z5]46NM0VG@VTNK"$7
MTAC#>7'S@T ;-EHNA:E?-8QRRB>,?,5D.\UGOX6U#PI<BYTVY>2T>4"1)><#
M-<=X9\0:EI_BI=9N;9A#)P\<8RRCWKW9((/$FEPM#*/(E7>06P=WO0!4;1UU
M(*B6D+&1,M( ":CL_#TF@7,5Y;W DFC^Y%BKL&C+:3*T%\4*C!BW9-:5RZ1Q
M!I(?G4YXH Z70?BSXC6V$1VP@?*#+&"N:Y'6?VH/%]GK']EZG:106Y)6&X2+
MY''X5IVCW%]E(E\J(+\QDY&,9S6/*MAK_A2Z>S=+G8Y#>8 3&1QE: .FMXM.
MU]86N;:TGBE4/N6+')KT3X<>%],T>2[-O:"&'RF)*@D@]L"OG/PEXWO/#MO)
M9:]IDEM:6_$5\ISNYXXKUOP!\93KEC(=)?=-"3&Y*_?';% '$>$?'$LWC;7$
ME2WB=)6C#NNUR,UZA;ZS&JA>%?&2>HKF+KP'IVK^)3J<$9^U3<RC&WYJZO3?
M!D<FJ?9YKN--H!*!LD4 <7\6_B>NA^%[FV>R^UHXQ@KD'_"OES5= ?QO:MJ6
MFQ+86F=K[W(RW<#-?HB_@319;&6.XMH+E>C^9'NKF+[P%H.G6RV3:);3V>[S
M,!-O% 'QWX-^$NN_:K35+#6K*S>WP8LR L37H?Q%\>3PZ9#9ZYJ OM2*E2(/
MN^U;OQR^$5C)HK^(/"EO+836PS):6\A V^N*^8EOKR[+NX:>?.PK(<L/I0![
M3\/_ (KI$([*<J6Z*.XKVO0=,M9]EY>.)9&^:*)3P#7R';> ]4L=2T<ZE%/8
M0:E)LBE;Y6/TKU&2_P!8^&?B6PT^XN[B\L0H8%OF84 >Z^%O%)EUJ]M]0$=H
M8WVJC'M[5UNHZ,FHVC-8S+YDG)<]*^>->U:'QS\2=).]K2R107DCR#*<=S7L
M$GB[2_#MNFF:;*UU?[#^Z3YBOUH 'A6WN4@A8&-05NGDY4UA65K9:!K7V^V"
MHD[995& >>M7]'6_GT:[CU6!8'N<[67J :JQZ;;V^G1VUTQ:.+[I8<T /^*%
M[;:CX7OEN90EMY>,X]:^]/V=XDA^ _P_2,[D71H #ZC!K\T/B7=7-AI<45O>
MB[M+@X>(@<5^F/[/8V_ OP$,8']CP#'YT >@T444 %%%% !1110 4444 %%%
M% !1110 4444 %!Z44'I0!^<O_!:K_DE_P -3_U%KK_T4M?DW;DG(YQ7ZR?\
M%J<_\*N^&WOJUS_Z*6OR6A0EN^* 'M&7=CP*;CC[X%.8>622<BF%BQ)#*/PZ
MT >A?!SPI-KOBBUNFA,EC9GS9Y >% ]:N_&;Q#;:OXG$=F0;>'A0.QKUOX-:
M'!H?P'U>Y"!;_4$<[^X4"OEZ1YOMDAD?DL>3WYH ]*^&6LRQ:;?V97,<A^0C
M^]BO:/A]X;U33M+.;Y8H&;<WR@8S[UX;\*H/)\1Q6EQ,JQR8(;U]J][\4:KI
M^A:?+:12DW4H^2%,DGB@#1UW1->O+1);:\AO4B/RAL CZ5:\,W4VMM+I^JVI
MCG10#(IP/SJO\)O$$.J:4;&ZF"WL;96&8XD(KLKK1KQM52]@"IQMV.,#\: .
M<NO EC#-%-IUO*\P8Y=B379?#GQ)<_#^[:>[B8$MC"^E3Z5=W^UXKF)(8P?]
M9'T-2S6MN+@>=(LRMR-QH ]5?X\:1I-E]LDTV=XD&Z1T^:N/U[XQ^%OB[;G3
M%M6FMI&W! V&!'O7-7JQ-9R>7 8[<G#M)\J&N&\1>%+#P5JUKK%A!)%N8/.D
M>2I'J .U '9O\$?#6IS9M$EMF8[MCG*_C7I,]AI_P^^%%Q/:H50 QRX^4_4"
MN%T'XA:)LANFU",0NP#1N_EE?P/->@:_JVD^+?"TFBL@DAGC)CN4?(H Y;X=
MZEIPT&$V0,9G.]F8?,Q^M=G%=P!2S$R+U:O,O G@K5]%C>!'DN(8LJJE,X'K
M7=:%X6U&_<JZR)'GDKQ0!YW\<[WPI=V4$$EQ%!?'D2 8(/O7S!?VNMC6VBLX
MKF:USQ+'&2&%?:OC?]F70/&<8EOFNA<J01M?&:@;X!Z*!#;Q:S>::8(PJGMD
M4 >6_ ?XC^-/!%NVGW>FWC:8X(C,J?*A]:L^/OB5=OXG@NKK4"[\*8HR,**Y
M+XG>,?&?P[UB\T*YNFNK1AMM[@QXWI['O7DES=3ZA< *D\UVX!VH"6)]A0!]
M8V/B*RUNTBDMA]HE/W47DYKHDT6'3+)]6U23=(@R(P,X]L5\N_"NZ\4Z?J$]
MQI,08VS9F@N =X]>*]Q\!?%.T\2PWT>J>7%+M97@E<!O? H ]8T*SM/$>E_:
M(8D^<?QX7]*S-5\+O;7D<5K9H W#R]0H]:\]^%>K:MK^KZA':7:)I5M-B+>,
MDCOS7IGBWQM;:?I;6L,@O[IB%>.W.XC\J .>U30;74[.\LA&\#0C"SPG"OGW
MJY\/9AH6GG3)')6+IO.2PJ/53.VC63V ,9W S1OW%4KBSGAD^UVSK)(V (FH
M$QKV(N?CG\.[N!52/^W[,D9Y_P!:M?J!/_KY?]X_SK\G_"^MRZM\?O =O-"]
MO<0:[9[E+84_O17ZOS<SR_[Q_G0,91110 4444 %%%% !1110 4444 %%%%
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MHT/B;P_J-A<XS+ RJ7Y0-CBOC#P)\+=3U+Q=>:7/8B]M;1BLAC&!U]Z /?\
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MV)!^AH ]?HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#THH/2@#\Y/\
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M4 %%%% 'A'[=W_)G?Q9_[ K?^C8Z_GVC8[>>>O%?T$_MW_\ )G?Q9_[ K?\
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M+#RJ1/0P.'^LUHP9>^%V@KXBU!'NI))I'?=@\X_"OM7X;_#Z2/38HY+"-T)
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M'^=?E%\.O[&\,_%+X=Z98QI:0KK=DF(P%RQE7 /O7ZNS?ZZ3UW'^= QE%%%
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MD^+O">K:']CUB[>&.:[A667RAD(_KFOKEM8T7XL:5XN\57UIHVL:]*IBM)9
MO[GT(QWQ7G%WX&N=<\(7%MJ=I'+;+%D20MD@_2F!%\#OVEKB![?PSXEB%W,[
M8BN44<)CC/Y53^.GQ,F@\9:;=Z1-NC:$EHRV!D&O"+*.7PAXH1)&_>H1Y+'L
MN<8)J]\0YYI]3WE",$85><4 ==/^T[<W7FQ'3U,\?[HLYR 3TQ3;2'43I_\
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M_(U^)O[4MX%U?1M/#;_)M Y]03R:_;']C<D_LI?"8GK_ ,([;?R- 'L=%%%
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M*P^&OK_:]S_Z*6OR:"\_-D#O7ZR?\%I^/AE\-"#R-6N>/^V2U^3@W, WYB@
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M(=0086#.W?3OB(PU?P;/:O&LC9&PGMS7CEUIU[X"UC1-3SY,R2(V^(_>&>E
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MN[X8_#4#K_:US_Z*6OR9#E6 ZU^LW_!:;(^&'PU/_47N?_12U^38(.T8Y'-
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MW-?57QYUF1+;Q-=K(#'(PB48KY*3>[#G*CUH$ST?]F!&3]I+X6$C_F9]._\
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M^G?^E"5_1G/_ *^3_>/\Z (Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M/"/V[O\ DSOXM?\ 8%;_ -&I7\^C."H'(S7](GQ[^&#_ !J^#7B_P+'?KI3Z
M]8FT6]>,R+"2RL&*C!/W?UK\]U_X(L7('_)3+'/_ &#I?_BJI.P'YA8R?3 Z
M^M*N5!YX]*_3QO\ @BS>-U^)UB?^X=+_ /%TG_#E>\Z?\+-L?_!=+_\ %4F!
M^83DG@4B9V,,\YK]/Q_P17NO^BF66?\ L'2__%4#_@BQ= ?\E,L2?^P=+_\
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MY?\ XJIO^'1-Z(3'_P +'L^>_P!@D_\ BJ /SW6ZCA?=& <_>%.FF2YM&#8
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M^0=+_P#%5^B'P;^'Q^%'PH\)>#6O%U!M"TZ*P-TB%%E* C< >1G- '8T444
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MBB@ HHHH **** "BBC/- !1110 4449% !1110 4444 %%%% !1110 4444
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M3%<-X/\ @KXR\5^-M,O/B!IM]]E?PKJ6A:U>ZAK:7RW-Q</!\]O"O$49\MR
M ,84$9&: /;?&WQ T[PY;ZW81:M86>OV6C/K 6^#M!#!N*+-+LYV;@1QR<'%
M<O!^TAX3M?%6I>&M2NITU#2=&M=7OK^"TE:S*2QL[%6QPH5"W/8@=0:XCPG\
M%/&A^#GQ&M_$RVMUX]U[3CHEF5N T?V.VB\FT!D[&3YI6ST:1JZ;PCX+\3>$
M?BE<7%WH4.I^&-:\,Z7I-]>+?1JME):I*LJO&W,BL)."O'!S0!Z9%XVT.?5=
M%TV+48I;W6K-]0L(H^?/MU"EI ?[H#KR?45N5\X_LI^%+N/7/%&HW=Q%J&F>
M&BW@[PW?0R>8EQ812M,\H;H23(D;8[P5]'4 %%%% !1110 4444 %%%% !11
M10 4'I10>E &=XAU4Z'H.I:D(_.^QV\D_EDXW;5)QGWKA_#'Q1U6_P!4\,V^
MM:-;6-OXD@::PGL[DR;65=Y20$#'R\Y%=GXKT^;5_"VL6-NJM<7-G+#$K' +
MLI R>W-<AX$^$=GH.AZ<]^;B778].-FTL]RTJVI9<,(AT4>XKCJ^U=1*&UOU
M/<PGU..&F\1\3=EWVT>_1[[]C;M?BCX6O;FYMX-8BEDMXWE;:K8=4^^4.,/C
MOMS5U/'&@S7EK:)J<#7-U9G4(4!^_;CK(/:O-_"WPW\0M)X,TK6+&TL],\,+
M,C7L,X<W@92@"*.5!!R<US;_  .\5PZ)<- T']K6UT+&Q;SA@:;AE//9L.3C
MVKF>(Q"2?(>FLNRR4G#V]K>:?5I.Z7DFUT3/1O''QDT30/"%SJ.G:A#=7\M@
MUY8Q"-G#KT5F 'RJ3W.*V)_B)H^AZ/I-SK=]'9W%[:I<&-59B 5!9L*#A03U
M/%<!XB^&GB+2Y/%MCX?TRUU+3M>TN&QBFDN1"]J8TV;2#]Y3UXJ7Q'\,M:_M
MG3-2ALY=5@;0TTB\LK?4!:.A&"3NZ,AY!%/VN(YF^7MT\]_,%@\ME3C'VF[;
MOS*[T5EY:W6N[7F>A#XB>'6U^+14U2*74Y2@2WB5G)W+N4Y Q@COTJQXO\:Z
M'X"TI-2U[4$L+229;>+*EWFE;[L<:+EG8^@%<Q\.O 5SX0\5^(KIK2.VTRYM
M[."Q42B1U$:$,I/7@D<]ZI_&#PQXANO$WP^\7>'-*B\0W/A:_N99M%EN4MVN
M(I[=H2\;O\HD0MD9Z@GFNZE*<HWF?/8R%"G44,.[JRUTWMY;6VZG/>!_VG-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_011.jpg
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %/ K,# 2(  A$! Q$!_\0
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M][Q:6M[9W-DUR<9Q$9XT$AQSA237L6,=J2II]0N=;]MM_P#GO%_WV*/MMO\
M\]XO^^Q7)8H"Y( ')I^S7<.8ZW[;;_\ />+_ +[%'VVW_P">\7_?8KS#P?\
M$/PWX_EUN/P]JT&JOHM^^F:B(0?]&ND +1-D#D9'3(KHL4>S7<.8ZW[;;_\
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MC%'LUW#F.M^VV_\ SWB_[[%'VVW_ .>\7_?8KDL48H]FNX<QUOVVW_Y[Q?\
M?8H^VV__ #WB_P"^Q7(LRHI9B%51DLQP /4FFPS17,22PR1S1.-R21,&5AZ@
MC@CZ4>S7<.8[#[;;_P#/>+_OL4?;;?\ Y[Q?]]BN2Q1BCV:[AS'7+=0N<+-&
MQZX#"D^VV_\ SWB_[[%<YIH_TD_]<W_E50#@4O9KN',==]MM_P#GO%_WV*/M
MMO\ \]XO^^Q7)8KGO'_C[P_\+O".H>*/%.HII.@Z>JM<WCQO((PS!1\J L<D
M@< T_9KN',>G?;;?_GO%_P!]BC[;;_\ />+_ +[%?-G@W]L;X->/=>M-%TCQ
MQ;+JEVP2VM]1M+BP-PQZ+&9XT#D^@)->S%<$@C!%)4T^H7.M^VV__/>+_OL4
M?;;?_GO%_P!]BN2Q1BG[-=PYCK?MMO\ \]XO^^Q1]MM_^>\7_?8KDL48H]FN
MX<QUOVVW_P">\7_?8H^VV_\ SWB_[[%<D!DX YKG/"WQ$\->-;G7[?1-8M]0
MET"\;3]45,K]DN%&YD<L .!W''O1[-=PYCU#[;;_ //>+_OL4?;;?_GO%_WV
M*\Y\3^,=#\&>%+_Q-K6I06.@6$!N;G4"=\4<7'S97.1R.F:O:3JEGKVDV.IZ
M?.EWI]]!'=6UQ']V6)U#(X]BI!_&E[-=PYCN/MMO_P ]XO\ OL4?;;?_ )[Q
M?]]BN2Q1BG[-=PYCK?MMO_SWB_[[%'VVW_Y[Q?\ ?8KDL>U>>2_M!_#N#Q^/
M!4GB>V7Q$;H6'D&*7R1=%=PMS/M\H38Y\O?N]J7LUW#F/</MMO\ \]XO^^Q1
M]MM_^>\7_?8KR;6_B;H>A?$/P[X(E-S=>(]<AGNH;6TA\P6]O$/GGG.1Y<>X
MA 3G+' '7'68H]FNX<QUOVVW_P">\7_?8H^VV_\ SWB_[[%<GL.W=M.W.,XX
MS535=3M-#TJ]U*_F6WL;*"2YN)F. D:*68GZ &G[-=PYCM_MMO\ \]XO^^Q1
M]MM_^>\7_?8KQ+X"_$N^^,GPHT/QK?Z(OA\:RLES:V0F,I^R^8PAD8D##.@#
M$=LXR:] "Y. ,FE[-=PYCK?MMO\ \]XO^^Q1]MM_^>\7_?8KYMU+]L;X+Z1X
MKE\.77CZP74X9_LLIC@GDMHYLX\MKA4,2MG@@OP:U_BM^TK\-O@CKMEHOC3Q
M$VDZK>0&Y@M(]/N;IWB#;2V(8WP,C'-')'N%V>]_;;?_ )[Q?]]BC[;;_P#/
M>+_OL5XW\,/C;X$^-%G=7'@KQ-9:\+0@7,$.Z.>WST\R)PKIGW45V^*/9KN'
M,=;]MM_^>\7_ 'V*4W4(4-YT>TG .X8KD<59<?\ $MA_ZZM_(4>S0<QTGVVW
M_P">\7_?8H^VV_\ SWB_[[%<EBC%/V:[AS'6_;;?_GO%_P!]BC[;;_\ />+_
M +[%>3_$WXI^%?@WX4E\2^,M571=$CEC@:Z:&2;]XYPB[8U9B2?05QW@#]K+
MX1_$[Q#!H/A_QI:RZU<'%O87UM/8S3GTC6>-"Y]ES2]FNX79]$_;;?\ Y[Q?
M]]BC[;;_ //>+_OL5R6/:C%/V:[AS'6_;;?_ )[Q?]]BC[;;_P#/>+_OL5R6
M*,4>S7<.8ZW[;;_\]XO^^Q1]MM_^>\7_ 'V*Y+% 7)  Y-'LUW#F.M^VV_\
MSWB_[[%'VVW_ .>\7_?8KRWPA\2?"WCVRU:\T#6[74;72;Z73;^96*);7$7^
MLC<L!@KGKT]ZG\:^.O#_ ,.?"=[XF\2:I!I6@62J]Q?RY:-%8A5/R@DY) &/
M6E[-=PYCTO[;;_\ />+_ +[%'VVW_P">\7_?8KC;:XBO+:&X@<2P3(LD;KT9
M6&01]014N*?LUW#F.M^VV_\ SWB_[[%'VVW_ .>\7_?8KDL4 9. .:/9KN',
M=;]MM_\ GO%_WV*/MMO_ ,]XO^^Q7A]C^T'\.]2\>_\ "&6WBBVE\1&Y>R2
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MUIO_ !\G_KF_\JJ#H*MZ;_Q\G_KF_P#*J@Z"EU#H+7SC_P %$_\ DS;XB_\
M7&W_ /1Z5]'5YK^TA\'Y?CY\%?$G@.#5(]%EU>.-%OI83,L6V17Y0$$YVXZ]
MZ'L",7]I_P %:#X__9A\76_B.W@FBLO#DM_;7<R@R6D\5OYD<D;]58.HY'K7
MSS>_M8^(M+^'G[/_ (8N?$[>$=5\4>%(];USQ6='DU2YB@1!&@AMU5@9)6!)
M=P5 Y[UZUXA_9Q^)WQ8T:+PS\3/BS97?@EA&E[H_A+0O[-DU&-""(IIWD=@A
MP,A<9KK/BG^SY/XEU[P;XJ\!>(Q\/_&/A&V?3],NDLQ<V<EDX :UFAR-T?R@
MC!!!S^$N[U0S@/V<_CWK_C#QKX[\)7'B&Z\=Z+I>D)JND^+[K0)-)F9CE9+:
M>-D1&=&VE610",YK@?!/C7]H;QQ^RM9_&F/XEZ59W5EI-QJL/AM-!ADAU.&W
M:3S#=3'#)(PB? B"J..O)KZ8\(>'/B/I.G>)+SX@^/K/Q=)<63);66EZ0+"U
MM-JON<9=W9FR <M@8X%?*'[,'P'^(OQ-_8Y\':'9_%?^QOA_XDT^4:AI4FCI
M-?V\+7,JRP6MSN 2-PO1E8C<V#@XI:Z#/4-6_:#\8?&+6_A%X.^'FH6O@O4O
M&OA8^+M4UNYM%O'TZT "B.")_E=S+N7+9  !QS6QX \??$7X=?M"CX2>-_$5
MM\0H-7\/3:]H6O?8(]/N@\+E9+>>./\ =X/4,H':MWQ]^S&;J\\ ZY\.?$?_
M  @?BKP1IYT;3+N:T%[;3V!4*;:XB)4NORY!!!!)/?B?X>? #7]+^(&K?$3Q
MUXV3Q7X^N=+;1=/N]/TY;.RTBU+%B((2S98N0Q9B<XQT-/6XM#S/]FSXP^,/
MB!XTL+?QC\4(M%\:BXG&L?"S5?#\=EY$:LP LYCB24@;&\P,ZG)X%$^L^*OB
M7\,OVI--@\2)X;ET+Q!?VEM>6.E6K.UG'8I(]NX* .7W,IE;+@'@\"NPA_9Q
M\>^+_'G@G7/B9\2=-\4V/@V__M+3(M*\/K87<\P5E7[1-O;*X;)5 H)[5V'@
M7X#KX7A^+]KJ.JKJ%G\0=8NM2=;>(Q-:136RP&/))W, I.X8'/2BS \"^&=O
MXS^%_P#P3XU'Q5+XZD\1H/!$5YHVEW^BV@@TG;&2$&%/VA>0/WH/W1ZUW/BO
MXL>./$>O_"#X7^"=6LO#/B#Q/X97Q#J_B.:P2X^Q6L<*9%O;G$9=W) !^50.
MF*O>'/V9?&UA^SQXG^$>M?$/3]9T:YT4Z'H=RFC&"6QBRV&G(D/G-@J.-OW?
M>MOQU^S;J.L_\*ZU[PGXN_X13X@>"=-&E6NL-9"YM;RW,2)+#/ 6!*,4W##9
M&319V QOAUXW^(?P[_:/L?A+X\\46_Q T[7M$GUG1_$']G1V%W$\#8F@GCB^
M0@CD, *\O\(^,_V@?B/\#O&'Q%M/B;I>A1^&[O6/[/TY="AG;4TLYI<I=2,/
MW8VH$7R@#QEB2:]V^&'P'US1?BC<_$OXA>,(O&OC0Z>=)L38Z>+&PTVU+;G6
M&+<QW.?O,Q)[4_X=? "X\"_ 3Q-\.9-;AO9M9EUB0:BENR)%]N>1@"A8D[/,
MYYYQVHLP.R^"GQ!;XI_"3P7XT>W2VEUS2[>_D@CSL1V4%U&><;@<>U?+WQ/^
M%OB#X4>#]:B\0WFBK\,++QTOCL:O'<2-K-S+]H$T6G16^S#323;8UD#_ '3]
MWBOIWX*?#N3X1_"'P?X)EOTU230--BL&O8XS&LY3/S!225SGIDU@^*/A7JOQ
M ^-&@Z[XBN+23P/X6C%YH^C1,S/<ZJV0;JY! 7$*\1J"?F8L<$"FU=:@>*?"
MWXQ:)\,_$WB[Q-\1+'6;CQWK-_:0>*=;L['SM+\+B;'V'2GFW JL2NF\JI&^
M0EB.*^K?$NLGPUH&I:I_9]]JQLH'G^P:7#YUU<;1G9$F1N<] ,C)KP3QQ^RA
MJGBW5?'>F6_B^VL?A_X[UBVUO7](DTTR7IFB,1=()]X5$D,$6=RDC!QUKZ-9
MMS$],T*X,^)-/_:CO4_:[US4C\+?BP]E)X&M+9?#XT#-W%(+^5C=&W\[ C88
M029R2I&.*],_;#\2WWB;X1^&? .C1W6G:[\4M1M="2"XCV7%K9N!+>M(F>"D
M*LK#/&XUZS;?"VRM?C5J'Q*6_N&U&]\/0^'6L2J^2L4=P\XD#==Q+D8Z8%>8
M:'I.H?$K]LW7?$=_87,'AWX=:,FC:/)<P%([G4+O]Y<S1$CY@D86/<.A^M*S
M [#QY\</AW^SM#H?AO6Y]2TZ%+)(["#3]%O+Y%@C C4%H(G"D #@D'O7HNF:
ME:>*/#]M?6CRFQU*U$L4C1M%)Y<B<':P#*V#T(!!ZUI1SR1 A)'0'KM8BJU_
M%+=V=S%%</:SRQNB7* ,T3$$!P#P2#S@\<58CXQ\&ZUXI_81\&-X.\>^#8O%
MOP<MM0EE@\;:,J2RVJ33%PVH6K#)*L^/,7/0<G@5WNI7T=Y_P4,\"W=I.)K>
MX^'5]-%-&>)$:>-E8'T((-.\5?LY?%OXH>&W\&^._C+8ZGX(NF5=1CTKPXMG
MJ6H0J03$\_F%%#8&XJ@_I6Q\1OV>_%]]\8?#'C_X=>+]%\)W.A^'G\.1V6L:
M1)?QF!F4Y&V1,8"*.?3WK.S&<M\>])L_!?[7W[/_ (HT"&*Q\0>(KV_T35UM
M4"&_LA!OS*!]_8W()Y&!7U,:\4^'?[/&IZ=\2X_B1\1?&4GC_P ;6MH]CIC1
MV2V6GZ5"_P#K/L\ ).]NA=F)QQ7M=6A!5E_^0;#_ -=6_D*K59?_ )!L/_75
MOY"A] *U%%%,#YD_X*&G'P$TPCK_ ,)9HW_I4M;O_!0+PGH_B']FOQYJ^HQQ
MQ:MX=MSJND:F!MN+2ZBD5HS')U7)XP#SFNF_:;^"=]\??ABOAC3=;M_#U]%J
M=IJ<-]=6IN(PT$F\*4#*3DCUKCO$'[-_C[XPSV=G\7_B99^(/"5O<QWDOAKP
MSHG]FP:A(C;D%S(\CNR!@#M! ..:AIW&C@/BK^U1K&F^)/AQX'?Q5)\/YM3\
M*0>(M>\1P:&^JW:LZJJ000!'56=MS,[J0 ,#FM_X%_M >)?%NF?&#2+C79_%
MD'A72&U+1/&4VAOI;W8:WE;RY8'15,D<B#E5"D$<5Z/\5O@3K'B3X@:#\0O
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M $9&#R*;%%'!&$BC2*->B1J%4?0#I3J* "BBB@ HHHH **** "BBB@ HHHH
M**** "E+LP )) X )Z4E% !1110 4444 %%%% !5E_\ D&P_]=6_D*K59?\
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M_=%4*[([(S>X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#M)4@CD#H1TJEXI^&OACQMH>EZ-KFCPZCIFEW-O>65M(SJL$T'^I<%6!^7'
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M<1J<]K,,CW[%8V8;1R!FJ/V:;_GD_P#WR:OZS<S1WS*DKHNT<*V!5+[9<?\
M/>3_ +Z-=4;V1F]QOV:;_GD__?)H^S3?\\G_ .^33OMEQ_SWD_[Z-'VRX_Y[
MR?\ ?1JM1#?LTW_/)_\ ODT?9IO^>3_]\FG?;+C_ )[R?]]&C[9<?\]Y/^^C
M1J W[--_SR?_ +Y-'V:;_GD__?)IWVRX_P">\G_?1H^V7'_/>3_OHT:@-^S3
M?\\G_P"^31]FF_YY/_WR:=]LN/\ GO)_WT:/MEQ_SWD_[Z-&H#?LTW_/)_\
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M_P">3_\ ?)H^S3?\\G_[Y-.^V7'_ #WD_P"^C1]LN/\ GO)_WT:-0&_9IO\
MGD__ 'R:/LTW_/)_^^33OMEQ_P ]Y/\ OHT?;+C_ )[R?]]&C4!OV:;_ )Y/
M_P!\FC[--_SR?_ODT[[9<?\ />3_ +Z-'VRX_P">\G_?1HU ;]FF_P">3_\
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MV:;_ )Y/_P!\FG?;+C_GO)_WT:/MEQ_SWD_[Z-&H#?LTW_/)_P#ODT?9IO\
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MW_/)_P#ODT[[9<?\]Y/^^C1]LN/^>\G_ 'T:-0&_9IO^>3_]\FC[--_SR?\
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M_P!=6_D*3Z 5J***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1O#%Y>P17" %H_,C0J2 1^8I/3=C/>OL _Y^;?\ [[_^M1]@'_/S;_\ ??\
M]:LG1M5AU[1['4[9)X[>]@2XC2ZA:&5590P#QL R-@\J1D'@U<IV?<1:^P#_
M )^;?_OO_P"M1]@'_/S;_P#??_UJJT46?<"U]@'_ #\V_P#WW_\ 6H^P#_GY
MM_\ OO\ ^M56BBS[@6OL _Y^;?\ [[_^M1]@'_/S;_\ ??\ ]:JM%%GW M?8
M!_S\V_\ WW_]:C[ /^?FW_[[_P#K55HHL^X%K[ /^?FW_P"^_P#ZU6'LP;&)
M?M$/$C'=NX/ ]JS:LO\ \@V'_KJW\A2:8Q?L _Y^;?\ [[_^M1]@'_/S;_\
M??\ ]:JM%.S[B+7V ?\ /S;_ /??_P!:C[ /^?FW_P"^_P#ZU5:*+/N!:^P#
M_GYM_P#OO_ZU'V ?\_-O_P!]_P#UJJT46?<"U]@'_/S;_P#??_UJ/L _Y^;?
M_OO_ .M56BBS[@6OL _Y^;?_ +[_ /K4?8!_S\V__??_ -:JM%%GW M?8!_S
M\V__ 'W_ /6H^P#_ )^;?_OO_P"M56O)?B'^U1\.OAEXHN?#FJ7^IZCKEG"M
MQ>V.@Z1<:E)91L,JT_DJPC!'(W<TGINP/9/L _Y^;?\ [[_^M1]@'_/S;_\
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M_P"NK?R%)] *U%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I5^\OU%)2K]Y?J* .RHHHKB-3"U8VPO6\U9"^T
M<J0!5/=9?W)O^^A4NN?\A!O]T50KJBM$9O<M;K+^Y-_WT*-UE_<F_P"^A56B
MJL*Y:W67]R;_ +Z%&ZR_N3?]]"JM%%@N6MUE_<F_[Z%&ZR_N3?\ ?0JK7A7[
M5?[3D_[-&G>%KFV\(R^+WUJZN(Y+>"[\AX(8(3/+(OR-O(16.WCIUI/09[_N
MLO[DW_?0HW67]R;_ +Z%8/A[Q-IGB?POIOB*PNTDT:_LX]0ANB<+Y+H'#'TP
M#S]#7B'[-O[6J_M&>+/&NF6GA.;1-.T2&*[TV^FN_,;5+:1Y%CEV;!Y8;R\C
MD\,*/F!]&[K+^Y-_WT*-UE_<F_[Z%<;\,O%.M>-/!EIJ_B#PQ/X-U65Y5ET>
MZN8[AX51RJL73Y2&4!O;-<1\5_BAK/A3XR?!/P[I%S:MH_BO5;^SU0>6LK.D
M5F\J!'_@(91G'6@#VG=9?W)O^^A1NLO[DW_?0JO"8OM5O%+(B&5PJJSA2W..
M!W_"OCZ\_::\>0_L4>,/B8EW8CQ;I>OSZ=;3-9(85A75DM0#%T)\IB,^O/6A
MZ ?9.ZR_N3?]]"C=9?W)O^^A5%9E6TCFE=(D**S.[!5!(]33U8.BNK!T895E
M.01[$=:=A7+>ZR_N3?\ ?0HW67]R;_OH51EN8("!+/#"3T$LBKG\S3HY8YDW
MQR)(G]]'#+^8XHL%RYNLO[DW_?0HW67]R;_OH53BECG4M%+',H."8W# '\*1
MKB%%W-/$J[MFYI% W?W>O7VHL%R[NLO[DW_?0HW67]R;_OH56P>?;DU'%-'<
M(7AECF0'!:)PP!],BBP7+NZR_N3?]]"C=9?W)O\ OH55HHL%RUNLO[DW_?0H
MW67]R;_OH55HHL%RUNLO[DW_ 'T*-UE_<F_[Z%5:*+!<TK$VAG.Q)0VQNK#I
MCFJX:RP/DF_[Z%&F_P#'R?\ KF_\JJ#H*5M1EO=9?W)O^^A1NLO[DW_?0JK1
M3L*Y:W67]R;_ +Z%&ZR_N3?]]"JM%%@N6MUE_<F_[Z%&ZR_N3?\ ?0JK118+
MEK=9?W)O^^A1NLO[DW_?0JK118+EK=9?W)O^^A1NLO[DW_?0JK7F_P 4/'7Q
M#\.ZI::=X$^&)\;R20>?-?7NM0Z99Q'<0(@[!F:3C. N,$<T6L,]2W67]R;_
M +Z%&ZR_N3?]]"O$/A-^TYHOQ!^%_BWQ?KVF7/@J3P;=7-EXDT^^<2FQF@0/
M(%=>)%VD8('/3%<!-^V5XHT'PSI7Q \3_""^T'X1ZG+#Y?B/^UXIKZVMYF A
MN;BR"Y2-L@\.2 1QS2T[AJ?5VZR_N3?]]"C=9?W)O^^A51&655:-A(C@%64Y
M# ]"*XB^^)4MC\==(^'!TAV;4-!N-;_M'S"-GE3+'Y?E[><[L[L\8Z4[>8'H
M6ZR_N3?]]"C=9?W)O^^A5;:0VT_*<X.>U?/WQ7_:#^)7PTM=?\0Q_!.YU+P-
MH1DDO-3DU^WBO9+>/[]Q#:!6+(!EOF93@9P*3T ^BMUE_<F_[Z%&ZR_N3?\
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MH:+^T7J/QA@AMVBOM,N+^RNX(I21B5! H:+'9<D<]:6E[6'J?0?]HR_W(?\
MOT*/[1E_N0_]^A7%_$GXJ>%?@_X>37O&&J'2-(:=;<7 MII_WC9(&V)&;L><
M8KYP_9P_;3\%>+O%GC71-9\=7&I7^H^,9[?PU;SZ==$&R98A#&K"'$:[M_#D
M$9YQ1[J=@U/L/^T9?[D/_?H4?VC+_<A_[]"L/Q/8:CJ7A_4;/2M5_L+4YH6C
MM]3^SK/]E<])/+8A6QZ'BOE34-0\:?"#X_?"S0]#^,6M_%6+Q->30:]X?U<V
MUS]EM5C+?;(V@1?LZ*W&#UX&30[+H!]C_P!HR_W(?^_0H_M&7^Y#_P!^A54]
M:*=D*Y:_M&7^Y#_WZ%']HR_W(?\ OT*JT4607+7]HR_W(?\ OT*/[1E_N0_]
M^A56BBR"Y:_M&7^Y#_WZ%']HR_W(?^_0JK119!<M?VC+_<A_[]"C^T9?[D/_
M 'Z%5:*+(+EK^T9?[D/_ 'Z%3O?2"PB?;%DR,/\ 5C'0=JSJLO\ \@V'_KJW
M\A2:0[B_VC+_ '(?^_0H_M&7^Y#_ -^A56BG9"N6O[1E_N0_]^A1_:,O]R'_
M +]"JM%%D%RU_:,O]R'_ +]"C^T9?[D/_?H55HHL@N6O[1E_N0_]^A1_:,O]
MR'_OT*JT4607+7]HR_W(?^_0H_M&7^Y#_P!^A56E'!Z9HL@N6?[1E_N0_P#?
MH4?VC+_<A_[]"OB;]I$_$'X&^$CXRTCX^:WXD\<_VG!#9^#I(+3[#J9DE"FV
MCLXT,BD*2<[CC&3CJ/HSXV?%M/@[\,)_$4MB;_79Q%9:5HL?^LOM2F 6&W4=
M?OGD]E5CVJ=.P]3TW^T9?[D/_?H4?VC+_<A_[]"OF#]CO6?B WB3XO>&?B)X
MLN/%NK^'=8L[<3RX\N!I;1)I8X@ ,1AW('LHKU[XI?&WP3\$K/3[WQMK1T6U
MOY6BMW%G/<>8RC)&(8W(X/?%-6:N&IZ#_:,O]R'_ +]"C^T9?[D/_?H5\E?L
M>?M<^%OB9X;TWPWJ_C2XUOQ[>ZGJ AAN;&Y#O )Y&A'F^4(P!$!@%@0!@\U]
M#?$+P?=^.O#4FDV7BK7/!L[RI(-5\/2QQW:A3R@:1'7:W?BA6:N@U.O_ +1E
M_N0_]^A1_:,O]R'_ +]"OB[4/#WC3PK^U1\./A]X>^-/Q \4%H9?$'B>WUV\
MMY;>#38SMC0K'"IW2R?*,GISCD&OL@G)/&/:A)/H!9_M&7^Y#_WZ%']HR_W(
M?^_0JK13LA7+7]HR_P!R'_OT*/[1E_N0_P#?H55HHL@N6O[1E_N0_P#?H4?V
MC+_<A_[]"JM%%D%RU_:,O]R'_OT*/[1E_N0_]^A56BBR"Y:_M&7^Y#_WZ%*N
MHR[A\D/7_GF*J4J_>7ZBBR"YV5%%%<9J<WKG_(0;_=%4*OZY_P A!O\ =%4*
M[([(S>X4444Q!7S5^U!I'B'P9\6_A7\9=%T*^\3Z7X5^VZ=KNEZ5%YUXMG<J
MH\^*/J^PKD@<X].M?2M*"5.0<'U%#5P/CSXZ?'ZQ_:<^&.K?"_X0Z3KWB'7_
M !2B:==7]YHMU8V6CVS.IFFN))T0<*" JYR3^?8WWA1_#/[7_P #]/M8IYM-
MT?P)JNFB[\LE!Y:01IN;H"0G0FOI1YY)1AY&<>C,330[!2H)VGDC/!J;7W'<
M^3?A%+XJ\+ZQ^U[JWAS1I+[Q"OB:ZN]%M+B-E2]G6US&%SC<"P X//KS7S_X
MQ\67_P 2_#/PLFN?&WQ+\;>,AXLT2[\0:)>Z*UIH^CR"X D#I]G4(RL=J[7;
M(!)XK],F=F !8D*,#)Z4\W$IQF1S@8Y8TN72P7/DCQ)XRM_V<OVR?'WC3QO8
MZNOA#QCH6GV^E^(+#3)KZ*UFMQMDM7$*LZ%C\XXP<C\(_P!I;Q7/XR^"WPV^
M(-CX/UW2M&T;X@:=KU]83:>5OEL8;A]]VUN@+#>,/@C=AQGFOKF.5XCE'9#_
M +)Q0'97W!B&_O \T["N?(OQ=\>6DOQ;^#/Q]L]*UKQ!\-=/L]3TZZGM]+G-
MUIKS$".\^S,HEV':REMN0/KSI^"_$D/[1?[8/@SQ_P"#]/U6'P9X0T*\L;SQ
M#J6G2V*:A/<.NR")9E5W"!2Q)&!FOJ?S7W[][;_[V>:'D>4Y=BY]6.:+7'<^
M=?V"M-FT;X%78ELWL;B7Q/K,SB2(QN^;V3:Q! )^4#!/8"OGKQIX,UK3?C;K
MG[,EG9W"^"_'GBBU\9QW48/E6VDC,VH6V>V9X4 '3YN?O5^AS.SG+$L?4G->
M>:7\&[*Q^.6N?%"ZU2YU+5K[2H=&L[.:-5ATVV0[G$1'+&1_F8GZ4-:)!<[Z
M1X;*V=MHBMH(R=D:YV(HZ #T X KXB^ O[1G@?XE_M"7GC_QS=ZK9^*;BZ_X
M1_P=X;N-"OF32K$N%,K2^3Y:S7#<LV[Y5P"1V^X:E-U,P(,TA!XP6--JXCXH
M^ GQBTG]DG3_ !EX#^)&C>(K3Q(/$VH:I:W.GZ)<7L?B"*>3?')%+$C*7(PA
M#D8P.>N.-U+X6>(_"7[$.AZ?K>AW%G?ZQ\1+37!H1A,DEC;3Z@'6%T .,)\S
M#H-Q!K]!TFDC4JLC*#V!(IJNR'*L5/3(-+E'<^=/VH+.[N/VB_V9KFUMIIH[
M;Q-J7G30QEEBC-HH^8@?*IY'/%> VMK%\#OB_P#%>R^(7CSXH_#]->\2SZYI
M&H^$K5I].U6WFP5YCMIF$R8V$,0.!C'?]"0[*" 2 >" >M.2:2($([)G^Z<4
MG$+GDO[+?@_P]X'^#&DV7A1?$<>BW%Q=7L7_  E47DZ@S23,SM(FU=H9LLHP
M.&![UZA8Z?::7;"WLK2"RMPQ80VT2Q("3DG:H R222>Y-6"2QR3D^II*M:""
MBBB@ HHHH M:;_Q\G_KF_P#*J@Z"K>F_\?)_ZYO_ "JH.@I=0Z"T444P"BBB
M@ HHHH **** "BBB@#YB_;=\#C53\+/&EYX6D\:>'?!_B+[7KNC16WVIGLI(
MRC2B'&9/+;:Q4>E<CX'_ .$9^,/[7/@3QM\(_"]QHOA3PWH]_!XAUU=#?2+>
M^,H5;>U5'1#*R$.3\N!GKP*^S%8J002".XI9)7E.7=G/JQS4VUN.YROQ&^*7
MA[X/>&SXB\3WES8Z6LR0&6ULI[M][9VCRX4=\<'G&!7SM^SO^T%\,-!\5^,-
M)LO&&H:OJ'C?Q;/J]E"/#&IVRQ>>L:+%(\D 4$%.6)"\U]9I(T;;D8H?53BG
MM=3,"#-(0>H+&F[W$<[X\\1VO@_P?JVKW^FZAJ]E:PYN++2K4W5S+&Q"L$B'
M+X#$D#^$$]J^$=4@^'/B'XF_#J7]EWPIK'AWQI;ZU"=:OM-T>\TS3XM*S_I$
M=Z)U5'!'0 $Y'!Z5^A8)!R#@T]YY)!AY&<>C,30U<!KXW''3/%)113 ****
M"BBB@ HHHH **** "K+_ /(-A_ZZM_(56JR__(-A_P"NK?R%)] *U%%%, HH
MHH **** "BBB@ ID\OV>"64(\AC0OLC&6; SA1W)["GT4 ?GO^T!KWP2^(&B
MZY<?#_X?^)K+X_74_GZ5+I?AV^T_5(=1+C][-/M$849.[YR",U[EXR^"'QA\
M8>)/A5XPM_%GA2+7/"NAK'<:?XBTZ>ZM_P"UI(PMQ>((74%\?*I)^7+$#G-?
M31N)2FTR.5_N[CBHZGE'<^2/V4=#^*>G_M"_'&X\5:CX<FT^36;<ZH;#2[F
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M *]=*G%)$-.YC45L_P#".G_GX'_?'_UZ/^$=/_/P/^^/_KT^>/<5F8U%;/\
MPCI_Y^!_WQ_]>C_A'3_S\#_OC_Z]'/'N%F8U%;/_  CI_P"?@?\ ?'_UZ/\
MA'3_ ,_ _P"^/_KT<\>X69C45L_\(Z?^?@?]\?\ UZ/^$=/_ #\#_OC_ .O1
MSQ[A9F-16S_PCI_Y^!_WQ_\ 7H_X1T_\_ _[X_\ KT<\>X69C45L_P#".G_G
MX'_?'_UZ/^$=/_/P/^^/_KT<\>X69C45L_\ ".G_ )^!_P!\?_7H_P"$=/\
MS\#_ +X_^O1SQ[A9F-16S_PCI_Y^!_WQ_P#7H_X1T_\ /P/^^/\ Z]'/'N%F
M8U%;/_".G_GX'_?'_P!>C_A'3_S\#_OC_P"O1SQ[A9F-16S_ ,(Z?^?@?]\?
M_7H_X1T_\_ _[X_^O1SQ[A9F-16S_P (Z?\ GX'_ 'Q_]>C_ (1T_P#/P/\
MOC_Z]'/'N%F8U%;/_".G_GX'_?'_ ->C_A'3_P _ _[X_P#KT<\>X69C45L_
M\(Z?^?@?]\?_ %Z/^$=/_/P/^^/_ *]'/'N%F4--_P"/D_\ 7-_Y54'05OVV
MB&WE+^=N^4KC;ZC'K4(\.$#_ (^!_P!\?_7I<\;A9F/16S_PCI_Y^!_WQ_\
M7H_X1T_\_ _[X_\ KT^>/<+,QJ*V?^$=/_/P/^^/_KT?\(Z?^?@?]\?_ %Z.
M>/<+,QJ*V?\ A'3_ ,_ _P"^/_KT?\(Z?^?@?]\?_7HYX]PLS&HK9_X1T_\
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M=/\ S\#_ +X_^O1_PCI_Y^!_WQ_]>CGCW"S,:BMG_A'3_P _ _[X_P#KT?\
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M_A'3_P _ _[X_P#KT?\ ".G_ )^!_P!\?_7HYX]PLS&HK9_X1T_\_ _[X_\
MKT?\(Z?^?@?]\?\ UZ.>/<+,QJ5?O+]16Q_PCI_Y^!_WQ_\ 7H'AT@@^?T/]
0S_Z]'/'N%F;5%%%<IH?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_012.jpg
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* M # 2(  A$! Q$!_\0
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MGCU.Z1BSY=)5V)G"%E(X)8@@ 5]+:4\IL+<W$0@N6C4R1*VX(V!E0>X!R,T
M<)_97Q=_Z&CP3_X3=Y_\GT?V5\7?^AH\$_\ A-WG_P GUZ,9 !GMZTGF#\:
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M_P#A-WG_ ,GUZ*6XXS2+*I'7)H \[_LKXN_]#1X)_P#";O/_ )/H_LKXN_\
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M#WP:])656. >?2GT ?-WQ5\;_'WX5?#W6O%=W<_#>_@TR)96MH;#4%:3+JN
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MW8SZ_,#SQ^(H ^[/'_[<'BCX=)I37TVDW*ZBID0VWA:X/E+G ,G_ !,?ERW
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M2/B"]\5?&3PWX@O9[IFOC)9VME?87[+9!#)L5%^4<[3GN>O6BV9RBIP %^7
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M9929@&9VY8[>X &.?I0!Z)\5_%GB>^DMKZUMX]5T#1F+W,<N8FD!_P"6Z+Z
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M[>W1%:($YZY!R#@MZ&@#UG7?"/P]:QTN#4HM834H]0>T6YN)#-;VL)C&]F0
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MN?[S' H _5/]BF$P?LS>!U;[WV>4GZ^<]>XXR<UXG^QL(X_V;/!*Q9\M;>0
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M+B61[0C[-&[#]XQX*X]?Y5I0^!KG16M-8TV:1'MA'_HT@/F3O@%^1P%/3TH
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M6!Z#)'4&NM\6^)_&6CV7_",6O]B:3KTS_OM8MRUU;W*-T9V P#@$'TP!CG%
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M$ 4 >7QV8CP<AB1U7O3UAP..>>2IJS&H4(>,'!]L>WO3[B)UA9D905!.#ZT
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MBOPS'!J]AJBE;I972VD8 ]4#$;@>H^E>+>%]$\4_"SQ7H^J6\T9#7,4$EU;
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MI^D?%?P%I7AR.RU.STW54C2_M&5]T/EL78GN1G:2IZD^M '2?\%,[#7+_6=
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MI7YG^"_B3K.E:?ILQM9-.^WO*;F_E0NMXG *H0!M4'KC..M?I#^PIJTOB/\
M9&\83W,$4#_:-2B(BZ,/)^]^M 'Q_8317,>8I5F0,0LJ?=D /##/)!XZ^M3A
M &48^4''/'/?BLK18_LEC"@Y55P>>:W=!TF]\2ZQ;:98()KRY<1Q1,X7)/\
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MD'Y8.,'!.*^BM&\>:#K^EIJ.KW.G:AH$1*ZDUK)ON[TY!6-3@[0Y_B)!&":
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MYGM]05E6VT^XVI<Q*I.)/3)'?I^-;_B;1+KP0=$U?4=$N(B8!;36019$B R
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MJ+@&+]V/FR> < USFL?\$E?V@+O5[V>ST30H+.2=WAB;6(R40L2HZ=ABJO\
MPZ/_ &B3_P PG0/_  <1_P"% &SX-U/X5>*O">AS>)?B_:^$M1@NXKA+>&"2
M[FCA4$&*<X Y.&^4DYS5*Y\6^"I/'"_;]2TW4+AK=M]Y9/+$_EQ@RV]Q$P7.
M" 2W?G\Z7_#H[]HD#']DZ#C_ +#$?^%2#_@DM^T;N#?V;H98+M!.LID#T^E
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M&WN;E8[+45*"$2E3'.Q'*GT&,^F,4 <+:V]YI^D6^FZ2T]MITJB2:6U7YBI
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MV;@XSP1F@#Y^T:2QU37EN->E,JS;F>:9R<OC@L?2OK+X*ZO8^/O"[64;I-'
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M,&C<<&-7 R%/)('\J\;6U<;HY8VBE0E&C<$,I'!!'8UZ3\'/B2_A2#4/"_\
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MUKA_AE_R6'XQ?]A+3O\ TVP4 <4W_*0B/_LES?\ IV6OH1SCK7SVW_*0B/\
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M=A7Y?RKRU0;,+/&H\R-@P)&:VHM-U#4?#1O;&":26W=K>682+$N#R #]#TH
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M<]:Y;]ESX\^-_B/\;?B]H.LZ[_:.F>'=-@^P1>2BB.?G>^0,DDX'/I6[I4\
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M,>8VSTP.G/UY_E6OJEG)X?DM[>&XAO;62,3K#,N=C="'7/Z]Q4%LUW?W$7E
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M"!E+123 @9)'3 XJA<ZQ=>&/B1<>*_! GU2SBNFN+>\:S81JQ4[TP?3)Y]*
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M)=1>'-0GT3R@]NT;!B\1.0\G.>ISSVQ0!PWC;QW<>-IK>Y6)K14"2&+>3LF
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MM4'_ $&YY/3&]:^.=&\-C4XYFCD4>4N[.TG>2<<>U 'L%KXGT62S9EU,W:0
M;(D4C9D?2J_B+QU!>V:6&DM)$LJ;I9F7:Z^P_#J:X^TT9+'3E\\<*"I . Y/
M))[GZ'IBHK2*W&N6,%W*T$$\FW@$DGL".P/ H M:=:VKSE;SS'AWX"I\I/\
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M#UAH\0\N!I3<S,/OROT /J!U ]36+:WMMI]S>3BWDDM()_,2,L%EVM@@LP[
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MGIC&: ,?Q)JS>)'%W/IXW0@*DB,<H!SC/H>N.E9-C:1-:EWGW&;#*I7YCD\
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M&KHWVF.Y&&C51G<&!P><\'J<5H_L\Z5I=AX<U3Q'K5M'$DX^RZ;J"SF.XMY
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M]C>9(6@N(AFW&.5#=4;=R!DYR: '7UJFM:;%I\T30ZC;PXAWDF*XA'(9">A
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MM4CTSU)K[U^%7A*V\ ?#WPW96]N@>V3,CN!^\(Y=B?4\\T >#>&M!\??!?\
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M8V<-]HFI:K:7"P?9($DE29P6G1R 2O3&&[>AS6))<Q7'V=YT8YS]G.#@(#T
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MJ?"NBE6#+]BAP5Z$>6O-<)\,O^2P_&+_ +"6G?\ IM@H XIO^4A$?_9+F_\
M3LM>C_'B]M].^%6OSW186_DA'95W;0S 9QWQFO.'_P"4@\?_ &2YO_3LM1?\
M%"6F3]D'XAFW>XBE-M" ]KGS%'GQY*XYSC- 'Q/XILVM+V2VEARK,3'-G/'I
M]/K6#':R17VX!F2[C*,&R6<X^\,_[7K]*^:(_A[IMY<72/\ $?7(X$M&GBFG
M$O,@)PI7KR !@=R#TK$M_"$;:IJ%G-XRUTFWA62&Z02"*7,;-@$]P=@('<F@
M#ZGEL'5(V*M SD@@#YE/N",X[Y_"F:CX(N/$$"G2K.2]U.4?+:6T3.TCCCY,
M#GKG'6OFZX^&*7<-I<CXI7=J[VT<LUM=0W$LD+D<IN7@X/8= :A\-^#[FQA2
MZG^(^KV^H2PR30KI[3QF)UW@+(Y^Z6PI^7/RMZ\4 ?>_A'P+KOA_X<7&C:QI
MDFE:DLXGN5O(&PRRJ"I7C[R[<$BO.?#/B'Q%\&/B9!KFG@W&FJ^S4M-8Y2YC
M[E?^F@(X/K7S.?#]SJ>H:!!>_%/Q+-:W]I))>;[F9C9SJ!C<3QM89(ZGC!K,
M\1?#=[>6Z>T\9:[/'''.]N7=Y#(5^Y@CJ#@Y].* /V4TVXM_&'A:T\3Z5=RP
MZ3J4"2>7"QC:;G@<=&7D$=B#VK!N-.BT_5I + W=FY"VUJT9$S#KEMIX.<X.
M:_#BU\2_$&QMA;VNI>)K:!6++##/<*@)ZD &GCQ9\20VX:OXIW<?-]HN,\=.
M<T ?N0]OJ%\\-M%8?V1"[N A7S'*D8WY.<MU%?/7[1GQ;T?1_!FJ^!/#%[)+
MJB3K:W<D,9*M'C+^6ZG (/RGO7Y?_P#"8?$LLK'6?%1*\ _:;G(_6J4.H^,(
MK*]MO)U60795I)9(Y3(""3PW49R<^M 'TYX$T6*[^(WAR%U55DO$^611\Q!Z
M >Y%?>\NG_9M)@M&+'Y/G?:?DS@8QUP#U/O7XZ-KGC WLMT+._6:2V%L&$$@
M\L  !DXX;C.1SDFM-/B)\2!-92M=:Y(]I T";S.P8$,,L#U/S'GZ>E 'ZNW7
MA5-8TK489+3R[K3VVO(C;U967*O[8/3MQ4L/Q.TC4KZ&UOX'TW6(E0WT10NF
MT?*\BJ>2I SD<C\*_*'0/%_CPW^D6DVH:]:6T=TIDN TVXJS#=O)^\HQT/ Y
MKT^;P6-3TK41%\1[V+5GO9&MWN5D"NH;"Y<<JI4].F>>E 'Z6Z[X6@U33A?Z
M=<_;K&8;H9(N8Y8L?*R^O?-=7\ ='DL].\>!H6)ETLQA&&=Q.X8K\=O'FL^,
M/#-]=6>C^+=2UVSOD!D;3H[F".W8/G;&A/R@GTZ@U]:?\$Z_$_BS7/#7[0,V
MK7&J/+#X-VVXG,O#JD@#*#_'W)'- 'K/C719]'OGTJ.P\F"!?*C4IQE0"2/0
M@D\^E.\#>!;[QGXD_LFW0?;H+>2:-P^V-UCP2@..>N1G%?".D^$X-<N-)ENO
MB/XC@6[A+7,]RTNZW?8O!ZG"L6!]1P.:H6.@366O0V8^('B,6T\'F?:[5ID4
M$R!/+8D\$KN;Z8H ^XM?O&\7:I#&;?.BZ0[16<.WY;AP06G8?[W '2M&0#[+
M;1K"^^<-)*^3\_/RJ >AXZ^]?#4?PY,VEV4B?$[4-*N)3)YL-R)Y%**Y"L"G
MW25P=K<Y(YYJGI'@65KUO[5^).J26GVHV\?V);@2$ *1*0_"H02OKD>E 'WN
MFE:S?6]S=?V9<0Z18R-$;F.(E"^,J6;NO&#SWK*@6YU*[C:2)KJ:YY$"@KYB
M[LLB8_'\*^*_^$=NK?1-)B_X67XA\JYU(V=[IL4\S!;;)VS*.%P" #N]<BM"
M_P#ARUMJ,#V'Q#\021J\:"Y6:0ELK\Q3&,'D +WY- 'WYXAT_0K7P=I>IZ1I
M":1=>>\?EQJ6\U N?GSD%@V.>^3GBN4GLI)%E,0N;B&5?-=G@51'(3D\#A5!
M/8C-?F-J.I>.HKF>V&H^(+F&*1E1O,GVMSC<!VR*@CUCQY&I5;SQ$JGJ!)/@
MT ?J'#&HM_+F@=XS@E5X79GYAGKUYJ]IEO\ \3)HE7]V9!):F8<+SG:?J,^V
M:_*P:GXY4 "Z\0@=AOGJWIWB3Q[IKS-'-KDAFA:$^;YS;0PQD9Z,.Q[4 ?K/
MXIU]O%/B6)I8)M,M8;5(Y)6.[S ,G+!>,^F,<5D7^IFZ\/W.E6<,XN]0OO/=
M4X_<)]Q..><9P/2ORXM?&GQ!LWTUDDUEA8;MBR+,P?)).\'[W7'/:F0^+?'U
MO;6L*2:T/L]P;E'(FWEN.">I7CI[F@#]&Y[*X$8=(G)&9%(&6"]_P]ZVM%\-
M2>*-6T?2+<):W=ZRH+AQB, Y)8@=2/0<\5^9<OC#Q]-'J,9EUJ,7TOG2&/S@
M5P2=J^B\]/85[+H^C'4YKZ>[^(FJZ;-/86Z1Y1\1NR#>%Q]TJ1DE><;AU- '
MV5)HEQ-?W-K*3(T4CP^;"/E9E."1VQQQ7L7P M[2#XR>'ELQ+&%@D66*;)<,
M(QESP,!B3@=17Y2>+X_%/@VSTR[L/&DNNZA'#]DEL[&.XQ$K(?G+='//WO45
M[7_P36\0^+-1_:\\$6VL3:K):Q17N7NC+\Y:(GYRW7&!C/2@#ZQ_X*CNT?C?
MX>.GWEL;G!QW\Q:^/X]7U&*),2L8E 8(WS#GZ\U],?\ !670+7Q+\5/AG9:A
MJ=_I%D=)NV$]I&S*9/.3"L1P"1NY_I7PL_PMTLZ);W2^.]06]:6426CQR'*(
M"RL,#C(&T ]6([&@#Z$TW48]1TY;@F1+DMS&#@8'!.?6K&G7#B!+7RQ%+$3@
M!=H//48XSZU\V^%_AWIVKVNC37'BS6]*6[E\NX>4,!;#RBQRO7&X* >X)J+4
MOA<]I$AM?B:]X\DRQA!;W2A5+!6=CV !S[@4 ?9R3V5MX(U(2[Y[^:$J)]^2
M7; 5,?ER.E<7IGAZ6TO88KVUDMY&7</-C* KZ@]J^<[;X<Z>LEE"?'&L2-]L
M^SW<R&1$5-IS)%GJ"0,%L<>YK0TSX?VNH#65N?B#KEU<65Q+;63+)(B740 \
MMTW<XY)/3I@4 ?4-QI4-KI[37]RD=C%(6@WM@..A8^V.]>4ZU\?K/2I)[;2=
M'^URP38ANYI"(F4=2%ZCFO /B+X-U'1M(BELM>UK6PUT8#;R"1@J;<@D=FR#
ME?<5YU_97B _\N6ID?\ 7*3_  H ]XO?'%]KGB>?5;R:4W5WA"D!V(HZ!0/2
MO</A3/)J?AN[>\W/##(40(3G.,X/Z?7-?"XTKQ#D'[%J>1T_=2?X5;MCXNLU
M*P?VW"A.XK'YR@GUXH _1"\MYY+KR@N#Q)C;P!CG/^<FJT-K=13"X\G<SY"K
M@CW)]NE?"47B_P =PW-A.%U1GLX3"FZ.4AP=W+>I^;K["F0^*/'4$>GH!J[B
MRF,\?F)*V]B0</G[PXZ'U/K0!]WVUA+>W;IY 8AMS%.BCUKL-&9+:[B\Y3/"
MV #C#2C&"1ZD9K\W/^$C\<"QN+7&K+%/<+<LP24,& . #V7GI["NI\+2Z]XQ
MG\1/KNJZII#-;K+ 0D@7>'7Y$!^[QG[M 'V%XZ\11V>MWC174U]%:;8H?-(\
MMWZ%L#ZX^HKR_6/$EQK]T/.?S$BRL850J)ZL1[^M<9K/@"W>X%S9?$-8K;[
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M*1&&WQ>:L9!Y0/N P<8Q7&_\))JG_04O/_ E_P#&@",:1?#_ )<;G_OPW^%
MT>^'2RN1_P!L&_PJ3_A)-4_Z"MY_X$O_ (T?\))JG_05O/\ P)?_ !H C.CW
MI(S8W/\ WX;_  H&CWPZ6%SGU\AO\*?_ ,))JG_05O/_  )?_&C_ (234_\
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MI#HU[P?L%R.1_P L&_PJ3_A)-4_Z"MY_X$O_ (T'Q'JAP#JMYC(_Y>7_ ,:
M/Z:_AD,?#CPF""I&DVG!_P"N*URGPR_Y+#\8O^PEIW_IM@KK?AFV_P"''A1B
M2Q.DVA))R3^Y6N2^&7_)8?C%_P!A+3O_ $VP4 >=^-]4F\!_MJVOBW4=$UZY
M\.2_#YM+74-*T>YOXQ=?VD)?*;R$<J=BEN1TQZBO1X_C[X4U))$?3/% 0#!6
MY\*:B@;\&@YKTP'YJ=WH \N_X6[X(Z_V-K.?^Q5O?_C%!^+O@D_\P;6?Q\*W
MO_QBO4J* /+!\6_! _Y@NL?^$K>__&*4_%SP.?\ F"ZS_P"$K>__ !BO4J*
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MK>__ !BO4J* /+/^%M^!R<_V+K'_ (2M[_\ &*7_ (6YX([Z+K/_ (2M[_\
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M!X,GQ ^$L9)3X>ZJI((ROP\OAP>H_P"/6F_\)[\(O^B=ZI_X;R^_^1:][HH
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@I67V1]5TZ>Q>81V,*.5CF56P&4C.,9!KU^FCM0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_013.jpg
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* '@# 2(  A$! Q$!_\0
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9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_014.jpg
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %X M # 2(  A$! Q$!_\0
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M(M)9;2&21XU9G9 23CJ:O?\ ".Z9_P ^,'_? H\._P#("L?^N2_RK1H SO\
MA'=,_P"?&#_O@4?\([IG_/C!_P!\"M&B@#-/A[3!UL8/^^!1_P (_IG_ #XP
M?]\"K\@R!CKVKRVP^(FIZ!I'C&X\0W=I>76GZO\ 8;+RXO(B)D2,Q1G)/ ,G
M+$] 30!Z'_PC^F?\^,'_ 'P*!X?TP_\ +C!_WP*\4T#XE^)/$/A[4)(?$5C+
M>:#IT]_<W-O;H8KV19IE5"/X4VQ=L'Y@<UNZ-\1-:U2?1]=-PL>F:CK9T?\
MLAH5_=IM;$F_[V\,F2.F#TXS0!Z=_P (]IG_ #XP?]\"E_X1W3/^?&#_ +X%
M7RP522>!R33+6YBO;>.>"1989!N1U.0P]: *?_".Z9_SXP?]\"C_ (1W3/\
MGQ@_[X%:-% &=_PCNF?\^,'_ 'P*/^$=TS_GQ@_[X%:-% &=_P ([IG_ #XP
M?]\"C_A'=,_Y\8/^^!6C10!G?\([IG_/C!_WP*/^$=TS_GQ@_P"^!6C10!G?
M\([IG_/C!_WP*/\ A'=,_P"?&#_O@5HT4 9W_".Z9_SXP?\ ? H_X1W3/^?&
M#_O@5HT4 9W_  CNF?\ /C!_WP*/^$=TS_GQ@_[X%:-% &=_PCNF?\^,'_?
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M>#./"FE?]>Z?RK6N/^/>7_=/\JR?!G_(J:5_U[I_*@#:HHHH **** "BBB@
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M+?[.MUIUO>3_ #LQDFDB1G<EB3DGFN_H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SO$7_("OO^N3?R
MK1K.\1?\@*^_ZY-_*@ \._\ ("L?^N2_RK1K.\._\@*Q_P"N2_RK1H ****
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M-O+_ +I_E67X,_Y%32O^O=/Y5JSC%O+_ +I_E65X,_Y%32O^O=/Y4 ;5%%%
M!6%X\_Y$?Q%_V#KC_P!%-6[6%X\_Y$?Q%_V#KC_T4U &9\'O^23>"_\ L"V?
M_HE*["N/^#W_ "2;P7_V!;/_ -$I784 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%(3BC<,T +12;AFD\P X.1]: '44FZC/UH
M6BDSQFFF15QD@9X&: 'T4F[V-)N% #J*0'(I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L[Q%_R K[_KDW\JT:SO$7_("OO^N3?RH
M/#O_ " K'_KDO\JT:SO#O_("L?\ KDO\JT: "BBB@!",T8]Z6B@!NWWI0,4M
M% $=Q_Q[R_[I_E63X,_Y%32O^O=/Y5K7'_'O+_NG^59/@S_D5-*_Z]T_E0!M
M4444 %87CS_D1_$7_8.N/_135NUA>//^1'\1?]@ZX_\ 134 9GP>_P"23>"_
M^P+9_P#HE*["N/\ @]_R2;P7_P!@6S_]$I77T +16%9^.?#E_J8TZU\0:7<Z
M@7:(6D-Y&TN]<[EV YR,'([8K=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!C'KQ7!_%3Q#X]T*TL&\">%+#Q1=22,+E+_419K"@'!!P=
MQ)_*N^Q2; !TJ9+F5KFM*:I34W%2MT=[/ULT_P 3XV_:'^*'[1UA\)-=GB\
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M*],H **0G!Q2;L]J '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%D1NC(<@_C4E<G\++6.Q^'WA^VBL9]-CAM5C6UN1^\4#C)X'7&>@X(X%=90
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M2 ?J*MQ>&]*BUE]733;9-3==K78B'FD8Q][KT 'X4 7ISFWE[_*?Y5E>#/\
MD5-*_P"O=/Y5JW'_ ![R_P"Z?Y5E>#/^14TK_KW3^5 &U1110 5A>//^1'\1
M?]@ZX_\ 135NUQ?QA\6:/X/^&GB*_P!:U&#3;,V4T(EG;:&D=&55'J23@ 54
M8N;48J[8TFW9$GP>_P"23>"_^P+9_P#HE*["O-_V>?&&B^,/@_X6FT74H-1C
MM-.MK.X,+9,4R1*'C8=00?6O1P0:)1E!N,E9H&FG9GFFG?\ )QVM_P#8KV?_
M *57%>F5YGIQ_P",CM;_ .Q7L_\ TJN*],J1'E7[1\>JV/PWU/7M'\1:IH-[
MI4)E0:>\828LRK^\#(V0,G&,5W?A70Y?#NC0V4^K7^MRH2QO-2=&F;)S@E54
M8'0<5QW[2/\ R0_Q?_UZ#_T8M>DQ_P"K7Z"@!U%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "8H( HSBN;\9_$7PU\/K>VF\1ZS;:1%<N4A:Y8C>P&
M2!@4FTM69U*D*47.HTEW>B.A]S0%'I7BWCC]K/P%X<\-W5]I&M6OB'44 $.G
MVKD-(Q..21P!U)KG/A7^V3X<\617L?BUK7PE=P$&)GE9XIE/]TXR"/0U@Z])
M/E<CPY9]EL,1'#.O'F:OOI]^R^\^CL=J-HK@O#OQS\ ^+-9M]*TCQ787^I7!
MQ%;Q.=SD#)QQZ5C>&/BUJ>O^+YM%^SV.7FU""'Y98S$UN^U"[M\LF_J0G*X-
M;J2ELSV:->EB(\U&:DO)I_D>K[11M%<3X9\9ZAJ%CXG-_%:22Z).\(NK$MY%
MP5B#L &R05)*MR>1^%<QX#^-=]XG&@6^H:7#::G<6MS/J-I!(7,+)'')$8\X
MW+(D@()IFYZYM'I[TNT5Y_;?&;1;H6:1V]TUY<WDEB+7,>Y9$56;YM^P_*ZD
M!6).> <&IY?B[H-MI4.HR?:UMI8;N<'R>0MO((Y,C/!W$8]N>* .YVCTHP*P
M8=?N=5\*OJFEV(>Z>)F@M[J955F[9="PV]\KFN?L_B6\/P@A\::C:H)C8BYD
MMK=SL,A.T*K'G&XCD^M '?;0/:C:,YKSJS^*\-M9VR7>-9U6YN7MDM-&MG4H
MZQ>:5<2D$?*"0QP",46_QMT:\CMO(L=4>XO(XIK&W> ))=QN&PR[F &-C9W$
M=/<4 >BXYI:\_L_C-X>NKSPU;O*;.;7;=KB&*Y=5DB7 *AUR>6SQBL^^^+%S
M#XB\1:?';VZ6=K:77]GW18EY[NVC#SHR]E7>N,==K^E 'J%%>/Z)\<EMM/NY
M==C$LXE000V056,8M8II7.]@,*9#WR<@ &NC/Q?T<G4G@MK^YMK'[.C74<0$
M<LDZHT,<9)&2PD7T SR10!WM%>:R?';0K:UAFNK6]M&+3>;#,(P\"12^4\C#
M?RN\$87)."<5LZ9\2],U7Q$NDQ6U]&TEQ<6D5U-$%AEFAYD13G/3D'&#@^E
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MMY #%<>]=OX4^'NG>#KNYDT^258)2WEVS!-L(9MQ (4,1DG[Q..E=1BB@ '
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M<Y/I6J1D8KQOQ=X.T&3]HCP-=/HFFO=36&I7$D[6D9=Y4-OLD9L9++V/4=J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFKRBS/\ PG?[7E_/]^P\#Z$MLA["\NSN;\1$H'_ J]9\=_\ (D>(O^P=<_\
MHIJ[*_N0IT_*_P!__ L;U/=C&/S^\S?@]_R2;P7_ -@6S_\ 1*5V%<?\'O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;11169(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6=XB_Y 5]_UR;^5:-9WB+_D!7W_ %R;^5 !X=_Y 5C_ -<E_E6C6=X=
M_P"0%8_]<E_E6C0!R?Q FFTK2;S66\22^']/LK*8S-':QS ,0-DF&!)9<'"C
M@[N1TKSGX;>,M8O?&FFV>MZ]XHMUO(Y'M++7_#]M9QWVU<G9)'DAE'S;3M.
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MMM=()7R(;C;M\P'&X]2=I. S$T =Q.<V\O\ NG^59/@T8\*:5_U[K_*M:?\
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MN5_OP^'[PCZ?ZNG]9H_SK[S+^Q<R?_,/+_P%GO\ 7F?QW_Y!?@__ +&O2_\
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M?F\,1Z5?W"@$[@P<^8H/)*;A[T >^445%<W4-E \UQ-'!"@RTDK!54>I)Z4
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M\1 R<=\8KR7X3?%>\\1ZMH>B6GB*7Q5<1ZAJ"ZA<O:"-OL:AO(EDPH$;%M@
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MP]6<UBYM/9.S2\O>3N?*^JVWP6O=R^+_ (#II&[AY+KPI%*GO\\2M^=9%O\
M!']CGQ5+LC\*>#[2X)QLV/8R*?H"A!K[ *@C!Z5BZQX)\/\ B!"NIZ)I]^I_
MY^;9'_F*TM475?<=WLLPA\-6,O6-OQ3_ $/G*#]@']G_ %=OM&AV6HV)_ADT
M7Q1>H%^@68@?E7QM\>O^"637_P"TGHUAH'CV"W\->)6>XD?7+F2YU&T$2IO7
M<V3*6R=A8CT/3-?H[?\ [,_P[N9/.M]"_LJ?.1+IEQ);,#[;6%?+7Q4_9P\6
M6_QEL-+TNYFU"#5F,FF7][>-)+''$%+[V8[LQ[LCUR,5G.=2"34;GE9AF.98
M""G'#*HVTO=E^EKGJEK^Q3KNE6D-OI'[1'Q5L8HD"(LFJ13J   .&CZ8&,4X
M_LH_%:S(.G_M0^-HR.0+W3;*Y''3.4'_ ->O08?A)X\MX$2#XM:D"J@'SM-@
MD&<?A4G_  @/Q6M?]1\3K2X]KG0X_P"C5ISOK%_A_F>I]=Q"2;PTODX?_)'G
MR? 3]H>P&+7]I9KD#H+_ ,(63_7E2#2#X:?M6V+YA^-'@K45!R!>^$S'GV^2
M6N_/A[XUP'Y/%_AJY7'_ "UTMU_DU.,?QPMONS>#;S']Y+B/^1H]I_=8_P"T
M)1WH3^Y/\FS@?["_:[L/N^*OA5JH''[W3+V GWX<_2F'6_VP+$?-X8^$NJ+_
M -,]3OX6/X&,CBO0AK'QLM_O^'_"=W_UROY8_P":F@>-?B];D^=\.-)G'<V^
MN@$_@8Z/:+L_N8WF5-?%3FO^W)?HCST?$G]JVRSY_P &?!6HX_Y\?%ACSZX\
MR/OV_6HW^/?[1^G-B]_9J2Y [Z?XQM'Y^A4<5Z.?BC\1;;_7_">[D _Y]=5@
M?^>*8OQL\4P_\?7PF\2Q_P#7*2"7^3T>TC_28O[5PRWYEZPDOT//3^U9\6;0
M_P"F?LO>,P!R3::K93\?0,*;_P -K^([)MNJ?LY?%>SQP3!IL%P,]\%9>:]%
M_P"&@IX3BY^'/C2 =RNF^8!_WRU'_#2^A0\7?ASQ99-W$NBR\?EFCVL.X?VM
M@MG4MZW7YH\_/[?&@VHSJ/PI^+.FCN9O"4C >GW';K7SA^UW_P %2/#VDVOA
MW1O"?@[6;R^6_MM5NAXDM)=,\I8)E=45&7<Q8H1N' ]S7VA'^U+X%_Y;2:O:
MC_IOI,Z_^RU\H_MQWWP?_:#G\-"YT&;Q!JFG,'_M6*:6R>.WWY>V.5RP?YN<
M?*3D<U,J].*NV88G/<MPM)U:M967;5_<M3U'P+_P4[^#OBOPCI6KWSZ_I5[=
M0!Y[%-#O+I8).C()8XBC@$'Y@>?;I70I_P %&O@61^]\1:I:M_<N- OD;ZX,
M5:OPF^/GP?\ "GPX\/Z/I<MOX4L+*T6"+1O)D?[*!_#N"G=SD[L\YR>375-^
MTO\ "ISE_$5JQZ9-K*?_ &2J56FU=21U0S3 U(J<:T;/S1P8_P""C/P$R-WB
MZZC7N[Z->A5]R?*X%2?\/&/V>O\ HH=O_P" %U_\:KMF_:2^$[ @Z_9D'@@V
MDG_Q%1?\-#_" ?\ ,9T__P  9/\ XW3]I#^9%_VE@O\ G]'[T<E%_P %%/V=
M7!+_ !.TZ _W9K>X0_7!CJ1?^"A_[.C, /BII')QS'./_:==*_Q_^#<IR^JZ
M:YZ9;3W/_M.F-\>/@NZE6U'2F5A@@Z<Q!_\ (='M(?S(/[2P7_/Z/WHQ?^'@
M/[.__15]!_[ZD_\ B*G@_;U_9[N5+)\6?#H ./GG9#^JBK'_  N+X$_\]-"_
M\%)_^-5!/\5/@!=,&G3P[,P& 9-&W$?G%1[2'\R#^TL%_P _H_>B1?V[/V?F
M8 ?%KPSDG'-YC^E7C^VA\"#_ ,U9\*?^#./_ !K(;XD_L\LI5K7PR5(P0=#&
M"/\ OU53_A,OV:_^@1X1_P#">3_XS1[2'\R#^TL%_P _H_>CIK?]L7X&W()C
M^+'A(@'!SJL0_F:^??VY_P!K[X2-\%S!IGB_PQXNN+B[$?\ 9]ILU";_ %;D
M.FR1?*(('[PY SC!S7JMQXE_9BNRIGT#P9,PX!D\-QMC\X:\(_;"\!_LX?%K
MX3OIGA_3M.T;Q%#.)M/N_"^DQ6DJR;2")3Y:AXL'E<YZ$<TU7C3]^,K6\S*I
MF^!H0=65>*4?/_(Z_P#8._:#^%7C+X*BWO-7\)Z+<VMXT+:;?1PV,P^16+.)
M)&,I))S(#@],#%?1$]C\&O$YS)'X'U,G'.;23KTKX]_9,^!'[,'A?X4QZ9XJ
MTW1M8\1-<&2^O?%\,1F=\  0GHL7' !SUSFO:!^S!^R)KO\ J?"O@63=GFVN
MEC//^[(*N.*<GSJ>K\S6AFV$Q,%5I5DT]=_Z9Z9-^S?\%_$;AU\%^&[A^<-:
MQHI]\%"*HS?L=?"QVWVVB7FF..C6&JW4./H%DQ7GR_L&?LP7QW67ANPM\]/L
M&N7"8^FV:K"_\$]?@RQ#:;=>*=-(^ZVG^++Q,>X_>'Z5TK%U^E1_>ST8XKF^
M&I?YG:_\,E:!:D-IOC'QUI3#[HM_$,Q4?@V:0_LZ>*;1LZ=\:_&UN .$N7@N
M%_\ 'DKD1^P%X4@ _L_XC_%33@.@@\87) 'IALTO_#%&K6A']F_M!?%JQQR
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M9[O'^TC\*Y<[?B#X>X]=0C'\S6C;?''X>7;*(?''A^0L,@#4HN1_WU7S7/\
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M*** (KG_ (]Y?]P_RKYWO1_;?[0?P:T[&Z/2=!U#5V] S*D*_P#H35]$7/\
MJ)/]P_RKYB\-^)K31?C9XS\3WY_T+PKX*L+7=_MRL\Q4?[1PH_$5V8?W>>?:
M+_'3]32,XTHSJ2=DDRS^TI\4=$T/7'N->ESX1\"6P\0:PBD$W-T?ELK11W=G
MY"_2O'/@W^R]I_B;XM^"_B3\7O#MMJWQ%\8KJ'B2ZL[Q2T.F!!;_ &.V6/[I
M,2$9W G<3Z5%\)_"UU^T_P#&WRM47[1X*\&ZH-?\1OUBU3Q XS;V?HT=I'M)
M'3><=Z]F\=?'6QTS]H_0+:X\.:^MKHBW6FW>IFT_T4&X\@B8/G'EJ$8LQZ5Y
MM/;G?4\?+:<IQ>(FO>J._FE]E?=^-STOX_\ Q=7X/^ Y+^TMSJ7B749ET[1-
M+3E[N\DX1<?W1]YCV KQCQ++'^R#^SM<OJ<)\1>-_%L\G]JWK/M^TWLZ,9'9
MNNR-<JH'8#IFN4LOB]#\0OC ?B#_ &9/XHU&$2Z=\/\ PI;<LT>=LVISGI$C
MD85F_A'%=UX[_9GUOX@>"]8\1?$+Q*E[XL%M)/';PP^98:;$JEC#!&6'SG !
ME.3QTKT\!0I>TCC,=_#Z+K)=TNS[]MCV<XKU<+AY93E[_?;U)=(OI%O^[U7\
MSUV10^ ?[8VB7/P[TW2=3\.ZY_:.CP16##1]/DO8G1$"K(64?*2!]T\_A7I/
M_#4VD3#_ $;P3XYN2?N;="D&[\R*N_LL?#>S^'7P;T.*V>*:74X(]2FGC@$3
ML98U8*V"=Q7.,^@Z"O7CGUKJQ-; RK2=&B^6^EY?U^9\_AJ&/C1BJ]9<UM;1
M_K\C\Z]!_:_\;7/[14FJ)H0NTOI%T8^'XH,77D)(Y1 2<B4%F)SQVZ"OJ@?&
M/XG:@Q73O@OJ,0/W7U/5K>$?B!DU>TOPGH\/[3VMZ@FDV:7O_".6L_VD0*'\
MQKB96?./O%5 )ZX%>P 8K?%X[!UG%T,,HV5GJ]_E8PP>7XVBI*OB7*[NM%M\
M[GPI^U_X\^,S^"[&WUKP[#X5\.W,S)=MI%X;LRG@JDSA1L7N,=2.M=]\"_'O
MQ\O/AAI5W-X2T[Q'&P;R;O5]1:SO)8P?E+J4/X,>2/U]5_:@UK3M,^#/B6WO
M;^TM)[FUVP17$RHTI#H2%!/S8'I7H^CZK8:W817>FWMMJ%HWRK/:2K)&2."
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M+_%?B+QYI_B2R\<0Z8FFB5;&S.CI,(DE5%E#.7!8G9P<#&:Q5_:T\)1,5O\
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MP4D^C5SE/ &B^%XO!VD)X>L8UT,0#[()H&#"/MGS!OSU^]S70C2+#'%E;_\
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M&6BOSC_C\3K^=:$/Q1\'7 )C\4:0^#CB]CZ_G1-\,?"$_P#K/"^COVYL8_\
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M !-9FAA:/\$?!^A>+CXGL].GCULLS&Z>^G?.[=D%6<J5RS$+C SP!7=U@_\
M"::;_=O/_ .7_P")H_X333?[MY_X!R__ !- %S5_#>D^(/*_M32[+4O)R8_M
MENDNS/7;N!QGVJ;3='L=%M%M=/LX+"U4DK!;1+&@)Y)"J *S?^$TTW^[>?\
M@'+_ /$T?\)IIO\ =O/_  #E_P#B: -ZBL'_ (333?[MY_X!R_\ Q-'_  FF
MF_W;S_P#E_\ B: -ZHI+6*4Y>-'.,990:QO^$TTW^[>?^ <O_P 31_PFFF_W
M;S_P#E_^)H W$01J%4 *. !P!3JP?^$TTW^[>?\ @'+_ /$T?\)IIO\ =O/_
M  #E_P#B: -W&*",UA?\)IIO]V\_\ Y?_B:/^$TTW^[>?^ <O_Q- &;KGP@\
M%>)=;;6-5\,Z=J&JL48W<\ :3*XV\^V!77[16%_PFFF_W;S_ , Y?_B:/^$T
MTW^[>?\ @'+_ /$T ;N*,5A?\)IIO]V\_P# .7_XFC_A---_NWG_ (!R_P#Q
M- &Z5R*^9OB=^Q+I'Q,^)=YXPE\1RZ=)<RQ2M80Z?&T+% !\^2"V[')XZU[Y
M_P )IIO]V\_\ Y?_ (FC_A---_NWG_@'+_\ $UTT,36PLG.A)Q;TT.7$86AB
MHJ->"DEKJ#^!O#MQ&J2Z!I<H4!0'LXR,>G(K-N_@]X%OAB?P=H<H_P!K3XO_
M (FM+_A---_NWG_@'+_\31_PFFF_W;S_ , Y?_B:S56I'52?WERH4I?%!/Y(
MY6X_9N^%MT<R^ M")]19(#^@K+N?V3/A)=9SX(T^,^L)=/Y-7??\)IIO]V\_
M\ Y?_B:/^$TTW^[>?^ <O_Q-;K&XI;59?>S%X+"RWI1^Y'FS?L@_"\#]QHMW
M9^]MJ=RG\GJ$?LC>#(CFVU7Q79G_ *8>(;H#\BY%>G_\)IIO]V\_\ Y?_B:/
M^$TTW^[>?^ <O_Q-5]>Q76HW\[D?V?A?^?:^X\Q/[+UG /\ 0_B!X\LL=-FM
MLV/3[RFFC]G?7;;BT^,7CB/''[^XAF_G'7J'_"::;_=O/_ .7_XFD_X3/3?[
MMY_X!R__ !-/Z_B=N:_R7ZHG^S\-_+;YO_,\O/P1^(D#9MOC;K@]KC3;:0?R
M%'_"L?C':<6OQ>M[CT^V:!$3_P".D5Z?_P )GIW]V\_\ I?_ (FE_P"$TTW'
MW;S_ , Y?_B:/KU7JHO_ +=C_D#R^B]4Y+_MZ7^9Y<OA'X\VPRGQ \+7A'_/
MQHCIG_OEZ^:?VK]:^.?A?7-%_M769ELG@(CN/"4<\-L\F_@2#)/F=,>QK[F_
MX3/33VO/_ .7_P")H;QAI;##1W;#KS92G_V6NW"9I]6JJK.E"273E2_&QQ8S
M*?K-)TH5I1;\V_PN>"?":_\ VA3\.= DEM/#4[&V4_\ $_EN%OY!V,V!@.1B
MNM.M?M (,_\ ".>"7 _A%_< G\=M>G?\)EIN?NWG_@%+_P#$TH\9Z;_=O/\
MP#E_^)KEGC5.;E[*.OE_P3IIX!P@H^VGHN__  #R_P#X2?X_+S_PA7@]\<[1
MK,P)]L^71_PF7QZ7D_#KPNP'4+X@?)^G[JO4/^$TTW^[>?\ @'+_ /$TG_"9
MZ;_=O/\ P#E_^)J/K47O1C^/^9I]4DO^7TOO7^1YG_PGGQP7D_"_12!R0OB$
M9/\ Y#ZT?\+(^,R\GX269 YPOB"+./\ OGK7IO\ PF>F^EY_X!R__$T?\)GI
MO]V\_P# .7_XFCZU3_Y\Q_\ )O\ Y(?U6ITK2_\ )?\ (\R/Q6^+:C)^#,A
MYP-?MLFD_P"%R?%$<GX(:ECOC7+,G^=>G?\ "9Z;_=O/_ .7_P")H_X3/3?[
MMY_X!R__ !-/ZS2_Y\1^^7_R0OJM;_G_ "^Z/_R)YA_PO#XACD_!'7MHZXU*
MU)_+=2_\+[\9CEO@MXI '7$]N3^6ZO3O^$TTWTO/_ .7_P")H_X333?[MY_X
M!R__ !-#Q%%_\N%]\O\ Y(%AJZ_Y?O[H_P"1Y@?VAO$JC)^#7C3 ](X3_P"S
MUY[\:OVQ_$7@CPFD]A\.=<\/W]S,(8;SQ);*EL."3@*Q+-@<#BOI$^,]-/\
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MOOE_F=/L,1_S^?W1_P CR_\ X:1UG_HCOCW_ , 8_P#XNC_AI#6?^B.^/?\
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MU)54 ]2<<U?^+NIZE;>&3JVDWUS:36,?GW#6MXB+;!2"[/$1F7 ##9D=".M
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MQVYD*>:<@E5!'.>1UQBM5?BIH)MKI]UTL]O/%;?8VMG$\CRC,6Q",L' )!]
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M^?Z#_OL4?\)%IG_/]!_WV*** #_A(M,_Y_H/^^Q1_P )%IG_ #_0?]]BBB@
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5O3[C2+R**\A>1XF"JK9).*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_015.jpg
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %^ M # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGACP;>:YH=N[HM\;N. W.WAC#&V2PR#@DC-/UWX]:-IWPQM?'%G:SW^G2S)
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M=NK!0":JI0<G)Q=N96?X_P";(PF80H4Z4*L'+V<G.-G;5VNGH]/=6UGOY6\
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M[Z&='-H0DI3IN248Q<;KEERJWO+E=]==+-='U'1?<I]%%=Q\X%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 TQ@G//YTH&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GA'_P!\B@";>O\ >'YT;U_O#\ZA^P6W_/"/_OD4?8+;_GA'_P!\B@";>O\
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M^M>0_$7X)7_C3]H+X4?$.WU*VMK'P;%JD=S921L9;G[5"L:%&!PNTJ2<]0:
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M?B.RTZUT$^)89;[1Y(/MUBLB1226^[B38\B*P![Y&1S6G9?LA:':>-X_$O\
M;NJ/<IXBUKQ'Y!6+89=2M%MI8_NYV(J@KWSU)%8TW["GA.]\(Z+X<O-;U:YT
M_3/!-SX'7_5J\EM-)%)YY(7B16A0C'R^HH 7XZ_MHZ3\+;BYL=&\.ZMXHUC3
MM5T2QU"VM[5MD46I$F)T8'YG*HP5.[E5R,YKJK?]K[X?S?$.S\'.^J6^HW%]
M#I#74U@PM(-2DB$J6$DO19]I&5Y /RDYXKCKC]A^SU/3O%9U;XA>)-5\0:]-
MHMX=<FBM%EM+G2V8VLD<:1",CYN592#C/4FKND?L1^%]'^,;_$./4Y)M0N=0
MCUB]@N-*L)7GOE4!IDN&@,T*NRAS'&ZKNR1C- &7\0?VN8?$'P#\:_$7X8K?
M2P^$YHKQKG5-,:.UU2UBN-MTD#MU^1)1GAE(4XP:]3^)/[0OAKX6-X4@O[/6
MM7O?%*SMI%EH>G/>3W)BB$K*$3H=A!&>.N2!7B7Q _8QU/3OAS\4K+PMK-WX
MB\3_ !%^R:7?7%^EI8P6UIY_[ZX:.".-99A$\F9"#(Y"BO>O$/P8TW7_ !U\
M-_$PO;JTF\#"\6QM8]ICG6XMOLY$A(S\J\C!'/6@#A?!_P"W!\+/&4,EW!>Z
MKIFE?V)<>(8=4U;2YK6UN;.W(6Y:)V7YVB8A64#KP-U+9_ML?#:^\*:[K,C:
MU82Z1)912:/=:8ZZC<&\.VS\F 9,GG$$+CT.[;6+I_["7@Z#PCX7\-7VL:MJ
M>E:'X=U?PULD,:/<V^H2+)*[,J_*Z%1M*\<#(-5-%_8*\,:+X$U'P_!KUU;7
MTMY87]CK>G:3IUA<V,]DYDMY (($69MS'<90V[VYH P/A=^UMXA\:?%!M&NO
ML]CIMYX]U#P_;6.J:5/!?QVEOI:71CVJ<+,LA;)D!!' YP:[Z^_;C^'&CVGB
M>?5H/$6C/X?MK:^N;;4-'EBN)K6>Y6VCGAB/S.OF, 00&']VJWAW]B_1]$\5
M6OB*[\7:_K.K)X@O?$<]S=&!'GN+K3A8RC,:*$4*-Z[0-IP.@%<1X?\ ^":O
MA#P_I.MV,?BS6)/[5L+739)UM+.&3R[>^CO(W<QQ+YLI:(*TLFYF!Y/ H ^A
M/A/\;/#_ ,83X@ATBWU33M1T"]%CJ6F:U8O9W5M(R+(A:-^=KHRLI]#VKOZX
M'P%\(K'P#X]^(/BFUOKFYN?&5];7UU!,%\N!X;=(%$>!G!5 3G/-=]0 4444
M %%%% !1110 4444 5;/_67/_74_R%6JJV?^LN?^NI_D*M4 %%%% %:?_C\M
M_H_\A5@=*KS_ /'Y;_1_Y"K Z4 +1110!7NM0M;$1FYN8;<22+"AED"[G8X5
M1GJ2> .IJB?%VABPN+TZS8"SMY/*FN#<IY<;YQM9LX!R1P?6JWB_PU/XCT^"
M"WN8+66*\@NA)<6YF \N0/@ ,N"2H&<]">.:XO3/@O=Z3H\MG#KT3N;Y;]'F
MLC(JN%V8*F3[I4M\H(53C:% VD ]'L=9L-3FN8K.^M[N6V8).D$JN8F(R P!
MX./6K>:XKX<_#1?A]'+"FH&]A6%+6WS#Y;)$LDD@WD$[VW2M\V!P!QG)/82V
MYE((EDCQ_<(Y^M $U%5OL;?\_,__ 'T/\*/L;?\ /S/_ -]#_"@"S15;[&W_
M #\S_P#?0_PH^QM_S\S_ /?0_P * +-%5OL;?\_,_P#WT/\ "C[&W_/S/_WT
M/\* +-%5OL;?\_,__?0_PH^QM_S\S_\ ?0_PH LT56^QM_S\S_\ ?0_PKSSQ
M_P#$BZ\$ZG+9QV3:@S6D<UOMN@'>1KA(=K)MX0>8&R"2>@% 'IE%>0^)?B_/
MH,&CWL=NMQI.IV,<L%\\[(CW4A.V'[N44 ;BS#IGN,5W7@[59/%'AZWU&1W@
ME=I(Y$AE#Q[DD:-BC%02I*D@XZ$4 =)15;[&W_/S/_WT/\*/L;?\_,__ 'T/
M\* +-%5OL;?\_,__ 'T/\*/L;?\ /S/_ -]#_"@"S360-U%0?8V_Y^9_^^A_
MA1]C;_GYG_[Z'^% %@* <@<TM5OL;?\ /S/_ -]#_"C[&W_/S/\ ]]#_  H
MLTUE##!J#[&W_/S/_P!]#_"C[&W_ #\S_P#?0_PH L#@4M5OL;?\_,__ 'T/
M\*/L;?\ /S/_ -]#_"@"S15;[&W_ #\S_P#?0_PH^QM_S\S_ /?0_P * +-%
M5OL;?\_,_P#WT/\ "C[&W_/S/_WT/\* +-%5OL;?\_,__?0_PH^QM_S\S_\
M?0_PH LT56^QM_S\S_\ ?0_PH^QM_P _,_\ WT/\* +-%5OL;?\ /S/_ -]#
M_"C[&W_/S/\ ]]#_  H LT56^QM_S\S_ /?0_P *?#;F$DF623V<C_"@"'4/
MNQ_[X_D:EL?^/*W_ .N:_P JBU#[L?\ OC^1J6Q_X\K?_KFO\J )Z*** $/0
MUQ-M\6-*O?#8UJW@O)X6N#:I;11H\\DF"<; _P O +88J<#ITKMB,C%<G/\
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M\_4G_?*_X4 6:*K?9YO^?J3_ +Y7_"C[/-_S]2?]\K_A0!9HJM]GF_Y^I/\
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MT4 5O[1MO^>R?G1_:-M_SV3\ZLT4 5O[1MO^>R?G1_:-MC_7*?QJP>E-Z$4
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M.K-% %;^T;;_ )[)^=']HVW_ #V3\ZLT4 5O[1MO^>R?G1_:-M_SV3\ZLT4
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M$F]_M.ZANI)8XXVN8I'9[MU>1C/+N'#[75,9;B,<XP!WDL4KXV2^7CK\H.:
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MZU]JE_Y]9?S7_&C[5+_SZR_FO^-612T 5?M4O_/K+^:_XT?:I?\ GUE_-?\
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M15;=>?W(?^^C_A1NO/[D/_?1_P * +-%5MUY_<A_[Z/^%&Z\_N0_]]'_  H
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MQQOL<2KQY6^VNG^9W7_#75O_ -"Q-_X%K_\ $UZ!\*_BZ?BDNI-;Z5]@^Q%
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MEU_SPB_[^G_XFOIC\5+--8X%0>9=?\\(O^_I_P#B:1I+HC_41_\ ?T__ !-
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MO^_I_P#B:/,NO^>$7_?T_P#Q- %FBJWF77_/"+_OZ?\ XFCS+K_GA%_W]/\
M\30!9HJMYEU_SPB_[^G_ .)H\RZ_YX1?]_3_ /$T 6:*K>9=?\\(O^_I_P#B
M:?"\S,?,C1!V*ON_I0!#J'W8_P#?'\C4MC_QY6__ %S7^51:A]V/_?'\C4MC
M_P >5O\ ]<U_E0!Q,O@WQ!-KVM7":Y:0:7>W$<@LIM.6X+1K&BE2[,,9*M@8
M(&<]Z[Q3D"EHH 0]*\BD\-^)+SPCJ]M]AU>POIM0-Y;6XU&.8* 0%0R&8,4;
M&Y@&7&Y@HX&?7>E4_P"V+3[-)<?:8/L\;%7E\U=BD'!!.< YXQ0!+9B=;& 3
MA%N1&HD$9)4-CG&>2,^M-VW?_/6/_OV?\:LJ=P!]:6@"KMNO^>L?_?L_XU\A
M_M*[Q\4[@.0S?9(.5&!T-?8U?'G[3/\ R56Y_P"O2#^1KXSBS_D7K_$OR9]O
MP?\ \C)_X7^:/*J^A_V3!(8O$OENJ_/!G<N>S^]?/%?17[(_^J\3?[\'\GK\
M_P"&_P#D94O1_P#I+/T/BG_D4U?^W?\ TI'T&JW7/[V/_OV?\:7;=?\ /6/_
M +]G_&K"]Z=7[D?@B*NVZ_YZQ_\ ?L_XT@2Z)&98_P#OV?\ &K1Z4T]10P/@
MCQ^"/'?B+<06_M"?) Q_&:P1UK?^(/\ R/OB/_L(3_\ H9K '6OYRQ7^\5/\
M3_,_IS!_[O2_PK\CZ]_9L$Y^%%CY;HH^TW'!0G_EH?>O4=MU_P ]8_\ OV?\
M:\T_9G_Y)/8_]?,__HPUZK7[OE'_ "+Z'^&/Y'\]YO\ \C'$?XY?F5=MU_SU
MC_[]G_&C;=?\]8_^_9_QJU17KGD&;?+<_8KC]['CRV_Y9GT/O7Y\GJ?J:_0V
M^_X\;C_KFW\C7YY'J?J:_,.,MZ'_ &]_[:?J? ^V(_[=_P#;A#TK[D^%"W'_
M  K7PSLD0+]@BP#'S]WZU\-GI7W7\)/^29>&/^O"+_T$5S\'?[S5_P *_,[.
M-_\ =:/^)_D=)MNO^>L?_?L_XT;;K_GK'_W[/^-6J*_5S\@*NVZ_YZQ_]^S_
M (UP7QT6<?"7Q)OD0KY"Y 0C_EHOO7H]>?\ QX_Y)'XE_P"N"_\ HQ:\_,/]
MSK?X9?DST,N_WVA_CC^:/B>K6D\ZK9#I_I$?_H0JJ:M:3_R%++_KXC_]"%?S
MW3^->J/Z2J?!+T9^@86ZSQ+'_P!^S_C2[;K_ )ZQ_P#?L_XU86G5_2:/Y<15
MVW7_ #UC_P"_9_QHVW7_ #UC_P"_9_QJU13&5=MU_P ]8_\ OV?\:-MU_P ]
M8_\ OV?\:M4A.* *VVZ_YZQ_]^S_ (T;;K_GK'_W[/\ C5G.:6@"J5NL?ZV/
M_OV?\:L)NVC<06QR0*=10!5L_P#67/\ UU/\A5JJMG_K+G_KJ?Y"K5 !1110
M!6G_ ./RW^C_ ,A5@=*KS_\ 'Y;_ $?^0JP.E "T444 (1FDV+Z"E;..*\@M
M/&_BR70]4^W0WMA>"_1#<06+3"VMS+MD\M#$"Q1=N<^8#NR"<$  ]?"@= !2
MUYM\*?$?BS7)KG_A([>6"40!I8)+0P+;3>8X"(V/G#1A')RV"V,CH/0Y99(R
M L329_NX&/S- $U9OB/_ ) .I?\ 7K+_ .@&K'VB;_GVD_-?\:S_ !!<2G0M
M2!MI!_HLO.5_N'WH>Q</B1^3J?=%*.M(GW12U\2]C^DD?I=^S7_R0GP5_P!>
M _\ 0C7IM>5_LWS2+\#/!86!W L1\P*\_,?4UZ5]HF_Y]I/S7_&OLJ?P1]$?
MSQC_ />ZW^*7YLM455^T3?\ /M)^:_XT?:)O^?:3\U_QK0X2P_2OS)_:'_Y+
MEXU_["#?^@K7Z6M<38YMI/S7_&OS1_:&.[XX^-3@K_Q,&X/^Z*\G,?X<?4^\
MX/\ ]\J?X?U1YZ:^V/V"O^1%\3?]A-?_ $4M?$]?:G["$CQ^!O$NV-I/^)FO
MW<?\\E]37!@?XZ^9]=Q1_P BR7JOS1]3T55^T3?\^TGYK_C1]HF_Y]I/S7_&
MOI3\5+5(W2JWVB;_ )]I/S7_ !H-Q-C_ (]I/S7_ !H ^*?V\O\ DH/AO_L%
MM_Z.:OF2OIC]NYVD\?\ ALM&T9_LMN&(_P">S>AKYGKY;%_QY'[KD'_(LH>G
MZL^A?V'/^2Q7O_8)E_\ 1D=?>HZ5\$?L0.4^,%Z50N?[)EX&/[Z>M?=WVB;M
M;2?FO^->OE_\!>K/SKBK_D9/T1:HJK]HF_Y]I/S7_&C[1-_S[2?FO^->D?'E
MFF3/B)R#@A20?2H3<38_X]I/S7_&N-^)WQ8TKX3>'XM8UZVO39R7"VP^RQK(
MV]@2.-PXPIJ9244Y2V-*=.=::ITU>3T2.*E^)GB>'X;W%XES!<Z[;7QB>:&
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MD*M55L_]9<_]=3_(5:H **** *T__'Y;_1_Y"K Z57G_ ./RW^C_ ,A5@=*
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MKQ)=:#\/O$>J6'F07UGI\T\$C19"NJ$J<'@\U\*K^UU\5"H_XJ&'I_SX0_\
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MC 'Y"C^SK;_GBGY5)#.L]O',I&QU#@Y!&",]:;]MM_\ GO%_WV* &_V=;?\
M/%/RKY#_ &ED6+XIW"H JBT@X'T-?7WVVW_Y^(O^^Q7R%^TLZR?%.X96#*;2
M#D'/8U\9Q9_R+U_B7Y,^WX/_ .1D_P#"_P T>5U]#_LF0QS1>)=Z!\/!U^CU
M\\5]$?LERQQ1>)=[JF7@QN..SU^?\-_\C*EZ/_TEGZ'Q3_R*:O\ V[_Z4CZ&
M73[8Y_<I^5+_ &=;?\\4_*A;V#G]_%_WV*=]MM_^?B+_ +[%?N1^"(:=/MO^
M>*?E2?8+<$?N4_*GF]M_^?B+_OL4W[9;DC]_'_WV*&!\'>/U">._$2J, :A.
M !_OFL$=:WOB P;QYXC(((.H3X(_WS6".M?SEBO]XJ?XG^9_3F#_ -WI?X5^
M1]??LUVD,WPHL2\:L?M-QR1_TT->H_V=;?\ /%/RKR_]FJYBB^%%B'E1#]IN
M.&8#_EH:]2^VV_\ S\1?]]BOW?*/^1?0_P ,?R/Y[S?_ )&.(_QR_,;_ &=;
M?\\4_*C^SK;_ )XI^5.^VV__ #\1?]]BC[;;_P#/Q%_WV*]<\@J7UC;_ &*X
M/DK_ *MNWL:_/D]3]37Z#WMW ;*X'G1D^6W1AZ&OSX/WC]37YAQEO0_[>_\
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M6HVEH(Y[=XR2C;CP2,C\J[S[?#_TT_[]/_A7UE/2$;]C\%QLE+%591=TY/\
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M;!]QFI?M\/\ TT_[]/\ X4 3^6G]U?RKX^_:8 'Q5N<#'^B0=/H:^NOM\/\
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M@8Z57_M"$?\ /3_OT_\ A5A6#J&&<'U&*^Y/@RM9_P"LN?\ KJ?Y"K55;/\
MUES_ -=3_(5:H **** *T_\ Q^6_T?\ D*L#I5>?_C\M_H_\A5@=* %HHHH
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M^(VD^$=7M=.U%IDN+J"2>+RXMRL$95*YS]X[\@=P#Z4J?$SPU)<S6Z:S;M/
MTB31_,&C,>-^X8^4#<O)X^8>M6O$7@71_%;*VJ6@NF4(%)=E*[95E4C!&"'1
M3GZCH36-'\&O#,?G!;:X"32RS/&+J3:7=-A/7L.GIUZT ;$?C;2[E[Z.TNTO
M9K*%IIXH,ED4%EYS@ Y1Q@GMZ<U0'Q-TP^']*UOR+S^S+]Q&)_+7$!+[ 9/F
MZ;CC*[L]1QS4VF?#?2='9WM6O(Y'MGM#(;N0N$9R[$-G.\L2=W7TJ&7X7:/+
M;6<!DU 16KR2HHOI0"T@(D9N?F+;FR3W9NF: &1?%_PA+9SW2Z]:M!!@R,-^
M0#TP,9/X \<]*Z^&59XED1MR, P([@\BN \5_!31O$=A%!;S3Z5-'*LHN(6\
MQN,<8?([+S_LBO0(8S%&J%BY QN/4^YH =CW-&/<TM9+^*-.CUQ]':8C4%A-
MP8C&P!C&,D-C:<9&0#D9Z4 7KZ[33[&XNI=QC@C:5MHR<*,G _"N/TGXQ>&-
M7L;6\&H?8X+IHTB:\0QY=X]X0^C 9!!Q@@BM#_A-O#6NZ=-#)J=LD,X>WDAN
MY/LTG]U@4?:PZ^G<8[5A1?#?P/J&IEK5(VO+:\2=TMKTDI.J*JAE#<-MB4X(
MY*DGOD W&^)7AM+#[:^LVR6QC$H=RP)4KN!P1GE>1Z]JZ6"031)(,X89'!''
MXUY1:>'?AW=I;"VOYI/M(ELXG6\F_>/YODR''3=ODV;L=&&.,5WUKX@T/2=-
MMHAJEE%:Q1F.-I+M""L?RM\Q;G;C!.>.] &YCW-&*S+3Q/I=^\*6]_;3/,6$
M*K*N9=OWB@S\P'J,BM,'(H J:A]V/_?'\C4MC_QY6_\ US7^51:A]V/_ 'Q_
M(U+8_P#'E;_]<U_E0!/1110 AY%91\)Z*;>6 Z18F"5BTD1M8]KDL&)(Q@DL
M <^H!K6HH 3: H X ["C&*6B@!,>YKBU^+/A\7^HVMQ=&R-C=FR>2XV[7E )
M(4*Q8  9)8 8YZ5VM<5J?PHTG5+[SWN+^.-KJ2[EMDNW$<C2(RN,9^56W'<H
MP#WH B?XP^'H=3>SN+A[54MC<M=2[?)"C.02&)SP>V"<#.3BMC2/'FAZ]?I9
M:?JEO=W3P+<K'$Q.Z(@,&!Z=&4XZX(JK)\,/#TEA>6GV!!%=QI%*0QW;4?>@
M5LY&&Y&.X%7M.\%:7I=[#>00L+J($"1I&.<QI&21TSMC4=.WO0!NXHQ[FEHH
M J:E?QZ5875Y-N,-O$TSA!EMJ@DX'K@5R>F?%_PSJ5C:7?\ :(M(;ID2)KM#
M'N=HQ)L]F ."#C!!':NOO[&+4K*XM+A=]O/&T4BY(RK @C/T)KD9?@]X8DO4
MNUL7AN%NA>;HIW7]Z%10V,X_Y9H<>HSW- %YOB1X;2P%XVL6Z6Y57#,&!(*A
MEP,9.000,<Y&.M7?^$GMQKO]E,DR3&T:^$K1D1&,,%(W?WAD9&.,U@CX-^&U
MC*+%>(I@:W;;>R\AOO,>?O$<;NN.!BMF3P3I\FJP:@9+M9H;462(MT_E^5N#
M%2N<'.T9)Y..M &!8?&WPE>64%U)JL=I'< M"D_+,@_BPA;:#@\-AN#D#%=+
MHGBW2O$5Y>VNGWT=W-9D+<+%DA"<XYQ@_=;D$]#6/9_";PY91NB6LK[P%+R7
M,C,5561023G"HY4#L,#L*D\!?#FV\ 2ZL;2^N+F&_N#.(9@H6'D\ @9/4#)/
M8>^0#K<>YHQ[F@G )K/;Q!8IK4>DM/C49(6N$@VG+1J0&;.,<%AQG/- %Z1O
M+0MZ<G-</H_QE\,:Q8Q7BWS6=O(T48:\C,>V21W58SUPV8SUXP0<\UKP>/\
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MNX,"'4XX+F:.&1+696$Q$IQ'\H!SD\<9J;5=1\+^)H4@N]0T^\2$FX\HW2<
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M=A'K-_ FI7'GW,D:0#S#\N5*^7MPP7#<9;+$\G-=U45RI>(H"1N!&Y>HXZT
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M)N?^?E?^_7_UZ/)N?^?E?^_7_P!>K-% %;R;G_GY7_OU_P#7H\FY_P"?E?\
MOU_]>K-% %;R;G_GY7_OU_\ 7H\FY_Y^5_[]?_7JS10!6\FY_P"?E?\ OU_]
M>CR;G_GY7_OU_P#7JS10!6\FY_Y^5_[]?_7H\FY_Y^5_[]?_ %ZLT4 5O)N?
M^?E?^_7_ ->CR;G_ )^5_P"_7_UZLT4 5O)N?^?E?^_7_P!>CR;G_GY7_OU_
M]>K-% %;R;G_ )^5_P"_7_UZ/)N?^?E?^_7_ ->K-% %;R;G_GY7_OU_]>CR
M;G_GY7_OU_\ 7JS10!6\FY_Y^5_[]?\ UZ/)N?\ GY7_ +]?_7JS10!3:SFE
M9?-N RJ=V!'CMCU]Z(K6XB146Y7:H &8N?YU<HH K>3<_P#/RO\ WZ_^O1Y-
MS_S\K_WZ_P#KU9HH K>3<_\ /RO_ 'Z_^O1Y-S_S\K_WZ_\ KU9HH K>3<_\
M_*_]^O\ Z]'DW/\ S\K_ -^O_KU9HH K>3<_\_*_]^O_ *]'DW/_ #\K_P!^
MO_KU9HH K>3<_P#/RO\ WZ_^O1Y-S_S\K_WZ_P#KU9HH K>3<_\ /RO_ 'Z_
M^O1Y-S_S\K_WZ_\ KU9HH K>3<_\_*_]^O\ Z]'DW/\ S\K_ -^O_KU9HH K
M>3<_\_*_]^O_ *]'DW/_ #\K_P!^O_KU9HH K>3<_P#/RO\ WZ_^O1Y-S_S\
MK_WZ_P#KU9HH K>3<_\ /RO_ 'Z_^O1Y-S_S\K_WZ_\ KU9HH K>3<_\_*_]
M^O\ Z]'DW/\ S\K_ -^O_KU9HH K>3<_\_*_]^O_ *]'DW/_ #\K_P!^O_KU
M9HH K>3<_P#/RO\ WZ_^O1Y-S_S\K_WZ_P#KU9HH K>3<_\ /RO_ 'Z_^O1Y
M-S_S\K_WZ_\ KU9HH K>3<_\_*_]^O\ Z]'DW/\ S\K_ -^O_KU9HH K>3<_
M\_*_]^O_ *]'DW/_ #\K_P!^O_KU9HH K>3<_P#/RO\ WZ_^O1Y-S_S\K_WZ
M_P#KU9HH K>3<_\ /RO_ 'Z_^O1Y-S_S\K_WZ_\ KU9HH K>3<_\_*_]^O\
MZ]'DW/\ S\K_ -^O_KU9HH K>3<_\_*_]^O_ *]'DW/_ #\K_P!^O_KU9HH
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MPNOC'#!J-IX&UO1_#ERDKVVM:A<69BFV2%,"..=Y%)(8C<HX'.*]4H ****
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MQ^S5\6/%7AOQ?'>Z!'!J6J?#JY\-F)[W3H;:34&N()%2WBMHT$=OA9BAD+,
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MM0\3Z#HUUINA^']9B,*.EQ#IEU>:BES#;0*X!*Q1%XPX &%(& 0*^K@BCH*
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=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_016.jpg
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &5 M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGFNRK+\+W]YJOAK2;[4K(Z;J-S:137-FW6"5D!>/_@))'X5J52,WJ[A1113
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MTDKWMNUV/< U+FO$?#O[0&M>)[Z^T*Q\"7<GBFPG:&\M3>(MM;@<;WF([D'
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MV.V<A< <<]Z[*E.4JM.:V5_Q1X>%Q5.E@L30E\4^6WRE=GFW@O\ Y.W\;_\
M8*A_E%2?LXC_ (N'\7_^PU_[/-7I6E_#+3](^).K>-(KBY?4=2MUMI8'*^4J
MKMP5&,Y^4=Z/ OPQT[P'K?B74[*YNIYM>N_M=PEP5*QMECA, <?.>N:Y*>&G
M&<9/I*3^3V/:Q.:8>K0JTXWO*G2BM.L.6_Y:&7\4OA$GCZ\T[6=.U6?P_P")
M]*!%GJ4 W  \['7NO^)ZYK$^'GQ*\36GQ!D\ >-[:UDUD6QN[35-/XBNHQU+
M*?NG@^G0\5U_C+X;1^+M5MM3BU[6M"O[>+R5ETJ[\M67.<,A!5CD]2*K>"_A
M!I7@[7[K7FO=0US7KF/R7U+59_-E5/[JX "CIT':M)4I^VYZ:MKKKHUZ=SEI
MXS#O NAB9<]HOD7+[T97Z2_EZM:K79/4\^^#W_)Q/Q8_WHJ]ZXS[UYKK7P*T
M[4?&&H>)-/UO6O#U_J*!+W^R[A8UG P.<J2#P.E=]HVDQZ)I5K812SS1V\8C
M62YE,LK =V8\L?>M,-"=).$EU;OZNYSYMB:&,G"O2EKRPBU;9QBHO7KJC$\6
M?#'POX\N[>YU_1;?59K=&CB,^XA5/)P <?C7E7P>O;GPK\;O%W@33[R>_P#"
M]I;K<P132F7["YVYC#') ^8C&>P]Z[S7OA-=:_J-Y,_CCQ1:6ERY<V-I=I'&
M@/\ "I";@/QK9\"?#70?AO83VVB69A:=O,GN9I#)/.WJ[GD_RK.5*4ZT9J/+
M9ZOJ_+_AS>EC:5#!5,/.JZG-&T8V?+%W3YM=FM5[JUOO8\H_9<O%T"_\<^#;
MMQ%J=CJTEPL+\,\;8&X>H^5?^^A3_B=<IXN_:.^'>AV+">313)J-YLY\D<$!
MO0_*/^^A7;>/_@3X?\?ZU#K;37^BZY&NS^T=*G\F5UQ@!N#GCC/6K_PW^#_A
M_P"& NY-+2XN=0O"/M.H7TGFSRX[%NPSS@5A'#U>2.':7*G>]^B=TK'HU,SP
M3K3S*+?MIP:Y;:*4H\LI<U]5NTK7N[':7',$O^Z?Y5X/^QUQX"UX'_H,S?\
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M!Q"Q"['*G@XPQP?0UT?BKX*>)O&^A76CZO\ $>\N].N0!)$-*MTW8((Y&#U
MZ5V-Y\+M%U3P.?"NJ_:]9TYLDRW]PTLY;<6W^8>0P)X].G2N8M_@!;QVD.GW
M'C+Q7=:1%@)8-J.U !T4LJAB!Z9JY8>4JDY2C=22TNUTM;S1ST<TIT\-1I4Z
MO)*BY6;@I73?,FKW::?31;:DGCCX(Q^)K'P]<:9K%QHOB30+=+>QU:%0<J%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0_\ H K9IR^)BC\*"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#F_!/^KUO_L*W/_H0KI*YOP3_ *O6_P#L*W/_ *$*Z2@
MHHHH **** /&)O\ DVG4_P#KWNO_ $H>O9Z\8F_Y-IU/_KWNO_2AZ]F)P* .
M>UGQK:Z/J,>G_9=0NKV22*-4M[&9H\.P&3*$V *"6.6X -7M7\,:-K[QOJFE
M66HM&K(AN[=)=H;[P&X' /<=ZX/Q1$NK_%?1FCN;5_L,822TGE5)5<R*^]$D
M4[AM_BC.>V?31^)7CB_\*7VF0V36^VZ242"6WDE:/&W$GRG&U06)!ZXZB@#K
M]-T#2]&>9]/TZTL7E"B1K:%8RX487) YP.E4['_D<=7_ .O.U_\ 0IJY/X7^
M.-;\5ZA>Q:I!'&D2/\J6DD)CVR;8V)8D,)D_>@#[HXYZUUEC_P CCJ__ %YV
MO_H4U4MG_75$O=&Y1114E!1110 4444 %%%% !1110 4444 %<[XPU;5=)_L
MO^S%LV^TWB6TOVL/P&Z%=O<8/6NBKF_&OW=#_P"PK;_S- '1KG'-+110 444
M4 %%%% !1110 5SGA'_C\\2_]A5O_1,5='7.>$?^/SQ+_P!A5O\ T3%0!T=%
M%% !1110 R;_ %,G^Z:Y+X/?\DL\*?\ 8-@_] %=;-_J9/\ =-<E\'O^26>%
M/^P;!_Z * .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH *XKXU?\DF\6?\ 8.E_]!KM:XKXU?\
M))O%G_8.E_\ 0: .UKS?QGXDUO1_$C6D,WD:?=FU"7\D4@BL3YF'#$1E7WY
MY88) ..M>CFO+/B%H>M7_C+29X-'-SHWG6XN+M+F69@ Q)S:^8J8!"?-M<\D
MX&T4 >I\&H;S_CSG_P"N;?RK@OBEX4UWQ)/IKZ&QADM]_F2&]:%70C#1D*,Y
M9<@,#P>2.!72>&]-NM(\(PVEX<3QQR?)YIE\I26*1[SRVQ2J[CUVYIK<3V)_
M!W_(HZ+_ ->4/_H K9K&\'?\BCHO_7E#_P"@"MFG+XF*/PH****DH**** "B
MBB@ HHHH **** "BBB@#-F\06%OKD&D/,PU">(S1Q")R"@."VX#:.<=3W'K6
ME7.W'_)0K =O[+N/_1L-=%0 4444 %%%% !1110 5S/B7X@Z5X5NS;7JWIE\
MAKD?9[*6561?OX95()4$$C.0.:Z&XN(K:)GFE2&,=7=@H'XFN-USPQX=\1ZO
M-?WVM2.)K463VBWRB Q;P[ +U&X@!L$;@ #G J7)+=BND96A?$G0-!MM9>^O
M6@S+=ZKM\B1F%N&3D@#(8[QA/O'G X->DPRK/$DB'*NH8'U!KQRV^%_@/Q?>
M:Y?ZY%!=7TM]>1FX>\*,R.0 WRL!E5&%/4"O5-,NM,MX+:QLKJ!EBC6**)9@
M[;5& .N3P*7/'N%T:5%)GFEJQA1110!XQ-_R;3J?_7O=?^E#U[,>E>,S?\FT
MZG_U[W7_ *4/7LQZ>M 'G?B/Q'K6F>,!IZR>5IUW<VGEWTD<BQVPW /$2(BK
MF3E02XP7 XP,^B''>O+_ !AH>LW?Q%T>Y72&ET07,!FO([F6<_+N(W6YD5$
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MHU9G9YG+O([,69F8\DEB23[T 9O@_4;0>$M%!NH,_8H?^6B_W![UL_VG9_\
M/W!_W\'^-<^WPK\%NQ9O"&@LQ)))TR'))ZG[M)_PJCP3_P!"=H'_ (+(/_B:
M;=W<25E8Z'^T[/\ Y^X/^_@_QKXT_:GO[4_%F4BZAQ]A@Z2C_:]Z^JO^%4>"
M?^A.T#_P60?_ !-9?B#X>?#;0-.EU+5/!WAY+:(JK2'1H9&RS!5  C).2P'
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M4%G;.S1YQN  Y7/&>E:7_"J?!/\ T)V@?^"R#_XFOMHJR2/=2LK'0_VG9_\
M/W!_W\'^-']IV?\ S]P?]_!_C7/?\*H\$_\ 0G:!_P""R#_XFC_A5'@G_H3M
M _\ !9!_\35#.A_M.S_Y^X/^_@_QH_M.S_Y^X/\ OX/\:Y[_ (51X)_Z$[0/
M_!9!_P#$T'X4^"?^A.T#_P %D'_Q- '%_M-ZC:-\(-4 NH"?-@_Y:+_ST7WK
MXK^W6W_/S#_W\7_&ON:'1?A+J$UU;?V'X6+6TTD$RSZ; @22-U1E)9 ,AG4#
MUSQFK)\ ?"D12RGPUX.\N(D2/]AM,(1G()V\8VM^1]*^<S'*'CZJJ\]M+;7_
M %/,Q."^L3Y^:Q\(?;K;_GY@_P"_B_XUZ/\ L[7]J/C'X?/VJ#&9O^6J_P#/
M)_>OJ2X\#?"FTOHK.7PKX56XDM'OE7^R8"/(3&Z3<$P%^8=^><9P:K:7X?\
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M 4 =A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7%?&O\
MY)+XL_[!TO\ Z#7:U@^.X='N/!>N1^()OL^AM9RB]F#E"D6T[F!'(('(QS0!
MNYHS7BG]N>$^_C7QM_WZO?\ XQ1_;?A+_H=?&W_?J]_^,4 >UYHS7BG]M^$O
M^AU\;?\ ?J]_^,4?VWX2_P"AU\;?]^KW_P",4 >UYHS7BG]M^$O^AU\;?]^K
MW_XQ1_;?A+_H=?&W_?J]_P#C% 'M>:RO$_AVU\5Z--IEVSI!(T;EHPI(*.KK
MPP93RHX((->4_P!M^$O^AU\;?]^KW_XQ1_;?A+_H=?&W_?J]_P#C% '3P?!+
M16^V&_N;K4'N7FSN*1JL<DC.4"JH&,N<D_A@<"W+\&O#4FIWEZ+8Q-<E"T42
MQJJ;8_+ 4[=P&W'RYQD @ UQO]M^$O\ H=?&W_?J]_\ C%']M^$O^AU\;?\
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M[3O^@G\2O_ .\_\ C-&[3O\ H)_$K_P#O/\ XS0!['FC->.;M._Z"?Q*_P#
M.\_^,T;M._Z"?Q*_\ [S_P",T >QYK%\6>$=.\9Z<MEJ2/);JS,%1]IR8V3.
M?4!R0>Q /:O-MVG?]!/XE?\ @'>?_&:-VG?]!/XE?^ =Y_\ &: -N/X#^'8[
MF6?S]09Y42-RTREBBHR;=^S=@ACD9YZ=!BM72/A=8:*UX\&H7[37=N\$TLCQ
M$ON<N78>7AFR2!N! !( P3GC]VG?]!/XE?\ @'>?_&:-VG?]!/XE?^ =Y_\
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MB4!CDBTO/_C->D>!4TJ/P;HBZ$[R:,+.(6;R;MS1;1M)W?-G'7/- &[1110
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MC:+?(V_=[$$XH ]BL-0MM4MQ<6=Q'<VY9E$L+AE)5BK#(]""#[@U88A5)+8
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M]@V#_P! % '84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPU\ ZSX4UF[N=0E@\B1)@BPW,DIV/(K10X8#"PJ&13W#9P.E '66'_(XZO\
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M,D"DJA;;N..!GM]:\<F_Y-IU/_KWNO\ TH>O8YX([F"2&50\4BE&4]"",$4
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MEKUK]JW_ )+]XJ_WX?\ T2E>2U^YY=_N='_#'\D?G.*_CS]6!Z5^EW[+/_)
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M^#_&-Z=5>ZA6ZL[?R6ALIYU;:TNX9C1@"-PX/K2_\+E\*?\ /U?_ /@IO/\
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M#'_0QZ3_ .!T7_Q5'_">^&?^ACTG_P #HO\ XJIQX0T(#_D"Z=_X"1_X4?\
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M7_0%T[_P$C_PH @_X3WPS_T,>D_^!T7_ ,51_P )[X9_Z&/2?_ Z+_XJI_\
MA$="_P"@+IW_ ("1_P"%'_"(Z%_T!=._\!(_\* (/^$]\,_]#'I/_@=%_P#%
M4'Q[X9/_ #,>D_\ @=%_\54__"(Z%_T!=._\!(_\*/\ A$="_P"@+IW_ ("1
M_P"% '-:F?AQK+N][=^'[F1]^9'NHMWSE"_.[(R8T)_W158:?\+Q)'()_#XD
MC?S$D%Y&&4[0HP=V> JX],#&*Z[_ (1'0O\ H"Z=_P" D?\ A1_PB.A?] 73
MO_ 2/_"@# 2\^'L4%A"E]H"I8#;:XNH<PC!'RG=D=3]<FJUI%\-+"-TM[GP[
M$KYW 747.0P(^]TP[#'8' XKJ/\ A$="_P"@+IW_ ("1_P"%'_"(Z%_T!=._
M\!(_\* .9\'3^!_ UC/9Z9XCL/(FG:X*SZG')M8XR%RW X[5O_\ ">^&?^AC
MTG_P.B_^*J?_ (1'0O\ H"Z=_P" D?\ A1_PB.A?] 73O_ 2/_"@"#_A/?#/
M_0QZ3_X'1?\ Q5'_  GOAC_H8])_\#HO_BJG_P"$1T+_ * NG?\ @)'_ (4?
M\(AH7_0%T[_P$C_PH \KDN(7_9AU*=98V@-K=2"4."A7[0YW;NF,<YKTW_A/
M?#/_ $,>D_\ @=%_\56LMC;I:_9EAB6VV[/("#9MZ8V],>U4!X0T(#_D"Z=_
MX"1_X4 0?\)[X9_Z&/2?_ Z+_P"*H_X3WPS_ -#'I/\ X'1?_%5/_P (CH7_
M $!=._\  2/_  H_X1'0O^@+IW_@)'_A0!!_PGOAG_H8])_\#HO_ (JC_A/?
M#/\ T,>D_P#@=%_\54__  B.A?\ 0%T[_P !(_\ "C_A$="_Z NG?^ D?^%
M$'_">^&?^ACTG_P.B_\ BJ/^$]\,_P#0QZ3_ .!T7_Q53_\ "(Z%_P! 73O_
M  $C_P */^$1T+_H"Z=_X"1_X4 0?\)[X9_Z&/2?_ Z+_P"*KE6TKX8OJ"WC
M7NB,ZB7$;7Z&,&0@N=A;&2178_\ "(Z%_P! 73O_  $C_P */^$1T+_H"Z=_
MX"1_X4 8,NH> 98[5&U/1 MK*T\&R]C4QNQ)8@AAU).1T/>KFF^)O!FCQM'9
M:SHMJC;=RQ7D0!VJ$7^+LJJ/H!6E_P (CH7_ $!=._\  2/_  H_X1'0O^@+
MIW_@)'_A0!!_PGOAG_H8])_\#HO_ (JC_A/?#/\ T,>D_P#@=%_\54__  B.
MA?\ 0%T[_P !(_\ "C_A$="_Z NG?^ D?^% $'_">^&?^ACTG_P.B_\ BJ/^
M$]\,_P#0QZ3_ .!T7_Q53_\ "(Z%_P! 73O_  $C_P */^$1T+_H"Z=_X"1_
MX4 0?\)[X9_Z&/2?_ Z+_P"*JIJ?B;P7K,(AOM8T2[B&["37D3#YD9&XW=U9
MA]":TO\ A$="_P"@+IW_ ("1_P"%'_"(Z%_T!=._\!(_\* .233_ (7QN66;
MP\N2A*B[BVG:"%RN[' )QQU)/6I;.+X;6$4D=O>Z%$CP-;,%OD_U;-O91\_&
M6^8D<D@'M74?\(CH7_0%T[_P$C_PH_X1'0O^@+IW_@)'_A0!R[0_#5Q:AKKP
M^PM1B$-=Q$)TZ#=_L@_7GKS56YT[X<S^(M,UN/6=,L[[3RQC-KJ,<:OGLX#?
M,/;WYKLO^$1T+_H"Z=_X"1_X4?\ "(Z%_P! 73O_  $C_P * (/^$]\,_P#0
MQ:3_ .!T7_Q5'_">^&?^ACTG_P #HO\ XJI_^$1T+_H"Z=_X"1_X4?\ "(Z%
M_P! 73O_  $C_P * (/^$]\,_P#0QZ3_ .!T7_Q5'_">^&?^ACTG_P #HO\
MXJI_^$1T+_H"Z=_X"1_X4?\ "(Z%_P! 73O_  $C_P * (/^$]\,_P#0QZ3_
M .!T7_Q58&ICX;:RTC7MUX>N'D#AG>ZBW$.RL_.[/+(I/TKIO^$1T+_H"Z=_
MX"1_X4?\(CH7_0%T[_P$C_PH Y,V7PR,RS?:M!\Y7:19?ML>\,0%SNW9X  '
MI@8Q5Q;OX>)#81+>^'U2P3R[7%S"#"N,84[L@8[=ZZ#_ (1'0O\ H"Z=_P"
MD?\ A1_PB.A?] 73O_ 2/_"@#EK6#X9V5N\$%QX=CB<%64747(*LN#\W]UF'
ML#CI4G@RX\$> ]*?3M+\26/V5I6FVW&IQR;2<9 RW XZ#W/4UTO_  B.A?\
M0%T[_P !(_\ "C_A$="_Z NG?^ D?^% $'_">^&?^ACTG_P.B_\ BJ/^$]\,
M_P#0QZ3_ .!T7_Q53_\ "(Z%_P! 73O_  $C_P */^$1T+_H"Z=_X"1_X4 5
MIO'OADQ/_P 5'I/W3_R_1?\ Q59WP<8/\*O";*0RG38""#D$;!S6U_PB&A'_
M )@NG?\ @)'_ (5J11)#&J1JJ(H"JJC  '0 4 /HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_017.jpg
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &[ M # 2(  A$! Q$!_\0
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MMHYF5>@+*"<>W-:0.:Z8R4E=&B:DKH6BD)Q29IW&.HI,\=:0'GK0 ZBFD\T
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MOK^5BJ%1UE[39=AYI"":7-+7IG6>9_M%Y_X4UXD_ZY)_Z,6NT\*9'A?1N?\
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M^@"M1NE>Y#X%Z([X[(\C_:<'_%N;?_L+6G_H=>L1<J.W KR?]IS_ ))S;_\
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M3\1/BCX9O8M3%CHL:QDVNC65SO-S+V,TI &T=0!WQ7O!4$Y(YH,:DY(%<U3
MTZBE%M\LMU<SE1C*ZOH^A0\/6SV6A:?;2C;+!;QQ. <X95 /-7V_2E  Z<4$
M9KO2LK&]K*R/._C?X2U+QOX/ATW28HY;I+^WN"LD@0;$;+')]J] B& !W %/
M\M<YQS2@ 5G&E&,Y5%N[?@2HI2<NYROC;4_$^F):GPUH=KK3NQ$ZW5X+<1@#
M@C(.<FO*]-TKXG:;\1-8\6#PCILD^I6L5JUJ=64+&$QR&QDYQZ5[\5!ZBD"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_D"V'_7O'_Z"* /*?!W@Q_',_B34=1\3>)HI4UZ_M8XK+6)H(8XHYF1%5$(
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M@V'=CD'T-7-,^*5K#9:M=:FXF2RG$;QZ797$[VZ^1'*WF@*>@?.Y?EP1WS0
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M_P @[Q/_ -C-JG_I2U>@4 %%%59=3LX;V.S>ZA2\D0R);M(!(RCJP7.2!ZT
M6J*H3Z_IMJCO-?VT*)((6:295"R'&$))X;D<=:O*P89'2@!:*0,#2T %%%%
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M%% !1110 5@^/O\ D1?$?_8-N?\ T4U;U8/C[_D1?$?_ &#;G_T4U &GI/\
MR"K+_KBG_H(JW532?^059?\ 7%/_ $$5;H **** "BBB@#C?C-_R2+QK_P!@
M:[_]$M72:'_R!;#_ *]X_P#T$5S?QF_Y)%XU_P"P-=_^B6KI-#_Y MA_U[Q_
M^@B@#C?@Y_R#O$__ &,VJ?\ I2U=AKKM%I-\R72V+BWD*W3@%83M.'.>R]?P
MKC_@Y_R#O$__ &,VJ?\ I2U=;XCNH;+0]1N;B%;B"&UEDDA?[LBA"2I]B.*
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M2?QI_P!@6]_]$/0!N>&_^1=TO_KUB_\ 0!6E6;X;_P"1=TO_ *]8O_0!6E0
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MA#;UD^1L @Y)KTG_ (7<QZZ1_P"1_P#ZU+_PN]O^@1_Y'_\ K5YO]JX3^?\
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M$5S?QF_Y)%XU_P"P-=_^B6KI-#_Y MA_U[Q_^@B@#C?@Y_R#O$__ &,VJ?\
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MT'I7J?5Z/\B/-^L5OYV?0WPQUJ]U_P ,+=W\WGSF9UW[0.!C' KK:X7X,_\
M(EI_U\2?S%=U7QU=*-627<^MH-RI1;[!1116!N%%%% !3#]VGTP_=J7L!\V^
M/?\ D=-9_P"O@_R%8-;WCW_D=-9_Z^#_ "%8-?=T/X4?1'Q5;^)+U"NM^%7_
M "/6G?23_P! -<E76_"K_D>M.^DG_H!J<3_ GZ%X?^-#U/H44M(*6OB#[(**
M** .-^,W_)(O&O\ V!KO_P!$M72:'_R!;#_KWC_]!%<W\9O^21>-?^P-=_\
MHEJZ30_^0+8?]>\?_H(H XWX.?\ (.\3_P#8S:I_Z4M7?LH92K $$8(/>N ^
M#G_(.\3_ /8S:I_Z4M7H% %6#2[.UE\V&T@ADQC?'&JG'U KG=7^'MMJGB==
M;6]O+:<"-C%$R>4TL8=8Y2&0G<HD<#G:<C() KK*YF^\>6-CXL@T!HKEKB38
MK7"H/)C=P[1QLV<[F$;D8!' R1D4 <W/\!?#EZL@NVOKIE8?97:Z*-:1^:9?
M*C*!3L+DYW;C@@9X&.V\0KL\-:H/^G67_P! -<FWQDTM8;B;[!J;V\$B[YE@
M3:86D:,3C+Y*;T8=-QQPIR*ZSQ$2?#6J;L9^RR]/]PU4?B0GL1>%O^17T?\
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M60_Y>X/^_J_XT?VI9?\ /W!_W]7_ !J2BU7S=\1/^1XUC_KM_05]#_VI9?\
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M$5S?QF_Y)%XU_P"P-=_^B6KI-#_Y MA_U[Q_^@B@#C?@Y_R#O$__ &,VJ?\
MI2U>@5Y_\'/^0=XG_P"QFU3_ -*6KT"@ KEM7^'NGZMXD76VENX+Q448AGVQ
MEU#!)"N"-ZB1P#Z-T.!CJ:* //\ _A2^C1S)+;WFJ6K1W2W48BN_E3:SLL85
ME(V*TCL%.<,V<\#'6^(EV^&]5'_3I+_Z :I>+?&5EX.LX;B\CN9O-<HD5I%Y
MDA"H7=L>BJK,3[=SQ5G6KA+OPGJ$\;B2*2RD=''1E*$@_E51W0GL-\+?\BOH
M_P#UY0_^@"M@=*P/"NHV@\,:/FZ@_P"/.'_EJO\ <'O6L-4L\?\ 'W!_W]7_
M !I2^-BCLBU39/\ 5M]#5?\ M2R_Y^X/^_J_XTV35+/RW_TN \'_ ):K_C4O
M8M;GS++_ *U_]X_S--J*6_M?-?\ TJ#[Q_Y:KZ_6F_;K7_GZ@_[^K_C7Y0X2
MOM_5S]>BTTM5]Y-WKN_@S_R-DW_7JW_H2UY]]NM?^?J#_OZO^-=U\&]0M5\5
MS$W4&/LS<^:OJOO7H9?%_6J>G4\W,Y+ZI45^GZGNM%5?[4LO^?N#_OZO^-']
MJ67_ #]P?]_5_P :_2#\R+5%5?[4LO\ G[@_[^K_ (T?VI9?\_<'_?U?\: +
M5%5?[4LO^?N#_OZO^-']J67_ #]P?]_5_P : +5>:?&__D%:9_UW;_T&O0?[
M4LO^?N#_ +^K_C7FWQMU&T?2],Q=0']^W_+5?[OUKS,R5\)42_K4]3+-,93]
M?T/*O2BJXO[7 _TJ#_OZO^-+]NMO^?J#_OZO^-?G/++L?IUUW7WHG]*^AOA[
M_P B7I'_ %P'\S7SE]OM?^?J#_OZO^-?0GP^U.S'@S20;N ?N!_RU7U/O7TN
M1)JM*ZZ+\SY;/VG0A9]?T.KHJK_:EE_S]P?]_5_QH_M2R_Y^X/\ OZO^-?:'
MPQ:HJK_:EE_S]P?]_5_QH_M2R_Y^X/\ OZO^- %JD/2JW]J67_/W!_W]7_&C
M^U++_G[@_P"_J_XT 3MTKYL\3_\ (RZK_P!?4G_H1KZ*;4K,\"[@S_UU7_&O
MF_Q/?6O_  DFJ_Z5!_Q]2?\ +5?[Q]Z^8SQ-TH6[GU/#_P#&GZ?Y%.BH/MUK
M_P _4'_?U?\ &C[=:_\ /U!_W]7_ !KX[EEV/N;KO^*.M^&O_(ZZ=]6_]!-?
M0(Z5\\?#6_M1XTTX_:8.K_\ +5?[I]Z]^&J66/\ C[@_[^K_ (U]MD::P[OW
M/@,]:>*5GT+5%5?[4LO^?N#_ +^K_C1_:EE_S]P?]_5_QKZ(^<+5<C\7_P#D
MD_C3_L"WO_HAZZ>*^MIV"QW$4C'H%<$US'Q?_P"23^-/^P+>_P#HAZ -SPW_
M ,B[I?\ UZQ?^@"M*LWPW_R+NE_]>L7_ * *TJ "BBB@!#7 _!W_ ) WB#_L
M9=7_ /2R6N^-<#\'?^0-X@_[&75__2R6@#OZ*** "J.N:/;^(-'O=,NPQM;N
M%H) C;6VL,'!['FKU% &1X8\-P>%].:UAFGNGDE>>:YN6#2S2,<LS$ #/T '
M XK,UCX6>#?$.HRW^J^$M!U.]E(,ES>:9#-*^!@;F923@8'6NJHH XG_ (4C
M\._^A"\+_P#@FM__ (BC_A2/P[_Z$+PO_P"":W_^(KMJ* .)_P"%(_#O_H0O
M"_\ X)K?_P"(J&Y^"WPVMHS+/X$\)QH.K2:/; ?F4KO*XKXJ^$KSQ?HVFP6<
M$5R]KJ$5V\,LJQAT57! +(XSE@<%3T[=: ('^"WPVCV[O /A4;N%SHUL-WT^
M2DB^#'PUG4/%X"\*2H<X=-'MB/SV5R]CX*\9:K)J#WDSVUL]U.$M[N]>8.F;
MA495VXB 5XUPOW@,G&,4[2OA1XA\,2>&XM+U>6*P@8S:A!:R);*\Y$8W;%CV
MM'M3;M 4DDMG))IW8K'5)\$OAP3D> /"P/K_ &+;?_$4_P#X4C\._P#H0O"_
M_@FM_P#XBI?AWX;UGPW:7,&KZA+J/F"%U>>Y>=A)Y8$V&;HI<$@#@9Z"NQI#
M.)_X4C\._P#H0O"__@FM_P#XBC_A2/P[_P"A"\+_ /@FM_\ XBNVHH XG_A2
M/P[_ .A"\+_^":W_ /B*/^%(_#O_ *$+PO\ ^":W_P#B*[:B@#B?^%(_#O\
MZ$+PO_X)K?\ ^(IK_!7X=("3X!\+X')/]C6W_P 17<5F>)+"35-"U*SAV^=<
MVLL*;N%#,A S[<T <N/@Q\-Y1@> O"K#@\:/;'Z'[E'_  I+X<9Q_P *_P#"
MW_@EMO\ XBN$MOA)XT\.Z0]AHFJQ0+'<V?V:5;EXY%MXH=OEN=I#!7+#!SN0
M+T.:W+;PGX]MGB5+\&)KE_,>;4I'E6'[1'(&)V;2Q19(]JA5 9>.33N!NO\
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MPO\ ^":W_P#B*/\ A2/P[_Z$+PO_ .":W_\ B*[:B@#B?^%(_#O_ *$+PO\
M^":W_P#B*C;X,_#A6VGP)X6!QG!T>V''_?%=U7EGQ$^&6J>*/%4>LZ;/!!(D
M%K:,LS,!+"MSYLR, /0(RG^\N.AH V3\$OASDD^ /"Q/7_D"VW_Q%(?@G\.,
MX_X5]X6S_P!@6V_^(KE++P+\0EOIWN-8)CDOIGCQJ4IC@A>/;D+M#,0<%$+$
M Y)SVUO#WASQK%K>DWNJ3*(89I/M%NNI221",PQ(I"A%WN71F^;Y0)&X)P0[
ML5C3/P9^&@5F/@+PIA?O'^QK88^OR<4Z+X+?#>0*\?@+PLRD9#IHUL1CZ[*Y
MJ/X6^([6T\9V\EY8ZH==FAN!,Z- 9&3!991EAAPHCXX"C.#TJG8?"GQ?9^:]
MOK#Z:GF336^GVFH2I;6V[YHX@JJ 55R<\<CMCBE<9V@^"GP[/_,@^&/QT:V_
M^(IW_"D?AW_T(7A?_P $UO\ _$5C_!^#Q*D_B.3Q'#J23/>XA:\F+1M&&;'E
M(6.T8(SC"GC &#7IU '$_P#"D?AW_P!"%X7_ /!-;_\ Q%:&A_#/PEX7O_MN
MB^%M$T>]V&/[38:=#!)M/4;D4'!QTKIJ* .,^,HV_"'QH/31KO\ ]$M72Z'_
M ,@6P_Z]X_\ T$5S?QF_Y)%XU_[ UW_Z):NDT/\ Y MA_P!>\?\ Z"* .-^#
MG_(.\3_]C-JG_I2U>@5Y_P#!S_D'>)_^QFU3_P!*6KT"@ HHHH Y[Q?X*L_&
M5K;PW4]S:F!V=)K.0(^&1HW7)!&UD9@>,\\$$ ULVUE%:64=K$@6"-!&B'D!
M0, ?E5BB@#B!\$?A\6);P)X8?/.3HUOG/_?%+_PI'X=_]"%X7_\ !-;_ /Q%
M=M10!Q/_  I'X=_]"%X7_P#!-;__ !%+_P *1^'?_0A>%_\ P36__P 17:T4
M <')\&/AI!(B2>!/":/(<(K:1:@L?0#9S39?@Y\,X%9I/ GA.)5&XE](ME '
MKRE5OB1X1U;5/$EAK>F0)<-9:==0H1*J21S/M*.H:-L\KV9#G'.*YB+X7>+-
M=T:WBU.\2*-_*9K>\G-\\.)H)&!:1<29\N4[6X&X+T%*R'=]SLU^"OPX<97X
M?^%R.Q&BVV#_ ..4Y/@E\.MW'@#PN"?31K;_ .(KF1\,_%.G7U[9Z=KE]'HH
MLH;.Q OO+\E%\O?E0F0_RR$.K#APN, 5Z)X1TR]TC1(;2_N'NIXGE EDD:1C
M'YC&,,S<L0A4$GGCO19!=]S$_P"%(_#O_H0O"_\ X)K?_P"(H_X4C\._^A"\
M+_\ @FM__B*[:BF(XG_A2/P[_P"A"\+_ /@FM_\ XBC_ (4C\._^A"\+_P#@
MFM__ (BNVHH XG_A2/P[_P"A"\+_ /@FM_\ XBC_ (4C\._^A"\+_P#@FM__
M (BNVHH X:3X+?#F)26\!^%E [G1[8?^R4@^"WPXDR!X"\+-CJ/[&MN#_P!\
M5J?$7PNWC/P;JFAJ$87R+$PD8JI7>I89'(^4'\:\Z@^''CO3KNQ%OK"?9TU*
MYN+B:"[>*2X@;:L>]2I5GV+SD</\V2.* .Q_X4G\.<X_X0#PMG_L#6W_ ,13
M&^#/PU1D5O 7A1&<X0-H]L"Q]!\G-<Y9>#_'\%M;VTU^Q@:'$LD.JR&=&$5P
M@ 9T8%F:2%R_ !CX7 %7=4\"Z]J]CX-^U6UG+J6DRQ3SW9NG<(R,"0-ZL\FX
M#&=ZG<<G(XI678=WW-4?!KX:F4Q?\(#X5\W&[9_8]KNQZXV9Q4J_!7X==!X
M\+X'IHUM_P#$5R.H_##Q9>^+=2U&VU!=/M]1G2:X>&[*S&/9&!"KK&'0*5;H
M^U@1PIJC>^%_'6B:YX5M6O-7U;3OM22W<EK>NQ!VP!_,<E<H76<[6RNUB  <
M8+(+L[__ (4C\._^A!\+_P#@FM__ (BC_A2/P[_Z$+PO_P"":W_^(KM:6F(X
MG_A2/P[_ .A"\+_^":W_ /B*/^%(_#O_ *$+PO\ ^":W_P#B*[:B@#B?^%(_
M#O\ Z$+PO_X)K?\ ^(H/P1^'8'_(A>%__!-;_P#Q%=M2-T- '"GX-?#A20?
MGA8,,$C^Q[;(_P#'*7_A2?PYYS\/_"^[O_Q);;_XBL;QA\,=4UOQU#XAL)X(
M2IT^&:.5FQ-;Q3/+*I 'W@2C+ZX8'&:R=-\!_$12YN=9;S'GN61O[2E:*%9(
M JL%VAB5D&Y0Q(4,<@G!"L"T.O'P4^'!Z?#_ ,+_ /@EMO\ XBF-\&?AJHD)
M\!>% L?WV.CVP"_7Y.*SO#_A[QK%XEL-1U.=?LX:X\^U&H/+%$C( FU=J[WW
M+U;Y0I.!GFLJR^%WB33-&\26,UQI^N'4M1AU(O(K6XN2AB+QS [Q^\V,O'
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M?%/_ $3?6?\ P/L/_C]'_">^*?\ HF^L_P#@?8?_ !^H_P#A _&/_12]2_\
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M _&/_12]2_\ !59?_&J/^$#\8_\ 12]2_P#!59?_ !J@"3_A/?%/_1-]9_\
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M8_\ 12]2_P#!59?_ !JC_A _&/\ T4O4O_!59?\ QJ@"3_A/?%/_ $3?6?\
MP/L/_C]'_">^*?\ HF^L_P#@?8?_ !^H_P#A _&/_12]2_\ !59?_&J/^$#\
M8_\ 12]2_P#!59?_ !J@"3_A/?%/_1-]9_\  ^P_^/T?\)[XI_Z)OK/_ ('V
M'_Q^H_\ A _&/_12]2_\%5E_\:H_X0/QC_T4O4O_  567_QJ@"3_ (3WQ3_T
M3?6?_ ^P_P#C]'_">^*?^B;ZS_X'V'_Q^H_^$#\8_P#12]2_\%5E_P#&J/\
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M]\4_]$WUG_P/L/\ X_1_PGOBG_HF^L_^!]A_\?J/_A _&/\ T4O4O_!59?\
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M5E_\:H D_P"$]\4_]$WUG_P/L/\ X_1_PGOBG_HF^L_^!]A_\?J/_A _&/\
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M\'?^0-X@_P"QEU?_ -+):[XUP/P=_P"0-X@_[&75_P#TLEH [^BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ KD?B_P#\DG\:?]@6]_\ 1#UUU<C\7_\
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M!9 2!@CW(I@/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:***S+"BBB@ HHHH **** "BBB@ HHHH **** "J]Y]I,$HM6C6X*GRVF4E
MW;(!!(^AJQ10!SG@'6]0\1>&[>_U,6JW$KR#;:*P0!7*_P 1)S\I_.NCKE/A
M;_R(VG?[TW_HYZZN@ HHHH **** "BBB@ HHHH *Y?XBC'AGC_G]L_\ TICK
MJ*YCXC?\BR/^OVS_ /2F.@#I@,4M%% !1110 4444 <;\9O^21>-?^P-=_\
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M)\S]WEE8*1D<8(KNFC1V+.BL=N,E0>/3-*L:QM\J!2QRQ QN/J?7M0!@S_\
M)0K;_L%R_P#HV.NE'05S4_\ R4*V_P"P7+_Z-CKI1T%:3^SZ$1W8M%%%9EA1
M110 4444 %%%% !1110 4444 %%%% !1110!RGPM_P"1&T[_ 'IO_1SUU=<I
M\+?^1&T[_>F_]'/75T %%%% !1110 4444 %%%% !7,?$;_D61_U^V?_ *4Q
MUT]<Q\1O^19'_7[9_P#I3'0!T]%%% !1110 4444 <;\9O\ DD7C7_L#7?\
MZ):NDT/_ ) MA_U[Q_\ H(KF_C-_R2+QK_V!KO\ ]$M72:'_ ,@6P_Z]X_\
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M61_U^V?_ *4QUT]<Q\1O^19'_7[9_P#I3'0!T]%%% !1110 4444 <;\9O\
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M_P#7K%_Z *TJS?#?_(NZ7_UZQ?\ H K2H **** $-<#\'?\ D#>(/^QEU?\
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M_;9Z]7K]!PU7V]&%6UN9)_>C\WQ%+ZO7G1O?E;7W.P4445TG.%%%% !1110
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M7'/4DGVH ].LO&FE:AX@GT2*2X748H?M!26TEC1H]P7>CLH5QD@?*36Y7/\
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MYP*U?$"[/#.IKZ6DHZY_@-:M9OB7_D7-5_Z])?\ T U4?B0GL0>%O^17T?\
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M#I7ZUPC_ +E/_%^D3\=XQ_W^'^'_ -ND+1117W!\(%<C\7_^23^-/^P+>_\
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M?X+_ .NUS_Z"E?'U?B/$?_(SJ?+\D?N?#'_(JI?]O?\ I3"BBBOFSZH_2/\
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MK_T.7B__ ,&Q_P#B:0_"10/^1R\7_P#@V/\ \34E'@_[?/\ QX>"QW\VY_\
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M  J13_S.7B[_ ,&Y_P#B:7_A4:_]#EXN_P#!L?\ XFOU0_)SOJ*X'_A4:_\
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M+P)_T&9O_!9=?_&J/^&@O G_ $&9O_!9=?\ QJ@#T:BO.?\ AH+P)_T&9O\
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M<<UC6>M>-5T7Q,-9M-4L;V348GA^R(LYBLR8O.%N8PV=JEL9RQ.[ )&!O?\
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_018.jpg
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %\ M # 2(  A$! Q$!_\0
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M0!0_L'3?^?&W_P"_8H_L'3?^?&W_ ._8J_10!0_L'3?^?&W_ ._8H_L'3?\
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M)_(5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMBVX;"@#D5Z5XK^+&A>!(]&M+Z6]U/5M3CW6>G:;9O<WETJJ"T@B0<*,C).
M,XKYSO)GT_\ 9R^-G@RXM;N+Q%8ZAJ5V]HUK)^\@GNB\,D;;=KJRG^$GH:]!
MU[58?AC\<M'\9^(HKF+PQ?\ A2/1X]32W>:.RN5F\TI)L!*!U(PQ&"5Q0!ZY
MX"^(^A?$C3KJZT6XE=[.=K6\M+J%X+BUF !,<L;@,K8(/(YSQFO*/B%K&O:O
M^T /"T/CZZ\%:+'X;34@;=+;]Y.;AHR,S*?X>P]*[SX5>+]/\>77B/6M)\.2
M:3ILMVD<.KSP>0^L;8P#-L*J^U?N*S=<''%>._%^;P-8?M.)<_$/2XK_ $-O
M"B1V[76F27D0N/M3'@(C8;;GGTH ZGX9^/O%%U9_%+2KW7(_%-GX:3;IGBF&
MW2+[0YMV=XVV?(SQ, "RC'.#S72> ?BM:Z-^S[X4\8^,]5(DNM-MI+BY,>Z2
MXGD485(T&6=F. JC\*\Y^&&G1:SXK\=GX=Z1J&E?#6[T P0V]S;R6MI<:HQ<
M%[6*0 JNP@,0 "<?6L+2KJ:]^!_P@U.WT[4KI? &KVG_  D6E"RD%Q;F*%XY
M&$9 +^675_ESP,CI0!]!>#_C!H7C'7I=#2'4]&UQ(/M2Z;K=C)9SRPYV^8@<
M8=0<9P21D9Q61K7[17A#1=0U.%O[5O;+293!J6K6&F37%E8R#&Y99E4@%<C=
MC.WOBN/F\3V'QG^.7P^U/PA]HOM+\,I?7&IZS]FDAA430B-+8,ZKN9FPY S@
M(,US?P[^(.D_"'X6ZQX"\46%\OBVUN=0C738K":9]8,TTCQ21,JE7$@=1G/&
M#G&* /<?&7Q:\-^!](TN_O;N2\&K.L6F6VFPM=3WS,NX"%$!+?+SGH!U-</X
M&^+DOCKX_P"I:/8W=W%HUKX<CN)M*OK0V\UM>?:2I\Q'4.&V%?8@@BO-M*\/
MZC\#Q\"M=\6V]Q)I6AZ+=:1J<T$3W']ESSJC1NX0$[0%,18#C/I7:> /%5GX
MY_:BU;6M*M+T:0WA&&&'4+BT>".[(NR2T98 LHSC) S@XXYH U_V@-;\0VWB
MGX9Z#H/B"Z\.+K^KS6=W=6<4<DGEK;O(,"16'51VJEINL^+OAA\:/"OA'5O%
MC^--'\3VUVR?;K:**\L)8$#[\Q*H:)A\O(X/0U7_ &FO"L'C+QM\'M*O(;N7
M3Y]=G6X:TDDB=%^RR$'S(R&3D#D$>E>@>!?@?X-^&^IW&J:+IDG]JS1>0U_?
M7<UW<"/KL5Y68JN1G QF@"CX5_:(\%>,H[B?3+ZY>QM+26\N[^:SDCMK5(R0
MRRRL JOP3MSG'.*?X;^/OA;Q)K&F:>B:KIK:L#_9=SJNFS6L&HX7=B%W4!CM
MY ."1R :\?\ "G@O5O%7["UWH.EV4IU>YMKMDM"OER3,MX[E,$?>95P,]<BH
M;*_\,^-->\#V5GXD\>^,-6@U6VO&T>["P+I+Q EIKDFW7:(^5*[LMNP,T >S
M^)?CWX7\,:OJMA)'JVH?V0 =5N=,TV:Y@T_*[L3.BD [?F(&2!R<5?\ $?QD
M\->'K70Y4GN=:GUR(SZ79Z-;/=SWD04,9$5!]P*RDL<#D<UX9\0]3T3P_P"-
MO&UW:Z]XB^&/BIY=PMA:F^T_Q#B)1',L!C97+<1D*0PV\U?\67%E/X=^&.H>
M-M*UGX=ZJ-+9E\1^'0T,>CSLJ;K22-5<*DF,A74KE,<&@#UH?';PB? FK>+3
M>7":;I$XM=0ADM9$NK2;>J>7)"0&5LNO;H<]*Z/Q1XWTKP?/H<.I2R1OK-_'
MIMF$C+[IW#%0<=!A3R>*^9]0;Q/X^_9W^+%LD4GB9([R)]*UN/2Q9W.MPQ&&
M1W:,*-[+L9 X'S;>*WOB#\6=$^*NO?"E?#$&IZC!;>*[.>[O#ITT4%L?+D C
M=G4?/ST&<8.2.,@'J^H?'3PKI_CF?P>9KZY\1PSP0/8VEC+,R^:H99"5! C
M(W.2 .G6J.K?M&^#M&O;])7U.?3=.N#:7^MVNFS2Z?9R@@,LDZKM&TD!B,A>
MY%9_PSM'C^/7QEG:%XQ(^DA)FC(# 6K9VDCG!]*\(\/P:;X&^'>K^#O%OB?Q
MQ8>(;>2]M7\+Z9$K)JBRRR%#;'[.VY9E<<ES@LV<8H ^U(9DN(DEB=9(W 97
M4Y# ]"#Z4^L#P!I@T3P-X>T\6UQ9"TT^W@%M=RB6:$+&HV.XX9AC!(X)%;]
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M8HQ2T4 )BC%+10 F*,4M% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(UA'#,T'GW(C=D SMVL>,@^@H U**H?V9+_T$;O\T_\ B:/[,E_Z"-W^:?\
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M_GC;?]_&_P#B:-^H_P#/&V_[^-_\35ZB@"COU'_GC;?]_&_^)HWZC_SQMO\
MOXW_ ,35ZB@"COU'_GC;?]_&_P#B:-^H_P#/&V_[^-_\35ZB@"COU'_GC;?]
M_&_^)HWZC_SQMO\ OXW_ ,35ZB@"COU'_GC;?]_&_P#B:-^H_P#/&V_[^-_\
M35ZB@"COU'_GC;?]_&_^)HWZC_SQMO\ OXW_ ,35ZB@"COU'_GC;?]_&_P#B
M:-^H_P#/&V_[^-_\35ZB@"COU'_GC;?]_&_^)HWZC_SQMO\ OXW_ ,35ZB@"
MCOU'_GC;?]_&_P#B:-^H_P#/&V_[^-_\35ZB@"COU'_GC;?]_&_^)HWZC_SQ
MMO\ OXW_ ,35ZB@"COU'_GC;?]_&_P#B:-^H_P#/&V_[^-_\35ZB@"COU'_G
MC;?]_&_^)HWZC_SQMO\ OXW_ ,35ZB@"COU'_GC;?]_&_P#B:-^H_P#/&V_[
M^-_\35ZB@"COU'_GC;?]_&_^)HWZC_SQMO\ OXW_ ,35ZB@"COU'_GC;?]_&
M_P#B:-^H_P#/&V_[^-_\35ZB@"COU'_GC;?]_&_^)HWZC_SQMO\ OXW_ ,35
MZB@"COU'_GC;?]_&_P#B:-^H_P#/&V_[^-_\35ZB@"COU'_GC;?]_&_^)HWZ
MC_SQMO\ OXW_ ,35ZB@"COU'_GC;?]_&_P#B:-^H_P#/&V_[^-_\35ZB@"CO
MU'_GC;?]_&_^)HWZC_SQMO\ OXW_ ,35ZB@"COU'_GC;?]_&_P#B:-^H_P#/
M&V_[^-_\35ZB@"COU'_GC;?]_&_^)HWZC_SQMO\ OXW_ ,35ZB@"COU'_GC;
M?]_&_P#B:-^H_P#/&V_[^-_\35ZB@"COU'_GC;?]_&_^)HWZC_SQMO\ OXW_
M ,35ZB@"I$]Z9!YL<"Q]RCDG^56Z** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *H:[_R!;[_ *X/_(U?JAKO_(%OO^N#_P C0 :%_P @6Q_Z
MX)_(5?JAH7_(%L?^N"?R%7Z "BBB@ HHKA/C=!JS_#/7[C2-=N?#\]G97%TU
MQ9HIF<)$[!%9L[,D#Y@,X'&.M '=T5Y1XLM=2USPKI%U::IJ]YJ$&D"Y_L'1
MM02SN;V1EC'G-*2#A/FX^Z2W.3@5PJ>(=7\8^&[^^/C#48GT/P5:ZM;W=A(;
M9+F[<7!DGE3'S -;JNQACEN.: /I&LK7/^/C2/\ K\'_ *+>CPIJDVM^%M'U
M&YC\FXO+.&XECQC8SH&(_ FH_$4ODRZ4^QI,7@^5!DGY'H V:*H_VI_TYW7_
M '[_ /KT?VI_TYW?_?O_ .O0!>HJC_:G_3G=_P#?O_Z]']J?].=W_P!^_P#Z
M] %ZBJ/]J?\ 3G=_]^__ *]']J?].=W_ -^__KT 7J*H_P!J?].=W_W[_P#K
MT?VI_P!.=W_W[_\ KT 7J*H_VI_TYW?_ '[_ /KT?VI_TYW?_?O_ .O0!>HJ
MC_:G_3G=_P#?O_Z]']J?].=W_P!^_P#Z] %ZBJ/]J?\ 3G=_]^__ *]']J?]
M.=W_ -^__KT 7J*H_P!J?].=W_W[_P#KT?VI_P!.=W_W[_\ KT 7J*H_VI_T
MYW?_ '[_ /KT?VI_TYW?_?O_ .O0!>HJC_:G_3G=_P#?O_Z]']J?].=W_P!^
M_P#Z] %ZBJ/]J?\ 3G=_]^__ *]']J?].=W_ -^__KT 7J*H_P!J?].=W_W[
M_P#KT?VI_P!.=W_W[_\ KT 7J*H_VI_TYW?_ '[_ /KT?VI_TYW?_?O_ .O0
M!>HJC_:G_3G=_P#?O_Z]']J?].=W_P!^_P#Z] %ZBJ/]J?\ 3G=_]^__ *]'
M]J?].=W_ -^__KT 7J*H_P!J?].=W_W[_P#KT?VI_P!.=W_W[_\ KT 7J*H_
MVI_TYW?_ '[_ /KT?VI_TYW?_?O_ .O0!>HJC_:G_3G=_P#?O_Z]']J?].=W
M_P!^_P#Z] %ZBJ/]J?\ 3G=_]^__ *]']J?].=W_ -^__KT 7J*H_P!J?].=
MW_W[_P#KT?VI_P!.=W_W[_\ KT 7J*H_VI_TYW?_ '[_ /KT?VI_TYW?_?O_
M .O0!>HJC_:G_3G=_P#?O_Z]']J?].=W_P!^_P#Z] %ZBJ/]J?\ 3G=_]^__
M *]']J?].=W_ -^__KT 7J*H_P!J?].=W_W[_P#KT?VI_P!.=W_W[_\ KT 7
MJ*H_VI_TYW?_ '[_ /KT?VI_TYW?_?O_ .O0!>HJC_:G_3G=_P#?O_Z]']J?
M].=W_P!^_P#Z] %ZBJ/]J?\ 3G=_]^__ *]']J?].=W_ -^__KT 7J*H_P!J
M?].=W_W[_P#KT?VI_P!.=W_W[_\ KT 7J*H_VI_TYW?_ '[_ /KT?VI_TYW?
M_?O_ .O0!>HJC_:G_3G=_P#?O_Z]']J?].=W_P!^_P#Z] %ZBJD.H>=(J?9;
MA,_Q.F /UJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5#7?
M^0+??]<'_D:OU0UW_D"WW_7!_P"1H -"_P"0+8_]<$_D*OU0T+_D"V/_ %P3
M^0J_0 445'-/';IOED6).FYR /UH DJIJVEVVN:9=Z=>Q"XLKN)X)XF) =&!
M5EXYY!-6E8.H92"",@CH:6@#EM?^&7ASQ-%8)?V#$V$)M[:6VN9;>6.(@ Q^
M9&RL5(5<J3@X%4]5^#?@[6H=.ANM"A\BPMA90102/"GV<$$0NJ,!)'D ['R,
M]N37:T4 -10BA5 "@8 ':LS7/^/C2/\ K\'_ *+>M6LK7/\ CXTC_K\'_HMZ
M -3%&*6H;J[ALK>6>XE2"")2\DLK!511R22>  .]&XF[;DN*#P.E>?Z7^T!\
M-]:M=1N;/QMHLT&G+NNI/M:J(QTSSC(SW&:\PU']J#6_B/>S:3\&?"5QXHD5
MC')XBU-6MM,@/J"<%_IQ]#7KT<IQM:37LW%1W<O=2]7*R7YOH>?4S##4TGS\
MS>R6K?HD;_QQ_:T\*? S7+;1;^TO=7U>6,3R6U@$_<1G[I=F(&3@X YQS7I'
MPV^(NC?%7P?8>)=!F:?3KL' D7;)&X.&1U[,#P17R3\2/V'/B%\1[Z/Q)JWC
MG2]4\579 OEFMFAMXD PBQ% 20HXY49KMO"7[+7Q(^#>A0+\/?B<%GQYMUI.
MK60:PFF(&XIC+)G &>O'6OJL5EO#_P#9]&.&Q:^LW]YOFY7W^SHNSZ]3P:&,
MS98NI*M0?L>B5N;RZZONCZH HQ7S7<_M(_$#X602'XH_#*ZCL81\^O>&I1<V
MN/[S*3E 3ZD=>E<I\)OV^%\??$RQ\.:MX9CTC3M5N/LUE=PW1D>-V.(Q*" "
M"<#(Z$]Q7C4^&<TK4:F(HTU.G!7<HRBU;RL]?3?R/2EG>!A4C2J2<92TLTT_
MGI^.Q]?XHQ35..#Q2YKY:Y[HN*,4"@G I@&*,4FZG4 )BC%+10 F*,4M% "8
MHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2TF<4 &*,49S2T )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,
M4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*6BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J&N_P#(%OO^N#_R-7ZH:[_R!;[_
M *X/_(T &A?\@6Q_ZX)_(5?JAH7_ "!;'_K@G\A5^@!,9KQ'X@>#O#Y\8PZ>
MW@>;XBZ]?PRZA(VKWZ^3:P*ZKA?-)51N< *B]!DU[?7A_P"T'-I\>L:5<-I_
MB+4-4T^SFN0VA:L-.6WMV>.-F=RR[BS%0%&> 3QB@#J/AC\/[70W.HP^')_
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M_:=G_P _<'_?P?XUS'P]^(_@KXL:*VK>#M;TOQ'IR2&)Y["19!&_]UAU4^Q
MKJ?LMO\ \\(_^^!0TXNS5F).ZNAO]IV?_/W!_P!_!_C2'4[/_G[@_P"_@_QJ
M3[)!_P \(_\ O@4TVMOC_41_]\"D,;_:=I_S]P9_ZZ#_ !I6U&U0_-<PCZR
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M_P">$?\ WP*/L<'_ #PC_P"^!0 S^T[/_G[@_P"_@_QH_M.S_P"?N#_OX/\
M&G_8X/\ GA'_ -\"C['!_P \(_\ O@4 ,_M.S_Y^X/\ OX/\:/[3L_\ G[@_
M[^#_ !I_V.#_ )X1_P#? H^QP?\ /"/_ +X% #/[3L_^?N#_ +^#_&C^T[/_
M )^X/^_@_P :?]C@_P">$?\ WP*/L<'_ #PC_P"^!0 S^T[/_G[@_P"_@_QH
M_M.S_P"?N#_OX/\ &G_8X/\ GA'_ -\"C['!_P \(_\ O@4 ,_M.S_Y^X/\
MOX/\:/[3L_\ G[@_[^#_ !I_V.#_ )X1_P#? H^QP?\ /"/_ +X% #/[3L_^
M?N#_ +^#_&C^T[/_ )^X/^_@_P :?]C@_P">$?\ WP*/L<'_ #PC_P"^!0 S
M^T[/_G[@_P"_@_QH_M.S_P"?N#_OX/\ &G_8X/\ GA'_ -\"C['!_P \(_\
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MXS\<]'L_&&N:7X?A\-ZEK>M26<UQ]HT[51IIAM1)&&5I"?G#/Y9V;3RN>,4
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MLGTZQT'1F'GP)*N#/,W2.,#)YZC/09(^+/@+_P $QOB3?_%[3(OB1X?L]/\
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M:+<)4<#YLY;()Z@@ \8'UQ^P!HFD_L]?LLZ;?^-KS1/#-YK=S+JK2SSQ1RO
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M)+>_H>/_ +.'[)UA\"6U2^N=8DUO6M0C6!IXD-O'%"#NV*H8DY."23V' KW
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M10!0_L6W_O7'_@0_^-']BV_]ZX_\"'_QJ_10!0_L6W_O7'_@0_\ C1_8MO\
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M+;_WKC_P(?\ QH_L6W_O7'_@0_\ C5[-96N>+-$\-0M)J^L6.EQJNXM>7*1
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M*&D/+[6D9=QYPHR371_&#08-?^&WB2)].CU*[CTVZ:T1H!*ZS&%PIC!!(?G
M(YYH U-?\=:!X6T:#5M7U>TT[3IS&L,]Q(%$A<@(%'4D[AP!53Q/\3O#'@S4
M8;#6M7AL;V:+SHX&1V8INV[L*#@9XKA/B]X5.L_ 5%32/MVLV]E9K;J+;S+B
M(^9#O"<;E.%YQZ<]*K?%\MIWBC4[^TN/%>FZY)HZ1:9+HUMYUM=SH\K1Q';&
MWS!W&5D*J5;/8D 'M:.)$5E.589!K+US_CXTC_K\'_HMZGT%[Z30].?4XTBU
M)K>,W4<1RBR[1O"^P;-5?$2R-+I0B94?[8,%ER!\C]J /D[]OG41\2?%WP@^
M!=L^Y_%NO1:AJJ+U73[<Y;/H&.XC_KG7U[-/9:%ICRRR0V.GVD66>1@D<,:C
MJ2>  !7P7^SQJ\W[0W[?7Q$^(:SI/I/A6UDT;2)&C+1[%;R=RC/&XF9NO\5>
MN?MJ>.H[KP++\,M-NI=5\;>)&ACM='TJ(M,8Q(&)E^;Y4(4CGK] 37;FS_L^
MA3A+=1YK><M4OFK'7D&"EG681PT'92E9R_EBOBD_**NW?30]<\+_ +1GPT\9
M?VA_9'C72+D:>I>Y+S^4$0<%\OC*^XR*\^\2?MI^&9]2DT;X>Z-JOQ-UW[HB
MT2!OLR'_ &YB, >X!'O7RG^SK^Q9XOU[XE6DWCWPI)IGA;3RTEU%J1 %VV"$
MC0(V6&[!)SC ]Z_1+PUX/M?!^F1Z?H5GIFCV* !;>RLA$@_ 'D^YKY;"5L9C
M*?--*G\G?Y)[?.Y^C<0Y9PWPYC?886K+&:)_$E!7Z2E&[D^MERV36I^=W[1W
MP2^.GQ-\6P^-=:\$DS:A$EO'INBS_:FL40?*D@SP3DDD<9)Z5[]^S?\ L1>&
MM#\$Z=J'Q'\/0ZOXKD+2-:W<S2PV<9/R1; VPL!R>O)]J^JO*O\ _GY@_P"_
M)_\ BJ/*O_\ GYM_^_)_^*JJ654*=>5>5Y-][/Y[&6/\0,UQF5TLIHJ-&G3V
M]GS1=ME&_,W;OU?4CT?P_IOAVT6UTK3[73+5< 0V<*Q)^2@"H--\(Z'HVH7%
M_8:-I]C?7&?/N;:U2.27/7<R@$_C5ORM0_Y^;?\ [\G_ .*H\K4/^?FW_P"_
M)_\ BJ]CE6FA^<>UJ/F?,]=]=_7N>8?$O]EOX;_%"5KK4O#\=CJWWEU;23]E
MNE;L=R<,?]X&OB']K[0OB'\%+C1O"TOC[Q%K_@RYC-Q937DI0K(I*F%Y%.7*
MC:0"?XN!7Z6^5J'_ #\6_P#WY/\ \55#5O#J:_:&UU2#3=2MB0WDW=F)4SZ[
M6)&:\O&9?#$P:@^23ZK];;GW7#?%^)R3%4ZF*C]8HPO[D[.VF\7)/E:\CXC_
M &2?@C-^T+X1A\2?%#4]=\1:)IEQ]ET;2;Z\?[)*B@%I",Y<!B5Z]NIZ5]T:
M+H6G>'--@T[2K&WTVP@4+%;6L0CC0>R@8IEII]S8V\=O;O:6\$:A4BBMMJJ.
MP #8 J;RM0_Y^;?_ +\G_P"*KHPF%AA::BM9=7U9X^?Y]7SW%SK27)3NW&FO
MABO)*ROW=M66]HIU4O*U#_GYM_\ OR?_ (JCRM0_Y^;?_OR?_BJ[CY@35='L
M->L9++4K*WU&SD^_;W42RQM]58$&G:9I-EHEE'9Z=9P6%G$,);VL2QQK]%4
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M+_MU_P!X[:*1945U8,C#(93D$'N#3\U\NC]F_P"(_P &RUU\(?'TDNGH2_\
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M=#]3@<TN:^<X?V?OBX(D!^/6J9"@'&EQG]2W-/\ ^&?_ (M_]%ZU3_P51?\
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M'2?^"FWBK1=5GTWQ/\)XM9>$[3>>#-7%Y&Y]54KR/?=7T=H/[&GPQT"3S?\
MA&K/59\Y,VKF6Z8_]]/C]*]2T/P;9>&H]FD:?I&EH!C;9V"Q#_QTBOE9XC*(
MP:Y)5)=[1IK[DY7_  /<A3S"4DVXQ7;67^1\;>,?^"J6A^'&-N?AQXDT:ZPO
M/B:$V2+D9Y 5C]/6M;P=^TWX\^.(B'ASXC?"KPLEP!LA741=7JGKCRW/WO48
MKZ^U+1GUBV:VOUL+ZW;[T-S:>8A^H)(KR3QI^QA\(/B!(\FM?#KPQ).Z[3/9
MZ>;23Z[HG4Y]ZBCF.#HPY8X:*E_,[S_"3Y?P+JX.M5E=UI6[*R_%*_XF'#^S
M7XR\8P1S>+?C9XBU2WE&9+;0@EE X] 5)R/?%;.B?L5_"G2Y5GOM$N?$5V#D
MW&M7LMPS'U(R%_2O.9O^"<7AC0ITN/ 7Q!\<?#N:/E4T?6)'A#9X.QR>GIG%
M2'X$_M0^!EQX4^/FF^*[<$G[/XQT-=V.P\V/<QS^%:RS;%S7+1Q7(NT5[-?^
M2*QG'+L-%WG1YGW;YO\ TJYW?Q!_8I^&?CRZL[B+3IO#<EN@C*Z&4@25,Y 9
M"I&>3\PP?7/%>P>"O!ND_#[POI_A_0[46>EV,?EPQ ECUR22>22223W)K\AO
MVS?VDOVB?#_Q0@\,>,M>'@J]TJ"*XBM_!UU-;VEWNR5N Y.^3G*X8X!4C'7/
MZ2_L5_$3Q1\5?V:O!GB7QB&?7;N&59+EXQ&UTB2ND<Y4 #+HJMD#!SD=:RS"
M>82P=)8FNYTT]%=NU^O];%X6EA85YRHTE&3W=K'N-%%%?-GL!1110 4@&*6B
M@ HHHH **** "BBB@ HHHH **** (9[."Z*&:&.4H=R>8@;:?49Z56UW_D"W
MW_7!_P"1J_5#7?\ D"WW_7!_Y&@ T+_D"V/_ %P3^0J_5#0O^0+8_P#7!/Y"
MK] "&N9U77M'L/%>EZ"^G/=ZGJ*23Y@M0Z0Q)C=+*W15+$*.I)/3J1T]>+_%
MB]EFU/2]7TFV\:Z3KL N;-;W0]'2[5H5D 99HY,J59E#HW!QR#@D4 >B^"?%
M6F^*K*]?3[2?3Y;*[DL[JSNH!#+#*N#AE''*E6!!(*L#71UY]\%K2&'PW>W'
MD:^M_=WKSWUSXEM1;W=U-M0>9L7"A-H55"@ !<>]>@9H 6BDS1G-  :^5?VW
M/VO/"?P/\(:KX>MM:1_B-+9.^GZ9 C.\+21M&DLK ;8\;RX#$$[>!7U4>E?B
M/^W;\.->?]K3QY/]D?9J%W'<0F>0#,9A0!@3_!\IQCI@CM7I9=2H5L5"E6E;
MF=DN[Z+YA+#XJM1JSPL'+DBY2MTBMY>BZ]MSWG]C7QW?_"WX52>%OA]IP\2_
M$_Q5<#R1]ZWL;=$_X^9VZ8W.Y /ID]@?MKX"_L\V?PF6[US6+UO$WC_5OWFJ
M>(+KYG9CR8XL_=0?KCL  ./_ &!/@]I_PQ_9W\,73:4+/Q'JUL;C4;N4'SIL
MR,8QSRJ;=I"].<]37TJ!Q7-F<_KV8U<74[VBND4M%\[+<]BGBXY?ET<JP4>5
M-?O)?:J2W:;6T$]HK?>5W:QM% XI:*YCQPHHHH **** "BBB@ HHHH ****
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M_<U&0?S>H'\?_M.0D9^&/A2;_KGJV,?G)7TI2UV_59?\_9?A_D?,_P!N4>N
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M[L@^2I YP2H+%B >#7J4:V!C3FITW=[:W_16_$Y)PQ#DG&2^XPO^'G'[/_\
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M/;RH8Y(I%#*ZD8((/!!':@#P_P".6D#4/V?[74GO[ZW>QM+*58K:Y:*.5S)
M 9 N"^.P)QSR#53XQ6NE:KXJ\<MK]R86T;PHE]HVZY:+R)2UQYD\0!'[P.D
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M>W_?U:O44 4?MEY_T#V_[^K1]LO/^@>W_?U:O44 4?MEY_T#V_[^K1]KO/\
MH'M_W]6KU% %'[9>?] ]O^_JT?;+S_H'M_W]6KU% %'[9>?] ]O^_JT?;+S_
M *![?]_5J]10!1^V7G_0/;_OZM'VR\_Z![?]_5J]10!1^V7G_0/;_OZM'VR\
M_P"@>W_?U:O44 4?MEY_T#V_[^K1]KO/^@>W_?U:O44 4?M=V?\ F'M_W]6D
M%U=C_F'L/^VJU?HH Y#Q7X(T3QU:O;^(?"&GZS$PVD7L<4AQ[$C(_"O%M;_8
MD\$R7CWWA:/7O .HLV\3Z!JI10?]QB1CV!%?3%)7/4P]*MK.*?\ 7<]C!YQF
M.7KEPM>45V3T?K'9_-'PA^T5I?QX^"'PRO9U^(]WXC\,7$JVUQ<-;+'J%HK9
MP3,N2%. I8-GYNV:\Y_9 ^)?QOU#4M;T?P-+!XEMUA6XG3Q+<2/;VK;L!E?=
MD,W/RYY )QQ7Z7WEE!J%M+;7,,=S;RJ4DAF0,CJ>H(/!%4/#WA31O"=HUIHF
MDV6D6K-O,-C;K"A;U(4#)]Z\F>62>(C5A5DHKI=O[FS[_#\<4(9-6R_$Y?2J
M59N_/RQBNFKC%*[71IKS\_GIM+_:JU@[GUOP/H _N6]N\WZL#3#\'_VB-7&=
M2^,EOI^>J:3I,0'_ 'TV#7T[BEKO^IQ?Q3D_^WG^ECY/_6.O'^%AZ,?2E!_^
ME*1\PG]EWQ[JD7EZU\:_&MTA^\EG+' #^.XXJ.']A_0YFSJWBKQWK0[I<Z\
MI_(9_6OJ&EH^HT.L;^K;_-B_UHS=?PZW)_AC"/\ Z3%'S5;_ +"OPHC??<^%
M-0U)_6\UF5R?R<5T]E^R=\)[")4C^&&ER =YW\TGZEF->VXI:T6$P\=J:^Y'
M-4XBSFM\>,J/_M^7^9\L_%3]@_P3\2M9L[[389_ S1QB&:+28X6@E4=#Y?\
M"W;<.O&0<5[[\-?AYH_PJ\%:9X7T*)XM-L$*(9&W.[$EF=CW9F))^M=1BC%.
MGA:%&;J4X)2>[(QF?9IF&%IX+%XB4Z5/6*;O;]7Y7O;H+11174>"%%%% !11
M10 4444 %%%% !1110 4444 %%%% !5#7?\ D"W_ /UP?^1J_5#7?^0+??\
M7!_Y&@ T+_D"V/\ UP3^0J_5#0O^0+8_]<$_D*OT %>0?&35?%6D^(]-'ANV
MO#/<6,UM:2VE@)D:[D=$07$NT^7%&K--R5#&/DG&#Z_7E?QEMTN;W3S8Z3XC
MN]?CBD:#4-#O_L,5K'D;O/F=A%M.,[75R<'"]: -?X076J3Z3J\5]?ZCJUE;
M:C);Z?J.K0"&YN(55-S, JY42^:JMM&5 ZC!/>UY;\.+GXEZ=?:=:^+)=)\0
MZ7>QRN-2TO*RV;#!C64X5)@P)&]%3YATP<UM_&.^\1:5\/M9O_#>H6NF7EG:
M3W+W-S;F=E5(F;$:Y"[B0!EL@#/!H [>BO)M1UCQ'XL\0>&_#^G:])X?,_A]
MM8N;ZW@BDEEEW1(B8D4J$R[,V!D\ $5QZ_$CQ5X@T#0?$MP_B+3]$?P]%?7D
MOANSM9HQ<!Y//9C,"=H5%(5,G#=#0!]$UE:Y_P ?&D?]?@_]%O5O3+Z#4]-M
M+RUF%S;7$2313#I(C %6_$$&J'B*98)=*=\[1>#. 3_ _84 ;-%4?[9M?[TG
M_?E_\*/[9M?[TG_?E_\ "@"]15'^V;7^])_WY?\ PH_MFU_O2?\ ?E_\* +U
M%4?[9M?[TG_?E_\ "C^V;7^])_WY?_"@"]15'^V;7^])_P!^7_PH_MFU_O2?
M]^7_ ,* +U%4?[9M?[TG_?E_\*/[9M?[TG_?E_\ "@"]15'^V;7^])_WY?\
MPH_MFU_O2?\ ?E_\* +U%4?[9M?[TG_?E_\ "C^V;7^])_WY?_"@"]15'^V;
M7^])_P!^7_PH_MFU_O2?]^7_ ,* +U%4?[9M?[TG_?E_\*/[9M?[TG_?E_\
M"@"]15'^V;7^])_WY?\ PH_MFU_O2?\ ?E_\* +U%4?[9M?[TG_?E_\ "C^V
M;7^])_WY?_"@"]15'^V;7^])_P!^7_PH_MFU_O2?]^7_ ,* +U%4?[9M?[TG
M_?E_\*/[9M?[TG_?E_\ "@"]15'^V;7^])_WY?\ PH_MFU_O2?\ ?E_\* +U
M%4?[9M?[TG_?E_\ "C^V;7^])_WY?_"@"]15'^V;7^])_P!^7_PH_MFU_O2?
M]^7_ ,* +U%4?[9M?[TG_?E_\*/[9M?[TG_?E_\ "@"]15'^V;7^])_WY?\
MPH_MFU_O2?\ ?E_\* +U%4?[9M?[TG_?E_\ "C^V;7^])_WY?_"@"]15'^V;
M7^])_P!^7_PH_MFU_O2?]^7_ ,* +U%4?[9M?[TG_?E_\*/[9M?[TG_?E_\
M"@"]15'^V;7^])_WY?\ PH_MFU_O2?\ ?E_\* +U%4?[9M?[TG_?E_\ "C^V
M;7^])_WY?_"@"]15'^V;7^])_P!^7_PH_MFU_O2?]^7_ ,* +U%4?[9M?[TG
M_?E_\*/[9M?[TG_?E_\ "@"]15'^V;7^])_WY?\ PH_MFU_O2?\ ?E_\* +U
M%4?[9M?[TG_?E_\ "C^V;7^])_WY?_"@"]15'^V;7^])_P!^7_PH_MFU_O2?
M]^7_ ,* +U%4?[9M?[TG_?E_\*/[9M?[TG_?E_\ "@"]15'^V;7^])_WY?\
MPH_MFU_O2?\ ?E_\* +U%5(M4MYY%1"Y8],Q,!^9%6Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *H:[_ ,@6^_ZX/_(U?JAKO_(%OO\ K@_\
MC0 :%_R!;'_K@G\A5^J&A?\ (%L?^N"?R%7Z $/2OFV/P5JGB+Q+=^&M4\,:
MDMK=>(9]9\1ZS<C=::G9Q,[6<$9W'>#F%3%@ "-@1SS])T4 >9? ;29=,T/7
MY8M(N?#^B7NL37.DZ3=0^2]M;%(P?W7_ "R#2+*X3C ?H,XKO=?T6W\2:'J&
MDWF_[)?V\EK,(VVML=2K8/8X)YK0HH XOQ%\*M*\0Q:7_I>I:7=:;;-907NF
MW1AG-NP4/$S8.5.Q#TR"H((-4]3^">@W]M#:VUSJFCV*Z?'I4MIIEZT45Q:H
M"%C<<] SC<,-ACS7H%% $%E90:=906EM$L%M!&L442#"HBC  ]@ !5'7/^/G
M2/\ K\'_ *+>M6LK7/\ CXTC_K\'_HMZ -6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_WP* +FX>HHW#U%4_[%L/\ GTA_[X%']BV'_/I#_P!\"@"YN'J*-P]15/\
ML6P_Y](?^^!1_8MA_P ^D/\ WP* +FX>HHW#U%4_[%L/^?2'_O@4?V+8?\^D
M/_? H N;AZBC</453_L6P_Y](?\ O@4?V+8?\^D/_? H N;AZBC</453_L6P
M_P"?2'_O@4?V+8?\^D/_ 'P* +FX>HHW#U%4_P"Q;#_GTA_[X%']BV'_ #Z0
M_P#? H N;AZBC</453_L6P_Y](?^^!1_8MA_SZ0_]\"@"YN'J*-P]15/^Q;#
M_GTA_P"^!1_8MA_SZ0_]\"@"YN'J*-P]15/^Q;#_ )](?^^!1_8MA_SZ0_\
M? H N;AZBC</453_ +%L/^?2'_O@4?V+8?\ /I#_ -\"@"YN'J*-P]15/^Q;
M#_GTA_[X%']BV'_/I#_WP* +FX>HHW#U%4_[%L/^?2'_ +X%']BV'_/I#_WP
M* +FX>HHW#U%4_[%L/\ GTA_[X%']BV'_/I#_P!\"@"YN'J*-P]15/\ L6P_
MY](?^^!1_8MA_P ^D/\ WP* +FX>HHW#U%4_[%L/^?2'_O@4?V+8?\^D/_?
MH N;AZBC</453_L6P_Y](?\ O@4?V+8?\^D/_? H N;AZBC</453_L6P_P"?
M2'_O@4?V+8?\^D/_ 'P* +FX>HHW#U%4_P"Q;#_GTA_[X%']BV'_ #Z0_P#?
M H N;AZBC</453_L6P_Y](?^^!1_8MA_SZ0_]\"@"YN'J*-P]15/^Q;#_GTA
M_P"^!1_8MA_SZ0_]\"@"YN'J*-P]15/^Q;#_ )](?^^!1_8MA_SZ0_\ ? H
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M16P1D9P>HK,US_CXTC_K\'_HMZ -6BBB@ HHHH **** "BBB@ HHHH ****
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M8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\
MQ-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 3
M0!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O
M])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_
M +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_
MSQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\
M/'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%
M8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\
MQ-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 3
M0!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O
M])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_
M +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_
MSQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\
M/'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%
M8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\
MQ-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 3
M0!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O
M])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_
M +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\ /'3/^_TG_P 30!LT5C;_ !!_
MSQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%8V_Q!_SQTS_O])_\31O\0?\
M/'3/^_TG_P 30!LT5C;_ !!_SQTS_O\ 2?\ Q-&_Q!_SQTS_ +_2?_$T ;-%
M9=H^LFX3[3%8+!_$8I'+?@"H%:E !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4-=_Y M]_P!<'_D:OU0UW_D"WW_7!_Y&@ T+_D"V/_7!/Y"K
M]4-"_P"0+8_]<$_D*OT %%%% !1110 QXDD WJ&P<C<,X/K0T:.5+*&*G(R,
MX/K3Z* "BBO#OB;$WB+Q[XHLK_5K_2K30_"PU33S9WLEL$G9YM]R2C .4\I
M V5&3D<T >XT5A^!M2NM9\$^']0OO^/V[T^WN)_EV_O&C5FX[<D\5N4 %%%%
M !1110 4444 %%%>)C19H_BI!)X?U75]6U.SNY[O7[V:\D:S2W:-_*L!%GRM
M^YHB HW*J;F.6&X ]LHKYX^%MW<6VH_"[6(]9OK^_P#%UI>2ZTEQ=22QS,L7
MF[UC9BL7E28C&P  -M/:OH>@ HHHH **** "BBB@ HHKYS^./Q;M!XIM])C\
M2?V!;:#JVG-=QB1HI;Z1YXRR<<F&.)BS=F8@=%.0#Z,HKYUO+^\GU#5_%O\
M:6H?VY9^-[?1K6V2]D6 V9EAC\CR,["'CD:3)7=DAL\5]$B@!:*** "BBB@
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MA?\ (%L?^N"?R%7Z\XM/&M_9VZ6Z) 4B 12RG. ._-3?\)]J/_/.W_[X/^-
M'H-%>??\)]J/_/.W_P"^#_C1_P )]J/_ #SM_P#O@_XT >@T5Y]_PGVH_P#/
M.W_[X/\ C1_PGVH_\\[?_O@_XT >@T5Y]_PGVH_\\[?_ +X/^-'_  GVH_\
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M?:C_ ,\[?_O@_P"-'_"?:C_SSM_^^#_C0!Z#17GW_"?:C_SSM_\ O@_XT?\
M"?:C_P \[?\ [X/^- 'H-%>??\)]J/\ SSM_^^#_ (T?\)]J/_/.W_[X/^-
M'H-%>??\)]J/_/.W_P"^#_C1_P )]J/_ #SM_P#O@_XT >@T5Y]_PGVH_P#/
M.W_[X/\ C1_PGVH_\\[?_O@_XT >@T5Y]_PGVH_\\[?_ +X/^-'_  GVH_\
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M?:C_ ,\[?_O@_P"-'_"?:C_SSM_^^#_C0!Z#17GW_"?:C_SSM_\ O@_XT?\
M"?:C_P \[?\ [X/^- 'H-%>??\)]J/\ SSM_^^#_ (T?\)]J/_/.W_[X/^-
M'H-%>??\)]J/_/.W_P"^#_C1_P )]J/_ #SM_P#O@_XT >@T5Y]_PGVH_P#/
M.W_[X/\ C1_PGVH_\\[?_O@_XT >@T5Y]_PGVH_\\[?_ +X/^-'_  GVH_\
M/.W_ .^#_C0!Z#17GW_"?:C_ ,\[?_O@_P"-'_"?:C_SSM_^^#_C0!Z#17GW
M_"?:C_SSM_\ O@_XT?\ "?:C_P \[?\ [X/^- 'H-%>??\)]J/\ SSM_^^#_
M (T?\)]J/_/.W_[X/^- 'H-%>??\)]J/_/.W_P"^#_C1_P )]J/_ #SM_P#O
M@_XT >@U0UW_ ) M]_UP?^1KC?\ A/M1_P">=O\ ]\'_ !J&[\:W]Y;O;ND
,24%&*H<X/IS0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_019.jpg
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &) M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#].-&T:PFT
MFSDDLX'=H59F:,$DXZFKG]A:=_SXV_\ WZ%&A?\ (%L?^N"?R%7Z *']A:=_
MSXV__?H4?V%IW_/C;_\ ?H5?HH H?V%IW_/C;_\ ?H4?V%IW_/C;_P#?H5?H
MH H?V%IW_/C;_P#?H4?V%IW_ #XV_P#WZ%7Z* *']A:=_P ^-O\ ]^A1_86G
M?\^-O_WZ%7Z* *']A:=_SXV__?H4?V%IW_/C;_\ ?H5?HH H?V%IW_/C;_\
M?H4?V%IW_/C;_P#?H5?HH H?V%IW_/C;_P#?H4?V%IW_ #XV_P#WZ%7Z* *'
M]A:=_P ^-O\ ]^A1_86G?\^-O_WZ%7Z* *']A:=_SXV__?H4?V%IW_/C;_\
M?H5?HH H?V%IW_/C;_\ ?H4?V%IW_/C;_P#?H5?HH H?V%IW_/C;_P#?H4?V
M%IW_ #XV_P#WZ%7Z* *']A:=_P ^-O\ ]^A1_86G?\^-O_WZ%7Z* *']A:=_
MSXV__?H4?V%IW_/C;_\ ?H5?HH H?V%IW_/C;_\ ?H4?V%IW_/C;_P#?H5?H
MH H?V%IW_/C;_P#?H4?V%IW_ #XV_P#WZ%7Z* *']A:=_P ^-O\ ]^A1_86G
M?\^-O_WZ%7Z* *']A:=_SXV__?H4?V%IW_/C;_\ ?H5?HH H?V%IW_/C;_\
M?H4?V%IW_/C;_P#?H5?HH H?V%IW_/C;_P#?H4?V%IW_ #XV_P#WZ%7Z* *'
M]A:=_P ^-O\ ]^A1_86G?\^-O_WZ%7LTM %#^PM._P"?&W_[]"C^PM._Y\;?
M_OT*OT4 4/["T[_GQM_^_0H_L+3O^?&W_P"_0J_10!0_L+3O^?&W_P"_0H_L
M+3O^?&W_ ._0J_10!0_L+3O^?&W_ ._0H_L+3O\ GQM_^_0J_10!0_L+3O\
MGQM_^_0H_L+3O^?&W_[]"K]% %#^PM._Y\;?_OT*/["T[_GQM_\ OT*OT4 4
M/["T[_GQM_\ OT*/["T[_GQM_P#OT*OT4 4/["T[_GQM_P#OT*/["T[_ )\;
M?_OT*OT4 4/["T[_ )\;?_OT*/["T[_GQM_^_0J_10!0_L+3O^?&W_[]"C^P
MM._Y\;?_ +]"K]% %#^PM._Y\;?_ +]"C^PM._Y\;?\ []"K]% %#^PM._Y\
M;?\ []"C^PM._P"?&W_[]"K]% %#^PM._P"?&W_[]"C^PM._Y\;?_OT*OT4
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MQ2T4 )BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:[_P @6^_Z
MX/\ R-7ZH:[_ ,@6^_ZX/_(T &A?\@6Q_P"N"?R%7ZH:%_R!;'_K@G\A5^@
MHHHH **** (;N\@T^UEN;J>.VMH4,DDTSA$10,EF)X  [FL+3?B-X7U?0;O6
M[/7K"?2;/(N;L3J$AQ_?)^[U&,]<C'6J'QAT>'7_ (::_8W O#%);[C_ &?;
MBXF&U@P*Q$CS,$ E/XAD=Z\1NXM6\2ZAK?BBX0ZYH]O=:$UY+8Z1+:QW*6US
M)),4A<M)+Y:.A).<X*@?+0!]&^'O$NE^+-+CU'1[^#4K&0D+/;N&7(X(/H1W
M!Y%:=>:_",_VCKWCS7;2WFM]$U;58Y;$S1-#YVRVBCEF", 0&=&Y(^;;GO7I
M+<*: %HK&TN?4M2TZWNOM%O'YR!]GDDXSVSNJUY&I?\ /W;_ /@.?_BZ +]%
M4/(U+_G[M_\ P'/_ ,71Y&I?\_=O_P" Y_\ BZ +]%4/(U+_ )^[?_P'/_Q=
M'D:E_P _=O\ ^ Y_^+H OT50\C4O^?NW_P# <_\ Q='D:E_S]V__ (#G_P"+
MH OT50\C4O\ G[M__ <__%T>1J7_ #]V_P#X#G_XN@"_15#R-2_Y^[?_ ,!S
M_P#%T>1J7_/W;_\ @.?_ (N@"_15#R-2_P"?NW_\!S_\71Y&I?\ /W;_ /@.
M?_BZ +]%4/(U+_G[M_\ P'/_ ,71Y&I?\_=O_P" Y_\ BZ +]%4/(U+_ )^[
M?_P'/_Q='D:E_P _=O\ ^ Y_^+H OT50\C4O^?NW_P# <_\ Q='D:E_S]V__
M (#G_P"+H OT50\C4O\ G[M__ <__%T>1J7_ #]V_P#X#G_XN@"_15#R-2_Y
M^[?_ ,!S_P#%T>1J7_/W;_\ @.?_ (N@"_15#R-2_P"?NW_\!S_\71Y&I?\
M/W;_ /@.?_BZ +]%4/(U+_G[M_\ P'/_ ,71Y&I?\_=O_P" Y_\ BZ +]%4/
M(U+_ )^[?_P'/_Q='D:E_P _=O\ ^ Y_^+H OT50\C4O^?NW_P# <_\ Q='D
M:E_S]V__ (#G_P"+H OT50\C4O\ G[M__ <__%T>1J7_ #]V_P#X#G_XN@"_
M15#R-2_Y^[?_ ,!S_P#%T>1J7_/W;_\ @.?_ (N@"_15#R-2_P"?NW_\!S_\
M71Y&I?\ /W;_ /@.?_BZ +]%4/(U+_G[M_\ P'/_ ,71Y&I?\_=O_P" Y_\
MBZ +]%4/(U+_ )^[?_P'/_Q='D:E_P _=O\ ^ Y_^+H OT50\C4O^?NW_P#
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MY5J5E^%_^1=T[_KBO\JU* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:[_R!;[_K@_\
M(U?JAKO_ "!;[_K@_P#(T &A?\@6Q_ZX)_(5?JAH7_(%L?\ K@G\A5^@ HHH
MH **** "BBB@ I&^Z?I2TC?=/TH S/"__(NZ=_UQ7^5:E9?A?_D7=._ZXK_*
MM2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J&N_\@6^_ZX/_ "-7ZH:[_P @6^_ZX/\
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M Z7_ +^)_C1]NNO^@=+_ -_$_P : +]%4/MUU_T#I?\ OXG^-'VZZ_Z!TO\
MW\3_ !H OT50^W77_0.E_P"_B?XT?;KK_H'2_P#?Q/\ &@"_15#[==?] Z7_
M +^)_C1]NNO^@=+_ -_$_P : +]%4/MUU_T#I?\ OXG^-'VZZ_Z!TO\ W\3_
M !H OT50^W77_0.E_P"_B?XT?;KK_H'2_P#?Q/\ &@"_15#[==?] Z7_ +^)
M_C1]NNO^@=+_ -_$_P : +]%4/MUU_T#I?\ OXG^-'VZZ_Z!TO\ W\3_ !H
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M<'_D:OU0UW_D"WW_ %P?^1H -"_Y MC_ -<$_D*O$9JCH7_(%L?^N"?R%7Z
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M479HMI-69\>_!SXX^*OV>?'=A\%_CE>_:8[D^5X2\?2?+;ZM$,!8+AC]R<9
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M?\]Q^1_PH_MNR_Y[C\C_ (4 7J*;'(LJ!U.5(R#ZBG4 %%%% !1110 4444
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MB[#$&X+!/,W%>Q7/:OU!K/%X?ZK6=)2O8JC4]K!2M8****XS8**** "BBB@
MHHHH **** "BBB@ HHHH **** "J&N_\@6^_ZX/_ "-7ZH:[_P @6^_ZX/\
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MK1UGI-^4-^2/I[TEN[:'A_A;]C7X7>%_!.I>&ET(ZE!J+;KB^OGWW>X?=*2
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MNMI;BX<#RWE:)=A171V.#@.* /8*1ONGZ5SG@+Q-<>+=!74+@:6&:5D4Z1J
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M<?4FM/4/V-- TBY>]\ >)?$'P\OR=P&EWC26V?>)SR/QJL9/VB_AJ?GB\/\
MQ4TQ!U3_ $"^(_1"?SKY6IDN QCYL-7BY=I_NY?^!7<?_)T?8X/B?.,KA[*2
ME[/LK5(?.$E_[:RD?%G[1WPO.-:\+Z+\4=*0@&[T.7[+>E>Y,9&"?8+6IX=_
M;=\ 7-\FF^*H=6^'VKD[6M?$5D\2@^T@!&/<XJ33OVRO#.FW26/CSP_K_P .
M]0+;2-7LG: _25 <CWQ7I\-[X$^,FC;8Y="\7Z<Z_</E72@'KP<E?TKS<3D^
M8X!*4KJ/1R7-%^DEO][/9H\09-F;Y<3AHJ75TG[.7S@^:/R48F_H'BC1_%=B
ME[HNJ6>K6C $364ZRK^:DUJ \5\\:_\ L0^!'OGU+P?=ZS\/-7)RMSX>O7CC
M![9C)(Q[#%9@\-?M)?"[;_9/B+0_BGI4?_+MK$?V.]*CL)!P3[EC7F^WJT_X
MM/YQU_#1_@SL_LO+L5K@<8D_Y:JY'_X$N:'WRB?3611FOS0\6_\ !0;XHP>/
M)9;>RT_1-/L9O)FT&:$2Y9#B19)3ALY#<KC'H>_TI9?M*_%CQEIUI=^$_@7J
M)M;E%>.ZUG44MT8$9# $ E>>#W%<U'-<-7E*,+W7D_TO^)[N8\ 9UE=.E5Q*
MIJ-173=2"2\FY-)O_"VCZ;R*"?2OD_Q;XY_:&TK39-2\1ZI\._AEI."WVB\F
M>XD7_9 ^8.WL!^%>/6%_^T!\;]52#PCX[US5=*5BLNMQV2Z/IV.^QL;Y!^&?
M:O>P>&Q>.7/1HM06\Y6C!>KDU]RN_(^2Q."P6!]W%8ZDI](P<JDGZ*$6OO:7
MF?H!KOB'3/#&F3:CJ^H6VEV$(R]S=RK'&OXDU\Q^/?V[=#^W2:1X @M-8O.0
MVL:U=+8Z="/[V7(9Q],9[9J?PO\ L):7J%DDOQ(\6Z[XUU+.\H;Z5+>-N^W<
M2Q^I(^@KT/0?V/\ X/\ A[:T'@73KF53N$M_ON6S]9&->K-X+ K]TE7J>=XT
MU\E[TO\ R1>IXF$A2Q,Y/&3G2I]%",7-^K<N6'W3?H?+M]X_^''BW4DO?B]\
M5[SXA7<;[D\,>%K6==-C/H JKYF/7(^IK0^,7[6":'\)7TKX2>"]=\%Z:94A
M?7)M)%I;PQG(Q&>1O8X&X\]>^*^V]&\$>'O#FS^RM!TS3-HPIM+..(@?\! J
M[K.B6'B'2[C3=4LX-0T^X0I-;7,8DCD7T*G@UX6/Q69YE2]E5KJ,>D8QY8KT
M2=EZVOYGUF4XCAO)L73Q-/ 2JN+3;J5%)R]4H*_HVUY6/B'_ ()\?&?QMXS\
M6>(/#6N:C<ZYHUO8_;4GNCO:UE\P*%#>C@L<'NN1WK[LKF_!?P[\-?#K3Y;'
MPQH=CH5I(_F2164(0.WJQ')_&NDKCP5"IAZ*IU9\S74GB;-<)G.:5,;@<.J-
M.5K15NBLWII=^04445W'RQ!<V5M>;?M%O%/MZ>8@;'YU1OO#.DW]I-:W&EV<
MUM/&T<L;P*0ZD8(/'<5JT4FD]RXSG'X78\ \ ?L2_#+X=>.%\4:?97MU=0N9
M+2TOKCS;>U8]T7&21DXW$X^O->XC1-./_+A:_P#?E?\ "KU)6-*A2HKEIQ27
MD>CCLTQV9U%5QM:5225DY-MV70YGQI\/M.\;:19Z?--=:8EG>17]O-IKK%)%
M-&25894CJ3QBN5\2?"+4-4?PM##XFU:Y33=7?49KZ[N5^UQJ;6:)1$RQA?O.
MIVL""-V<]*]1HK<\O<XG2_A%HFE1V&R6]GN+5[N9KJ>;=+<2W(Q-)(< %B.F
M  ,# P,5MZ;X0TW3O!UMX8\HW.CP6*Z=Y5P=QD@">7M8]\KP:VZ* //[;X,:
M7'I\ME=:MK>IVYBAMX4O+S<+>**5941 % /S(N6;<Y P6KI],\*V6D^(M:UJ
M R_;=6$ N=SY3]TI5-H[<$YK9HH **** "BBB@ JAKO_ "!;[_K@_P#(U?JA
MKO\ R!;[_K@_\C0 :%_R!;'_ *X)_(5?JAH7_(%L?^N"?R%7Z "BBB@ HHHH
M CN/-\B3R AFVG8)"0N['&<=LUYY:?#C5=)^'<.EVEYIUWXA>Z&I7USJ-KYU
MM>W+2B2;<IY52?E5AR@5<=,5Z/10!Q7PZ\%W_AJ]\2:IJCV27^NWJW<MKIJL
M+>#;$D0 + %F(3<S$#)/3BNS?[I^E.I&^Z?I0!PNIZMI?@CX87OB>_15MM*T
MR6_F9Y"HQ'&7/?'.*_,C]G;3[V__ &;/&^MRH[>(/B3XJM='BE))=@\AFEQ_
M>'S '-?6G_!0?Q^W@O\ 8UN]/@D*7WB9[71(0O7$C;I/P\N-Q^(KS;]F;P4C
MZK\ O"*Q[8=*T^\\8WR#L\KE+<G\$C/XU]#D]H8JE4>T.:H_2G&Z^^32*Q4'
M'*<55ZS=.BO6<N:7W1A^)]VZ+X2T[1=(L=.@@ ALX([= &(^5%"CO[5<_L6S
M_P">/_C[?XU=7I2U\^VY-R>[(244DBC_ &+9?\\?_'V_QH_L6R_YX_\ C[?X
MU>HI#*/]BV7_ #Q_\?;_ !H_L6R_YX_^/M_C5ZB@"C_8ME_SQ_\ 'V_QH_L6
MR_YX_P#C[?XU>HH H_V+9?\ /'_Q]O\ &C^Q;+_GC_X^W^-7J* */]BV7_/'
M_P ?;_&C^Q;+_GC_ ./M_C5ZB@"C_8ME_P \?_'V_P :/[%LO^>/_C[?XU>H
MH H_V+9?\\?_ !]O\:/[%LO^>/\ X^W^-7J* */]BV7_ #Q_\?;_ !H_L6R_
MYX_^/M_C5ZB@"C_8ME_SQ_\ 'V_QH_L6R_YX_P#C[?XU>HH H_V+9?\ /'_Q
M]O\ &C^Q;+_GC_X^W^-7J* */]BV7_/'_P ?;_&C^Q;+_GC_ ./M_C5ZB@"C
M_8ME_P \?_'V_P :/[%LO^>/_C[?XU>HH H_V+9?\\?_ !]O\:/[%LO^>/\
MX^W^-7J* */]BV7_ #Q_\?;_ !H_L6R_YX_^/M_C5ZB@"C_8ME_SQ_\ 'V_Q
MH_L6R_YX_P#C[?XU>HH H_V+9?\ /'_Q]O\ &C^Q;+_GC_X^W^-7J* */]BV
M7_/'_P ?;_&C^Q;+_GC_ ./M_C5ZB@"C_8ME_P \?_'V_P :/[%LO^>/_C[?
MXU>HH H_V+9?\\?_ !]O\:/[%LO^>/\ X^W^-7J* */]BV7_ #Q_\?;_ !H_
ML6R_YX_^/M_C5ZB@"C_8ME_SQ_\ 'V_QH_L6S_YX_P#C[?XU>HH H_V+9?\
M/'_Q]O\ &C^Q++_GC_X^W^-7J* ,G4?"NDZM:-:WVGP7ULW#0W2^:A_X"V17
MD/BC]C?X;ZY=F^TJPN_!VJC.V^\.W36K ^NT97]*]TI,5W8;'8K!N^'J./HW
M9^JV?S.6MA:&)5JT%+U1\TM\)_C?\.<MX9\<:=X^T]/NZ?XJA:.<CT$R'^9%
M,7]I.]\$L(?B;\+-?\+J.&U/3LW]D??<IR!^=?3)4&F.@*,I 8'@@\@UZ/\
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M']Y>OS#(&#D\5?\ $WQ0\+^$$A.J:O!"T\0FABCS*\B$X4JJ DAB0%]3P,T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCI5;7?\ D"WW_7!_Y&K]4-=_Y M]_P!<'_D: #0O^0+8_P#7!/Y"K]4-"_Y
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M)FD\[A+,JD;2JRG-^LI-OUWT\BE_9\O_ #_7'_CO_P 31_9\O_/]<?\ CO\
M\35VBOESN*7]GR_\_P!<?^.__$T?V?+_ ,_UQ_X[_P#$U=HH I?V?+_S_7'_
M ([_ /$T?V?+_P _UQ_X[_\ $U=HH I?V?+_ ,_UQ_X[_P#$T?V?+_S_ %Q_
MX[_\35VB@"E_9\O_ #_7'_CO_P 31_9\O_/]<?\ CO\ \35VB@"E_9\O_/\
M7'_CO_Q-']GR_P#/]<?^._\ Q-7:* *7]GR_\_UQ_P"._P#Q-']GR_\ /]<?
M^.__ !-7:* *7]GR_P#/]<?^._\ Q-']GR_\_P!<?^.__$U=HH I?V?+_P _
MUQ_X[_\ $T?V?+_S_7'_ ([_ /$U=HH I?V?+_S_ %Q_X[_\31_9\O\ S_7'
M_CO_ ,35VB@"E_9\O_/]<?\ CO\ \31_9\O_ #_7'_CO_P 35VB@"E_9\O\
MS_7'_CO_ ,31_9\O_/\ 7'_CO_Q-7:* *7]GR_\ /]<?^.__ !-']GR_\_UQ
M_P"._P#Q-7:* *7]GR_\_P!<?^.__$T?V?+_ ,_UQ_X[_P#$U=HH I?V?+_S
M_7'_ ([_ /$T?V?+_P _UQ_X[_\ $U=HH I?V?+_ ,_UQ_X[_P#$T?V?+_S_
M %Q_X[_\35VB@"E_9\O_ #_7'_CO_P 31_9\O_/]<?\ CO\ \35VB@"E_9\O
M_/\ 7'_CO_Q-']GR_P#/]<?^._\ Q-7:* *7]GR_\_UQ_P"._P#Q-']GR_\
M/]<?^.__ !-7:* *7]GR_P#/]<?^._\ Q-']GR_\_P!<?^.__$U=HH I?V?+
M_P _UQ_X[_\ $T?V?+_S_7'_ ([_ /$U=HH I?V?+_S_ %Q_X[_\31_9\O\
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M:E$52Q<@8W'J:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:-^M_P#/'3_^_P __P 36K10!E;];_YXZ?\ ]_G_ /B:-^M_\\=/_P"_S_\
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M_P#Q-&_6_P#GCI__ '^?_P")K5HH RM^M_\ /'3_ /O\_P#\31OUO_GCI_\
MW^?_ .)K5I,T 9>_6_\ GCI__?Y__B:-^M_\\=/_ ._S_P#Q-:M% &5OUO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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*[^QKRFG+0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_020.jpg
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( /$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!#TXZTT,,[>_I0Y"J68[0.IJD+J![6,
MRS ^8VQ7A+'/S<<B@#0HJ-7W$#&TXR5/6I* "BBB@ HHHH **** "DI:* "B
MBFM@#).,4 (& (4D!CV]:=BJ(NH7M'>292C.R!H221SCMR#5I'R%!RIY^5NI
M% $M%%% !1110 4444 %%%% !1110 4444 %%%% !2$XQ2U%*P"X.1[T 5YK
MED_A!!8]^=M9EIJ6GWL!@4R6MQ,AE:&;,4H']X@88#H,^U.OD>>[2%A%]G;(
M,4@#>:V RD>X*FL'Q3%#^[F^RS7+S(T BA1-S*>IPPXXR,Y_ U&QO&">C.UC
MDC=R@(:1 "<]<'H?YU/7/>%;@3V+;9%81MY6T!<QE2?D)4 ''3C\S70U2=U<
MRE'E=@HHHIDA1110 4444 %%%% "'C!XJI/<M&&P%8;L#GKQ5B4J$.[.*QM1
M$DTL<'[O[,Y*RI*-WGJ5;Y1Z'./PS29<%<9;ZGITQ\IA+:W-P60).OE22 9R
M1WQWR/6MB%XR1"&WNB*<GDD'H?TKD_$L,"6\=X]O)*\3;%CB5=\F<C ##MG/
M6KG@^8/9M$&VB +&8"%)AX!VEE !.".E2I:V-)4UR\R9U%%%%68!17AFC_M
M^?XK33=7TRWM+!IVA>Z25B8^<!B#VSUKW(," 0<@]"* %HHKB/B3\0?^%?:5
M:7@TW[<US*8@OG>6%P,YSM- ';T5\]Z7^T!KFL^)=+TZ+1]/MX+N\BA<LSNP
M5G"G!R!GGTKWV[NK>QM);J[GC@MX5+R2R,%55'<F@">BO%O$/[1.B6,CP:'I
MT^HLIQY\C>3&?<<%C^0KBKC]H;QA<S$6EAI<*9X40R.V/?Y_Z4 ?3U%?,5K^
MT3XLMY,7FGZ7.O=?*>-OSW?TKO?#7[07A_59H[;6+2;2I6X\W=YL(/NP (_+
M ]: /8**BAFCN($FAD62)U#(Z'(8'H0:D)"C)Z4 (S!1D]*PM7U6:V>*%+)Y
MC,2H:.0#'&<_ESQ4^JW_ ),)\K)DS@E5W!1UY]*\^U/6Q>ZE"Z->)#'(SM()
M=IB. .OH?0]A]:SE-(Z*%&535&U=3ZCIR2MY$3HS/-YBD_>X^5>6/7GG'2N=
MO=5O9V#/=_99(8]\K*RR;2IXQP<9SD<=JIC4;O5KR5(XIXQ;VBSJ6E 23;\I
M9SR-I'M[\#FNM\)^'7 @O'D^:14EDEAD;#$#A5XVLOW@>N>.G6E#WM3?$TY4
M:;C>[9TWAJTDM-(02RS2F0[U:?\ UFT] W Y%;-(JA%"KT P*QO%?B6U\(^'
M+G6[V&::WMR@9(<;SN8+QD@=ZU//6QMT5Y?9_'WP/<@>;/?6I])K8G'_ 'P6
MKTFTNH;VTAN[=]\,R"2-L8RK#(/Y4#)Z*** "BO-=4^-WAC1/$-]HVH0:C%-
M9RF)Y5B5D8CTPV?TKJ?"WC70O&=M//HET\ZP,%E#Q,A4GD?>'MVH Z&FLP12
MS< 4I.!FLO4K_P B!RG,@("[5W8SW- )7=BOK.K2V'E;+%K@R/L38ZC)YXYX
MK!N9M1MC+*((W25@^<DE65#QU)W$!0>!Q6#KFM&]NXXXA=[5E\Q]L@5EVC!8
M'MG/2L\:C=:MJRV<)N1Y<,DBSB;B7:W5BN01D8Z'KFL7.[LCTJ.%DXWEHBU?
M:K>7*1K)/]GD5&+L'5]J[2P;:<X/R@=.M=]X3M98])%Q+///]H/F(UQ]\*0.
M.@P/;%<KX5\/2SR6]_(R,\J*SRP2MA &)VJ0,'!QWYR>*](1%C0*H^4=*N*Z
MG#6;=5NUEL/HI**LS/@S5?\ D+WO_7>3_P!"-?1_P-^(:ZQI2>&=3N0=1M%Q
M:ENLT('3/=E_ECT-?.&J?\A>]_Z^)/\ T(UM6^EZUX>TG2/&5C(R1/<,L4\?
M_+*5&^ZWU'Y\B@#[:KQ+]I/_ )%K1?\ K\;_ - KT;P)XPMO&WA:VU6$!)O]
M7<PY_P!7*.H^G<>Q%><_M)_\BSHO_7XW_H% 'A/@S_D>?#__ &$K?_T8M?17
M[0TLD?PXA5'95DU&)7 /WAL<X/KR ?PKYU\%_P#(\^'_ /L)6_\ Z,6OHC]H
MG_DG-K_V$HO_ $"2@#YBLP#>P*PR#(H(/UK[PM;2WLX%CMK>*",#A8D"C\A7
MPA9?\?UO_P!=5_G7WLOW1]* ,?7_  MHOB>QDM-7T^&X1Q@.RC>A]5;J#7Q=
MXDTAM \2ZEI+,6^R7+PACU8 \'\17W57QM\7%"_%37P/^>ZG\T6@#V/]G?79
M[_PKJ&DSRF3^SYU,0)^[&X/R_3<K?G7KMY,D-N7D+!1@9523^E> _LTD_P!H
M^(AGCR8./Q>O?-0LDU"RDM9&=5<=48J?S%)@>;:KK-U+-<V*301S2RKY6,@R
MKN4-O)SM&.3CTP*CB\,QW%P4>[2:)D($'D@QK\YPI?G<P]S^%;ALQX;NVGU#
MRQ:&( 7 #DALL2-O/ '\77GOTHFNH6@*Z?;[0MRNZ-5VGG.6;KQ@#KCZUDJ?
M,O>-WBYT[>S5D:MGH%K<VD,5Y$@$;A]L+F,$@Y&0I&1TZ_E70P0PV\$<-O&D
M<2*%1$& H]!7'P7<Z32PI,5<\HRG< ?3MD5O:=JWG2+;R LZC#O[_P ORJHV
M7ND2<IZLV*\]^-W_ "276/K#_P"CDKT*O/?C?_R276/]Z'_T:E:&9\AU]U>&
MACPMI ]+*'_T 5\*"ON[0!CPYI@]+2+_ - % &C1110!\7_%#'_"S?$./^?Q
MOZ5ZY^S5_P @?Q!_U\1?^@M7D?Q17;\3O$/_ %]L>OTKUS]FK_D$>(/^OB+_
M -!:@#VR[E6*W9W+ #NJDG]*\WUO7)UN[RWADB1K@*L$B@[Y&XX.[('7\*]'
MO;5+VSEMI"X21=I*,5/YBN-DTI]!NA>7.QK1%8O.0VY#E0O0G/N3Z=16<DVU
M8TIS4'=JYA1^&TEG DO5:-E?]PL647GHTG)).,@$CK75Z?X<M)]/%E=0H(5;
MD6[M%TQC.T@FLZYO+>2SN/[+B^;S(W C7!DR5^;H>,'/(]:FAN9HIVB29HS(
M/E93D(V.../;BI=-1?,/ZS5J7C([&VMX+6!8;:)(HESM2,8 YJ85B6.KL9$M
MI@7DSAGQC'],]/\ (K;!R.#6J=S-H6BBBF(^"]4_Y"][_P!?$G_H1KZ5^$NA
MV7B3X(_V3J$6^VN99E;U4[N&'N#@_A7S5JG_ "%[W_KXD_\ 0C7U/\!?^266
MG_7S-_Z%0!Y)X:U;4O@O\2;C2]4W-ILK!)R%XDBS\DRCU'_Q0KM_VBYXKGPG
MH,\$BR1273.CJ<AE*<$5T_QA\ 'QEX<^UV4>=7T]6> #_EJG\4?]1[_6OFN[
M\4WM[X.L_#5U\\-C<M-;N3RBLN"GTSS^)H B\&?\CUX?_P"PE;_^C%KZ(_:*
M_P"2<VO_ &$HO_1<E?._@S_D>O#_ /V$K?\ ]&+7T1^T5_R3FU_["47_ *+D
MH ^8(9/*GCEQG8P;'KBO>A^TP  /^$3_ /*C_P#:J\'M55[N!&&5:101^-?9
MG_"M/!+88^&--R1V@ H \L_X:9_ZE(_^#'_[57CGC#Q"/%7BN_UP6OV7[6X?
MR?,W[<*%^]@9Z>E?6P^&7@D?\RQIO_?D5\N?%"QM=-^)&M6=C;Q6UM%*H2*)
M0JJ-BG@#ZT >C?LT?\A+Q%_UQ@_]">OHFOG?]FG_ )"7B'_KC!_-Z^B* (;B
MWANH'AGC62-QM96Z$5RE_H$NF7CW6FV\<EO,1YT0'S=2<CD#OCIW.:["@B@3
MNU8\]C1U5RZ7$BH^6?S%9I!GE ,\?GV[5:U-%LK&+S6=KFY<+!$QW;&/11C/
M3FK?BC3([>.348IE0+\QA9B%=O7V/'I7&VFJW/B/4[EI)7!B2-42([A&?F!"
MYZG+8/3\>T&D%*1WWA74)+JP\F9)%$3LD1D?<S(O +=\_P#UJY_XVC/PFUCZ
MP_\ HU*VM$ ?6':&"6""*+R@"R[7QC[J\D <>GWJS_B_"9_A3KR#M$C_ /?,
MB-_2K(M8^.*^[= .[PYI;>MI$?\ QP5\)8K[F\)2B;P;H<H.0UA V?\ MFM
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MW3JIS][<.N:Z4  8 P/05M%&#G<6BBBK("BBB@ HHHH **** "BBB@ HHHH
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>formdrsa_020.jpg
<TEXT>
begin 644 formdrsa_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BC(IBS1
M/G;*C8X.&!H ?11D4F10 M%(651EB !W-!=00"P!/3/>@!:*,TUI$1=SLJCU
M)Q0 ZBD# XP0<\T9% "T49IAFB&<R(,'!^8<4 /HHS29% "T4FY22 1D=?:C
M(H 6BC--9U499@![F@!U%-WJ6*AAN'49Y%+D>M "T49HS0 44UG5!EF"C.,D
MXIV10 449HS0 449I-PSC//I0 M%&:9YT6_9YB;_ .[N&: 'T4@8$ @Y!Z4%
ME52S$ #N: %HIJNKJ&5@RGH0<@T,Z* 68*"<#)Q0 ZBDR/6D\Q"6 =25Z\]*
M '44@(/0YI<T %%(74$ L 3T!/6ES0 44F0>]&1ZT +129%&10 M%)D#O1D4
M +137DCC&7=5'JQQ2A@P!!!!Z$4 +11FDR!0 M%)N&,Y%+0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -?&QLC(QT]:X'3;"]T7
M0;6XAMI(IGNB9E-JH:*(%S\WJ <'/6O0,4A4'(/0T@/.+#4/$D]HEQ#/?73.
M[!HT5#Y9RA7G &"-_P">*TM-/BE[_3FNI[I+=GD>8/;J<_.0$."-B[<$'GO7
M91010)LAC2-<YVHH _2GXI@96I1SSZ9J<5U;)/;O&5CCARSR CD$>OTKD/L&
MO0R:85LYYIK""XAM)'.0<H-COSPV/EY[@^M>B8HQ2 \]NKKQ?;QVRV_]H3M]
MFDWS&V4 L0VWY.<," .35V\BU.^\'SP7=I<75RMXHB$\ +,@93N*@C(ZUVN*
M,4P//+O3M8T"WFM])BO[F=;:-4N(U&TMO=MN#G"C(&!SCO4MW=^+7W^4E\B^
M86!CMUSCRR0N#T&_;SWSVKOL48H X2"^\4"\T^-K;4'C%X1,[QJ%:$XSN [C
M)QTX'>KTVG,-9U.!M+=TO9X9TG"@Q_*!DL<\$8/'?-=;BC;0!P=C<>*'BV7A
MU(*SJTDBVZ!UY;A1T(X7/UI;N;Q:99 GVV-3/ME$<*-A<M@QG^Z5VY/K7=XH
MQ0!Y]]O\13V<D]I]HDE#^7(D,2!@_DK@'MP^03GO4/\ :WB&YCU5K66\FN P
M6"*%4PA!/S=#QT!')ZFNCOM1N+#QIHVDV[1)9WT%P\D8C (=-I# ^^[FL[P]
MXAN7\/Q7TUO#+<SZF]I)+#&$&T2E S8[X'YFA 5;/_A+5N(AYEXBM/)*_G1!
MPQ(&V,\_*F,\]C4VG65Y-H?B#^U-/O9C=E6\N4#>YV ,$ / !'!_&NYQFC%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0Z[@/F4]QBM.M4T]4<$X2A)QDK-"T444R HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBV. W^\O1JHCQ'K7AUA%XEL?/M<X&HV:EEQZNG44<[C\:']6A5UP[N_Y7O\
M+H_EKY':4HZ53L-2LM4M4N;&YCN(6&0T;9JWD5HG?8XG%Q=FK,6BBBF(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+:1_I?B<#['5JH4!1P , 4ZDI:P&%%%% !1110 4444 %%%% !1110 4444
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M&.@KOC6G##RIQ>DGK\O^'/,MK<FI:**Y2@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 )BHIK2WN!B:"*0?[: U-1
M33:V QIO"NC2Y(LUB8_Q1,4/3':H6\-R1'-EK%];C^Z7WC]?K6_16BKU%U_7
M\Q61@"W\26_W+ZSN@.TL10GIW'X_I2-JNN6W_'QHGG#NUM,&]>Q_SS6_BBCV
MJ?Q13_#\@L<^_B+39%\O4+*YASP1/;$C\_\ /6LJ30O ^K-O@^S0S'D/;RF%
MLGZ8]17:D CGFJ5SH^FW8Q/8P/[E!G\Z35&7Q1_7\S:G7JTG>G)KYG-)X5U>
MR0-HOBJZV?PQW8$R?GUI?[2\:Z8/]+TBSU*,=7M)=C'_ ("U:K^%=.R3;FYM
M6/>"9EQU[?C33HVJ0'-IKLV,_=N$#CJ._P"?YU'L*?V)M??_ ,$W^NRE_%@I
M?*S^]6*"?$+386":I9W^FR9Q_I$!V_\ ?0XK>L==TK4E#66H6TX/9) 3^59K
M#Q&D92>VT^^3'/)0G\#Q6%J&D:3</NU#PC-!)G_76>,@\\_+CT'YT_8U?LM2
M^8<^%GO&4?35?C9_B=]FC->:Q6\-H0=)\6ZC8$=(+]#(OT^8>X[UHV^M>++?
MI'I.LQ 9W6LXC<_@>*B2J0^.#0_JT)?PZB?K[K_'3\3N<TM<@OCZUMSMU?2]
M1TUN[20ET_[Z6MK3_$>C:H/]"U*VF/\ =#C/Y=:E3B]$S.IA*]-7E%V[[K[U
M=&IFEIH8'H<CVIU6<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 13SQVUO)/,X2*)"[L>P R37!^(_'&CR>&5U(N\2
M6]Y 625!YF#AU91GG*D$<]/2N[NK:*\M)[689BFC:-P.X(P:X?4_A;INH>&+
MK2WGD>YD9'BN2 "C(FQ!@=MH /KS6E%4W42JM\O6PUIJ>/WGQ!F.IW4ND12O
M<WTJHYW'+Q 8V#OEC^7:OI+245-*M0MJ;7]TI,!QE"1R#CO7#Z!\)M.\-R/=
MZ9?SQWYC"B:6-) C=R 1QS752:3J1A81^(+I9-ORL88R ?7&*[\;5P?)&C@X
MM15VV]VWW+JUJE:;J5/33HD;5%8DFDZFT+"+Q!=))CAVAC(!]<8HETG4VB81
M>(+I).S-#&0/PQ7F&9MT5A76E:M]FD^RZ[<"?'R>9''MS[_+3YM)U,QD0Z_=
M(_&&:&-A[\8H VJ*Q9=)U)H_W7B"Z1LCEH8VXSSQM]*)=)U-H\1:_=(^1AFA
MC88SSQCTH VJ*Q9=)U(H/*\072-N!),,9XSR/NTRXTK5MJ?9]=N0WF+OWQ1_
M<S\V/EZXH W:*Q9=)U,J/+U^Z4[@23#&<C/(Z42:3J9V^7X@NEPP+9AC.5[C
MIP?>@#:HK%?2-3)3R_$%TH#9?,,9ROH../K1)I&IG9Y?B"Z7# MF&,Y7N.G'
MUH VJ*PI]*U;?#Y&NW&WS/WNZ./.S!Z?+USBGOI.I;XRGB"Z50?G!AC.X8[?
M+QSB@#:HK%?2=2+1E/$%TJALN##&=PQT'''.*1])U,O&4\072H"=X,,9+#'8
MXXH VZ*Q6TG4O-C*^(+H(,[U,,9+<<8..*9+I6K>?!Y6NW'DY/F[HH\D8XQ\
MOK0!NT5BMI.I^;&5\070C&=ZF&/+>F#MXH.DZEYJ$:_=", [E\F/)/;G;QWH
M VJ*Q6TG4C*A7Q!=", [E,,9)/;!QQ0=)U/SE(\077EA3N7R8\D]CG'% &U1
M6&=*U;[6I&O7'V;RSN'E1[M^1C^'IC-..DZGYP(\070CVD%?)CR3V.<4 ;5%
M8O\ 9.I^>&_X2"Z\K;C9Y,>=V>N<?I1_9.I>=G^W[KR]OW?)CSG/7.W]* -J
MBL7^R=3\[/\ ;]UY6W&WR8\Y]<X_2F#2M6^V-G7;C[-Y8Q^[CW;\G/\ #TQB
M@#=HK%&DZD)6)U^Z,9 VKY,>0>YSM^E TG4Q,S'Q!=>5M&U?)CR#W.<4 ;5%
M8JZ3J?FN3X@NC&0-J^3'D'OSCFA=)U+S7+:_=%#C8HACR/7)QS0!M45A1Z3J
M_P!JFWZ[<?9\+Y0$4>[/\6?E^E/72=3$DA;Q!=%#C8HAC!7UR=O- &U16*ND
MZD'D+Z_=%21L AC&T8[G'/-"Z3J0DD+>(+HH2-@$,8*C'.3CF@#:HK%32-3#
MR%_$%TRD_(!#&-HQT)QS3(=*U??-Y^O7!7?^ZV11\)@=?EZYS0!NT5BII.I
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MK+!-.'EC61&TQ@-I5&8^V#N'M6B^J^)VN(!#YS.QF:6!K$@(RJ2J!SQ@GO\
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MC:1T'UK?HH 04M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>formdrsa_021.jpg
<TEXT>
begin 644 formdrsa_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'E R # 2(  A$! Q$!_\0
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MB]\!^-?".@>'/%+7>K1^,AJZ6MEX?L;6XUNUU*UETZ[B6]*VYX[]GK_@J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC?[#/+*P_P",JO@?D;6R!_R._P#=  ]  !P!1)R=URIIWOK;?<9^84/_  3
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M1X@\/7'[4_[5WC0?"^7QGY*>)OA;^T3\"/V;OAKH?C"?4Y]*;3++QQX0\3?
M/4[6Z\)7UA>6ESX4\>WWV+Q#'?VMQ:W/ ?#G_@G=^T!\#7_8P\1> %^'/B7Q
MC^R?HV@_";Q-=ZMXGU+3;#XL_ SXI^)O$.O_ !)\)VCR:7>3>'/^&09M7TK_
M (9!&IQZO+:Z=I?B/3))/#UGXUOK:T^U3_P5>_X)<J1M_P""C/[#6TC '_#5
M/P0PHP0-H'C8@D+\H!QA0 .*D_X>P_\ !+<\'_@HO^PSZ_\ )U/P0]2>_C8=
MR3[$Y%-/9KY=0LM=-U=^G?T/S8^(W_!+[]I'Q;^RYH/P5^W?#G4_'OP7_9-_
M;Q_9B\-^.[K7IK/_ (:2/[45E%X;^'?C/XEW?]E7>H^'+G3[**/XG?%--4;Q
M)<ZQ\56U.^T&21;@:W)Z-X^_8E_:@T_]H3QS\;O"WPV^'WCWP!KGQXN?$6J?
M FV^.GB7X/S?$'X=>.OV2OAS\$/$.N?\)7X5TB#2]&\8^!/&7@=YD\-:[9:O
MH_C?P-JVH*-4T;6+>P8?;P_X*P?\$N01N_X*-?L+X (P/VJ?@>"!V _XKC\_
MZD A_P#P]A_X);?])&?V&>/^KJO@=W&/^AW]./8<4TVFVMWO_7^0WJDGM';^
MNOS//?VKOV3?B#XG_8>^"O[-OP \#^ ++4?A+\3?V,]=TCP2/&FJ^&O!'AOP
M)^S+\8_AE\2KWPIX=\2:_IGB?7=0CA\._#M/!OAN76K>6\N)[FVU75[A!!<6
M\O._M,_#K]L_XY>(OA9X[TKX->![30?@3\3;+Q GP1E_:2U_PU>?'/PSXW\#
M>)_!_C+7;GXB^"O#VE6WP]\0_#*?6--O/!6E7UKXET[QAI]UXNM]3N]'GNM+
M">R?\/8O^"6__21K]AGCI_QE7\#O?_J=_<X^M(/^"L/_  2WYS_P4:_8:/)(
MS^U5\#N/8?\ %;]NQZU$;WE)IIS>W;E5D_*Z0)6272-[?-MOUU;W/)_!G_!/
M\^"/BI^SCXN^'VA_#SX3_"[P]\ -)^"'QZ^#FB/K?B73KOP[\&/$D'Q"_91T
MCP9KNKO+JFHWWP<\;:AK=G<^(=<N)7O/#UO#INC6VDV%Q%:)\>Z'_P $[/VD
M+C]ES_A6?BGX1?"F;]HWX<:5^R9\&;/]H.3X_P#C_P 4W/[0WPP_9I_:P^%O
MQON/&-UHOBRQU6U^$LGB[1? .N^+=0\%-;:]<6GQ,\57=CI^K1>'89+JX_1K
M_A[#_P $M<Y_X>,_L,YX/_)U7P.[8Q_S/'; P.@[4O\ P]A_X);=/^'C/[#/
M'3_C*OX'\8Z8_P"*X[=O3GU-6I-;=-?U_0"I\ /V=OB_\*?VH_C)\18-<70_
M@-\5)/'7B/4_A-JWB&T\?VVB_%G6?&VG2V7C[X.ZY<:9I_BCX:>%_'WA;2Y/
M$'Q2^$]_?ZSX/C^)%X^M^$;>PN)M6N-3_0V,8C0>BC@#&..F,#&.F.HZ')YK
M\^O^'L'_  2X)8G_ (*-_L,')!&/VJO@>.,C<#_Q6_=0!U.:E_X>R?\ !+C_
M *2-_L-?^)5_ [_YN*3DI2NU9OKJK^6K?](F,>56OIV_X/Z?\,OT#HK\_/\
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M ,/9/^"7/_21K]AG_P 2L^!__P VU+_P]D_X)<?])&_V&O\ Q*OX'?\ S<4
M?H'17Y^?\/9/^"7'_21O]AK_ ,2K^!W_ ,W%'_#V3_@EQ_TD;_8:_P#$J_@=
M_P#-Q0!^@=%?GY_P]D_X)<?])&_V&O\ Q*OX'?\ S<4?\/9/^"7'_21O]AK_
M ,2K^!W_ ,W% 'Z!T5^?G_#V3_@EQ_TD;_8:_P#$J_@=_P#-Q1_P]D_X)<?]
M)&_V&O\ Q*OX'?\ S<4 ?H'17Y^?\/9/^"7'_21O]AK_ ,2K^!W_ ,W%'_#V
M3_@EQ_TD;_8:_P#$J_@=_P#-Q0!^@=%?GY_P]D_X)<?])&_V&O\ Q*OX'?\
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MB=J$&G:\_P"SGXXT.R\%7MO!!::)X2N+3PDNN6@T>QT^V'HK@]+>?^=C]R_
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M/'_A3]ISQ!X5M+_QO9'1_#</A+Q!::%\2[)-,T^3QA8W-OY.B^*I=/CN;?\
M>.,C'5>7?&#S@,<#!P<A<9!SCZ8I)W5RGH[?UT_S,W^PM$X_XDVE<_\ 4.M.
MF#_TQ]<?G7C>C?%SX(>(?C/X[_9[TC7/"5U\8?AGX,\$_$'QQX#73D36-$\&
M?$6\U_3O!^O/YEFMM<6>K7WAG6+;%M-/):2VL:W:0B^LR_L.MZA-I>F:EJ$6
MG7VL3:?87U_!H^E);OJNJR6=K-<1Z;IJ75Q:VCWU^T:V=HMU=VD#3S*)KB"/
M=*OX=7WP2_:V\#_'#]C7]NW0_#/B;QOXQ\7_ !-\8>%OVE_V?]%^'?@OPO\
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M^T(RV=GL=G8JBHYA"LSD$(JEF+*RXR.?YLI?V5OVN/$GA.T\3^./@[\9-?\
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M(/\ 9:^&'[26E0?LX?#7]K;]F_\ :+^(VD:E^S%^R%#X*\?P_$.QDU;]GO\
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M)M4G,3SFS6T47$GO8TG0V",ND:.Z/C#"PL2AW/L0*XCV,[/P$5F()P,G /\
M.G\5?@/^WQ/\6?%WQG\(?!?7]*^./Q$_X)T7L_Q.UOP#XK\)P>&)_CAKW[3O
MPP^*WCS]EWP'X_US6/MZ>(;?X#^%?$'P2^&?CZ[\(Z=X2;6H]*\6:O>Z7J&K
M:M.EC]H+X)_&'5?V>?$WAS]FW]E_]KRWN/CIX7_;>\2^&(/BEXH\&Z?KO[/7
MQ>\:?L]:)HGP^TK1?@OX.\;^%OA[\/-&\=?$+2&U+X>^,!JVO'X/_$:V\0>-
M-$TS2;SXE7^JQT_+\]/O)3;;OI:6G6\-/3UM_P $_HG&D:)N5?[%T<%LE5%A
M:!B%($F$, <F,L ^$^4E=WWN)GT/1%&1HVDGE1@Z?:#@L 3GR>P)_P \'\ O
M!OP!_:/U']I'P/\ '>]^"OQETC4'_P""@OP0\>3>(/$.OZ$FN:#^SSK_ .P%
M?_#WXL_;-,C^(FH6^D^##\9Y-#L/B'X.TJW/]J>+M,A\2PZ#K4VE6>LP_P!"
M+DJ <$\C@8!)R,8+8'7@Y(X)/:FTU:]M>SN4FG>U].ZL?%_C7]KKX!>#O$'Q
M?T&T\.>+OB"/V>M/74/CYK'PN^&%]XZT7X1R2>';3QA%H7B.;28?M^M>,/\
MA$;VT\3W/@CP)I_B[QAINB7NF7NK:)8)K&C?VE]0:%)X3\2Z+H_B#1]-TBZT
MO7M(T[7=,F;3;6&2?3-4M(KZSG,+P^:OF03Q%@RCRG9HVRZ,!^6'[''@WXN_
ML4^+/VO/@]XV^"_Q2^*&B?%?]K[XR_M/?"/XR?#^T\.Z_P"'?'/A/X]3Z)XB
MD\(^.)M1\2Z3J?@CQS\,]<@UGP1<P:Y9R:)J'@G0_"^M:-K-Y)=W>CZ;YI%^
MS]^UAJ/Q:TZ]U#1/$&F_$3P=_P %$]6^+'_"X--U:UC\(>)OV"->^%.H:>?@
MI9/;7=LMYI>G6S:'\+&^%%Q8VUG:>.M&M/BS81I)--JQ2U5_ZWL/_@G[/ZD/
M".C6DM_J]OX8TFP@DMH)K[4TTNPLX9[ZY@LK&*>ZN1'!#)?7MU;6=G'+(CW=
MQ<P16XDEE1#H'2=$7[VBZ0IV&0AK"S1@@'S$JT7"KQN=B(P6 +Y!)_E6A_8C
M_:A@_9\\ ^&]2_9S^*^J7MU^QQ^PQ-\<O#.JZYX<\1ZMXV^,'[//_!1#X;?%
M'Q5HVM6^I_$C54\9?%/P[\!=$\77V@7MQJ$T%]X9EM/".G>*(I9K71++[2\1
M? SXF:-K7[6OQ9N/V5/B]\0?%_BS]OKX:_\ "L+AO%]U)>Z)^RSKG@#]FY/$
M_B?P[\/+/XL:5I/C3X;^%/B7X(\6W_B/X'ZE?>$-/\17J2ZUJFGWVA#[/>-)
M=79>E_\ +^NXK[:;MK[K?G?_ ()^ZS:3HJE1_8NCDL?E'V&T!D #$E-T() 5
M&<D*PVA0,ABZ4=+3PGKEE;:IHUOX<U;2[T,]EJ6F1:5J&GW:(\L;O;7MH)K:
M=$>":-C%*Y5UP>591^#7[+_P0_;&\*WG[)NK^)_!OCO6-0\"ZMXX^$OQ>^'O
MQWT70)-%T_X;R?&SX^W/@;XY?!;XF>%_&FN:AX#\9^!?AUK'A70=8^'6JZ=>
M>!/BC\//$GA?18+73_$G@^SU2S_0C_@EU\,?$?P5_8"_9;^#_C/X:ZK\)_&7
MPO\ AAIG@3QCX)UJUT>RN[3Q-X:N[K1]?U>$:#J6KZ;?:3K^HVD^N:)K"7GF
M:OI5]9W\]M82W3VD,V]USZQUC'K)--7OI;[F2YV=DF];/R?W=-_Z5_;_ (]?
M'KX-_LX6GPWNOB3I.H*?BW\3-#^#OP_MO#7@E_$MYKWQ*\46NH7WAGPJEMI\
M)>TN];M-(U::SN[SR-+0:9=+>7UHWD+/T7P<^+OP4^/>@^(/$7PON](UZS\'
M^-O$OPU\;6%WX;NO#WB#P-\1/!\EI'XG\$>,?#OB'3=,UKP_XBT4WME-<65_
M91K=V&H:7J^G2W>D:II]]=?%O_!3KX1_%7XR:3^Q9HOPH\,?$G5+GP;^WC\%
M_B=XV\7_  O;P.GB3X6> /"WACXC:/K/Q%MF\?R3:)--X>OO$^CW$%@FA>*+
MC4(Q=Q#0KV%9DKXC\'_ G]H3X;?"W0O@!XU_92\>^./' _;%^*&L_&W]J+PG
MXGMO&/A+]H&]^(/P=\4Z9I'[:'B?X0:O\3-!TW7]7^(K3>&O!7Q$^$7B40?#
M?]GKQU:-X@^&7A*X\*>$?AU8V3LN5-63E)W3UMRJ/YW\K,M:NWDW>^G73IY(
M_<WQMXO\!^!=,U+4;[0FUZZTB\\)6FH^&O!/A:3QGXQM8_&GBC3?"FCZE)X3
M\/VM[KBZ/#>ZC_:&JZJUD+/3-!L-6UNYE6PTJ^DA[PZ3HBLZG1]&!12^/L%I
MN$>X@2%3$&V# W/MV AL,P&:_F4\(?L]?MEVGP:\>^(]3^!7Q\A_:+^(G['G
M_!''2;_QE9^(?#]C\2]5\;?LV_$S1[7]JGP;XE\>6OQ'T^_?Q5]@BU+7M<L;
MS7)-&\?>%;B=KC4-9:]N-(?[4LO@/^UAJ'QUT'6M0LO$^G?$/P7_ ,%*/$WQ
M:O\ X[#4_)\*>-?V"?$OPYU6WM?A3&D-_*YL;.UG\(_#B7X5W6GQPV'CKPF_
MQ5MX_MES=:M>TU9O797_ *U_KL0I/K&VK6]]OE_7<_4#XD?%GX)?".'7KKXA
MZQX4\,VGA7X?>+?BQXJN;RQBEC\+_#/P1;-<^)/''B$6MK.^E>'K/RY+>WO)
MD+ZI>J]AI<%Y>PW%O#Q_@S]H#X4>._&'A;P)HO@KQ?;^*?$VBZSXBFTS6?AG
M>:.?"FB:3INB:I#J/B^[O8DL=)CUJW\2Z%%HL$%U?7LVHZ@VD:A:Z;J=EJ%M
M:?.4'P@LO$?[9W[:/A/XY:$GBKX5_M3?LW_ 3P]X%T34FN#I6O\ A7X>V?Q<
M\.?&GP-I^I03VEQ9ZJE_XW\-^(+FQTJ_MM2:UU.UUU6M18Q7HI?"?P7^TQI7
M[1[>)]5T"]\*?#CQ9\/?#^N61<:3XAUB#4V\9:Y:O\//B?X@OY[N]TE?"7PW
MBM?$UW:>&(H5\1?%7QY>1'7;_P +_#O0[..$TVE:]Z<IIWV:=ETU77=7V&V]
M;:<LHQ?G?5_Y?,^^/!>N>!/'^AP^(?#%MHNH::UWJFG7)73+:*ZT_5M%O9],
MUC1M2LY(O/L=5TC4K6XL=1LIPLL%Q$P&Z(QRR\]\3_B)\+?A!IOAW4/&T6D6
M<GC/QEX?^'/@G1K33+*ZU[QK\0/%/VIM!\'>&M-Q&;W6M0@L=0O]LLT%G8:1
MIFK:SJEW9:3IE]>P?-_[%N@^*+;QE^VWX^OI9F^'OQ<_:_UCQI\(/-B @U3P
MEI'P2^"?PYU_Q3I4LCF9]%U_X@^"?%L6GLT,=M>1:5+KNFM<Z?K5M>3=_P#M
M?_!/1OC-X"\%:C*OQ*M_&OP/^+7@OX]_"#5/A.F@W7B_2OB=X)M]<TG36&D>
M+98?"7B#0-;\.>)_$GA+Q5H?B&>WL;[PUXAU(6UYI>J0Z=JU@N9)J+NWRIMI
M.VM_\AK>7:^GDK+2_4Y2\_;9_91M=#BUZ+6[35$M=$^+_B?Q;HND^$I-0\2_
M#GPS^SUXF?P;\>/$'Q"T*&!;WPWIWPJ\4PSZ%KVY;N\U;4(98_!UGXGC6.2?
MIM8_:N_9IT;6/%&EMJ5GK-CX'\*>'O&'C7Q1X4\(W?BOPEX8TOQCX5U#QWX0
M74]:T"ROU\_Q/X'TK4/%^FM:V]U8P>'8K;4M6OM-CU71EU'\G/AI^Q=^TO\
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MIXI\.?"+XAZ;^RIXS_:L_90\8:E\&+O4K71[#PAI7A_]FK]J/P=^T7XM\4^
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M"ZAGU3Q'J%_K\^@>'O%OB#6-(TS4=5N/$>IV%[I6G)JEUK!^V)NROUO9+O\
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M=> ?#?PM\!:#J&K:[JFKB^77]0%EHWAZ*XU"]C6/H/VAOV>]>_;)_93^-WP
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M%,84444 %%%% ##&K$DC.>O)P> ,_48&/0\C!)-,,,>=V  .3C@D@ !B1SD
M=<YZ8(Q4U)SD=,<Y]?;% $0AC(X7 /(QA<9!Y& -K<G++AB>I.!@^SP@$!
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M0_QH =13=Z?WE_[Z'^-&]/[R_P#?0_QH 4@'!(SCI[9X/Z<?3(I-B9!VKE0
MIP,@#H![#)P.V3BC>G]Y?^^A_C1O3^\O_?0_QH -B^@[_KG)^O)YZT;5Z[1G
MCG'/&,$^I&!R:-Z?WE_[Z'^-&]/[R_\ ?0_QH 3RT_NKW &!@9!!P.@R"0<=
M<GU-."@8P ,9Q^.,_P A2;T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\
M&C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G
M]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^
M^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C
M0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZB
MF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_
MO+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_W
MT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\ &C>G]Y?^^A_C0 ZBF[T_O+_WT/\
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MT_O+_P!]#_&C>G]Y?^^A_C0 ZBF[T_O+_P!]#_&C>G]Y?^^A_C0 ZBCKTHH
M**** "BBB@ HHHH 1MV#MQGMGO[=1UKXU_;)^+_[5WP<\!^&_$'[)/[)UI^U
MWXUU+Q7'I7B'P1>_&3PM\%E\.^&WT^ZN'\2)X@\5V5]9:IMO(H+ Z=!&MP!<
M>;\R1L#]E'/8X_#-0NIR2""R\D D$MU VCY<D #<<X!;M2;LF^P'X2']NO\
MX+6D_P#*$C1![_\ #?7P9_IX;'3^M(?VZO\ @M;_ -(2-$/_ '?W\&?Z^'17
MZ\:W^T'\&/"WPK\5_&_6OB3X7M?A!X(N?%MKXM^(:7K7WAGPW<> /%&J>"O'
M*:SJ&GQW0LE\(^*M#UG0_$4LT<4.D7VE7\=\]NMK-(M]/C7\,CKGPO\ #9\6
M6R:]\:])U;7OA?IC:;K4=SXST?0](M/$&LW^E^;IZ)!!I>CZA9:C>'47LWM[
M6]M))(L7,/GKF6JWLTG_ -O6:_/7]0/QX_X;J_X+6_\ 2$C1/_$^_@U_3PY1
M_P -U?\ !:W_ *0D:)_XGW\&O_F<K]/O#/[:/[,/C'7O!OAOPQ\9?"VLWWQ&
M\4ZIX'^&^HVD.M#PK\2?%^B:;KVKZOX>^'GCB?2HO!?CO4M.TSPOXDO;N#PE
MK^KO'#H.L9 ;3KI(_J-&W#/H2/J1P2/;.:H/ZOW/P>_X;J_X+6_](2-$_P#$
M^_@U_P#,Y1_PW5_P6M_Z0D:)_P")]_!K_P"9ROWCHH _!S_ANK_@M;_TA(T3
M_P 3[^#7_P SE'_#=7_!:W_I"1HG_B??P:_^9ROWCHH _!S_ (;J_P""UO\
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M\=% 'X.?\-U?\%K?^D)&B?\ B??P:_\ F<H_X;J_X+6_](2-$_\ $^_@U_\
M,Y7[8:GX^\'Z'XJ\)^"=;\5:#I7BWQVNOMX+\-7^HVMKK7BO_A%;&UU/Q*-!
ML)I$N-2?0M/OK.^U%+59'M[*<7,B>2/./7I(&SD]SC /W< @\9SUY(X].,4
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M7[QT4 ?@Y_PW5_P6M_Z0D:)_XGW\&O\ YG*/^&ZO^"UO_2$C1/\ Q/OX-?\
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MX?T[PIX8\3>,[#P=H7B#X7?%/XG:#J%AXID\+>*/"VL:_HNHBYEFTJX_I=W
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ME^)FO^%=.$'BOX9?#S6=:U3P%XE^'/B_5M+'BF_/@SQEHVH3:S;_ -@?IRQ
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MI]MK7QCTO]C>5KGX^_"CQ?-IFL?%74S\"[/PSJVJ>,K'4/!+-^R7_!-KPO\
M%?P5X,^//AGXOW4_C_Q%:?M$:[>V7[3.I>#F^'/B+]JK2;WP/X"73_BCXN\
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MIA@4'*\$L"_JP'8D<GJ3@\$LQ(R22]%*@@\Y8G^0![]<9]LU3BFTWNOEUO\
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M,GC/&['.,\;WQ[NQ_B.0Q#YOF?YL?Q'CDD]^C9P1TP .@IO5)/9.ZTMK^O\
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MLC6'BKQ=X2LK[2+)O'F@^$->\':QXRN+CP^NJI>-\+-971SJ6K6VG6UWQ(^
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M6TM-?CET&PTJWTZSD[;Q5-\7_B?^R?\ M6?LS?$_XG_%R#Q[\3?$?[3WA/\
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M<9^5?NBQ421",\'CGC'=CN8DYY)/)]223DDFI:H25DEV"BBB@84444 %%%%
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M M%%% "*H7..Y)_$TC+GO_"R_P#?6.?PQ2Y&<?KVSZ?7VI: $ P /0 ?E2T
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MY?2VWAVXUGP_;WMQ<6MI+90O-J<26KW'VLI,T"1-X-\<?^">NB?&C4/CWO\
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MBCP5<2Z#XH_;\7XO:EK^D^+M%^T>#OV>_P!FK]F;Q5\-/V?-%N;&&[M+H/\
M$SXC_$+Q]XD\1VT$M_/;:2VC:)JMEMED5_HS]D?]BNWT#X#O=_M,^'UUGX\?
M%R3QYXM^*VGR^+=2\3Z)\/T^(GQP\5?'[PS\*?"OG7]]X<&F_!+7/$.E:)X?
MUG3[.[C;5?"\5_I]Y<Z6-.MH22:6MM5)V\DW;[U9M;_*PDTU='W'\*OBGX4^
M,?@O3/'O@N;5I=%U.,JG]NZ#JWAV]@NDMK::XM)K/5K2U^T/9M<K;2WVERZA
MH\US'/%8ZI?+;M-7H9R P,@W!ER2&Y4MA7;YE.XE=H.Y,[1M8*@(_![]J?\
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MUC^Q7^T3\7OBE_P4XU?P?\'_ !_=Z]^T*/V4!^ROXF_X6WHOAGX-W/CCX&>
M;RP?Q;^T'\-]0U[4/!WQ ^%_A7Q[+I&L:S\//B7\.O'+?$GPQI$^AZ/I^G:D
MVCW-GF[J>[:>OWW&E92_K=_H?T5PS1RJC1,LB2HLR2(0\<D;@,DB.I*LCJ0R
ME3@@Y%/9U0\YSCK@XQGIZ=JR="34TTC24UJXM+K68M-L8M7N--MYK/3;G5([
M2*/4+C3[2=Y);:PFNUEELX99))(H&BC>1V&XZC#<X4XP%W\Y.><8X(X[U?5K
MM;\5<1X7\4?VAOAE\)/'OP-^&OB_5=0@\9?M$?$"_P#AQ\,],TS1M0U=;KQ!
MI?@?Q?\ $2]N]>N[.)[7P]H4'A_P3K4,>L:I)':7&L/8Z/:F2\N0J>8?"?\
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MPKX;\;?#?PO;S13:G:G5]4TZ+5].U2;2=4\/:=J6FZMKEO9Z=<K<'U[]F_\
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M>)/M9T\716W:]\DVPE8(9<GC6K^>[XI?"C]H/0/VR/ _PW\)W^F^,?%GCO\
MX*=^ OVT-+^)'AKQ&USXE^%_[(&B_L^Q?#SXL?#/XJ>&OL<+^#/#FG_V+9^
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MYTK*@>61VU:/E;5O3S=_PV!*W6X4444#"BBB@ HHHH 9(,H1C.<9!&01D9!
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M:Z>SG3['4-99&OY].TYI97L-.:?[%9RR23V\$<SN[>17/[(/[,5QX/N/ /\
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M*X'(KN:AACC2.-8D2..-1'''&JI&B(-BHBJJA450JJH"@*B# QBIJ8!1110
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M/$K1JS12@"5&8!MC^67B+)OVNT<CH75@K,H#5-+RHXS\P[9['H?X3_M $KU
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M/K_GH?2BZWNK=^GWB:NGVV'$9Q[$&EI-R]-RY],CMR?R'-(SJN,Y.3C@9Y[
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M:#\-YY]+U#P//87]_<O/IPM_>_B[\"OBA^W/\!=2^#/BSX=^,_V:I]9_8_\
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M\,:+\1O&>@:/9:;XQ\<66O>(UDU2?4I]8O\ [A"-C<-HRI( !!^8-@<8Y&0
M>W;T+DKIKHUO\^VXCQW]H'X\^ /V:?@[X[^.GQ1?78/A_P##G1XM:\67/AK0
M-3\4ZS9Z9/J-GI:W-KH.CP7&I:@D=Q?1271M87^R6D<]W/LM[>>2.GX]_:"^
M'7PW\?\ P'^&GBF?78O$O[2'B/Q)X5^&)T[P]JNI:1<:SX5\$:C\0M5MO$>M
M6ENVG^&$?PWI-]+ITFKSP#5+N$V-DLMRPCKPS_@I'\+/B/\ &_\ 8;_:3^$/
MPB\)/XY^)7Q#^'DWA;PAX577-"\-KJFJ7^KZ5E;C7?$MY8:)IMI:6L-S>W4]
M[>1;X+:2"W+7<MK')SG[1WPE^*/CC]H3_@G%XS\(^"+W6_"GP5^+?Q!\6?%S
M65UOPYIP\#:'KW[/WC/P#H]W-IFIZA;ZGXAEO/%6OZ?ITEGX7M]1N[&V-UJ5
MY%%81-/4P3;Y&THIVNUH]W;_ (?J^PF[:?W>;UE>UO6Q[/I7[5?@*^_:$MOV
M<+[PK\4?#GBW7O#OC#Q'X$\4^)/ &KZ;\.OB3;_#B[T.S^(-AX.\7%9K2XU+
MPM)XDT5KBVU--,&K6MQ/>>'VU6TLKF9+'Q#_ &IO G@#XR>"?@5%X3^*7Q \
M?>,+?2K[4(OA=X&O/&VD?#70-=UE="TCQ9\7-5T^YCC^'GA>]NTOY;;6];B2
MUFL])U:X@,@LF5OGBX^&_P 3/''[7W@+]J+0?"OQL^&,_P ,/"GQZ^#GQ4\#
M>+?B+9WO@?XT^ EDTR_^%,G@?P!9>-=:^'EMJ>N^*].M_&VB^/X8?#'B+0M,
MDO/#'C:8O>RZ5I7FGQJ^ UQ^U'\4O@U\1XOV2_%GP _:3^%7C7]E7XJ^&?VJ
M-2UGX86GB7P_X%MO$FB^+_CW\#+[QG\-/&.O^)/$EDOA"/QI\!O&_P --7BO
MO OC._\ &,7B'0Y=6\-:<GB?3JY=8M-):\T>NCMTLMMK]PTNTE:UK/UU?GON
M?4O@/]MKX3>._C]+^S;_ ,([\7?!/CO5/"GB?QQ\-M7^(OPR\0^$? OQK\'>
M"-6TS1?&VN_"7Q;?PG3_ !);^&+S7-!N=2LKL:7JLNB:_HOB/3K"^T+4K?43
M]D*V[/&,,1]<8YZ#KFOSP^&FH_&CQW^UA?\ C/XJ?L7_ !&^'6F>%M%\>^ /
MAI\9?%7Q4_9W\3>!] \ #6M/N#=^&?!_@GXF>*/B78^*_C+-I6EZEJ<NH>$-
M)&D^'-'T?P[K-S97%B]O=?H;&00<9^\<YQUP.F., 8Z9 .1G((#&(?E<\_ZS
MO_=V#]<_ACWKAOBA\1?#OPE^'/C_ .*7BXZDOA3X:^"/%'C_ ,3MHVE7VNZP
MOASPAH=_XBUI]+T3389]0U;44TS2[M[/3+&&:[O[A4M;:-YI46N[==P''<<^
M@SS^8Z_K7S[^U7X4\4>/?V9/VC? O@K1)/$OC+QO\"/B]X/\(>'([W3M.;6_
M$_B7P!XAT+0M)&I:M<VFDZ>FH:IJ-I:O>ZI=6VGV:R-<WMQ%!"2(J-J+DMXM
M-=]79V^3$]&K:\UT_*R=F_OZ:GF_B3]M_P"!OAOP[X.\2&Z\5:W;^,OV>=4_
M:LCTK0?"FKZAKV@_L^:#I>B:UK/Q%\2Z/# ;O3(K2T\0Z?:67A\I+XEU[5TO
M](T#2]2U#3[F%.V\1_M5_!/PSXE_9K\,/XJ.N:A^UKJDNF_ VY\+Z;>^(='\
M26D7P[USXIIXCN];TZ";3M%\+7O@[P_=W>F:UJ=Q#;:M?7%IIVG27%Q-M3\W
MK']F7]H?X=P?#3X@Z+\,O^$J\3ZA_P $DM._8HUWX?GQ+X?%SX.^.OA*#3]7
M\*6VO:F]\^C7/@3Q%K>K:[X?UOQ?HEQ>Z=HT>B1:Q=P3V5_:D\9X5_X)Z?MJ
M_"34?^":GA;PA\9?@!XW^&7[*/B?X&Z)XR;4?@1XFM_&OASP#\'_ -C76/V?
MKY_^$TG_ &EM#LO&5GKGB"369O"]IHWPRT2_\.ZW\0+?Q1K%GXCTSPQ?Z1JM
M--S:O[GM)+7^3EE;O>[M^/045:*;:YN6$7_V[%:_???78_1O]IO]MOX?_LLG
M4I_''PJ_:1\;:)X?\%7?C_Q=XI^#/P,\8?$_PKX/\.63W'G'Q+KNA6_V6SU;
M[/9WFH1Z':-?:K)IT'VD6N+BU2?USQ7^T#\-O!GQF^#WP#UO4-27XF?&_3OB
M%J_@/1K+2+^_M#I/PRTG1]:\67GB+58(#8>&UBLM<L1I4&KS6]SK=Q]I@TR*
MX:RO3;^%_&#1/BG^T3X&^ _A#4/A3XB^'OA_Q5\>O#OB'X[^&_%>O^#+W6_"
M?PS^#7B;7?'7AG?J?A3Q#K^C7=S\1OB!X(^%L\%AI%YJLDO@S7-9TG78]-OE
MO[>U^8/B-^R7^W+JG[:_P$^-7ASXV_ O4?AKX=\8?M(ZUK^MW/[/6O)X_P#
M'A+XA^ /#GA3P7X8N=4U#]I[[!XVU&RM=+.E>'-7T+X>Z-H7AW48+[7_ !'X
M0\0)KUS!&1C&RNK:OMW=M=7^MM!O5-=U8_6;Q!KEOX=T'6O$%Y;W]U9Z#I.I
MZW=V^DV5QJ>I3V^E6,U[<P:9IMM&UQ?WLL<+QV=E;AKB[N&BAB0M+E?D;Q)^
MW)\*]+_9[^$7[2_A#P1\<_B_X"^-OPP\+?&;P1H_P@^$7B;QOX[/PK\5^%M$
M\<VWC'7?"5K'!?:'#8>&M?L+RZTF_9-?O+UY-$TC2M2UA)+0=?IGP^_:"T"S
M\6WGC/XUV_QAL)/ _BG3].\#:9\+O#/@/4-4\076GM_99A\11>(YXXIG<O8Q
M17 LK &[2YO;N!+<R5\;> O#_P"U+^S_ /\ !.']B+]G/1OV8/B=\2?B5X>_
M9<^"OP$^/NG_  E^+'P%\'>*OA0_PX^#'A7P;XRF\->*OB3\2?"/AK7;[7-9
MTS4]%\(:[X9UK46TV*7_ (2=Q:S6]I;R)7YI7VTL"5DEV1],W?[=_P #[>3]
MG75=-L_B3XC^&O[4%O\ #*3X8?&WPY\.]>U+X3RW/QC\/2^*?A99^(/$2Q)>
M:(?&NE1PM:SSZ0]EH][JNC6GB*ZTR74XO+]+^+G[2_PV^#7B?1/!&O)XBU[Q
MWX@\$_$#XGV/@GP7HESXC\3I\//A;;Z9<^/?%\EA9_,MAI?]K:;8:59!SJWB
MO6[R#0O#-CJNJ.UJGQ?\1O@IX]^,/AS]FCP)\/\ X._%K]DSQ5^R_P")?V:?
MB+\*+W2OB9X>@^"_A'PAI.JV>B_$_P"$GB'0/AUXUUCPKX]U#P[\$K#Q1\(I
M=$U7PUK.C6FL>-M/UWX?:Q<Z5I]QXJLK?C_P#\=+_P#:P\/?MAZ%\$/$=S#%
M^RW^TM^RI?\ PJU/Q'X#_P"$J&L'XNZ'XP^#OCJSU+3?$&J^'[?P?\6AX4<7
M4]]JEOJ'@C2=>T*\\8Z7IDEKK%O86N6]I:II_>E=#>A]::I^UW\!M/U#]F"T
MM/&#>)%_;"OK6+X":CX6TO4M<TCQ9I5[\/\ 4_B?9>);K5+6W%KH7A>\\):7
M)>V.K:PULE_>7=CIUJLMW++%!]/(^_/&, 'USG/3CD<=1UK^??X:_P#!.G]N
MOX+Z5_P30\&:3\:_@!X[\&_LO>-O@6/B/'>? WQ0OBSPMX(^&?[-'B3X6>(]
M.TWX@WO[26@V?B[0F\0ZUXBM/ EMI/PHT75]'NO&6F^(_$5IXBL_"MWI.J_T
M!PI(O)^4$L2I.2 <8 .!@ Y(7G:#C)ZF-HR=MF[1ZV27E;6[_'N):]+>I8HH
MHJAA1110 5\7>(_VXO@_X1^/'A;X$>+] ^+/A>?QUK?B/PGX$^+6L?#/Q';?
M WQG\0_"GA/6?'?B#X:Z'\1DCDL;CQA;>$O#GBG6+"TN+6UT[7?^$1\4V&C:
MC?:GH=S:5]H'.#CK@X^O:OSJ\7:O\;_&/[5_A&#Q+^Q5\2]>^%7P>\3:I>_"
MKXR2?%7]G9?AQ%K^K>"-1LM8^+5]X"NOB>?BTGB"SL=2UCX8^!;7_A7[:CI+
M>(O$.L7<T&CZ[/J=D >L? ?]LCX:?'GXE?$'X/Z5X3^+GPT^)?PZT+PSXVOO
M!?QH^&NM?#K5_$?PX\9WVIZ;X;^)'@E-5+V_B#PCJ&KZ/JFCW=Q!<1ZKH>LV
MCZ9KVE:=>R0Q2?7U?GS^RO??&;QA\7_B9\3_ (W_ +'7Q _9^\9^+?#/AS2#
MXU\??%3]G_X@V)\,^&M5U9O#7PN\!6GP@^(GCK7M.L;'^T;WQ9XKU'Q%!H-C
MKGB'4I9K=;S[/866E_H-0 4444 %>(?%7X\^ ?A+XC^'/@O7Y=4U7XA?&#5]
M3T'X8^ ?#&EW6N>+/%D^@V=OJ7BC5X-/M(F33/"G@_3KVSOO&'B_5YK+P_X<
MM[VP74+U;K4].M;KV^OR2_;3_9 U/XN_M-V'QEU3X3#XU^$+O]BCXY?LYZ!I
M.G:[::!XM^&?Q4\6>+?"_C;PIXO\-ZI?:CI[>'V\93Z+9^'I?'FCRPZA\/\
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M!T<MQXDN]$3^W9=/M](D@NYO<Z_"FY_88^-&C_M%>/\ QWX.T%/#OQ'\8_\
M!3#X8_M:6W[2&CZW:6C7?[,3?!_X<^"/BU\&/$DT3PZ_J\,\7@36OAE;?#?4
M[-M'U+3_ !-X-\9V;W7_  C&J2:5^ZU'*HI)?, HHHH **** "BBB@ HHHH
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M[MX+BVECGM;R-)(IH'CEM[JWN$1X9(I(W,4L$T94I+"\D<B,'BD^;=7F&B?
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MGXW^(?@;PY<_%.^U>/4/AKX;^,L_Q8\9_"']EGQQX1OM?\7Z-/X%D^S?L_?
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M_4$?IG(]P*=10!6\CC&0005.0?F'^V/NM]",5((L C=@EMQQW)7!//3.<X&
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M_,QP 6PO=51".FQ1@!@&JS10!6$'1N ><YSGE@V"<[B!M7(+'. #D!<6:**
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M_P!; ]C]HEV#&&SC."6R3G Y)Y/YYS2L$<<D8&"<$<9'&3[@_B#7Y?\ PO\
MVU;GPI:_LE_!_P"+UAX]\0?$'XZ>'?@KX-M?BOJD'@&PN?'GQ)^)?P&\8_&.
M^\8:?X5\,V^F6-GX-T1OAYXK\/\ B74SX=\/VUAXIFT+2O#_ (>UW31J]_8>
M!_LX_P#!3+4M._95U/Q7\5+'Q;\</BE\$/@=\3_VE/C_ *IH%KX-\/:K:_!C
MP_\ 'SXR_#WP_J&EZ3:IX=T'5_'+>"_AEX@\1Q>&M-T_0[+5M.\):E#83?\
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M^$/'_B#P9\68]2GDM-&UQ(M7\'Z?'J^G7$NI>(_#&BZK]=_M ?';6O _C/\
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MKP_<>.[M_&.D7GAOPA%XT\1Z#K^B36$+P*[NDTM?^#_D,_H6\Q,XWIGTW#/
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MB^;3+R]UOPOI>LZSXF71=$L--\3Z_8:G^B]%)W][NVFG]VOY_P#! ^"O"_[
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M3^*/#WC#3)-/N(-9_P"$@OM6@-EK<&FZA:_>5%.[Z.S[[_UU$U=-=_\ -/\
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MEZ9H_P '_'_P:US1!8ZW\)?%W@*TT;39]#UGPCJ-I<O?6[7FI_:[B]U%KC]
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MWBF_@\-ZWX):PC\0W.LQ:A;Z/::DFF7TD"UYFFU9*/WM*_\ PWR ^Z"RKG)
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M*:K\2+N/P=\.?@-\6?CC\&].^&</PO\ %.L?%OXAK\"OAU\+/BAXJ^*WA+Q
M/%<.FWVBZ3H7CG5X-4\%6G@S5]6UB*+PK>Z!JEO?7LFDZG]5?"K]M/X)?&SX
MHW7PJ^%$OC[QGJ.G^$_ GCG5O%FF_#?Q=!\-])\+?%+X=Z5\4?AKJFH^-]4T
MRPTJW7QSX1U-9_#T(=IY-0L]3T>]M[34;-H*8'UU12 Y'3![CC(X!YQ]:6@
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M'OQ,_:Z_9$_9]\,_$JW\"_$O3[70?#_QN^)>B_"KXR6'Q4^&,_Q@L/$?P_\
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M'@'O[#K1;\-4!^:7PL_X)WI\+/@#^PA\ -/^,6J:QI/[!_Q)\,>/O"/B2_\
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MAEA^BP,# Z#@44G%/=#/S4U/_@G]XIU^*7Q%XC_:4\4:I\7O$O[.OQ)_9/\
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M-?\ A_X$U#QJ=7BOKS_A3&NVVG^"/ UTL6D^'[/X1Z7H>@7VA07N@S^);O\
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MPP-^T3_TEJ_X* _^"']AC_Z#6@#]-Z*_,C_A@;]HG_I+5_P4!_\ !#^PQ_\
M0:T?\,#?M$_]):O^"@/_ ((?V&/_ *#6@#]-Z*_,C_A@;]HG_I+5_P % ?\
MP0_L,?\ T&M'_# W[1/_ $EJ_P""@/\ X(?V&/\ Z#6@#]-Z*_,C_A@;]HG_
M *2U?\% ?_!#^PQ_]!K1_P ,#?M$_P#26K_@H#_X(?V&/_H-: /TWHK\R/\
MA@;]HG_I+5_P4!_\$/[#'_T&M'_# W[1/_26K_@H#_X(?V&/_H-: /TWHK\R
M/^&!OVB?^DM7_!0'_P $/[#'_P!!K1_PP-^T3_TEJ_X* _\ @A_88_\ H-:
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MOVB?^DM7_!0'_P $/[#'_P!!K0!^F]%?F1_PP-^T3_TEJ_X* _\ @A_88_\
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M8]_^K->G'\J/^&!OVB?^DM7_  4!_P#!#^PQ_P#0:T ?IO17YD?\,#?M$_\
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M<C0/V&",!E)5@/V-E;:PZE&23:&"."<, ?IW14<;;@0?X2 .,<8&,XP,]<@
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M@DFG+33F>OSLOZ^1_1!;ZIIUU8MJ5MJ-A<Z?&+G??P7<$MD@LY98;O?=QR/
MOV66&:*Y)D_<RPRI)L9&"Q7FK:7:>?'>:EI]H]O83ZK<1W-[;0-!IEL4%QJ4
MXFEB:&PMF9!<7C[8(BRAY 6 /X.W_P"R%K'QDOOV?_%!_9,^-O@?PGXZ_;6T
M7XJ_M2?##XW_ !8\#ZM9:9X'L_V._C-\ O$]U%\/?!?C_4O .F^#]0\1:]\/
MM%U;0_!":C<_$N]TH?$?6='N'L+;Q!/1LOV'?BY<?M%0>,]5^!EQ<^"[K_@H
ME^U!\0-2N[OQEX=O(C^RY\1/V1/"GPZT)-0TQO%,D][X*\8?%CPS"L?PR2"^
MN+&]MK3Q1J7A[2X_,N4(OF;3TUM^-NMO^'\BU;J[?*Y^Y-MXSBD\>S^ ?[ \
M8":U\'VGC#_A+7\-WZ?#VYM[[6+O2DT&S\9D?V3=>++?[(VHW?AV-C?V^C3V
MFJ28M[B/=T\FLZ5#:/?RZIIL=BETUDU[)>VR6<=ZEZ=.>RDNFE6%;I=0#6!@
M+"5;P&U9//&P_P S=W^Q+^VUJ'[*'B#X;7OPH\:3^.[_ /X(O^#_ -E>/1YO
MB[X83[5^TEX1^)>M3>'O#(U:'Q]#ID>K:!X7NK&\C^)+:A!9RZ:J6+>(=0NX
M!9)ZMXK_ &7?VB?!_P 5?BB/^&>OB3XV_9-\>_M%_%R3Q5\)OA7XW^&UEXB\
M0^$?C;^R-\#_ (9:?\5/#NC>*_&>GVL=AH'Q2\)_$32?%.GSZAX;\6^'M0\1
MK\5-!LKE8KW56;TDXO=)NZUB[-*U^[OIY"Z)]W:WRO<_:WXY_'_P#^S[I?@O
M6O'K:\UKX^^*'P^^$FB1>'=(?6KZ/Q-\2O$=GX5\-WNI6<<T,ECX:BUB_M+;
M5];8/!IOVJ"29=K@'V.ZO+:Q@:XU*]M+*W$\</GW=Q%;0F2:188(C)<,L8EF
MF=(XD+%I)&58PQ90?Y[?'/[*W[4,FL7/PU?X$>.?B%I/AW]J;_@G9\7O@/\
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M:'\]-6_8C_; @^(WQ%\<_"WX?7'PU^)?C;XZ?\%4;SP]\6Y?&OA"W3P_X?\
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MI:CH%VEVVMQZ<BII-S>?9+,?#?PD_8P_: ^'WC+3OA+\4_@Q\9O''[-GBSQ
M/'O[.]E\*?C-X1\,K^QQ?^"_VOO'_P >O ?PQ\<Z]J'B?3O&_A_PSIW@_4?A
MI>V.N_#G4?%,<.@>&?$?P'N;'6/#QT;3/$,Q?-'F_O-6\DVK_A_P2;ZM=E<_
M?SQKXZM?!S^'HIM!\7>(Y_$'BG1/#"VW@KPY>>*;S0_[>>[2V\2>);33@\VA
M^#;)[">/6/$]ZBZ?IK2VXE?,A*==#>6\US<V,5[:RWE@(6O;6&>)[JT2Z#26
MK75O&S2VXN8XY&MS,J"X$<CQ91<#\%O"O[%WQE\.?#_PYXEM/@?K.G_&AO\
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MS\6?#+6=+^%_PL_;,\%^([/PN_BA]0NM>_:9_:PN?VAO#MSX?;5=%T^";2]
M\/7J>'O$<NI36U[?ZU;B^L+-K5@5'%2NW=/D27:Z;;^>VJM?OH*UK675?=J?
M:&H_MI_LNZ%XN^,'@SQ'\8O"OAK6_@3XN^%_@/XH)XD>\T33_#WC?XS:0VM?
M#/PE#JVI6MMINM:]XKLGB73-,T:XO[N6]NK;3'0:A=0VK[B_M:?LR2Q>'Y)/
MCA\-[2V\4> -6^*>@7>J>(K32;+5?A]H/A'3_'OB#Q-:7NIM:6AL=!\#:O8>
M+M?@>9+W2/"]ZFMZG;6VFEYA\(?&7]@[XW>.OBY\=/%_AKQ3\*V\+?%']J[]
M@/\ :8\/)XFO_%D.N:*O[*.O^&-2\?>$KVPLO#.I6(N?$-OX(TP^!M>LM7*6
MVH:O<-JNF6D6EP'4<;5OV!_CY9^-?VL+OPM)^REKR_$KQ;^T!\;/V:?C7\6?
M!OB/QM\5_@O\5/CU\)#\/=6\&:[X#U'2+_P#JO@K2]6@B@;QW;:Y?7^J_"^X
M;X::U\,M1MK*/6KXOJHI7LE=N]]59_UU"W_MU_GM?O\ H?>>H?MC_LT6/B'X
M7^%F^*N@WFO_ !@^+=_\#? >G:9;ZKJ4^H?%/2O TGQ+U#PGJB66G2G0+^U\
M%I9Z^6U\:;;O::MHLT<[+JMH\G*S_P#!0']B6VTO5]9E_:;^$$>EZ)X6UCQS
MJFH#Q1;RV=IX.T'Q9?\ @/Q'XI:X6-EET#PSXRTO4/#?BC5+8O9^&]3LI;77
M)=/\H"OB3X8_L"?M'>#OBIX2^*>LZ_\ " 2:7^W+IO[6&O:%!\0?BEXJU/4/
M#OBO]B[2OV9/B;X=OO&GB'P1::AXD\9>'_%FB6WC;PMK-[I6FZ5XWTF\O;'5
M].\$7]E#+=^<6W_!+;X]Q_#&S\#7'COX,-JB?LJ_\%//@5/>%_&+64?B[]O'
MXQZW\2_!6KVX;PPLLOAOP=I^MQ:9XVMVA2_U;4+&.?28/),:DY(+175[[<R7
MG>SM]^X+2.OE?KW/U6^(GQ._98N?%WA[P?\ %'Q=\*;OQ;X1&M_%'PCI/BRY
MTNXNM"N_ASX=@\5^(/%WAF:^1H+;7_!_@[5X?$.HRZ5<'7M'\*ZC+J\B1Z-=
M3RR<)J'_  4$_8SLO#\7BBV_: \#:[I$_C;X*^ DNO"T]]XF=O$/[1$:77P9
M)M]#T[4;E=#^(6FR3ZWX?\2>5+H%_I5CJ-]%JC1V5RT7QK\+O^"?GQC\"^*/
MBM:>(],_9@^(/A[Q OBOXA_"CXI>)8O'M_\ &SX:?$SQ_P#LYZ'\$_&'@JQC
MN=!.@6OA2+6]&EN-"^+6DZG9^*(?AG=Q^ ]1^'=Y=0)XEKS7PS_P3 _:#\):
M+\*QI_CSX.7FM_"3X4_\$I/!6F6\FH>.-+T_Q#KO[ WB;6;KXD)=ZA;>%[J\
MT'P_X]T#Q%=W7@6=-,UJ\T_6+6&S\0:<MC>W%U:4E%/D3LEKIMZ^HG?E32NV
ME;;6_GMM?\C]HO#GQ1^'7BWQ'J_A'PUXMT;6_$6@QZG)JNEZ9.UP]I%I6O7/
MAC6666-!:W/]D^);"]\/ZL+6:9].UNRN],O!%>030IX1^T)^UUX,_9X^*'[.
M7P[\4^&]=U2P_: ^)MC\,M0\<Z=/:1^&OA)?^)M*UR/X;:S\0'N<S6^C?$CQ
MWHT'PN\,W<!6%_''B#1K"Y>-M0MGDX']G3]ECQU\$OC]\;?B=;>*M)\+?"OX
MQ3^*_$&J? _PAK_B?7OA[)\5M:^)&IZY!\:_"_AWQ?8(/A/XI\7^!I=/M_BY
MX8\&:M=^#_&OQ#?5O'*VEGJT\]]?>3_M0?L"^*/VL/ '[8FF^._$=EX>^(GQ
M6TBQ\-?LV^(/!WQ+^)>B>'_AI:_#NST;Q9\"?&?B_1+.QM+,^.?A]\=M./Q9
MFGTBPU:SNGTWPUIT/EW.DR7=U,E[T6KM+K9Z:J_3M?3_ #*6RTM;L?I+XP\:
M>#_A[X>G\3>-_$>C>%- M;_1=,EU;7+V&RM%U3Q)K>G^&O#FE)+<,AFU/7_$
M6KZ5H.AZ?%OO=6U?4['2[&&>\O(8G\ \3_ML_LA^#--T_5?%?[0OPM\/6&J:
M1JOB*SN=4\2VEM_Q(] \<GX:>(=9NHCB:QTWPS\0TD\(>*;V^6VM_#FOQ7.G
M:W+830S;.9^,'@#]J?XA_LJ>%/"&G>)/@WIG[2]M?_ W6_B!JHB\26WPN\1W
M_@7X@>"O$WQ5T_P+KLOAW7O%OPUOO&FBZ%K\'PX\>0^%_$GB?X3Z_JNB^(M)
M@O\ 6?#UIJJ?FBW_  2Q_:(N/AY\;_ 1\9? ZR3XC?LP_P#!2O\ 9U\+7MGK
M'Q#OFL!^W/\ M*>*OCIX1\1Z[-J?AB:_>#P7IGCG5/#WB^TCO=1N_$6H:+9:
MM:7K1:M<6^GD7=SV]VW)YMKS^>^PE:*6NO-KO>]]'?R=K=ON/TS^.O[7GA/X
M/_$?]GGX8:39:#X]\1?&W]HWPE\!/$-A!XN;2]3^'D7C/X7_ !.^)>G>*I+6
MVT#7;77[Q=.^&R)/X4NM3\.7C:1KT/B'^U$A2SL=4P_VCOVL?%/P,^.W[/7P
M/T3X=> O$7_#0'AOXW:]9^.?'WQKN?A7HGA2?X'Z'X9\0ZQ8ZNJ?#+QV+P:]
MIWB:Q&E7R7UIY%S:WW]H006427$ORLG["'[1MG\8K/5;;QA\&[_X7Q?\%!?
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M4[3SL[P]^VS^SF=/^%]CX_\ C)\&O"/Q'^(_A;X(ZU_PA>C?$FP\9:3:ZO\
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MVNOV?/V]?V;M&\7ZUXQ\5ZIX7_:(^%WBCP+XO^+6@?$VYFTBVU&?X<?''7/
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MAN75_@5H'QO\"ZY\/_%]YK>E^'_%WA+XUZ5X0\W6='UW1M.\0W&A>+/"VO>
M-!FMC+X?U2QU_0]0US3[B2QNHM'O8/"/V ?V#O%7[$WB#QGI\GBWPOXO\!:E
M\ /V7/A+X;U"Q&I6/B2+7/@7#\5;CQ-<W6AS:<^FZ-X,OM5^*5Q:?#[0-/\
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MQ9K5I<^,)K>T\0:3J>C"2Y\(7VOWLUEI]]]'_LY_L7_#S]G>X^*GBB+6=?\
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M:>,O"FK:-<:IINA7%AK6HZEH6KQVG]CSW\_F/CK_ (* >&O#GQ$N/V9/BO\
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MF^6%K72+$FYO)H(""WXU^$_^"8WQ^\.?LX?#+X!6GQ&\#>#M?_9>^)7QIO\
M]B/X]^ ?'?Q,L_BI^SW\(O$^OP7OP:^'7B:+5] OM ^,O@SPEX.N;WX4?%;X
M4>+8%\!_%7X=>'O!&C";0=7TF'Q':_=G[;G[,GBO]IGPCX2TSP'J^E_#_P >
M>![SQ;XH^''QIT[Q9XK\"?%'X(?$N\\+W&B>#_'/P_UKPQI^L66MZ'%)J-_#
M\3/AAXPL;SP7\3/#<T7A[7[::UWJ@_=Y;6;VZ:>2?31[?\,'>V^_S%^$/[<_
MPL\??&GXS_ +QK?>#OAE\2OAW^T+XO\ @?\ #_PU?>.5UC5OB_IWA'X.?#'X
MR77C'3+6YT#08]'O&\/?$:5+CPI]JUR>VM_#>IZM:ZOJ-HTPM/73^UE^S(TE
MO"_QO^',3W6L?#?0K$W/B*T@74-2^,.LS^&_A2NFR3-$E_:?$;Q!;3Z%X,U6
MQ:;2_$FL1-I6F7EQ>%8G_/'Q7_P3G^+GCK4O&-GXC\=^ $T#QY^WMJW[4_B+
MQ#H%]XDT7QHG@3Q'^PK>_L>>(++1TC\,S:=I?Q+36;Z?X@:/-%=GP[I"-!I,
M=R98A<IES_\ !+GQSXT^%7A_PG\0?B3X,T;X@_"S]@;P-^QK\)O&_@;3-72T
MF^(/P>\?>!OBK\(OVEM<TB[M-+/AK4/!OQ*^$'PT\?Z'\+--NO$MCX<U2+Q%
MIR>,]:L[BWDE)1CS-OX4DT]=[>]HK6L[:_,45:*OO=MKMVU^\_25_P!K+]F6
MW\(ZEX^E^-OPYM_!>BP?%F75_$TGB&TBT33(?@-=2V?QFDOM0<K%9Q_"^[BN
M(?&;RM&- DANOMOE&"<IVGPQ^-OPA^,S>+U^%?Q"\+^.YO /B./PGXWMO#NI
M1WMUX7\0S:38:[;:7J]J ES92W>CZGIVIV$LD20:AI]W'=6<L\1+C\S-8_X)
MJ^/D^ W[?_PETCXM>'];NOVPOA%\5]$\&P:_H^IZ9X4^&WQM_:3^&TWAW]I3
MQZ]K:R:S=P>#_B'\0X=+^(NG>$]'CW^'DNO$NBPSW,>J)-;?67[/7[._COX8
M?M"?M2_&7Q;J7@V71_CS8?LU6GAO1O"]SK=UJ.A2?!?X5S>"/$*:[/J6E:3:
M2Q:EKMW<3Z$VG+)C2HH#J$-O=RRPP$HQ<79W;22T[M/=N_=^OF-NVK^\F7]M
M_P#9_P#"/A#_ (2CXV?%CX*?"Z:?5/CU-ID.G_%*Q\;:5>>!_@-\0]2\%^*O
M%JZU;Z'HOV>?P]I\6A:G\4="&G3)\*]>U:[\*ZUK%^VAOK%S[%\3?&GQ+TG0
M?"6H_!'X<>&?B[=^)=6MUN[C7?B9'\._!WAWP9)H6HZK)XSF\2:=X.^(&H:M
M%/)!I>F:)HNA>'+R34IM;BNY+K3],LKF[C_)J[_X)D?'B^\.P:+_ ,)A\%[)
MK7PW_P %@-'C\JY\82VS7G_!2+X@2^.OAU+-;CPO"J0_#TO_ &?X]>-!)J[3
M2WNAQ!0\-S^L/P@\#>*?A?\ L^_"_P"&5RV@ZQXS\ ?!?P5X GE@O-2LO"NI
M>)/"/@?2O#TLL.I3Z9<:O;:%?:CIYFBN)M+N-3MK*4O+82S*8Z<G&+=EK=-)
M+IRQ3=DM-4_7<6_*]GRR4O5VMMO:UT^E^FI\$_ +]M_PC^UO^S7\,?BY^U+\
M"_A-\(_V<_VE_A!X?^*/@"T\9_&'3/BW#XFNHFU3Q7JGP_\ %O@;5OAAX+F/
MB/P7X?\ "Y\?WD^AQ>-/#EO86,U\=7M+C2I)$]FT']O_ ."T/[2_Q(_9J\=^
M(OA]\/7T'4?V==(^"7BO4/B-!JD'QXF_:!\$^(O$_ARPT*QFT"PM-'U.&X\-
M7^E:#!#XD\30>+WGL+C3]0M[^\325^3/AU_P3\_:D^'G[$_[#7[)-EX]^!]W
M%^S]X&\7_"3X\7\$_CK3!X\\%Z_\,?$W@G0/$7P\\66OAL^*]!GTOQ!JNG:]
MXO\ AY*NC6?Q!T>UN-!NO'FAPPPO<9G@C_@F'\66^&NI?"GXE>*_A?#H/Q)^
M%O\ P30\+?$C6_!-_P")I]9\)>)/V Y_#VJZO#\/K;4?!^DPZSIWC[5O"FDR
M>$_$^I7WA?5O HU"^O3H>JWFF:>L[G&*J-1E[BFU!JZO'76R\DM&@5^5-_&X
MWDNTMK)[=]4?<WPE_;A^&?BKX,>(_C-\8)O#OP(TGPS\8OVD?A3J,.O^,$UW
M2UM/V;_C1XS^$/B'QO+K1T/0SI_AZ[/A*+Q+K-SJ&F6ECX.LM3CM-7U1H;<:
MC<=-^UO^TG?_ +,_PY\#?$/0_ FG?$R'QI\;?@;\&DT]_&@\'QV$GQT^)'AG
MX::'XIAU1/#'BJ+4K'1]2\566J:C916T$USI,<S:?<37*P6TGYW6W_!-[X^Z
M)J?AWQ!,O[,'Q<M]5\3_ +=GA;XH?"KXM7?Q&E^&VI?!O]LS]H[Q!\>=,UW1
MKK3/#EQ?ZIXX\$1:]<>!/'/@#6]*A\'_ !:\*RW&CKXL\$.T>JG[?_:^_9M^
M('QO^!WPC^%?PWOOA_H][\//C=^S)\4=2NO$(UO0?#LFB_L]_$[P5\1[C0-
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M@7&J:':W4TUE>>((-)M=5MVT>3498_KI@%7'.WG=ZD'/ ]RQ _&OGO\ :2^
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M3_,M:I_P4,^%.F_$B]^%]C\-OCCKVM1?'7XA_LS:?J.E^$_#</A[6OCU\/\
MX4Z-\9X?AYIVI:QXSTJ:!O&GP]U1]1\'^+M6M-+\!S7FD:II&N^)]"OXK2"\
MQ]!_X*>_LS>)M)^"^M:*_C^^T_XR'X&V\B6GA-;S5_A9JO[15UJ^E?"_2?BK
MX?L=2O-;T>YU#Q/H6K>$?$=_X=T[Q1H?@[6+,7/B75],T*XMM5.Q'^P+X,B^
M(L'Q*7XH?$;^TH/VS_$O[;9TH67@4:7+X[\1? >#]GR3P3*4\*)J!\":5X2@
M35;,+>Q>*I_$+>?J?B2]TYDTT\+\ _\ @FW8_LT^*O"6K?"?]ICXYZ-X;MO
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M%;7^T+V>[D'F/<NLDH0^K?$+]F_X&?%3P7X2^'WQ%^&?AOQCX,\!2Z1=>#=
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MX<:W_P *_P!8^'L&E)K'A;1]-UKQ9HNF:9XI\77>FCQ/<ZAJ4E]XIO8-8O\
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M[Q5:?L\? VY_9L_9\T;Q+/I\MA\+O@[/JVEWD6@P7%K907?B+7K;P]X;\%^
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M>(IWTUH=<\-V_B'17-U%V?A7]OKX.^.?$^M?#GP[X?\ B9%\4K7Q5IWA+1O
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M\0?#OPW^#-_\!=)CGL?#WA#Q?J7PO\1_!'6_@/X_\ ZWX\\ Z5X7\1:M\/\
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M2".2 >C $#GN,CH1D&I:AAQM)'3@#KT '7)))SD$DDDCYB2":FH\NJW^>J_
MK\^H4444 %%%% !1110 UQE2/;Z<]CSCIUZ]J^1?VR_B=#\)?A-X7\77,?CU
MK2[_ &C_ -DKP#<R_#GQ;IO@_7;9OBO^TS\*OA?ITM]?ZC8ZG'JO@Y]8\7Z;
M;>/_  Q;6?V[Q-X,GUW1;&XM+FY%W;_77.&[D9P#CG@''YUXU\9?@OX"^//A
M*U\$?$>RU/4/#FG>//AI\1[6TTC7=5\.W2>,/A%X\\/_ !,^'VH27>CW%K<R
MIH?COPIX?\01VDDS65S>:59+>02PI(K8:J3:MI4N_NE_P!7YEVYD]>WJ>,_
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M/B>TOX+K7Y)H]3&BZ='<I:1>S>&_V(?@-X;LOA'IE[??$WQ=K'P4\6WWQ+\
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MC<V?B.'X:6?C;2?#.I:?\(=9\2ZAI.G^"?$0T[5X!_9SVFEZC*/#_P![2_\
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M5D^+_P 2/'_@?Q?:>$E\->!OB1K4_BJ7X=ZMH,.JV_B*\\.^+=2$GB+4=/\
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M1:UX=\!> ?V>=#\5_%#Q-\:?!GP0T^PN?CBFC?#B/Q'\1/V6_&_[2GA;4?\
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M5/\ "O2?V>/$NF?#[X)?#WPUX[&A7WP_\96/BJUM='^'?@*VT_7XI]*\0?\
M"36PM;72-)GMIQJDA5(XF8[*]0L_A%\)]+L]%T_3_AC\/K&P\+Z!K?A/PQ96
MG@OPY%!X?\+:\HA\0^&="@721%IF@Z]#'&FNZ/8".PU0AAJ5O<9 ,.3U]R7\
M6/V;WM%P;5M=)22?1.U]+M..VK=Y1235KIW^[RV/R4^,O[:?[0?P<\">,+W4
MOC)^R]XIU/6)_CUXT_9X_P"%?:[8^.?B+\0?A_\ "[]G&U^+L.G>-6NX? 7P
M:\,WGA#QL^JW7C+5=+U>\N/$?P1U#PBGAN"T^).HW%U=_+?[5'[5WQC_ &F?
MV//^"D<NM>*_A9X2^$?PQ_X)S_"'XR?\(OX6TK4U\3ZEXB_:8_9EUOXEZ?))
M\2Y?&T)T2#P/XVT)-4\'W>GZ,AU_3+VTL;\22V_VR[_6'6O%7_!-KX;Z'XK\
M$:Y/^R3X+\,_LT>(]*OO%WA+4-'^'&D:%\$?%7Q)MIM(T:\U+2)=-@L?!NL^
M-+*[FTO3I3;VDVO6<[Z;";BV6.(>I^!IOV._%>J^/O@C\/--^ &MZOH7A'P)
MIGQ+^%_A[0?!EU+9> Y--,/PVL/&OA>UTX++X6CT:SE@\&V>L6LVGQ:?;&/2
MH8HH947T*F59G3H2K5<NS&G25/VKQ%3 8ZG15*5/#UHU'5GA(4E3]EB\)551
MSY'3Q6&DI2CB*#JJ,X\ZY9)NZBD^6\G>6RZWY9))7UC+^5V^>OAU^TA\:=0_
M:W\<_LF^)[7PQ:ZKHFN>%OCI\/=:LO#>IMI_BG]B#Q%X ?1W2:^GO9H3\4_#
M/Q\L)_!FMZM [:+=Z%=:!-;V%O>W5U<-XE_P4$_:G\2_LT?&+XI^*O _ASX-
M3>./AK_P2D_;0_:3\&^,/&FG:]?^,+77_@=J/A?Q%IOA6XCMO&6A:1?_  O\
M17SVA\26::7%KR:K#8W,'B6TMB;&X^E];\=?LZ?L<?$+QQ\1?VI?VNO"EGXE
M\;:7J^H>!9OC%<?"WX<6?PD^ &@ZO;7:_#_PNOA7P[X6BG\!>&_$M]'+>^-O
M'%QK/B34+R?2K#5_$-R=.L8SZ1X9^-7[$_[1OC=O"?AOQE\!?C)\1+[P7XUT
MBXT$IX8\5>+)_AUI^I>'(/'NB7%GJ-I<:DWA"/5==\*?\))H\ZC2KJYU#1YK
MVTF9[>0<$I7Y5%=$Y6\K;I]_3Y ]VY72O[KMZZ'P3IO[>GQ6T']HO6OV8_'?
MC3X<7(UC]K#X0?![0OC!!H-EH%KX4\,?&#]E#7OVC8_!EUI\^LZQH,OCO4M<
M\-7?A?X476NV]PGB+PQ<79UF'5?$.F07FO?!'[-/[8+?LO?"F?Q,OAKX2>,)
MOAQ^SE_P4&^)(^(36_B&3Q-I,>@_\%9?B%\,]9N[]['Q?/IUI^S[X.M/$D7Q
M*\::78:9>:WH6B>$=0CMO%,=JD /]*6M_!;X,^([;6;+7_A+\-]9LM>O_#FL
M:[!?>"/#MRNKZUX2MX+'PAK&HB736>]U;PK:VL-GX8U.8OJ&@0VT=KH]Q:)"
M(1\R^,/C_P#\$Y/@QXRN?AIXS\=_LK_#KQU:+K'P\G\(:E#X$T+7%7QGITOC
MGQ'X!CTU=/CDN'\3Z5/<>+=?\*0+*^KV<EQK>IZ=-$9;D.+C&3NM>5J[;ZI^
M?GVO84U*4'%/EO*,E:S7NM-KK\5M?-Z-'QE^V=^WA\5?V6OA)\3/%_A7X]?L
M\?&/6]&^%/[5/Q]^#^A>&]*TRX\5^+O!/P)^"OA/QYH^G^-]7_X3+2OALGA?
M1/&EUXBMOB3JOAB71O&.M_#WQ'X L_AYHUWXRT[Q!J.L\;X]_:E\;3?'KXD:
M-XRUCX9_%3P?X._X*X?L:? GX4^&/&NEP6Z?"SP7\2OV>O"?BK_A(_ ]]X2U
MSP]?ZEX\NO%'B_7=4\)Z]XO/B+29K*>]L(]&U6.VM%L?U5\"?!K]D?QW\,?A
MK?\ P]^$GP"\4?!Q] NO$GPE;PUX \!:AX"C\-?$/0(+;4=1\'6EKH[:5;:7
MXQ\.74-MJBV<(M]7T]K6WO5GB@BC@]'B^#'P>MKH:A#\*?APE\D_@Z\%\O@K
MPXUTE[\.[*2Q\ :@)O[-:5-0\%Z;*]AX2OE_TW0+$K;Z3<P6X58VY):-7OUU
MT\W]]M1M.ZL[)+5::W_5'XH:?_P47_:GAN[[7+67X(_$.XUWPY_P6)L_ WPV
M.G+X(TP^-?\ @G=\4K[P]\'3?^.;SQA/) OCC3GLM#^*T^IRV.B:6(8-<TPZ
M$L=X][^D'[&?Q8^-GQ;/Q<UOXBWO@_7OAI8^)/!1^!'B?2?#\?ASQUK7AK7_
M (=^&?$_BVT^(^BVOB+4]/LM7\,>,]2U;PUIGV/0?#&_2=/MXKZ._P!4L]0U
M.Y]1^+7[,GPL^*'PW\:?#ZRT/1/AS<^*]!\=:)9^-_ WA#P+#XF\-77Q#G%W
MXXU'38M=\-:SH=^/&=_$6^(6B:]I6I:'\1+)[[2?'&GZUIU]=6[^7?"+X1?
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M6=1MXI?$MSX7U"UNM5DGTF>)G44D]/Y4GZWV]?+HAO5)+1OKZ?Y_J=-^T_\
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M/#/C!H+BR\12Z9$_AUO=_P!H?]NS]I'6O@7^WC\6/@[\3/@=\,=-_9V^%?\
MP4:\)ZOX)UC6].U+X_\ PR^)W[,7@W7=0^"OC;P_X'N?#MW;7>H>)YO#.I>/
M?&.C_$'4K#PR?AAXP^&'B3PK+#.^JR:M^U+_  2^#LVEMHK_  A^&#Z0?"=M
MX$.D2^ ?"QTIO!-E?C5K+P6U@=*-HWA*VU:-=4M_#A@.CV^H;+Z*SCO$\T0R
M_ SX-S^)O&GC*?X1_#.Z\8?$70AX6^(?BFY\"^%IO$7CKPNU@-)D\.^,-9ET
MLW_B?1;G1HH='NM-UJ:[M+C3(K?3[A;BSMH880#\B_VA/VG?C9>:%_P4XT"X
M\1_ OQA\)?V.OV$]'^+.I^!_%G@.]U>U^.1^+'[,?QC\7ZEHWQ%\0Z!\1M!F
MT'PC<ZW\.@UL/"5IH\^H>'?$6HVW]I2RV5K>GZ(^#G[5?B7XP?%?5_ASX;^(
MOP5^'$GP3\=?!/PKXL^#?B>W^T^)OB1\+/B)\ M&^(D?CKP)"NN1Z]"NN^)?
M$FEZ7\)]<M)=0\+?V3X"^(=MXBL_$.HM9WF@??5K\'_A78:9K6D6OPP^']OI
MGB7PYIOA#Q)IUOX.T$6?B/PGHUB^EZ1X:\0PC3_+US0M,TV273[+2-6%Y8VM
MG/<6D4*VT\L;,A^#OPGMO&NB_$>#X5_#N#XA^&_#47@_P]XYM_!7AN'Q?H'A
M"!9(;?PKHOB6'2TUC3?#UM!/<16VD6MW%96L-S=PVUNJ74PD::U35U:WSZ/S
MLKKY]R;2NGS:)--66M_\O(_.7]OC]N7Q;^R[XYTS1/!GB7X<WM_I/@WX+>/]
M=^'6M0PV?B=?"WQ#_:W^&/P UWQGXU\1:]JVFZ1I_P -$T#QKKVF^&K;P4MW
MX^_X6=:6&J:A;W/@G3M5L=0^<-._X*.?''2?'.NZEXT^(?[/>A?#:&\_X*P^
M'?M7B+PMKUCX2\!6G[!-]I&L> ?B/XPU;0/$FK^*]6L+3P_=ZBGQJTS1XG-S
MIUC'J?A'2M"U.-TG_:7QO\%_A)\2[Y=3^(GPJ^'OCW48]"U#PQ%?^,O!?A_Q
M'?1>'-3N[6_O]!2[U>PNY5TB]OK&RO9]/1Q:-J%K!>^5YL:R),WP>^%#+)&_
MPL^'3Q2OXO>2)O WAPQR-\08C;>/7=#I07?XWM";3Q@Q$A\36^(=<.HQ )4Q
M5E9Z]F-K?6RLK+LT]==]3\&[O]JSQ=\>?C-^S+X:\9ZKH\>I_!W_ (*F_!3P
M=X2UV&;P[H?B/7O#'Q5_X)X?''XEI'XF\.>$/%.K:/%!<Z[J=T^BZ)<7::N_
MAVRT>S\3:5:>+-(U*5?=?"W[;W[7^M?"CXFVB>!_!_B_]H3]E[Q]=? O]H;X
M9^!K?1/"7B3Q]\0[7XHQ7=CJ7[-UG\4_%5AX7U;Q%X__ &5Y+#XW?"7P1XHU
M]],U_6?$FG>!M5UNSU:WD1_U/TS]GOX+^'+:)?!OPD^&7@S4]/CT9M UOP[\
M./!=IJ/AW4_#.BWWA_PEKFD^9HDL$6J>$=+U&\L= GEBF:STZ>33$9K&>Y@?
M ^%'[.VE>"?AY<^$OB+XDU#X]>*_$7B+_A-?B#\2_B-X<\%:9KWCCQS%::?I
MUCXHG\/^!_#WAKP;X8N=)TS2-(T_1;;P=H>AVVF)IR7ENO\ :5S>WERQ_P"1
M^5]C^V5XR\5_$_QGXP_9]\*_"3XG>-==_8$_9E^+_A;Q%XDL+GX(_&CX@KXA
M_:9\6_#'Q=\,]3TCXD>-8?!'A#QG<6FF^)-*^$GA'Q;IV@:/;_'V[L_"WB[Q
M;=^&+N9]/^H_%G[=5SX:_P"":GC']M_P;I.O>.;_ ,*>%O%]^^F?$CX=ZW\,
MM<\+:EX9^*NI_#+Q=_PN7X?07!U3P_=? N\T_6[GXU6>B7=I8WB> _%VH>%K
MRPTF[TZXM?O"?X2?#"\::2X^&G@66:ZT+1/#-Q._A/0Q=/X<\-:DNL^'-":\
M^P_:FTKP]K4<.LZ'IZSK:Z1J\4>KZ;%::D@E'36GA;P]9:"_A2W\/Z1#X;EL
M[S3I=!33K7^QI;#43/\ VA97.GF![2ZM=2-S<2:BEQ'*+Y[JYDO%EDFE+*R:
MMT_KY@?@S^US^T5\8]0\<ZQ^S;J/Q"T;_A#?!_[<?_!+[2M(^*=EHFD6(^)_
MP]_:5\3:]K7B+X1^-+!'3P9X@N])U/P7IVINF@6^F0Z[X \2^%M-UW2+V62Z
MO_$OZ$?'OXL3_LI^)?V#OA)\-K?P!X(^%'Q/^-%[^SOK%EK-I):67A;P?H7P
M!^)WC#P;:^";Z;5;'3]%U'2]9^'VCZ=I]AJ2:C:7FD/=Z7#8R.D$T7UQ'\(O
MA=#I&G>'Q\-O!$FA:1K^F^*=)TB?PKHMYI^F>)=&9?[&\1:?:W%K+'9Z[HB)
M#'HNKP[;_2(8(K;2YK6"&*,:_C#P)X,^(&G6>D>.O!WAKQGIFGZQIWB'3]-\
M5Z#IWB&PL/$&C3&;1]<MK;5;6ZB@U/3G+-:7L*)=0&294D5)I5<7NIV6FETN
MMK?H*R?R/YTM=_X*N?M.R_LX:-\:]+\0_ ;2+_0O^"9NE?MU^)K0>&IKS0/%
M'C;P[^T*OPZ\2^$C>77CAYO#O@#Q;X3BOM*EGM#/XAT#Q3);7]CK<HLKS0;_
M .O/B'_P4(^(>A?!7]K']I+P'KOPN\23?LO_ /#9WA?QA^RAJ%C=7OQ8T?6_
MV>-9N=%^'OB/5(](UVT\46-CJ6GZ-=_&+XCBZL;JWOO@QXO\'2^$=/TS5[6X
MU;6_U,E^"7P<N--DT6X^#WPQN-&F\./X.FTBX\ >%)-.E\'3:PWB&7PE+8'2
MFL9/#3:^?[<;0GB.DR:UG5FM&OL7-7;#X1?"W3/%_BGX@Z=\,/ %CX^\;Z9:
MZ-XT\<6G@[P];>+O&&DV5I!I]GIGB?Q'%I\6K:_86]A;6EE':ZK=W40L+.TL
MRGDVEO&C;3E.RLN=\J_NZ62[I7M?K8?G^'?]?^'/R*^*'[;?[1/@#]H[1_V=
M-$\8?##Q#X?\7?'S]BWP-X=^-EQX5M;RY'@[]J?X;_M#:[XK\-0:=IFOZ3X7
MNO&_A_6_A#H7B[X8ZC!::A97O@WQ)!;^*M*\036@U/6?F^Y_X*"?&2#X87/[
M0UUX7^!7B'XP_#G_ ()Z_P#!3KQW:_$V/POX@CO-;\8?L1_M Z]\/;"W2ULO
M'?\ 8.G^ ?BJ/ %CXF\<>&8+$ZCI6NW,Z^'O$]A:6<.FM_0'I_PB^%VE6&DZ
M78?#3P-9Z=X>UO3O$V@6,/A71'M=$\1Z+!-::'KND1O8LFF:QH-G<366B:A9
M&*YT73C_ &?I4MI:,UL/$O#?[('P^T;XOZQ\5]5=/$5J/!OC+X<> /AO)X/\
M">'?A[\-O /Q*U+1M>^)/A?3="\*^']%@\56OCCQ'I)UO6K[QM'K^J2W&IZM
M"]V]M="%2ZO:SND]=;:IVUVT>MOO%?2]GZ=3X7US]OGXIW/Q@^*OPZT77/AG
M-\.O#G[17[,'PTN?B7X7.B:CXC^'/P]^/G[-?CCXG:CXFALM2U[4O#_C?5-/
M^*/AKPIH&FQ)HLIM/!/B3Q!K=[I^H#PY-J-GYWKG_!0_]H[X>:)^SNGQ:UCX
M 0_&74_#O[%NJ?'_ .#_ (&LTL-/\(']J?\ :+T[X(ZKX@UK7/%GQ#U:[L_#
M;Z-K*7'PTT?P!J?BOQ=_PG/A_4KSQM:CP,&CK[Y^.O[!?PK^+7ACP5X6\&1>
M&O@II?@O7M/UA]%\,?!?X(^-/ OC"UT?0+WPUHFE^-?AU\3?A]XK\):X?"NE
MWDY\$ZU]@M=?\(33W0T348+;4=3L[KU#P?\ LA_L[>$_#'AKPV?@W\,?$ \,
M:&N@:=JVM_#KP;<7L6FCQ6OCL6%C;PZ)#IV@Z';^-HU\4Z1X8T"ST[P]X>U=
M(;K0M,T\Q)L27NI/5VU?=_\ #:=!W3V5C\B?AW^WA^TMXAT(?!W2?B]\%;?X
M^^+M5_X*1^+_ (:?$;X_7OA[X?\ PWUC4?V6OVVOB)\"/A=\%=<M-#TBZGN/
M"NB^#],\+ZS\7;KPM;+\4+3P3<2>)?#<@U43376I\1?VE-4_:"^./[*M]K>O
M^$O#"_!?_@L/9_L]0_#S3Y83JMRVB_L;_&W6U\73:QJ,VG^(9H/'FI>)IM:\
M+VTFGQZ5XB^'I\':FNC6FMW%Z\7[*ZS^SU\"?$BI'XA^"?PGUV*#QQ>_$N&+
M6/A]X5U-;?XC:E!!!J7CNU2[TFX2V\6:I#:Q0ZIX@A1-3U*, W\T_FS*VK/\
M&/A+=^-)?B/=_"KX>W?Q!N+G1;^Y\;77@SP_/XGFU/PU;7=GX<U-]:ETZ343
MJFAV5]=V&EZJ)S?Z?8W,ME:7"VK>6C)L_P";\/Z_IGY<?\%%/VU?CS^SEXO^
M,ND?"?Q/\+/#]A\'/^"=_P 8OVW/L7C7PK/XBU;Q-XI^"OQ&T*Q3P=>W \4Z
M%!IW@3QMH5Q?^&=<N[2QA\1:=>W]IJ6AZOI]];BUFP/B]^VYK^H_M#^,_P!F
M]_%'PQ\4_#/Q?<?M7_!;Q0FFM:Z2? E_\-OV1? 'QOTSPGJFHZMX@MO%^K_%
M8/XWU/4/%MWI.DR?#(_#S7O!46@W-AXRTSQ']H_8#Q%\-?A]XRN+N[\7_#_P
M7XKN[_PY=>#]0N_$WA;1-;N;[PG?74-]?>%KN;5;&[DO/#=]?V\%]=Z'<.VF
M7%[!#=S6LEQ&DB<S=? 3X(WOB&]\67OP9^%UYXHU*^AU/4?$=SX \+SZW?:E
M!X;E\&Q:A>:E)I3W=W?1^$9I?"IO)9WGD\-.FAR22Z9&+92^JVMRR35EJW>S
MO:^E^_0I=+ZV?I?6_2WYGX+_  1_;I^,7P\_8ETA_ $7A[4KW]CO_@GY_P $
MVOC'H'@CQ''-KOB#]JW2?C1\-],?QGX;T;55N+C6EUW4(]'E^'/PLU7PRUVT
MGQJU;2F\5KKVD.F@:C[+XT_X*5?&;X/ZU^V)X?\ B!=_"W7-0^"%SX5\1?!/
M4-+\/:K8>&_BG\"_BG\=/ /PIU_XSZI?#7)VU:V_87N/$/BGPU^U/I_A%TT2
M?6O#\>K-K7@D:@^B:)^S\7PH^&D-QX7NK;X=^"[6;P3IMGH_@^2W\-:-:GPO
MI.F7-M>Z7I.@QPV,2:9I6EWUI9ZCIFFVJQZ?IFH6-E>V%O!=VD$T:3?"GX8S
M&V>?X:^ 96T_2/$_AZP>;P;X>D:T\/>-[G[7XTT.UDDT]V@TCQC=,UQXJTU#
M'9^(+@F?5X+N1F>DDE\E9":=[IV7:U^_]?(_)'QG^V3^TEHW[5&@?LH:1XV^
M'/\ 8_B/]I_P;\)=&^.$_@^TU'6]7\ ?%+]COXT_'VRLM-TB'5M/\$W/Q1^&
M'C+X5V$NHZA9Z?>>'];\ ^,?#?\ :7A33=0AFU36O//V?/\ @I!^T%^TQX7^
M""^%O$G[+W@'XDG]GW]B_P#:"\?Z;\2?%5YX7\%_&'PO\=_$/BS0/C9=_#NS
MCM/$WB_^S_"5EX/U>U\ /X8NK\V7Q8U7PSX6\<7]WHMS>PS?ME9?"?X::?!X
M>BLOAWX*@7PIJ5QK7AH_\(UI$L_A_5[S2&T&[U;1+J6U:ZTS5;C07;0;C4;2
M2*]FT9VTMY7L,6PP3\ O@;_:/@358_@I\*(]5^&%O/9_#/4D^'?A.&]^'=G/
M,;B>S\%72:0DWAFRFN&-Y)::,]C;O>K'=>4;A$EC<;J/*]?>;3LM(ZV6FKLN
M]WYZC;;M;2V_G^I[#$00<9QN/7W /X=>W!/(X-25%$&&2W?'KUR<G!R1VQDD
MXP"3C-2T %%%% !1110 4444 -/1L#=DXQTSP!WZ5Q/C>#2(?#^KZ[JL%GN\
M.:'XAU2PU.Y@2>XT23^Q;N*ZOM.E\F2YL[@63S6YELG6XD@GFMQN$C(W<4U@
M2I"D!N"">G!!YQ]*CE^+7=Q>VW+)2_3R^8DK<OE?YGXQ_P#!,GXA> /V<_\
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MX1"7TD#7DC_VR))S'K5[&]MW;>S;NE?=:7?R]/49ZOX:^-'@'XV_!;7OB?\
M#3Q+K$W@Z\\.^+(K+Q.N@^)/"VJ65YI&G7=MJZV5EKVD66LV^N>%-:2[T35X
M!IIN]"\7Z'J_AN_M8]?T34=/M?R:_98^+_[5^H^(OV!-3^)&K>.?BMIWQ1_9
MO_9=T[XX>%9AXG^&?Q1^!/QKNO@AXVUOQU\1_&6@W>A)X'^,GPD^('B+3+C2
M?BYI N?#/C+X*_$_2OA\+--9T_Q;-I.D?L'\)O@?X(^"=GXKTWX?Q:QINE^,
MO%MWXXU72K_Q!JFM:=:>)M5L-,M/$%_H-KJ,TL6A?\)/>Z=)XE\30Z:MO!K?
MC'6/$/BV]BDU_7]6O[KUPI(<Y?&<C )(P2".O/0<\]R.E)*S;ON!^!7[=WBS
MXY:E^T_^TK\./@_\<?CMX-^)7AG]A_X0_%7]EGX;_#;Q7J%CX>U[]IS_ (7#
MX^T?PG9:UX7@M'T3Q+X6\;:KI_A7PI\4-#\5->>&)/ $NM:SJPTJWL&UFQ\\
MD^+7[0G@B7QM\5OB)\1OV@+;X2ZO_P %#OVB?@5\8_%>NV_Q5\4>$O@U^S]:
M1>([SX(:WX9^'_@O4O#7B#0_AOJ'Q&U#2/# ^-/A9UDLM*FT#2]=UN\\*1/<
MVG[L6/P(\ Z;\=/$7[1EG:ZK'\4?%7PZ\/\ PJUK4Y-<U.;2+CP3X7UK5O$.
MC:;%X=DF;2+6YM]7UW5+Q]2M[>._F:Y:*6=X/W0]@5'!^^20,9;G.><#TP0,
M]R/PI@?@9J7C/]MSX8ZA\+] ^&GQ \<?MAZW+^SE9>%_#\OC?0=;^ WQ1TGX
MY:-\%?CWKWPX^-?Q&\%3VI^'7Q,^#7QOU?PYX0T#XLZ+JFJ>%_&OPV^)'_"N
M-<FGNM/\4ZAH>G\;X:^(?Q4^)6D_LY>,? '[3/[3_B;PA\9/VN?V8?!7Q@\'
M?\*Z^+/PAU3X/6%M\ _CMH7QN\':UJGC*ZUKQEI4_B'XBVG@75/BAIUEJ%AX
M5^'WC6P\.WFA7>F2^)-]Q_1(P==IW8+. <$X&<G('3D\L#ZD=\TJQR!0#(6(
M[DGD]R<<G.3@9PN!COFFT[:;*V__  !15FW?K?\ &Y_*[H/Q9_;%\/:'X(^)
M]MJ'[0_BSXG:7^Q!^T'X1\*KKVG^/-<UGQ=IOPG_ ."@I\/^)_$,W@LOX?M?
MB!\?-!_8[M9/''A8:DUKX\^(=S%I5_X;EO-2U99IOKWPY\:_%.B>+_@I/-\?
M/C=\3OV./CSXQ_:6UFV^,$/@/XJ^!K7P3XXU+X;_  ^'P7^!D6M:PVK_ !/L
MO EMJ)^*.M^!]>\2ZC);:A\3;BW^&\-[=7?AC0M'/[RB-^"7)88[D*2,<E>F
M>N#GC"^E((WVX\QLC@'<2<#(4EBN2V#R#\I/S=>J;;WM]W]=Q1BH[7?J[]O\
MD?AWX'USXM_"S_@C'_P3N?P/)\1O GQ6\+^"O^"7/@G7=%L/#FIV7B^QTR+X
MA_ #P5\=/#/BOPY>:+<WMKI6G?#?_A8W_"817]E:QZ9IFEW^IM=0"TCE?G/A
M'X[_ &D(_P!N70)-9\<?M ZI\.]:_;L_;@^$=QX>\1R>*[[X8_\ "DM*^"/P
MN\5?#(G2+BR71+'1]'^)=AXIM/AQXY(@DGDN_$GAJTU;4[606\'[T>6V<AL$
MXR<G)P  25"DG  .>.,@#)R;)#_&, D@9;#;N"'ZG ZKM(Y[ 5*5FY+=V3OJ
MK6MM_6MF4?D=^WEHAM/VO/\ @E!?Z!X=NA:V7[9?Q'\9>.]3T#P[>W5EI=OJ
M?[,'Q3\"VWBOQIJFEV4EMH]OJFLZQX>\*V^LZ]);P7M[?Z;IJ71>..)?@O\
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M/B#HU]K>MW?BB_AN%\-Z)T_C70/B]'X[^'%OH7C3XR?&7]F:7]KG_@ESXX\
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M2:!1110 4444 %%%% !1110 4444 %'X_P ORZ?_ %_>BB@ H_S_ )_,T44
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4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>formdrsa_022.jpg
<TEXT>
begin 644 formdrsa_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '= =,# 2(  A$! Q$!_\0
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M%6/<CKA J@GH=Q)[UZ?110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 )C/6N2@\"VL6L/>27#R1%V=8<8Y/
MJ:ZWM7#V/CBZN?$KZ>U@/)WLBA,F0;<\G\JF5-3W0UC98;1.W-H=)_PCNF?\
M\#_WV?\ &C_A'=,_YX'_ +[/^-2_VFW_ #X77_?'_P!>C^TV_P"?"Z_[X_\
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M-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&:
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MTEBA.Z2:3S)7 VC., *,G"@  #-;-%% %"31]/ED:22TC9V.23W-)_8>F?\
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M,_Y\X_UH_L/3/^?./]:OY'K2U1F9_P#8>F?\^<?ZT?V'IG_/G'^M:%% &?\
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M#*\,?\BGHW_7C!_Z+6M6LKPQ_P BGHW_ %XP?^BUK5H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I*6F.ZQJ68@*!DDT ,N+B.U@>:9@J*,DF
MLRQMY;ZY&I7BE<<6\1_@'J?<TR%6UNY6XD4BQB/[I#_RT/\ >/MZ5MXJ%[VO
M0W?[I<J^)[^7E_F(G"+\NWCIZ4ZF1X\M<$D8ZFGU9@,9%<8901[BJ<VCZ?,<
MR6D1/J%P?TJ]2TFD]RHSE'9V,@Z#"G-M<7,!_P!B4D?D:/L6JP_ZG4A(/26(
M']16L*"*GE1I[:?77U,G[1K,/^LLX)AZQR8/Y&J.J^*FTJS\V739UD+;55\!
M2?K7256O;&WU"V:"ZA66(\[6Z9I2C*WNLNG5I<R=2.GD9&E>++/4+)9Y5>!\
ME6386 /U J]_;^F$\W0!]U(_I5FTL[>SM4@MX4CB4<*HX%3[$/\ "/RII3MJ
MQ3E0<FXQ:7K_ , HC7=,/_+Y%^)IXU?3VZ7D/_?0JR;>%NL2'ZJ*C:PM&ZVT
M1_X *=I$7I=F(NHV;=+J$_\  Q4BW5NW2:,_\"%0-I5@W6TA_P"^!49T333U
MLXOP%'O!^Z\RZ)HSP'4_0U4U#5[+2HEDO+A8E8X7/))]@*9_8.F'_ET0?0FL
MK6?!UEJ,*^2[V[QG(*_-D>F#4R<[:(UI0P[FE.32]#H;>XBNK=)X)%>)QE67
MH14M8%GIU_H5I'!:,MW;(/\ 5M\KCN<&M"UU:VN7\HDPS]XI1M;_ .O3C+ON
M1.E9MT]5_6YH44459@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 97AC_D4]&_Z\8/_1:UJUE>&/\ D4]&_P"O&#_T6M:M !115>[61K*=
M8D#R&-@BEMH)QP,]OK0!8SFBN2\!Z3J&CZ;=PW\'E,\RNF0JD_NU4_*A*CE3
MSG+=3R:ZV@ HJA);ZDTK&._A1"?E4VVX@?7=S2?9M5_Z"4'_ ("__9T :%%9
M_P!FU7_H)0?^ O\ ]G1]FU7_ *"4'_@+_P#9T :%%9_V;5?^@E!_X"__ &='
MV;5?^@E!_P" O_V= &A16?\ 9M5_Z"4'_@+_ /9T?9M5_P"@E!_X"_\ V= &
MA16?]FU7_H)0?^ O_P!G1]FU7_H)0?\ @+_]G0!H45G_ &;5?^@E!_X"_P#V
M='V;5?\ H)0?^ O_ -G0!>)QUK%F9M;NC!&Q%C$?WKC_ ):'^Z/:L/Q=+K<$
M=O;P79E\S)9;>+8V!^)XK6T2TUB/1[99;F&W<)S&UON(^IW#FL>;FER':J7L
MJ*K75WMY>9OHBHH50 H& !3ZSOLVJ_\ 01@_\!?_ +.C[-JO_01@_P# 7_[.
MMCBN7USM&<9]J=68EMJFQ<:A HQT-KT_\?I_V;5?^@E!_P" O_V= &A16?\
M9M5_Z"4'_@+_ /9T?9M5_P"@E!_X"_\ V= &A16?]FU7_H)0?^ O_P!G1]FU
M7_H)0?\ @+_]G0!H4C?=/&?:J'V;5?\ H)0?^ O_ -G33;:I@YU* #_KU_\
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M;>.OI0 ZBBB@ HHHH 2H+BUANHC'/$KJ>S#-6*2@$VG=&,=-O+#+:=<DQ_\
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M8,?IBMVD"A1@  >@I: *$FHR1RL@TZ\<*<!E5<'Z?-3?[4E_Z!5__P!\I_\
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MY:XSC'>GTBC._M27_H%7_P#WRG_Q5']J2_\ 0*O_ /OE/_BJT:* ,[^U)?\
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M81C.Z4+CZ<,:N44Q!1110!E>&/\ D4]&_P"O&#_T6M:M97AC_D4]&_Z\8/\
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M*&0_KQ6-J_CK^R[F*W^QK,X&]V28%0/;%%NQ$ZRIJ\]#M:*HPZM830QRB[@
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M@K=_DG_Q- &C16=_9US_ -!6[_)/_B:/[.N?^@K=_DG_ ,30!HT5G?V=<_\
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M"MW^2?\ Q--;3[@8SJMWU]$_^)H TZ*SO[.N?^@K=_DG_P 31_9US_T%;O\
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M_()'XW*UITR3!3D$\C@4 4/MFI_] G_R96C[9J?_ $"?_)E:TJ* ,W[9J?\
MT"?_ "96C[9J?_0)_P#)E:TJ* ,W[9J?_0)_\F5H^V:G_P! G_R96M*B@#-^
MV:G_ - G_P F5I#=ZD<9TC.#_P _*UITQSC;R1SVH H?;-3_ .@3_P"3*T?;
M-3_Z!/\ Y,K6E10!F_;-3_Z!/_DRM2VUQ>2R[9['R4QG=YP;GTP*NT4 %%%%
M &5X8_Y%/1O^O&#_ -%K7):C<I8^-[F6*61(FN;=;H9M\F0JBKL5E,C#&W)!
M]<=#76^&/^13T;_KQ@_]%K7,:G=NWC*2UB>TDD\^'%T;61YK-=JDQ K&5^;K
MRPQO.>U '>4444 %%%% !1110 444UB%4D\ "@#)B_TGQ)*_5;:((/\ >;D_
MIBM>LG0E+VTUVWWKF5G_  S@?RK6J([7-JVDN7MH4-6D*63JK8>3]VH]R:N0
MQB*%(UZ*H%<%J3^(I/',<40E:V65710/W8C[D_K7H%:O8X:53GE)VVT%IK]!
M\V.1_.G4ULX& #R.M2= ZBBB@!KY"'! /J:=37&4/R[O:G4 %%%% #(\&-<-
MN&.OK3Z:N=HSC/M3J "BBB@ HHHH *1ONGG'O2TA^Z>,^U "+]T<YXZTZFK]
MT<8XZ4Z@ HHHH **** "FMG:<8S[TZF/@QME=W'0=Z 'T444 %%%% !1110
M4U_N_>QR.:=37R5X )]#0 ZBBB@ HHHH **** "FMGC&.O>G4QQDKQGG\J '
MT444 %%%% !1110!E>&/^13T;_KQ@_\ 1:UQMY+Y'B0:A+J%H[37<<;VVGZO
M*KN=P1281\K$#&X>@-=EX8_Y%/1O^O&#_P!%K7,W]U>:3XI7['X<T]+5[A(5
MN5M6,LA8*6(91@?>;D_W&S0!W=%%-8[5+ $X&<#J: '45GZ5J0U.WED^SRP/
M%*T3I+CJ/0@D$<UH4 %%49-7TZ*1HY+Z!74X92XR#3?[<TK_ *"%M_W\% %^
ML_6IC!I4Q7[[#8OU)Q_6E_MO2O\ H(6W_?P5E:EK&FW.HV%L+^W*!S*_[P8P
MHX_6IEL:T5>:OTU^XW;. 6UI% O1$ J<G S5#^V]*_Z"%M_W\%5=0UFRDLI$
MM[R%W;Y?E<':#U)JDNAC.6\F3Z:/.EFO6SF9B$_W1P*TZRH=6TJ"*.)-1M@J
M+M \P5+_ &YI7_00MO\ OX*;%!61H4Q\8&<XR.GUJG_;FE?]!"V_[^"FMK>E
MD<:C;#G_ )Z"D4:-%4/[<TK_ *"%M_W\%']N:5_T$+;_ +^"@"Y)CRSDD#U%
M/K.;6],VG;J%KGWD%._MS2_^@A;?]_!0!?HJA_;FE?\ 00MO^_@H_MS2O^@A
M;?\ ?P4 7(\>6N 0,=#3ZSDUO2PHSJ-L3Z^8*=_;FE?]!"V_[^"@"_15#^W-
M*_Z"%M_W\%']N:5_T$+;_OX* +]%4/[<TK_H(6W_ '\%']N:5_T$+;_OX* +
M](WW3GIBJ/\ ;FE?]!"V_P"_@I#K>EX.-0ML_P#704 7D^X,=,=Z=6>-;TL
M9U&V)_ZZ"E_MS2O^@A;?]_!0!?HJA_;FE?\ 00MO^_@H_MS2O^@A;?\ ?P4
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M%+10 FT>@HVCT%+10 FT>@IKJNQOER,=!3Z:YPA^;;QU]* %VCT%&T>@I:*
M$VCT%&T>@I:* $VCT%&T>@I:* $VCT%-=1M^X#[4^F28V<YQD=* ';1Z"C:/
M04M% ";1Z"C:/04M% ";1Z"C:/04M% ";1Z"FL%^7Y<\_E3Z:W5?FQS^= "[
M1Z"C:/04M% ";1Z"@ #M2T4 %%%% &3X9&?"6CC./]!AY_[9BN!T748-4U^W
MAU#Q+)Q,TUJDT]H[.R/MPRB,,CGT!SCOQ7?^&/\ D4]&_P"O&#_T6M6!I.FB
M;SAI]J)=V[>(5SGUSCK0!=HHHH **** "BBB@"CJ\WV?2KF4'D(0/J>*=IT
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M^;[_ ,"Y/\: -&FO]P_-MXZ^E4/[(A_Y^;[_ ,"Y/\:1M'BVG%Q?$^ANY/\
M&@#2HK._LB'_ )^;[_P+D_QH_LB'_GYOO_ N3_&@#1HK._LB'_GYOO\ P+D_
MQH_LB'_GYOO_  +D_P : -&BL[^R(?\ GYOO_ N3_&C^R(?^?F^_\"Y/\: -
M&F28V<DCD<BJ/]D0_P#/S??^!<G^-(VD18XNKW/O=R?XT :5%9W]D0_\_-]_
MX%R?XT?V1#_S\WW_ (%R?XT :-%9W]D0_P#/S??^!<G^-']D0_\ /S??^!<G
M^- &C16=_9$/_/S??^!<G^-']D0_\_-]_P"!<G^- &C36ZCYL<_G5#^R(?\
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M3J ,[.L?W+'_ +[?_"D9M8 'RV(Y'\;_ .%:5-;.!@ \B@"AG6/[EC_WV_\
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MK1HH SLZQ_<L?^^W_P *1VU@+]VP'OO?_"M*FOG;P 3Z&@"AG6/[EC_WV_\
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MLG_^(I#\3/#Q&-FJ\_\ 4,G_ /B* .P7[HXQQTIU<:/B9X> QLU7C_J&3_\
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M4?\ <,G_ /B* .RHKCO^%F^'O[FJ_P#@LG_^(H_X6;X>_N:K_P""R?\ ^(H
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MT5Y5_P +F_Z@'_DY_P#84?\ "YO^H!_Y.?\ V% 'JM%>5?\ "YO^H!_Y.?\
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MY.?_ &%'_"YO^H!_Y.?_ &% 'JM%>5?\+F_Z@'_DY_\ 84?\+F_Z@'_DY_\
M84 >JT5Y5_PN;_J ?^3G_P!A1_PN;_J ?^3G_P!A0!ZK17E7_"YO^H!_Y.?_
M &%'_"YO^H!_Y.?_ &% 'JM%>5?\+F_Z@'_DY_\ 84?\+F_Z@'_DY_\ 84 >
4JT5Y5_PN;_J ?^3G_P!A10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>formdrsa_023.jpg
<TEXT>
begin 644 formdrsa_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9 D # 2(  A$! Q$!_\0
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MV]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\
MC0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%
M+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'
M_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H
M45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\
M[_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L
M_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_
M -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_
M (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O
M^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:
M1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?
MV]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\
MC0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%
M+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'
M_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H
M45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\
M[_K_ (T?V]I'_04L_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L
M_P#O^O\ C0!H45G_ -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G_
M -O:1_T%+/\ [_K_ (T?V]I'_04L_P#O^O\ C0!H45G?V]I'_04L_P#O^O\
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MC_[Y%'V>'_GC'_WR*DHH C^SP_\ /&/_ +Y%'V>'_GC'_P!\BI** (_L\/\
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M** (_L\/_/&/_OD4]45!A5"CT Q2T4 %%%% !1110 44F:7- !1110 4444
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MT?\ 0+U/_P !C_C1_;H_Z!>I_P#@,?\ &M:B@#)_MT?] O4__ 8_XT?VZ/\
MH%ZG_P" Q_QK6HH QI=;#0N/[,U,94C)MC_C7EY^\?J:]EG_ -1+_N'^5>.,
M/F/U-<.+Z'T>1_;^0S%%.Q25PGT@F*5.)$/^T/YT4Z/_ %J?[P_G36Y,OA9Z
M?'K@$:C^S-3. /\ EV/^-._MT?\ 0+U/_P !C_C6G%_JD_W13Z]M'YV]V9/]
MNC_H%ZG_ . Q_P :/[='_0+U/_P&/^-:U% C)_MT?] O4_\ P&/^-']NC_H%
MZG_X#'_&M:B@#)_MT?\ 0+U/_P !C_C1_;H_Z!>I_P#@,?\ &M:B@#)_MT?]
M O4__ 8_XT?VZ/\ H%ZG_P" Q_QK6HH R?[='_0+U/\ \!C_ (T?VZ/^@7J?
M_@,?\:UJ* ,G^W1_T"]3_P# 8_XT?VZ/^@7J?_@,?\:UJ* ,G^W1_P! O4__
M  &/^-']NC_H%ZG_ . Q_P :UJ* ,G^W1_T"]3_\!C_C1_;H_P"@7J?_ (#'
M_&M:B@#)_MT?] O4_P#P&/\ C1_;H_Z!>I_^ Q_QK6HH R?[='_0+U/_ ,!C
M_C1_;H_Z!>I_^ Q_QK6HH R?[='_ $"]3_\  8_XT?VZ/^@7J?\ X#'_ !K6
MHH R?[='_0+U/_P&/^-']NC_ *!>I_\ @,?\:UJ* ,G^W1_T"]3_ / 8_P"-
M']NC_H%ZG_X#'_&M:B@#)_MT?] O4_\ P&/^-']NC_H%ZG_X#'_&M:B@#)_M
MT?\ 0+U/_P !C_C1_;H_Z!>I_P#@,?\ &M:B@#)_MT?] O4__ 8_XT?VZ/\
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M:M%97VO6/^@7#_X%?_8T?:]8_P"@7#_X%?\ V- C5HK*^UZQ_P! N'_P*_\
ML:/M>L?] N'_ ,"O_L: -6BLK[7K'_0+A_\  K_[&C[7K'_0+A_\"O\ [&@#
M5HK*^UZQ_P! N'_P*_\ L:/M>L?] N'_ ,"O_L: -6BLK[7K'_0+A_\  K_[
M&C[7K'_0+A_\"O\ [&@#5HK*^UZQ_P! N'_P*_\ L:/M>L?] N'_ ,"O_L:
M-6BLK[7K'_0+A_\  K_[&C[7K'_0+A_\"O\ [&@#5HK*^UZQ_P! N'_P*_\
ML:/M>L?] N'_ ,"O_L: -6BLK[7K'_0+A_\  K_[&C[7K'_0+A_\"O\ [&@#
M5HK*^UZQ_P! N'_P*_\ L:/M>L?] N'_ ,"O_L: -6BLK[7K'_0+A_\  K_[
M&C[7K'_0+A_\"O\ [&@#5HK*^UZQ_P! N'_P*_\ L:/M>L?] N'_ ,"O_L:
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M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8GBW_D7+G\/YUMUB>+/^1=N?P_G45/@9TX7^/#U1YG12XHKQC[T2BEQ28H
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M_P#@.W_Q5'D:Y_S_ -G_ . [?_%5JT4 97D:Y_S_ -G_ . [?_%4>1KG_/\
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M^CM_\53O(US_ )_[/_P';_XJM*/_ %2?[HI]>R?G[W,KR-<_Y_[/_P !V_\
MBJ/(US_G_L__  ';_P"*K5HH$97D:Y_S_P!G_P" [?\ Q5'D:Y_S_P!G_P"
M[?\ Q5:M% &5Y&N?\_\ 9_\ @.W_ ,51Y&N?\_\ 9_\ @.W_ ,56K10!E>1K
MG_/_ &?_ (#M_P#%4>1KG_/_ &?_ (#M_P#%5JT4 97D:Y_S_P!G_P" [?\
MQ5'D:Y_S_P!G_P" [?\ Q5:M% &5Y&N?\_\ 9_\ @.W_ ,51Y&N?\_\ 9_\
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MD_V&_P#T&-4_[_+_ /$T?V&__08U3_O\O_Q- &M163_8;_\ 08U3_O\ +_\
M$T?V&_\ T&-4_P"_R_\ Q- &M163_8;_ /08U3_O\O\ \31_8;_]!C5/^_R_
M_$T :U%9/]AO_P!!C5/^_P O_P 31_8;_P#08U3_ +_+_P#$T :U%9/]AO\
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MM_(;1BEQ25Q'T(E.3_6)_O#^=)3D_P!8G^\/YTT3+X6>K1_ZI/\ =%/ID?\
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MF/F ^M '2T44A90<%@/J: %HIN]/[R_G1O3^\OYT .HIN]/[R_G1O3^\OYT
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M6*9E<!2ZYQQ7/LE=;X,&+:Z_WQ_*HGL=.#7[Y&E)X?TA8G8:=;@A21\E>?$
M,0.F37J<W^ID_P!T_P J\M/WC]37F8KH?=9/]OY"4E+17&?0"4J@%U!Y!(!H
MI4_UB?[P_G36Y,OA9Z"GA[2&C4G3K?) _@IW_".Z/_T#K?\ [XK0C_U2?04^
MO61\(]S,_P"$=T?_ *!UO_WQ1_PCNC_] ZW_ .^*TZ*8C,_X1W1_^@=;_P#?
M%'_".Z/_ - ZW_[XK3HH S/^$=T?_H'6_P#WQ1_PCNC_ /0.M_\ OBM.B@#,
M_P"$=T?_ *!UO_WQ1_PCNC_] ZW_ .^*TZ* ,S_A'='_ .@=;_\ ?%'_  CN
MC_\ 0.M_^^*TZ* ,S_A'='_Z!UO_ -\4?\([H_\ T#K?_OBM.B@#,_X1W1_^
M@=;_ /?%'_".Z/\ ] ZW_P"^*TZ* ,S_ (1W1_\ H'6__?%'_".Z/_T#K?\
M[XK3HH S/^$=T?\ Z!UO_P!\4?\ ".Z/_P! ZW_[XK3HH S/^$=T?_H'6_\
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MH_\ KG_6L4K6UXC_ ./Z/_KG_6L>NN.QX]=?O&0%*8RU9Q32E48-%1DKJ?"
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M>KVC^+]/UN_^R6R3K)M+9D3 P*%),+HZ"N%U),ZC<?\ 70UW-<5J'_(1N/\
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M/_A7N'V6W_Y]XO\ O@4?9+?_ )]XO^^!6%2FI[GIX;%SP]^5;GAW_"=>'?\
MG^;_ +\/_A1_PG7AW_G^;_OP_P#A7N/V6W_YX1?]\"C[+;_\\(O^^!67U:/<
M[/[6K=D>'?\ "=>'?^?YO^_#_P"%*OCKPX'4F^; (S^X?_"O</LMO_SPB_[X
M%'V6V_Y]XO\ O@4?5XB>:UFK61QB?%OP4J*#K'('_/"3_P")IW_"W?!/_08_
M\@2?_$UV/V6W_P"?>+_O@4?9;?\ Y]XO^^!72>2<=_PMWP3_ -!C_P @2?\
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M_P#H(M_WX?\ PKUY(;.4$QQP. 2I*J#@CJ*=]EM_^>$7_? JO:,Q^J0/'O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/^(3?:1:ZAJ+B :C<%;.,I@A3G:I]^"<T =)17FD=QXBT^_A:4:A<6<M]=3
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@,T0*HY'*@]<?7 J:B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>formdrsa_025.jpg
<TEXT>
begin 644 formdrsa_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %$ D # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM_+WJ(V9<+D[3P,UST.G>)'^+NL+;Z_:Q2_V= Y=K -F(R/M3&[J.?F[YZ4
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M>06C:-'$)MOR%Q,Q*Y]<'-=910!R4%E=K\4=1O?(D6V?1X8DG*_(7$KDKGU
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MRL__ ![_ !I?^%I:M_SXV?\ X]_C1]0K]OQ#ZS3/6,TF:\H_X6EJW_/C9_\
MCW^-'_"TM6_Y\;/_ ,>_QH^H5^WXA]9IGJ^:,UY1_P +2U;_ )\;/_Q[_&C_
M (6EJ_\ SXV?_CW^-'U"OV_$/K-/N>L9HS7D_P#PM+5_^?&S_P#'O\:/^%I:
MO_SXV?\ X]_C1]0K]OQ#ZS3[GK&:,UY/_P +2U?_ )\;/_Q[_&C_ (6EJ_\
MSXV?_CW^-'U"OV_$/K-/N>L9HS7D_P#PM+5_^?&S_P#'O\:/^%I:O_SXV?\
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M5PJO<PI$"1M*>2=N[/5,XSBN8E_Y!5K_ -=9?Y+2/9WTC0^9;7#&1<190DL
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MKBFJ:_F#F?8VH+;2KAQ)Y4:/LD"P"0D,5< 'EASMR>HS6)=K$E[.L"LL0<A
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M"3B+RU5FXSYOF9Q^E>K><1_RRA_[\K_A2><?^><'_?E?\*E8B/\ )^(_8/\
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M7/\ X[_A1_9M7N@^MP['N_-'->$?\)=XC_Z#-S_X[_A1_P )=XC_ .@S<_\
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MR&F7Z*!16105S7C\%O!&I  L=J< 9/WUKI:0@$<C-5&7+)2[":NK'SAL?/\
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M[5 W<Y_V06'M4IT-VD$C1VY<# 8O(3CZYJ"3PQ'+=+<O;VYF5=JMYLG ].M
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M%:*,S.Q$3!,G8?SJU8Z3%82%XYIY,@\2ONP3C)_2J:W<UWJ%@9;22!DFD4Y
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M_P#(7L?]V7^2T 7JSUFB@U.\>:1(UV1#+' S\U:%9IMH;O4+V*= Z%(L@_\
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ME89!&P4 4IM2MK^YTTV\N<71!4G:?N-_">2.:W!TK*O;>*"ZTT0Q*@^T\[%
M'W&K5'2@ HHHH **** "BBB@ HHHH *HW SJ]E[)+_[+5ZJ4GS:O"O39"S?7
M) _I0 6N%U&]0=RCG\1C_P!EJ[5$9CUGT66#\RI_P-7J "BBB@ HHHH I:I_
MJ(?^OB+_ -"%)<_\A>Q_W9?Y+2ZI_J(?^OB+_P!"%)<_\A>Q_P!V7^2T 7JS
ML2-?:@(B!(88]A/'.&Q6C5*#_D+7G^Y%_P"S4 9\<-]%?Z?]MF69O.D(8)T'
MEGC/05NUG7N/[4TSIGS),=<_</X5HT %%%% !1110 4444 %%%% %.\YNK)#
MT,I./HI(I%^75V)/WX!@>NUCG^8HN1NU*Q']TNW_ ([C^M%P/+U"TE/"G=$3
M]<$?RH N"L[6M1;3M/9XD#W,A\JW0CAI#T!]JT1TK$.F+?>(CJ%P9=MJHCBA
M8?(3G._TR.W0CO0!9T+33I6E1VSF)ILEY7C3:'8G)./\]*TZ!10 53O/^/RP
M_P"NK?\ H#5<JG>?\?EA_P!=6_\ 0&H !_R&&_Z]Q_Z$:N53'_(8;_KW'_H1
MJY0 52G_ .0M:?\ 7.3^E7:I3_\ (6M/]R3^E &3J.HS7-A?0M92QHHPLF,@
MX?'?%='69KXSHMSQG@<;=W\0[5IT %%%% !1110 4444 %)BEHH *H$$ZZ#V
M%L<_BP_PJ_5*,;M7G)_AA0#\2Q/\A0 FFG,4RC^&>1<>G-7<53L\)>7L7^V)
M /9A_B#5F:3RXG<E0%!.6Z#ZT <_KN=8OH=!AN/+20&6Z=>3Y:D?(#V))'X5
MT2J%  Z 8%96B:9;VBSWB)_I%[(99GW[LG/;VQCMVYYK7H 3%&*6B@"F?^0P
MO_7N?_0A5RJ9_P"0PO\ U[G_ -"%7* "BBB@ HHHH **** "J-K_ ,A+4/\
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M>+*XP-A#9XZYK2MK9([>)#'&&11G:O /?% [F>!8^86.L2%2.%^U]/?K3_\
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M** $P*6BB@ HQ110 48HHH **** #%%%% !BBBB@ HQ110 8HP*** "C%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>chart_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart_001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2* X0# 2(  A$! Q$!_\0
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MPW0_0_RJ[']T_P#70?\ HLU2;H?H?Y5=C^Z?^N@_]%F@VAN_3]42=U_WE_\
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M5Z?YDS=#]#_*K-5FZ'Z'^56:"AR??_X"W\UJ:H4^_P#\!;^:U-0;PWI^J_\
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M_P")_FSIC\2]?\R1?]6?^!_^A-4R??\ ^ M_-:A7_5G_ ('_ .A-4R??_P"
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M:1VRW%W*ZW\UN8C++=6J+9O'>F$E7N;1+=;3$Q>:W1/)0QH75ML]3_P'_P!
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MP_[[_P#H1IE/A^X?]]__ $(UN>068^B_\#_]#J5?OK]3_P"@M44?1?\ @?\
MZ'4J_?7ZG_T%J#:/PKT_S)FZ'Z'^56:K-T/T/\JLT%#D^_\ \!;^:U-4*??_
M . M_-:FH-X;T_5?^DL%_P!:G^Z__LM6.Z_[R_\ H0JNO^M3_=?_ -EJQW7_
M 'E_]"%!M'>?^.7YLL4^/^/Z1_\ H=,I\?\ '](__0Z#:&[]/U1,OWU^I_\
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M7HOR0M%%%!TA1110 C=#]#_*K-5FZ'Z'^56: "BBB@ J]IO_ !^VG_7U;?\
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MM(\2R^"/#T&B_&*VBL0%@MM<F^SZ/XSE01_9->&EZX6;^V=2DM?WN_X(5?\
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MQM\-[ZZ,'B3X6^,)HP8KR\TRTFF\*^*;-VD>XM9=.\00+')>V;0_W7?L,?\
M)F'[)7_9NOP>_P#4"T6O-_\ @H[^PKX'_P""@G[,WBCX+>(ULM,\:Z>;GQ3\
M'/&UQ"C3>#?B+:6LL>GR/-Q*F@^(HP-"\301L!-ITZW022YL+4+2C>*:W3;]
M7V_(_-.'N(HY'Q)G&'QO[W)<TQV/PN9X><5.G&,\=CJ<,4H-J\J7M'&K:_/0
ME*ZYJ5-O^5G_ (. ?VG_ (;?MD? '_@G5^T/\*;L2^&/&^B_&8ZAI<LJ2:EX
M0\764_@&#Q/X+UQ%(,.JZ#J&^'<RJE]8R6.J6V^TOK=F_ ?]D3_DZS]F?IG_
M (7_ /!_/_AP_#_Z=<5QWQ6\)?%3X.^*/%?P#^*-KK_AO7?AIXSURRU_P+JL
M\RV^A>+[<PZ9J]Y#9N3;B74+:SL\7]H!'J=A%87"2SV_V<UV/[(G_)UG[,__
M &7SX._^K"T#'Z5%VY)O^:.GS7S/WC+LMH91D53 86K[;"TL-F,\-4YN>^'Q
M*QF(HQYTVI\E.NH*:DU.,82NVV?Z#'_!P7_RBQ_:-_[#7PO_ /5G>'Z_S7@<
M8^G)]!NZ]Z_TH?\ @X+_ .46/[1O_8:^%_\ ZL[P_7^:^O0GN%X_-O\ "KJ=
M/G^A\CX5_P#)/XO_ +&E;_TQAS]B?A#_ ,$V?^"PWQ'^%OP_\>?"#X>?'#4/
MA7XP\*Z9XA^'M]H?Q?T_2=%N/"VHI%+IESIFE2>.;.33K2XB^>*TDLK=HPGS
M0H54'T;_ (=2?\%R^_PQ_:$Z]OC?IG3\?B%U_*O[>?\ @E;D_P#!-[]B0DDD
M?LY?#H<_]@QL_P#UAV' XK[\I*GHO>>R_K<^?QOB%FF'QN,H0R_)YPH8O%4%
M*>&GSS5'$5Z2G-QLG.2IJ4FE9RE)JUS_ "R/VROV-?\ @H5^S/X.\&>)?VR/
M"7Q,\/>#_$_B2_T+P;<>.O']KXPL[CQ%9Z8-0OXK&TMO$VN&SN4TS:\EP\,(
MDB3R_,;&ROACP+_R.OA#_L:/#_'_ '%[+G_/I7]OO_!UW_R:S^R?[_'WQB3W
M_P":? <_@<5_$'X%P/&WA'G(_P"$G\/\_75K.ER\LDM]G][_ . ?I7"^:5LY
MR2CF&(I4*-6I4QE.5/#P=.BE0Q%6E%QBVVG*,4Y7>KUZG^Q1I_\ R#M,_P"O
M"Q_](XZO+]]?J?\ T%JHZ?\ \@[3/^O"Q_\ 2..KR_?7ZG_T%JV6R]%^2/YX
M6\_^OD__ $IDK!<'(##:P*L-RLK*5974Y#JRDJRL"&4E2"K$'Q+4?@GX;T"]
M\3^+/ =MJ7A_4]<T=[#7/#_A-[#14U^*..Q@MDM)[:UMKJ&^TNPBU0Z);3ZB
M=.&IZK<W$ME+-/&8O;FZ'WR/IQUZ&GW=Y8Z9:W%[J5Y;:=:01O<37E[,EM;Q
M001-)+*\LK(BQQ(K2.^<*H!YR*F4H05ZDH03OK.48JRWNY-:+SLCT,NKX^AB
M:;P$\0J\J]&I"E1]I-5Z].I'V$:E&+DJUZCC%0ER.3:BJD4V?+_@FS\)7WB+
MP=X.\)>)/B1I?AWPG<WE[K5U?ZW?66H^(]4L701Q^+I-9TI=<O;&'4KJY=;P
M7!T>75H+BVCC7[7',_C_ ,4OC/8?'KXB67@_X=:Y%J/ANPT_XB>#?!.I>#UM
M8O%W_"\(%NO"-WKGA'4M6U0Z-<:9X4T&\\07$^I7#7&G Z=<VYCBEC19?/?V
MI_$WASXUZAH_P^^#.GOJOCVQ\3G5X+J#QPW@#0_B%/X;TUYX?!RZGI,&HPZI
MHVNWSKHE[<ZU D]C8W5[J>EPW4T-G M[]COX=_%WX3_#1[+XJZ3/IOCS3?B7
MXXOK718WTC6VO;'6M,_M\7$]Y>2Z?HD6FVNN1WUE=^+TM1+K]@EC?ZJ\XU.V
MN7\'^T,/.,G@Y0K4OK%IUE%<JE'1QBKRYK1O)N#Y6U9ZM'].87AJGBLHQ.+X
MOQ&=9-CY9;"$<O=7"X.CB*U6M4E!XC QEC*T7BO9X/W5B7">%I.A4^IU%*L_
MN'X&C2/"WA/3_@Y9OJ\E]\)=&T?PW)+KEW>W]]?V5O)J5DNK?;[RVCN[RWO]
M4L-3V7^I/;ZEJ5Q!-=W&FVJO&\GXY_\ !R[9FZ_X)5>.IOF!T[XS_!:]! ."
M'US4-/Y^4Y %[NY*C(!)) %?KK^SU<#7_#^I>-O^%C:S\5E\2WUPUOXNU&WM
MM,TLM9W=U:WFF^$]"BMK*ZTCPU!-;P3V,-_;O/<7$]Q+'(D2R1S?FM_P<->$
MI_%G_!)S]HJ2",R-X5UGX5>+G"@LR0:5\1O#]K.X*JVT*M_F0G8HCW9<DA#[
M[ESTW.Z:E'F5HN*5UHE%MM)6:7E=V6I^,XR4*/'6"A[">&GAL;EN%Q=)N,G]
M=IX6G3Q=1-*+E&KB*DJUYKVBC4C!N?)&3_S*QP6(XP3^7S<8^H'TZ\=:_P!@
M3]C>ZCOOV0_V4[V$AH;S]FWX(74) V_N9_AIX8DB) 51G8PR0H!.2!7^/V.I
M(YP>,XY)!_7N.Y.,<XK_ %K?^"8WBFW\9_\ !._]B;Q%:N)(+G]FCX4:>) 2
M0\OA_P +V/AVYSEF8,ESI,T<@8APZL&52"!%-I-WZJR]3Z+Q!@Y8/+)ZI0QE
M5-VT][#O1O[.UUW:MN?=<?WE_P"NO_M.KM4H_O+_ -=?_:=7#T[?CC/T]\]P
M,YZ>XJ/Q3_Q/\V?F*W7JOS/\_P _X.S[Y9/V[/@'I@4%K/\ 9/\ #]^Q$@?"
MZC\6?BI;HA3)\ED.F,Y#!6D22-P64KC\OO\ @AA:2WG_  5H_8?6(X-M\7#?
M.V 0L=CX5\2739!(^_Y0C!ZAG! )Z_=7_!TQXLCU[_@IQ9>'XW61O ?[-_PI
M\/2HCE_L\VJ7/BSQF(BH!5&:+Q1#-M7DFX!(SC/S=_P;L>#Y/%__  5J_9H=
M4=H_"47Q'\9S%4W*D>A_#SQ(0[G!V+YMS$@;'^L=%!#,#63W?J_S/V?!KV/"
M$;MQMDV(E=Z-<]'$SOY?&FO5-G^G\@ #@= HQW_O]SS4W=?]Y?\ T(5!&<AS
MZJ/_ &>I^Z_[R_\ H0K3[4/3]#\CI[/U7Y$^P,Q!Y#^;&ZG[K(P<,C <,K#A
M@0002,8KYC\3_LZ^%M!G\8>,/AQ9:GX;U#7=$DM/$'A7P8UCHD'B""VTZVT^
M%])2RL[:XCUK3=)M[^'0-.>_31FU#6+Z>>V:ZN5G7Z>7[XXS\[Y'/(^?(XYY
M&1534=5TS2+66\U?4]/TJSMH7N+J\U&[@L[>WMH%$LUQ---(JI#!&#+-(Y"(
M@WL0IS6$W!)NHX):ZS<4M&]N9J[\EKY'HX'$8RA7I?4Y5G5]O2J4Z--5)JI7
MIMJD_9034ZD;M0;7.K^[+H?#?@.+PC>^+/!G@SPMXB^)>E^'/!5[K4VM3ZEK
M5YI5]XBU>QF@#VOC"]UO2X?$5_9IJQ"W,,UU%IE]JAO[.)7MY7:[\>^+?QIL
M/VBOB;;^!_A?X@MM2\+KIWQ%\!> M7\,&"S\22?&JTN-0\%ZSKOAF\U2\MM
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M:JSZW<U%%%!D%%%%!M#X5\_S"D;H?H?Y4M(W0_0_RH*+-%%% !4L?W!]6_\
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MJWWAFZDO+*WC;6++4++[-/),RW(:U>3:%,3*P.?QD'_!KQ^Q7D@_&W]HQMV
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MTLK9^%/Q U73](BFDD+M*F@>(XO$>FQH"Y"06L=M#$H5(T6-=AAP::<=;/\
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M_FM3KU/^XW\UJ!/O_P# 6_FM3KU/^XW\UKH/X<A\/S99BZR?[R_^@+4HZ_\
M T_FM11=9/\ >7_T!:E'WL=]Z<?BO^%!NOXC]/T1:7[Z_4_^@M4PZ?BW\S42
M@[E.#C).>V,,/Y\5*.GXM_,U,/A7S_,WI[OT7YL='_K&_P!Q?_0FJY#]X?[Y
M_P#1=4X_]8W^XO\ Z$U7(?O#_?/_ *+JCKC\*]/\RW0G6/\ S_ U%"<%,\=?
MT4Y_*@UI[OT_4M1=9/\ >7_T!:FJ&+J_NRX]_D7IZU-0=<?AC_A7Y(LP=/\
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MJ*I8_N#ZM_Z$: 'T444 (>GXK_,4]/\ 61_[W_LK4P]/Q7^8IZ?ZR/\ WO\
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MT^/[Z+P+XYUVRTN_^(6KZ%KM_INAZ?=Z'%;V=IHXMTLK74=0=9IIFA>/G_\
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M2_MI=(.DQB\:\BN/M4)L]DW/3H4:,:CHT^2\V[W;U<G)MMN]VV][O:[O=O\
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MHM=/T?X)G?E=.%7,\NIU(QG3GC\'"<)*\9PGB*4)PDNL91DU)=4[/2Y\D_\
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MP.\!:KXF\5_L>_LXZA"Q\(?LQ>/OC+<_;?CMXC\,QN3!(FK7UND/P\MU#?\
M"%:7XA\66.GK:+=P%_Q]_P"#<V+^R/VT/^"OW@WS)[>'0/CM/<16<$[K"88_
MBI\8-)9;BUE8JT#1I9&WN88X[P3)$6F^SQNISQ%-UJ<Z4YS@JD)0<Z-25*I%
M.UW"I'WHR[-:ZO>[/H,BJ99@L/FF,P\,+BJV6K!9MAZN8X##8VA4Q%.NYX7
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M1Z."QN*R[&PQF"K2P^)I1G[.K%0<HJI2G1J)*<)QM*G5J0=X[2T:980'>O7
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M'@"PL1X-\'^##?6$D6G)X@:]:R\&V-X?M.IRPK=7=T!'Y?EJOZ2+]\?[[_\
ML]3UF]WZO\SJI8BM0554JC@J])T:R2B_:4I-2E3;E&349.*<N5Q;LKOM^<G_
M  4<_P"":OPO_P""E/@WX/\ @CXH>/\ QW\/[#X.?$Q_B?HE[X#AT"6\U;5'
MTE]*_LS5EU[3[^)=.\@B7=9>1<B0L/.P1C]%[*T2PL;2PC9GCL;&TL8F<@NT
M5G;I;1LY  +ND2LY  WEL#:0!*OWU^I_]!:I3_%_NC_V:G#^)'T?YQ.AUJLZ
M5&A.I*5'#N;HTWR\M-U9)U''1.\WK*\I7>R6MYOX5_W5_P#1(JX>I_X#_P"@
M+5/^%?\ =7_T2*N'J?\ @/\ Z M2*&S]?T04^'[A_P!]_P#T(TRGP_</^^__
M *$:"RS'T7_@?_H=2K]]?J?_ $%JBCZ+_P #_P#0ZE7[Z_4_^@M0;1^%>G^9
M,W0_0_RJS59NA^A_E5F@H<GW_P#@+?S6IJA3[_\ P%OYK4U!O#>GZK_TE@O^
MM3_=?_V6K'=?]Y?_ $(577_6I_NO_P"RU8[K_O+_ .A"@VCO/_'+\V6*?'_'
M](__ $.F4^/^/Z1_^AT&T-WZ?JB9?OK]3_Z"U3U OWU^I_\ 06J>@U"I%_U9
M_P"!_P#H35'4B_ZL_P# _P#T)J:W7JOS!;KU7YHLQ_<'U;_T(U-'U;Z+_-JA
MC^X/JW_H1J:/JWT7^;4CH):0]5^O]#2TAZK]?Z&@%NO5?FB1>C_3^AJ9?OK]
M3_Z"U0KT?Z?T-3+]]?J?_06H-(_%+^NI/1110:!4L?W!]6_]"-15+']P?5O_
M $(T /HHHH 0]/Q7^8I:0]/Q7^8I:#2GM+U_1!1110:!3D^\?^N<G\A3:<GW
MC_USD_D* )J*** "BBB@ I8_OM]$_P#:M)2Q_?;Z)_[5H*A\2^?Y$]%% QN7
M=]W.6/H 1S^6>._TH-NWFTOO,F^U:.T806\+ZC?9B;[#;2PQ-%%*6(N;RXFD
M2WL;8*I/G7#;GX2".29T1_)?BC\6_"'P]T&\U;Q;K%G'Y:L;:P,Y6TEF!*PI
MY!*3:KFX!$AD\N)MH3[ N#)7EOQ'\5_&W1T/@SX7_"[5?$'BS48I+N[\3W\T
M&E^%$O9;MXYM1N=7DD9'):8-$SK<S0VD5C;F*2:$L/FW3_\ @G;XR^)%QJ/C
MW]I/XTZUXK^(+:=J3^#_  ?X3N;C2OAMX+UV\MITM-0OQ(!J/C*[M#*L,DVH
M/'911[WM+2&<"9^FG[*G%5G[\[VC3DHN-TK\S7O)I2V4HVLKZO0]6C# 86"J
M5)PK59-2<4U44'H_=BKJ,HMZRD^:Z=DEH?D_\>?$7C#XW^.=;UN[U:_MO#,D
M[BRTBPF$(F169)/,E0"*&"=!E88(V:(+ACSM'@T_PTO+>PEM[&Q_L^$8 $<9
M1Y@5 1Y)6(DG=!N!E,ASYC$D\5^I_@[X&7ENMUINL:>;35=)N[O3;^!45S%<
MV<SVMRA4*,!I-LD;#<9(I4;*_,!T&K_ ]%B#&U*B-3D%#DC)7.2.,$@D\ >U
M92H/$N->I-^_S+E@HI+E<MXQC&*L[I>7+MHCZR,X0H4^1.4K)N\K1:DDTT]7
ML[[:K9]3\3+_ .&%TTGFR1^:J;E*&/+A2-[(Q&\D*21S\Q4#/)-9EWX$>SB9
M%MXU) .XH,JNW) Q@!E/&2023C/0#]4O$7PB2U,I%LO.YMVP <GD;F4IDC<,
M'GGCC 'SMXM\$FWCF5XR "_RG:A*AL9   QC=SR?E.2=M4J2IVBKVBENV[)[
M7NO\O*X>U=KM<NO+:S=WT^S?7TMIN?FMXM\.B*%B5#X#8^55PRD$DY W'.0,
MY!&>HKY7\4::"TJ!<#S"X8KD*"''3.&!ZG+#&>,BOTQ\0^!+W69VM;. A-Q!
MN)0?L\0)9?WK)C@  E59<;=Q;!)/CWB2U^$7PIS>ZX$\7^)(BABT\+;RVEM*
MHRKA#F-%#,H5I6=@<,O5L>;C\91I*5*-ZU>3Y8TJ4H^\U_>M-)=;I75M5:Z.
MJ%*JU[T>7?66B]-$_-_)GQ+X(_9W\>?$.YBN8%C\.>&2Y:X\2ZW'/!9NBR;6
M2PL52.[U&<#YE2(I"<9>Y1=P'T9:1_L\_ *.2#3()?'OCN& 1?V_=3QRSV%[
M(C)-/I4-NYL-!F0./*N[1Y-7MI%BGCO()84:O!_BQ^T+XZ\7-)I]M/+H6B%G
M$6GZ<7@'EJV$6>XB9';:O#)&$C*YQD5\OM?O)*SR/(), Q%I&WALY;+A@[%V
M'1OO8"L&"@#RY4,7B4JF+J<E%12A1IU)N<M4DIS@K)I:OEC%/NCIYJ$(\L%!
MS27OMN7F_BLDNUFVNUC[H^ ]C\*O!GCG6/'GA+P1IEMXW\3:E-J6K^//$NIZ
MS\0/B)>M<2(BV\GCSQQJ&N^)(K6SCAAAM[>VO[>&.)%X8",C]>_ ?C;67.E^
M*-(O7@U_0[NUU'3;OS6:2.[M9(V25I6<$-Y;F,YD$;Q!E.%4L/Y_? 7B.:SN
MH?WQ5E=0=N2Q(())Y4_AD* 0>1@5^IOP*^(7FQPVLDY82+&C1N&"R-'PV 3M
MR< */F/1>I%=%"FJ=124596UE>4M$DO>G>3:MHN9*R7NWU>L(JI2J0DDU4@X
MVLFKOF6JV:UU75:,_LL^!_Q4TSXS_"_PG\0M,*))K5A&FLV8='?3-?M MOJ]
ME)L/RB.]5VB!"L8)8F(P=Q]7;H?H?Y5^%O\ P3P^.]OX*^*-[\*=?U06OASX
MH(;OP^ES*D5I8^,+")V@\I9"D<*ZOIZ364S(P#W-M8AUW,I;]S8Y[>X1W@GA
MG16>)F@FCF594!WQ,T3.JRI_'&2'7^(#BO6C)22=U=K:ZOUZ7/SK'X2I@\34
MI37NIWA)7Y7!V4=6DO)*]_=VV+U%%%4<85+']P?5O_0C452Q_<'U;_T(T /H
MHHH 0]/Q7^8IZ?ZR/_>_]E:F'I^*_P Q3T_UD?\ O?\ LK4&E/:7K^B)J1NA
M^A_E2TC=#]#_ "H,ELO1?DA:***#I"BBB@!&Z'Z'^56:K-T/T/\ *K- !111
M0 5>TW_C]M/^OJV_]'+5&KVF_P#'[:?]?5M_Z.6@JG_$I_XX_FCTJBBB@]X_
M %/O_P# 6_FM3KU/^XW\UJ!/O_\  6_FM3KU/^XW\UKH/X<A\/S99BZR?[R_
M^@+4HZ_\#3^:U%%UD_WE_P#0%J48R.G+*1],J/Z4&Z_B2_PK]"TOWU^I_P#0
M6J8=/Q;^9J%?OK]3_P"@M4P('4@<MU^IJ8?"OG^9O3W?I^HZ/_6-_N+_ .A-
M5R'[P_WS_P"BZIQ_ZQO]Q?\ T)JN0\G/8,3^'EBJ.N.T5UM_F_R3?HF]BW0G
M6/\ S_ U%"=5_P!DD'VPK"@UIZW:U3M9J[3UEL[6>SV;V9:BZR?[R_\ H"U-
M4,763_>7_P! 6IJ#LC\,?\*_!*_W75^UU?<LP=/^ 1_R:INX^A_FM0PD ?\
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MSI: "BC(]1W_ $Z_EWINX>A ]<<?7\:!72W>^PZEC^^WT3_VK24L?WV^B?\
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MWI6>EDHWUOIJ?C%X^A\6ZA#<6UC%/I-K(K+MM 1(WR_,K21X901M) [Y))W
M#XC\9?#BZ+R32K).Q\QW\QRS$_*26)4E@_&P X!0]<FOWG\;?#""V69?LRD
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MUY=W>I:W?:3K+ZD]KJ/C7PPOAS1/#YT7PMH6K6FN)J5VT5W'[E_P55_:B?\
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MC.#7\XO[#'[</_!;']N_]G_X<?M/_#3X,?\ !*C0?A-X]\0>*-,AL/&?BO\
M:YT7Q_;VG@?QQJO@KQ--_9NEZKXKT"WN9KO0M1FT-VU:\BF@>RGOK> M+9I]
M"_M&?MI?\%"+G_@I-XK_ &"OV'?AK^Q1X@@\&_LD^%OVIM4\5?M7ZC\=]#OY
M=+UGXCQ?#G5-'LM2^$>NW-E-<0WVN^&;BPL9_"]KBV&MW-WKUQ,+.R;E?^#;
MD _\$>?V9N,_\59^T2>?4?M _$3^1)Q7S7\<OB_^T/\ !;_@X+^*WB7]FO\
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M&K_8DDU7Q#J/VWQ#X6\47.GR0:8UG:6_S]_P6%_X*B_'G_@G!XY_8TT?X+_
M3P9\?M%^.,?[3GC/XQ>']:_X2F#QOI/PJ_98\+_"OXF_$35?AIJ6B>*-$T/2
M=8L?A;XA^(^OWVH^+=$\8Z=9-X;TN\CT:YAM+[3-5^7_  ?^VC^REX)_X+T>
M$_%/[/?[2WP3^,7PQ_X*H? "S^%/Q?LOA1\3_"7C"'PC^US^SBCI\%_%?BNS
MT"_NWTJ/XA?#FXT[X2>!+=HT.O\ C/Q9XGN T[65W);_ $Y_P4(57_X+"_\
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M)9[6\MIHWBGMYY8I$9'96Y/_ ((O>,M&_8R\(?\ !1C_ ()T?&;Q0=!\-?\
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M#I?A_P 6306\NNV(L4L;@WC1<7%Q/;J\RP+(_P \_MC_ +?7[?GQ>\">"_\
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M2[67Z(<E=;NZU5VWLGY_H?GKXIL7@N9PTJ27"R0VTDZJ6MFOD@6;2M55R/\
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MA]BJTM96V;V2U>C/TJJ6/[@^K?\ H1J*I8_N#ZM_Z$:ZCY,?1110 AZ?BO\
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MAJ.$]ZA6Q4\$O;4,-3C5<:*DG>=-QF[G\_-W_P $]OVBF_X*_MX]A\)V,O\
MP3UU?]H#PK^W_JFJC7_#:K8_M8>$?@;XD\)VMN?"\GB%?$]UKVJ?&?5#XXN=
M43PNVG+HUY'NU>2[MKG=]:_\%<_V>?VBOC%\'O@E\4OV.O#L?B+]JS]F#X^:
M!\3OAI9)K'A_P_?:CX6\1^'M>\%?$OP]::QXFUC0-$MXM3@O?">L:K!=ZM;M
M?:7X5GM+;SKN6*&;]6H@"9#_ +2\CN-@X^A_6IB >HJ7"+I4Z322I3E.#22<
M6Y1MRZ-1480A2TOS034K\SOZRXCQ[QV69A.GAZD\NP5+!1HSA4=#%T8TJE+$
MO&)SYJM3&JI&6*E%Q4Y4:/+'EARR^4_V!?V>A^RE^Q?^S+^SU/8Q:;K7PU^$
M7AFS\9V5O<6UW!%\2O$BW/C;XIB"]M3);7D#?$GQ-XK:WNX))H;FV\F2*:6(
MK(_U7K$$MUI&KVL"-)/<Z/JMM;H&5/-GN+"XAAB+N5C0R2NB!Y'2-2VYW55)
M%N#I_P  C_DU2D D9]#_ $JZK=9U'+1U%*[CHXW@H+E>_NPC&,;WM&*7KY+Q
M-2KBIXJJ_:5*N(GBIN;?OU*E=XBIS-/FM*7NNTKQIJ,8M<MS\X/^"/\ \!_B
MS^S+_P $XOV:O@7\<_"$W@/XK> K7XM1>+/"<VK^']?FT=O$7QV^*/B_0Q+J
MWA;5M=T"Z:_\->(='U3_ $#5;H0+>K:W7D7L-Q;0P_\ !3'X!_%WX^Z?^P;!
M\(?"$OC&?X-_\%,OV4_V@/B3'%K'AW1_^$9^$7PXM?B5#XS\82-XBU?1TU.+
M1)-?TD-H^BMJ7B"\^UJUAI-VL4YC_2J,#:I[[Y!^&YS]*F7[Z_4_^@M3<I2E
M&<G[\9T:ETK7E1=.4';6U_94[^CTU/5IYE5688C,U2H^UQ%7,:LZ7O\ L5+,
MJ./HUDK257EA',:KA>?-S0@W+<^"O^"D_P"R%JG[8'[.MSI?PTUG_A"_VF?@
M?XMTG]H#]D?XEVL\.GZGX+^/?P^E.I>';--5F:*.UT3QW#"WA/6%U"630].U
M"X\-^-=1TW4KOP3I=L?"OVAOV8?VC?VY_P!F[]DW]H$:-8?L<_\ !3']ES7H
M/BW\.;;Q+?:-XC\!:%\31'9Z-\5?AEXGNO >L^.-,OO@E\:E\+Z1J^GBVN_$
M6J:9H T/0/%.FR17OC?29_UP;H?H?Y5=0#:W'_+0?^BS6;CHU%N"=6G75OL5
MZ:<56IZI1E.FXTZB:E&HH1E-2GJ;X3-<3AZ6&I15*?U2KB)T*E2,IM4,92=/
M'8"I!R5&O@<7-NM.A47-"M4KRI3H^VDX_D)8?MU_\%)K32;;PMXC_P"",?Q3
MU#XUQVBV]Q)X1_:C^!$/[.NK:M&WV=]6LOBSJEWJ*^&M"OI8FU&#P[J_]N:W
MI=E)#I=WKVHW#?VU+ZU^P)^R!\7OA%XU^/O[6_[7WBGP7XU_;3_:VU7PS)\1
MH_AQ;WI^%_P2^%O@:U33_AU\!?A?=ZF&U?4M)\.Z?!82^+M>N9I8]=U72-!M
MQ=^);OPU<_$+QO\ I)@97C^)?I]X=NG>K&!Z?Y]/I[=/:J3Y&YI+VG).'/:S
MA&:@Y^RC%\M.4_91C*2;?LU[.+C&53VFM7,(NA5PV%P.$P%/$>S^M.A/%5*F
M)C3G[6%*53%UL1.CAE6:K/#4;1E.%)SK3]E"WYB_\$O/V??C%^S[I7[>5O\
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ME"@Y1G&"A'FA1E*"C.IAZ&&HSERT7S?B[_P5"_X)D>"_C!^R/K]W^Q#^S_\
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M>%?#7Q1FUSQQJ/A[5_%NF7#>'/"M_I6C6ES<7VAVM[_1DO\ K4_W7_\ 9:L
M8(/?>O/U8<>F/;I[5#2M72VQ%+V4]4VM*,95(M)6J5(453G)J\H<LOCA3E'I
MH9A5I4/JWLZ52E3QE+%04U/FC[&LL1&AS1EK1E6C&<H.ZOSM*]2;E^4O_!/?
M_@EM^S=^S;^Q1^S;\'OC%^S+^SO\1?C-X<^&VF:Q\:/&'Q%^"_PC^)7B[4?B
M]XYNKWQY\1M-U+QSKOAKQ!?^([/PKXJ\2ZCX*\/ZG_:]W:3>&?#6C"R86"6Z
M)YUJG[$_C3]FC_@KA^S;^U?^Q_\  3PMHG[-7QT^ /C_ /9B_;B\)_"33/A?
M\,O#/P^/A_6K'QK\&?C:/ B:KX,@U[5-2\23Z!X:UNY\&Z!K_B#2_!_@#7F:
MQEO/$<-KK'[3T^/^/Z1_^AU<I.595M(M3G+V5/W*3C4ISI3I.,;/V4J<[6MS
M*<85(R4N9,IXNOS8CFJ2JK%4ZL*L:LZDKRG5C756FE.4*=6G6C"5)QA:,::@
M^:',I_CS=_MY_P#!27X?>+?%O@?XA?\ !&7XS?$-].\:>*]&^'/Q-_9\_:-^
M!NN_#SXD^$;37;ZW\'>+-<L->U:YU+X.'7/#[:1=ZEI_BS7=9NK&XFU"6YM]
M+>"XT6P^.=(_93_X*3^ /V:/^"P_[6%A\$/#>E_\%"/^"I&H^"="^'O[+'PH
M^*_@74;']G7P!HGA_P 0?";3-=\4?&G5-;\(>!/$'Q>\.?#[XC>.O%^N^(?"
M^JW>FZIXU\->$M8T^2SU+Q9XAT+PC_2BH^91V)((R<8VMVZ5/@>G^?7Z^_7W
MJ'&+YE+FDYT)8><F[-TJDJ#KI1BE34\0L/"-23CLY\L8J32ZH8[V,DZ&%P]%
M>VH5YQC]8J*I+#2G4HP?M*K=.E3JRC44*;;<J<4ZG*E _//]F7_@F)^QM^SY
M^SM\#O@AK'[,7[+OQ&\0?"WX6^"_!GBKXA^)OV?/A1XHUWQ[XSTC0K.'QKXW
MU#6_%7@_5=>O)/%OBUM:U^--1OIY+.#48;&(1VUO%$/F[X5?L:_$C]D;_@K_
M .+_ (R_LV_!+0M"_88_;2_9AT#P]^T-9?#?_A7/@+P7\%/VF_@.^K0_#/QC
M%\+[*_\ #UZV@^,/!-E_PB\9\ >&=4#^.?B=XN\1>(HM/B%YJ=Q^SN .<=.?
M\X_3T[5*OW">_P _/_ B:UE4E.M[;2+<JS<$OW;C7IU*4Z;BFO<2E3E!7;@Z
M%-IIWD\8XFLH5Z,YSK4\135.:JSG-I^TIU8UH6E:%6%6$JD7&,86J3@X\C<7
M_-3^R]?_ /!4']@SXG?\%$_#OA'_ ()*^-_VF_ W[1W_  4L_:O_ &L/AY\4
M-$_;,_9G^$-C?_#_ .*OB/2['PC"/"?BB3Q3K\,MYHWABW\0&;57T>_BAUV'
M3;S0["[TVX-Q^[/[*_Q4^.GQB^%K>,?VB/V6];_8^^(H\5:UHO\ PI_7_B_\
M/_CA?/X<T^UTNXTCQDGCGX;6MEX=^RZ]/?ZA91Z));1ZIIDVB7$ETTMO>V<C
M_0B*"@R.A8#D]-S8J>( %L>B_P#LU3%J,%#E4N2%*E"3]UQC1C""=HZ2<H04
M97]UMRDDG9+IQ.)^L3J5)4*-.M5JRK5*M-UKSG)+G]VI4E!)N*LHQ7*HQ2=K
MM_C+_P %G_@;^T]\7?#/[ 7CC]E?X#7_ .T;XS_97_X*-? 7]JGQ7\,]-^('
MP_\ AI=ZOX(^$>D>,=3O[:+Q5\1M;T?1;"75]3GTG0()X(M:O+.XU5+\Z/>V
MUK.E8NM?M0_\%O\ XUZ=>^ O@[_P2X^%?[%?B;7(9K.']H_]J?\ ;4^$?QP\
M%_#<3XCDUO3/@Q\%/#,WC'QGXDL()6OO#8OK?4_"$.MVUHGB?0M<TAKS3KC]
MN2H/)%)@ KCUQU/H:F*Y8RB[M2J2J6NX>]4A3A.\H6FTXTH*R<=+J^MTX8IQ
MC1BZ%"<J*Y*52K&I4E%.M.M_#=2-"24ZDFE.$T_M*2O%_ _[%?["GA;]A?\
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M_7U;?^CEJC5[3?\ C]M/^OJV_P#1RT%4_P")3_QQ_-'I5%%%![Q^ *??_P"
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M.I.X^A_FM1Q_Q_2/_P!#J3N/H?YK5&G6/^*/YLDC^\O_ %U_]IU=JE']Y?\
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M1:EX1TQ+1EU*.^T%;83QWNH7&D^!?\$GM;T/P]^S[^V%XD\2ZK::'X9\.?\
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M2A1Y?;2YJ^&H^QA3<(U(T:CII1=2_P"S^C?M1>&KS]L7XH?L4^(?"GB/P?\
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M%_M"?M9?\$F?A]X ^%?[='@&Q_:#_8=^%.D>"OA3X+_X*#_L]:9?1^*?A/\
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MXZN])^$Z_%R:\\'I#<%[&VFTESI,2:W]G<:B8I6(MGF$&'_P3&8/_P $V?\
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M*PNXDN++4=/NX2T%W8WUK)%=6=S"[17%M+'-&61@:_%__@J%X&\'?%#XL?\
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MT/\ *EI&Z'Z'^5!DMEZ+\D+1110=(4444 (W0_0_RJS59NA^A_E5F@ HHHH
M*O:;_P ?MI_U]6W_ *.6J-7M-_X_;3_KZMO_ $<M!5/^)3_QQ_-'I5%%%![Q
M^ *??_X"W\UJ=>I_W&_FM0)]_P#X"W\UJ=>I_P!QOYK70?PY#X?FRS%UD_WE
M_P#0%J4=?^!I_-:BBZR?[R_^@+4HZ_\  T_FM!NOXC]/T1:7[Z_4_P#H+5,.
MGXM_,U"OWU^I_P#06J8=/Q;^9J8?"OG^9O3W?I^I\1_M\?LS?$+]L'X0>$/V
M?_#7B/P=X:^&'B[XW_"36/VG6\2ZGXEL->\4?L[>!O%5IXR\7^ ?AW%H'AG7
M+6?QKXJUS1O#1LYO$.I>&M"M['2KVTOM4\O4SY7VGJ7ACPEXCTS6/#OB#PKX
M?U/PQXATS4_#VN^'9-)L5TS4O#FM6$VF:MH4D"VZJ-/O=*NKG3VB4(!;R[1A
M1@VX_P#6-_N+_P"A-5R'[P_WS_Z+H<8N-2#5U5E*4V]9-RH_5TD]XQC2YHQB
MK)<\Y.\I-OUGC,1+#8+#>T5.E@98BIAU3O!^UQ5>GB*U:I*,U[6LIT*$:=22
MC*G1HTZ<&DN8_&;1_P#@G5^T?8_L&_!+]C35_B=\(O$6I?LX_MB_#KXC_#7Q
M[J/B+XB,-?\ V7?A5\6KKXB>$-!\9_\ %LA=:5\8;'0M5OO!EIX:T73]7^']
MGINC>&X8O'R0K<R6OZ4?M5?LY^!?VN?@?\0O@5X]GU'2-+\:6L=]X<\8Z(S0
M>*?AI\0-!O!K?P_^)WA"[AN;.YL_$W@?Q+;V.KV@M=1L?[4L8]2\.WMVNCZU
MJ4<OOE"=8_\ /\#53UC*$FY*;C*3;]]RA1I4%-2M=2Y*-)W47:K!55[[:??5
MSC&XC$4<4W1H5\-B\9CZ,L-0C0A#$X_&1QV)DJ:G5@H2Q,)RC125&%.O7H*F
MZ%25-?A_X)_X)X_MM:1_P3,_: _8[\2?&KX"S?M$?M0?'GXB>-?BW\9?#VN?
M$1/!-M\-/C=XH\,Z[\97\/VTOP;T?5K_ ,>>*=#TWQ-X3B\+W/A/P[X-_L[Q
M;=7"^,K VT5JG[4>$_!7@WP!X;\*>"_!?AG1M&\)>!?#_A_PEX0T9-+T][?2
MO#'A+2[/0_#NE(OV?:T%AI&GV5FH8 /'%\^=S9Z*+K)_O+_Z M34V^923LU)
M4E);*4:.'6&IQ:6G+&BFFDES2DY2;>AMB\RQ6.5ZSITU+%XK'N.&IK#P6+QK
MP[JU4H5)-N$,-1I8>,IN.'HQ=.',I.;_  ]\4?\ !,#X[/\ \$Y/VY_^">7@
M+QS\%;3P1\5?C;J7C+]C*[UWQ#\0-/TSX3_!KQ1\</ ?QIU'X4?$ZWTSX7:O
M=:-)X1U3P_XOE\+7O@V'Q];>(M1\62'5YO"MO&S1?N@YW'=G&5S\I)&0%4[2
M0I*Y'&54^H'010=/^ 1_R:INX^A_FM**Y59-ZQHQD^LEAZ+H4G)[N2IM<TM'
M.482E=QN]L9FF+S"2^L>RBOK>,QMJ5+V?^TXZ&"CBJEU4D_WLL!1J.*LE5GB
M*D6G7G"/QEJ?[-OC?4?^"BO@?]L*'6_!J?#;PM^Q5XR_9JO?#<U]XA'Q!NO&
M_B7XX:=\3;76K+34\,OX6;PC:Z)IKV-Y>W/C"UUW^V)XX;?PY/8I)J,;/^"A
M/[,WCK]KK]F#Q!\#_ASKG@OPYXKU?XB_!+QE:ZKX_O\ Q!IOAE-/^&/Q;\)?
M$#6K6XNO#'AGQ?JZZA?Z3X>O++2(X]#EM9M3FM4O[S3K-IKR#[4C^XO^_)_Z
M$]3+]]?J?_06H2M[-+3V-95Z=NE2.,HXY-VLY+ZQ1@[-KW?=NDHVVHX_$0Q&
M#Q:]E[7 T,/AJ'[M<GL\)1Q=&BJD(S2DU#&5N=IP527+*45RV/&?VM/AIKGQ
M\_9K_:@^#'A&_P!&T?Q-\</@/\</A7X6U3Q3-J%IX=TG7_B=\//%'A#0]0\1
MW.C:;KNJVVB6&HZY:W&L3Z3H^LZA#8QW$EAIFHW*Q6DVI^S/\.=<^#/[./[.
M?P?\4WNCZGXG^#WP'^"/PJ\4:EX;FO[OP]J7B+X:?#'POX+UW4/#UUJVEZ%J
MESH5]J>AW5SH]QJFC:/J$VGS6TM_I>F73S6-OZPW0_0_RJ[']T_]=!_Z+---
MI3C=\LY4Y-7=DZ4:L8.%K.#Y:U12<;.5XW?[N'*H5YO#1P;Y?8PKU,2M+3]I
M5P]'"S3FG>5-TZ%-Q@TN6HI5(RYIR1^,'P+_ &<O^"JW[+5S^T#X9^"Y_P""
M9?B_X=_%K]K/]H+]I+P]??%WXB?M@6'C[3[/XU>+HM;L_#^MVO@7X*+X:M[K
M2M-L-/CNH].N=3A74)+M8]5OK=+>X?Z2US]EWX^?&C]K?]BS]H']H75_@4G@
M/]E#X+?$G6KSX<?#'5_B+K=IXA_;+^+5A9>"=;\7:7HOCOP%I>GW7P;\"_#V
M"XN?AKKOB/Q*/B3IGC::6X?PK8VE[=ZDGZ(]U_WE_P#0A5BIM;D?Q.E&"@Y:
MN/L:$Z%/72ZC"2M%JW-"G+>"/4JYOB*M2K6^K8"E7Q%/%TJV(H865.O46,A2
MIUYN;Q=5*K*%.RJPITY156O%-1K31\=?MZ_LGV/[9?[(7QK_ &>-.N]$\(^,
M_&?AVWU;X5>-;E;C2(/!/QA\#ZU8>,_A?XEN=;T'2M3\0Z'I</B[0],TSQ/J
MWAW3=2UVV\(:IXA33-,U:[EBTZY\BNOV5?VC_CU^U#^S)\9?VP/%?P4U3X4_
MLG?#SPOX]\$_"3X3:UXYUZV^('[>EYX<T[3?&/[1GCRT\8_"_P ":1I?A#X9
M7UUXG?\ 9Q\/:?=:]X@T>]DL?&E_/X4O=9\0^#G_ $FCZ+_P/_T.I8^A^D?\
MS127*E);NI"HE=VC4I4ZM"G4BDTE.-*<XI]9*C5:=3#T'&5F>*I8=89.G*#^
MN0IU*D'.M1AF%.E1QD:-64VZ?MZ=/DFU&4K5<1RRIO$59/X%\4?LG?$CPU^W
M]X)_;2_9X\1_#_P]H?Q-\"1?!S]N[X9>-=2\4:';_%_PAX4B@'P7^+G@)_"W
M@WQ99WGQU^% >X\.QMXO&@Z5XB^'EG:>"[7Q1X475=;U>7Y[_9,_9B_X*4?!
MKQ5^WMXP^(?BC]@S1_$/[6VK>+?C5X UCX2ZU^T5XT7X?_M'MX0\*^#? =EX
MB\-_$GX7>$-/O/@?!::1J6J^+OLVJZ[X\>^.GV6EQ76GSWCVO[$1_P ?TC_]
M#J3N/H?YK0HI)6<E:-6$6GK&%:I&K.$;PM&/M4YPLFZ3G4C!^SDXF\,TQ'LW
M1J4\+752&!H2G7HRJUI0R^K4J8/VDWB(>UE1]JZ?/5IR=3#QIT:BG&G":_'7
MXT?"3_@K1^UK\$O''[+'Q6TK_@GM\!O!WQ>\//\ #KXS?'OX5>.?V@_BSK<_
MP_U^ Q>-1\$_@MXU\">$([/Q#JEB'TBU/Q0^)45MIFG7VH3:?J/]LIIVL6'W
MYHW@[X]?#CXI_ +X;_"NV^#D'[$/P[^ <O@#Q=#XNO?&=]^T;!XS\$Z58>&/
MA1#X5N[&&W\"7_AB+P[I6A1^(;O5[:+4;N9?&%S)';W<GA)1])1_>7_KK_[3
MJ[2A)J4K6_B*I.ZYE5DJ%3#051/1QA3JRY8QY%SVG+FDDU=7&SK*--T,)2I)
M5U&A2H3C"%7$RH^TQ2<\35J/%*.'ITJ56I5J1HT>:G2H1C)MV[.189;>5]VV
M&:.1]O+$1R!VVY(!)QP,@9ZXYKX>_P"">_[,OCW]D?X*^-/AI\0-?\%Z_K_B
M+]I/]H;XTZ9J/@#4?$.H:1;>&_B]\1+WQCX<TZ\N?$GACPEJ</B32[&[2VUZ
MVMM-N-*MKU"-,UK58"9E^VE_U9_X'_Z$U3)]_P#X"W\UJ9>ZTTW=TW3>KUCS
MQJ;;7YEO9WBW%WBV1"M-4J^'7+[*K6HUI7BG+GHTL51BE+F3473Q=:+BM[J5
MTXZ_BSX0_P""6GQ ^%G_  53^'W[8?PI^(?@+2OV/=!F_:1^*&J?L\:I=^)+
M/QEX"_:&_:E^%J?#OXP:Y\(]*T_P/J7A-_AYX[U7P9\-?&^IZ-K7C_PY'X9U
MB;QC9^$_"\.F0Z?#J_TOXCU7_@KEX8\?_$32_!'@;_@G=\8/A?K'CSQ=??!3
MQCXS^)W[0WP?\=>!OA]J>KWM_P"#M!^.7A3P]\,/'.B>+]7\*:?=V?AVZU7X
M7:EITWB33M(BU.]%IK=_>7$?Z+I_'_NC_P!GJ;NO^\O_ *$*>T:-)-\E*G.%
M*-U[L)3<W%MIRGRNT:<IMRIT_P!W&4HI<OHO,*M>I*MBZ.%Q=3V&&PU\31E-
M>SPRFX2:A7H)U*CG+ZRY.4<3I[:"L^?\?= _X)3W>K_L)_M(_LU_%3XV0W/[
M0_[6'[1_C_\ ;>^(?QZ^'GA2YTKPM\-_VO/&'C3P?\0]"\1?"/P;JFHQZQ%\
M/? NN^ ?"VBK8:MK-AX@\7:$WBNZ,_A*X\0V6F^'M75OV=_^"AO[7NN_ ;P;
M^W?)^QYX!^ _P3^*W@?XY?%/3OV9O$_Q;\<^*/VL_B=\)9X=:^&NA3:1\1?
M_@[P_P#"3X%2^-2OC?Q[X=OKCQ9XPUV_T'0_#>CQ:-I<DFN:5^NR_?'^^_\
M[/4]1%\CO%12C*C*,+)PC/#05/#347O*C"$%!MOF]G3]I[3V<;;/-<9-SG.=
M*K5E/%3A7G0A[?#RQU)4<5]6G&4%056G3@DO9UHT904\/&C-RG+\SOCW^S;^
MU#X+_:Z_X;D_8ENO@GXF\9?$+X.Z-\"OVG/V?/C[KWB[P'X.^+/AWP+K6J^(
MOA7\5? OQ+\$>&O&%_X7^,G@:;5[OP7<VWBC0+_P;K/PWEFM8?L'B"%)]0Q_
MA[^Q_P#M4:-X%_;_ /C9XK^*WPGTO_@H?^V_\/[GP=X4\6_#J]^(.E_ 7]F;
M2OA[\+O$?PY_9L\&^ /$6N>'-6^)-_;^!=6\07WQ(\>_$2/P-IVH^)_&^HK>
M6?@>=O#=EJOB']2E^^OU/_H+5*?XO]T?^S44XQ:=)J\73K4XWUE3IUYJ=:%.
M>DDJDY23E-SE&%2I2BU3JU(O:&85X0IP4</^[6#BZCH1E4K4\OJ0G@Z%>4JC
MC5HT7"DE3]E34XT,/&K.HJ%%+\4_V9O@7_P6 _91_9^^$W[.?PH^'_\ P1?T
MKP)\)O!NC>%]/>+XB?MU:??>(M5MK& >(_'GB5=*^ ]G:7_C;Q[KOV_Q9XOU
MG[.L^K:_JM[=R'#(B_LMX,?QI)X,\(O\2(/"5M\1G\*>&W^(5K\/[O6[_P
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M/\J#);+T7Y(6BBB@Z0HHHH 1NA^A_E5FJS=#]#_*K- !1110 5>TW_C]M/\
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M00?R.*#0*<GWC_USD_D*;3D^\?\ KG)_(4 344A('^?\^^/7&!1N'K_G_/\
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M?[*M];V=WXTU#XD>![*&WEU'P#X]U-]2:&Q,124:%K-U-<ZCII@E5U@D@N#
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MHUG?Z7?M8:]IMG+JNE:UX>UOP^=8T3Q'H&HZG_)1^Q[^V%^PQ^Q1_P %CO\
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M_P#%[1O@?\-OVL-)G\<^*M;L/#7@A_&'PX^+GPY\+>.?$&IEH['1M!\7^/?
MGA[0M/U"\NA'ING6WC*Z\*/K>KW=AI&@#5M1O[2VE^WO!G[8O[-?CS]J?XD?
ML0^%/B<NI_M4_"+PE:^/_B-\(KGP-\3M!O?#G@[4AX$FT_7$\8^)?!&C?#C7
M[>]M_B=X#N[>W\+>,M<OY;+Q%%?"T%GINN3Z7_$E^W[^U=^PA^WM_P $WO\
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M_$K]J#XO_L8^ _BG'XF_:7^ ?A;3/&GQA^'%CX(^)D-IX%\/ZO%X.ETV>_\
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M>#?"/P1\9^.O =S\+E^$/PO\5Z/\2/$FM^/-#TO3/'>@>%)/&_B'X>>!VO\
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MDN=3UG6];^$/C+3-(TG3K:(&2ZO]2U&YM;.S@C!>:YFCBB!=E4_S\?%'XC_
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MQOD.3AY"^5K]#:\X\;:397-_H=ZZ!9A)<V\KH@+31&-'42' 9Q X1B"X"1@
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M8TENG>KA<;BE)-/X/8X&I"^_)*G%-T5.W9#!XB=&O6G)TXTEF#K4ZDJD9Q6
MIX2M7C4BY1;E5^NPE%3NN:$Y5$GR37Z)6.F:983W]W8Z7I=E=:EN?5+FSTZR
MM;K57D:=I'U2X@@2;46D,]QYC7LD[2&XN&<L;B8OC:)X#\">&]*M-!\-^ _
M_AS0K'5+O6['0_#_ (/\-Z)HMEK>I30S:EK-EI.EZ9:Z?:ZOJ$\$,U_JD-O'
M?7DL,<ES/+(@:OG'Q/\ MX_L7>!?C1!^SKXO_:>^#_AOXT3ZWI_A63P-JOBA
M(9=+\7ZN&;2/!7B7Q(MO)X-\(^.=8RJZ1X'\5^)-$\6ZFTD26.C3O/ LO<?&
MO]K#]FC]F[^V5^/GQS^&_P ))_#W@&X^*FK:?XU\0PZ9K$7P]LO%^D^ 9O%%
MGH:I/K.L6;^-]=T7PE:6NBV&HZIJ/B'5+/2M-L+N[F6(N,G=3C>TH\BDOA7L
MDY6IM)*/L]9)1^#648KXEK"AC7)4W0Q?M:B]K"G[+$>UG"*4'54;.K))RC!U
M-4E-0E)1DJ<_6Q\//AY_PFL7Q&_X5UX /Q%@ C@^(;>"O"Y\>P)$7,20>-#I
M1\30I&Q9XUCU1%1V9E 9BQU=8\)>%/$.H^'-8\0^$_"_B#5_!^HR:QX.U?7O
M#FC:UJOA#5Y=@EU7PKJ6IV=S>^&]3E$48EO]%GLKJ01H&F8  ?+?Q8_;^_8I
M^!4?PZG^+W[3/PL\"GXL>#](^)7@"QU/5;Z]UG7?AIXBMGNM$^)5SX?T;3M2
MUWPU\-]1A680^/\ Q;IV@>#TGL]2M;C6H+K2]2AM<3X\?'OX>_$S]DOXY?$/
M]GS]NWX0_ +3_!NMV7@>^_;'TO3_ (<_'CX<_!;QEHOC'P$?$&G:MHOB'5H_
MA]XEN]:TOQ'IG@Z*.]U9K6S;X@:-X@TN>XNX]-$V335U&$I>SFX\L5=PDJL:
M3BE9\LU5DH.*Y*CJOV>M24:;UIT,3-T93C7ITZ[C2AB*E+&5*;A54EHZ=.K*
MK"4(2_=T8U74C%QA2G:R^RT\/^'Q'>6HT#0A:ZG.+K4K0:+I@M-3NT<3QW6I
M6PM1!?W,<R"5)[M)I4E'FHRN23KPP06L,5M;00VUM;10PV]M:Q1V]M;P0@)%
M!;P1*D,$$2*%CABBCB1 %50HP/$_C[^TI\ _V6?#NG^+_P!H?XK^$/A)H6LZ
MU+X=\/'Q1>7,FM^*M?BC66XT7P=X0T2SU?QAXSU>SMY8[K4--\)>']:O--LY
M$N[V""U83U6TC]J;]F?7O@0_[46E?'[X077[.$.ES:Q=?'%_'>@6GPUT^T@U
M*+1;BWU3Q/?7EM9:3K,'B":'PY-X:U-K3Q+'XGGM_#+Z,NOW-OIDM*2@Y.]X
MQT;35ERVIP;O9**3C&/,G:,HQ23=I5"EB9TZ4E1Q$Z5:2A1ER5JD:M5IKDI2
M<9JI4?).+5)SE)4FKR5*U/\ -3]A_P#X)E_$?X!?MI?\%4/CY\>7^ OQ+^#7
M[=_QAE^('P]\ V9UOQUJ6G:)!\5?B9X\TZ#XJ>%/'GPVT7P?;ZM%IWC+2&CM
M]#U;QE:6>M65\L%_);P6.I7G[9VL:6$5E;Z?%%I]OIEO9VFG6UC''9V^GVEC
M!%#96NGP6JQ165O9PQQPVD-JD$5M$BQP+&B@#YP_9[_:R_9N_:OTSQ5JO[.G
MQ>\-?%:T\":AI>D>,TT6S\1Z/JGA:_UNSO+S1(=<T#Q=H7AW7K"'7;33[^[T
M2^DTTZ;K%O97DNF7EW':SM'V?QP_: ^"'[-7@K_A8_Q^^*W@CX0^")-:T[PS
M8Z_XWUF'34UOQ3JMM>76E^$_"^F()]:\7>+M2LM+U74-/\*>%M-UGQ%>Z=I.
MKZA;:9+9:5J$]O*3A3I4FK0ITZ=*"DK-Q7.H<S:7/*3G-)VL[V@DKI]=>IBL
M7BY5*T)_6I2C%TH4IPDI4<)AL/=4+2G&?U?!TI32C'2+FU9<R['0?A_X!\*Z
MYKGBCPK\/_ OA;Q1XH!3Q/XG\->#?#.@>)/$JEQ(R^(->T?2[/5];#2*DC#4
MKRY#2*KL"RJPZ*ZTK3-5ACBU72]+U6&"=IH(=4TZRU**"8?)YT*7L$RQ3;05
M$L:K)L.TO@XKPCX4?M8?LU_'3X4^)_CG\(OC;X \=_"7P./%(\>^-=)U:6UL
MOA]+X(TM]=\767Q!TO6;;3/$7@/4O#FA*==U72_%^C:+J5MHDD&KM:?V=<VM
MS/YWH7_!1+]A/Q%\2? ?P>\/_M:?!#6_B-\3X_#,OP_T#2O%\5]9^*[WQQH^
MF>(O!GAO3/%MO;R>"!XY\7:+KFB:CX8^'=WXEMO'VO6VLZ2VF^&IWU.P2Y=G
M)PA9MI15."3T4M8>SBM5=IN#CJW?D;=[3[+%+VLG2Q2=)RC6GR5TZ7)%N<*L
M^5.DH04I2A.5-0CS3LH-M_8LNEZ7=W5IJ5WI6F7>IV)8V.I76GV=QJ-D1*T@
M-G?3PR75HWFNTH:WEC*R,SJ=YW5G^)?!W@_QQ86NC>./!WA+QMH]EJ5MK-AI
M7C/PSH7BO3+'6;%6^PZQ9Z=KUAJ-E::K99;[)J-O!'>VN]O(N$W-GQ+]H']K
MK]F+]E&S\+77[1GQO\#_  FE\<7>I67@K1=>N=1U'QAXPDTD02:U<>%_ GAC
M3M=\;:_IGA]+NRD\2:SI7A^[T?PW'>V4FN7VGK>6IF^?/V*?VG;_ /:0_:%_
MX*$0:'\5O#/Q:^!7PR^*/[,^G?L\ZSX+N/!^L>$K'P7\1?V2_AK\2_$W]A>+
M/"EHDWBBWUGQQXAUC59[G7]6UN_TJYEET2VETRVL6TR$C>;:5G[.G5K7T:A[
M.5"+2MI&<Y8F-GIS2IRNW*,;]-.C76'EB+5*<*<:,8R:K04E4JU**A1J-Q5H
MNG+GA&=I133A*TK?H8NG6$=_=ZM%INFQ:M?+MO\ 5HM/LXM4O4!B(CO-1CA6
M\ND_<0'9/*Z?N(>/W2;<*\^'/PZU'QC9_$74?AUX U'XBZ?';Q:?\0[_ ,%>
M%KSQ[816:".T2P\9W.E2>)K-+6-52V6VU2(01JJ1%$  X#X[_M'? 7]F+P;!
M\0/VA/BWX)^$/A&^UBU\.:3JGC'5?LMSXD\2WT,]Q9^&/"&@6<5YXC\9^*+J
MUMKJ\@\-^$]'UK6Y+*TN[U=/-I:7,T.;\-_VM/V9_B_\%_%/[17PS^./P\\8
M_!#P)9^,+SQ_\1=,UL1:+\/8_A]HH\2>.K3XAVFHP6.M^ M8\'^'7A\0>(M!
M\7Z3H^N:3H=WI^K76GQZ?J6GW%REK[RU5).\EK[--Q4KR7P<TG'F;<;RDK^]
M)*4\E91C4]G54:KA2A4Y:JC4:O"G3A.R4W:$H0IQG)\L94XQ:4HKWC^R]-FU
M&'5IM,TR35K>![>VU:73;*75+:W83(T%OJ+PM>PQ-'=W2-'%/&A2ZN4*E)Y
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M/VT_Z^K;_P!'+053_B4_\<?S1Z51110>\?@"GW_^ M_-:G7J?]QOYK4"??\
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MX#\:ZIXO\,^'_"/CNZT.?7M3\1+X1C;Q#^@NA_LM?$7Q'^V3<?%3]JW]H/\
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M^%]!\9>%/#'P$^!OAKPM\1O".A_#WXC>%_#GP?\ ASH7AOXA> /"_A&?X?\
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M:!I^GR>*/'6M6>C:1::QXQUUK_Q'JEKI.EV]]J5Q#I]HD/QC^U)X,^+O@_\
M9UO?V6OV$/V:?!^A_P#"W_ GQ-^$FA>-/"U]\%_@W^S_ /L@VOQ":+2M9^*?
MBCX<?:])\0^)4MX/'WCKXA^'?!_P<^%WCV?Q;X\\,76F^-K30X/%T>M7>5W&
M$(TU%58T<NITTTHTG7P5158RK+2,:-2HZT:LFXRA0Q-=<[G"C%[4\9&OBYM^
MTI4\1CGB:LJE9-T\-5RU9=BH*4K^^Z3G5BX0?-.EAY*E*M"-OSRUZYTS]HK]
ME?\ X+I?\%#K:_M?$/@_XS?LH?MA?LM?LI>(;2YTG5M)OOV2OV0O@'\;_!US
MXV\'ZSIRDR^&OCO^TSJ7QO\ B/"S7$T&HZ#IG@?4(W"B*-/3_A%^T?\ 'F?4
M_P#@F=^P_P#LOVOP%\!_%GQ)_P $H/A!^TSX@^/W[0G@SQG\2+;2?AE;>%?A
M-\-;KX6?!+X=?#WX@_"+Q%XQ^(FN^)-(TSQGXWCU'XG:)X4T/P5X7TK5M5TG
M6;^+2!9_JC\+?V?OA5\*?V?/ 7[+.B^%M)U_X*> _@WHOP'C\(>,='TCQ!I'
MC#X>:7X.C\$ZKIGCO0=1L[K0_$T7C?1OMY\=6&J6-YIGB6?6M;35+>[M]2NH
MILWXK?LD_LK?'3PSX"\$_&C]FCX!?%?P;\*X;2U^%_A/X@?"'P#XI\.?#?3[
M*RTK3(-&\!:/JF@W-AX0T#^RM!T+2)_#N@0:?H5WH^BZ1I5WIT^G:;9VD-S<
M83<:<N:,*E!0;<US4\-1Q]+VLFE"7M*U?%_66O=4HI1G[.=DG#&T91M5P\TO
M:XNI3A'V;5!8C#8+"T*7LIS<*BP]#!QISA4J.G*<W*/-*DE/\-OV.O%_[-/_
M  RO_P %V-?_ &Q_BW\+OCM^RW=?MO?&UOV@OB7\./ T/PR^'7Q-3Q5^SU^S
MYI'C.]^%7@W3_'_Q DL_&/C'XA366@_#+5/#OQ(\2>(_&7Q4D\)>*?#7B>X\
M1ZQI-]'ZU_P2A'Q/T3XE_M ^%OV]X=7C_P""E%O^RW^S[/X=N?'6KV.N^(KW
M_@GOIGP\T^T\ :?X5U)H+.^NO&7A?]H:^^)^G?MPW-C;2Z?JG[4=Y:ZJNI:I
MX3N_ANFG?LI'^SW^S[#IT>CP_ 'X%Q:/#XV\'?$R+1X?@[\-X=(B^)7P[TC1
M_#WP]^(\6EQ^&5L(O'_@#P_X>\/Z%X&\9QVZ^)?"&B:!HFD^'=4TW3]*L+>W
M[;5/ '@'7O%7AKX@:]X#\$Z[X^\%:9XGT7P9X\UOPCX=U?QMX/T7QG%;VGC'
M1_"GB[4--N?$'AS2/%]M96=MXJTW1=1L;'Q'!:6T.LP7L<$2IA.FY4*M&FXQ
M=7 K!*HX)\LH87%4J=91C:\O:UZ<*D+N/U&-?#QES5E-:2S"G)UERUTJV.EC
M7^^BN67M,N_<I6DG2J0P<ZN(^&57&4\!6<9PPS4_P+_9!_9?\??&G]@O_@B+
M\</V<OCA\-_A-^V5^RC^ROXO\3? CPS\8O"LGQ%^&'Q4\'_%OX=>%_A_\9?#
MOC/P1X;\2^%/BGINEVT%MX&MW^*OPNU237O 4>LSZ==Z5J<?B^P^Q?JS^P9^
MUGXG_;&^"_BKX@^/?A_I/P[^)?PR^//QK_9L^*&F^$O%EU\0/AAXA^(?P#\6
M-X+\1^-O@WX_U#2-!U#QE\+/%$B6]UX<U/4-*@OM+O(=7\+7=UK$F@?VYJ?:
M?$;]BC]C;XQ>"?A]\.OBI^R;^S;X^\ _"6SNM,^$_@WQ-\$_ASJ'AKX5:3>G
M35U#1OAII#>'5L? .B:HFBZ,FK:)X3ATC2=4CT?2H]0L[E-.LA;^_>#/!G@W
MX>^%M!\"?#[P?X4^'_@7PGIEOH_A3P/X%\-Z+X/\&^%](@>62#2?#?A;PY8Z
M;H6A:9#)+++'8:586EHDLTTBPAY7)Z)U(SJ5ZCC_ !:KJ4UI^[<JE*4FK)>]
M.-.2DHMP<Y1DN24'SYU:\*E&$'&4JD:C:J3C3BX495,74E2BX-SJ7E7I\LJD
M(3I<DX0G.$U&/4TAZK]?Z&EI#U7Z_P!#69RK=>J_-$B]'^G]#4R_?7ZG_P!!
M:H5Z/]/Z&IE^^OU/_H+4&D?BE_74GHHHH- J6/[@^K?^A&HJEC^X/JW_ *$:
M 'T444 (>GXK_,4M(>GXK_,4M!I3VEZ_H@HHHH- IR?>/_7.3^0IM.3[Q_ZY
MR?R% $U%%% !1110 4L?WV^B?^U:2EC^^WT3_P!JT%0^)?/\B>BBB@V!.H_W
MC_Z$:L573J/]X_\ H1JQ3>[]7^9$=Y>OZL****184444 %.BZR?[R_\ H"TV
MG1=9/]Y?_0%H FHHHH YWQ3?MI^C7<D>?.G46<. Q??<_NR4V)(Q8*S;1Y<B
MN3Y91LFN(T6V,<$<:@EMH[!0#@ELHKN -QE8#>6#,P))SG;\>.ODZ- Y<)+J
M+2D1G!=H(@BKP-P)%PW[Q662-0619 &"\CJ6M6^G6FU'4/M!)# @ER78_.S$
M;I6>3;DA"V !@UT4%I*5^RMZ:W].A]-E45'"*5E>=6;NEK:/+&S[N[NO+0Z&
M_P!4L=-@<RLA8*S%BX7Y@,[>"#VSM.  1DXS7RY\5/C,UE:W<-O.J*$D12IV
MC( Y;JVY@&)P""._%0^-?%MW<QSQ6X=F7<J^6N[>7.U%54!+R,<*0,L3CY<=
M?D3Q_$A6XG\1:A]E)"3-86RK-J;*RX"F OY-H6*[?,NG4$DY5QFM_;<ND8Q?
M=RUOVM;;?R/1Y*DG9;75[Z67SU>W35'@?Q2^)^IZ^TL-F+B:269XO*2.0O/+
M)A8UC1,L=Q)4$(VT],\"O@#XCZ,D,MW<>*KZ5;D-F+1+)TEO\L5*_;II7D73
M$B.=\4C2W;'</)0X"_6OC'Q%,D=Q:Z!;II5L T;RQ2J^HW<6,XNM0\I9"&&<
MQ6A@MS@'=(%!/QWXQM'E:Y9HVR[DF.3!92[<DGD'GYNISP6Y!QC4G.2;YK+7
M1>JT3W5O4Z(QC'X5;OOK;U;\SXV^(&IW+"YL]/@ATK32V6M[+S$FN X +7]X
MS?:;YCM *3/Y& %,7EJ5/R9K^G&/SRRJI.X1,B@$X+-M;: !DLW"C RV .!7
MVAXNT<-)*#'OW1N-K,0HVN2I SM!()SG(&"?XL5\W>)M**  +\C%QC/S(Y&#
MSS\JGCW#$]!7+)735]^KUZW&?+6K60 =O+92S9)# [AANN<?Q$ YQG/3BO.-
M2M%#!CE< !AR&&265<]\'//U.,Y-?0&JZ<2\BLH7E@ 1P JNV1G@' R?PSV-
M>2:U9LDA( X(P0H/17!W,0S$#.[Y"HSCL<')P:3=U^()R4DT]+/UN>>%6!93
MP!_$V<8*@\XR>N5XSC&2?6U'(R,@R <X+-U.,%1@ @YRX^@(R<U+=0E,N6;>
MRM@AB-H5".A.<Y#<XX)]0:IH25<8YW+M)QE<!B=ISQU'0]\*.*AI/1FZ:LM5
MLNOD>B:'?B,K[,&!).>C<9[ 9S@>F<'K7T3X(UL(%@+L2)%9<8Z[!DC)Z'J<
MXSDYYX/R987+PR(4 4-M3.2!M.[:V!W;!'J H!X.*]B\+:FL1CR[*XQN^8EN
M<=2N3P.,CG!('!K*<>6[6W;6][/N:TZJA?3F>ZLU==_O:1^BG@#Q&B%%=\@D
M%QGT10"!G@JP Z\D<D9K[)^#?Q5UWX0?$?P?\4?#,S)J?AG5;:ZD5"=M_I4F
M8=3TVX4?*\=]923Q$2':#.<$, X_,+P1KQS;@LP)"@Y8D*2N[/7!Y'.<D=#G
MC/V+X2UE+NVBB+;\JZN5? QE<*P# GKDY&>GL:YDW%IK1K5:;?)K]#N<(8BC
M*G42E"K%QG%O2TM&FU:S6FNEFKZ6/[@?AYXZT+XF^"/"WQ \,W4=YH7BW1+#
M6["6-@P1;Z!)9;63#,5GLYS+:W"%B4EB922P8UV=?A7_ ,$H/VBYK74-9_9P
M\37Z_8KE;WQ)\/)+ASE;XE9=7T*"1CMQ-"K:A;P*.3&XCP0ZG]TQT_%OYFO5
MA)3C&2=]%?5-IVU3ML_(_/\ &8:6$Q-2C).R<I0T?P.34=7\2M:S6_KJ#=#]
M#_*K-5FZ'Z'^56:HY0HHHH *O:;_ ,?MI_U]6W_HY:HU>TW_ (_;3_KZMO\
MT<M!5/\ B4_\<?S1Z51110>\?@"GW_\ @+?S6IUZG_<;^:U GW_^ M_-:G7J
M?]QOYK70?PY#X?FRS%UD_P!Y?_0%J4=?^!I_-:BBZR?[R_\ H"U*.O\ P-/Y
MK0;K^(_3]$6E^^OU/_H+5,.GXM_,U"OWU^I_]!:IAT_%OYFIA\*^?YF]/=^G
MZCH_]8W^XO\ Z$U7(?O#_?/_ *+JG'_K&_W%_P#0FJY#]X?[Y_\ 1=4=<?A7
MI_F6Z$ZQ_P"?X&HH3K'_ )_@:@UI[OT_4M1=9/\ >7_T!:FJ&+K)_O+_ .@+
M4U!UQ^&/^%?DBS!T_P" 1_R:INX^A_FM0P=/^ 1_R:INX^A_FM-?HS2'Q+Y_
MD21_<7_?D_\ 0GJ9?OK]3_Z"U0Q_<7_?D_\ 0GJ9?OK]3_Z"U(ZX;/U_1$S=
M#]#_ "J[']T_]=!_Z+-4FZ'Z'^578_NG_KH/_19H-H;OT_5$G=?]Y?\ T(58
MJOW7_>7_ -"%6*3V?H_R-22/HO\ P/\ ]#J6/H?I'_,U%'T7_@?_ *'4L?0_
M2/\ F:4/A^<O_2I&D]X^OZHM1_Q_2/\ ]#J3N/H?YK4<?\?TC_\ 0ZD[CZ'^
M:U1IUC_BC^;)(_O+_P!=?_:=7:I1_>7_ *Z_^TZNU,?BG_B?YLZ8_$O7_,D7
M_5G_ ('_ .A-4R??_P" M_-:A7_5G_@?_H35,GW_ /@+?S6IJ=/G^AI'>7K^
MK+"?Q_[H_P#9ZF[K_O+_ .A"H4_C_P!T?^SU-W7_ 'E_]"%/[4/3]#>GL_7]
M"ROWQ_OO_P"SU/4"_?'^^_\ [/4]9O=^K_,T%7[Z_4_^@M4I_B_W1_[-42_?
M7ZG_ -!:I3_%_NC_ -FIP_B1]'^<3H6Z]5^:)OX5_P!U?_1(JX>I_P" _P#H
M"U3_ (5_W5_]$BKAZG_@/_H"U)K#9^OZ(*?#]P_[[_\ H1IE/A^X?]]__0C0
M668^B_\  _\ T.I5^^OU/_H+5%'T7_@?_H=2K]]?J?\ T%J#:/PKT_S)FZ'Z
M'^56:K-T/T/\JLT%#D^__P !;^:U-4*??_X"W\UJ:@WAO3]5_P"DL%_UJ?[K
M_P#LM6.Z_P"\O_H0JNO^M3_=?_V6K'=?]Y?_ $(4&T=Y_P".7YLL4^/^/Z1_
M^ATRGQ_Q_2/_ -#H-H;OT_5$R_?7ZG_T%JGJ!?OK]3_Z"U3T&H5(O^K/_ __
M $)JCJ1?]6?^!_\ H34UNO5?F"W7JOS19C^X/JW_ *$:FCZM]%_FU0Q_<'U;
M_P!"-31]6^B_S:D=!+2'JOU_H:6D/5?K_0T MUZK\T2+T?Z?T-3+]]?J?_06
MJ%>C_3^AJ9?OK]3_ .@M0:1^*7]=2>BBB@T"I8_N#ZM_Z$:BJ6/[@^K?^A&@
M!]%%% "'I^*_S%+2'I^*_P Q2T&E/:7K^B"BBB@T"G)]X_\ 7.3^0IM.3[Q_
MZYR?R% $U%%% !1110 4L?WV^B?^U:2EC^^WT3_VK05#XE\_R)Z***#8$ZC_
M 'C_ .A&K%5TZC_>/_H1JQ3>[]7^9$=Y>OZL****184444 %.BZR?[R_^@+3
M:=%UD_WE_P#0%H FHHHH \[^)\-X_AB6ZL81-<:;=07;C>%<6C[[6Z$>058X
MN8GF5RF84?80^!7@5XSS6BW6H3& .@98%:-[IU9"Z@(25&\E2SN5VJ6(7*\_
M7LD22H\4B+)%*C1RQL,J\;J5=2/1E.#CV/;GXQ\7V,VB>(=4T;Y@BNSVK%L&
M2UD"2*K-E"Y19$C9R<R!D+2,691K3E;F3ZJRZ6U/H<GKJ2^KRT<7*<+]8MIM
M)]7S+5=-'Y'E'B?6IQ%)%IL0M$,<B"Y&V6_;Y3E3<\K H/RJ($C8 LWF8("_
M*WBZVE=)R[22.P=B9&+;R"26)S][YO7N3U-?4&MQ*,A@HC=<Y&& .& 8 8R,
M8Y''!QVKQ'Q/IH8OD * ^XGY0,\$G/(QQCW SDBK/?/B7Q1ISI-(I4$!D5LC
M&?G'S<'.3D\<\8!'%?.WBW2CF? D?8_FL0<1LC')X(XVDD  <'DANM?9WBO2
M ZS2*&)<LJE>1N8J00,9V8(YST/&.#7SUXBT]B9-Z8 #12#!RP))+#G@X *Y
MZ'J#W4E=-;Z?Y ?#GB[3%CD?)! <' 4[@KGC)QT//0#&>AR:^</$VEJ&E1AR
M&Z$$X(!((]#QS@\YYS@8^V/&>D&,S-&54%PQW(,>4,Y.<=N>>N1D=!CYG\4Z
M>I4E06))0O\ PDY !'&<X/S9/!P0,#%8 ?(_B+2MA=A&V\$@L4/RC_8P<-D9
M!SU!.>:\:UG3RQ<@C(W%5(*D DG)'!SL],],9XQ7U=K^G9CD0@*=F%( !R,G
M*D[AG:.3@CIC' KP3Q#I[1.I<$,3C(&& ".!N!)YQ@9'!YQQC"DKJVP'S]J=
MJ$<+M^7S,C!P""I##D9 ##@9P2Q&3C-<^8"J,5PH !;N,-GD8P<D*>.G'/6O
M1-8LR1*P^8AV)[D;E^8#M@ \<'!ZDC%<-,I1E0L&ZY/J0!\OH0%8D]>?3!K%
MIK=->J C@GV.1A0Q(4EL%%V@L,9Y!P>O3C'<Y[/1M0\AU)"D$D%PRY8,1@;0
M,@@# R<< 'L:X(IM;:>3@'=TY))Z9/3;U.3U'2M33IBDN6+$'*L/E .,LA)P
M,87.2.1Q@=<YSU6FNO3T9M%):IIONCZG\)ZV4,2EAM95.-XW@@_*QSURS!<8
MQ@!<9!-?5_@3Q&X,,HD &UU;INX"@C)YXYP1Q^!Y^!= O]DD(9B%(#*Y8G:%
M5&(8D<+NY#'H3W X^E?!6L&.11G*L<X)P ^02?\ =.>3GD#J1@US.-Y-[;:O
MJ=U"JK<C;<F[J^B2[)VU?6Q^CO@?QIK?A'Q#X<\=^%K^73]?\-:C8:SI-[:N
M\<T5Q;3Q3+@@X82&(0S#;CRW)8%"RM_8+^SU\:-$^/WPC\(?$_0RL0URQ$.L
MZ<9(VFTGQ!8$6NL:?*L9^41WJ/)!N5=]M+#(HVMFOXH/!NL)/%%%ORI63 _N
MN&R <9^4N,$#G:.H.37[-_\ !+']HK_A7OQ+O?@IXAO#'X3^*,YNO#AD8&#3
M/&T"H(E5YI<6]MJ]DLL$B+A9+J.R8JKJ[#IP[Y7R7T=WV5^_S^%'FY_@XUJ,
M<3"+56CRQ:3OSP;:E=6;;N^96T5M4?T7-T/T/\JLU5/W3GKM^88QSCT/Y?IV
MJU76?&A1110 5>TW_C]M/^OJV_\ 1RU1J]IO_'[:?]?5M_Z.6@JG_$I_XX_F
MCTJBBB@]X_ %/O\ _ 6_FM3KU/\ N-_-:@3[_P#P%OYK4Z]3_N-_-:Z#^'(?
M#\V68NLG^\O_ * M2CK_ ,#3^:U%%UD_WE_] 6IX]AEC$A98S,@D*#+!,C<5
M!X)"Y(#<$]3CFD]GZ/\ )F][2D^T;_<D_P!"=<;X_<DC(//RL.#]>/KQ4XZ?
MBW\S7X7?L4>,O^"P.L?\%(?VF_#_ .U;X8NM/_8STMOB)_P@UW>>%/!FD?#V
MV@3Q/%_PI5_@?XPT?2[3Q/XUGNO#(:'Q,FIZOK,T&ESZC=?$J*R\?VFB1P_N
MB.GUR?S.:(6=*E-/2HN9+LKV?X[=TGHFF>WF>62RG&RPD\9@<;+ZOA:_MLOK
M_6*"6)I*LJ4IV7+6I:PJ0:37NR2C&:2='_K&/;8/T+$_I7YF^'?^"O'['GB'
M]NV^_P"">6G3_$[_ (7?8>.?$WPT?Q;<^&?"$7P9N/B!X2\-7VN:UX0M_%Z?
M$2;Q6^N6^J:;J'@&*UF^'\ N/B!:2:(DGV&:TUB?Z\_:=^/7A_\ 99_9V^-_
M[1WB5+6?3/@S\-/$?CB'3KV016VN^(K"U-KX+\*O(<!)/%_C6\\/>%;9F(47
M.LPG(()'^?))\??V<_"7[$7[/OQH\(_&J?6?^"HW@/\ ;X\7_M9>)8M5\"^.
MTOHM'\3W&E0RV&H^.9/#,'@GQ!<1>)OA%\.OB:EI#XCD.SQYXLT[(U%+G3;>
M5./MHQF^6G!T?:I?$_;55!*/VK4Z7-6G:S4%&]XWM]?PCPO1SS!XZOB:.-GS
M5(9=EU3#*HJ5#,*F%QN*>*QDJ<9KZC1=+!8>K*=H>UQJ@_?C%/\ TIUR1[^@
MYZ].GZ#D\CKFB,@L@!&?UX5A_/CZU_.%_P %M/VWOBKHO[#'[$7[2O['OQ9\
M:?">/]H3XL?#WQ%I]_X0\4:GX>N-2\'>._A+XB\76?@OQ9<Z)<6US<V6FZG)
M:6'B#2W99(-7TNX1XXKJSA$/"ZYK7[<_[#G_  6@_8U^#OQ%_;O^*_[5?PW_
M &RM-U<_$;P'XRLKCPO\,= UW5-0\9>%]9L?AM\(8_$'B3P9\.M$\.^(-'\-
M^*? EYX&@\+:K!:1W?@S6H+G0_[5;Q+M3ISE4IT9+EJ3QCP";:<7B/9QJI)I
MM<DHMN_,U%+F<ITY4W+APG#.(JY=]=ECL+0Q$\!G>.IY;5I8I8J<>'ZLZ>84
M958PJ8:A4C*,E3=2<TZB]AR3E&=2']0,1&7/8LA!]<HK#'KD8/'8@XP<U-N
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M"A3K1=*A5=&FJN&A74)8GGGAJM>$905>A3<*E"IS7A4IVF>._LO_ +<'A_\
M:=^./[7?P,TGX*?'+X::E^R/\1+;X>:YXR^)WA6WT;P?\1;F:_UVQBU7P5>V
M]Y<R)#>?V!)X@T6QU!1=ZQX&UGPWXMB\A-4N=,TS[C#<CD=Q^/!QSU( .>^
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M:M.+IQC3F_ZI8_O+_P!=1^J8'YGCZ\=:N9'O^1]_;V/X@CJ#7YT_\%0OC1X
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M/QV^+X\#6GQ!\*^&[NVB_:)M)?$'A-=&U+0/C!>^(O!FC?!VQ\-?#+X>^%?
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M]+WXRV/[/7[)'Q"T3X8V?B'1[/QWJ/@*S^%W[.WBGQ=KFI?8_'_C[PK^T/\
M%7XEZS';ZW)X/;1O!^@1PZ-;*I)4G)3U4/:N;CJ^2C&4Y3A"5JDDX0;BFX-<
M]-3E!RLHPN&EBJOLHR<9.:IWY)3BJDZWL(PJ24HQIKVMH2DW)-QFZ4:G*K_O
MT"#T/^?\]?3O1D>O^>.?IR.>G(YY%?)/[ ?QC\:?M$?L-?L>?'GXDW-K?_$3
MXP_LS_!?XA>/]3L;&QTNRU?QIXF\!Z+J/BK6+72M,M;/3-)AUK6Y;W55TK3+
M6WT[3!>_8+"W@L[>&,?DA=?$2_\ #W[<'QA\+?\ !2O]H']O/]E[7O%7[7<6
ME?\ !/7QE\,/BS\7?@[_ ,$\/B+\ 4N[+5O@9\+YO$'PR6Z^!/B#X[^*8=&\
M0VGQZ\)?M4VC:WXBN=2L-#\-ZA'9ZCI>F0:.$E7CAY<JDVU*2;2NI4H<M.+7
M/4FY5%*-->_*"O&,IR4"*-'VD*]1S:5",I.,8.=27+*O&3Y$[QIP^KS=6I[R
MIQG3G)*+FX_T2Y'K[_AUSVXQR3T'(/0TL9!<D'(PG(&>TAXQUX(/T(/0@U^-
M_C/P?\9?VB?^"J7[2OP)U3]IW]H'X4_LQ?#_ /8U_9(^(VM_"SX%_$GQ)\(_
M$^N_$WQG\2_VC]'L;C1/B=X7N8?&7PO\,7NF>&+RZ^)$'PNU+P5XV^(FJ>'O
MA?INL>.%\%>&/$?A#QA\B^/?VW/CS_P3F^$O_!:_X>?\+%\<_M-']@#PK^R1
M\1/V3O'?QZUZ3XH?%?1H/V[=*N/"WAOX=?%_Q>=-L==^*NC_  4^*MK/XN\.
MZKXQFUOQWXK\!ZJGA[Q)XFO+>WTR:PRA.,Z<*BNE4IU:E*%FY5/98B>'E!62
MC&<IJ$H<Z47&4E)QG!J?33P-256-&$HRK*>%56#4HQI1Q=*,X3=76,U2<[5H
MP2E\,J4IQE[O]*.1QSUZ>_7IZ]#^1]#@R#P,D\\ $GCV R/\XK^9/P'\3?VA
MOA]\<?V-=7^ &E_\%V?BUXU\5_M'?#CX7_MI?\-S? ?X_P!K^ROX]^ WQ9U"
M?P[\5?C%9^#_ !GHUU\./V9->^#7B2^T/XD?#R7X)P_#3POHO@_2==\$^+['
MQ5X;N[F:W^N?@'X!^(7_  4AUK]J#X[_ !>_:>_:T^$OPV\(_M2?M%?LQ_LU
M?!C]E#]HKX@?LR:%X&^'W[/'C>X^%%Q\4/B#>_"Y_#/BOXE?&7XB>,?#GB+Q
M??6?Q&UCQ9X'\'Z5>Z/X<T3PRUE'-"MIJZC>\E&4YN-W",(5:-!33:4IJK5K
M1C3LHR485*E6$(N">D\,J;4JE3DIRA&4)2@U5E.:JOV3HIOV<HJC.4G.:BXN
M"BY/G4?U_N/B-X"LOB'HOPEN_&7ARW^)_B/P=KWQ$T+X?2:K;?\ "7:GX$\+
MZUH7AWQ%XQM-#5S>MX<TC7_$V@Z+>:M)%':#5-4M+&*66?S$C[S(]?\ /I]?
M;K[5_/=\:OV0D\=?\%MO@_%+^U1^VWX/D\4?\$[/C+\0)+KX>_M#W7A*XT*7
MX=?'3]E/P(G@WPR]MX5N(]$^'OCP1?\ ":?$SPI:P?9_%?Q#=?%!N-/\E+!O
M0/!W@[X[_M5_\%3?^"D_@+Q5^V#^T]\+OV<_V3?B%^P+XL^&7P<^ OQ-?X:0
MZMXV\<_LN^&_'?B'1/%7B"#2-3UE?@S/>V>IZEXA^%'A^^TCP]\3?$GCG6M8
M^(4>K2>$_!R6+I+VBYN:UI8MS:C)QC2P^*I4.?1N3E:M!.,=95(MKEC4BXQ/
M#PINI:I=0PN#Q$O<<I>TQ>'JU(P7*U%\]6FU"UG2@I>UNTG+]T=R^HZ9Z]O7
M\>WKVS1D#']<^WY^YZC\Z_-3_@E_\4OB1\5M4_X*'1?$SQMXD\=Q_#?_ (*V
M?MA_"#P!'XGU&74U\&_"SP=/\,!X4^'OAQ)B!IOA3PV-4U$:-I$&VWLC>W)A
M"^:=WY(?##]H7]K;XI_\$J/^"$WBG3/VJ/B[X+^,O[4__!0+X:?"#XS?'6QU
M32]>^(GBSX=>(T_;53Q'IVJGQ?I'B;PSXFO$TSP5X<E\.6WC?PYXI\+V?B'P
MSX3U'7/#FO:;HTFD7=PI3GV3:PC3;=F\9&K*"=ES<L%3O4;5TFW",G'6Y81Q
ME4BYQM2JUZ+E:3O*CAWB6TE]F4%RIWTFTGH[K^IK</7ICGMR2!STY((^H([&
MC(YYZ=<<]/7'IN'TS7X#7_[/GQE\+?\ !2G0?V)_"/[=/[;%I^R9\:?V//$?
M[77Q*\.^*_VBOB#\0_CQ:>+_ (*?&#PO\&)? _P@_:@\8ZMJOQI^"'P[^)<_
MQ8\&^+O'VF_#WQ'I&N/??#ZZTGPKXC\+Z'XPUC3H?KG_ ()W:I\1?!_Q0_X*
M&?LI^-/B_P#%+XZ^%/V3_P!ISX>Z/\&_'_QO\6W'Q!^+=E\,_CM^S/\ "3X]
MP?#?Q;\1-2MH_$OQ M?AUXG\9>(M,\,^+?&^H:_XUN=!O;?2]7UV]L]*TN*U
MB-IWL[6IUJFS=XX>O2P]1;I1DJE:FXWYHU(-N+A*+3SJT84X\T*JF_W#<53E
M&T<5"K.B[NZE)NC-58QLJ5KIU>:*7Z@9'ZXS@GD\@>Y(&0."1STYIT1&9/=@
M1P0<;%.<?_K'(]17YD?\%#O'_P $M*U+X(?#OXF_';]NKPIXJ\0'X@>+O"O[
M-_\ P3L7XQ-\?/V@M.\-VGAZSU#4_$E[^SEX/U7XV^'/AK\.;J]CF.HZ=\0?
MA%X*U77_ !#';>+M>\0PZ7;:1:_E]X6_:>_:%T7_ ()=_P#!;^QM?B)^UUX<
M\3_L9^(?BCI7[-GC?]J+4UTG]LGX:> O%?[/WPN^,'A'0?'WC+3-9USQ/K7B
M#P=KGC'Q!<^"_'7BSQ;KOQ$OO!>L>&H_$6H:??:7;Z3I<<R4*LFOX,)S:C*,
MN:,*F%I5+2NDG"6*BG&U3EE&=.<J51<IK#"2G"A-2Y?;5Z%%<\9PC%XEXA4I
M)^]*<7]7<FXQC%QG"=.4X\S7]/V1[_D?7'IW/ ]3P.:"0<X/Z'_/3GKT^;D<
MU^"W[0?P[^//[(L?[ _[5&F_MH_M1_$[XL_$/]LW]C[X$?M/^$?B'\4]?U;]
MF/XP^ ?VK_%FC_#;Q_IO@K]F"*>V^$WP/G\"7^K:;K'P;UOP!HUEXG\/:?H\
MD'C?7OB%XGUG6/%UYZHOASX@?MX?MW?MN_#CQO\ M _M(_!G]G+]AJ_^!?P7
M^'GPT_98^//CK]F[6OB5\6/BM\$]+^-OQ-^+WQ?\??"R7PU\3=?AT&V\;>$_
M ?PT\$1^-_\ A7=I:^'M6\4WWAF^U[6;FYDJ:Y95*7_+RE+$0JV3_=^PA%U)
M*Z_>6]O2Y%#5M24K<DF9>RI\M.K[:V'JT(5H5.27/+GJSH*$:>]_:P;4I.*=
M-<S2E*,7^A?P(_:+T7X\>,/VIO"&D>&=6\/3_LM?M&W_ .SCK][J=]9WD'BW
M6]/^$_PI^+$GB?1X;2*-]-TF:P^*UAI,5A?//>"YTBZNGE6*YAABV_C5X;:]
MT>/Q#91 7>DD->,H^>6S8HID. 2S0.D/S-A0HB!W1Q[!^=/_  2.\%^,?ASX
MC_X*H>!?'GQ/\0_&?Q%X4_X*<^,=$/Q.\8Z;X=TOQGXNT.R_9._9+C\)7_CB
M/PEHWAWPUJ'CB#PE_86G>,_$>B>'O#]AXK\3V6J^)X- T4:O_9EK^P%S!%=6
M\]M.@DAN(G@FC/(>*1=CKG!QE2<,#E3AEP0#26M.DXR3<Z-*HY132<IJHVXI
MV<5HDH[)Q=F[IG0I_5<5.45I0KSA:,G=Q2HMVE:[7[R35ULXII<J/SKO8!.B
ML54A=O& V,JKD<$*R88@#@<'! Q7F?B2P9TE(7&,L!L R!D 9!/7\<8&#S7N
M/BG0;CPGX@U3P]<@^5"9;K2K@)M2[TJ?)BD)!VF>%S_I$:@",S*  &4#SO5+
M,2Q^8-Q<B5-HYP<,N0Q(.,\C.,Y'&1ST1DI*^FFCMT:M=>NS^9]@I1FHRCM*
M,9+;:45V;6ZDM[Z:I'R5XFT\J9 (PJF,,@"\!D(QDG'\(Z8Y(Z@$&OGGQ-I^
MQI)'4@?/DX)P"0>F<_>!SZC /7-?8WBC2PY?"?=5CR/]H' ('J>3@< 9XZ?/
MGBG26P[$<LK(1M[;LGJ,XP,<=?7'-,9\6>,-(\PR+M!0QLX8<JZLS;ER "&(
M;:!@'(.>Q/S1XFT@&25%B&23C Y "_WL 9R>,]1GIT/W%XFT@*DK*D:^4ZX5
MQM5MYR2S %N .F-H'0&OFOQ1IX20L IW X88 7APW'09P0/J.AR!BXRN]'N_
MS]0/B_Q-I"()61 2A?<>S,B_>)P<CDD'&3GH,BO!?%&F;R^<#(,B9!.XC("$
MC&"!T'? &1FOL7Q'I$9,JMP6X=>,_-P0><J0".N.#GW'SKXHL%C9D"@_. N>
MNY&8$D#LVT8SSS4CM>,G_*KM?A^>G4^5M:L"5$FT(V&#$XX4*P XR0<D8XQG
M\*\NU*T*NPR<,S!\9(S\V .XP<DGI@CUKZ"UNP#O+D+E#(NP9!,1(*G'ID\L
M>F  3FO)=>TXJ7;)7#'..X('&!G'."3C..#GBIFFUIW1*=TGW2?WJYYNY!C(
M;.67:0.T@+ @^W X&1DCUI+=@K*G&P\*695^90 H!)R20.F%)((&1S5NXB4.
MO5BK,<J#C<0G9<X!P>OTK.;:5&<X4!CCJ, @'D#.6('IU/0&L'L_1_D:1E96
MM^)WNB:@0Z_/R0B\\%5)YXYQUR.<9.1U->Z>$-6$96,L,LX YP2O'S#(Y'OQ
MZC(Q7S/8W CV_,/,8#D=,Y5><?PY&2>B@GOD5ZKX=OB[J6<< ,I4Y(8%<CCC
M#+D,!G@<<#-<_7TUZ_+]3II?&K;]._2_X7['WSX$UX*PC:3:20=H8%1M*%&Y
M Y8=1CJ #CBOI_P[K=S87>G:EIMS+:ZG87=MJ.EWD,K1R6U[87$=Q:3QNA#*
M\4J*RLA#*"Q'0@_GYX/UW:T*>8RML^]O+*=I4@!0!CY>N23D97(Z_6/@_7EF
M$+,0Y P.^W( SAL84#J<''&1G!&<FU*Z;T::UV>AZ*2G&SL[IIW\[K71]'V9
M_:+^R/\ 'ZQ_:,^"/ACQV9($\3VL!T#QQIT1"FP\3Z7&L-Z_E;G>*UU((-0L
MF=BLB32!"2C ?4E?RY_\$X_VD(_@?\;K7PWXBO'@^'WQ8-IX:U;][BSTGQ+-
M,!X<UZ=%7"9GDFTV[<E0(;I<D,.?ZBQQP>H SCD=.H.2"/0@D'UKTJ<U."EZ
M)K>SZJ_?9_,_/L?A983%5:;7NN3G"2V<9WD_FI-IKM9WZ):***LXPJ]IO_'[
M:?\ 7U;?^CEJC5[3?^/VT_Z^K;_T<M!5/^)3_P <?S1Z51110>\?@"GW_P#@
M+?S6IUZG_<;^:U GW_\ @+?S6IUZG_<;^:UT'\.0^'YLLQ=9/]Y?_0%J4=?^
M!K_[+44763_>7_T!:E'7_@:?S6@W7\1^GZ(LH!O7OG/Y;2>V,].Y/%3CI^+?
MS-0K]]?J?_06J8=/Q;^9J8?"OG^9O3W?I^I\1?\ !03]BY/V_/V>;K]F_4OC
M%XD^#'A;6O&GAGQ7XNU?PKX6TSQ9?^*M+\)KJ-YI7@^^L]5UG1+>UT<^*IM
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M[::C+I,NK:#J.J:=I]WH&J36/B#3H?"__!$_6[WXG_L/?&CX]?\ !0/]H/\
M:)^(O[#?Q"\'^*/!DOBWP3X?T3P7K?@[X?>)/ /B7P;\.](\')XS\0R>!C"W
M@FYL_%WCV3Q!XU\9>.DU;3'UFZCB\'Z#:#]=?BI\7M#^$DGPMAUSPO\ $;Q*
MWQ<^,?@KX):&WP[\%7_C1/#?B+QW%K$VG>+/B =/EB/A+X9:.NBW"^*O&]RM
MS:: ]WI[7-J\%Q+/;^QIRI'^V"1_VS;COZ Y_P ,TH/E<)P;3I2IJ%KN,)8>
MC"G345HE*G2JQ@_><E"IRMI-IZ3SO/'&I4JXFI;'RQU:56>'P<IUWBH1P683
MC-X9U:<,0J<:==498:%:I3I5&IN"9^-/_#ESX->.O%?[>?Q&_:2^*_BK]HCX
MH_MW^"$^'FK>-=;\&Z)X3'P-\-V.JZ7XA\,6GPET2#7?$=O /!'B/P;\*;[P
MB-6O)_[.TOX5>'O#MR;W3M6\1KJ?-?%O_@BGIOQQ_8!^!/[ ?Q(_:\^)&O\
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MW<W,SZ)JOAV3Q!X7M?%7A/Q!!<O:>(O#&HZU;:9JUNL4=ZES C6[_ O[.?\
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MLVHO\<O!?_!#7XG?LY>*?B=I_P"P-_P51_:C_8F_9M^+WB_5_&_BK]FOPCX
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MZ5&LW%4U%JM3I4U.,HRC)J4N5.<F?AQ^QC_P1,MO@3^U;X<_;H_:]_;;^/\
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MMY=!1)7QE^T!^P#\>/VKAXX^$'[17[<,WCO]B7Q[\5M$^(NO_LX:)^RU\-_
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M;Q3XW^'^I_#'Q'\0;C3+?Q3XI\/>,(OB]\.Y_'<]_P"(;+P;8Z9?2^'$_4#
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MJ\U("-V,\[TX_P"^:#H7QOT_R+:_?7ZG_P!!:IAT_%OYFH%(WKR.I[C^ZU3
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M.=0\7#D#'3_A$#_,Y^F*=_PW+\2_^C>KC_P/\6__ #'U^E$<TY,G[Z7[R_\
M+23^X/1Q_G\,2^=/_P ]Y?\ OY+_ /'*/K&'_P"@.'_@VM_\F=4>&^+$D_\
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M ,M)/]K_ &^V.V*F\Z?_ )[R_P#?R7_XY1[?"_\ 0''_ ,'5/_E@?ZH<:_\
M1T\T_P#$5X:_R/R57_@HO\7@1C]E^\X_ZB'C8=NQ/@LC\Z=_P\9^,'_1KU[_
M .#'QE_\Q=?K4L\P=?WTW)(_ULG]UC_>]JE,T_.)YA@9_P!;(<]?]KVI*MAI
M.RP<4[=:U6W3^^^YLN#^.7_S=3-O_$6X;M]Z3/R3/_!1SXPG _X9<N\#&/\
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M?6,-_P! D?\ P;6_^3-8<&\?OFOXNYNGS?\ 1)<+O77;]RC\;O\ AYK\:?\
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M]'_#TWXX_P#1H5[_ .#3XA__ #MZ_;C[5<_\_$__ '^D_P#BJ/M5S_S\3_\
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M?_'*/M%U_P _,_\ W^F_^.4?6,+_ - <?_!U7_Y8'^H_B#_T>3//_$0X4_\
ME9^(O_#U#XW_ /1GM_\ ^#;Q[_\ .YH_X>H?&_\ Z,]O_P#P;>/?_G<U^W7V
MBZ_Y^9_^_P!-_P#'*/M%U_S\S_\ ?Z;_ ..4?6,+_P! <?\ P=5_^6!_J/X@
M_P#1Y,\_\1#A3_Y6?B+_ ,/4/C?_ -&>W_\ X-O'O_SN:5?^"J/QP4DC]CV_
M.0!SJ_CX=,_]4X/KZ9_*OVY^T77_ #\S_P#?Z;_XY3H[FZW,/M,_(3GSI?\
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M^F_^.4?:+K_GYG_[_3?_ !RCZQA/^@)?^#JO_P F'^HGB-_T>G.__$/X1_\
MF8_#K_AZQ\<O^C.;[_P<>/?_ )W-2)_P59^-Z@G_ (8YU ECDC^V?'N 1P,9
M^''3&,@YR<_=/7]P?M%U_P _,_\ W^F_^.4^*YNLR?Z3/PR_\M9?[H_Z:?\
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M/?7O[!?D?AO_ ,/6_C?_ -&<:A_X.?'G_P [BC_AZW\;_P#HSC4/_!SX\_\
MG<5^Y'VFZ_Y^KC_OZ_\ C0;FZP3]JN.!G_6O_C1]8PG_ $"?^5JG_P D5_J+
MXC?]'JSS_P 0O@[_ .4GX=?\/7OCG_T9KJ/_ (./'G_SNJY+QG_P4F^*_P 0
M=(3P]KW['VMZ=:/>VMPFJZ?J'C>ZU'2VBE427=E;S> +>*XD2$N3:R7$$=R
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MY_@:@UI[R]%^;+4763_>7_T!:FJ&+K)_O+_Z M34'7'X8_X5^2+,'3_@$?\
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MQ(89!$QVK(8W$;-UPKE=A/T/8^AJ(_%/U2^;>GW]._0Z5O'MS+7INUOL*O\
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MQ?M%MRR3LEIHVXW;Y6XZ*SW2]O,X913QDHY)6QM?!?5<)+VF/IPI5_K4J/\
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MU+0];L=._(/X+V.FW/\ P=,?M8:I<V=G-J7AK]DCP)J_A_49[:*6]\/ZS/\
M G]E/0I=5TBY=3-IVHR:#K6M:/)>6KPSOI6K:C9&0VM[.DGYP_ #X+_$/XO?
ML_?\'-?P6_9]\.WMUXTNOVA_A;-X2\!^#[&6/4=6\._#_P#:._:)\9>(?!/A
M31-)@\^[O]4\!^$=<T/0O"VD6KW6OW#67A?3[*>;4;>UD%*2HPD[3?U;'8I6
M25O99G4I.,N6[E=57.UHQC1A&*VE)?0XO)\KS&A@%6=; 8O"9-X>4J^,]KAX
MX3V&;T_J-;FPJPU)QKT;2J3KU<0^;$58N<8P4U/^ACX*?\%LO^">'QW^,?AG
MX*^"?BGXPT[6_B+KY\+?";QEX\^%GC+P+\,OBWXG6ZM]/C\/^!O%FOV5O/%J
MUU?W-M86-MXTTCP:+S5;NPT.W>37=4TO2[[]0_&'B_PO\/O"?BCQWXY\0:5X
M2\&>"?#^L^*O%_B?7KH66C^'/#?AW3[C5M<UG5;DJ[0V6F:=:7-W<&.*:8QP
MLL$,\[1PO_#5\ I_@=^VA\$?V#/V1OB7_P %8?B[HOC[P)\3_A)X<^%_[$VG
M?\$\-,MM:^#OQ;L=4?P4[VOQH\*ZCX5T6^\(:<VI:KKWB/QIXB\?KXBO-),O
MC3QQX.F\:Z=-86?]CO[<=S\&+C]DS]IV;]HRV\4GX#ZA\)O&D/Q;'@2&*X\8
MZ;X'U:W-EK&K>%$E1H/[<\.1WT>N:7)-;7D$5SI,<KZ7J2Q_V=<U-J%&<T^:
M4:E6FI1:Y)1C3I2C.ZYHW=2HX.,9<MG3<IQ:G;S<\R+ 9=F658/#PS",<35=
M'%4)QKU*TH1S!8:G5P-3%87!2Q$\1AVI*$:<J$<2G"A6JTI4YS^0/@E_P6K_
M &#_ (^>.[WP'\.=>^,MTD7A+XH^--%\<ZW\$?&&@?#SQIX=^#'P_P#%GQ,^
M(5SX1UR\W:K=7>C>#_!GB*_CTW6_#^@:C=W=DNEVMM)J,\-N_P =?\$[O^"[
MW@K]L/\ ;-^./[/'CNZ\->'_  YXI^*.F>!OV#K?P9\.?'=KJWQ+\)6FJ?%&
MYU7Q3\6M:US6-;A\/>(]4\(:-\/=3-K-;>$M(L;[4=4L+715EANY(?BO_@E7
M^TK\0OA/^W1\"_V(/V%?VT/&?_!0?_@GOJ?A;QGXG\<6/B[X!>/_ (;/^RGI
MY'C/6[5H?$GCG1--UC1)=.\0QZ//#J6C7FG_  V\;:SXWN_#EEX-LO&6J:1-
M:][_ ,$WOVD](_95_P""MW_!8S]GCXDZ'X\MOCM^UE^U%XD\6_L_^!AHNIK9
M?$Z?P_XR_:4^*GAVTU;78I&31-,\=>$OB)X3\3>&/$M_!-I%YH5_=:G%?+.E
ME!?I-*5.;;E#V6(=I1M*3I<L:OLU&3C.INJ,J;<7)1Y+SG>/M5>'\OPL.(</
M1R^K5KK+<KQF72JXV?UG#4*^95,//$8JABL)A*N"G1A!8S,*%>E)QP5&K3IX
MB-"M#$Q_4'Q)_P %W_\ @G!X-^(TOP^\0?$3XHV&DV?C/4O &H_&"?X'?$*W
M^"^F^+M+U&\TO5-'NO%=YIUMX@G?3K^ROH;N\TSP?J.FK%975ZE[)81&ZKZR
M_:2_X*+?L@?LA?$+X6?#C]H;XK1_#_6/C!X>U/Q=X+UR70-<USP3+X7T>2XB
MO]=U7Q?X?L=3TFPL%$#RVVQ[JXU&%[=]-M[PWEDES_%=^TK^W#\2_P!LC_@G
M3\>[S]H?]LO]I#Q+^T9X?^)^D+K?[ _PZ^ \/PT_9H^ WPUT;XL>$='TKQE\
M5=8LO!":1<^']+UW5+7P5X534/&MK\2-.^)^L^#M#\0:7XA@?6/$E[^GW[15
MAIGB+]N[_@V3M?$-A9:Y:W/[.G[-.H7-MJMM%J-K=:A::9X"U.PN;B&Y26&Y
MN(-5M+>]A:1) MY!%*5W 9=&,ZBH1G4ASU<90PTZD4IKEKX'%8N52RE&,>6M
MA_9Q4935ZE.A.7/*4SHQ/"V682MAHU*6848+"\0U<51CB93E[7*,)A<50E0Q
M.*P.&]I"K[6493CAHX:LH2JT'[.+D_WC_8D_X*H?L9_\%"?%WC[X?_LU^./$
M^K^-_A]ISZ_J7A7QGX+U/P;K.N>#H]9T[P\_CCPK!=2WL6K>&8];UC1],NDN
M)M.\2:;<ZQI?]K>'+"&\CEKX%_;9_P""ZO[ LWPR_;&_9M^$O[1?BBS^.UI^
MS_\ M >'?AW\4O!>A>+-)\ #XS:+X!\4VWA_P]X#^+FE26M^WBMO%-G%:^$?
M&.@V*^"-7UF*QF\,^.[Z*^TJ[O?GNV\.:MK_ /P<F_MW^'/!%Y;Z!XU\>_\
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MGSMMQFU.,HPC3O/;#9)EG]I8OZKA,QQ3RK.<OP2H_6\-&<'*NZM7,JJG1]_
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M\;:_#:F\FT;P;X0T"TO]9UF>TMV@EU;4C!:^'O#\5U8R^(M:TE=0T_[7\L_
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M#W@CQ9XN^)GQ!UGP[9:S\2_"6NW&IP>)9?#[:UXT\1WFEZ)HD=EK$E[\!?\
M!/#XCZ)_P4C_ .#AO]IG_@HU^ROX/\6Z-^R)\-_V;[SX<^+?B[KWAF]\(VOQ
M?^(MY\)/"OP[LK;4[&X7S3XD\07\5UXITO2M4D;7O^$%^&NC^(_%5KH6LZE;
M:,GY;?LF%1_P:%?\%.MS9'_#>WA!02>2P\6?\$X" .025R#C&2.3P*RE:$9U
M%=5)X6@YTVTY>]FCH7L]N:E&.(7+9J,K-J"<5LL#0O5PZ<U2ECLO<US04Z<Z
MV"KRG3E44)7E2=HZ.TE;VBE+DD_ZP=!_X.*?^"3'B;XZ?";X :!^T/J^I^)?
MC%8_#MM"\9P?#SQ*/A9X8\2?%/3M"U'P=X"^(/C.=(7\,>+V;Q)I&E>+,:3J
M/A;X:^('U/0?B5XH\(ZMX:\46FB_37[=/_!63]BK_@GAXE\'_#S]H'QKXQU3
MXP^/=,F\0^%?@;\'? .L?%#XLWOA.UN+ZTN?%^HZ!ILFGZ3X<\.K<:;J<5A<
M>)?$&D7WB#^R-=E\,Z=K4'A[79=-_E<_X+,>%?".A_\ !!C_ ((&7VB^'?#V
MCWNF0?LJ2Z;>:7I5C87-A)\0_P!E6P\;?$.>UFM(H9;:7QOXRM;'Q9XMD1DF
M\0>([>'7=4>YOPDZ;W_!235/BC^Q)_P<3_'O]ISXL_M?_$K_ ()V?![]IGX%
M^%=*^!G[:7AW]D[1?VN/#5Q:>%OAU\$O"_BGX6GPEK.GZU)X6N;/Q-\-/$=C
MX@U#P1IFK?$/2$G\(7.IZ!:_#OXMZCK[[2IQ2:3:]GCL=@Y-M2]JL+A,)B:<
MU=QC%5IXOV:G=)PH3Y5*HTEG1P&&K.G*+JJ,L).K["4USRJTLPJX.5JD8.:2
MIT_:2A&E)^_",G3@I5#^F74O^"RW_!.[3_V+=+_X*!6WQQN_$'[,.I?$.Q^$
M5WXH\-> _&FK>+/"_P 5+RTN]0?X?^-?AXFDP^+O"WB*QL;1=0NDU/3DL+K1
M]1\/^)-&O]7\,>)_#VM:GXSX"_X.%_\ @E)\1OVFO#?[*?A+]H34M1\;>+];
MT7PAX6\?2> O$-M\%=;\?>(KR#3=+\"6OQ$E0+'JUQJUW!I4?B.YT:#X;S7T
MB&T\<W-I+%=O_*C^UY\#O@=\/O\ @@[^UA\8_P!GC]KKQK^V'\./VBO^"H'P
MJ\277Q-\5?LXWW[,.C:EX_T#P;X_F\>^(? WP^O]>OKI_#>O:OXLBL&OAX8\
M#6]EJ7A>^T"Q\.I9:/;2UZ+_ ,%(_P!J7X-_\%4_A9_P2E_X)>_L,? 3XH>'
M?VL/A+XT\ Z3XI\)Z_\ "/5O 5Y^REI&@_#31O _B_P:;Q[6.YM?!]E>1V?Q
M(\;>+-)2W\*:5X7^&FB^*==OHKMA#ISA2<ZR@[Q7UW+\---N/LH8S#4J]:I.
M4XJ]/#JI[1-*\J#3;]V3*>782-/FYJ]2+692E7E.G3IT(X.JZ=)5(V3E*>L9
M627/%I\LW&+_ $>^+'_!2_0_V)O^#B[]MZ\_:Q_:A^)W@C]CWX<_L<_#O5-
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MM6C*)OE!3*DD+DG$AX'X-U&<X [UF#@VV[K\3YUUVS*22@@'<?F ^;;SR<9
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MMXQ\2WD6G:+X:\-:7=ZSJ^I7D[".&&SM+%))<[V1Y;E_W%M&K37#P1*\\?\
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MZ_%XW;XNW'BFX@-SH>K2GP99^'[B37;!9]7L_LWTU\:OVVOV6/V=-;T#PO\
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M_"->,?%NAZIXK\/^ O"GP_\ BQ\9OB1>^#]&FGLM4\<7'PU^!?@'XE^/=(\
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M7VGW3P2"6%KFQNXYK6=H9462%I(6,4B*\95@#7A7[/'[4?P$_:OT/Q%K_P
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M33]%UG4M.TZ6[O;'2]2NX8;*?XL_9-_9U^+G@[XH_M&?M3_M/ZU\.=6_:/\
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M#P-=?%/XG2>,]-\/^$- 3QCX9\,QZ;H/B$'2?$6H7T%M#^B^A:1I'A_2M/\
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MT+SS]4OGGZ*P\/>'].U?7?$.GZ!H>G^(/$QT>/Q-X@T_1].LM=\2IH%G-8Z
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M!_B'XB?LZ? +Q;8> O$M]J,UEIFE>,DMK'6-/N-*FGM[J]U/0-4M;.&>>W,
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M]A7@YVHU9J=3'TL=&2IXR]*4>>%2-6+E!^T<*U.7M(IG\\/[37PI^"_[._\
MP39^%US\2OVE?AM^V!^S_P"-?^"T?P6_: ^+?Q1\+?#[P]H7P5'A+QS^U5/J
M?[0'P^\*_#_P7XY^+WAR?X>^%O%&C?$RWOM T'Q%J]H;F_U[0(],$]I)'/\
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M@^'/$;7QF7,UQ*\X>2.43/\ ;O["/@O_ ()'> _BU\/KS]E?]M;X>_%#X_\
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ME_#35OVN/ ?[?/PE^(.N>'M5^*GBK]HGQ;\9_BU;_$/P3XW^'=W=S>*/B?\
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M7^B>']:U"_73-,U6_L-(U;4X(9].TC6+ZST?4[JTU.[@M7_!SXI?"/X;VO\
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M3OHGA^Y67GH+VL:-WRPE#"Q;E?G7MJ%:LYRTFYN/+%J'+[2LUB%"3>'47-;
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M=6TS5+7Q59?#V\UB_P!)U/7;VVFNJ_B2?]J?0_\ @LQ_P2OL/VJ/%7[(-O\
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MO+IA:6/B*-)=!OKT/96FHRW4<D29?Q4_;4_8Y^ _CK2_A;\;_P!K']F_X/\
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MCK9Z?XD$3Z#J-X39V.I3W2M"NDO[4/[-,WCSPI\*[7]HCX&ZA\3O'/BSX@>
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MZ?I]K#96%C:01VUG865M&L-O9V5K L=O:6EO"B16]M!%'!#$JQQ(L:A18HK
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MA+\0K5/VOOB]\>?AJGP]US]LW]H_Q-\2H_@=XLO_  CXUU/PA\$='^%'P]^
M_P .?"GQ6C\-7WBGX?W?C?QCX-^'M[XK^(7A30_$7C'PUI5MXRM?!VH:MJ>H
M:5K48[;X.?\ !/#]AG]GSX@0_%;X*_LL_"'X=_$.P.N?\(_XHT;0KF[NO!(\
M36]W:>)$^&EAK>H:KHWPJBU^QO\ 4--UB+X;:;X3BU'2M1U#2;I)=-O[RUF^
MPE^^/]]__9ZGK.T8\J@K*$(TH>]*34(*2C'FE>3^.;>N\Y.-N9I]%7&XBK/$
M356I2CBI<U6C2G.G1<52IT(TW3A.,94X4:-.DE-3;7.ZDINI*WR5\<?V"_V,
M?VF/'&G?$?X\_LU_"[XF>/[#2X=!?QEK&DWVG>(M;\/6BQBT\->,]2\-ZCHD
M_P 0?"UHD$45KX7\>MXE\/VT$:P0:;'""E=E\7?V1_V8_CS>_"O4_B]\#_ /
MC74O@7?PZE\']1N=-N-%O_AXUO\ V>%TOP[>>%[S0[B#PM(-&T=;OP5=277@
MV_32=-2_T"Y6QMA%]"+]]?J?_06J4_Q?[H_]FJJ7NSBDDE&7M(V25JD6FJBT
MTFG*5I*S7-))J[3T5>NU3BZ]9QI4YTJ475J6ITJD?9U*<%SVA3J4Y.$X12C*
M#<))QT7,>'_ /@CPIKWCWQ;X9\*:%H7B?XK:YI?BGXE:]IEC';ZGXY\1:1X7
MTWPCIFL>);D9;4[ZP\+Z1I?A^VDG!$>EV%O;!=B9/S1\-O\ @G/^P=\'/BA:
M_&7X5_LE_!+P'\2-*U"YU?PYKOA_PFD&G>!M9O@&O-:^&?@R:YN/ 7PKUFX#
M,LFK?#;POX4U'RW>-;E8W=6^Q/X5_P!U?_1(JX>I_P" _P#H"U*;333:<4HQ
M:>L8I-)1>Z23:2325W:UW?2G7KJ%2*K55&KI52JU%&HE!02J)32FE'W$I)^Y
M[OPZ'#K\,_AZOQ,D^-"^"_#@^+<WP\M_A)-\2%TRW7QC+\+[7Q3<^.+?P"^M
MA1=-X6A\8WEUXFCTDL;==9N);Q5\QSFUX<^'G@3PQXI^(/CKPWX1T#0O&?Q7
MU'PYJ?Q,\4:9IT-KK?CO4?!?ANU\%^$KSQ/?Q@S:K<>'/"=A9^'='DN&)LM)
MMXK6(*@-==3X?N'_ 'W_ /0C1=Z*[TBX+5Z0E)SE!:Z0<VYN*]UR;DUS.XG)
MO>4GI".K;]VE94XZM^[322@MH))144DCRWXJ? +X&_'FVT"T^-WP@^''Q<L_
M"X\7#P[8_$;PEH_C"PT<>.?#-_X(\8?8;'6[6\LXCXC\(ZG?Z#J9:%C+87+*
MACFC@ECX'X)_LI_LT_L<^&_B!=_LT_L]>&O UYXCM)_$7BZW\!V1U/XD_$^]
M\,Z;J-UH'AR^\:^.->N/$7B2:W,MWI7@;0/%'C2W\)^';O5I8-./AZQO;ZY'
MTS'T7_@?_H=2K]]?J?\ T%J6J4DFX\UV[::NWO-:)OW8ZO5\L4VTDEU0K5%1
MC1=2I*ANZ'M)JE)<\I-.$9<FK<G?ETE)R2YK,_.;]EGX5>-OB+^U3\>_^"A'
MQB^#FN? _P 2_$CX1_"G]EW]GCX8_$:U\%P_&SP-^SI\/]4U;XF>-];^,0^'
MWBSQSX6TWQ;\8?C1XG.J6OA*'Q3K>J^$?!/PT\$:=K.I_;;MM-L/TE9$DC:.
M1$>.2-XY8Y$62.6.52DL4T<BLDD4J%DDC=6CD1F1E*,P,+=#]#_*K-/11C!)
M*,$DHJ[5TY3E)WO>4ZDYSDWU:2]V,4:5Z\JU5U6E"7[N,5"Z5*G0C&%"$'*4
MIJ-&$(J-WS.;J592=2I*WQ+X!_X)J_\ !/[X8:IJ^K^ /V/O@1X7U#6M;T;Q
M'++8>#8IH=&U/P[XUT;XC:-'X)L-0N+S3OAOHEEX^\.^'O&3>%?AU:>%?"MY
MXDT#0=6OM%NKO1M-DM?N42.)!*'82A_,$@)#A\[MX8<AL\Y'.>:K)]__ ("W
M\UJ:E>\5%O1))1=[645!7NV](I05V_=2C>RL:^UJUIPG5JU*LU:TJDYU))6<
MK*4Y2<5S)2LFE=)VOJ>2:)\!/@IX=^##?LW:#\+/!.C_  !F\%>)?AU+\'M.
MT.VM? $G@3Q=%JD'BCPFV@1!;;^P]?BU[6DU2R&([K^U+TR9:9C61\9_V6OV
M<?VB_AOHGP@^.?P4^'WQ/^&_AF;1[GPEX8\3:(C+X(O]"L5TG1M6\ ZUITMA
MXD\ ZYI6D@Z38Z_X,UG0M:M]+>73H[\64\T$GN2_ZU/]U_\ V6K'=?\ >7_T
M(4/WFW+WG)QE)RNW*4%:$FVVW*"TC)MN*;2=FT]:=6I"<IPJ3C.-2I*,XSE&
M4954U4<9733J+2;33FDE*Z22^:/!G[%'[(?P^^"OC+]G+PC^S;\(-+^!GQ'D
MN;CXD?#6Y\'V&OZ%\2=0NC8L^M?$6X\2_P!LZUX\\2PR:7I,]CXJ\6ZKK'B7
M2[K1]'O-+U6SNM(TV:UR_@K^P7^Q?^SQJ?A/7O@I^S/\*/A]XG\!77BF^\(^
M,]-T.;5/'VCW?CKP_:>#?%DW_"P/$E[K7C;4CK'A#3['PHT>L:_J$5CX;M8=
M#TJ.QTQ?LI^LZ?'_ !_2/_T.FFTW):2:47):-J*<8IM6=E&4HI=(R<=FT]HU
M:KYXNK5<9N<YQ]K/EG.2@I3DN:TI24(*4FFVHQ3TBK><:)\%/@]X>\.?$CP5
MHWPN\!V7@SXS>)?B/XP^+OA$^%])N_#'Q/\ $WQACFC^*VL>/=!O;:YTOQ3<
M_$>&>>V\:IK%K=6OB*TN)[/4H+BUFDA;RGX<?L.?LA?"/P!X.^%GP[_9\^'O
MA_X>?#SXS:+^T/X#\*3VNJ^(]/\ !OQQ\,V5MIGACXH>&IO%NJZ]J&C^*?"^
MF6=KIGABXLKV*T\.Z9;PZ=HMI8V,:0#ZC7[Z_4_^@M4]):6MI:-.*MI:-)P=
M.*[1IRIP=-;4W"/)R\L;:>TJ)22G.TI2G)<\K2G.,H3E)7LY2A.492:O*,I1
MDVI-/A];^&?P]\2^.? 'Q.\0^#/#NM?$3X4VGC>P^&GC74M,M[GQ+X$LOB5I
MVEZ/\0;7PQJCJ9]*@\9Z5H>C:=XBCMV4:E9Z99P3Y2%0/FOXI?\ !.;]A#XX
M_%*3XX?%S]DWX,>/?BM=S:3<Z]XMUKPPR-XXNO#S0#P_>_%#P_IMY8>$_BY>
MZ'':6<&CWWQ2T#QC=Z;:65C96<T-I96L$/V94B_ZL_\  _\ T)J:;4H--ITY
M<T&F[Q;:;<'?W6VDVXVNTGNDTX5:L'>%2I!N,8-PG*-X)NT'RR5XKFE:+T5W
M9*[O\L?$+]A+]C/XO_&O2/VD?BA^S/\ "/QU\<]&?09(_B/X@\-)<ZMK-QX1
M>T/A"\\;:='/#X<^(^H>#CINE_\ "'ZC\1-%\4W_ (3&DZ0OAVYTQ=)TX6OI
M7A3]FS]G_P $Z!\'?"?A#X._#_PSX9_9WU75=>^!&@Z+X>M+#2OA)K6O:7XG
MT36M3\"6<(6+0;S5-(\9>+-/O9;9<S6WB'548?Z2Q'LT?W!]6_\ 0C4T?5OH
MO\VH3:CRIM14E+E3:CS1E.49<M[<T95*DHRMS*52;33G+FW=2I)1C*I4E&$7
M",93G)1@X*FX13DU&+II0<5:+@E%IQ22\*_:$_9;_9U_:P\'Z=X#_:2^#?@;
MXR>%]#UA/$/ARU\8:6[ZMX1\0HL:#Q!X)\5Z5/IGB_P/KK10Q03:QX0U[1-2
MN+:-+6XN9;8>56E\"/V<_@/^S!X(?X;?L\?"7P/\'_!-SKFH>)]2T/P3HT6G
MMX@\4ZK!:V^J>+?%NL3M=>(/&?B[4;33M.LK[Q7XMU;6O$-UI^F:9IT^I/8Z
M;8P6_M%(>J_7^AI)VYK:<UW*VG,VDFW;=M))WWLKW#GFXPIN<W3C)2C3<I.$
M6Y.3:@WRIWG-W2WE)Z.3;_+[]L_]CUOVI?VU/^"?NM?$#X*>%?C/^RY\.OAQ
M^W[X7_:&L/',7@_6?"6EW?Q=\!_ 2/X.PZKX0\1:G#K6N76J>,?A]J-YH.K^
M%-&U6[\':_X>TSQ!<WWAVZ@T?5*^QOV<_P!D[]FK]DC0-<\+?LU_!7P/\(-*
M\6:G!K'C"?PU9WEUXC\::K9Q7L5AJ'C;QKXAOM:\:^,KG2H=1U"VT9_$_B+5
MAHEI?WUII LK:\N8IO?UZ/\ 3^AJ9?OK]3_Z"U4WS4XTVER1C4BU;XXU:LZL
MXS6TDW-QL]'#W7%JZ>[KU)VIN4HPI1A&,5*2C[DJCC)QOR\W-4D^:U[J.NB:
MY'X<_#?P#\(? GA?X7_"SP=X>^'_ ,.?!&DIH/A'P1X6TV'2_#7AS1(I9YDT
MK2=,A'D6UBLUS<2>0 R&2:4MDL:^5?A?_P $T?\ @GY\%/BI:?&KX3?L?? O
MP#\2])OKO5?#&O>'_"*P:9X"U>__ ./[5_A=X)N+JY\ ?";6;Q<QSZO\,O"O
MA+47B9X/M0@DDC?[?HI<TK\W-*]FKW?-9N[5[WU:3WWUO<%.I%2C&<XQG?G2
ME)*=[W<DFE)N[NVNK[M/SGXE_![X3_&;3?#&C?%SX;^"OB;I/@KQYX8^*7A#
M3?''A[3_ !'9>&?B1X*EO)?"7C?1;?4H9X[#Q+X?;4-033=3A59X8+^_M&+V
MMY=0S:OC3X:_#[XES>!KSXA>#?#OC2Z^&?Q#T;XM?#VX\1Z;#J<W@SXG>&['
M7-)T#Q[X>>X#'3O%&CZ;XDU^RT_58<3V]OK%_&A N'KL:EC^X/JW_H1I+3;3
M7FTT]Y))2T:]ZR2OO9)7LDA<TM-6^5.*NV[1DYMQ5V[1DZDW)*RDYR;3<FW\
MC?'/]@']B;]IGXB>'_BW\?\ ]F#X0_%?XD^&]*BT"T\8>*O#C2:IJ_AJWF$]
MMX2\<II]U86/Q,\&VLH+6O@WXD6GBWPM;*\L4&D1Q3SQR>RZ+\!_@?X>\#>/
M?A?HWP>^&=E\,_BGK7C[Q%\3/AS_ ,(5X?NO 7Q UCXJW%Q<_$N[\8^#[VPN
M?#OB%/'<]W<GQ39:GIUQI^KQW$L%U:/;R-$?5Z*.C725^97TES2YI<RZWD^9
MWO>7O:2]XMU:LN5.K4?)R\EZDWR<ME'EO+W>5646K-)))V22^.?V?_\ @GO^
MQ'^RKXMO/'_[/'[,OPP^%WCB[L+[1H?%VD6&J:QXBT'0-3D234O#'@O5?%FK
M>(;OP!X2O72/[7X3\"R>'/#<Z11Q2Z6T42(OT?X%^&OP^^&-KXEL?AUX,\.^
M";+QEX\\8_%#Q9:^&]-@TR#Q'\1_B%JSZ[XZ\;ZND  O?$GBS67?4M<U.7,U
M[=GS'(P .V/3\5_F*6G=[7=G%1:N[.*DIJ+5]8J:4TG=*7O?%[Q:G.?,YRE)
MN2;<I.3;C'EBVVW=QC*23Z*4DK)NY1112&%.3[Q_ZYR?R%-IR?>/_7.3^0H
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M'^G]#4R_?7ZG_P!!:@TC\4OZZD]%%%!H%2Q_<'U;_P!"-15+']P?5O\ T(T
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M+BHR;=6$82=.*2]Z4HU8.'+=235FM+ZX?AG.:U-UX86FH1AC*CC5QN!H5>3
M8EX/&R]C6Q5.JH82LI>WJ2BJ=.FO:2JJ,H*?]#<?W%_WY/\ T)ZF7[Z_4_\
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MUX5Z;E1Y;1G.-1JF?M$W0_0_RJ[']T_]=!_Z+-?A!\?O^"S6N>!K?]@GX=_
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MQ3XMU/1]!T^;4M0NK;3].BO-0ADOK^XAL[99+B14/Y4?\%8/^"LB?\$VK_\
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MZ1X??PK\'_"^L?$+QS\1M3\0:AH?A:_4>%M1UJ>IH?\ P<L?!F;_ ())3?\
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MX\ZUXOT'5+_49_&<6BZNNI^'+F#5(H/#NHZQ<0HP@O(;>[!MZ_4+]HO]E/\
M:#\;?\%[_P!BC]L3PK\.+_5OV;?A5^S)XQ\!>/\ XH1ZYX8M[+PYXMU6Q_;
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M%7A[]H'0OBEH.AW'P??X@>&_"OA+XQ>%?B1\.?$%MI<$TMYX5NWOO OQ'O\
MQQX3\':')XF4ZK<^)K[0+CP[9_WG>*O#MEXO\,>*?"&ISWMOIGB[PYXC\)ZE
M<:=);PZE;:=XETB_T2_N-.EN[6^M8M0@M+Z:6RDNK*]MDNDA:XM+F%6@?Y7_
M &#_ -A?X._\$[?@&G[-_P "_$/Q.\3> (_'/BCXA1ZE\7-=\*>(O%ZZWXMM
M=!L]5M!J7@SP-\/='.C1IX=LI=/MW\/O?PS3WQGU.[ADM8;.%)/ZQ&=U&>%P
MV'A&#O&<J>/GBJJG#X::Y9*I3<4DJJ:?-;7KCGT'0JU*V&HXK%?VI@<90I8R
M6.Q%.C3P6 KT*52&)J8AXAUJ>(E"?LZM22J4W44(J"=OY[_VC_\ @D7^U?X*
M_8M_X(H?LR?"3P0/C7XK_9"^//BCXF_M%ZWX5\0>%-'T7PG/\0OB5X<^*GB6
M2PG\7Z_X<GU_1O#FI:SX@\+:3?Z-;7%]K.G^$H]:GTK3GU2WM3^AO[3/[(W[
M1?C[_@X7_P""?W[:7A'X9W^L?LP_!C]FCQ%X"^)GQ5CUWPE:Z=X5\6W]Q^V4
M]KH]SX?OM?M?&%_+*GQ/\"N+G2?#NH62KXA@WW2FTU$6G[HHH#*!QDD$]_NG
MO^ J1EY/.,#..N<YY]OP]:J-24I4^7E3ABZ^,5XM)3KX2AA)024G:G"&'H.$
M6W*\9^\N>ZY7F^*J0E"<*4I5<OS++JM2TX2G3S3%RQN)J\J<HJK&O4DJ*7[O
MD4?:1;2O^"?_  0N_8Z_:2_9*\3_ /!2+4/VAOA5?_#.W^.G[4^F_$3X77-]
MKW@W6F\9>#;?4?BU<?VO&/"?B'7Y["&VB\3Z5*EKK:Z==+_:K-;V[L+P1?''
MP4_X)U?MH>%/A[_P<MZ/X@^!FKZ?J?[=OC+7=4_9/M#XJ^'T\OQ@T^\\=?M:
MZM#=:6UMXNEB\.*=-^)'@J\,?C63PW*5UN./9Y]K?Q6O]7?.T8_NK_Z+!Z=/
M7W X''%6BN3C/ V\?1%Q_P#7]?:LI-NG&G=)0P%/+5:-V\/1CAJ=*;=[*JHX
M.BZC2Y9/GY>5RNMHYSBGB,;BE1H<V-Q6%Q56+]KRPJ8.M1JTHT[2NZ4Y4TJG
M,_:<KDH24DFOY-OVA_\ @G5^VGXV_P"#<C]EC]B'PQ\"M8U3]J;P!\0_#VK>
M,OA*GBOX>6^HZ'I&F?%+]H+Q#<7TWB*[\80>#+N-=(\7>&;U8M.\1WMV\>L0
M0BW\^WO8;3^I'X+:5J'A?X3_  @T#Q!8R66K>&OAI\-M"\0:7Y]N\UGJ>A^#
M-"TS6=--S:S3VKS6UY:75H;BUN)[9I(_/@FFAV2-W&W/USG@#GGN.<CV[]\'
MFI(AE#QT=S_X^?IZ^O7FKJU'6^M<Z3^M556J6O%)QP3P3C%WNHNDY-MOF4W>
M+2BCGK8VK7HX>E*,(_5\1C\1"4.:[GC\3'%U8M3<U:%6*]FM;1]V7,[M_P ;
MW[%_[-?_  6(_P"":O@/]MO_ ()O_![]B#PS^T%\-?CKKOQ1\3?!/]L34OB[
MX?\  ?PZ\'6?B_X=CX;7WC?Q-IDL.M7/BO5-4\(:#X2NM#^$5Y>^ _&.A^.+
M'489CXJT/5%$7-V/_!%3]M?XI_\ ! +PK^R)JWP\MOAS^UI\&_VR/&?[2GAC
MX1^+O&'@H1?$;PM<^#]5\%R^%;+Q=I/BJ^\$:%KNNV/BNYUKP[?>(/$%C9"]
M\+3Z#J4^C)X@M]7M?[3D7"+U"G=CL2"Q"G;U(.#@@8XQV.)$7##D');MZJ3D
M?UP>:B[Y7&_-*5+#4_;N*]HU@ZWM*,G%:-K]Y&I9WE[2I&\?=Y/8>?8B52&(
MAAL'3J2QD,=5DHUW*M6>'J8:<JG-4:M6I5$X^S]FJ3BI4U4YFS^6#_@F9^PQ
M\,+?]JOX(^/]9_X-_?'/["&O_!V_U'QIK_[2_CG]O'XW?$30?#/Q!\-:%<'P
M[#\,/A%XL^($L_CZP\7>+&MK4WE__P )AHOA_P /R78U&3Q#N76+3RSX,_\
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M2K#2M+_K!1<J.>F1],,P!ZC\..OXT_S(8E=YIHHHP8P99G2*-6DD\I%9Y"J
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M_P!CSPOXQ\"?M??LMZG^T!JV@^+_ (A_!KQ%\7]>^)7@/P/X5^.&F>)-%O\
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M&VI<MD\XXRH[P<(<LZ>-I.SDG;'8CV]26[M*#25-+1I>\US>[_*Q\<?V>?\
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MRQQSL?.,7 _\% ?C1^T7XV\(?\$G_B[:_LE>,_ 'QTLO^"J7A^^L?V8/BO\
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MQIXM\,69U#PIX#U:\NK33I?,_P!C#]J_]K;XT?M1_M9_##XJ_LO?$/P?\/O
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M+/V>_A;^S#X1_:GT*3Q!\;_%&HZ_K/Q@\ ?M1V7[&R'XP:#\>M TN7P-X?\
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M3G@O]K/XZ?"7X6_L\?$#PM\2O@)\1] ^#7[.6F+!X7TGXI_&'Q_^T;=Z!:_
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MOZQXRTF+X=_'G]FC7/'[ZIX8T[3KG6K"/P/H_AW7]6\827=E%'X;TW0M7O\
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MNOPQXB\;?L+?MP>"O!V@:[XK\7^-/V-?VI?"7A+PKX8TB_\ $'B?Q1XH\2_
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MOC/P-\'/V@/$FB2>&/AE=^,;?1O%LT6J^&O%7B#PQHGASQ9X4NM<^)/VW?\
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M^-;WP[KEIX2M-;OK&X\1W6B:I;Z/'>2Z?=K#\W_L7:U+^S_XF_X*O_ SXW_
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MS)&?%OV+O#=[\./VQ_@_X._X)ZQ_MN:+_P $\;WX:_&5OVH_@A^UY\*/VEO
M7P-_9P\6:3I6@-\!?#W[(6H?M>?#[P?\3]!\<:IX\OO$5M\1OA9\./%/COX5
MZ?X,DO-<O+;0+VS\.L_U3_P6T^''Q&^+W_!+[]IOX=_"7P#XU^*'Q!\1:E^S
ME)H/@7X=^&-;\:>,M<70?VLO@/XGUUM&\,^'+'4]:U1=&\-Z+K/B#5C9V4ZZ
M?H>E:GJMX8K"QNYXNJC!.M@U&<:2GB</:4Y7=)1S/"*,ZSBX1<81IQJ3G"5.
M%:A&I5M1C*4*;HQIT\QH*2A&DG%R@I2BVI83%RM-593E3J)QBIQG*3IU90LY
M*I&*Z^P_X*%^.++]H+X,?#;X]?L2_'#]FKX:?M6^,=:\!_LW_&KQ]X\^#_B-
M=>^(MOX4\4?$+1? 7QG^%G@SQ/J?B[X ^*?'OA+PIJ][X&T37K[Q/KESJD8\
M-^+=*\'Z_I_B2P\.:W[3O[:/[0/[/5[\5O%'AO\ X)X?''XT?L_? +PW-XT^
M+?QPT+XQ_L]>![O4/"&B>"[7X@>.]<^ _P '_%WC4>/OC$OP_P##D]W;ZM:Z
MTOPKD\1>*M"U_P *^!7\4WMA!/?4O^"D?@'QO\0/'G_!-&[\$>"O%GC>R^'W
M_!6+X&?$SQ]=^$O#>L^);;P/\-]&^"/[4ND:O\0/%]QHUE>P^&?!&DZMXB\/
MZ9J/BO6WLM!L-0UW1[.XU"&YU*S2;\C/COX>^(OQD3_@IO\ #_\ :M^$W_!4
M#XW_ +4%_P#$;]I3PC^Q)\!?A+>_MD> OV+]7_9P/AB^M/V8O'/AGQ)^SUXB
M\#_LFZQH,VCZG::E\==2^./B_P 0?%;Q'XGT_7/ 5E\/_%OCR30?AYKO+4;C
M2G.*BYP^MN,6[JHJ:H*BFE%2G.4JM5OD=-2I156,;TZJ'A:-#$8B'M(1C2G'
M#*HX2J/V;J5ZU"K5C>I'V=-4Z4)2E4G4C3K2BDE&I!'[A>"OVX?A9X__ &@?
M@I\#_#>D>)+G0_VE?V.X?VS_ -GOXTS_ -G6/P^^*W@B/7?"]EKW@31K#4+F
MT\4VGQ'\->$_'G@/XDZEH]QI,EN/!?B=+Q[FWNM-OK9."\>_\%)?@Q\,+S]L
MRY\2^#?BCJ7A?]C7QS\"O@I?ZYX$T+3_ !QK/[0'[2WQY\/:'KGAO]F?]G?P
M5I.J)K7C/XOZ1>>._AIX7U[3-7F\.Z3I?B/QY9_VOJND^'_#OBWQ!HOPGXM^
M#7QF^&7_  33_P""/_[27@?X&?$SQ=^U/_P37^&'[%7C+7/@-X=^'>HZE\??
M%OPL\4_L_P#@/]GC]M;]GC0O &I0V6N6?Q O/AMXFU/Q#<>&;RRAURP\8_"'
M2;"33AJEI]D/G?QM_P"">WQOG_X)7_L]0:CX)\8?%/\ :F\"_MK?"#_@JE^U
M[\,OA%XCU#X6?%SXV_%CQ9\2/$OQ,_:>^&OPM\9^#_&'A/6]"^)7@CPW\3=1
M\)?![4_#GC/2O%,C?!KP9I_A+4&\8RZ+;SZ5XQIU:ZC=4:&)JT&TXN4Z=3&T
ME0KQG[T+4\O>)E4<8SIK$4J=6I^[<J%54:&'YZ2;O[6].$.:\HUL+2QE3$<R
MBX_[S6A@*-"/-&T<55Y9\U/VE+].OA1^W#X\U#X_?#_]FC]JK]DGQ]^QQ\4/
MCEX5^(WC']G<^(OB]\&_C?X.^+5K\);#2=<^(O@:7Q1\)-=NU\&?&#PEX5UJ
MW\8ZAX*OM.U;PUJ/AC3]?U#PU\0]?DT9[:?[=\=^*+KP3X*\6>,++P=XQ^(=
M[X8\/:IKEEX!^'EGHVH>._&E[I]K)/:^%_"%GXCUWPOX=F\0:U.D=AIK>(/$
MOA[0XKF>.;5];TO3X[B]A_(3]EOX:?L'^/\ ]I/X/_$#X0_ W_@IOK'Q/^#>
MB_$KQGX9^*/[7NH?\%0+#X6_ +Q)XC\%K\-/&/@W48?VZ/B/;>!-7^*_B[PK
MXYU7PW#HOPU\-?$L0V6G:MK5]K.BVNCZ+JMS]:?\%-]9_::\/_L._&_5_P!D
M*R^)5]\;K2/X??9(_@GHNC>)/CI;_#6;XH>"X/CE?_ SPYK]O=:;KGQ@T_X+
MR^.[SP!IRVMSK3Z[!;S>$K>X\70Z#;S3*,E3III*<[0<G**@G*O0H*HZEZD8
M*#JSG5FX.$:5&=?DG%24FZ=.6*C3A%P@_9\T9J5W)4ZLZB4(OVEIJDHTX>T5
M1U:JIN5*\91YOX4?MU?$>^_:/^''[,'[5/['/C[]D'X@?'OP;\2_'7[.>J:K
M\9_@S\>/"'Q1MO@W:>']8^*'@?6-:^$^KS2> ?BCX4\.>)]-\4G0)[+Q'X-U
MG0K77)=%^(=[?Z;%8:AZ!_P4A^+/Q7^"'[#7[4WQ*^"O@+QIXW^(/AWX$?&&
M[TF]\ ^+_ 7@OQ%\+TM_A5XUOF^-:ZK\0/%/A.RNK'X575C9^*+O2/#-YJOC
MN^:VA/A/PYK5["]NOXY_#?X.^"O$?_!4O_@F3\;?V7O@E_P4=\5?!_X?Z/\
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M\?M*_LJ_LM^)_B3X/^/?[2?@SQW\&_ Z7&M_!>U>?XU+^S?\(OB'XIT;QO\
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MNO\ O+_Z$*L57[K_ +R_^A"K%)[/T?Y&I)'T7_@?_H=2Q]#](_YFHH^B_P#
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M3GG\7W>G^'[O\:O^"@?_  4YLO\ @H?_ ,$8/C'XRT#P-K'PF^)GA?\ :7^
MOPN_:3^'LVH2ZY:VMI<IXH\4^$]9L?$<VGZ7J&I>&/$&O?#[2$M-,UZQM?$/
MA77?"UUX=U ZC96.B^(->]._X+$Z5HO@[X'?\$'-2^%T=M;>*? WB[X5:/\
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M%)2C_8*O^K/_  /_ -":I4(SGL%.200!ROK]#G^[CGK7\C?[#/[9/[;?AO\
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M#L[.[\"VD*:O<1ZK+)8_HW_P5Z_;G_:H_8<\3?\ !/+_ ()A']N7XE^%-?\
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M]E]:G?DA1J8SEA-IR]G@YRC5DY-N%XQA-J*4G.4)1CHX<W]6_P /_P#@KO\
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MHOA27Q/\+/#^MZX+?4_$'@+P'8Z[(L,VJ3S?2'_!2WQK_P %!_\ @CY\-O\
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M=>._#,O@?2-"TKX':=X?LK^+3/&$S6NM_:FLE;1A;ZM^ET'3_@$?\FJ4@9'
MZ'M_NT1T<&F[PJ1K*3UDZL$XPG*3=Y.$5RQOI;?>QW3XBS>OB*=>IBH<].GC
MJ=.%/!X*C1BLSI5*&85/8T,/2ISQ&,ISJ1K8BK&I6ESR:DFS\Z/VW/\ @GGI
MW[:OQO\ V%/C7>_&&^^&<_[$/QEU;XPV'ABT^']OXSC^)UUJ/C/X+^+?[ O=
M:F\;^$G\&0VY^#JZ;_:D&D^*Y)1XD>^_LU/[%6SU7A/VP?\ @F/K?QU_:;\
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M\0Z1I/B#0-;L+[2M:T'7M-LM:T36M(U"&6TU#2M7TC4H;G3M3TS4+66:UO\
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M*,:5&M3G"'LO94U3FHJI%PYU)3E)O^>'QK_P;M?!K5OV!_@+^PGX!_:.\9^
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MUTGQ)K_@/2M.\&Q:OX?M;5+T_I1H_P#P3/T"S_X*H?&?_@IKK'Q=E\3'XW?
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M<)^./PH_X(G:-\,?^"0WQ=_X)-K^TSJNNZ9\6=7\1:Q-\?6^#%II=_H#Z_\
M$+P%X_-M#\*Q\5=3MM4CM7\"QZ29G^(]@TZZK+J C@-DEG<_N,H&&X[?XU,O
MWU^I_P#06K%Q352+6E:%.%3?6%.HJT%HU:U2*E=.[U3T;O5'%5Z3C"G4<8T<
M4L935HODKQHO#*JKQ;YG1?))/FBXI:)Q1\!>%?\ @G;\)C_P36\,?\$R?C#K
M>J?%GX3:;^S_ *)\ O$_C"RTFV\!^(M>M_#[6U_HOCW0=*EU#QM8^%/%/ASQ
M+I^C^+?"T=U>^+-/TS7]#TN748M<L4N;&X^)/V0O^"4_[?'[*%Y\$?AE9?\
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M? 3]LS_@IKXX_:T\4?M>?!N+X+>'?'%]^SEX&^%'@K]GO14T7X@Z3=ZWX/\
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M1Y;.'PSX9\)Z1X:32;'1?WVEE\V:20<"0EMN<XZ8^G4G'8DY]!53J/\ >/\
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M"^(UNKSP^[?;U.N-)I?@'_!Q+^U3^PY\,O\ @GA^TM^S-^U7X\AL/B-^T!\
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MQP .,^*@<<<^].'[>/PL)_Y%+XA]0Q_T;PGQC'KXKQV[T?4\3_SYG_Y+V?\
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MC_D;>N#^?;M1]3Q7_/F7_@4/_DS2''G!J;OQ#E^MNN*Z7_Z@3[VBZR?[R_\
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MGWM4P_X*O? <]?A[\8QST^Q_#L_^] _SBCZCC/\ H&J_='_Y(O\ XBIX=?\
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M!^&__P \:C^S\9_T#5?_ "3_ .3-?^(P^&'_ $6V4?\ @&;_ /SB/UL3J/\
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M .2#_B,7A?\ ]%KE'_@&;?\ S@/UMIT763_>7_T!:_)#_A\?^SM_T33XW_\
M@O\ AO\ _/'I5_X+(?LZH6_XMG\<3N()_P")=\-<< #C/Q(![#MUSS1]1QG_
M $#5?NC_ /)!_P 1B\+_ /HM<H_\ S;_ .<!^NE%?D=_P^3_ &=?^B9?''_P
M7_#7_P">31_P^3_9U_Z)E\<?_!?\-?\ YY-'U'&?] U7[H__ "0?\1B\+_\
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M,.EO^I-Y'Z\T5^0O_#YW]G#_ *)G\=/_  !^&'_SR:/^'SO[.'_1,_CI_P"
M/PP_^>31]1QG_0-5^Z/_ ,D;?\1I\*?^BXR/_P "S#_YSGZ]45^0O_#YW]G#
M_HF?QT_\ ?AA_P#/)H_X?._LX?\ 1,_CI_X _##_ .>31]1QG_0-5^Z/_P D
M'_$:?"G_ *+C(_\ P+,/_G.?KRW0_0_RJS7X^_\ #YW]G#_HF?QT_P# 'X8?
M_/)I_P#P^@_9Q_Z)E\<__ 'X8?\ SRJ/J.,_Z!JOW1_^2#_B-/A3_P!%QD?_
M (%F'_SG/U_HK\@/^'T'[./_ $3+XY_^ /PP_P#GE4?\/H/V<?\ HF7QS_\
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M(OA_\/R>? /@4_.1SX.\-GC9GOIGKS70Q_ZQO]Q?_0FJY#]X?[Y_]%U7//\
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MO^I><4?A7\*RH_XM=\-/NK_S('A'_GD#G_D#]<]^*M'X4_"K)_XM;\-/X?\
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ME>ET4>VJ_P#/R?\ X'/_ ##^RLI_Z%.4?^&?)_\ YTGFG_"EO@Q_T1[X4?\
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M?^#:G_R0?V7E/_0IRG_PU93_ /.@\O;X(?!3!_XLW\)NA_YIMX+]/^P)4_\
MPH[X)?\ 1&OA-_X;?P9_\I*](;H?H?Y59H]K4_Y^5/\ P;4_^2#^R\I_Z%.4
M_P#AJRG_ .=!Y=_PH[X)?]$:^$W_ (;?P9_\I*/^%'?!+_HC7PF_\-OX,_\
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M:37EN]+M=-VKJ>IV%BQL+^^*7%U&KA02U?C]^WI_P5-_;"\,?\%$-(_X)?\
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M19HHHH *EC^X/JW_ *$:BJ6/[@^K?^A&@!]%%% "'I^*_P Q3T_UD?\ O?\
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M:V7]X-A,L5U:W$Q)2*\@GE;[SE4G220XX+.0#@$AB3@XKX$_8-_X)N_LC_\
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MEF%:5?VKA1:>'K825.<:DJ<J%>LJ]12_>RJ2DZJ3C+VB2C[K327+_)S\8/\
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MM++J05+VMVZ;;BFEKS>ZH^[?:7.FG?WHJ<DK1U]U</9K"OE.'GAXTJN<Q4\
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ME/A^X?\ ??\ ]"-!99CZ+_P/_P!#J5?OK]3_ .@M44?1?^!_^AU*OWU^I_\
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M*<GWC_USD_D*;3D^\?\ KG)_(4 34444 %%%% !2Q_?;Z)_[5I*6/[[?1/\
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M_7U;?^CEJC5[3?\ C]M/^OJV_P#1RT%4_P")3_QQ_-'I5%%%![Q^ *??_P"
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M]H?[/'[;W[7_ .WIX9^%_P#P3\\._M#?$7]F3X:0Z=^T+^U5\=_VQ/&'P(\
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M5?K_ $-+2'JOU_H: 6Z]5^:)%Z/]/Z&IE^^OU/\ Z"U0KT?Z?T-3+]]?J?\
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M/<M;:;I=G<W4D5I;W-Y<"+R+.VN;J2*!_P ,O^"DO[8^J_%#]@#QA>']E_\
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MWG]@>(;2PO\ 5-/M-?TN6Z_LS6;6PU34[*WU."YAM=1OK9([N;XX^&_[:O\
MPNGQ1')\&_V9/VBOB3\!E^*&N_""?]JC2'^ ^C?"F?Q1X5\6R^!?%WB3PWX/
M\5_'#0?CKXP^%'A#Q;9:QH7B+XEZ!\*;G38[WP[XA;0K'7[32S=3:<MJBIR:
MC+F<7=JRM)1NY7Y>5RDH1DY*,IODBW+0BCAJ]=5)TXIPH\KJ3E4HTXQ;4Y1@
MG5K4N>K*%*K*%"G[2M.-.;A2:C)K[E$4L:PRO&Z132%HI&1E2554HQC<@*X5
MQM8J2 PP><59K\._A%\>M?\ AW_P4<_X*[>!_ 'P+^-G[2OQ%NO'O[$WBJV\
M ?"A_AWH6G>%O"EI^QGX!M+S6O%'Q#^-GQ$^%GPO\-2Z_JEQ-:>%/"%CXGU?
MXB^/]3TS69_#?@O4]'\->*-=\/\ V_I__!0_]G"^_9'T?]LR9_B;I?P^U[Q$
M?AUIGPSO_AQJT_[1EY\<CX]O?A;'^SC9?!C1[C5]8U+X[W/Q(TZ]\(VO@[3=
M0N]-DGMY/$DOB*#P+!=^*[;-))<]T^:E2K65^9*K.5+D4$G*<HUU&A>FIJ5:
MI"E%.HU%^E/*\93J453HRK0K3P=.E.G[/FE6Q>!HXZ%.=)5YU:,I4YUY4W7C
M2C4I8:M7C-TJ=2</NE?]6?\ @?\ Z$U3)]__ ("W\UKX?\&_MJQ2_%[X9?!'
MX[?LV?M!_LH>*?CM<^(++X$Z]\9#\$_%/P^^)6LZ!I$WB6[\"7'C;X _&/XR
M:3\.?BW/X9L]6\06'PV^(Y\-ZCK%GHNIV'AW4M<UY+?1[E\O_!0#X$:?^RS\
M<OVN=9TSXFZ)X$_9S\<?%GX6?%7P%J'ASPO)\8M&^*?PA^)Q^$6L?#:R\,:5
MXYU3PI?^,/%/C>;0;'P'8'QY;VVM6OC#PM<:I>Z!+>W]KIDU&E'GNN2*DY23
MNHM3C3:?+S6G&I*$'!\LU.I3CROVD')++\:JJI?5YRJ5:N'I4E!TJD:L\4ZZ
MPZHSI5JE.JJLL/B(1E";@IT*T*CISIS2^Y4_C_W1_P"SU-W7_>7_ -"%?+]O
M^UM\);X?L8?V&GBSQ)-^WS-I4OP!M=$TW06N6\,7_P %-0_: U#Q[XWCU7Q1
MI0T/P;X5^'-I;3^*KK0'\7:_::[KOA_1M,\.:O\ ;Y;JT^1[3_@K1\./$GP=
M\<?M%_#C]E3]LOXD? 3X-:K\1-.^/GQ-TCP7\%-!MOA(/A1XG\2>'_'ES#X7
M\6?'K1_%GQ?@\,:7X=C^(GB._P#@AI'Q!\/^%OASK^E7WBG7]%\96'BWP+X8
M<O<J2A*T94G4C5NU:GR5(4IRG*[C&$*E2G"51R=-.<??:=S?#8#&5H1E3P\Y
M*HX*G>5.FY2J/$PI4XQJ5:<W6K5,)BH4:/)[6K4H5*=.$JBY7^L*_?'^^_\
M[/4V0?P]>,?G^-<_X7\1^'O&OA[POXQ\):U8:_X2\::'H7BSPIXDT]Y9-+UW
MPOXJTRUUOP]K]A(\*3/IVK:-J-EJ5H[P)*UK<1L\2.2B_EM^SM^WM\:/B=_P
M4*_:_P#V:O%'[+W[26G_  P^%UW^REH?@#49_ WP$T^U^#;?$+P/\2->\;>/
M?CMXAL/V@M1U^]\(_%F_T?2=>^$\_@O3/'>J67@_0C#KO@_P=X@N[NTU>%&3
MJ^RY6JG[QN+7*XNG.,9QDI6Y9*4N6SMRN,E/ETN4<+6KTL76IQC*&#I4ZU:]
M6E"7)4K.BG"-2=/VG*TY-0ES<JM%3J.%.7ZWM#+#)&LT4D3.JRJLJ-&S12(6
MCD < F-U(*.!M8$$$BE/\7^Z/_9J_G[_ &+/VS9O@E\%?VU+KPY^S+^T_P#M
M):-\#O\ @H!_P4-\5?'+Q'\$]%^%R:3\-/#R_M >//%DVD:0OQ@^+'PMU;XO
M>/M.\'1VOC&_^'7P3TKQWJ'A[PWK>@WWBN\\-W/B+0[+4_UD\2_M1:?)\*_@
MQ\5_@;\&OC9^U7I7[0NA^'_$WPLT_P""6C>"-+BE\*>*?!"^/M!\9?$+Q?\
M&SQY\)/ ?PI\)7FC7%A8-?>-?$ECK1\1ZG9>'K#P[J.IFZM[8IM)4JCVG1PM
M32[:>+P^%Q$(J*]]Q3K3IQGRJ,G1FT_=E;T,3EV)PV(G0Y5.FL3B*%.NYTJ=
M.;P[C*3FYXA1P\G3:J1AB)TY.#C**DI)GU-_"O\ NK_Z)%7#U/\ P'_T!:_.
M*_\ V^5UO]G7]JSXA>#?V??V@-/^/7[*,^O>!_BK^S/K7A[X4ZG\6/AUX_\
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M_*W^5YNQC'YI7<(]^-OF%?F"9W$<@4MNK2.RQJSL\B*BJ-S,S!5554 EF)P
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MJ5K+XKN/"^F6IU'PKXOA$1M="GO7_7"WEN87:6VDN(]@PSPO(A7<&3#.A!4
M$@ G 8@8'2I#([2&1I&>5L[I"[&1MRD'+$EFR"003C#''4YFDN6-"_O1H/"\
MB:7O+"5L).FYNUY3=+!4Z,II1YN:=64'4E8^KAG>&EC89J\M?]J_7(XO%5UC
MZL<)B:SIXB.(JQP;P4G1J8N==5JUL96HPK^VJ4(T_;RI4_AGPUH6N1?\%,/V
MM/%$FB:O'X8U?]CC]F71-)\1MIEZF@ZIK&D?$S]I.[U+2-.UEH!I]YJ>GVFJ
M:;<WMA:W$MW:V^H64L\*1W<#2?&'@WP'XWA_X-[+OX<2>"?%<7Q!/_!/CXC>
M'!X"E\-:Q%XR;Q'=:!XLB@T-?"KV0ULZS<W$T/D:>+#[9+-)&8X6>12W[:QE
MMVPLV$7<HW,51F)&4!.%; P2!D]SZWHG8R>87<R;_P#6%B7R(P-Q=B6+84 L
M3GDY-"C:/)=-/#TZ#=M7&GB\7BTUJUK/%.,HNZ_=1FGS.T:I9U*#R^3PT)2P
M.,R+&1;JM*H\CRW^SZ<6^23I_6$HU)./.Z2=2G&4O=E+\Q[WX?\ BSQ%_P %
M"? #V]AXD\/:%K'_  1V^)WPND^((T;5H]'\+^-O$?[0GP;%CIDFK+:"TM_%
M=C90W_B&#0O/76C::/=7<5F8K61EX_\ 81_:C^'/P/\ @7^S;^Q3\;?"OQ.^
M$G[57PE\)^$O@'JWP5_X4=\9/$:>*=6\)7J^![7XH> O'/@[X?ZW\-?%?PK\
M=);1>/Y?B3;>+8?#.DZ;J>J:CXDU'3K:U^W7?ZY!GQMWL4+;MI)*[L$;L9QN
MP0-V,D#!)S4D=Q<B,P?:)A;R9WP>:_DME2?FCR$(XZ%2!@#IT:34Y3NN6JZC
MJ05U?FQV*QL8P:DERQ>*JT'S*[IO76$"_P"U:>)P-++\5A)3H87"8&GAW1Q4
MJ%18C!8+,,%&M5G]5Q$9TJU/'1G5HJ,)TZN&A4PU>*K5XG\]GQ=^)&O_ !!\
M=?MT_#C]I?XC_M]:;\;]#^(/QP\'?L=_L7_LU0_'7X7_  S^*_[.MKX&MK'X
M&?$J'QC\#/!6GZ9\1--^(^JW^NZW\9O'/Q9^-T'A#P EI>:+XG\/>$?#FC6V
MGZQZW\*? GCFVM/^#=!;CP7XMM_^%:_!SX@6GQ&\WPUK4*_#Z[G_ ."<MSX9
M@M?'!DL4'A.ZG\2.OA^"WUXV$L^M'^S(4>\!@'[@PSW"Q26ZW$PMRZ,T(F<1
M,5 8,T0/EL5)R&*Y!^E.WN?,S*Q\TYDRQ/F-N+J7R<,0_P PSSN^;K2C%Q4/
MA3BL*K134/\ 998B2ERMN7/4^L3<YN;<IZQC3@E!^M+B%RH0HT<!3HTTL=)4
MXUHQHPECLB_L64:-.CE^&<*,%_MB]M5QN(E6G5A5Q512C47Q9_P4B^"7C_\
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M8FAF+HTL/2>'A45#*,1E+]I*2A.-?,(XYU9*"YW&\50=*,H\T)R?-"7+*/\
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MY:EB0DI" D[5!0DA5. N>P  '0#M5LM(2I,C%E"*C%FW*L841A3G(\L( BC
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M$?A+Q9923Z#?_:+>'4T_,+P'^SS^T1)_P33AU[PQ\'/C]K'AG]CO_@J3X/\
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MB'X!_LA_!SXK?!#X<? _PQI\>C>"/&W[,/QE_9[\*Z;H^K:I>9;0+_XJ^%-
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M')QI>RY\37Q<_P!].K>KB(R4[.48VC%S?+=2G;E4YR<5)_C5\=_'>A_LY_\
M!93X-?'7XOP>+?#7P;^-'_!.75_V2_ GQ$TCX=_$7QYX;U#]HM?VQ="^(VF?
M"O5[GX=^$_%LGAC7?$7@S64UOP[=>)H=(T34X]-U:%-52XLG0^\?\$U/"WB3
MPQ\5/^"G]UXG\-:[X;MO%G_!6?XR^+?#5UX@T;4=%C\2^$KKX$_LMZ;9^*-
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M1@S@L<.P.5+C.&8$G#,"P!(R,U,&=U4N[N558P68E@L9(4 DD@+SM X48
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MCX'>%?\ @N)\4?V=O"?Q'TSXB:Q^VG^RMJ/A3Q;X3^%=Q\1O&-A\'[W]G?\
M8]\$_'+XM_![X?:MH>J:7\6->^&_@"+XA:AIUA::?KNG6&M:!>:A=V=Y+X=N
M-/D_H*_>;?+5R$^9RF2%) !+;1QP .<?+@'.>:<))1L*RN/+.8B'8;"#N^3:
M0$(;# I@AANZUB[/DLDG3CB(:Q]R?M\12Q#<E&<)WBZ*IW4XRDIR=UI;1XF]
MN:G%KEPL7>3<F\)3Q,(R4I0G%2;Q#J*].I&$Z=)\LXJ<9_RZ_![3OAC\0?\
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M1>7D5I'&OYA_L^? S]B+XE?LS?!#]A7]J_XO_P#!:30_VB(OAM\*_@'\:_\
M@GQ+X[_;6UCPEH_BKP3;^'_!NI-X;\)>'_ /BCX!Q?LP6^I>'(/'7@#XAP>/
MG^$.C?"X:%=W6OZ5>:?<Z-9?U_99V7>Y; "#<S,<*2 ,DEL#!VC/';&,F_\
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M%DD6-SP"7C#!6)  )((("@YVBOCKXS_LK7/Q:_:W_8<_:CA^(47AN+]C6?\
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MM*^!/Q=GA\5^(_#GAKQSX+T[XQZ=\8X_ 2_ VV_9Y\<6_D?%'6/CUJ?CVV\
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MVO\ [,OQ#\0W<<-M%-.D'A#X3?#?XD?$75=06&2'1M#\'ZEK%Z$L+.YFA_I
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M_:0^ 'Q*^ TGQM\'^#5TJY\6>)OA!>>/-&L+'Q?'X9L-;T;6->\,RW&E>/\
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MQHFI6ESILT$,MJ\:\S^UQ^U=KOA7]MRW_9O^)'[<OA;_ ()N?L^Z/^R_X?\
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MX:49U*\L12J5EB9>T<?JD(-0C2A"I[5T<OA4C6A2KUI3HQ?]!OBOQCXVL?\
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ML.^$/A3\>_@1XB^#_P ,_!G@[5_ WQ5_:]_9^^(&H>*?$WP:UKP?KWPG\4>
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M[7/C_P".7AG6/$6C?$/]C_P%^R/\9_%/[7GPE?PG9^%=1UW6?BU\%].T!I?
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M]GC0?!?@CP-J_B5O'CZ1IOA/QWXH\=>+-*TF/7]9TJRTZTN8_P!3:0]5^O\
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MGNI($6%Y6C55$_FR>4L'F2>0DGG+#O;REEQM$HCSL$@4 !P-P  !P!3**/\
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MJ+#7=!UG0;6]\36Z6?@CX?7-SX<T^^U)/(U'^RO#VM]9\4O^"N?[9%U^V?\
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M  4\1_%OQ?\  #0/BS\/M:^.7@/0H/%GC;X1:9XHTN\^(GA/PS<Q>''M]?\
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M;?$7XG_%6V\.?%CQ3X>^'NA0^+?%?B#PUX;M?&&@2Z9<Z/X.N[/Q1K^A^'/
M_P 8E\+VEVEE<ZSJUU!.HE2C&*7,[Q52565O<A&,U&-5O=4YJ3UG%-25E%I2
M<=UE']H3E/*)SJX2E+#4IU<UG@LNFL7B'-4\+#FK3HU:M5PBZ4*<Y3?,E)13
M3?\ 4+'_ !_2/_T.I.X^A_FM?SU?M)?\%W=$^&W[$?[%_P"VW\#_ (*+X_\
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M1!G\W:C-LC#-M!;:@S\[8&53YA\S  9&3R,S=U_WE_\ 0A7\C/\ P5B_:?\
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MT/A7S_,*1NA^A_E2TC=#]#_*@HLT444 %2Q_<'U;_P!"-15+']P?5O\ T(T
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MAT76/$#0^#%URUG\6^,/"WBSPU\0+G2_"'Q!\ >)FTK4?$6D-X;31_%W[T
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M%J"X_%+^NI/1129'J/S%']?A?\M?37;4T%J6/[@^K?\ H1J*I8_N#ZM_Z$:
M'T444 (>GXK_ #%+2'I^*_S%+0:4]I>OZ(****#0*<GWC_USD_D*;3D^\?\
MKG)_(4 34444 %%%% !2Q_?;Z)_[5I*6/[[?1/\ VK05#XE\_P B>BD+#W)]
M .W3^?\ CF@$GL1]<?T)H>ED]+JZOI==UW^1MW\M]5I\KW_ 5.H_WC_Z$:L5
M73J/]X_^A&K%-[OU?YD1WEZ_JPHHHI%A1110 4Z+K)_O+_Z M-IT763_ 'E_
M] 6@":BD)Q_@.I^GT[TM'_!_"U_NNK^J[A_P/QO;[[.WH^P4444&T/A7S_,*
M1NA^A_E2TAZ'W!Q^5!19HHHI75KW5N_0 J6/[@^K?^A&H00>AJ:/[@^K?^A&
MGU:ZIV:[/L^S\G8!]%%% "'I^*_S%/3_ %D?^]_[*U1D@C@YY7^8J1/]9'_O
M?^RM1U:ZIV:ZI]GV>IK#9^OZ(FI&Z'Z'^5+2-T/T/\J#%;+T7Y(6BBB@Z0HH
MHH 1NA^A_E5FJS=#]#_*K- !1110 5>TW_C]M/\ KZMO_1RU1J]IO_'[:?\
M7U;?^CEH*I_Q*?\ CC^:/2J***#WC\ 4^_\ \!;^:U.O4_[C?S6H$^__ ,!;
M^:U.O4_[C?S6N@_AR'P_-EF+K)_O+_Z M2C[W?[XQCU 4]^.U11=9/\ >7_T
M!:E'WNY!< @<$@@#U^GTZ]J3O9VT=G9VOK9]&TGZ-I/9M*[-UK4:O:Z2O:]K
M\JO;K:^W75'PM\8/VJ_BG=?&_6OV6?V/?A)X1^-/QS\$^&?#/B[XU^,/BCX\
MOOAY\ _V;]&\=6=UJ7P]L?B1J_AO0/%?C?Q;X^^(&EVDFL^'?AGX)T./6_\
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MZCXSO-?\?:QIFG)X>M_#5I=:3I]A"FA3ZC'>7]W\J?\ !+W]DG]E'QK^QO\
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M=RW&H:C=W=_=7-S+\M>-_P#@GW^S;\2_%WB/Q!\0H/C5XR\*^,?%T?Q"\8?
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M5/B9\2_#>F^)9?&EG=?$CQ7\2_''BJ\\:^*[?79HXK3QEK:W/BC3/#&F>'O
M.D:KI_P^\+^&_"VD[GP3_9*^#O[._C'XD^+OA&OQ)\-VGQ1USQ'XHUKX:WGQ
MD^*?B/X(>&_%/C?Q-+XV\>>)OAK\%?$7BK4_AQ\-]<\:^++F?6=?OO"/A_3&
M5II]+T9-'T*ZN]*N/I:'3[^X $%C>3X@CG/DVTTI$#1[5F.Q&'EM@E7SL;!
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M)T;WI.DU%Q^+O@9_P3V_9>_9X\8>#?'G@/0/B9KVO?"GPSKG@CX$P_&/X_\
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M%348S2DOAWP[_P $X/V6/!7Q!M_'?@#3?C3\.-&A^)-C\9I?@9\.OVG?VB_
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MT/A7S_,*1NA^A_E2TC=#]#_*@HLT444 %2Q_<'U;_P!"-15+']P?5O\ T(T
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MK_[3J[4Q^*?^)_FSIC\2]?\ ,D7_ %9_X'_Z$U3)]_\ X"W\UJ%?]6?^!_\
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M '7_ /9:L=U_WE_]"%5U_P!:G^Z__LM6.Z_[R_\ H0H-H[S_ ,<OS98I\?\
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M?_1(JX>I_P" _P#H"U3_ (5_W5_]$BKAZG_@/_H"U)K#9^OZ(*?#]P_[[_\
MH1IE/A^X?]]__0C0668^B_\  _\ T.I5^^OU/_H+5%'T7_@?_H=2K]]?J?\
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M'^578_NG_KH/_19HOKOKZZ_Y]?Q-8)7>BV?1>5^GDK^BOMI(!T'8LO&XX/S
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M1UWHR%H]ZAU9<HQ4JP# $JPY5AD$'()J2@WAO3]?TD"_ZU/]U_\ V6K'=?\
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M16@OK"S3^T:>+]@ZN.H8RCA,+AJ5*BE&/S;^VA^V1^T5^QCH7Q/^,GC3XO\
M_!/:/PKX \3#7/#7[).K:EXM\/\ [2/Q3^"!\4Z=I\-[H'Q&\3?&GP]9_P#"
M[M6\&7K>+;#PGH'[/?B+P;9WP'AZVUKQ?##%KNJ^P:ZT;?\ !8/X7/$S/#)_
MP2Z^-<D,C)Y;O#)^UW\"GA=X\ML9XV5F3)V$E<\9K\S[C_@GQ^UY#^Q=^T)^
MQQIG[*O[,&H_'7Q_;?%Q?%'_  4?\5_$3P#J'C#]HU?B!\4=?^(T>M7.@_\
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M\./$&@7WA.&UUOP=K4?C"VF\,???[;_[/7C7]HSX(:/HOPJUSPQX=^-?P?\
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M$Z?V>?C/^SGX"_:6TSXZ6WPVL_&/QC_;>_:#_:+TVU^$5Y=7/@"S\)?%6U\
MOI-AX?MK_2M&U#2=/TV^T#6=-TS2=2L(-3CT6RTR\U**VO;V>RMJIQTJ^T=F
MX-0BF^6%2.+I4W!2LU*^&ISJ_NVJ+C*,DG5CS'+66!IY;!\V!EC'7P-93PCP
M<:C51X^>/H1C0K5<9.GA9QH4G/&^SI-JC/ 0CA^2I6\2_:'O_C5;_P#!5_\
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M#6_AE^S;X.\;-\0/C1)XA^)/C**TNO%GC;0O@]\,OAS\,/$?Q1^)%EX4&O\
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MEY)X8^#]CH\LTFG:A=PS?.GQE_9?_9CLO^"N7_!/SPG9?LU_L]67A36_V/\
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M_%OX6Z;X+M-+\5^*->E\3?%?2IET[0?"6L>$=#\-?!SQMXE;Q-XNTCYCT/\
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MJVL^(KG]AC]JC]I7]AW0_$7B"YCO-;UKX8_ ?Q[)_P *'N-4NHX8OM-_IGP
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M[5_[*G[.7[/OPJU#7_V8%^ EWJ?QH^.OQG\5>"_A3JD'QQ^%&E_$VQT2;0/
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M7]J)(F_9G_:;C3,D#?L\?'I$,RJIDA;X5>, IECRR@NA!D3<0"2H.!D_B/\
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M5V5YRLNRYJDY6VYIS>\F:-N3NVV[)7>ND8J,?NC&,?\ #&*VB@J6/[@^K?\
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M/VT_Z^K;_P!'+053_B4_\<?S1Z51110>\?@"GW_^ M_-:G7J?]QOYK4"??\
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MY8C&XNLZ<\SCFSYL1CJU6K*7UA.G%)PA3P[5*E2IJG&1^(7Q _8Q_:)\:_\
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M63_>7_T!:;3HNLG^\O\ Z M $U%%% !1110;0^%?/\PI&Z'Z'^5+2-T/T/\
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M /@+?S6IUZG_ '&_FM0)]_\ X"W\UJ=>I_W&_FM=!_#D/A^;+,763_>7_P!
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MA73=/\5>$=2\0>%7\5>!O$7Q8UKP[XR\%>)+'.DZH;">]T[4/#'CCP5XAMA
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M=;EE6ITU)4:RC[2=*I!?HBW0_0_RJ[']T_\ 70?^BS7P!^S[^V]I7Q*_8_\
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M+[^J5.%&?5OU8_XBOSCF_P""G?P(T[X@^#O"7BOX4?M@?#OX??$3XC:'\(/
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M%-E\/I= O-+U'4.C\??M^_LP>!O@/\&_VB=/\8Z]\5_ _P"TC+H-C^S9X?\
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M5VX)4FW4I*M!IJ2=-R<&VTDH24E&+A)WYIQ@G*7,H_=- RP8@$A,%B%)"@G
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MM5=OEE9+71Z=ZIPG*FYJ,G"-^:5O=5K-W>R45*+D]HIIMI.Z_0*AP5W*P*L
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ME)-)J2;>L6FG&=E3?,DIN34!^PJZ^X_@53=:0=[-N]KRLW&-W-I.7(H?O#]
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MQTU?PDGQ'G^"'[*OP?U7XR_$7PM\+VU.[T5/B7X\AAU#P]X6\#^$+W6=/O\
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MU[:/7Y;FZ_B/T_1'X]:+\;?"'_!.']JC]K'0/VG#J7PZ_9K_ &N?C/9?M-_
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MVF$D$DD;_/&[H6C?YD8,<U*\L\\J23323.JK&C2R.[*D:;8T5G+,$C10J*"
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M,Z#S+BSUK]F_7/C1I$]@&1=1FO;:TF:.*1Y$_(;XK^,?B5^S#\"/@Q_P5O\
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M[3GP%O+6RAOM4M/C=^ROXKT/]H+X>6VBQ38V:EXJU7X>-X#,D,MM,VG^*KZ
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M:21V=V( 4$NQ+'"@ 9/   I@)$TUR"/M5S"MM=7051<W5O& (K>YN% FG@B
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M.:K66(7+S1KJ3496<8RC0]C"4E9N\7:47"2]V$:=3F@Y4Y?S(ZW<^!?V=?\
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M$>%O &M?'?Q-J5EIS+J>NZ;IOPUFO_#.G/'J'B2WTJSGAGD[/X-?M5_LZ?M
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M7HOR0M%%%!TA1110 C=#]#_*K-5FZ'Z'^56: "BBB@ J]IO_ !^VG_7U;?\
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MW*[;3;YKMN^[?-=N_5MOS/(?B%^S?^SE\8-%\)^'?B]^SM\!/BWX>\!1P0>
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MM[))>I'H]W9HEVSW*J)G=S[+D>_Y'_"C(RO7KZ$=CZBC5;7C;F>FFLK<TO\
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M ('7Z94(.4Y//7D_W2?6FL9+K1PWSH1?Y)&T.!,+LN)>-E:VW$^,CWWLW?\
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M #VI?VA5_P"?.%_\)Z9I'PLP,HK_ (S'Q%23V7&&8/56ZMK?T/QN_P"%:_\
M!4W_ *'S5O\ PXWPV_\ CM2#X:?\%4"!CQ[JI' Q_P +'^&@X]#NEY.!UY]^
MM?L9M_VF_.I(AE3R1\[]#_M'_#^='U^IUI87_P )HFG_ !"W ?\ 18^)"].,
M<??Y.[M8_'1/AE_P55()3QYJ@!//_%Q_AH,_E(V:?_PK+_@JR2,>/M4)[?\
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MG[0 O%UF6T=85T(W8L1>27\B::)C:-,XD\@CX7_X)R:A\.++]K+]H'0/ /\
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MXPT[P%XG\/V7B[]H?X=:GI5NVFZQXD;7+CPWXLUSQ=?6VG3ZCJL=[!W7PO\
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MH4Y1P=*NE.:K1YJT:LY<M&,+3I1;G)3BT?T8-%-;N8+B*2"5"=\4R-%*A)+
M-&^'7/H5&,CU&9[:"YN&86\$L[912L,4DIW,S*B8C!.]V.$7'SG(49Q7Y)_L
M5>(OA5^R)#^TY\"-<\2>(/ OPCT?_@J-'^RO^R+X/\2W7Q(\?6VB3?&']EC]
MF/XP^%?@WX$U&]A\7:SI'@FZ^(GBWXOZWX>FUW4K3P3X32YU6RGUW2[&*WB&
MI^WK\'= ^/O[57_!-'X3^/K?QYJ7PD\4>+_VR&^*7ASP;XW^(7@#2O&&@Z1^
MS/)J^D^$OB%K?PWUSPWK=_X'UCQ#8Z>-4\*7>MVFC^,/LR^'-;M]6T74=5T;
M45%*?LG!MPK2A&$II1<7*G.HXSLVN:"A9J/2K0E:TU<^KJ%>I1K5'"%.-63J
MQASN<:2IRO2@Y4T^;VJ@[RE&G.%9-R5/3]7TMKN2?[+';S/<@E6MTAE>=7'W
MD,*@N"HY8%01D9&"#2+;73RM"MO,TL3!9(UBD,B%F$:AT +*69U4;@,LZCN,
M_P N=W9^"_"'PT^#/PI_:]D^.C_\$O\ X+_MI_\ !6_X&>.;,:O\?O%GA;0[
M#X4_M()X8_8 \$_M!>*/ E]K7QL\1_L_>&/ 2_%S0?!4_B75]8\"MXITGX16
M/C"]N+'2O""1]IX"^$,WQF\&?L/?"GQ*W[2UO^Q]XV_X*N?M9)^S3I?C7QM\
M>/AE\7-4_8.L/V$OVH]:^&_A7QAXBUC6O#7[0>G_  5\7?$'2/&FC^!="^)^
MJV/BCQ5^S7K7@7PUK);PWKME:RURQY>92BU)TW!J7-&,*L,-.*KSC%\M11Q,
M:G+",DZ5.<HNS4X;O ^S3E4K?PW6]JE3NI>Q6+?^RMU5*O*/U6+K4Y*'LUB<
M.E.7,G5_I=2UNVF:U%K<?:LA3;&";S\XR?W6P.",_P!TCU(Z4I5HY2DBLCQL
M0Z.I1T;##:RL 58'&0P!'?'6OY#_ -HSPK\7/A]\!KOX$Z%J=]X>_8*^!/\
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MWQFF\9^*]<T4Z_IND^ ->U+Q.?B5K%W<>&X(O$FMI#)Q/B'7/@#X4^!7[?\
MJ'[)_P (/B=\4_\ @F_XIN_V$O#5M:?%/7?VXO#7P)\'_'_4/B_\76_:P^-D
MX2Z3]J?5_@[\-_"EO^S=KG[36A> K>32_&_CFPU3P_XKF6TF^*&HVF=ERJ2D
MY7A&5G9.+G2HR]_;DBJDJM&E+7GJJ$)+EDY*X8'FE*/MD_WJA#D2:E"4TH/F
ME-.5;V4XUJE'ELJ:G.#?NP/ZJC:W8F:W-M.+A &>$P2^<%8HJLT14.JLTB*C
M$?.S!5R644OV:YCDE26WFC,41,RO#)&T2R;%1I%9=R*S21 ,P )=1G+"OY#O
MV=_!&O\ Q&_9L^'?P*U#7/&UO\'7_P""[GP*\(^%E^ =Q^VQ\ /#&E_L\>./
MV$M!\>>)]&^"\_Q[\;ZE^U%\+_@;X\\0^*_&.HR75OXZT_P_?+XZ\3^)/A1J
M^@^$O$OA2ZL_LC4/A+<_LV?#3]M[5O@5IWQ L?!'_!+C_@I%\)/VK_@/\.#X
MT\:^)TTSX I^Q?\ LS^.?VSO@QX!U+QQJ?BK6Y/ _CCX2?'+]J[4O"WP[L;V
MY\/6GQ)UG38-(T^RN(HA"+E<U%J=.+@Y\U2"IQIQA]45255RFHQ4)8KFUE&+
MHT:U2<J:IW(EA%"<J<:ZJ5HR<(THPTG)U*]"CRSYI*=2M4H*+@HVC*M1@FY3
MT_<GXD_&WPE\+/'?[/WPWU[3_$>I^*_VE/B+XD^'/P^L/#EGI-\;"7P=\+/'
MOQ;\5>-O%4.H:WI.H6'PZ\/:'X"DT'6?$NAV'B.;3O&7C#P%HEYI<,'B/^T;
M'V22"XB2.26"2**90T,DL3HDRL,AHF8 2(P(*LA93E1G+ 5^=W_!-_PK:^,O
MAK<_MH>+_#5A>?%+]LWXD?%+]I/P_K&OZ;877B_PA^SS\9;_ .'FD_ #X4:=
MK5]8)K'AKP_=?LP? K]EV_\ 'O@VVN+;1K_XB:!)JVK6EWJ.EV-U;? ?_!'V
M]^%VC?'_ /:.\#_#)/%W[0D]WX(@\9?$;]O#7]"_:_\ AWX]\;>+IOB&\5G\
M%?VNOA;^TTS>%M/_ &J;"UUG4_$:^)OA%/:V=SX.\/ZUI^J?#+X(Z"/"7A76
MKA3;J.G)/F4.=I*SC*3H+V<HNS7L'*K&M4>DJRE2@DZ/-44Z-/DJRI3YH4*E
M.ASI>[6G*M*G*M&3FXJ+YH.C3AS2J4HTZUI1KR6'_H06WNGC:9;>9HUC$K2+
M%)Y:QEF19&?;M6-FCD57)"EXW0$E&PWR+GRC/]FG$ 56,QAD\H*[%$)DVE1N
MD1XQSG>I3&[BOY-OVM;CX*:O\;?^"J>CK<?M4:C_ ,%$++]J#PY;_P#!-*T^
M&$W[5$WA[1OCM)^PM^QC>^#[CX1W'A*3_AFC1_%EIXUN['4OVE'\72VVL0_
MR?1YOB*$\ W6D)<?=^O? #Q3X@^(/_!;C]I?X-6'Q$UK]M+X8^/?C!X*_8HN
M[;QYX\;0/ _C/7?^"5G[+(TF;X1_"ZYU^'X6/XR\=^-_$%OIUWK>K^%M4/B'
M6_#?@&SU.9/^$0TR2UYH56X0GR3M.A4KNT>:%X4X2]G&5T[IU5&M=)T8I5+S
M<G3-'@E%4W*NDZE2G1BIQ2DIU:E**F[5(_N6IMTZCC&4^22]G3T;_=J:"YMU
MC:>WFA$@S&TT3HL@P"2A*@.N&4Y'&&4Y.1GQOQE\;?"G@'XX? KX!:]I7BQO
M''[16B?&C7? %W8Z38S>&K2S^ ^B>$=?\8Q^*+^ZUBRU33Y]2L/'.DIX572=
M$UV+4[NVU.'4)M'C@M9[W^?#X.0_#B7XL2ZO_P $78_VBSXZB_8S_;0B_:LG
M^+Z_M3?\(IJ7[1__  KKP(_[']K\=3^U*K> K_\ ;-C_ &@1K,EPWATMXTM_
M R_%>/QU(O@.X\-13>2?LU>#OV</%W[0G[$]I^QMH_[4M]\4M3_9 _;U\+_M
M6:O\9U_:VL;5?VK?%/[/GPCTW4;7XI:[^T*UO\,]/_:HU+QM#XNA^)5]\-YK
M?68]*MM"C\9W4/A*V^$\8Z'!R:Y9)+V&*JSM>34L/A<VJQE%*[CAZE3 4Y4Z
M_/5E.%2G"-.4JL7/;#X&E.HE.LZ:DZ2BZL52=!U7A7;%)U'[.K".)<717-SN
MG5:J0]ERG]:ACE E)B<"!]DQ*-B)MS+MD_YYL2C !\$E6 !(..(^*?Q$\%?!
M'X<>,_B_\6O$%MX#^&7P[\,ZGXQ\;>,M:M=2?2O#OAC1X1/J>LW:Z=9WU]+:
M6D1#R"RLKN9P5\J)R5!_F8^%_P"T7XY^+_A#_@EO\.?V3D^,MU^U#^S=_P $
MR/VS/A7XTL_&_P &_C)\/_#_ ,/OVSO"7[$_P/\ !/@SX4_$+Q+\7/!7ACP#
MK_Q.T+XS>"=6&J>&UU7Q,=+M+>'Q!K,EKHGBSPSJ'B+A?&?P2_89_:!_X)9_
MMN>#/V9_AW^U;\4/VD;#]B^Q\>_M%^'OBE8_MJ7?B&\_:F^'>DV/B"?4/BM9
M?&"6W\%:[^V'I?BQ/'=U=Z#X'&H>)=5\.#5;._L+_P  -X%M6<J:5Y*I3C!R
MJN$]7>A#&>PAB.7FNJ,Z*E5G6<^6+E3Y5.$E*6D<$OW/M)2BZDZ4)TX1@Y49
M3IRE*G6G*I&*J\WLX1C&+4I2G)27+R'];;PS03-;S1/%-&^UXGP&#<.!@9SN
M5U9",A@RD$9P+?V2\$PMS:7(G*[EA\B4RE1W$83?TY& 1C#<J03^0?QCD\(+
M_P $A_B7<_\ !+"U^(%E\.KCX9ZW>? ^+X):7\2=)^+G_"M+[XSFZ^/5]\%M
M/^(5M:?%-/BC=>!KGXR:E\,;Q+=/$]QXQGT#4?AZSR3^$YY?SQ^.GB3_ ()V
M:!^P]XQL?V*OA5XS\?\ [,/CG]ICX->&/B=XG^.MS_P5(L/V0?@MX@U'P?\
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MXA\3>(=8\"Z5XR\#^%OAQH&FZ]X>2Q2Y^$WBS5OAI97&JZMP?@7X=>%/A?\
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M#X#>"/\ A(_V)OVI_#GPY^/.BZU\$O&7[67_  2$\->$- _8X\"?\%"/@1X
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MM/\ KZMO_1RU1J]IO_'[:?\ 7U;?^CEI$T_XE/\ QQ_-'I5%%%![Q^ *??\
M^ M_-:G7J?\ <;^:U GW_P#@+?S6IUZG_<;^:UT'\.0^'YLLQ=9/]Y?_ $!:
ML1M(KMY3.K,I1_++@M$PQ('"D9C*[MX(VE0=W -5XNLG^\O_ * M?)?[:NKZ
MMH?PG^'U]HNJ:GHUS+^U[^PCI-U=Z5?W6GSRZ1KW[9OP-T77=,N9[.:&5],U
MC2+^[TK5;.1S:ZA87=Q97<<T%P\3S)M))1<G.=*FHI7;E6K4J$4EU:E73MNT
MFDTW<]'!866-QU+"0G&$Z[E!3DG)1<,-C<0FU%QFV_J3@N5\RE6B]E)2^Q4>
M?R]@=_(\Q69%=S")-C!79<A=[(&4$C)7/) :K;7=Y*5#W5PY79LWSRN5\K*P
ME0S''E LL0!_=JY"XSS\-?&3QAKGA7]L/X12Z7J%TVG:7^Q/^WAXXNO#KWFH
M)H&JZWX-\??L<W'A[4-:TNUNK>&ZEL%U#5["RO'"7EG9ZUJEO87-J;^<MXQ\
M)OVM/CQXOT_]G&3XW>#?@K:>'?VS_P!B_P")?[0W@+2_A'?_ !1L]>^'>L>
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M>(/ UYXKUKP?_AN;XW_$WPY^TQ\.O"7BCX42^(8OV!?B;^UG\%_CKX._9_\
MVO?A3X-TFV\*:EIWAO6M'T&'X[WO@J;X^6EWHOBO1O$_PG_:-^"GC'1O _\
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MBS^T)\>_C;_P1R^._P 2_#7P3\/?"SX\_$'XY?&+X7>'/ -WX^F^(GPV\/\
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M?\%"OC#\*OBEX]^#OP3UK]E'P]\3_ W@[]EO6?!?PC^.^E_$7QW\9OVK-?\
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M=+EOM5GN-0OY[+0=&TZUN-1OYY]1U"6![N]GN+J665_D_P#X*#_'FZ_9I_9
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M@/$'QU\)Q^#?$GA[XA:KXAU:+QC\.?%_P%\2V<_C32]:M-$^)'A[7M"\00^
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M_!7+QW\:_P!H;]F)/@I^SW\?O"OA7X>V?Q(\'_&SP?H/PYU#Q=^R[^Q=XK\
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M*HD #8503@##Y9YYBC2SS2LC%E,DCR%68*&92[-M+!$#$88A$!)V"OQ5\?\
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M&TDTKO$>"2C.Y*'<J'*XY5>/E4C\=?@3^VC^V%^UGX<_9VTWX%>&/V8O!WQ
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MIFB$+S2M"H7;$9',2[>00A.T=2>@Z_FROQ3_ &$_^"D_[0/[57CWX%7/BO\
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MPDTRP^*GCOQ=9:)X+T]_#.FVNEV&BP:?/#:3:O\ ;+J_O-;U6]N^6UK]N_\
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MX7_#GQUX^\1>"/ O@^[M]+TY;?2/#NA6!LX=,T33XKD:/X;\-:=HVS>?M>_
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MOBA\.='U"\T?Q)*FN:MK=EHGA+Q$W7?VN]6^&7[0O[-O[+7Q0^%'C;7/B/\
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M;]G2C"'TQ^TI^S?IWQU_9'^)O[,/A_5_^$+/B'X66W@_X:>*;DW>J#X?>./
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ML?'?[(_P(^)/AC]J;P;XP\+:IJ/A[]M&32G_ &A[.#Q9XDTV7Q>^D?"[P/\
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M8_%"RUOP-XC\(^+? _CC0_%&F^-OAS?_  QU3X6_#-OA0G@C7]"@^'-I\/\
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MMI$/Q5C3QJO4C]D+X!_\(E+X&/A74O\ A&9?VL!^VT]@?%7B,R']HT?'N/\
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M\(/B-X*T/XA>&M9M0UE/'XEL;_5;33;K5]%TG5M.T3Q%XDTW6/,_VW?V1?\
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M?PR^#WPN^(-YI.FZ_P##B'P]I^J_$KP1=:(//_3! "%R ?O]?]^GQ]'^D?\
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M\2/!\/Q(NO"^K?%O0OB+K6D:YH4/B/6=$^$?A/6?&1M/#OJW_!0?]BG]H_\
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M>&F^(T/P_FUNY\ 1>/SH=B?&4?@2X\306OB6?P9'XD_M-?"L_B*UMM>ET+[
M^LP1:B;E!VE5CPIQZ&K--N[OMY+9=[=E>]ET5ET("BBBD 5>TW_C]M/^OJV_
C]'+5&KVF_P#'[:?]?5M_Z.6@JG_$I_XX_FCTJBBB@]X__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
